Begun as a one-room Laboratory of Hygiene in 1887, the National Institutes of Health (NIH) today is one of the world's foremost medical research centers. An agency of the Department of Health and Human Services, the NIH is the Federal focal point for health research.

NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to extend healthy life and reduce the burdens of illness and disability. The goals of the agency are as follows:

1. foster fundamental creative discoveries, innovative research strategies, and their applications as a basis to advance significantly the Nation's capacity to protect and improve health;
2. develop, maintain, and renew scientific human and physical resources that will assure the Nation's capability to prevent disease;
3. expand the knowledge base in medical and associated sciences in order to enhance the Nation's economic well-being and ensure a continued high return on the public investment in research; and
4. exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science.

In realizing these goals, the NIH provides leadership and direction to programs designed to improve the health of the Nation by conducting and supporting research: in the causes, diagnosis, prevention, and cure of human diseases; in the processes of human growth and development; in the biological effects of environmental contaminants; in the understanding of mental, addictive and physical disorders; in directing programs for the collection, dissemination, and exchange of information in medicine and health, including the development and support of medical libraries and the training of medical librarians and other health information specialists.

The NIH Almanac is compiled and edited by the Office of Communications and Public Liaison, Online Information Branch [http://www.nih.gov/icd/od/ocpl/index.html].
About the NIH Almanac

Published annually, the NIH Almanac contains pertinent facts about the National Institutes of Health—the Federal government's principal medical research agency. As of December 1, 2001, NIH was composed of 27 Institutes and Centers [http://www.nih.gov/about/almanac/organization/index.htm]. Of these, 24 receive direct appropriations from the U.S. Congress to award research grants and support scientific programs. The remaining three include the Warren Grant Magnuson Clinical Center [http://clinicalcenter.nih.gov/]—a combined research hospital and laboratory complex on the NIH campus—the Center for Scientific Review [http://www.csr.nih.gov], which supports the scientific review of grant applications, and the Center for Information Technology [http://www.cit.nih.gov], which provides, coordinates, and manages information technology for the NIH.


This page last reviewed on January 3, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Organization

NIH OFFICE OF THE DIRECTOR


NIH INSTITUTES

- National Cancer Institute (NCI)
- National Eye Institute (NEI)
- National Heart, Lung, and Blood Institute (NHLBI)
- National Human Genome Research Institute (NHGRI)
- National Institute on Aging (NIA)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- National Institute of Biomedical Imaging and Bioengineering (NIBIB)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute on Deafness and Other Communication Disorders (NIDCD)
- National Institute of Dental and Craniofacial Research (NIDCR)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Institute on Drug Abuse (NIDA)
- National Institute of Environmental Health Sciences (NIEHS)
- National Institute of General Medical Sciences (NIGMS)
- National Institute of Mental Health (NIMH)
- National Institute on Minority Health and Health Disparities (NMHD)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute of Nursing Research (NINR)
- National Library of Medicine (NLM)

NIH CENTERS

- Center for Information Technology (CIT)
- Center for Scientific Review (CSR)
- John E. Fogarty International Center (FIC)
- National Center for Complementary and Alternative Medicine (NCCAM)
- National Center for Research Resources (NCRR)
- NIH Clinical Center (CC)
Office of the Director, NIH

The NIH comprises the Office of the Director and 27 Institutes and Centers. The Office of the Director (OD) is the central office at NIH. The OD is responsible for setting policy for NIH and for planning, managing, and coordinating the programs and activities of all the NIH components.

The NIH Director provides overall leadership to NIH activities in both scientific and administrative matters. Although each institute within the NIH has a separate mission, the NIH Director plays an active role in shaping the agency's research agenda and outlook. With a unique and critical perspective on the mission of the entire NIH, the Director is responsible for providing leadership to the institutes for identifying needs and opportunities, especially for efforts that involve several institutes. The NIH Director is assisted by the Principal Deputy Director, who shares in the overall direction of the agency's activities.

In carrying out these responsibilities, the NIH Director stays informed about program priorities and accomplishments through regular staff meetings, discussions, and briefing sessions with OD and institute staff. The Director also receives input from:

- the extramural scientific community, including both individual researchers and scientific organizations
- patient advocacy and voluntary health groups that deal directly with NIH or indirectly through Congress and the media
- the Congress, the Administration, and the Director's Council of Public Representatives, which brings public views to NIH.

Ongoing discussions with these groups and others provide the basis for an established framework within which priorities for the agency are identified, reviewed, and justified.

The following describes the major offices in within the NIH Office of the Director:

**RESEARCH, FUNDING, AND COORDINATION**

**Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI)**
The Division of Program Coordination, Planning, and Strategic Initiatives identifies and reports on research that represents important areas of emerging scientific opportunities, rising public health challenges, or knowledge gaps that deserve special emphasis. Such research benefits from conducting or supporting additional research that involves collaboration between 2 or more NIH Institutes or Centers, or would otherwise benefit from strategic coordination and planning. The Division also coordinates research and activities related to research on AIDS, behavioral and social sciences, women's health, disease prevention, rare diseases, and dietary supplements and includes a new office on strategic coordination.

**Office of Extramural Research (OER)**
The Office of Extramural Research provides the corporate framework for the NIH research administration and works to ensure the scientific integrity, public accountability, and effective stewardship of the NIH research grant portfolio.

**Office of Intramural Research (OIR)**
The Office of Intramural Research is responsible for oversight and coordination of intramural research, training, and technology transfer conducted within the laboratories and clinics of the National Institutes of Health. Comprising less than 10% of the NIH budget, the program includes the NIH Clinical Center research hospital and the National Library of Medicine and supports approximately 1,200 principal investigators and 8,000 scientific staff.

**COMMUNICATIONS**

**Office of Communications and Public Liaison (OCPL)**
The Office of Communications and Public Liaison advises the Director and communicates information about NIH policies, programs, and research results to the general public. OCPL also encourages broad national public participation in NIH activities, helps to resolve local community concerns, and coordinates how NIH implements the Freedom of Information Act.

**POLICY**

**Office of Science Policy (OSP)**
The Office of Science Policy advises the NIH Director on science policy issues affecting the medical research community; participates in the development of new policy and program initiatives; monitors and coordinates agency planning and evaluation activities; plans and implements a comprehensive science education program; and develops and implements NIH policies and procedures for the safe conduct of recombinant DNA activities.

**Office of Legislative Policy and Analysis (OLPA)**
The Office of Legislative Policy and Analysis serves as the principal legislative policy, analysis, and development office for the Director and other senior NIH staff;
develops legislative policy and proposals; and provides analysis and liaison with Congress, the U.S. Department of Health and Human Services, and other Federal agencies on issues affecting NIH programs and activities.

ADMINISTRATION AND SERVICES

Executive Office (OEO)
The Executive Office serves in both a staff and an operational capacity for all administrative support activities for the Office of the Director (OD), excluding the Office of Research Services.

NIH Ethics Office
The NIH Ethics Office provides oversight and strategic direction of NIH activities relating to ethics policy, oversight, and operational activities; develops and administers the NIH policies and procedures for implementing the Government-wide conflict of interest statutes and regulations, the HHS supplemental conflict of interest regulations, and HHS policies; implements a program for trans-NIH ethics oversight that includes information technology (IT) support systems, periodic reviews, audits, delegations of authority, training, and records management; determines real or potential conflicts of interest and assesses ethical considerations in scientific reporting, clinical trials, and scientific conferences and workshops; and serves as the liaison and coordinates the NIH response to requests from Congress, the Inspector General, HHS, and the Office of Government Ethics, and performs appropriate liaison activities.

Office of the Chief Information Officer (OCIO)
The Office of the Chief Information Officer provides leadership and management support to empower NIH Institutes and Centers to acquire, manage and deliver IT solutions in ways that are innovative, well planned, secure and fiscally responsible. In this way, OCIO ensures that all Information and Information Technology used by the NIH supports the business needs in the best possible way.

Office of Equal Opportunity and Diversity Management (OEODM)
The Office of Equal Opportunity and Diversity Management serves as the focal point for NIH-wide policy formulation, implementation, coordination, and management of the civil rights, equal opportunity, affirmative employment, and workforce diversity programs of the NIH.

Office of Management (OM)
The Office of Management advises the NIH Director and staff on all phases of NIH-wide administration and management. The OM includes the following offices:

- Office of Acquisition and Logistics Management (OALM) advises the NIH Director and staff on acquisition and logistics activities and contract and grant financial advisory services; provides leadership and guidance to NIH components on acquisition and logistics administration and management; and develops/implements policies, provides oversight, and manages the operational components in the areas of acquisition and logistics management.

- Office of Budget (OB) has primary responsibility for NIH-wide budget policy, planning, analysis, formulation, and presentation. OB is also responsible for budget management once appropriations have been made, including reprogramming and coordination of the use of the Director's Discretionary Fund and transfer authority. OB provides budget advice to the NIH Director and to senior officials within the OD and the NIH Institutes and Centers.

- Office of Financial Management (OFM) advises the NIH Director and staff and provides leadership and direction for NIH financial management activities; develops policies and instructions for budget preparation and presentation; administers allocation of funds; and manages a system of fund and budgetary controls.

- Office of Human Resources (OHR) advises the NIH Director and staff on human resource (HR) management; directs HR management services; provides NIH leadership and planning on HR program development, salary administration, corporate recruitment, and other functions; and conducts studies and makes recommendations to senior NIH management for new or redirected HR efforts, programs, and policies, as appropriate.

- Office of Management Assessment (OMA) provides NIH-wide management of activities/oversight and advice to the NIH Institutes and Centers on management reviews/corrective actions involving program integrity (including fraud, waste, abuse, and mismanagement reviews), OIG/GAO/Outside review liaison, management control, quality management, risk management, best practices, continuous improvement, regulations, delegations of authority, A-76/FAIR Act, Privacy Act requirements, records and forms management, organizational and functional analysis, NIH manual chapters, and guidance and oversight on the control and safeguarding of classified national security information.

- Office of Research Facilities Development and Operations (ORF) supports the advancement of NIH scientific and program priorities by planning, designing, constructing, managing, and maintaining state-of-the-science facilities critical to new and expanding research initiatives and the NIH mission. ORF is the single point of accountability for all NIH facility activities and is responsible for assisting the NIH Director with the formulation and execution of the Buildings and Facilities appropriation; developing and maintaining policies and standards governing the use of real property; planning and directing facility-related services such as master planning and construction, renovation, maintenance, and management of real property; providing centralized acquisition services for architecture, engineering, and construction contracting and for real property purchasing and leasing activities; and protecting the NIH environment.

- Office of Research Services (ORS) provides a comprehensive portfolio of services to support the biomedical research mission of the NIH. Some examples of the diverse services ORS provides include: laboratory safety, security and emergency response, veterinary resources, the NIH Library, events management, travel and transportation, services for foreign scientists, and programs to enrich and enhance the NIH worksite.

- Office of Strategic Management Planning (OSMP) provides assistance to the NIH leadership with the development and accomplishment of goals and strategic and technical plans for emerging and ongoing human capital programs; preparation of NIH programs and support activities to achieve the long-term goals of the NIH mission; and implementation, operation, and evaluation of key workforce programs. OSMP develops and accomplishes short- and long-range initiatives through an active and ongoing partnership with the staff of the NIH Office of Human Resources and other NIH components.

Office of the Ombudsman/Center for Cooperative Resolution
The NIH Office of the Ombudsman, Center for Cooperative Resolution provides the NIH community with confidential and informal assistance in resolving work-related conflicts, disputes and grievances; promotes fair and equitable treatment within NIH; offers effective, efficient and innovative dispute resolution services; helps people use non-adversarial approaches in resolving disputes; and works toward improving the overall quality of worklife at NIH.
PROGRAM COORDINATION

Program offices within the Office of the Director are responsible for encouraging and coordinating specific areas of research throughout NIH and for planning and supporting research and related activities. The program offices fund research through the NIH institutes and centers.

Office of AIDS Research (OAR)
The Office of AIDS Research formulates scientific policy, and recommends allocation of research resources, for AIDS research at NIH.

Office of Behavioral and Social Sciences Research (OBSSR)
The Office of Behavioral and Social Sciences Research advises the NIH Director and other key officials on matters relating to research on the role of human behaviors in the development of health, prevention of disease, and therapeutic intervention. Established by the U.S. Congress as part of the NIH Office of the Director, its mission is to stimulate behavioral and social sciences research throughout NIH and to integrate it more fully into the NIH research enterprise.

Office of Disease Prevention (ODP)
The Office of Disease Prevention coordinates the activities of disease prevention, rare diseases, dietary supplements, and medical applications of research, and advises the NIH Director and senior staff on related matters.

Office of Research on Women's Health (ORWH)
The Office of Research on Women's Health promotes, stimulates, and supports efforts to improve the health of women through biomedical and behavioral research. ORWH works in partnership with the NIH Institutes and Centers to ensure that women's health research is part of the scientific framework at NIH and throughout the scientific community.

This page last reviewed on April 6, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

The National Cancer Institute is the world's largest organization solely dedicated to cancer research.

NCI supports researchers at universities and hospitals across the United States and at NCI-Designated Cancer Centers, a network of facilities that not only study cancer in laboratories but also conduct research on the best ways to rapidly bring the fruits of scientific discovery to cancer patients.

In NCI's own laboratories—almost 5,000 principal investigators, from basic scientists to clinical researchers—conduct earliest phase clinical investigations of new agents and drugs. Recent advances in bioinformatics and the related explosion of technology for genomics and proteomics research are dramatically accelerating the rate for processing large amounts of information for cancer screening and diagnosis. The largest collaborative research activity is the Clinical Trials Program for testing interventions for preventing cancer, diagnostic tools, and cancer treatments, allowing access as early as possible to all who can benefit. NCI supports over 1,300 clinical trials a year, assisting more than 200,000 patients.

NCI's scientists also work collaboratively with extramural researchers to accelerate the development of state-of-the-art techniques and technologies. In addition to direct research funding, NCI offers the nation's cancer scientists a variety of useful research tools and services, including tissue samples, statistics on cancer incidence and mortality, bioinformatics tools for analyzing data, databases of genetic information, and resources through NCI-supported Cancer Centers, Centers of Research Excellence, and the Mouse Models of Human Cancer Consortium. NCI researchers are also seeking the causes of disparities among underserved groups and gaps in quality cancer care, helping to translate research results into better health for groups at high risk for cancer, including cancer survivors and the aging population.

As the leader of the National Cancer Program, NCI provides vision and leadership to the global cancer community, conducting and supporting international research, training, health information dissemination, and other programs. Timely communication of NCI scientific findings help people make better health choices and advise physicians about treatment options that are more targeted and less toxic.

Information about the NCI's research and activities is available through its Web site, http://cancer.gov.

IMPORTANT EVENTS IN NCI HISTORY

August 5, 1937—President Franklin D. Roosevelt signed the National Cancer Institute Act.

November 9, 1937—The National Advisory Cancer Council held its first meeting.


January 3, 1938—The National Advisory Cancer Council recommended approval of first awards for fellowships in cancer research.

August 1940—The Journal of the National Cancer Institute published its first issue.

July 1, 1946—The cancer control program was established with appropriations to the states for support of cancer control activities. Staff was organized into 6 sections: biology, biochemistry, biophysics, chemotherapy, epidemiology, and pathology.

July 1, 1947—NCI reorganized to provide an expanded program of intramural cancer research, cancer research grants, and cancer control activities.

November 13, 1947—The Research Grants and Fellowship Branch was established. It became the administrative arm of the Advisory Council.

October 1948—A grants program to medical, dental, and osteopathic schools was initiated for improvement of training in the field of cancer research, diagnosis, and treatment.

July 2, 1953—NCI inaugurated a full-scale clinical research program in the new Clinical Center.
April 1955—The Cancer Chemotherapy National Service Center was established in the institute to coordinate the first national, voluntary, cooperative cancer chemotherapy program.

1957—The first malignancy (choriocarcinoma) was cured with chemotherapy at NCI.

November 1959—The Journal of the National Cancer Institute inaugurated a series of occasional publications as Monographs to be used for in-depth scientific communications in specific subject areas.

September 13, 1960—The NCI director appointed an associate director for grants and training, associate director for field studies, and associate director for collaborative research.

January 12, 1961—The Laboratory of Viral Oncology was established to investigate the relationship of viruses to human cancer.

April 2, 1962—An exhibit, “Man Against Cancer,” opened in Washington, D.C., to commemorate the institute’s 25th anniversary and inaugurate Cancer Progress Year.

May 7, 1962—The Acute Leukemia Task Force held its first meeting. It focused the combined efforts and resources of scientists on studies of therapy of the acute leukemia patient, and was the forerunner of other task forces on specific forms of cancer.

October 25, 1962—The Human Cancer Virus Task Force held its first meeting. The task force, of scientists from NCI and other institutions, stimulated the development of special programs in viral oncology.

1963—Studies were initiated at NCI in Hodgkin’s disease with combination chemotherapy.

December 1964—The report of the President’s Commission on Heart Disease, Cancer, and Stroke was published.

January 11, 1966—NCI reorganized to coordinate related activities. Scientific directors oversaw three newly established scientific divisions: etiology, chemotherapy, and a group of discipline-oriented laboratories and branches referred to as general laboratories and clinics. Two associate directors were named for program and for extramural activities.

February 13, 1967—A cancer research center, USPHS Hospital, was established in Baltimore by the institute to conduct an integrated program of laboratory and clinical research.

April 27, 1970—At the request of Senator Ralph W. Yarborough, chairman of the Committee on Labor and Public Welfare, the Senate approved the establishment of the National Panel of Consultants on the Conquest of Cancer.

November 25, 1970—The national panel of consultants submitted to the Senate committee a report entitled “National Program for the Conquest of Cancer.”

October 18, 1971—President Nixon converted the Army’s former biological warfare facilities at Fort Detrick, Maryland, to house research activities on the causes, treatment, and prevention of cancer.


July 27, 1972—A Bureau-level organization was established for NCI, giving the institute and its components organizational status commensurate with the responsibilities bestowed on it by the National Cancer Act of 1971. Under the reorganization, NCI was composed of the Office of the Director and 4 divisions: Cancer Biology and Diagnosis, Cancer Cause and Prevention, Cancer Treatment, and Cancer Grants (renamed successively the Division of Cancer Research, Resources and Centers, and later the Division of Extramural Activities).

June 20, 1973—NCI director Dr. Frank J. Rauscher, Jr., announced that 8 institutions were recognized as Comprehensive Cancer Centers to bring results of research as rapidly as possible to a maximum number of people. Additional centers were announced on November 2, 1973; June 13, 1974; October 18, 1974; April 8, 1976; December 30, 1976; July 27, 1978; and March 2, 1979, increasing the number of Comprehensive Cancer Centers to 20. (In July 2000 there are 37.)

September 5, 1973—The President transmitted to Congress the first annual report of the director of the National Cancer Program, a 5-year strategic plan for the program, and the report of the National Cancer Advisory Board. Preparation and transmittal of the documents were mandated by the National Cancer Act of 1971.

September 10, 1974—The Division of Cancer Control and Rehabilitation was established to plan, direct, and coordinate an integrated program of cancer control and rehabilitation activities with the goal of identifying, testing, evaluating, demonstrating, communicating, and promoting the widespread use of available and new methods for reducing cancer incidence, morbidity, and mortality.

September 12, 1974—NCI made its first cancer control awards to state health departments for a 3-year program to screen low-income women for cancer of the uterine cervix. At its peak in 1978, the program had grown to a total of 32 states and territories.

December 17, 1974—NCI and the National Library of Medicine established CANCERLINE, a jointly developed computerized service to provide scientists across the country with information on cancer research projects and published findings.

December 19, 1974—The Clinical Cancer Education Program was announced to develop more innovative teaching methods in cancer prevention, diagnosis, treatment, and rehabilitation in schools of medicine, dentistry, osteopathy, and public health; affiliated teaching hospitals; and specialized cancer institutions.
1975—The Cooperative Minority Biomedical Program, as approved by the National Cancer Advisory Board, represented a cofunding effort by NCI to implement and foster cancer research through NIH's Division of Research Resources' Minority Biomedical Research Support Program and the NIGMS Minority Access to Research Careers Program.

July 1, 1975—The Cancer Information Service (CIS) was established on July 1, 1975, following the mandate of the National Cancer Act of 1971, which gave NCI new responsibilities for educating the public, patients, and health professionals.

August 5, 1977—NCI celebrated its 40th anniversary with a ceremony on the NIH campus. Senator Warren G. Magnuson of Washington who, as a member of the House of Representatives, introduced a bill to establish the NCI in 1937, sent a message stating: "Those one and a half million Americans who are alive today—are ample justification for all that we've appropriated over the last 40 years."

1979—The first human RNA virus (HTLV-I) was discovered by NCI's Dr. Robert C. Gallo.

July 18, 1979—NCI and the National Naval Medical Center, Bethesda, Md., signed an agreement to cooperate in a cancer research treatment program.

July 10, 1980—The U.S. Department of Health and Human Services (HHS) Secretary Patricia Roberts Harris approved institute-wide reorganization. A newly created Division of Resources, Centers, and Community Activities incorporated functions of the former Division of Cancer Control and Rehabilitation and programs for education, training, construction, cancer centers, and organ site research of the former Division of Cancer Research, Resources, and Centers (DCRRC). Other activities of the DCRRC were incorporated into the new Division of Extramural Activities.

April 27, 1981—A new Biological Response Modifiers Program was established in the Division of Cancer Treatment to investigate, develop and bring to clinical trials potential therapeutic agents that may alter biological responses that are important in the biology of cancer growth and metastasis.

September 1982—PDQ, a computerized database on cancer treatment information, became available nationwide via the National Library of Medicine's MEDLARS system.

December 16, 1982—NCI purchased what is now the R. A. Bloch International Cancer Information Center through generous donations to the NCI Gift Fund. This building houses the Journal of the National Cancer Institute; the Scientific Information Branch, which publishes Cancer Treatment Reports and Cancer Treatment Symposia; the International Cancer Research Data Bank; and PDQ.

July 16, 1983—NCI launched the Community Clinical Oncology Program (CCOP) to establish a cancer control effort that combines the expertise of community oncologists with NCI clinical research programs. The CCOP initiative is designed to bring the advantages of clinical research to cancer patients in their own communities.

September 1983—The Office of International Affairs was reorganized to add a Scientific Information Branch and a Computer Communications Branch. The Scientific Information Branch is composed of a literature research section, cancer treatment reports section, Journal of the National Cancer Institute section, and the international cancer research data bank section.

Community Clinical Oncology Program, an NCI resource that links community-based physicians with cooperative groups and cancer centers for participation in institute-approved clinical trials, was created.

December 5, 1983—The name of the Division of Cancer Cause and Prevention was changed to the Division of Cancer Etiology.

The Division of Resources, Centers and Community Activities was renamed the Division of Cancer Prevention and Control (DCPC) to emphasize the division's roles in cancer prevention and control research.

1984—A policy statement regarding the relationship of NCI, the pharmaceutical industry, and NCI-supported cooperative groups was developed. The statement articulates the need for collaboration between NCI and the pharmaceutical industry in pursuing the joint development of anticancer drugs of mutual interest. It also sets forth guidelines for the handling of issues such as the joint sponsorship of trials, the sharing of information between sponsors, maintaining the confidentiality of certain classes of data, the funding of cooperative groups by drug companies, the review of protocols, and the publication of results.

The Comprehensive Minority Biomedical Program, DEA, was established to widen the focus of the minority effort along lines of the programmatic thrusts of the institute, thereby giving it trans-NCI responsibilities.

The Cancer Control Science program was established in DCPC to develop programs in health promotion research and to stimulate widespread application of existing cancer control knowledge. Branches include health promotion sciences, cancer control applications and cancer training.

March 6, 1984—HHS Secretary Margaret M. Heckler launched a new cancer prevention awareness program by NCI to inform the public about cancer risks and steps individuals can take to reduce risk.

April 1984—An NCI scientist, Dr. Robert C. Gallo, reported the isolation of a new group of viruses found in the helper T-cells of patients with AIDS or pre-AIDS symptoms, as well as from healthy individuals at high risk for developing AIDS. These viruses were ultimately named human immunodeficiency virus or HIV. This discovery made the control of blood-product-transmitted AIDS feasible by enabling the development of a simple test for the detection of AIDS-infected blood by blood banks and diagnostic laboratories.

August 1985—The Cancer Prevention Fellowship Program, one of the first formal postdoctoral research training programs in cancer prevention, began.

November 10, 1986—The International Cancer Information Center was established in the Office of International Affairs, NCI Office of the Director.
May 1987—As part of NIHs centennial celebration year, NCI commemorated its 50th anniversary.

October 15, 1987—The DCPC established the Laboratory for Nutrition and Cancer Research with the basic nutrition science section and the clinical/metabolic human studies section.

October 24, 1987—The Office of Technology Development was established in the NCI Office of the Director as the institute's focal point for the implementation of pertinent legislation, rules and regulations, and the administration of activities relating to collaborative agreements, inventions, patents, royalties, and associated matters.

October 26, 1987—The DCT abolished the following branches, sections, and laboratory: the chromosome structure and function section in the Laboratory of Molecular Pharmacology; the Drug Evaluation Branch and its sections; the drug synthesis section and the acquisition section in the Drug Synthesis and Chemistry Branch; the fermentation section and the plant and animal products section in the Natural Products Branch; the chemical resources section, the analytical and product development section and the clinical products section in the Pharmaceutical Resources Branch; the Extramural Research and Resources Branch; and the Animal Genetics and Production Branch; the sections of the Information Technology Branch; the Laboratory of Experimental Therapeutics and Metabolism and its sections; the sections of the Laboratory of Pharmacology and Experimental Therapeutics.

The DCT changed the name of the Laboratory of Pharmacology and Experimental Therapeutics to the Laboratory of Biochemical Pharmacology. The division also established the Laboratory of Medicinal Chemistry, Pharmacology Branch, Biological Testing Branch, and Grants and Contracts Operations Branch.

1988—In DCT's Clinical Oncology Program, the Clinical Pharmacology Branch merged with the Medicine Branch.

The International Cancer Information Center established a separate office in the NCI Office of the Director.

January 1988—NCI journals Cancer Treatment Reports and Journal of the National Cancer Institute were consolidated into a biweekly Journal of the National Cancer Institute.

September 30, 1988—The first Consortium Cancer Center was established, comprised of three historically black medical schools. Component universities supported by this core grant—Charles R. Drew University of Medicine and Science in Los Angeles, Meharry Medical College in Nashville, and Morehouse School of Medicine in Atlanta—focus their efforts on cancer prevention, control, epidemiology, and clinical trials.

April 1989—The NCI-initiated mechanism of supplementing research grants to encourage recruitment of minority scientists and science students into extramural research laboratories is published as an NIH-wide extramural program announcement. This initiative will be expanded to cover science students and scientists who are women or persons with disabilities.

May 22, 1989—NCI scientist Dr. Steven A. Rosenberg conducted the first human gene transfer trial using human tumor-infiltrating lymphocytes to which a foreign gene has been added.

September 14, 1990—Scientists from NCI and NHLBI conducted the first trial in which a copy of a faulty gene was inserted into white blood cells to reverse the immune deficiency it causes. This was the first human gene therapy trial and adenosine deaminase deficiency was treated.

December 19, 1990—The institute began its year-long celebration of the 20th anniversary of the National Cancer Act by inaugurating a series of articles in the Journal of the National Cancer Institute. The series described the growth in knowledge that has occurred in cancer research since 1971.

January 29, 1991—The first human gene therapy to treat cancer was started. Patients with melanoma were treated with tumor-infiltrating lymphocytes to which a gene for tumor necrosis factor has been added.

September 24, 1991—Congress held a special hearing to commemorate the 20th anniversary of the National Cancer Act. Dr. Samuel A. Broder, NCI director, thanked Congress for its "consistent vision, leadership, and commitment to the goal of alleviating the death and suffering caused by cancer in this country."

October 1991—NCI began its Five-a-Day program, in partnership with the nonprofit group Produce for Better Health, to encourage Americans to eat at least 5 fruits and vegetables a day.

December 18, 1992—Taxol (paclitaxel), an anticancer drug extracted from the bark of the Pacific yew, received approval by the U.S. Food and Drug Administration (FDA) for the treatment of ovarian cancer that has failed other therapy. NCI spearheaded the development of the drug through collaboration with the USDA's Forest Service, the Department of the Interior's Bureau of Land Management, and Bristol-Myers Squibb Company, made possible by the Federal Technology Transfer Act of 1986.

November 1993—The Prostate, Lung, Colorectal, and Ovarian trial, designed to determine whether certain screening tests will reduce the number of deaths from these cancers, began recruiting 148,000 men and women, ages 55-74.

February 1995—The results of the Community Intervention Trial for Smoking Cessation were completed and published.

1995/1996—NCI leadership initiated a major reorganization, based on recommendations of the Ad Hoc Working Group of the National Cancer Advisory Board and NCI streamlining work groups and quality improvement teams. Two extramural divisions were created—the Division of Cancer Treatment, Diagnosis, and Centers and the Division of Cancer Biology. Two intramural divisions were also created—the Division of Basic Sciences and the Division of Clinical Sciences—and one combined intramural/extramural division—the Division of Cancer Epidemiology and Genetics. The Divisions of Cancer Prevention and Control and Extramural Activities remain a part of the NCI structure, but in the extramural program.
November 1996—Cancer mortality rates decline nearly 3% between 1991 and 1995, the first sustained decline since national record keeping was instituted in the 1930s.

1996—The NCI Office of Liaison Activities was established to ensure that advocates have input concerning NCI research and related activities. The office supports NCI’s research and programs by fostering strong communications and partnerships with the cancer advocacy community, professional societies, and Federal agencies.

August 1, 1997—NCI, in partnership with government, academic, and industrial laboratories, launched the Cancer Genome Anatomy Project with 2 overall goals: to enhance discovery of the acquired and inherited molecular changes in cancer and to evaluate the clinical potential of these discoveries. The project included a website allowing scientists to rapidly access data generated through the project and apply it to their studies.

October 1997—NCI reorganization continued, with the creation of the Division of Cancer Prevention and the Division of Cancer Control and Population Sciences from the former Division of Cancer Prevention and Control and the extramural component of the Division of Cancer Epidemiology and Genetics.

1997—The NCI Director’s Consumer Liaison Group was established to advise and provide recommendations to the NCI Director from the perspective and viewpoint of cancer advocates on a wide variety of issues, programs, and research priorities and to maintain strong collaborations between NCI and the advocacy community.

March 1998—Cancer incidence rates showed first sustained decline since NCI began keeping records in 1973. The rates dropped 0.7% per year from 1990 to 1995. Cancer mortality rates continued to decline.

April 6, 1998—Results of the Breast Cancer Prevention Trial, testing the effectiveness of tamoxifen to prevent the disease, were announced 14 months earlier than expected: women taking tamoxifen had 45% fewer breast cancer diagnoses than women on the placebo, proving that breast cancer can be prevented. Rare but serious side effects—endometrial cancer and blood clots—were shown to occur in some postmenopausal women on tamoxifen. A study to compare tamoxifen to another, potentially less toxic drug was planned for fall 1998.

September 25, 1998—The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for the treatment of metastatic breast cancer in patients with tumors that produce excess amounts of a protein called HER-2. (Approximately 30% of breast cancer tumors produce excess amounts of HER-2.)

May 25, 1999—The Study of Tamoxifen and Raloxifene, or STAR, one of the largest breast cancer prevention studies ever, began recruiting volunteers at more than 400 centers across the United States, Puerto Rico, and Canada. The trial will include 22,000 postmenopausal women at increased risk of breast cancer to determine whether the osteoporosis prevention drug raloxifene (Evista) is as effective in reducing the chance of developing breast cancer as tamoxifen (Nolvadex) has proven to be.

October 6, 1999—NCI awarded nearly $8 million in grants toward the creation of the Early Detection Research Network, a network to discover and develop new biological tests for the early detection of cancer and of biomarkers for increased cancer risk. The awards created 18 Biomarker Developmental Laboratories to identify, characterize, and refine techniques for finding molecular, genetic, and biologic early warning signals of cancer.

December 8, 1999—The National Cancer Institute published the new Atlas of Cancer Mortality, 1950-94, showing the geographic patterns of cancer death rates in over 3,000 counties across the country over more than 4 decades. This atlas updated the first atlas, published in 1975. The 254 color-coded maps in the atlas made it easy for researchers and state health departments to identify places where high or low rates occur. For the first time, maps were presented for both white and black populations. An interactive version of the data was made available on the Internet for the first time, as well.

April 6, 2000—A $60 million program was announced to address the unequal burden of cancer within certain special populations in the United States over the next 5 years. The Special Populations Networks for Cancer Awareness Research and Training were intended to build relationships between large research institutions and community-based programs. Eighteen grants at 17 institutions were expected to create or implement cancer control, prevention, research, and training programs in minority and underserved populations. The cooperative relationships established by the Networks fostered cancer awareness activities, supported minority enrollment in clinical trials, and encouraged and promoted the development of minority junior biomedical researchers.

June 7, 2000—President Clinton issued an executive memorandum directing the Medicare program to reimburse providers for the cost of routine patient care in clinical trials. The memorandum also provides for additional actions to promote the participation of Medicare beneficiaries in clinical studies.

December 3, 2000—NCI established the Center to Reduce Cancer Health Disparities. The Center absorbed the former Office of Special Populations Research. The NCI Strategic Plan to Reduce Health Disparities is part of a major national commitment to identify and address the underlying causes of disease and disability in racial and ethnic communities. Because these communities carry an unequal burden of cancer-related health disparities, NCI is working to enhance its research, education, and training programs that focus on populations in need.

January 12, 2001—NCI announced the creation of the Center for Cancer Research, merging 2 intramural divisions at NCI—the Division of Basic Sciences and the Division of Clinical Sciences—to provide greater opportunities to translate fundamental research into pioneering clinical research and molecular medicine.

May 10, 2001—The Food and Drug Administration announced its approval of the drug Gleevec, also known as STI571, as an oral treatment for chronic myelogenous leukemia (CML). This marked the approval of the first molecularly targeted drug that directly turns off the signal of a protein known to cause a cancer. Clinical trials are continuing as clinical investigators test Gleevec in a variety of cancers that share common molecular abnormalities.

July 4, 2001—The largest-ever prostate cancer prevention study was launched by the NCI and a network of researchers known as the Southwest Oncology Group (SWOG). The Selenium and Vitamin E Cancer Prevention Trial, or SELECT, was designed to determine if these 2 dietary supplements can protect against prostate cancer, the most common form of cancer, after skin cancer, in men. The study was expected to include a total of 32,400 men.

September 4, 2001—NCI and the American College of Radiology Imaging Network (ACRIN) launched the first large, multicenter study to compare digital mammography to standard mammography for the detection of breast cancer.
September 10, 2001—NCI launched the Consumer Advocates in Research and Related Activities (CARRA) program—a landmark initiative convening a large network of dedicated advocates who bring the viewpoint of those affected by cancer to NCI. NCI staff, including researchers and scientists, are able to rely on the CARRA network of more than 200 advocates to give insight and feedback from the consumer's perspective to their developing programs.

February 7, 2002—Scientists from NCI and FDA reported that patterns of proteins found in patients' serum may reflect the presence of ovarian cancer, even at early stages. Currently, more than 80% of ovarian cancer patients are diagnosed at a late clinical stage and have a 20% or less chance of survival at 5 years. This new diagnostic concept is potentially applicable to the diagnosis of other diseases.

May 19, 2002—Researchers from NCI reported that the molecularly targeted drug bevacizumab slowed tumor growth in patients with metastatic renal cell carcinoma, the most common form of kidney cancer in adults.

June 19, 2002—NCI scientists used microarray technology to determine the patterns of genes that are active in tumor cells from which they were able to predict whether patients with the most common form of non-Hodgkin's lymphoma in adults are likely to be cured by chemotherapy. Trials designed to correlate clinical results with molecular data will allow researchers to identify drugs that are effective in subgroups of cancer patients, an approach that has already proven effective in finding new agents to treat breast cancer and leukemia.

July 16, 2002—An NCI-funded trial showed that postmenopausal women who used estrogen replacement therapy for 10 or more years were at significantly higher risk of developing ovarian cancer than women who never used hormone replacement therapy. The relative risk for 10 to 19 years of use was 80% higher risk than non-users, and increased to a 220% higher risk than non-users for women who took estrogen for 20 or more years.

September 18, 2002—NCI launched the National Lung Screening Trial to compare 2 ways of testing for early lung cancer in current and former heavy smokers: spiral computed tomography and single-view chest x-ray. Both spiral CT scans and chest x-rays have been used in clinical practice to detect lung cancer in asymptomatic individuals, but scientific evidence is inconclusive as to whether screening for lung cancer with either method will reduce lung cancer mortality. The trial will examine the relative risks and benefits of both tests in 50,000 current and former smokers at 30 study sites throughout the United States.

September 19, 2002—A new approach to cancer treatment that replaces a patient's immune system with cancer-fighting cells can lead to tumor shrinkage. NCI researchers demonstrated that immune cells, activated in the laboratory against patients' tumors and then administered to those patients, could attack cancer cells in the body. The experimental technique, known as adoptive transfer, has shown promising results in patients with metastatic melanoma who have not responded to standard treatment.

October 16, 2002—Patterns of proteins found in patients' blood may help distinguish between prostate cancer and benign conditions, according to scientists from NCI and FDA. The technique, which relies on a simple test using a drop of blood, may be useful in deciding whether to perform a biopsy in men with elevated levels of prostate specific antigen (PSA).

October 31, 2002—NCI researchers have discovered that a molecule best known for its antimicrobial properties also has the ability to activate key cells in the immune response. This newly discovered function suggests the molecule, a peptide called ß-defensin 2, may be useful in the development of more effective cancer vaccines.

December 12, 2002—A new clinical trial has shown that reducing the interval between successive doses of a commonly used chemotherapy regimen improves survival in women whose breast cancer has spread to the lymph nodes. While previous research has evaluated the use of various forms of "dose dense" chemotherapy, this is the first major controlled study to show a clear survival benefit for women with node-positive breast cancer.

2003—A novel approach to treatment of solid cancers involves therapeutic agents that inhibit the generation of new blood vessels in growing tumors (angiogenesis). The evidence linking tumor growth and metastases with angiogenesis is compelling: in colorectal and breast cancers, the density of microvessels in histologic specimens has been correlated with disease recurrence, metastases, and survival. Of the identified angiogenic factors, vascular endothelial growth factor has been shown to be the most potent and specific.

March 5, 2003—Taking daily aspirin for as little as 3 years was shown to reduce the development of colorectal polyps by 19% to 35% in people at high risk for colorectal cancer in 2 randomized, controlled NCI clinical trials published in the New England Journal of Medicine.

April 24, 2003—NCI, CDC, AHRQ, and SAMHSA, in collaboration with the American Cancer Society, launched the Cancer Control PLANET (Plan, Link, Act, Network with Evidence-based Tools), a web portal providing access to regularly updated cancer surveillance data and program resources including cancer control interventions. PLANET is designed to also help state- and community-based planners, program staff, and researchers develop, implement, and evaluate evidence-based cancer control programs. The portal is accompanied by in-person technical support meetings with state and regional public and private sector partnership staff who are working together to use PLANET resources for comprehensive cancer control. (Visit http://cancercontrolplanet.cancer.gov/ for more information.)

May 30, 2003—Under an agreement between FDA and NCI, the 2 agencies, overseen by an Interagency Oncology Task Force, will share knowledge and resources to facilitate the development of new cancer drugs and speed their delivery to patients.

June 24, 2003—Results of the Prostate Cancer Prevention Trial, testing the effectiveness of finasteride to prevent the disease, were announced about a year earlier than expected. Men taking finasteride had 25% fewer prostate cancer diagnoses than men on the placebo, proving that prostate cancer can be prevented. There was a note of caution, however; the men who did develop prostate cancer while taking finasteride were more likely to have high-grade tumors.

July 1, 2003—Data from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial gave fresh insight into the appropriate screening intervals for colorectal cancer after a negative exam. This was the largest study to date of repeat sigmoidoscopy screening after an exam. In 2003 the accepted interval for sigmoidoscopy, a technique in which the rectum and lower colon are examined with a lighted instrument called a sigmoidoscope, was 5 years after a negative exam. This recommendation was based primarily on indirect evidence. Exactly how often to repeat sigmoidoscopy is an evolving field of research. It was unclear...
whether data from this study, which measured the incidence of growths or polyps 3 years after an initial exam, might play a role in changing the recommended 5-year interval.

**September 2, 2003**—Death rates from the 3 most common cancers—lung, breast, and prostate—continued to decline in the late 1990s according to data from the “Annual Report to the Nation on the Status of Cancer, 1975-2000.”

October 9, 2003—A Canadian-led international clinical trial found that post-menopausal survivors of early-stage breast cancer who took the drug letrozole after completing an initial 5 years of tamoxifen therapy had a significantly reduced risk of cancer recurrence compared to women taking a placebo. The clinical trial had been halted early because of the positive results.

**November 6, 2003**—NCI scientists demonstrated that the growth factors interleukin-2 (IL-2) and IL-15 have contrasting roles in the life and death of lymphocytes, an observation that has implications for the immunotherapy of cancer and autoimmune diseases.

**June 3, 2004**—NCI’s Annual Report to the Nation found cancer incidence and death rates on the decline as survival rates showed significant improvement. Overall, cancer death rates for all racial and ethnic populations combined declined by 1.1% per year from 1993 to 2001 and also declined for many of the top 15 cancers in both men and women. Lung cancer death rates among women leveled off for the first time between 1995 and 2001 after increasing continuously for many decades.

**July 16, 2004**—An NCI Phase I clinical trial is underway to test the safety and efficacy of BMS-354825 in chronic myeloid leukemia patients with imatinib resistance. The effectiveness of imatinib (Gleevec), a small-molecule drug that inhibits the aberrant activity of the BCR-ABL protein tyrosine kinase, has been limited due to the problem of drug resistance. BMS-354825, a closely related drug, overcomes much of this resistance.

**September 13, 2004**—NCI announced the Alliance for Nanotechnology in Cancer, a 5-year initiative to integrate nanotechnology development into basic and applied cancer research to facilitate the rapid application of this science to the clinic. The initiative was designed to support the development of nanomaterials and nanoscale devices for molecular imaging and early detection, reporters of efficacy, and multifunctional therapeutics to combat the cancer process.

**November 18, 2004**—Scientists at NCI have created a model that predicts the survival of 191 follicular lymphoma patients based on the molecular characteristics of their tumors at diagnosis. The model is based on 2 sets of genes—called survival-associated signatures. Understanding the molecular causes of such differences in survival could provide a more accurate method to determine patient risk, which could be used to guide treatment and may suggest new therapeutic approaches.

**December 10, 2004**—An NCI study determined that a new molecular test can predict the risk of breast cancer recurrence and may identify women who will benefit most from chemotherapy. The test is based on levels of expression (increased or decreased) of a panel of cancer-related genes that is used to predict whether estrogen-dependent breast cancer will come back.

**February 16, 2005**—In preparation for the new generation of molecular-based oncology medical products, NCI and FDA established an NCI-FDA Research and Regulatory Review Fellowship program. The program is designed to train a cadre of researchers to bridge the processes from scientific discovery through clinical development and regulatory review of new oncology products. The new generation of targeted therapies and diagnostic products will demand new skills and processes that must be incorporated into the current research and regulatory system. The NCI-FDA fellowship program represents an innovative and collaborative approach to that objective. The NCI-FDA Research and Regulatory Fellowship program is an initiative of NCI’s and FDA’s Interagency Oncology Task Force (IOTF), a major collaboration between the 2 agencies. The IOTF was established in recognition of the fact that cross-fertilization between the NCI and FDA is critical for developing the knowledge base necessary to bring new, molecular-based therapies and diagnostics into the clinical practice of oncology.


**April 12, 2005**—NCI announced the creation of the cancer Biomedical Informatics Grid™. The program brings together open source, open access tools, applications, data and standards developed by the cabIG™ community to accelerate cancer research, prevention and care. cabIG™ provides the foundational infrastructure and specific applications to create a World Wide Web of cancer research. Over 800 individuals from NCI-designated Cancer Centers and other organizations (more than 80 organizations in all) are participating. https://cabig.nci.nih.gov

**April 25, 2005**—The combination of the targeted agent trastuzumab (Herceptin) and standard chemotherapy cuts the risk of HER-2-positive breast cancer recurrence by more than half compared with chemotherapy alone. The result comes from two large, NCI-sponsored, randomized trials testing, as adjuvant therapy, a trastuzumab/chemotherapy combination against chemotherapy alone in women with invasive, early stage, HER-2 positive breast cancer. For women with this type of aggressive breast cancer, the addition of trastuzumab to chemotherapy appears to virtually reverse prognosis from unfavorable to good.

**May 6, 2005**—NCI announced the Community Networks Program (CNP), a 5-year initiative to reduce cancer disparities in minority and underserved populations through community participation in education, research and training. Building upon the work of the previous Special Populations Networks, the CNP aims to improve access to and utilization of beneficial cancer interventions and treatments in communities experiencing cancer health disparities. For more information, see http://crchd.nci.nih.gov

**September/October 2005**—NCI implemented major components of its $144.3 million 5-year initiative for nanotechnology in cancer research. First-year awards totaling $26.3 million were expected to help establish 7 Centers of Cancer Nanotechnology Excellence (CCNEs). Each of the CCNE awardees is associated with 1 or more NCI-designated cancer centers, affiliated with schools of engineering and physical sciences, and partnered with not-for-profit organizations and/or private sector firms, with the specific intent of advancing the technologies being developed. In addition NCI funded awards totaling $35 million over five years to establish 12 Cancer Nanotechnology Platform Partnerships. The National Cancer Institute and the National Science Foundation launched a collaboration to establish integrative training environments for U.S. science and engineering doctoral students to focus on interdisciplinary nanoscience and technology research with applications to cancer. Through this partnership, $12.8 million in grants are being awarded to four institutions over the next 5 years. These advances are part of the NCI Alliance for Nanotechnology in Cancer, launched in September 2004 as a comprehensive, integrated initiative to develop and translate cancer-related nanotechnology research into clinical practice. http://nano.cancer.gov
The Patient Navigator Research Program (PNRP), an NCI initiative, was underway to assess the impact of patient navigators on providing timely and quality standard cancer care to patients following an abnormal cancer finding. The PNRP was designed to encourage research collaborations and partnerships with organizations serving diverse underserved communities within cancer care delivery systems.


October 11, 2005—NCI announced the Transdisciplinary Research on Energetics and Cancer (TREC) initiative to study the effects of diet, weight, and physical activity on cancer and to answer critical questions to help guide our nation's public health efforts. The TREC initiative was one of many NIH-funded programs designed to understand and reduce the increasing prevalence of overweight and obesity in the United States.

October 2005—The Patient Navigator Research Program (PNRP), an NCI initiative, was underway to assess the impact of patient navigators on providing timely and quality standard cancer care to patients following an abnormal cancer finding. The PNRP was designed to encourage research collaborations and partnerships with organizations serving diverse underserved communities within cancer care delivery systems.

November 7, 2005—NCI launched a cancer biorepository pilot project designed to standardize biospecimen collection and management among investigators of the NCI's prostate cancer Specialized Programs of Research Excellence. The project was expected to enhance the quality and availability of various biospecimens and associated data for the broader scientific community. This year, NCI established the Office of Biorepositories and Biospecimen Research (OBBR) in recognition of the critical role of biospecimens to an understanding of disease at the molecular level, and the OBBR has issues its First Generation Guidelines for NCI-Supported Biorepositories.

December 7, 2005—Results from several studies presented at the San Antonio Breast Cancer Symposium validated that a new test can predict the risk of breast cancer recurrence in a sizable group of patients. The studies also appeared to identify which of those patients might benefit most from chemotherapy. The studies were heralded by researchers as an important moment in the move toward individualized cancer care. Central to the investigations was a test, Oncotype DX, that analyzed the expression of a 21-gene panel in biopsy samples from women with estrogen-dependent, lymph-node negative breast cancer, which accounts for more than 50,000 breast cancer cases in the United States each year.

December 13, 2005—NCI and the National Human Genome Research Institute (NHGRI) launched a comprehensive effort to accelerate an understanding of the molecular basis of cancer through the application of genome analysis technologies, especially large-scale genome sequencing. The overall effort, called The Cancer Genome Atlas (TCGA), began with a pilot project to determine the feasibility of a full-scale effort to systematically explore the universe of genomic changes involved in all types of human cancer. NCI and NHGRI each committed $50 million over 3 years to the TCGA Pilot Project. The project was expected to develop and test the complex science and technology framework needed to systematically identify and characterize the genetic mutations and other genomic changes associated with cancer.


April 17, 2006—Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer—Initial results of the Study of Tamoxifen and Raloxifene, or STAR, show that the drug raloxifene, currently used to prevent and treat osteoporosis in postmenopausal women, works as well as tamoxifen in reducing breast cancer risk for postmenopausal women at increased risk of the disease.

May 23, 2006—Personalized Treatment Trial for Breast Cancer Launched—The Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, was launched on May 23, 2006, to examine whether genes that are frequently associated with risk of recurrence for women with early-stage breast cancer can be used to assign patients to the most appropriate and effective treatment.

June 7, 2006—Gene Expression Profiling Can Accurately Diagnose Burkitt's Lymphoma—Gene profiling, a molecular technique that examines many genes simultaneously, can accurately distinguish between two types of immune cell tumors, Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL). Burkitt's lymphoma and DLBCL appear similar when viewed under a microscope but correct diagnosis is critical because each requires very different treatments.

June 8, 2006—Statement from NCI on FDA Approval of the HPV Vaccine—Nearly 2 decades ago, researchers at NCI and other institutions began searching for the underlying causes of cervical cancer. That scientific quest led to today's FDA approval of the vaccine Gardasil, which protects against infection from the 2 types of human papillomavirus (HPV) that cause the majority of cervical cancers worldwide.
June 29, 2006—Scientists Identify an Inherited Gene That Strongly Affects Risk for the Most Common Form of Melanoma
[http://www.cancer.gov/newscenter/pressreleases/MelanomaGenetics]—Researchers at NCI have identified a link between inherited and acquired genetic factors that dramatically increase the chance of developing a very common type of melanoma. This finding appeared in an online version of Science on June 29, 2006.

August 14, 2006—Researchers Discover a Unique Pattern of Gene Activity That Can Predict Liver Cancer Spread
[http://www.cancer.gov/newscenter/pressreleases/LiverMets]—Researchers have found that a unique pattern of activity for genes in cells located in the tissue surrounding a liver tumor can accurately predict whether the cancer will spread to other parts of the liver or to other parts of the body.

August/September 2006—NCI researchers developed a new model for estimating the 5-year risk of melanoma. The model can be used by health professionals to identify individuals at increased risk of melanoma through routine office visits and help them plan for potential interventions. Also available is the Breast Cancer Risk Assessment Tool, a computer program developed by scientists at NCI and the National Surgical Adjuvant Breast and Bowel Project. This model allows a health professional to estimate a woman's individual breast cancer risk over a 5-year period and over her lifetime and compares her risk calculation with the average risk for a woman of the same age. [http://www.cancer.gov/melanomarisktool/; http://www.cancer.gov/bcrisktool/]

September 6, 2006—Annual Report to the Nation Finds Cancer Death Rates Continue to Drop; Lower Cancer Rates Observed in U.S. Latino Populations

September 27, 2006—NCI Creates Network of Clinical Proteomic Technology Centers for Cancer Research
[http://www.cancer.gov/newscenter/pressreleases/CPTACTeamsrelease]—NCI announced awards totaling $35.5 million over 5 years to establish a collaborative network of 5 Clinical Proteomic Technology Assessment for Cancer Teams.

October 2, 2006—NCI Scientists Identify Novel Protein That Ties Disruption of a Critical Cellular Pathway to Birt-Hogg-Dubé Syndrome
[http://www.cancer.gov/newscenter/pressreleases/BirtHoggDube]—Researchers at NCI have linked specific genetic mutations to defects in cells that lead to a rare disease known as Birt-Hogg-Dubé syndrome. The researchers discovered a novel protein that binds to the normal version, but not the mutant version, of the protein implicated in Birt-Hogg-Dubé syndrome.

October 5, 2006—The Biomarkers Consortium—The Foundation for the National Institutes of Health, NIH, FDA, and the Pharmaceutical Research and Manufacturers of America, a public-private biomedical research partnership, formed The Biomarkers Consortium to search for and validate new biomarkers to accelerate the delivery of new technologies, medicines, and therapies for prevention, early detection, diagnosis, and treatment of disease. The first projects, to be undertaken by NCI, will be 2 clinical trials, one in non-Hodgkin lymphoma and one in lung cancer.

October 16, 2006—NIH Announces 2 Integral Components of The Cancer Genome Atlas Pilot Project
[http://www.cancer.gov/newscenter/pressreleases/GCCCs-DCC]—The Cancer Genome Atlas program, created by NCI and the National Human Genome Research Institute (NHGRI), will accelerate understanding of the molecular basis of cancer through the application of genome analysis technologies. NIH today announced another 2 of the components of The Cancer Genome Atlas (TCGA) Pilot Project, a 3-year, $100 million collaboration to test the feasibility of using large-scale genome analysis technologies to identify important genetic changes involved in cancer. Lung, brain (glioblastoma), and ovarian cancers were chosen as the tumors for study by TCGA Pilot Project.

October 18, 2006—NCI Releases Preliminary Data on Genetic Susceptibility for Prostate Cancer
[http://www.cancer.gov/newscenter/pressreleases/CGEMSDataRelease]—NCI released new data from the Cancer Genetic Markers of Susceptibility (CGEMS) study on prostate cancer. This information could help identify genetic factors that influence the disease and will be integral to the discovery and development of new, targeted therapies. This was the first public release of a whole-genome association study of cancer—such studies examine the entire genome, with no assumptions about which genetic alterations cause cancer.

November 2006—NCI's National Community Cancer Centers Program (NCCCP) Pilot will examine the concept of providing a comprehensive approach to cancer care for all patients in local communities through a pilot initiative scheduled to launch in early 2007. The NCCCP seeks to improve cancer care in local communities by: increasing participation in early phase clinical trials, reducing cancer health disparities, and improving overall access to prevention, screening and treatment services. The pilot program will also provide the value of a computer-based knowledge exchange network that could be used to support the work of the community sites, giving them an effective way to share findings, best practices, and other information to advance the goals and improve the NCCCP model. The pilot program will be conducted at approximately 6 community sites over a period of 3 years.

March 28, 2007—MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
[http://www.cancer.gov/newscenter/pressreleases/MRIContralateralRelease]—Magnetic Resonance Imaging (MRI) scans of women who were diagnosed with cancer in one breast detected over 90% of cancers in the other breast that were missed by mammography and clinical breast exam at initial diagnosis, according to a new study. Given the established rates of mammography and clinical breast exams for detecting cancer in the opposite, or contralateral breast, adding an MRI scan to the diagnostic evaluation effectively doubled the number of cancers identified in these women.

April 1, 2007—NCI Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
[http://www.cancer.gov/newscenter/pressreleases/CGEMSProstate]—Researchers reported that a variation in a portion of DNA strongly predicts prostate cancer risk and that this common variation may be responsible for up to 20% of prostate cancer cases in white men in the United States. Researchers are scanning the entire human genome to identify common, inherited gene mutations that increase the risks for breast and prostate cancers.

April 18, 2007—Decrease in Breast Cancer Rates Related to Reduction in Use of Hormone Replacement Therapy
May 8, 2007—Risk of Lymphoma Increases with Hepatitis C Virus Infection [http://www.cancer.gov/newscenter/pressreleases/HepClymphomaRelease]—People infected with the hepatitis C virus (HCV) are at an increased risk of developing certain lymphomas (cancers of the lymphatic system). Researchers found that HCV infection increased the risk of developing non-Hodgkin's lymphoma by 20% to 30%. The risk of developing Waldenström's macroglobulinemia (a rare type of non-Hodgkin's lymphoma) went up by 300% and the risk for cryoglobulinemia, a form of blood vessel inflammation, was also elevated for those with HCV infections.

June 14, 2007—NCI Launches a Pilot of its Community Cancer Centers Program to Bring Quality Cancer Care to All [http://www.cancer.gov/newscenter/pressreleases/NCCCPilot]—NCI today launched the 3-year pilot phase of a new program that will help bring state-of-the-art cancer care to patients in community hospitals across the United States. The NCI Community Cancer Centers Program (NCCCP) was designed to encourage the collaboration of private-practice medical, surgical, and radiation oncologist—with close links to NCI research and to the network of 63 NCI-designated Cancer Centers principally based at large research universities.

October 2, 2007—National Cancer Institute Symposium Showcases HIV/AIDS Research and Introduces a New Center of Excellence in HIV/AIDS and Cancer Virology [http://www.cancer.gov/newscenter/pressreleases/HIVAIDSSymposium]—NCI held a symposium to showcase several important historic achievements in HIV/AIDS research made by former and current NCI scientists, introduce a new Center of Excellence for HIV/AIDS and cancer virology, and discuss new directions in the continuing effort to combat HIV infection, the devastating consequences of AIDS, and AIDS-related cancers.


November 27, 2007—More Accurate Method of Estimating Invasive Breast Cancer Risk in African American Women Developed [http://www.cancer.gov/newscenter/pressreleases/CARErelease]—A new model for calculating invasive breast cancer risk, called the CARE model, was found to give better estimates of the number of breast cancers that would develop in African American women 50 to 79 years of age than an earlier model which was based primarily on data from white women.

January 2008—Low-Dose Drug Combination Cuts Risk of Colon Polyp Recurrence—Scientists reported that results of a randomized phase III clinical trial show that a combination of low oral doses of difluoromethylornithine and sulindac greatly reduces the recurrence of colon polyps and is safe and well tolerated.

February 10, 2008—Researchers Discover Common Variations in Gene Segments that Increase the Risk for Prostate Cancer [http://www.cancer.gov/newscenter/pressreleases/CGEMSprostateUpdate]—NCI scientists and their colleagues reported that a set of genetic variations in at least 4 regions of DNA strongly predicts prostate cancer risk and that these variations may be responsible for a large number of prostate cancer cases in white men in the United States.

March 2, 2008—Changes in Adult Stem Cells May Underlie Rare Genetic Disease Associated with Accelerated Aging [http://www.cancer.gov/newscenter/pressreleases/ProgerinNatureMisteli]—Adult stem cells may provide an explanation for the cause of a Hutchinson-Gilford Progeria Syndrome (HGPS), a rare disease that causes premature aging in children.

March 6, 2008—Studying Mutations in Non-Hodgkin Lymphoma Yields Clues for Potential New Therapies [http://www.cancer.gov/newscenter/pressreleases/CARD11Staudt]—DNA mutations found in a type of non-Hodgkin lymphoma that has a poor prognosis has led researchers to a better understanding of how the cancer develops and how it might be treated.

April 21, 2008—Mouse Studies Identify Gene that May Influence Metastasis Risk in Breast Cancer [http://www.cancer.gov/newscenter/pressreleases/Brd4BreastCancerHunter]—Researchers identified a pattern of gene activity in mice that may help to predict individual risk for breast cancer metastasis and survival in humans. A single gene called bromodomain 4 (Brd4) regulates the expression of this pattern, also called a signature. The researchers found that one result of this Brd4 regulation is the suppression of tumor growth and metastasis in a mouse model of cancer.

May 2008—Chromosome Region Linked to Lung Cancer—In a genome-wide association scan of tag SNPs, researchers identified a susceptibility locus for lung cancer that suggests a direct role for nicotine in the onset and /or growth of lung cancer in people with the SNPs, should these individuals choose to smoke. This information could lead to improved assessment tools for preventive approaches.

June 23, 2008—Blocking a Single Protein Proves Toxic to Myeloma Cells in Laboratory Studies [http://www.cancer.gov/newscenter/pressreleases/myelomaproteinstaudt]—NCI researchers found that cells from a blood-borne cancer called multiple myeloma rely on the activity of a single protein, IRF4, for the activation of a wide range of genes responsible for cell survival and spread. Blocking the production of this protein can be strikingly effective in eliminating cancer cells in laboratory models of multiple myeloma.

September 4, 2008—The Cancer Genome Atlas Reports First Results of Comprehensive Study of Brain Tumors [http://www.cancer.gov/newscenter/pressreleases/TCGAglioblastoma]—This large-scale, comprehensive study examines the most common form of brain cancer, glioblastoma.

September 14, 2008—Study Provides Clues about How Cancer Cells Develop Resistance to Chemotherapy Drug [http://www.cancer.gov/newscenter/pressreleases/CisplatinResistanceGottesman]—NCI Researchers and colleagues have shown that increased expression of a gene called SIRT1 in cancer cells plays a significant role in the development of resistance to the chemotherapy drug cisplatin.

January 1, 2009—Gene Abnormality Found To Predict Childhood Leukemia Relapse [http://www.cancer.gov/newscenter/pressreleases/ALLTARGET]—Scientists have identified mutations in a gene that predict a high likelihood of relapse in children with acute lymphoblastic leukemia (ALL). Although further research is needed, the findings are likely to provide the basis for future diagnostic tests to assess the risk of treatment failure. By using a molecular test to identify this genetic marker in ALL patients, physicians should be able to assign patients to appropriate therapies.
Researchers Find Abnormal Cells in the Blood Years before Leukemia is Diagnosed

Researchers have shown that abnormal white blood cells can be present in patients' blood more than six years prior to the diagnosis of a chronic form of lymphocytic leukemia. This finding may lead to a better understanding of the cellular changes that characterize the earliest stages of the disease and how it progresses.

U.S. Cancer Screening Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening

Six annual screenings for prostate cancer led to more diagnoses of the disease, but no fewer prostate cancer deaths, according to a major new report from the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a 17-year project of the NCI. The PLCO was designed to provide answers about the effectiveness of prostate cancer screening.

Genetic Variant Associated with Resistance to Chemotherapy Drug in Women with Breast Cancer

Researchers have found links between an individual's genetics and their response to treatment with chemotherapy. The findings, by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and colleagues, show how a genetic variation, located in the SOD2 gene, may affect how a person responds to the chemotherapy drug cyclophosphamide. Cyclophosphamide is used in the treatment of breast and other cancers.

Cancer Drug Decreases Recurrence of Gastrointestinal Stromal Tumors

Results of a randomized phase III clinical trial show that targeted therapy with the drug imatinib mesylate (Gleevec) reduces disease recurrence following surgery to remove a localized gastrointestinal stromal tumor. (NOTE: preliminary results were first released in 2007, when the trial was stopped, but they were not published until 2009.)

Gene Duplication Identified in an Uncommon Form of Bone Cancer

Scientists have discovered that a familial form of a rare bone cancer called chordoma is explained not by typical types of changes or mutations in the sequence of DNA in a gene, but rather by the presence of a second copy of an entire gene. Inherited large structural changes, known as copy number variations (CNVs), have been implicated in some hereditary diseases but have seldom been reported as the underlying basis for a familial cancer.

Gene Mutation Linked to Type of Childhood Cancer

Researchers have identified a gene that may play a role in the growth and spread of a childhood cancer called rhabdomyosarcoma, which develops in the body's soft tissues. The finding has revealed a potential new target for the treatment of this disease.

Short Strand of RNA May Help Predict Survival and Response to Treatment for Patients with Liver Cancer

A small RNA molecule, known as a microRNA, may help physicians identify liver cancer patients who, in spite of their poor prognosis, could respond well to treatment with a biological agent called interferon. The finding, by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, and their partners at Fudan University, Shanghai, and the University of Hong Kong in China and at Ohio State University, Columbus, appeared in the Oct. 8, 2009, issue of The New England Journal of Medicine.

Researchers Find Abnormal Cells in the Blood Years before Leukemia is Diagnosed

NCI LEGISLATIVE CHRONOLOGY

Senator M. M. Neely, of West Virginia, introduced Senate Bill 3558 to authorize the National Academy of Sciences to investigate the means and methods for affording Federal aid in discovering a cure for cancer and for other purposes.

Senator M. M. Neely introduced Senate Bill 3554 to authorize the National Academy of Sciences to investigate the means and methods for affording Federal aid in discovering a cure for cancer and for other purposes.

Senator W. J. Harris, Georgia, introduced Senate Bill 466 to authorize the Public Health Service and the National Academy of Sciences jointly to investigate the means and methods for affording Federal aid in discovering a cure for cancer and for other purposes.

Senator W. J. Harris introduced Senate Bill 4531, authorizing a survey in connection with the control of cancer and providing that the Surgeon General of the Public Health Service is authorized and directed to make a general survey in connection with the control of cancer and submit a report thereon to the Congress as soon as practicable, together with his recommendations for necessary Federal legislation.

April 29, 1937—Congressman Maury Maverick of Texas introduced House Resolution 6767 to promote research in the cause, prevention, and methods of diagnosis and treatment of cancer, to provide better facilities for the diagnosis and treatment of cancer, to establish a National Cancer Center in the Public Health Service, and for other purposes. It authorizes an appropriation of $2,400,000 for the first year and $1 million annually thereafter. The legal office of the Public Health Service helped draft the bill on the basis of suggestions made by Dr. Dudley Jackson of San Antonio, Tex.

July 8, 1937—A joint hearing of the Senate and House committees was conducted before a subcommittee on cancer research and a revised bill was written. The Interstate and Foreign Commerce submitted Committee Report No. 1281 to accompany the companion bill House Resolution 7931.

August 5, 1937—The National Cancer Institute Act establishes the National Cancer Institute as the federal government’s principal agency for conducting research and training on the cause, diagnosis, and treatment of cancer. The bill also calls upon the NCI to assist and promote similar research at other public and private institutions. An appropriation of $700,000 for each fiscal year is authorized. (P.L. 75-244)

March 28, 1938—House Joint Resolution 468, 75th Congress, was passed, “To dedicate the month of April in each year to a voluntary national program for the control of cancer.”

July 1, 1944—The Public Health Service Act, P.L. 410, 78th Congress, provided that “The National Cancer Institute shall be a division in the National Institute of Health.” The act also revised and consolidated many revisions into a single law. The limit of $700,000 annual appropriation was removed.

August 15, 1950—Public Law 692, 81st Congress, increased the term of office of National Advisory Cancer Council members from 3 to 4 years and the size of the Council from 6 to 12 members, exclusive of the ex-officio members.

December 23, 1971—The National Cancer Act of 1971 provides increased authorities and responsibilities for the NCI Director; initiating a National Cancer Program; establishing a 3-member President’s Cancer Panel and a 23-member National Cancer Advisory Board, the latter replacing the National Advisory Cancer Council; authorizing the establishment of 15 new research, training, and demonstration cancer centers; establishing cancer control programs as necessary for cooperation with state and other health agencies in the diagnosis, prevention, and treatment of cancer; and providing for the collection, analysis, and dissemination of all data useful in the diagnosis, prevention, and treatment of cancer, including the establishment of an international cancer data research bank. (P.L. 92-218)

July 23, 1974—The National Cancer Act Amendments of 1974 aim to improve the National Cancer Program and to authorize appropriations for the next three fiscal years. The bill includes provisions for disseminating information on nutrition as related to the therapy or causation of cancer, for trials of cytology test programs for the diagnosis of uterine cancer, and for peer review of grant applications and contract projects. It also establishes a President’s Biomedical Research Panel. (P.L. 93-352)

August 1, 1977—The Health Planning and Health Services Research and Statistics Extension Act contains a provision to extend the NCI mandate for one year. (P.L. 95-83).

November 9, 1978—The Community Mental Health Centers Act amends the National Cancer Act to emphasize education and demonstration programs in cancer treatment and prevention, and stipulates that NCI devote more resources to prevention, focusing particularly on environmental, dietary and occupational cancer causes. (P.L. 95-622)

December 17, 1980—The Health Programs Extension Act of 1980 extends the NCI authorization for 3 years. (P.L. 96-538)

November 20, 1985—The Health Research Programs Extension Act of 1985 affirms the special authorities of NCI and emphasizes the importance of information dissemination to the public. (P.L. 99-158)

November 4, 1988—The Health Research Extension Act of 1988 provides a 2-year extension, which reaffirms the special authorities of NCI and added information dissemination mandates, as well as the requirement to assess the incorporation of cancer treatments into clinical practice and the extent to which cancer patients receive such treatments. A representative from the Department of Energy was added to the National Cancer Advisory Board as an ex officio member. (P.L. 100-607)

June 10, 1993—The NIH Revitalization Act of 1993 encourages NCI to expand and intensify its efforts in breast cancer and other women's cancers and authorized increased appropriations. Similar language is included for prostate cancer. NCI is also directed to collaborate with the National Institute of Environmental Health Science (NIEHS), to undertake a case control study to assess biological markers of environmental and other potential risk factors contributing to the incidence of breast cancer in specific counties in the Northeast. In FY 1994, NCI is directed to allocate 7% of its appropriation to cancer control, 9% in FY 1995, and 10% in FY 1996. (P.L. 103-43)

August 13, 1998—The Stamp Out Breast Cancer Act establishes a special alternative rate of postage up to 25% higher than a regular first-class stamp. 70% of the profits from the sale of the stamp, also referred to as a semipostal, would go to the NIH to fund breast cancer research; the remaining 30% would go to the U.S. Department of Defense breast cancer research. (PL 105-41)

July 28, 2000—The Semipostal Authorization Act gives the U.S. Postal Service the authority to issue semipostal stamps, which are sold at a premium in order to help provide funding for a particular area of research. The law also extends the Breast Cancer Stamp Act until July 29, 2002. (P.L. 106-253)
July 10, 2000—The Radiation Exposure Compensation Amendments of 1999 allows more workers who handled radioactive material for weapons programs to be eligible to receive federal compensation for radiation-induced illness. The law expands previously written compensation acts, making more grades of workers eligible for compensation, and to include compensation for brain, lung, bladder, colon, ovary, and salivary gland cancers. (P.L. 106-245)

November 12, 2001—The Treasury and General Government Appropriations Act of 2002 makes appropriations for the Treasury Department, the U.S. Postal Service, the Executive Office of the President, and certain Independent Agencies, for the fiscal year ending September 30, 2002, and for other purposes. Within this bill is a provision to reauthorize the Breast Cancer Research Postage Stamp through July 29, 2008. (P.L. 107-67)

January 4, 2002—The Best Pharmaceuticals for Children Act is designed to improve the safety and efficacy of pharmaceuticals for children, by reauthorizing legislation that encourages pediatric drug research by giving drug companies an incentive of 6 months of additional market exclusivity to test their products for use in children. (P.L. 107-109)

May 14, 2002—The Hematologic Cancer Research Investment and Education Act of 2002 directs the NIH Director, through the NCI Director, to conduct and support research on blood cancers. In addition, the CDC is established to publish and carry out an information and education program. (P.L. 107-172)

September 10, 2002—The Public Health Security and Bioterrorism Preparedness and Response Act contains a provision instructing Federal agencies to stockpile and distribute potassium iodide (KI) to protect the public from thyroid cancer in the event of a radiation emergency. (P.L. 107-188)

June 30, 2005—The Patient Navigator Outreach and Chronic Disease Prevention Act of 2005 amends the Public Health Service Act to authorize a demonstration grant program to provide patient navigator services to reduce barriers and improve health care outcomes. The bill directs the HHS Secretary to require each recipient of a grant under this section to use the grant to recruit, assign, train, and employ patient navigators who have direct knowledge of the communities they serve to facilitate the care of individuals who have cancer or other chronic diseases. The bill also directs the HHS Secretary to coordinate with, and ensure the participation of, the Indian Health Service, NCI, the Office of Rural Health Policy, and such other offices and agencies as deemed appropriate by the Secretary, regarding the design and evaluation of the demonstration programs. (P.L. 109-18)

November 11, 2005—The 2-Year Extension of Postage Stamp for Breast Cancer Research extends the U.S. Postal Service's authority to issue special postage stamps to help provide funding for breast cancer research through December 31, 2007. (P.L. 109-100)

January 12, 2007—The Gynecologic Cancer Education and Awareness Act of 2005, or “Johanna's Law” directs the HHS Secretary to carry out a national campaign to increase the awareness and knowledge of health care providers and women with respect to gynecologic cancers. (P.L. 109-475)

April 20, 2007—The National Breast and Cervical Cancer Early Detection Program Reauthorization Act of 2007 allows states to apply for federal waivers to spend a greater share of funds on hard-to-reach underserved women. This bill authorizes funding up to $275 million by 2012; $201 million is authorized for 2007. (P.L. 110-18)


December 12, 2007—The Breast Cancer Research Stamp Reauthorization Act extends through December 31, 2011, provisions requiring the U.S. Postal Service to issue a special postage stamp which contributes funding to breast cancer research. In addition, it requires the NIH and the U.S. Department of Defense to annually report to Congress and the Government Accountability Office on the use of any such funding, including a description of any significant advances or accomplishments. (P.L. 110-150)

December 31, 2007—The Openness Promotes Effectiveness in our National Government Act of 2007, or the OPEN Government Act of 2007, amends the Freedom of Information Act (FOIA) to revise requirements for federal agency disclosures of information requested under that Act. The aim of this bill is to speed up the FOIA process for public access to government documents. (P.L. 110-175)

May 21, 2008—The Genetic Information Nondiscrimination Act of 2007 prohibits health insurers and employers from requiring genetic testing or from using genetic information in decisions regarding insurance eligibility, coverage or premiums, or hiring, firing, or promotion. On March 5, 2008, the text of this bill, as passed by the House, was included in the Emergency Economic Stabilization Act of 2008. (P.L. 110-233)

May 23, 2008—The Temporary Extension of Programs under the Small Business Act and The Small Business Investment Act of 1958 is intended to temporarily extend the SBIR program authorities of the Small Business Administration through March 20, 2009. The SBIR program authorities were due to expire at the end of 2008. (P.L. 110-235)

July 15, 2008—The Medicare Improvements for Patients and Providers Act extends expiring provisions under the Medicare Program, to improve beneficiary access to preventive and mental health services, to enhance low-income benefit programs, and to maintain access to care in rural areas, including pharmacy access, and for other purposes. This bill prevents a 10.6% cut in payments to physicians treating Medicare patients, freezes current payment rates for 18 months, and provides a 1.1% percent increase in 2009. (P.L. 110-275)

July 29, 2008—The Caroline Pryce Walker Childhood Cancer Act of 2007 amends the Public Health Service Act to advance medical research and treatments into pediatric cancers, ensure patients and families have access to the current treatments and information regarding pediatric cancers, establish a population-based national childhood cancer database, and promote public awareness of pediatric cancers. (P.L. 110-287)

October 8, 2008—The Breast Cancer and Environmental Research Act of 2007 amends the Public Health Service Act to authorize the Director of the NIEHS to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The bill establishes an Interagency Breast Cancer and Environmental Research Coordinating Committee within HHS. (P.L. 110-354)
February 4, 2009—The Children's Health Insurance Program Reauthorization Act of 2009 increases the tax on cigarettes by 62 cents to $1.01 per pack and raise taxes on other tobacco products, in order to offset the cost of the program expansion. (P.L. 113-3)

February 17, 2009—The American Recovery and Reinvestment Act of 2009 provides $10 billion in additional funding for the NIH; of which NCI received $1.3 billion in Recovery Act funds to be distributed during the two-year span of 2009 and 2010. (P.L. 111-5)

March 30, 2009—The Nevada Cancer Institute Expansion Act provides for the conveyance of the Alta-Hualapai Site to the Nevada Cancer Institute, and for other purposes. (P.L.111-11)

June 21, 2009—The Family Smoking Prevention and Tobacco Control Act provides the FDA with the authority to regulate tobacco products and establishes within the FDA, the Center for Tobacco Products to implement this act. The Act also establishes a Tobacco Products Scientific Advisory Committee to provide advice, information and recommendations to the Secretary of HHS. The Act allows the Secretary of HHS to restrict the sale or distribution and the advertising or promotion of tobacco products, if appropriate for the protection of the public health, and to the full extent permitted by the First Amendment. (P.L. 111-31)

March 23, 2010—The Patient Protection and Affordable Care Act (HR 3590), the health care reform bill, establishes a private non-profit institute called the Patient-Centered Outcomes Research Institute to conduct comparative clinical effectiveness research, obtain and use data from the Federal government, and establish advisory panels to advise on research priorities, among other provisions. The bill requires NIH to conduct research to develop and validate new screening tests for breast cancer. The bill also requires the NIH Director to establish a Cures Acceleration Network (CAN) program, which shall award grants and contracts to eligible entities to accelerate the development of high need cures and therapies, including the development of medical products, drugs or devices, or biological products. (P.L. 111-148)

March 31, 2010—The Prevent All Cigarette Trafficking Act of 2009 prevents tobacco smuggling, ensures the collection of all tobacco taxes, and includes smokeless tobacco as a regulated substance. The bill amends the federal criminal code to treat cigarettes and smokeless tobacco as nonmailable and prohibit such items from being deposited in or carried through the U.S. mail. (P.L.111-154)

NCI DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carl Voegtlin</td>
<td>January 13, 1938</td>
<td>July 31, 1943</td>
</tr>
<tr>
<td>Roscoe Roy Spencer</td>
<td>August 1, 1943</td>
<td>July 1, 1947</td>
</tr>
<tr>
<td>Leonard Andrew Scheele</td>
<td>July 1, 1947</td>
<td>April 6, 1948</td>
</tr>
<tr>
<td>John Roderick Heller</td>
<td>May 15, 1948</td>
<td>July 1, 1960</td>
</tr>
<tr>
<td>Kenneth Millo Endicott</td>
<td>July 1, 1960</td>
<td>November 10, 1969</td>
</tr>
<tr>
<td>Frank Joseph Rauscher, Jr.</td>
<td>May 5, 1972</td>
<td>November 1, 1976</td>
</tr>
<tr>
<td>Arthur Canfield Upton</td>
<td>July 29, 1977</td>
<td>December 31, 1980</td>
</tr>
<tr>
<td>Vincent T. DeVita, Jr.</td>
<td>July 9, 1980</td>
<td>September 1, 1988</td>
</tr>
<tr>
<td>Samuel Broder</td>
<td>December 22, 1988</td>
<td>April 1, 1995</td>
</tr>
<tr>
<td>Richard D. Klausner</td>
<td>August 1, 1995</td>
<td>September 30, 2001</td>
</tr>
<tr>
<td>Andrew C. von Eschenbach</td>
<td>January 22, 2002</td>
<td>June 10, 2006</td>
</tr>
<tr>
<td>John E. Niederhuber</td>
<td>September 15, 2006</td>
<td>July 12, 2010</td>
</tr>
<tr>
<td>Harold Varmus</td>
<td>July 12, 2010</td>
<td>Present</td>
</tr>
</tbody>
</table>

NATIONAL CANCER INSTITUTE RESEARCH PROGRAMS

The National Cancer Institute leads the National Cancer Program through its operation of research components that provide support for extramural and intramural cancer-related research and through its outreach and collaborations within the cancer community worldwide.

Cancer research is conducted with NCI funding in nearly every state in the United States and more than 20 foreign countries, in addition to research conducted at its own facilities. NCI supports cancer research training, education, and career development, and provides leadership for setting national priorities in cancer research.

NCI Research Components

- Division of Cancer Biology
Division of Cancer Biology

The Division of Cancer Biology (DCB) supports an extensive, multidisciplinary extramural research program that investigates the basic, cellular, and molecular mechanisms of cancer and the role of biological, hormonal, chemical, and physical agents in the initiation and promotion of cancer. This basic biological research is crucial to building a foundation for cancer research and supporting emerging research areas and technologies. Six Branches and several innovative NCI programs coordinated by the Division’s Office of the Director sustain and promote a diverse portfolio of investigator-initiated research grants from academic institutions and research institutes throughout the country and abroad.

The **Cancer Cell Biology Branch** supports basic research directed at understanding the biological basis for the differences between normal cells and cancer cells, with an emphasis on studies that reveal processes with the potential for therapeutic or preventive intervention.

The **Cancer Etiology Branch** supports a research program dealing with biological, chemical, and physical agents that are possible etiological factors or co-factors in cancer and with the control of these agents and their associated diseases.

The **Cancer Immunology and Hematology Branch** supports basic research in tumor immunology and the biology, biochemistry, and molecular biology of the hematologic malignancies (leukemias, lymphomas, and multiple myeloma).

The **DNA and Chromosome Aberrations Branch** supports research that emphasizes cancer genetics and genomic studies at the DNA and chromosome level, including mechanisms of DNA damage/repair and related molecular, cytogenetic, and chromosomal effects during induction and progression to malignancy.

The **Structural Biology and Molecular Applications Branch** supports research on structural and molecular approaches to understanding processes involved in carcinogenesis and tumorigenesis, and promotes the development and application of technologies to advance cancer biology.

The **Tumor Biology and Metastasis Branch** supports research that seeks to understand the interactions of cancer cells with the tumor or host microenvironment to delineate the molecular mechanisms and signaling pathways of cancer development and proliferation.

The **Mouse Models of Human Cancers Consortium (MMHCC)** is a collaborative program that supports the development of accurate, reproducible models of human cancers by utilizing mice with heritable malignancies and cross-species comparisons to disclose features of cancer biology that can be applied to human cancers. It also provides information resources for the entire cancer research community. [http://emice.nci.nih.gov](http://emice.nci.nih.gov)

The **Integrative Cancer Biology Program (ICBP)** supports eleven “Centers for Cancer Systems Biology (CCSB)” investigating the development and progression of cancer through a systems approach to the study of the disease. An integrative and multi-disciplinary effort among all fields of cancer research is applied to the analysis of cancer as a complex biological system, incorporating a spectrum of new technologies such as genomics, proteomics, and molecular imaging to generate computer and mathematical models that can predict the cancer process. [http://icbp.nci.nih.gov/](http://icbp.nci.nih.gov/)

The **Tumor Microenvironment Network (TMEN)** focuses on expanding our understanding of the role of the tumor microenvironment in cancer initiation, progression, and metastases. Supported research focuses on the mechanisms of tumor-stroma interactions in cancer, the identification of tumor and stromal stem cells and their role in stem cell-stroma interactions, and the role of microenvironment alterations as well as inflammatory and immune cells in tumor development, progression, and metastasis. [http://tmen.nci.nih.gov/](http://tmen.nci.nih.gov/)

In addition, the Division sponsors several resources for cancer researchers including bioinformatics tools for analyzing data, such as a state-of-the-art X-ray crystallography experimental facility funded through the **GM/CA CAT Project** [http://www.gmca.anl.gov/](http://www.gmca.anl.gov/), and data and specimen repositories such as **The Chernobyl Tissue bank** [http://www.chernobyltissuebank.com/](http://www.chernobyltissuebank.com/) and the **NCI Mouse Repository** [http://mouse.ncifcrf.gov/](http://mouse.ncifcrf.gov/).

Additional information about NCI's Division of Cancer Biology can be found at [http://dcb.nci.nih.gov](http://dcb.nci.nih.gov).
Division of Cancer Control and Population Sciences

The Division of Cancer Control and Population Sciences (DCCPS) strives to understand the causes and distribution of cancer in populations; support the development and implementation of effective interventions; and monitor and explain cancer trends. DCCPS both generates new knowledge and seeks to ensure that the products of cancer control research are effectively applied in all segments of the population.

The Office of Cancer Survivorship supports research that explores the long- and short-term physical and psychological effects of cancer and its treatment. The Office provides a focus within the NIH for the support of research and education aimed at professionals who deal with cancer patients and survivors. In consultation with the medical and consumer communities, the Office articulates and coordinates a research strategy that will result in improvement in the quality of life, and a reduction in morbidity and mortality in cancer survivors.

The Applied Research Program evaluates patterns and trends in cancer-associated health behaviors and practices, genetic susceptibilities, outcomes, and services. The Program monitors and evaluates cancer control activities in general and specific populations in the United States and determines the influence of these factors on patterns and trends in cancer incidence, morbidity, mortality, and survival. The Program comprises three branches: Health Services Research, and Risk Factor Monitoring and Methods.

The Behavioral Research Program supports investigations ranging from basic behavioral research to research on the development and dissemination of interventions in areas such as tobacco use, dietary behavior, sun protection, decision making, and counseling about testing for cancer susceptibility and participation in cancer screening. The Program comprises the Applied Cancer Screening Research Branch, Basic and Biobehavioral Research Branch, Health Communication and Informatics Research Branch, Health Promotion Research Branch, and Tobacco Control Research Branch.

The Epidemiology and Genetics Research Program supports population-based research to increase our understanding of the etiology and prevention of cancer. Staff manages and fosters a range of etiologic research on genetic, environmental, infectious, hormonal, lifestyle, and pharmacologic factors in cancer etiology. The Program includes the Methods and Technologies Branch, the Modifiable Risk Factors Branch, the Host Susceptibility Factors Branch, and the Clinical and Translational Epidemiology Branch.

The Surveillance Research Program supports cancer surveillance and health services research to answer key questions about cancer incidence and mortality in diverse regions and populations of the U.S. The Surveillance, Epidemiology, and End Results (SEER) Program, a major component of the Program, collects cancer data on a routine basis from designated population-based cancer registries in various areas of the country. The Program includes the Cancer Statistics Branch and the Statistical Research and Applications Branch.

Additional information about NCI's Division of Cancer Control and Population Sciences can be found at http://cancercontrol.cancer.gov.

Division of Cancer Prevention

The Division of Cancer Prevention (DCP) is the primary NCI unit devoted to cancer prevention research. DCP works through 11 research groups that focus on either defined scientific subject areas or specific organ systems.

The Chemopreventive Agent Development Research Group focuses on the identification, preclinical development, and qualification of potential cancer preventive agents for phase I clinical studies. Research includes all classes of agents and a wide range of methodologies and technologies. This group also manages the Rapid Access to Preventive Intervention Development program (RAPID), which helps bridge the gap between discovery and clinical testing; supports clinical trial development, agent acquisition, Investigational New Drug (IND)—directed toxicology and related research; and provides technical support and research resources to extra- and intramural investigators and industry for chemopreventive agent development.

The Community Oncology and Prevention Trials Research Group works to improve clinical oncology in community settings via the Community Clinical Oncology Program (CCOP). Local medical facilities known as CCOPs promote interaction between community oncologists and clinical cooperative groups by allowing local physicians to participate in NCI-sponsored treatment, prevention, and symptom management clinical trials. NCI's large-scale prevention trials are coordinated through the CCOP program, including the Study of Tamoxifen and Raloxifene (STAR) for breast cancer prevention and the Selenium and Vitamin E Cancer Prevention Trial (SELECT) for prostate cancer prevention. The group also funds quality of life and palliative care research.

The Nutritional Science Research Group generates and tests hypotheses relating diet to the causation and prevention of cancer. It also works to establish a comprehensive understanding of the precise role of bioactive food components in determining cancer risk and tumor behavior. The group seeks to determine how specific genes and/or molecular targets are influenced by either essential or non-essential nutrients, allowing the identification of people who may benefit from a prevention intervention.

The Basic Prevention Science Research Group integrates fundamental research from intramural and extramural divisions to study the role of molecular markers in cancer prevention. Specific components of this approach include the molecular genetics of cancer risk and the molecular pathogenesis of precancer and cancer. Specimens under study by this group are generated from population studies as well as clinical trials, and the ultimate goal is to apply accumulated data to clinical trials in cancer prevention.

The Cancer Biomarkers Research Group is the principal resource in the NCI for biomarker information pertaining to cancer detection and risk assessment. This group of scientists supports research for the development and validation of promising early cancer biomarkers for risk prediction and early detection of cancer, including development of databases and informatics systems to track the utility of new biomarkers and novel or refined technologies for studying the molecular circuitry of preneoplastic cells. The Early Detection Research Network, a program of translational research to identify early cancer and cancer risk, is managed by this group.

The Early Detection Research Group develops scientific information and concepts to aid in the dissemination of knowledge of early detection techniques, practices, and strategies to reduce mortality and morbidity from cancer. This group manages and supports clinical trials for early detection and analyzes research
results on screening; fosters technology development and statistical modeling of new technologies; and encourages the publication of scientific findings and adoption of early detection practices. NCI's large-scale early detection trials are coordinated through this program, including the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial and the National Lung Screening Trial.

The **Biometry Research Group** plans and conducts independent and cooperative research studies on cancer epidemiology, prevention, screening, and diagnosis using methods of mathematical and analytic statistics. This Group provides consultation and advice on biostatistical methodology, study design, and biometry to investigators inside and outside of NCI.

The 4 organ-specific research groups in DCP are the **Breast and Gynecologic Cancer Research Group**, the **Gastrointestinal and Other Cancers Research Group**, the **Lung and Upper Aerodigestive Cancer Research Group**, and the **Prostate and Urologic Cancer Research Group**. Each group focuses on cancer sites within their defined organ group, overseeing and supporting research in chemoprevention, nutrition, and other prevention strategies that include nutritional, pharmacologic, biologic, and genetic approaches; vaccine development or immunologic intervention; cancer screening and early detection. These groups support clinical trials that lead to new technologies for identifying and modifying premalignant lesions as well as trials that develop agents based on measures of efficacy, such as cancer incidence reduction. Surrogate endpoint biomarkers studies also measure the modulation of the biomarkers as a potential indicator of efficacy.

Additional information about NCI's Division of Cancer Prevention can be found at [http://prevention.cancer.gov](http://prevention.cancer.gov)

**Division of Cancer Treatment and Diagnosis**

The Division of Cancer Treatment and Diagnosis (DCTD) takes prospective detection and treatment leads, facilitates their paths to clinical application, and expedites the initial and subsequent large-scale testing of new agents and interventions in patients.

DCTD has 8 major programs that work together to bring unique molecules from the laboratory bench to the patient bedside:

**The Cancer Diagnosis Program** stimulates, coordinates, and funds specimen resources, databases related to those specimens, and research on diagnostics and improved technologies to better characterize tumors.

**The Cancer Imaging Program** uses new technologies to expand the role of imaging in noninvasive diagnosis, identification of disease subsets in patients, disease staging, and treatment monitoring.

**The Cancer Therapy Evaluation Program** functions as NCI's primary clinical evaluator of new anticancer agents, radiation treatments, and surgical methods. The program administers the 11 cooperative research groups that unite researchers around the nation and the world in the pursuit of distinctive and effective new treatments for cancer.

**The Developmental Therapeutics Program** serves as a vital resource in discovering potential cancer therapeutics and acquiring preclinical development information. The program provides research materials and manufactures new agents in bulk quantities for use in investigational new drug (IND)-directed studies.

**The Radiation Research Program** provides expertise to investigators who perform novel radiotherapy research and assists in establishing future radiation research directions.

**The Translational Research Program** translates novel scientific discoveries from the laboratory and/or population studies to the clinic for testing in humans with cancer and determines the biological basis for clinical observations.

**The Biometrics Research Branch** provides state-of-the-art statistical and biomathematical analyses for DCTD and other NCI components.

**The Office of Cancer Complementary and Alternative Medicine** aims to increase the amount of high-quality cancer research and information about the use of complementary and alternative modalities.

Additional information about NCI's Division of Cancer Treatment and Diagnosis can be found at [http://dctd.cancer.gov](http://dctd.cancer.gov) or [http://cancer.gov](http://cancer.gov).

**Division of Extramural Activities**

The Division of Extramural Activities (DEA) is responsible for providing guidance to potential cancer research grant applicants, coordinating and assisting in the development of NCI's extramural funding initiatives, referring applications to appropriate programs, providing scientific peer review and oversight of NCI's extramural research, coordinating advisory committees including the National Cancer Advisory Board and the Board of Scientific Advisors, establishing policies and procedures for extramural research, research integrity, and grant applications, managing extramural staff training and career development, and coding and tracking NCI's research portfolio.

DEA staff members serve as chief NCI liaisons to the extramural cancer research community, processing approximately 12,000 grant applications for referral and recruiting thousands of scientific experts to review about 3,000 grants per year. The DEA's Committee Management Office handles the complex preparation and logistics required for NCI's advisory groups to function productively and for the HHS Secretary's Advisory Committee on Genetics, Health, and Society to act in its prescribed role.


**Division of Cancer Epidemiology and Genetics**

Through its broadly based programs in epidemiology, genetics, statistics, and related areas, the Intramural Division of Cancer Epidemiology and Genetics (DCEG) carries out population-based and interdisciplinary research both nationally and internationally to discover the genetic and environmental determinants of cancer.
DCEG is uniquely positioned to conduct value-added epidemiologic research projects that are high-risk in nature and require (a) long-term commitments of scientific staff and funding support through contracts, (b) a coordinated national programmatic approach, or (c) a rapid response to emerging public health or scientific issues. The Division develops multi-disciplinary infrastructures and resources for use throughout the scientific community, including database management software for genome-wide association studies, biospecimen inventories, family-based studies, a variety of software packages for environmental exposure assessment and estimation of dietary intake, and interactive cancer mortality atlases to generate leads into the environmental determinants of cancer. DCEG also has a firm commitment to training the next generation of scientists, and has trainees from the predoctoral to postdoctoral stage. The research conducted by the Division often provides a scientific basis for public health recommendations and policies.

The Epidemiology and Biostatistics Program consists of 6 branches that conduct independent and collaborative epidemiologic and biostatistical investigations to identify the distribution, characteristics, and causes of cancer in human populations. The Program investigates demographic variation in the occurrence of cancer by age, race, gender, geography, and over time (descriptive studies). Special emphasis is placed on the studies into carcinogenic effects of occupational and environmental exposures, ionizing and non-ionizing radiation, dietary and nutritional factors, medicinal agents such as hormones, infectious agents, and host factors including genetic susceptibility to cancer-causing exposures. The Program also develops biostatistical methods for family-based and population-based studies on cancer etiology and prevention.

The Human Genetics Program provides an expanded focus for interdisciplinary research into the genetic determinants of human cancer. Its branches and laboratory explore and identify heritable factors that predispose to cancer, including studies of gene-environment interactions. Program investigators study cancer-prone families to identify and clone predisposing genes; investigate the prevalence of identified genes in the general population; conduct pharmaco-genetic studies to evaluate genetic polymorphisms as determinants of cancer risk and treatment outcomes; and translate advances in molecular genetics into evidence-based management strategies, such as genetic testing and counseling, cancer screening and prevention strategies, and assessment of social and behavioral aspects of heritable cancer. The new Laboratory of Translational Genomics examines validated regions of the genome associated with cancer risk, laying the groundwork for functional studies to determine the causal variants and biological mechanisms involved. These activities complement by the NCI Core Genotyping Facility, where genome-wide association studies and candidate gene searches are carried out to uncover the heritable component to cancer.

The DCEG Fellowship Program allows participants to design, conduct, and analyze research related to the etiology of cancer in human populations. Predoctoral and postdoctoral fellows participate in protocol development and data collection; feasibility studies; case-control and prospective cohort studies; family-based studies; genetic and biochemical assays; and manuscript preparation and publication. Opportunities exist to initiate new investigations, compete for funding, and present at scientific meetings. Professional skills development and preparation for future careers in epidemiology and related areas are an integral part of the program. Postdoctoral training lasts for up to 5 years under the mentorship of NCI senior scientists, with opportunities to work with multiple researchers on a variety of projects. The fellowships may be tailored to one or more specialty tracks including molecular, genetic, hormonal, occupational, environmental, radiation, viral, and nutritional epidemiology, as well as biostatistics and cancer health disparities.

Additional information about NCI's Division of Cancer Epidemiology and Genetics can be found at [http://dceg.cancer.gov](http://dceg.cancer.gov).
rodent imaging, phenotyping core support, and an animal brain tumor therapeutic and diagnostic core. The imaging initiative incorporates clinical imaging, advanced imaging applications, experimental and innovative technologies, and animal imaging into an interrelated imaging resources program.

**Mentoring and Training.** The CCR places a particular emphasis on training the next generation of investigators in basic, interdisciplinary, and translational cancer research. Programs offered in the CCR include Accreditation Counsel on Graduate Medical Education (ACGME) accredited residency programs in anatomic pathology, radiation oncology, and dermatology. Additionally, ACGME clinical fellowship training programs in medical oncology, pediatric hematology/oncology, hematology/pathology, and cytolgy/pathology are available. Fellowship programs in surgical oncology, urological oncology, neuro-oncology, HIV and AIDS malignancy, gynecologic oncology, cancer epidemiology, cancer genetics and cancer prevention are also offered. Translational research opportunities include fellowships in Multidisciplinary Breast Cancer Research, Postdoctoral Fellowships in Radiation Sciences, Clinical Cancer Research Fellowship for Ph.D.s, and a Training Program in Veterinary Pathology. Interdisciplinary fellowship programs include a Biostatistics/Mathematics Training Fellowship (Informatics Training Program) and a Program for Interdisciplinary Training in Chemistry.

The Center is actively involved in the recently established NIH-Graduate Program Partnership initiative, which attracts outstanding graduate students to CCR laboratories. Areas of partnership currently under development include bioinformatics, chemistry, and comparative pathology. The Cancer Research Training Award and the Visiting Fellows program for foreign trainees are available in all the Laboratories, Branches, and Programs.

The CCR Office of Training and Education (OTE) was created in November of 2001 to support the training and mentoring experience for postdoctoral fellows. The OTE mission is to have a programmatic impact on the overall training experience of the basic scientists and clinical fellows in cancer research. This mission is achieved by facilitating and promoting training opportunities for fellows utilizing NCI, NIH, and academic courses; planning and implementing new courses and training programs to prepare fellows as successful independent biomedical researchers; providing opportunities for secondary mentors and expanded collaborative interactions; providing funding mechanisms to reward outstanding research efforts by postdoctoral fellows; implementing funding mechanisms such as the Career Development Awards (K22) to facilitate the fellows' competitiveness as candidates for academic faculty positions; assisting trainees as they transition into academic positions and offering exposure to alternative career paths; and assisting investigators in the recruiting of new postdoctoral candidates. The major responsibilities of the OTE include the CCR Fellows and Young Investigators Retreat, the Tenure Track Investigators Retreat, exceptional pay increases for Postdoctoral Fellows, the CCR Fellows Editorial Board, and the Summer Intern Program. The OTE serves as a resource for the fellows' community and as a liaison to the Office of the Director. The Office of Training and Education will represent the Center both within the NIH and at outside meetings and institutions to recruit quality scientific and professional staff for the research programs.

**Center of Excellence in Immunology (CEI).** CCR Investigators have been at the forefront of the paradigm shift illuminating the multifaceted relationship between the immune response and cancer. In the past 30 years, these research advances have begun opening the door to developing immune-based treatments for this disease and providing groundbreaking contributions in areas as diverse as cellular immunity, innate immunity, cytokines, and viral immunology. Translation of advances in basic research to the clinic has yielded a portfolio of immunotherapy research at the CCR that is unparalleled. Some bench-to-bedside accomplishments from the CCR include successful treatment of hairy cell leukemia using immunotoxins, radio-immunotherapy of refractory non-Hodgkin's lymphoma and targeting the IL-2 receptor with monoclonal antibodies to treat T cell leukemia, autoimmune disease and graft vs. host disease (GVHD). An exciting recent development is a cell-based therapy for the treatment of refractory melanoma that has resulted in improvement in 51% of patients involved in clinical trials. Given the bleak prognosis for those with late stage melanoma, these are remarkable and promising results.

The CCR is also host to several strong programs aimed at developing cancer vaccines. Basic research into the assembly of HPV has been translated into a vaccine designed to prevent infection by this virus. Further, therapeutic cancer vaccines from the NCI are in clinical trials throughout the nation. The unique blending of expertise in basic, translational and clinical research, as well as the ability of the NCI IRP to fund long-term, high risk research, have been key in developing each of these approaches to the immunotherapy of cancer.

The CEI was formed to capitalize on the strength of the immunology community at the CCR. Composed of a 19-member steering committee and a faculty of approximately 250, the CEI cuts across and is inclusive of many existing Laboratory/Program/Branch structures to promote information exchange and collaborations among immunologists in the CCR, as well as generate a multidisciplinary venue to further discovery, development, and delivery of novel immunologic approaches for the prevention and treatment of cancer. The CEI faculty includes two members of the National Academy of Sciences and five members of the Institute of Medicine of the National Academy of Sciences. Thus, the CEI is uniquely suited to catalyze advances in basic, translational and clinical immunology and use this information to facilitate the development of successful immunotherapy for cancer.

**Center of Excellence in Chromosome Biology (CECB).** The CECB integrates CCR's intellectual and physical resources to support outstanding research in chromosome biology. Its mission is to achieve a comprehensive understanding of the mechanisms involved in chromosome function, how aberrations in chromosomes and chromatin lead to disease, and how these defects can be corrected. The CECB brings together internationally renowned experts in the fields of gene expression and regulation, chromatin/chromosome structure and function, DNA replication and repair, epigenetics and molecular cytogenetics to achieve this mission.

CECB research programs have direct implications for translational medicine. Examples include: examining the chromatin fiber as a promising molecular target for a variety of therapeutic drugs, such as the histone deacetylase inhibitors or modifiers of DNA methylation; developing ligands for steroid/nuclear receptor superfamilies that are critically involved in the development and progression of many human neoplasias, including ovarian, breast, and prostate cancer; exploring interphase genome organization in the early diagnosis of tumor cells and cancer stem cells; utilizing high-throughput imaging approaches to provide useful methodologies for drug discovery; employing high-resolution mapping of genomic imbalance and associated gene expression changes as an entry point for the molecular cloning of novel cancer genes and novel targets for improved detection, diagnosis, and prognosis; and applying these approaches and results towards the realization of an individualized medicine in patients with cancer.

The current CECB steering committee consists of ten CCR investigators, including two members of the National Academy of Sciences. The steering committee meets monthly to plan initiatives and to catalyze advances in basic and translational research related to chromosome biology in order to develop successful therapies for cancer and move them to the clinic.
**Center of Excellence in HIV/AIDS and Cancer Virology (CEHCV).** The mission of the CEHCV is to facilitate and rapidly communicate advances in the discovery, development, and delivery of antiviral and immunologic approaches for prevention and treatment of HIV infection, AIDS-related malignancies, and cancer-associated viral diseases. The CEHCV coordinates existing structures and areas of expertise across the NCI-Frederick and Bethesda campuses, and is composed of members from across the NCI’s different branches, laboratories, and programs.

Current research is being conducted in the areas of AIDS malignancies, HIV virology and molecular pathogenesis, immunology/immunopathology, vaccines and immunotherapy, epidemiology, drug development/resistance, and cancer virology.

The CEHCV endorses NCIs longstanding commitment to making reagents and resources available, both nationally and internationally, as a means of diversifying the strategies that can be applied to these devastating diseases and of facilitating further efforts in this area. By leading new initiatives, projects, and collaborations, the CEHCV positions the IRP to play a significant role in interdisciplinary and multi-disciplinary translational research.

**Intramural Cancer Nanotechnology Program (ICNP).** Nanotechnology applied to complex biological systems and biomedical sciences will accelerate the progress in our understanding of cancer and the fight against it. For the potential benefits of oncological nanotechnology to be realized, the National Cancer Institute is poised to serve as a catalyst to bridge the gap between innovators of nanotechnology in the areas of physics and engineering, and those possessing the vision for novel strategies against cancer. In many of our new organizational initiatives, we are exploring opportunities to re-direct intramural resources to more effectively support NCIs overall research portfolio and mission. One good example is the reappearance of the Laboratory of Experimental and Computational Biology as a component in which larger trials are conducted.

The CEHCV endorses NCIs longstanding commitment to making reagents and resources available, both nationally and internationally, as a means of diversifying the strategies that can be applied to these devastating diseases and of facilitating further efforts in this area. By leading new initiatives, projects, and collaborations, the CEHCV positions the IRP to play a significant role in interdisciplinary and multi-disciplinary translational research.

**Molecular Imaging Program.** The goal of the Molecular Imaging Program is to develop and test targeted imaging agents for use in cancer patients. The MIP has a preclinical program in which new compounds are tested in vivo, a translational component in which compounds are introduced into the clinic and a clinical component in which larger trials are conducted.

*Pre-clinical and Translational:* Topics include imaging of angiogenesis, lymphangiogenesis and growth factor targeting in mouse models using optical, MRI and radionuclide/PET imaging probes. Key to the development of these agents is conjugate chemistry that links specific targeting agents to imaging beacons.

*Clinical Program:* The Molecular Imaging Program is introducing new contrast agents into cancer clinical trials. Examples include F-L-Thymidine (FLT), a new PET proliferation marker, and radiolabeled Herceptin. New imaging techniques such as Dynamic Contrast Enhanced MRI (DCE-MRI) and MR spectroscopy are also integrated into clinical trials. Promising new pre-clinical agents may also be introduced into Phase I testing. Facilities include an extensive chemistry and biology lab. We have microMRI, optical cameras and microPET. We are developing a new microSPECT unit. Future additions include an imaging center for human and animal imaging and animal holding/procedure facility.

**Inflammation and Cancer Initiative.** A new front in our campaign against cancer will integrate CCR's excellent basic, clinical, and core infrastructure with cross-cutting research activities around one of the major causes of cancer, namely, chronic inflammation caused by infections. A staggering 1.6 million or 18% of all cancer cases are linked to infection. Pro-inflammatory conditions such as obesity or gastric reflux also predispose individuals to cancer. In addition to causing cancer, chronic inflammatory state appears to play a role during the most deadly stage of cancer, cancer metastasis. We have identified CCR's existing research efforts related to basic, clinical, translational, and population aspects of chronic infection and cancer. Leveraging our significant strengths in the fields of immunology and carcinogenesis, 4 key areas of investigative opportunity have been identified for which the discovery and development of interventions (prevention and therapeutic) will have a significant impact on cancer with initiative directed at: cancer susceptibility, chronic inflammatory diseases; innate and adaptive immunity; stem cells; and inflammation-related molecular targets.

**Partnerships with Academia and Industry.** CCR is committed to forming partnerships that encourage technology development with industry, academia and the private sector. CCR scientists and clinicians have a history of successful research collaborations with colleagues nationally and internationally. The CCR is also active in the area of technology transfer and strives to ensure that scientific breakthroughs reach the public through formal agreements between the government and industry. During the last year there were over 140 active Collaborative Research and Development Agreements (CRADAs) between CCR investigators and outside institutions. These CRADA collaborations were with more than 85 different organizations.

In addition, CCR has further excelled through partnership by participating in many informal collaborations and formal collaborations by way of material transfer agreements, licensing agreements, and memorandums of understanding.

**Unique Aspects of the Intramural Research Program.** The juxtaposition of basic and clinical researchers in this large, diverse yet highly interactive Center provides exceptional translational research and training opportunities. With the resources available at the NIH Clinical Center, which houses over 50% of the NIH-funded general clinical research center beds in the U.S., CCR scientists have a unique environment to move new drugs and diagnostics quickly from the bench to the bedside. Medical care is provided without charge to patients enrolled on NCI protocols.

CCR is a center of excellence for vaccine development and cell-based cancer immunotherapies utilizing specialized expertise, techniques and facilities that exist within the Intramural Program. An example of the uniqueness of the Intramural Program is seen in the basic and clinical proteomics initiative—a collaboration between the NCI and the FDA built on Laser Capture Microdissection technology. Laser Capture Microdissection, developed in the CCR Laboratory of Pathology, involves identification and extraction of microscopic homogenous cellular subpopulations from surrounding tissue.
This technology is now being used to isolate tumor versus normal cellular subpopulations to identify potential molecular targets for cancer therapies. The long-range commitment needed to develop the technology to accurately identify specific targets for various cancers requires support that is unique to the Intramural Research Program. Another component of the proteomics initiative is the identification of novel markers for early cancer detection.

These types of long-term, high-risk projects can accelerate the pace of medical research with public health importance and have an immeasurable impact on improving the nation's health care.

The Future. With the creation of CCR, communication, collaborations, and translational research opportunities among the intramural scientists have been increased. To go from bench to bedside and back requires an environment that is not available to most individual investigators or at most research institutions. CCR is unique in having strong basic and clinical components within the same institutional organization and an institutional infrastructure that facilitates the translation of discoveries from the laboratory to the clinic and, in turn, submits clinical observations back to the laboratory for further analysis.

The CCR and the Intramural Research Program are an invaluable resource for generating initiatives that will help guide and shape the direction of the NCI. CCR will continue to serve as a model for interdisciplinary and translational biomedical research programs, and lead the development of new technologies, provide advanced training for the next generation of cancer scientists, and pioneer new avenues for cancer prevention, diagnosis, and treatment.

Additional information can be found at http://crcr.cancer.gov

Office of Cancer Centers

The Cancer Centers Program within NCI's Office of the Director supports 65 NCI-designated cancer centers nationwide that are actively engaged in transdisciplinary research to reduce cancer incidence, morbidity, and mortality. The two new centers that were added in 2009 brought the total number of centers to 65.

These NCI-designated Cancer Centers are a major source of discovery of the nature of cancer and of the development of more effective approaches to cancer prevention, diagnosis, and therapy. They also deliver medical advances to patients and their families, educate health-care professionals and the public, and reach out to underserved populations. They are characterized by strong organizational capabilities, institutional commitment, and trans-disciplinary, cancer-focused science; experienced scientific and administrative leadership, and state-of-the-art cancer research and patient care facilities.

NCI-designated Cancer Centers are funded through the P30 Cancer Center Support Grant. These awards fund formal research programs that foster interactions between basic laboratory, clinical, and population scientists; access for investigators to shared services and technologies that are necessary to their research efforts; and other scientific infrastructure. Requests from eligible institutions are subjected to a competitive peer review process that evaluates and ranks applications according to their merit.

Additional information can be found at http://cancercenters.cancer.gov.

Center for Cancer Training

NCI's Center for Cancer Training, established in July 2008, is committed to catalyzing the development of a 21st century workforce capable of advancing cancer research through a scientifically integrated approach. This is accomplished by:

- Coordinating and providing research training and career development activities for fellows and trainees at NCI's laboratories, clinics, and other research groups
- Developing, coordinating, and implementing opportunities for support of cancer research training, career development, and education at institutions nationwide
- Identifying workforce needs in cancer research and adapting NCI's training and career development programs and funding opportunities to address these needs.

The Center for Cancer Training comprises 3 intramural training programs—NCI's Center for Cancer Research Office of Training and Education, NCI's Division of Cancer Epidemiology and Genetics Fellowship Office, and NCI's Cancer Prevention Fellowship Program—and NCI's extramural Cancer Training Branch.

Additional information is available at http://www.cancer.gov/cct.

Center to Reduce Cancer Health Disparities

Established in March 2001, the Center to Reduce Cancer Health Disparities (CRCHD) is central to NCI's efforts to reduce the unequal burden of cancer in racially and ethnically diverse and underserved populations. CRCHD also trains the next generation of competitive researchers from diverse populations in cancer and cancer health disparities research.

CRCHD integrates studies across NCI's research division to identify scientific areas that provide opportunities to reduce and eliminate cancer health disparities. In addition, CRCHD coordinates and strengthens the NCI cancer research portfolio in basic, clinical, translational, and population-based research to address cancer health disparities. The center also leads NCI's efforts in training students and investigators from diverse populations that will be part of the next generation of competitive researchers in cancer and cancer health disparities research. The CRCHD creates state-of-the-art regional networks/centers dedicated to cancer health disparities research and care through geographic program management.

CRCHD supports researchers and institutions conducting basic, clinical or population-based research that explicitly focuses on cancers that are more serious or more prevalent in racially and ethnically diverse and underserved populations, and advances the development of the cancer research continuum for these cancers.
Community Networks Program: The Community Networks Program seeks to reduce and eliminate cancer disparities through community-based research, education, and training. Its goal is to significantly improve access to and use of beneficial cancer interventions in communities experiencing disparities. To achieve this goal, CNP is working closely with multiple community agencies and organizations to develop and implement effective ways to reduce cancer health disparities.

Patient Navigation Research Program: The Patient Navigation Research Program aims to tackle the problem of health disparities through a multi-site institution approach. PNRP's overall aim is to decrease the time between cancer-related abnormal findings, definitive diagnosis, and delivery of quality standard cancer care. To achieve this goal the CRCHD charged nine academic research institutions with developing innovative patient navigator interventions to reduce or eliminate cancer health disparities and test their efficacy and cost effectiveness.

Comprehensive Partnerships to Reduce Cancer Health Disparities: Formally known as the Minority Institution Cancer Center Partnership Program, the Comprehensive Partnerships to Reduce Cancer Health Disparities program focuses on creating stable, comprehensive, long-term and mutually beneficial partnerships between minority serving institutions (MSIs) and cancer centers (CCs) in the areas of research, training, career development, and outreach. Through these collaborations, MSIs and CCs work together to train scientists from diverse backgrounds in cancer research, and enhance efforts to effectively reach racially and ethnically diverse communities with cancer advances.

CRCHD is home to a number of training programs to increase the number of underrepresented individuals, individuals with disabilities, and socio-economically disadvantaged scientists conducting competitive cancer research. These programs include the flagship diversity training program, the Continuing Umbrella of Research Experiences (CURE) program.

Continuing Umbrella of Research Experiences (CURE): The Continuing Umbrella of Research Experiences (CURE) is a philosophy of training and career development aimed at increasing the diversity of the cancer research workforce. CURE introduces promising young students, researchers, and faculty from racially and ethnically diverse and underrepresented populations to cancer research, and provides them with a continuum of competitive training and career development opportunities leading to successful careers as independent cancer investigators. The CURE supports its trainees through CURE Supplements, Diversity Supplements, NRSA Pre-Doctoral Fellowship (F31) and Career Development Awards (K). The CURE philosophy embraces a continuum of competitive training and career development opportunities for promising students, researchers from the Minority Institution/Cancer Center Partnership (MI/CCP) program, and junior investigators from diverse backgrounds.

For more information about CRCHD, its programs, and cancer health disparities, visit http://crchd.cancer.gov.

Center for Biomedical Informatics and Information Technology

Reorganized in 2008 to integrate the activities of the former NCI Center for Bioinformatics and the former Office of Information Systems and Computer Support, the NCI Center for Biomedical Informatics and Information Technology (NCI CBIIT) serves as the central coordinating point for NCI-wide information technology (IT) systems. CBIIT leads the development and deployment of biomedical informatics and scientific management IT systems and services for NCI-wide intramural and extramural research initiatives and programs, and provides comprehensive IT support for the Institute’s business operations.

Central to CBIIT’s mission is ensuring that NCI’s informatics and IT assets are aligned to support the Institute’s strategic goals, most notably facilitating translational research and fostering collaborative science. The Center also leads NCI’s cancer Biomedical Informatics Grid® (caBIG®) initiative, maintaining and expanding public-private partnerships to develop and disseminate interoperable, open-source informatics infrastructure and analytical tools to the broader NCI-supported cancer research community.

Launched in 2004, caBIG® is an evolving information network designed to enable all constituencies in the cancer community—informatics experts, bench scientists, clinical researchers, advocates, and eventually, primary-care physicians and patients—to share data and knowledge with the goal of achieving the level of connectivity required to transform the vision of molecularly based, personalized medicine into reality. caBIG® has a distributed grid infrastructure and provides researchers with interoperable software tools for managing, sharing, aggregating, and analyzing data acquired from the use of high-throughput technologies, clinical trials, biospecimen analysis and management, and medical imaging.

Additionally, CBIIT serves as a focal point for nationwide cancer research informatics planning, and its core infrastructure provides a platform for projects conducted by NCI groups and the broader biomedical research community. For example, CBIIT is actively involved in the development of the Nationwide Health Information Network (NHIN [http://www.hhs.gov/healthit/healthnetwork/background/]), and maintains and disseminates analytical tools and large-scale data sets from projects such as The Cancer Genome Anatomy Project (TCGA [http://cancergenome.nih.gov/]) and makes them available through public data portals such as the Cancer Molecular Analysis Portal (CMA [https://cma.nci.nih.gov/cma/]). Additional information about caBIG is available at https://cabiG.nci.nih.gov.

SBIR Development Center

The SBIR Development Center manages the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs at the NCI. These programs are NCI’s engine of innovation for developing and commercializing novel technologies and products to prevent, diagnose, and treat cancer. A range of funding opportunities are offered to the small business community. The Center offers advice for applicants and fosters partnerships and collaborations between small businesses and third-party organizations. In addition, the Center serves as a mentor to SBIR-funded companies regarding their technology development plans, and their regulatory and commercialization strategies, helping to accelerate the development of novel technologies and products. The primary goal of these efforts is to enhance the return on investment of the SBIR program for the benefit of the cancer community and public health in general. SBIR and STTR serve as two of the largest sources of early stage technology financing in the United States.

For more information on the SBIR and STTR Programs, visit sbir.cancer.gov.

Office of HIV and AIDS Malignancy

The Office of HIV and AIDS Malignancy (OHAM) is an office within NCI’s Office of the Director. OHAM has responsibility for broad oversight of HIV/AIDS and HIV malignancy research throughout NCI. OHAM coordinates and prioritizes NCI research in HIV/AIDS and HIV malignancy and also directly initiates and manages certain...
research programs. OHAM interfaces with the NIH Office of AIDS Research and other NIH Institutes and Centers to effectively coordinate the HIV/AIDS research effort.

**Center for Strategic Scientific Initiatives**

Since the sequencing of the human genome, the pace of investigator-initiated research has been driven in large measure by advanced technologies and/or enhanced through technology-based strategies. In 2004, NCI established the Center for Strategic Scientific Initiatives (CSSI) to leverage cross-cutting advanced technologies, create foundational technology-based programs with trans-NCI benefit, enable the convergence of the molecular sciences with rapidly evolving technologies, and coordinate and, more recently, expand the Institute’s programs in the international cancer research arena. The Center is designed to fulfill a fundamental need in the cancer research community by enabling synergy between individualized, investigator-driven research and team-oriented, technology-based projects. These programs build databases, knowledge, tools and extramural trans-disciplinary scientific teams.

During the last several years, CSSI leadership has identified a number of key strategic trans-NCI initiatives required to enable progress across the continuum of basic, translational and clinical research. Several common themes shared by these initiatives include 1) fostering development of innovative tools and technologies that enable discovery research and enhance delivery of clinical interventions for cancer; 2) enabling the convergence of cancer biology and advanced technologies to develop new, innovative platforms for the prevention, detection, diagnosis, and treatment of cancer; 3) accelerating progress against cancer by supporting research infrastructure, common resources, and training in advanced technology areas; and 4) promoting dissemination through public- and private-sector collaborations, communications, and entrepreneurship.

The offices, branches, and programs within CSSI are focused on foundational advanced-technology areas such as genomics, proteomics and nanotechnology, and address key resource requirements such as biospecimens.

**Office of Biorepositories & Biospecimen Research**—The Office of Biorepositories and Biospecimen Research (OBBR) serves as the coordinating and management center for overarching biospecimen-related policies, practices, biospecimen research, and other related issues across NCI’s biorepositories. The OBBR is dedicated to providing leadership for biobanking activities that support all types of cancer research funded by the NCI. This is being done through a comprehensive approach to standards-setting, biobanking science, and education with the aim of improving the quality of human biospecimens and biobanking operations nationally and internationally. Most notably, in response to a critical and problematic shortage of high-quality, well-documented biospecimens for cancer research, OBBR is developing a national, standardized human biospecimen resource called the cancer Human Biobank (caHUB). caHUB will serve as a continuous and reliable source of high-quality human biospecimens and associated data for the broader cancer community, including basic and clinical researchers and the biotechnology and pharmaceutical industries that rely on biospecimens for cancer diagnostics and drug development. OBBR also is responsible for coordinating a trans-NCI Innovative Molecular Analysis Technologies program, which fosters the development of novel technologies to enable the molecular analysis of cancers and their host environment in support of basic, clinical and epidemiological research.

**Office of Cancer Genomics**—The Office of Cancer Genomics (OCG) continues a history of informing and enabling an in-depth understanding of the molecular mechanisms of cancer through the support of innovative programs to produce needed data and tools in the area of genomics. The ultimate goal of all of these over-arching initiatives is to advance the areas of prevention, early detection, diagnosis, and treatment of cancer. OCG provides a focus for scientific programs in genomics that are designed to build an interface between genomic and applied cancer research through the establishment of accessible research tools including clones, databases and informatics.

**Office of Cancer Clinical Proteomics Research**—The Office of Cancer Clinical Proteomics Research (OCPR) accelerates the use of proteomic-based technologies in cancer research through its technology-driven initiatives, collaborations with other government programs, and engagement with the private sector. OCCPR also facilitates the building of an integrated foundation of proteomic technologies, data, reagents and reference materials, and analysis systems to systematically advance the application of protein science to accelerate discovery and translation of biomarkers in clinical cancer research. The Office develops and manages extramural sciences programs, including the NCI Clinical Proteomic Technologies for Cancer and collaborates with both intramural research programs and other agencies.

**Office of Cancer Nanotechnology Research**—The Office of Cancer Nanotechnology Research develops strategies, and implements and manages extramural science and technology programs, including the NCI Alliance for Nanotechnology in Cancer Initiative, to leverage the use of nanotechnologies in fundamental studies of cancer biology, early diagnostics and imaging of the disease, and improvement of cancer treatment and care. It also promotes standardization and translation of the developed technologies to the clinic through collaborations with NCI programs, both extramural and intramural, as well as through joint efforts with regulatory agencies (U.S. Food and Drug Administration/National Institute of Standards and Technology), including the Nanotechnology Characterization Laboratory.

**Office of Physical Sciences-Oncology**—The Office of Physical Sciences-Oncology provides a needed interconnection to facilitate the translation and incorporation of physical sciences approaches to cancer research across the NCI, NIH, and interagency activities. One of the first initiatives being pursued is the establishment of a network of physical sciences-oncology centers. These centers will enable the convergence of physics, chemistry, mathematics and engineering with existing disciplines in cancer research by building trans-disciplinary teams and infrastructure to generate new knowledge and paradigm-shifting science. The ultimate goal of these centers and the branch is to catalyze new fields of study in basic and clinical cancer research by utilizing physical sciences/engineering principles to enable a better understanding of the disease at all length scales, which may lead to exponential progress against the way we treat and diagnose cancer.

**The Cancer Genome Atlas (TCGA) Program Office**—The TCGA Program Office serves as the primary office for the management of the TCGA Program, a highly visible, national collaborative initiative between the NCI and the National Human Genome Research Institute (NHGRI) to chart the complex pathways involved in more than 20 cancers. The Office provides oversight of the TCGA pipeline including data generation; tissue accrual; biospecimens collection, quality and distribution; informatics through management of several data generation cooperative agreements; NCI-funded contracts for dedicated TCGA biospecimens procurement; data coordination contracts; and data analysis cooperative agreements. The TCGA Program Office also supports the development and dissemination of genomics information, technology, methods, informatics tools, and reagents to serve the needs of the cancer research community.
The National Eye Institute (NEI) conducts and supports research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems of individuals who are visually impaired or blind.

Vision research is supported by the NEI through research grants and training awards made to scientists at more than 250 medical centers, hospitals, universities, and other institutions across the country and around the world. The NEI also conducts laboratory and patient-oriented research at its own facilities located on the NIH campus in Bethesda, Maryland.

Another part of the NEI mission is to conduct public and professional education programs that help prevent blindness and reduce visual impairment. To meet these objectives, the NEI has established the National Eye Health Education Program, a partnership of more than 65 professional, civic, and voluntary organizations and government agencies concerned with eye health. The program represents an extension of the NEI's support of vision research, where results are disseminated to health professionals, patients, and the public.

IMPORTANT EVENTS IN NEI HISTORY

August 16, 1968—National Eye Institute was established when President Lyndon B. Johnson signed Public Law 90-489. The new NIH institute was the first government organization solely dedicated to research on human visual diseases and disorders. NEI officially began operations on December 26, 1968, and the National Advisory Eye Council met for the first time on April 3, 1969.

January 11, 1970—Dr. Carl Kupfer was appointed NEI Director.

December 15, 1970—Reorganization of the NEI resulted in the formation of an Office of Biometry and Epidemiology; an Office of the Director of Intramural Research; and a Laboratory of Vision Research and a Clinical Branch as the foci of intramural research.

April 1975—Publication of the National Advisory Eye Council's report, Vision Research Program Planning, was the first comprehensive assessment of major needs and opportunities in vision research in the United States.

April 1978—Publication of the National Advisory Eye Council's 5-year plan, Vision Research: 1978-1982, which included review and analysis of vision research and research training in the United States and discussion of future priorities.

September 1978—The Laboratory of Sensorimotor Research was established within the intramural research program.

June 1981—The Laboratory of Molecular and Developmental Biology was established within the intramural research program.


July 19, 1984—The Office of Biometry and Epidemiology was transferred out of the Office of the Director and established as the Biometry and Epidemiology Program (now Division of Epidemiology and Clinical Applications).

August 1985—An Intramural Research Program reorganization of the Laboratory of Vision Research created the Laboratories of Mechanisms of Ocular Diseases; Retinal Cell and Molecular Biology; and Immunology.

1987—The National Advisory Eye Council's Vision Research--A National Plan: 1983-1987, 1987 Evaluation and Update, discussed accomplishments since the 1983-87 plan was published, evaluated the status of NEI-supported research activities, and revised priorities for the next 2 years.

December 1987—The Collaborative Clinical Vision Research Branch was established to provide overall scientific management and administration for NEI grants, contracts, and cooperative agreements supporting clinical trials and epidemiologic studies.

February 1989—The Office of International Program Activities was created to enhance coordination of NEI's international activities, particularly those relating to cooperation with nongovernmental organizations, international agencies, and the international components of other Federal agencies.

February 10, 1990—The Ophthalmic Genetics and Clinical Services Branch (now Ophthalmic Genetics and Visual Function Branch) was established in the intramural program.

December 1991—The NEI established the National Eye Health Education Program, following Congressional encouragement that NEI increase its commitment to the prevention of blindness through public and professional education programs that encourage early detection and timely treatment of glaucoma and diabetic eye
disease and the appropriate treatment for low vision. The National Eye Health Education Program is coordinated in partnership with national organizations in the public and private sector that conduct eye health education programs.


June 1993—The NEI and its advisory body, the National Advisory Eye Council, produced and distributed its fifth long-range plan, Vision Research—A National Plan: 1994-1998, that contained policy recommendations and scientific program priorities.

June 1998—The NEI and National Advisory Eye Council produced and distributed Vision Research—A National Plan: 1999-2003, that contained policy recommendations and scientific program priorities. In developing this five-year plan, the NEI and its advisory council assembled panels of over 100 experts representing each of NEI's formal programs and special interest areas. In drafting this plan, special consideration was given to the purpose, intent, and requirements of the Government Performance and Review Act.

October 19, 1999—The NEI launched the Low Vision Education Program, part of the National Eye Health Education Program.

2000—The NEI was designated the lead agency for a new focus area on vision in the U.S. Department of Health and Human Services Healthy People 2010 Initiative.

July 15, 2000—Carl Kuper, M.D., stepped aside after 30 years as Director of the NEI. Jack A. McLaughlin, Ph.D., is named Acting Director, NEI.

June 17, 2001—Paul A. Sieving, M.D., Ph.D., assumes duties as Director, NEI.

October 2003—The NEI published and released its National Plan for Eye and Vision Research. The first strategic plan produced through the new, two-phase planning process. This ongoing planning process involves the assessment of important areas in eye and vision research and the development of new goals and objectives that address outstanding needs and opportunities for additional progress. Workshops, conferences, or symposia in critical or emerging areas of science are conducted during the second phase of the planning process to explore how they might be applied to diseases of the eye and disorders of vision.

August 2005—NIH Director Dr. Elias A. Zerhouni and Dr. Maharaj K. Bahn, Secretary, of the Department of Biotechnology, India, signs a United States-India Statement of Intent for collaboration on expansion of vision research.

January 2006—Sayer Vision Research Lecture series established—Dr. Jane Sayer, a NIH research scientist in NIDDK, established the Sayer Vision Research Lecture and Award at the Foundation for the NIH, in partnership with the National Eye Institute NEI, to honor her family and the memory of her parents, Winthrop and Laura Sayer.

September 2006—The National Ophthalmic Disease Genotyping and Phenotyping Network (eyeGENE®) was created by the NEI in partnership with laboratories across the vision research community. Its fundamental purpose is to foster and support research into the genetic causes of ophthalmic disorders by broadening patient and family access to genetic diagnostic testing and by maintaining a national repository of genetic samples from highly characterized individuals and families for investigations of the causes, interventions and management of genetic eye disorders. The eyeGENE® Network includes a coordinating center located at the NEI, a centralized repository for blood and DNA, more than 10 Clinical Laboratory Improvement Amendments (CLIA) associated laboratories from around the country, more than 250 registered clinical organizations with over 400 eye health care registered users, and a shared genotype/phenotype database. Currently, the eyeGENE® repository holds over 2300 patient samples.

September 2007—The Neurobiology-Neurodegeneration and Repair Laboratory was established in the intramural program.


January 2009—Marks the 40th anniversary of the National Eye Institute with a year-long celebration that includes scientific symposia and other commemorative events.

June 2009—The NEI Glaucoma Human Genetics Collaboration (NEIGHBOR) was established.

May 2010—Deborah Carper, Ph.D., appointed to the position of deputy director of NEI. She is the first female deputy director in the NEI’s 40-year history.

June 2010—Rachel Caspi, Ph.D., chief of Immunoregulation Section in NEI Laboratory of Immunology, received the 2010 Friedenwald Award, presented each year for outstanding contributions to basic or clinical research in ophthalmology by the Association for Research in Vision and Ophthalmology (ARVO).

July 2010—Robert H. Wurtz, Ph.D., NEI neuroscientist was awarded the Gruber Neuroscience Prize for his pioneering work in establishing and advancing the field of cognitive neuroscience.

November 2010—Brian P. Brooks, M.D., Ph.D., chief of the NEI Unit on Pediatric, Developmental, and Genetic Ophthalmology, was selected by the White House to receive the 2009 Presidential Early Career Award for Scientists and Engineers (PECASE).

BIOGRAPHICAL SKETCH OF NEI DIRECTOR PAUL A. SIEVING, M.D., PH.D.

Dr. Sieving was named director of the National Eye Institute, NIH, in 2001. He came from the University of Michigan Medical School where he was the Paul R. Lichter Professor of Ophthalmic Genetics and the founding Director of the Center for Retinal and Macular Degeneration in the Department of Ophthalmology and Visual Sciences.

After undergraduate work in history and physics at Valparaiso University, Dr. Sieving studied nuclear physics at Yale Graduate School in 1970-73 under D. Allan Bromley and attended Yale Law School from 1973-74. He received his M.D. from the University of Illinois College of Medicine in 1978 and a Ph.D. in bioengineering.
from the University of Illinois Graduate College in 1981. Dr. Sieving completed an ophthalmology residency at the University of Illinois Eye and Ear Infirmary in Chicago. After post-doctoral study of retinal physiology with Roy H. Steinberg in 1982-83 at the University of California, San Francisco, he did a clinical fellowship in genetic retinal degenerations with Eliot Berson in 1984-85 at Harvard Medical School, Massachusetts Eye and Ear Infirmary.

Dr. Sieving is known internationally for studies of human progressive blinding genetic retinal neurodegenerations, including retinitis pigmentosa, and rodent models of these conditions. His laboratory study of pharmacological approaches to slowing degeneration in transgenic animal models led to the first human clinical trial of ciliary neurotrophic factor (CNTF) for retinitis pigmentosa, published in Proceedings of the National Academy of Sciences, 2006. He also developed a mouse model of X-linked retinoschisis and successfully treated this using gene therapy which restored retinal function. He maintains a clinical practice at NEI for patients with these and other genetic retinal diseases, including Stargardt juvenile macular degeneration.

Dr. Sieving served as Vice Chair for Clinical Research for the Foundation Fighting Blindness from 1996-2001. He is on the Bressler Vision Award committee and is a jury member for the €1 million annual Vision Award of the Champalimaud Foundation, Portugal. He was elected to membership in the American Ophthalmological Society in 1993 and the Academia Ophthalmologica Internationalis in 2005. He received an honorary Doctor of Science from Valparaiso University in 2003 and has been named among the 'Best Doctors in America' multiple years. He has received numerous awards, including the Research to Prevent Blindness Senior Scientific Investigator Award, 1998; the Alcon Research Institute Award, 2000; and the Pisart Vision Award from the New York Lighthouse International for the Blind in 2005. Dr. Sieving was elected to the Institute of Medicine of the National Academy of Sciences in 2006.

**NEI DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul A. Sieving, M.D., Ph.D.</td>
<td>June 17, 2001</td>
<td>Present</td>
</tr>
</tbody>
</table>

**MAJOR EXTRAMURAL PROGRAMS**

NEI’s extramural research activities are organized into six scientific areas: retinal diseases; corneal diseases; lens and cataract; glaucoma and optic neuropathies; strabismus, amblyopia, and visual processing; and low vision and blindness rehabilitation. In addition, the NEI supports research activities that cross-cut the major program areas. These cross-cutting areas of emphasis are ocular genetics; ocular infection, inflammation, and immunology; small business innovative research; research training; oculomotor systems, and collaborative clinical research.

**Retinal Diseases**

NEI-supported investigations include studies of the development, molecular and cell biology, human genetics, and metabolism of the photoreceptor cells and their dependence on the underlying retinal pigment epithelium; the mechanism of the retina's response to light and the initial processing of information that is transmitted to the visual centers of the brain; and the pathogenesis, etiology, molecular biology and genetics, and treatment of retinal diseases such as diabetic retinopathy; uveitis; and retinitis pigmentosa, age-related macular degeneration, and retinal detachment. Genome-wide scans have revealed inflammatory genetic factors associated with increased risk for age-related macular degeneration.

**Corneal Diseases**

NEI-supported projects include studies of the regulation of genes that express proteins unique to corneal tissue; details of the assembly of corneal extracellular matrices; mechanisms that maintain corneal hydration and transparency; physiologic basis for immune privilege in the cornea; cell biology of corneal wound healing; corneal biomechanics; corneal infections; and the pathogenesis of corneal transplant rejection.

**Lens and Cataract**

NEI-supported research includes studies of normal lens development and aging; the molecular and cellular characterization of lens transparency; control of lens cell division; structure and regulation of the expression of lens-specific genes; the impact of environmental insults on the lens; and the pathogenesis of human cataract.

**Glaucoma and Optic Neuropathies**

NEI supports a range of research designed to better understand the pathophysiology underlying glaucoma, the discovery of drugs and surgical techniques for its treatment, the basis of racial and ethnic disparities in the incidence and severity of the disease, and the development of procedures for earlier diagnosis. Studies include the molecular genetics of glaucoma syndromes; physiologic mechanisms regulating fluid flow in the disease; the cell and molecular biology of optic nerve damage; ganglion cell death; mechanisms of neuroprotection as a possible treatment strategy, and genome-wide scans to detect disease risk factors.

**Strabismus, Amblyopia, and Visual Processing**

NEI supports studies concerned with the function of the neural pathways from the eye to the brain, the central processing of visual information, visual perception, the optical properties of the eye, the function of the pupil, and molecular cell biology of the extraocular muscles. Support is provided for research on the pathogenesis and treatment of eye movement disorders, and the development of myopia. Particular emphasis is placed on studies of strabismus and amblyopia, as these are frequent causes of lifelong visual impairment.

**Low Vision and Blindness Rehabilitation**
NEI supports research in low vision and rehabilitation of people with visual impairments and blindness. Examples include projects aimed at improving the methods of specifying, measuring, and categorizing loss of visual function; devising strategies to help visually impaired people maximize the use of their residual vision; systematically evaluating new and existing visual aids; and studying the optical, electronic, and other rehabilitative needs of people with visual impairments.

**Ocular Genetics**

The study of genetic factors that underlie structure, function, and disease susceptibility is common to all scientific programs of the NEI. Therefore, the large-scale projects that employ a common genetic technology have been organized into an overarching grant portfolio. The program director not only manages these extramural grants but also serves as a liaison in integrating and stimulating the development of NEI intramural/extramural ocular genetics resources. Projects include NEIGHBOR, a collaborative effort to collect primary open-angle glaucoma cases and controls to sufficiently power a genome-wide association study to identify genetic variants that significantly contribute to the disease.

**Ocular Infection, Inflammation, and Immunology**

The study of immunologic, inflammatory, and infectious processes that underlie disease pathogenesis and susceptibility is common to all scientific programs of the NEI. Therefore, projects that focus on research in these areas have been organized into an overarching grant portfolio.

**Myopia and Refractive Error**

This cross-cutting scientific program supports studies to delineate the etiology of myopia, identify the biochemical pathways associated with control of the growth of the eye, and determine risk factors associated with the development of myopia and other refractive errors.

**Oculomotor Systems**

This program supports studies to develop a better understanding of the neural control, biomechanical properties, and anatomical relationships of the tissues around the eye muscles and the roles they play in guiding eye movements, as well as to attain a clearer understanding of how signals for voluntary eye movements are processed within cortical circuits.

**Collaborative Clinical Research**

NEI supports single-center and multicenter clinical trials and other epidemiologic and health services research. Collectively, these projects are directed toward furthering knowledge about the predictors for and natural history of visual system diseases and disorders and developing better prevention and management strategies for these conditions.

**MAJOR INTRAMURAL PROGRAMS**

**Office of the Clinical Director**

The Office of the Clinical Director coordinates, supervises and supports intramural clinical research on the cause, diagnosis, prevention, and treatment of diseases of the visual system and fosters the translation of advances in laboratory research into clinical applications. The Office provides infrastructure needed to promote high quality clinical research and to ensure patient safety, including protocol review, clinical informatics, and data and safety management; (2) monitors quality assurance of the intramural clinical research program; (3) coordinates the credentialing of health care providers within the Institute; (4) administers the ophthalmology consultation service to provide eye care for patients referred from other Institutes; and; (5) coordinates and provides clinical research training for NIH staff, fellows, and students.

**Division of Epidemiology and Clinical Applications**

The Division of Epidemiology and Clinical Applications has had three main functions: research, education, and consultation. The Division plans, develops, and conducts human population studies on the cause, prevention, and treatment of diseases of blindness. This includes studies of incidence and prevalence in defined populations, prospective and retrospective studies of risk factors, natural history studies, clinical trials, genetic studies, and studies to evaluate diagnostic procedures. The Division provides education for the vision research community in biometric and epidemiologic principles and methods. Finally, the Division provides biometric and epidemiologic assistance to NEI intramural and extramural staff and to vision research workers elsewhere. It continues to provide scientific support to investigators at the NIH Clinical Center as well as those in the extramural community.

**Laboratory of Immunology**

The goal of the Laboratory of Immunology is to perform cutting-edge, quality research in immunology and infectious diseases that is designed to help scientists better understand the normal physiologic state and the processes that perturb it, with special emphasis on inflammatory mechanisms in the eye as a model system. In pursuit of this goal the laboratory capitalizes on the unique research environment at NIH and the constant interaction between clinician and basic researcher.

**Laboratory of Molecular and Developmental Biology (1981-2009)**

The Laboratory of Molecular and Developmental Biology conducted basic research on cellular and molecular aspects of the eye, with a focus on gene expression and function. Much of the laboratory's research concerned development, evolution, and glaucoma. The focus was on the expression and function of genes.

**Laboratory of Retinal Cell and Molecular Biology**
The Laboratory of Retinal Cell and Molecular Biology plans, conducts, and directs basic research in normal and abnormal functioning of the retina, other ocular tissues, and in retinal diseases, particularly those of a genetic nature. Visual process mechanisms are emphasized as well as the function of neural, glial, and pigment epithelial cells.

**Laboratory of Sensorimotor Research**

The goal of the Laboratory of Sensorimotor Research (LSR) is to understand the fundamental brain mechanisms that allow sensory-motor coordination. The laboratory concentrates on the system within the brain that is probably best understood in the control of the complex activities of the visual/oculomotor system. LSR's center of interest is how this system works in humans, both normally and when it fails as a result of disease or trauma. The ability to guide movements under sensory control is one of the most critical of human abilities. The use of this ability ranges from the mundane coordination needed in everyday life to the precision of the athletic achievement. Disorders of this ability are devastating and cost billions of dollars in custodial health care.

**Neurobiology Neurodegeneration and Repair Laboratory**

The goal of the Neurobiology Neurodegeneration and Repair Laboratory is to develop novel treatment modalities for blinding retinal diseases based on the fundamental understanding of genetic defects and/or biological pathways underlying differentiation, homeostasis, aging, and disease pathogenesis.

**Ophthalmic Genetics and Visual Function Branch**

The Ophthalmic Genetics and Visual Function Branch plans and conducts clinical and laboratory research of gene expression and molecular interactions important to the eye, and applies clinically relevant research findings to the prevention, diagnosis, and treatment of diseases affecting the eye and visual system, including corneal disease, cataract, retinal diseases, and abnormalities of the visual pathways. Clinical and laboratory approaches to this research will be coordinated and training opportunities in clinical research methodology are available.

---

This page last reviewed on May 31, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives.

The NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public. It creates and supports a robust, collaborative research infrastructure in partnership with private and public organizations, including academic institutions, industry, and other government agencies. The Institute collaborates with patients, families, health care professionals, scientists, professional societies, patient advocacy groups, community organizations, and the media to promote the application of research results and leverage resources to address public health needs. The NHLBI also collaborates with international organizations to help reduce the burden of heart, lung, and blood diseases worldwide.

IMPORTANT EVENTS IN NHLBI HISTORY

June 16, 1948—President Harry S. Truman signed the National Heart Act, creating and establishing the National Heart Institute (NHI) in the Public Health Service (PHS) and the National Advisory Heart Council.

August 1, 1948—Surgeon General Leonard A. Scheele, by General Circular No. 36, Organization Order No. 14, established the NHI as one of the National Institutes of Health to assume responsibility for heart research, training, and administration as set forth in the National Heart Act. Intramural research projects in cardiovascular diseases and gerontology, conducted elsewhere in NIH, were transferred to the NHI. The director of the NHI was designated to lead and coordinate the total PHS heart program.

September 8, 1948—The National Advisory Heart Council held its first meeting. Dr. Paul Dudley White served as the Council’s Executive Director.

January 1949—Cooperative research units were established at the University of California, University of Minnesota, Tulane University, and Massachusetts General Hospital. Pending completion of the NHI’s own research organization and availability of further research facilities, the units were jointly financed by the NIH and the institutions.

July 1, 1949—The NHI intramural research program was established.

The Heart Disease Epidemiology Study at Framingham, Massachusetts, was transferred from the Bureau of State Services, PHS, to the NHI.

July 6, 1953—The Clinical Center admitted its first patient for heart disease research.

July 1, 1957—The first members of the NHI Board of Scientific Counselors began their terms. The Board was established in 1956 “to provide advice on matters of general policy, particularly from a long-range viewpoint, as they relate to the intramural research program.”

February 19, 1959—The American Heart Association and the NHI presented a report to the Nation on “A Decade of Progress Against Cardiovascular Disease.”

October 16, 1968—A Nobel Prize in Physiology or Medicine was awarded to Dr. Marshall W. Nirenberg, chief of the NIH Laboratory of Biochemical Genetics, for discovering the key to deciphering the genetic code. Dr. Nirenberg was the first NIH Nobel laureate and the first Federal employee to receive a Nobel Prize.

October 26, 1968—The NHI received the National Hemophilia Foundation’s Research and Scientific Achievement Award for its “medical leadership … tremendous stimulation and support of research activities directly related to the study and treatment of hemophilia.”

November 10, 1969—The NHI was renamed the National Heart and Lung Institute (NHLI), reflecting expansion of functions.

February 18, 1971—In his Health Message to the Congress, President Richard M. Nixon identified sickle cell anemia as a high-priority disease target and called for increased Federal expenditures. Subsequently, the Health, Education, and Welfare (HEW) Assistant Secretary for Health and Scientific Affairs assigned the NIH and NHLI as the lead agencies responsible for coordinating a National Sickle Cell Disease Program.

June 12, 1972—HEW Secretary Elliot Richardson approved a nationwide program of hypertension information and education. The secretary appointed the Hypertension Information and Education Advisory Committee, chaired by the Director of NIH, and the Interagency Working Group, chaired by the Director of the NHLI, to implement the national effort.
July 1972—The NHLI initiated the National High Blood Pressure Education Program (NHBPEP).

July 14, 1972—Secretary Richardson approved a reorganization of NHLI, elevating the Institute to Bureau status within the NIH.

June 25, 1976—The NHLI was renamed the National Heart, Lung, and Blood Institute (NHLBI), reflecting an expansion in blood-related activities within the Institute.

November 1979—The results of the Hypertension Detection and Follow-up Program, a clinical trial initiated by the NHLBI in 1971, provided evidence that systematic, aggressive treatment of hypertension saves lives.

October 1981—The NHLBI Beta-Blocker Heart Attack Trial demonstrated benefits to those in the trial who received propranolol compared with the control group.

October 1983—The NHLBI Coronary Artery Surgery Study results demonstrated that mildly symptomatic patients with coronary artery disease can safely defer coronary artery bypass surgery until symptoms worsen.

January 1984—The NHLBI Lipid Research Clinics Coronary Primary Prevention Trial established conclusively that reducing total blood cholesterol reduces the risk of coronary heart disease in men at increased risk because of elevated cholesterol levels. Each 1% decrease in cholesterol was shown to reduce heart attack risk by 2%.

April 1985—Phase I of the NHLBI Thrombolysis in Myocardial Infarction Trial found that the new thrombolytic agent recombinant tissue plasminogen activator (rt-PA) is approximately twice as effective as streptokinase in opening thrombosed coronary arteries.

October 1985—NHLBI-supported researchers Michael S. Brown and Joseph L. Goldstein received the Nobel Prize in Physiology or Medicine for their discoveries concerning the regulation of cholesterol metabolism.

November 1985—The NHLBI initiated the National Cholesterol Education Program (NCEP).

June 1986—Results of the NHLBI Prophylactic Penicillin Trial demonstrated the efficacy of prophylactic penicillin in reducing morbidity and mortality associated with pneumococcal infections in children with sickle cell disease.

March 1989—The NHLBI initiated the National Asthma Education Program. The program was later renamed the National Asthma Education and Prevention Program (NAEPP).

September 1990—Scientists from the NHLBI and the National Cancer Institute began the first gene therapy trial in a human patient, a 4-year-old girl with an inherited immune dysfunction.

January 1991—The NHLBI developed an Obesity Education Initiative to educate the public and health professionals about obesity as an independent risk factor for cardiovascular disease and its relationship to other risk factors such as high blood pressure and high blood cholesterol.

June 1991—The NHLBI initiated the National Heart Attack Alert Program.

July 1991—The NHLBI Systolic Hypertension in the Elderly Program demonstrated that low-dose pharmacologic therapy of isolated systolic hypertension in those over age 60 significantly reduces stroke and myocardial infarction.

August 1991—The NHLBI Studies of Left Ventricular Dysfunction demonstrated that use of enalapril—an angiotensin converting enzyme inhibitor—causes significant reduction in mortality and hospitalization for congestive heart failure in patients with symptomatic heart failure.

January 1995—Results of the NHLBI Multicenter Study of Hydroxyurea demonstrated that hydroxyurea reduced the number of painful episodes by 50% in severely affected adults with sickle cell disease. This is the first effective treatment for adult sickle cell patients.

September 1995—Results of the NHLBI Bypass Angioplasty Revascularization Investigation demonstrated that patients on drug treatment for diabetes who had blockages in 2 or more coronary arteries and were treated with coronary artery bypass surgery had, at 5 years, a markedly lower death rate than similar patients treated with angioplasty.

May 1996—Framingham Heart Study Investigators concluded that earlier and more aggressive treatment of hypertension is vital to preventing congestive heart failure.

The Treatment of Mild Hypertension Study demonstrated that lifestyle approaches, such as weight loss, a healthy eating plan, and physical activity, are crucial for reducing blood lipids in those treated for Stage I hypertension.

September 1996—Findings from the NHLBI Asthma Clinical Research Network indicated that inhalation of a beta-agonist at regularly scheduled times is safe for people with asthma but provides no greater benefit than use of the medication only when asthma symptoms occur.

November 1996—Two studies, the Dietary Approaches to Stop Hypertension (DASH) trial and the Trial of Nonpharmacologic Intervention in the Elderly, showed that lifestyle changes, such as modifying one's diet and losing weight, substantially reduce blood pressure in adults and eliminate the need for antihypertensive medication in some older patients.
January 1997—Results from the Pathobiological Determinants of Atherosclerosis in Youth program showed that atherosclerosis develops before age 20 and that high-density lipoprotein cholesterol, low-density lipoprotein (LDL) cholesterol, and cigarette smoking affect progression of atherosclerosis equally in women and men regardless of race.

May 1997—Results from the Antiarrhythmic versus Implantable Defibrillator clinical trial demonstrated that implantable cardiac defibrillators are superior to antiarrhythmic drug therapy for improving overall survival for patients with life-threatening heart arrhythmias.

October 1, 1997—The NHLBI is given responsibility for the Women’s Health Initiative (WHI), a study begun in 1991 to address chronic diseases in women.

March 1999—A large clinical trial of mechanical ventilator use for intensive care patients with acute respiratory distress syndrome demonstrated that approximately 25% fewer deaths occurred among patients receiving small, rather than large, breaths of air from a mechanical ventilator.

September 2000—NHLBI-supported investigators identified a gene for primary pulmonary hypertension.

January 2001—Results of the Dietary Approaches to Stop Hypertension (DASH) Sodium Trial showed that dietary sodium reduction substantially lowers blood pressure in persons with high blood pressure; the greatest effect was seen when sodium reduction was combined with a diet rich in fruits and vegetables and low in saturated fat previously shown to lower blood pressure (i.e., the DASH diet).

April 2001—The NHLBI released international guidelines for diagnosis, management, and prevention of chronic obstructive pulmonary disease (COPD).

July 2001—A self-contained artificial heart was implanted in a patient for the first time.

September 2001—The NHLBI, along with the American Heart Association and other partners, launched a national Act in Time to Heart Attack Signs campaign to increase awareness of the symptoms of heart attack and the need for a fast response.

July 2002—The NHLBI stopped early the trial of estrogen plus progestin component of the WHI due to increased breast cancer risk and lack of overall benefits. The multicenter trial also found increases in coronary heart disease, stroke, and pulmonary embolism in participants on estrogen plus progestin compared to women taking placebo pills. In 2004, the WHI component evaluating estrogen-alone hormone therapy also was stopped early because the long-term risks of the medications outweighed the long-term benefits.

December 2002—Results of the NHLBI Atrial Fibrillation Follow-up Investigation of Rhythm Management Trial indicated that a strategy involving rate control rather than rhythm control may be the preferred treatment for patients with atrial fibrillation. The rate control strategy involves the use of less expensive drugs and fewer hospitalizations.

Results from the NHLBI Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), the largest hypertension clinical trial ever conducted, showed that traditional diuretics are at least as good as newer medicines (calcium channel blockers and ACE inhibitors) to treat high blood pressure and to prevent some forms of heart disease. These findings were in addition to ALLHAT results from 2000, when researchers reported that an alpha-adrenergic blocker was less effective than the diuretic in reducing risk of some forms of CVD.

January 2003—A study demonstrated that magnetic resonance imaging can detect heart attacks faster and more accurately than traditional methods in patients who arrive at an emergency room with chest pain.

February 2003—The NHLBI Prevention of Recurrent Venous Thromboembolism (PREVENT) trial was stopped because treatment with low-dose warfarin to prevent recurrence of the blood clotting disorders deep vein thrombosis and pulmonary embolism was found to benefit the patients.

May 2003—The NHLBI National Emphysema Treatment Trial found that lung volume reduction surgery benefits emphysema patients who have certain clinical characteristics. The findings will help determine the Medicare coverage policy for the surgery.

July 2003—The NHLBI and Gen-Probe Corporation developed a test to screen donated blood for the West Nile virus.

March 2004—Preliminary results of the NHLBI Sudden Cardiac Death in Heart Failure study demonstrated that an implantable cardiac defibrillator can reduce the risk of death from arrhythmia for heart failure patients.


An NHLBI-funded study showed that nucleic acid-amplification testing for HIV-1 and hepatitis C virus further safeguards the nation’s blood supply.

October 2004—Researchers participating in the NHLBI Asthma Clinical Research Network demonstrated that genetic differences affect how adult patients with mild asthma respond, over time, to daily doses of inhaled albuterol (a drug used for relief of acute asthma symptoms).

November 2004—Results of the NHLBI Prevention of Events with Angiotensin Converting Enzyme Inhibition study demonstrated that many coronary heart disease patients who were receiving state-of-the-art therapy do not gain extra cardiovascular protection from ACE inhibitors.

December 2004—The NHLBI Stroke Prevention Trial II showed that children with sickle cell disease who receive transfusions to prevent stroke revert to high risk for stroke when transfusions are stopped. STOP II was initiated after an earlier trial demonstrated that periodic red blood cell transfusions reduce the stroke rate by 90% among high-risk children with sickle cell disease.

January 2005—The NHLBI issued new guidelines for managing asthma during pregnancy.
February 2005—NHLBI-supported scientists identified 2 genetic mutations common in individuals of African descent that are associated with a 40% reduction in LDL cholesterol.

February 2006—Results from the WHI Calcium and Vitamin D trial showed that calcium and vitamin D supplements in healthy postmenopausal women provide a modest improvement in bone mass preservation and prevent hip fractures in certain groups including older women but do not prevent other types of fractures or colorectal cancer.

May 2006—Results from the Childhood Asthma Research and Education Network showed that daily treatment with inhaled corticosteroids can reduce breathing problems in pre-school-aged children at high risk for asthma, but does not prevent them from developing persistent asthma.

The Prospective Investigation of Pulmonary Embolism Diagnosis II found that the ability to diagnose pulmonary embolism is improved when a commonly used imaging test of the chest to detect potentially deadly blood clots in the lung is complemented by an extension of the scan to the legs—where the clots typically originate—or by a standard clinical assessment.

June 2006—The Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial showed that treating heart attack patients who have a life-threatening complication called cardiogenic shock with emergency angioplasty or bypass surgery greatly improves their long-term survival. Improved short-term survival was reported in 1999.

July 2006—NHLBI scientists found that a hormone called brain natriuretic peptide—or BNP, which can be detected in a simple blood test—can identify patients with sickle cell disease who have developed a life-threatening complication called pulmonary hypertension. The hormone is also a predictor of death in adult sickle cell patients.

Results from 2 randomized clinical trials demonstrated that inhaled nitric oxide administered within the first few weeks of life helps prevent chronic lung disease in some low birthweight premature infants. Moreover, when administered within 48 hours after birth, it appears to protect some premature newborns from brain injury.

September 2006—The NHLBI launched a peripheral arterial disease (PAD) awareness and education campaign entitled Stay in Circulation...Take Steps to Learn about P.A.D.


October 2007—NHLBI-supported researchers Mario Capecchi and Oliver Smithies were awarded the Nobel Prize in Physiology or Medicine for their creation of a gene-targeting technique that allows scientists to create mice that are genetically modified to develop human diseases.

December 2007—The NHLBI announced a new strategic plan to guide its next decade of research, training, and education.

January 2008—Results from the ALLHAT study demonstrated that in people with high blood pressure as part of metabolic syndrome, diuretics offer greater protection against cardiovascular disease and are at least as effective for lowering blood pressure as newer, more expensive medications.

February 2008—The NHLBI stopped one treatment arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) clinical trial of adults with type 2 diabetes at high risk of heart attack and stroke after a review of available data showed that participants following a medical strategy to lower blood glucose below current recommendations to near-normal levels had an increased the risk of death compared with those receiving the standard treatment strategy.

The NHLBI issued the first U.S. guidelines for the diagnosis and management of von Willebrand Disease, the most common inherited bleeding disorder.

March 2008—The WHI Follow-up Study confirmed that the health risks of long-term combination hormone therapy outweigh the benefits for postmenopausal women. Researchers reported that about 3 years after women stopped taking combination hormone therapy, many of the health effects of hormones such as increased risk of heart disease are diminished, but overall risks of stroke, blood clots, and cancer remain high.

April 2008—Results from Stop Atherosclerosis in Native Diabetic Study (SANDS) showed that aggressively lowering cholesterol and blood pressure levels below current targets in adults with type 2 diabetes may help to prevent, and possibly reverse, hardening of the arteries.

August 2008—The NHLBI launched an educational Web site “Children and Clinical Studies,” which features documentary videos, text, and graphics designed to promote a better understanding of research in children for health care professionals and the public.

December 2008—The NHLBI expanded its open-access dataset of genetic and clinical data to include information collected from three NHLBI-funded asthma research networks: CAMP, CARE, and ACRN.

Researchers identified a gene that directly affects the production of a form of hemoglobin that is instrumental in modifying the severity of SCD and thalassemia.

March 2009—Results from the STICH trial showed that surgery to reshape the scarred left ventricle, the main pumping chamber of the heart, often performed in conjunction with coronary bypass surgery, failed to reduce deaths and hospitalizations in heart failure patients and did not improve quality of life compared to bypass alone.
June 2009—Results from the BARI 2D study in patients with diabetes and stable coronary artery disease indicated that while revascularization can be delayed for many patients receiving optimal medical therapy, patients with extensive coronary artery disease do better with prompt bypass surgery than with medical therapy alone.

The NHLBI joined with UnitedHealth Group’s Chronic Disease Initiative to launch a worldwide network of research and training centers to build institutional and community capacity to prevent and control chronic diseases globally.

**NHLBI LEGISLATIVE CHRONOLOGY**

*June 16, 1948*—The National Heart Act (Public Law 80-655) authorized NHLI. The act’s purpose was “To improve the health of the people of the United States through the conduct of researches, investigations, experiments, and demonstrations relating to the cause, prevention, and method of diagnosis and treatment of diseases of the heart and circulation; assist and foster such researches and other activities by public and private agencies, and promote the coordination of all such researches and activities and the useful application of their results; provide training in matters relating to heart diseases, including refresher courses for physicians; and develop, and assist States and other agencies in use of the most effective methods of prevention, diagnosis, and treatment of heart diseases.”

*December 30, 1963*—House Joint Resolution 848 (P.L. 88-254) authorized and requested the President to issue an annual proclamation designating February as American Heart Month, inviting governors of states and territories to issue similar proclamations.

*May 16, 1972*—The National Sickle Cell Anemia Control Act (P.L. 92-294) established a national program for diagnosis, control, and treatment of and research in sickle cell anemia. The act did not mention NHLI but had special pertinence because NHLI was designated to coordinate the National Sickle Cell Disease Program.

*September 19, 1972*—The National Heart, Blood Vessel, Lung, and Blood Act of 1972 (P.L. 92-423) enlarged institute authority to advance the national attack on heart, blood vessel, lung, and blood diseases. The act provided for expanded, intensified, and coordinated institute activities in accordance with a comprehensive, specified National Heart, Blood Vessel, Lung, and Blood Disease Program to be planned by the director and the Advisory Council.

It also called for establishment of prevention and control programs; development of 15 new centers for basic and clinical research, training, demonstration, and prevention programs for heart, blood vessel, and blood diseases; and development of 15 such centers for chronic lung diseases.

*June 25, 1976*—Title I of the Health Research and Health Services Amendments of 1976 (P.L. 94-278) redesignated NHLI as NHLBI to advance the national attack on heart, blood vessel, lung, and blood diseases, and to conduct research in use of blood and blood products and in management of blood resources. The NHLBI director and the National Heart, Lung, and Blood Advisory Council continue to plan the national program under the basic P.L. 92-423 provisions with some refinements.

*August 1, 1977*—The Biomedical Research Extension Act of 1977 (P.L. 95-83) authorized NHLBI, with continued emphasis on both the national program and related prevention and dissemination activities.

*December 17, 1980*—The Health Programs Extension Act of 1980 (P.L. 96-538) reauthorized NHLBI, with continued emphasis on both the national program and related prevention programs.

*January 4, 1983*—The Orphan Drug Act (P.L. 97-414) amended the Public Health Service Act to mandate development and support of not less than 10 comprehensive centers for sickle cell disease.

*November 20, 1985*—The Health Research Extension Act (P.L. 99-158) reauthorized the NHLBI, provided for the establishment of information dissemination and education programs, and provided for an Associate Director for Prevention.

*September 20, and November 4, 1988*—The National Bone Marrow Donor Registry (P.L. 100-436, P.L. 100-607) was established. With enactment of these authorization and appropriation measures, NHLBI was given the task of developing an implementation plan for the voluntary bone marrow registry. Responsibility for the Registry later was transferred to the Health Resources and Services Administration.

*June 10, 1993*—The NIH Revitalization Act of 1993 (P.L. 103-43) established a National Center on Sleep Disorders Research within NHLBI.

*October 31, 1998*—Section 104 of the Women's Health Research and Prevention Amendments (P.L. 105-140) instructed the NHLBI director to expand and intensify research and related activities of the institute with respect to heart attack, stroke, and other CVDs in women and to collaborate with other NIH institutes.

*October 17, 2002*—The Children's Health Act (P.L. 106-310) mandated that the Director of NHLBI, through the Coordinating Committee of the National Asthma Education and Prevention Program, develop a Federal plan for responding to asthma and recommended ways to strengthen coordination of Federal asthma-related activities.

**BIOGRAPHICAL SKETCH OF NHLBI ACTING DIRECTOR SUSAN B. SHURIN, M.D.**

Susan B. Shurin, M.D., is Acting Director of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH), where she oversees an extensive national research portfolio with an annual budget of approximately $3 billion. The NHLBI conducts and supports research to prevent, diagnose, and treat heart, lung, and blood diseases; fosters training of emerging investigators; and communicates research advances to the public. Through the support of research from bench to bedside, Dr. Shurin leads the NHLBI’s effort to transform new scientific knowledge into tangible improvements in health.

As Acting Director, Dr. Shurin represents the NHLBI in a wide variety of activities across the NIH and the Department of Health and Human Services. As part of the NIH’s global commitment, Dr. Shurin oversees the NHLBI’s Global Health Initiative [http://www.nhlbi.nih.gov/about/globalhealth/], which includes a network of...
Collaborating Centers of Excellence in low- and middle-income countries, focused on building sustainable programs to combat chronic cardiovascular and lung diseases.

Dr. Shurin joined the NHLBI as Deputy Director in February 2006, coming from Case Western Reserve University in Cleveland, Ohio. In her role as Deputy Director, Dr. Shurin has been involved in multiple intramural and extramural activities of the NHLBI and responsible for oversight of the Institute's clinical research portfolio. In October 2009, Dr. Shurin also assumed the role of Acting Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) while also serving as the Deputy Director of NHLBI.

Before joining the NHLBI, Dr. Shurin was Professor of Pediatrics and Oncology at Case Western Reserve University in Cleveland, Ohio; Director of Pediatric Hematology-Oncology at Rainbow Babies and Children's Hospital; Director of Pediatric Oncology at the Case Comprehensive Cancer Center; and Vice President and Secretary of the Corporation at Case Western Reserve University.

Dr. Shurin received her education and medical training at Harvard University and the Johns Hopkins University School of Medicine. Her laboratory research focused on the physiology of phagocyte function, recognition and killing of pathogens; mechanisms of hemolysis, red blood cell destruction; and iron overload, a serious chronic condition in which the body absorbs too much iron leading to a buildup in organ tissues.

She has been active in clinical research in many aspects of pediatric hematology-oncology, including participation in the Children's Cancer Group (CCG), now the Children's Oncology Group, as well as multiple studies in sickle cell disease and hemostasis. She also served on the Executive Committee of the CCG and founded and chaired the CCG Bioethics Committee.

Among other leadership efforts, Dr. Shurin serves on multiple NIH advisory panels. She has been on the boards or in leadership positions of numerous local and national professional organizations, including the American Board of Pediatrics. She is a member of the American Academy of Pediatrics; the American Society of Hematology; the American Society of Pediatric Hematology-Oncology; and the American Pediatric Society, where she is currently a member of the APS Council.

Dr. Shurin follows in the footsteps of two celebrated family pediatrician role models. Her maternal grandfather, Park Jerauld White, M.D., was a distinguished pediatrician practicing in St. Louis, Missouri, where he was a social activist and advocate for the interests and needs of children. Her great-aunt, Katherine Bain, M.D., practiced with Dr. White before joining Martha Elliott, M.D., in 1941 at the Children's Bureau (now the Office of Maternal and Child Health at the Health Resources and Services Administration).

### NHLBI DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassius James Van Slyke</td>
<td>August 1, 1948</td>
<td>November 30, 1952</td>
</tr>
<tr>
<td>James Watt</td>
<td>December 1, 1952</td>
<td>September 10, 1961</td>
</tr>
<tr>
<td>Ralph E. Knutti</td>
<td>September 11, 1961</td>
<td>July 31, 1965</td>
</tr>
<tr>
<td>William H. Stewart</td>
<td>August 1, 1965</td>
<td>September 24, 1965</td>
</tr>
<tr>
<td>Robert P. Grant</td>
<td>March 8, 1966</td>
<td>August 15, 1966</td>
</tr>
<tr>
<td>Donald S. Frederickson</td>
<td>November 6, 1966</td>
<td>March 1968</td>
</tr>
<tr>
<td>Theodore Cooper</td>
<td>March 15, 1968</td>
<td>April 19, 1974</td>
</tr>
<tr>
<td>Claude Lenfant</td>
<td>July 1, 1982</td>
<td>September 2, 2003</td>
</tr>
<tr>
<td>Elizabeth G. Nabel</td>
<td>February 1, 2005</td>
<td>November 30, 2009</td>
</tr>
<tr>
<td>Susan B. Shurin (Acting)</td>
<td>December 2009</td>
<td>Present</td>
</tr>
</tbody>
</table>

### NHLBI PROGRAMS

The NHLBI is organized into the Extramural Research Program, the Intramural Research Program, and the Office of the Director.

#### The Office of the Director

The Office of the Director (OD) of the National Heart, Lung, and Blood Institute (NHLBI) provides overall strategic planning, policy guidance, program development and evaluation, and operational and administrative coordination for the Institute. Offices within the OD provide critical management and administrative support to the Institute, and are responsible for the transparent and responsible stewardship of the NHLBI budget.

The OD is the focal point of relationships with the Director of the NIH as well as with other components of the Department of Health and Human Services (DHHS), other Federal agencies, Congress, professional societies, voluntary health organizations, and other public groups. The OD advises and guides the NHLBI's key leaders on the principles, practices, laws, regulations, and policies of the Federal equal employment, affirmative action, civil rights, and minority programs.

The OD collects, develops, and disseminates information on the diseases of the heart, lung, and blood and on transfusion medicine, with an emphasis on disease prevention, and conducts and fosters educational programs for scientists and clinicians. It provides leadership in the transfer and assessment of information for the scientific community and the lay public, and establishes internal Institute policy for program and administrative operations, maintaining surveillance over their implementation.
The Center for Biomedical Informatics

The Center for Biomedical Informatics (CBI) supports and provides leadership for the Institute for all aspects of biocomputing. CBI supports the Institute's information technology (IT), encompassing strategic planning, project management, and developing enterprise systems. The office oversees the continuous operations of the IT infrastructure, including new network development, user and network support, and information security. CBI also maintains and develops IT systems and databases for tracking and reporting of extramural and intramural programs. CBI recommends and implements IT policies and procedures; studies, evaluates and tests new technologies (hardware, software, and information systems); designs methods to communicate with all NHLBI stakeholders; and develops new methods for managing knowledge in addition to developing an information architecture for the Institute.

The Center for Population Studies

The NHLBI Center for Population Studies formulates a global view of the etiology, natural history, and time-period trends in heart, lung, blood, and sleep disorders. The Center performs coordinated studies of heart, lung, blood and sleep disorders; and conducts state-of-the-art research of these conditions with attention to early onset of these disorders as well as genetic susceptibility. In addition, the Center has launched a systems medicine project known as the SABRe CVD Initiative (Systems Approach to Biomarker Research in Cardiovascular Disease) in which researchers will obtain metabolomic, proteomic, gene expression, and microRNA data on thousands of study participants in an effort to identify molecular signatures of disease phenotypes in the population setting.

The Division for the Application of Research Discoveries (DARD)

The mission of the Division for the Application of Research Discoveries (DARD) is to advance the application of scientific discoveries for the prevention, detection, and treatment of cardiovascular, lung, blood, and sleep diseases and conditions. The DARD focuses on narrowing the gap between knowledge creation and application by translating scientific evidence into clinical guidelines that can be implemented in clinical practice settings; and community health promotion or education programs that can be implemented in communities. The DARD activities create opportunities for communication and collaboration among researchers, clinical and public health practitioners, patients, and the general public. Communities of practice, knowledge networks, social media, Web sites, conferences and symposia are some of the venues used to implement the mission. The DARD programs reach out to people in high-risk, low-income, and/or ethnically diverse communities with the goal of improving health and eliminating health disparities. The DARD activities also identify gaps in knowledge needed to inform practice that can be addressed by future research. The ultimate goal of the DARD's efforts is to improve the public's health by translating the science base into strategies, tactics, programs and products that can help improve the health of all Americans.

Office of the Director

The DARD Office of the Director (OD) provides oversight and vision for the Division’s activities and for collaboration with other NHLBI Divisions, NIH Institutes, governmental entities, and relevant organizations and groups. The DARD OD provides scientific, administrative, and technical support and coordination to achieve the NHLBI strategic planning goals and objectives and to fulfill the Division’s mission.

Research Translation Branch

The Research Translation Branch provides leadership for projects that take emergent knowledge and translate that knowledge into effective approaches for practice. This task involves synthesizing and organizing evidence around priority diseases and conditions, leading the development of evidence-based systematic literature reviews, and leading the development of clinical practice guidelines. The Branch also develops clinical decision support systems and other innovative implementation applications for use in clinical and public health practice settings, and it facilitates knowledge exchange opportunities for researchers and practitioners around issues of research applicability and relevance to practice. Branch activities also identify knowledge gaps to inform future research.

Examples of how the RT branch translates knowledge into effective approaches for practice include development of clinical practice guidelines, such as the Reports of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC); Reports of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP); Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults; and Expert Panel Reports on Guidelines for the Diagnosis and Management of Asthma. These guidelines, along with supportive materials and implementation strategies, are reaching clinicians nationally and internationally, to provide practical and useful evidence-guided recommendations for clinical practice.

Enhanced Dissemination and Utilization Branch

The Enhanced Dissemination and Utilization Branch (EDUB) collects, synthesizes, and communicates knowledge on the determinants of population health in order to maintain and improve the health of the entire population and reduce inequalities between population groups. The Branch translates research into effective community health promotion programs and practices, forges strategic partnerships to improve health and eliminate health disparities, and builds effective communication among organizations and communities to assure input and ownership for improving community health. Results are achieved by providing technical assistance and information resources to diverse audiences, including high-risk and underserved groups in a variety of community practice settings. The Branch identifies appropriate health outcomes for assessing successful implementation, and conducts evaluation activities to continuously improve and inform program planning. The We Can!TM (Ways to Enhance Children’s Activity & Nutrition) program illustrates how EDUB translates and communicates science-based information to communities, partners, and the public to prevent overweight in children. Through strategic partnerships, outreach, and communication strategies We Can!s array of resources, tactics, and tips are reaching families and communities in all 50 states and beyond with programming aimed at helping children maintain a healthy weight.

The Office of Research Training and Minority Health (ORTMH)

The Office of Research Training and Minority Health (ORTMH) was established by the National Heart, Lung, and Blood Institute (NHLBI) effective July 1, 2002. The office has an overall mission to provide leadership and oversight of the NHLBI extramural research training and career development programs and policies, including an emphasis on the elimination of health disparities through research and training of a future diverse research workforce. The office develops, implements, and evaluates IC policies and procedures for research, training, and career development awards; (2) provides leadership, coordination, and/or oversight responsibility of information concerning the NHLBI’s programs, policies, and procedures to the biomedical research training community; and (3) provides and coordinates targeted programs including efficient utilization of existing mechanisms and data resources to address research training, manpower, and research
priorities, such as inclusion of minorities in research studies and ensuring a diverse research workforce. In addition, the office is the Institute’s focal point for advice and guidance on matters pertaining to minority health and minority participation in research, including identifying gaps and needs as well as opportunities to address them. It provides leadership, coordination, and oversight for an NHLBI-wide strategic plan to improve research for minority and health disparity populations on diseases and conditions that affect these groups disproportionately; (2) develops and promotes strategies for outreach to improve minority enrollment in clinical studies; and (3) promotes effective dialogue between researchers and trainees, including those in minority and health disparity communities, by establishing professional, community and/or mentoring networks important in communication with various population groups.

The Office of Science and Technology (OST)

The Office of Science and Technology (OST) at the NHLBI provides support to the Institute’s Director and Institute Divisions and Offices. It establishes goals and implements procedures and policies to accomplish them, conducts program analysis, develops reports on Institute activities, and coordinates the Institute’s technology transfer function. The OST is comprised of four programs: Program Studies and Reports; Science and Special Issues; Public Liaison; and Technology Transfer and Development.

The Office of Communications (OC)

The NHLBI Office of Communications provides a comprehensive, integrated, and technology-supported communications capability for all matters relating to the communication of the Institute’s vision, Strategic Plan, and mission oriented program activities and accomplishments to internal and external audiences; initiates, develops, and implements a dynamic, proactive, communications program appropriate for intended audiences; involves multiple groups on a national and international level and leverages the communications resources of local, national, and international sources including audience-specific interest groups; evaluates the effectiveness of communications activities; and coordinates and integrates activities of the Public Affairs and the Health Campaigns & Consumer Services Branches.

Public Affairs Branch

The Public Affairs Branch implements and maintains mutual communications between the NHLBI and the general public and internal and external audiences; maintains the Director’s, NHLBI Newsroom, and the American Recovery and Reinvestment Act and Strategic Plan Web sites; acts as event coordinator; oversees media relations; and advances the public face of the NHLBI.

Health Campaigns & Consumer Services Branch

The Health Campaigns and Consumer Services Branch utilizes the latest health and consumer communications, behavioral and social marketing research in planning communications strategies; develops consumer messages and public education campaigns for COPD, women and heart disease, and sickle cell disease; provides consulting services for printing, graphic design and publication layout, and provides support for NHLBI exhibits, product marketing and printed media and provides clearance support for the NHLBI’s print and Web-based publications, ensuring the Institute’s disseminations meet the NIH and the HHS clearance requirements.

Extramural Research Program

NHLBI extramural research programs are implemented through 3 scientific units—the Division of Cardiovascular Sciences, the Division of Lung Diseases, and the Division of Blood Diseases and Resources—and a service unit, the Division of Extramural Research Activities. Additionally, the Division for the Application of Research Discoveries focuses on translation, dissemination, and utilization of research findings. Research grants, program project grants, specialized center grants, cooperative agreements, research contracts, research career development awards, and institutional and individual national research service awards are used to support research, research training, and career development.

Division of Cardiovascular Sciences (DCVS)

DCVS provides leadership and supports basic, clinical, population, and health services research on the causes, prevention, and treatment of cardiovascular diseases. DCVS represents the union of two previously existing divisions, the Division of Cardiovascular Disease (DCVD) and the Division of Prevention and Population Sciences (DPPS).

The Division fosters research in disease areas, such as atherothrombosis, heart attack and heart failure, high blood pressure, stroke, atrial and ventricular arrhythmias, sudden cardiac death, adult and pediatric congenital heart disease, cardiovascular complications of diabetes and obesity, and other cardiovascular disorders. Technology development for the diagnosis and treatment of cardiovascular disorders is also supported. Research also includes a number of well-known epidemiological cohort studies that describe disease and risk factor patterns in populations; clinical trials of interventions to prevent disease and to prevent or modulate risk factors; studies of genetic, behavioral, sociocultural, health systems, and environmental influences on disease risk and outcomes; and studies of the application of prevention and treatment strategies to determine how to improve clinical care and public health. The Division supports training and career development for these areas of research. In addition to the Office of the Director, the Division is organized operationally as 3 Offices and 3 Programs that oversee 8 Branches.

- Office of Research Training and Career Development
- Office of Biostatistics Research
Office of Research

The Office of Research provides statistical expertise to members of all Divisions of the NHLBI and performs diverse functions in planning, designing, implementing and analyzing NHLBI-sponsored studies. The OBR has primary responsibility for providing objective, statistically sound, and medically relevant solutions to problems. When presented with a problem for which techniques are not yet available, the OBR is expected to provide a new and valid statistical solution. The OBR is concerned with designing efficient studies and monitoring data while studies are ongoing. All members of the professional staff have interests in statistical methodology relevant to clinical research studies. The OBR's methodological interest concern survival analysis, longitudinal data analysis, and efficient study designs, including the monitoring of ongoing clinical studies for efficacy and safety. Recently the OBR has made contributions to statistical genetics and has extended its expertise to bioinformatics.

Office of Biostatistics Research

The Office of Biostatistics Research (OBR) provides statistical expertise to members of all Divisions of the NHLBI and performs diverse functions in planning, designing, implementing and analyzing NHLBI-sponsored studies. The OBR has primary responsibility for providing objective, statistically sound, and medically relevant solutions to problems. When presented with a problem for which techniques are not yet available, the OBR is expected to provide a new and valid statistical solution. The OBR is concerned with designing efficient studies and monitoring data while studies are ongoing. All members of the professional staff have interests in statistical methodology relevant to clinical research studies. The OBR's methodological interest concern survival analysis, longitudinal data analysis, and efficient study designs, including the monitoring of ongoing clinical studies for efficacy and safety. Recently the OBR has made contributions to statistical genetics and has extended its expertise to bioinformatics.

Office of Research Training and Career Development

The Office of Research Training and Career Development supports training and career development programs in cardiovascular research, offering opportunities to individuals at all educational levels from high school students to academic faculty, including programs for individuals from diverse populations. The programs promote opportunities for investigators, early in their research careers and under mentorship from senior scientists, to perform basic, preclinical or clinical cardiovascular research and to take emerging and promising scientific and technological advances from discovery through preclinical and clinical studies. The Office also collaborates with the scientific community and professional organizations to ensure that training programs meet both the current and future needs of the cardiovascular research workforce. Programs supported by the Office include:

- Institutional and individual research training programs and fellowships for training of promising cardiovascular scientists at the predoctoral, postdoctoral, junior faculty, and established investigator levels.
- Diversity Supplements to ongoing research grants for support of young investigators from diverse backgrounds, from the high school to the junior faculty level.
- The Pathway to Independence Program, which allows the recipient to bridge the gap between a career development award and a research award.
- Career development programs specifically designed for clinical research or for minority researchers and institutions.

Office of Special Projects

The Office of Special Projects will represent the DCVS on NHLBI and NIH policy committees, oversee and work with Division leadership on selected activities of the DCVS clinical studies portfolio, foster communication within DCVS by developing and/or coordinating Division-wide and Institute-wide interest groups on various topics, develop and implement specific cross-cutting projects, and provide expert consultation as needed for the larger-scale projects or initiative development.

Program in Basic and Early Translational Research

The Program supports and provides leadership for basic, pre-clinical and early translational studies on vascular biology and hypertension, cardiovascular surgery, and the development of advanced technologies for the diagnosis and treatment of cardiovascular diseases. The portfolio includes an integrated basic and clinical research program studying the biological basis for vascular diseases and hypertension, and their diagnosis, treatment and prevention. Research on cardiovascular surgery includes both basic and pre-clinical research on surgical approaches, and clinical trials to establish evidence-based surgical therapies. The development of diagnostics encompasses research on biosensors, imaging technologies, and the application of “omic” methodologies. Therapeutic development includes drug and nucleic acid delivery technologies, regenerative and reparative medicine, gene therapy, and device development. The Program also supports training and career development for these areas of research. The Program is divided into two branches: the Vascular Biology and Hypertension Branch, and the Advanced Technologies and Surgery Branch.

Program in Adult and Pediatric Cardiac Research

The Program supports and provides leadership for basic, translational, and clinical research on the development, maturation, and functioning of the heart throughout all stages of life. The research portfolio includes a broad array of science including cardiac development and maturation, myocyte structure and function, myocardial energetics and metabolism, cardiac electrophysiology, coronary artery structure and function, the failing heart, valvular heart disease, exercise physiology, nutrition and the heart, congenital heart disease from birth through adulthood, the intrauterine environment and cardiovascular risk, cardiomyopathy, and coronary artery disease. A key function of the Program is to provide collaborative leadership for the systematic oversight of clinical research
The Division is organized into 2 branches and 1 center:

- Airway Biology and Disease Branch
- Lung Biology and Disease Branch
- National Center on Sleep Disorders Research

The Airway Biology and Disease Branch supports research and research training in asthma, COPD, cystic fibrosis, and airway function in health and disease. Basic research focuses on elucidating the etiology and pathophysiology of the diseases. Clinical studies focus on improving asthma management and reducing health disparities in asthma, improving COPD treatment and management, and developing genetic, pharmacologic, and nonpharmacologic (e.g., gene transfer) treatments for cystic fibrosis.

The Lung Biology and Disease Branch supports research, education, and training programs in lung cell and vascular biology; developmental biology and pediatric lung diseases; acute lung injury and critical care medicine; and interstitial lung diseases and lung immunology including pulmonary fibrosis, sarcoidosis, and pulmonary manifestations of HIV/AIDS and associated infections with emphasis on active and latent tuberculosis (TB) and drug-resistant TB. Basic research focuses on lung development and cell biology, including stem cell biology and cell-based therapies, and mechanisms of disease etiology and pathogenesis. Clinical studies focus on evaluating innovative therapies for acute lung injury and acute respiratory distress syndrome, pulmonary fibrosis, neonatal lung disease, pulmonary embolism, and pulmonary hypertension.

The National Center on Sleep Disorders Research plans, directs, and supports basic, clinical, and applied research, health education, training, and prevention research in sleep, chronobiology, and sleep disorders. It oversees developments in its program areas; assesses the national needs for research on causes, diagnosis, treatment, and prevention of sleep disorders and sleepiness; and coordinates sleep research activities across the Federal government and with professional, voluntary, and private organizations.

The NHLBI sleep research program seeks to understand the molecular, genetic, and physiological regulation of sleep and the relationship of sleep disorders to cardiovascular diseases. It also supports efforts to understand the relationships of sleep restriction and sleep-disordered breathing to the metabolic syndrome, including obesity, high blood pressure and stroke, dyslipidemia, insulin resistance, and vascular inflammation.

Division of Lung Diseases (DLD)

The DLD plans and directs a coordinated research program on the causes and progression of lung diseases and sleep disorders including their prevention, diagnosis, and treatment. It supports basic research, clinical trials, national pulmonary centers, technological development, and application of research findings. Activities focus on understanding the structure and function of the respiratory system, increasing fundamental knowledge of mechanisms associated with pulmonary disorders, and applying new findings to evolving treatment strategies for patients. The DLD, through the National Center on Sleep Disorders Research, also coordinates sleep research activities across the NIH, other Federal agencies, and outside organizations.

The Division is organized into 2 branches and 1 center:

- Airway Biology and Disease Branch
- Lung Biology and Disease Branch
- National Center on Sleep Disorders Research

The Airway Biology and Disease Branch supports research and research training in asthma, COPD, cystic fibrosis, and airway function in health and disease. Basic research focuses on elucidating the etiology and pathophysiology of the diseases. Clinical studies focus on improving asthma management and reducing health disparities in asthma, improving COPD treatment and management, and developing genetic, pharmacologic, and nonpharmacologic (e.g., gene transfer) treatments for cystic fibrosis.

The Lung Biology and Disease Branch supports research, education, and training programs in lung cell and vascular biology; developmental biology and pediatric lung diseases; acute lung injury and critical care medicine; and interstitial lung diseases and lung immunology including pulmonary fibrosis, sarcoidosis, and pulmonary manifestations of HIV/AIDS and associated infections with emphasis on active and latent tuberculosis (TB) and drug-resistant TB. Basic research focuses on lung development and cell biology, including stem cell biology and cell-based therapies, and mechanisms of disease etiology and pathogenesis. Clinical studies focus on evaluating innovative therapies for acute lung injury and acute respiratory distress syndrome, pulmonary fibrosis, neonatal lung disease, pulmonary embolism, and pulmonary hypertension.

The National Center on Sleep Disorders Research plans, directs, and supports basic, clinical, and applied research, health education, training, and prevention research in sleep, chronobiology, and sleep disorders. It oversees developments in its program areas; assesses the national needs for research on causes, diagnosis, treatment, and prevention of sleep disorders and sleepiness; and coordinates sleep research activities across the Federal government and with professional, voluntary, and private organizations.

The NHLBI sleep research program seeks to understand the molecular, genetic, and physiological regulation of sleep and the relationship of sleep disorders to cardiovascular diseases. It also supports efforts to understand the relationships of sleep restriction and sleep-disordered breathing to the metabolic syndrome, including obesity, high blood pressure and stroke, dyslipidemia, insulin resistance, and vascular inflammation.

Division of Blood Diseases and Resources (DBDR)

The DBDR plans and directs research and research training on the causes and prevention of blood diseases and disorders. Areas of interest encompass a broad spectrum of research from stem cell biology to medical management of blood diseases, with a focus on nonmalignant and premalignant processes. The DBDR has recently taken a leading role in developing cell-based therapies, combining the expertise of transfusion medicine and stem cell technology with the exploration of repair and regeneration of human tissues and biological systems. The Division also has a major responsibility to improve the adequacy and safety of the Nation's blood supply.

The Division is organized into 3 branches:

- Blood Diseases Branch
- Thrombosis and Hemostasis Branch
- Transfusion Medicine and Cellular Therapeutics Branch

The Blood Diseases Branch supports research and research training in nonmalignant disorders of the hematopoietic system including sickle cell disease and thalassemia. Attention is focused on reducing morbidity and mortality caused by the disorders and preventing their occurrence. The Branch oversees a program of Comprehensive Sickle Cell Centers, which collectively form a sickle cell disease clinical research network—and which individually conduct basic and clinical research—and provide state-of-the-art patient care, educational activities for patients and health professionals, community outreach, and genetic counseling.
services. A thalassemia clinical network is evaluating new treatment strategies and ensuring that research findings on optimal management of the disease are rapidly disseminated to practitioners and health care professionals.

The **Thrombosis and Hemostasis Branch** supports research and research training in hemostasis, thrombosis, and endothelial cell biology. It oversees a comprehensive program of basic research, clinical studies, and technology development focusing on understanding the pathogenesis of both arterial and venous thrombosis in order to improve the diagnosis, prevention, and treatment of thrombosis in heart attack, stroke, and peripheral vascular diseases. The Branch also supports research on bleeding disorders (e.g., hemophilia and von Willebrand Disease) and immune disorders (e.g., idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and systemic lupus erythematosus).

The **Transfusion Medicine and Cellular Therapeutics Branch** plans and directs research and research training in transfusion medicine, stem cell biology and disease, and clinical cellular medicine. It supports research on the use, safety, and availability of blood and blood components for transfusion and cellular therapies. The Branch also develops programs for basic and clinical research related to normal and abnormal cellular biology and pathology. In addition, it collaborates with governmental, private sector, and international organizations to improve the safety and availability of the global supply of blood and blood components.

**Division of Extramural Research Activities (DERA)**

The DERA provides a number of services to the Institute. For example, it represents the Institute on overall NIH committees on extramural program policies and oversees compliance with such policies within the NHLBI. It also provides grant and contract management services to the Institute's program divisions, and provides initial scientific merit review of some research grant applications (e.g., applications submitted in response to an Institute Request for Applications, RFA). In addition, the DERA coordinates the Institute's Committee Management Activities and the meetings of the National Heart, Lung, and Blood Advisory Council.

**Division for the Application of Research Discoveries (DARD)**

The mission of the DARD is to advance the application of scientific discoveries for the prevention, detection, and treatment of cardiovascular, lung, blood, and sleep diseases and conditions. DARD focuses on narrowing the gap between knowledge creation and application by translating scientific evidence into clinical guidelines that can be implemented in clinical practice settings and community health promotion or education programs that can be implemented in communities.

DARD activities create opportunities for communication and collaboration among researchers, clinical and public health practitioners, patients, and the general public. Communities of practice, knowledge networks, social media, Websites, conferences and symposia are some of the venues used to implement the mission.

DARD programs reach out to people in high risk, low-income communities with the goal of improving health and eliminating health disparities. DARD activities also identify gaps in knowledge needed to inform practice that can be addressed by future research. The ultimate goal of DARD's efforts is to improve the public's health by translating the science base into strategies, tactics, programs and products that can help improve the health of all Americans.

**Office of the Director**

The DARD Office of the Director (OD) provides oversight and vision for the Division's activities and for collaboration with other NHLBI Divisions, NIH Institutes, governmental entities, and relevant organizations and groups. The DARD OD provides scientific, administrative, and technical support and coordination to achieve NHLBI strategic planning goals and objectives and to fulfill the Division's mission.

**Research Translation Branch**

The Research Translation Branch provides leadership for projects that take emergent knowledge and translate that knowledge into effective approaches for practice. This task involves synthesizing and organizing evidence around priority diseases and conditions, leading the development of evidence-based systematic literature reviews, and leading the development of clinical practice guidelines. The Branch also develops clinical decision support systems and other innovative implementation applications for use in clinical and public health practice settings, and it facilitates knowledge exchange opportunities for researchers and practitioners around issues of research applicability and relevance to practice. Branch activities also identify knowledge gaps to inform future research.

**Enhanced Dissemination and Utilization Branch**

The Enhanced Dissemination and Utilization Branch collects, synthesizes, and communicates knowledge on the determinants of population health in order to maintain and improve the health of the entire population and reduce inequalities between population groups. The Branch translates research into effective community health promotion programs and practices, forges strategic partnerships to improve health and eliminate health disparities, and builds effective communication among organizations and communities to assure input and ownership for improving community health. Results are achieved by providing technical assistance and information resources to diverse audiences, including high-risk and underserved groups in a variety of community practice settings. The Branch identifies appropriate health outcomes for assessing successful implementation, and conducts evaluation activities to continuously improve and inform program planning.

**Intramural Research Program**

**Division of Intramural Research (DIR)**

The DIR conducts laboratory and clinical research in heart, vascular, lung, blood, and kidney diseases and develops technology related to cardiovascular and pulmonary diseases.

The DIR is organized into 4 centers and 3 branches:

- **Biochemistry and Biophysics Center**
- **Cell Biology and Physiology Center**
- **Genetics and Development Biology Center**
Intramural Branches

- Immunology Center
- Translational Medicine Branch
- Hematology Branch
- Pulmonary and Vascular Medicine Branch

The Biochemistry and Biophysics Center studies the molecular basis of structure-function relationships of proteins and biologically relevant molecules. It performs state-of-the-art studies of protein structure and functional interactions, develops mathematical tools for generating models of protein structure-function relationships, elucidates mechanisms of enzyme function, and investigates relationships between protein structure-function and cell signaling pathways.

The Cell Biology and Physiology Center studies mechanisms that regulate cellular function and physiology. It evaluates mechanisms that control different molecular machines within the cytosol, including those involved in muscle contraction, and cytosolic and membrane transport processes. The Center studies cellular signaling events associated with hormone action, cytosolic trafficking, and energy metabolism; investigates the role of cellular processes on function and adaptation in whole animal model systems; and develops unique measuring devices for studying biochemical and physiological processes in intact cells, whole animals, and clinical situations.

The Genetics and Development Biology Center studies mechanisms that regulate cardiovascular development and the etiology of congenital heart anomalies and cardiovascular disease. It evaluates the function of specific genes and transcription factors in the development of the heart and other tissues, develops techniques and approaches for gene delivery and gene therapy, and investigates processes that regulate and interpret the genetic code in development and disease.

The Immunology Center studies intracellular and signaling processes involved in the activation of lymphocytes and mast cells, investigates mechanisms by which drugs and other agents result in allergic-autoimmune reactions, and applies the results to the development of diagnostic and therapeutic approaches.

The Translational Medicine Branch conducts biomedical research directed at defining at the molecular level, normal and abnormal biologic function. It develops diagnostic and therapeutic modalities for the treatment and understanding of cardiovascular disease and implements mechanism-based clinical studies.

The Hematology Branch investigates normal and abnormal hematopoiesis. It focuses on bone marrow failure, viral infections of hematopoietic cells, gene therapy of hematologic and malignant diseases, bone marrow transplantation, and mechanisms of immunologically mediated syndromes like graft-versus-host disease and autoimmune diseases.

The Pulmonary and Vascular Medicine Branch conducts research on the lung, heart, and systemic vasculature directed at defining—at the molecular, biochemical, and functional levels—normal physiological function and novel mechanisms of disease.

This page last reviewed on January 3, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

In January 2007, the National Human Genome Research Institute (NHGRI) celebrated its 10th anniversary as an institute of the National Institutes of Health (NIH), marking a decade that saw genomics emerge as a powerful research tool and looking ahead to an era in which genomics will transform medical care.

NHGRI, established originally as the National Center for Human Genome Research in 1989, led the NIH's contribution to the International Human Genome Project. The project, which had as its primary goal the sequencing of the 3 billion DNA letters that make up the human genetic instruction book, was successfully completed in April 2003.

NHGRI's mission has evolved over the years to encompass a broad range of studies aimed at understanding the structure and function of the human genome and its role in health and disease. To that end, the institute supports the development of resources and technology that will accelerate genome research and its application to human health. A critical part of NHGRI's mission continues to be the study of the ethical, legal and social implications (ELSI) of genome research. NHGRI also supports the training of investigators, as well as the dissemination of genome information to the public and to health professionals.

NHGRI is organized into three main divisions: the Office of the Director, which provides guidance to scientific programs and oversees the general operation of the institute; the Division of Extramural Research, which supports and administers the role of NIH in genomic research; and the Division of Intramural Research, which is home to the institute's in-house, genetics research laboratories.

Research guidance and guidance related to NHGRI grants comes from the National Advisory Council for Human Genome Research, which meets three times a year, usually in Bethesda, MD. Members include representatives from health and science disciplines, public health, social sciences and the general public. Portions of the council meetings are open to the public.

IMPORTANT EVENTS IN NHGRI HISTORY

August 1988—Program advisory committee on the human genome is established to advise the NIH on all aspects of research in the area of genomic analysis.

October 1988—The Office for Human Genome Research is created within the NIH Office of the Director. Also, NIH and the Department of Energy (DOE) sign a memorandum of understanding outlining plans for cooperation on genome research.

February 1988—NIH Director James Wyngaarden assembles scientists, administrators and science policy experts in Reston, VA, to lay out an NIH plan for the Human Genome Project (HGP).

January 1989—The program advisory committee on the human genome holds its first meeting in Bethesda, MD.

October 1989—The National Center for Human Genome Research (NCHGR) is established to carry out the NIH's component of the HGP.

April 1990—The five-year plan with specific goals for the project is published.

May 1990—The National Advisory Council for Human Genome Research (NACHGR) is established.

July 1990—The genome research review committee is created so the center could conduct appropriate peer review of human genome grant applications.

October 1990—The HGP officially begins.

January 1991—The NACHGR meets for the first time in Bethesda, MD.

April 1992—James Watson resigns as first director of the NCHGR. Michael Gottesman is appointed acting center director.

February 1993—The center's Division of Intramural Research (DIR) is established.

April 1993—Francis S. Collins is appointed NCHGR director.

October 1993—The Human Genome Project revises its five-year goals through September 1998.

September 1994—Human genetic mapping goal achieved one year ahead of schedule.
November 1995—NCHGR celebrates its fifth anniversary. J.D. Watson Lecture is established.

April 1995—Task Force on Genetic Testing established as a subgroup of the NIH-DOE Ethical, Legal and Social Implications (ELSI) working group.

April 1996—Human DNA sequencing begins with pilot studies at six U.S. universities.

April 1996—An international team completes DNA sequence of first eukaryotic genome, Saccharomyces cerevisiae, or common brewer's yeast.

September 1996—Center for Inherited Disease Research (CIDR), a project co-funded by eight NIH institutes and centers to study the genetic components of complex disorders, is established on the Johns Hopkins Bayview Medical Center campus in Baltimore.

October 1996—Scientists from government, university and commercial laboratories around the world reveal a map that pinpoints the locations of more than 16,000 genes in human DNA.

November 1996—NCHGR and other researchers identify the location of the first gene associated with Parkinson's disease.

November 1996—NCHGR and other researchers identify the location of the first major gene that predisposes men to prostate cancer.

December 1996—Report issued by the Joint NIH/DOE Committee evaluating the ELSI program of the HGP.

January 1997—Department of Health and Human Services Secretary Donna E. Shalala signs documents giving NCHGR a new name and new “status” among other research institutes at NIH. The new name, the National Human Genome Research Institute (NHGRI), more accurately reflects its growth and accomplishments. As an institute, NHGRI can more appropriately interact with other federal agencies and share equal standing with other institutes at NIH.

March 1997—Government-citizen group suggests policies to limit genetic discrimination in the workplace.

May 1997—NHGRI and other scientists show that three specific alterations in the breast cancer genes BRCA1 and BRCA2 are associated with an increased risk of breast, ovarian and prostate cancers.

June 1997—NHGRI scientists precisely identify a gene abnormality that causes some cases of Parkinson disease.

July 1997—A map of human chromosome 7 is completed.

December 1997—NHGRI and other researchers identify an altered gene that causes Pendred syndrome.

March 1998—Vice President Al Gore announces that the Clinton administration is calling for legislation to bar employers from discriminating against workers in hiring or promotion because of their genetic makeup.

September 1998—At a meeting of the HGP's main advisory body, project planners present a new plan to produce a “finished” version of the DNA sequence of the human genome by the end of year 2003, two years ahead of its original schedule. The HGP plans to generate a “working draft” that, together with the finished sequence, will cover at least 90 percent of the genome in 2001. The “working draft” will be immediately valuable to researchers and form the basis for a high-quality, “finished” genome sequence.

September 1998—A major international collaborative research study finds on the X chromosome the site of a gene for susceptibility to prostate cancer; this is the first time a gene for a common type of cancer is mapped to the X chromosome.

October 1998—NIH and DOE develop a new five-year plan for the HGP. This plan, published in the October 23, 1998, issue of the journal Science, is designed to carry the project forward for the next five years, fiscal years 1999 through 2003.

December 1998—The genome of the tiny roundworm Caenorhabditis elegans, is sequenced by NHGRI and other HGP-funded scientists.

March 1999—Large scale sequencing of the human genome begins.

September 1999—Scientists confirm they are on schedule to produce the “working draft” of the genetic blueprint of humankind by spring of 2000.

October 1999—President Bill Clinton and First Lady Hillary Rodham Clinton host the eighth Millennium Evening at the White House. The program is titled “Informatics Meets Genomics.”

November 1999—NHGRI hosts the first annual “Consumer Day” conference to inform patients, families and health care providers about the impact of the HGP.

November 1999—NHGRI, DOE and Wellcome Trust hold a celebration of the completion and deposition into GenBank of 1 billion base pairs of the human genome DNA sequence.

December 1999—NHGRI and other HGP-funded scientists unravel for the first time the genetic code of an entire human chromosome. The findings are reported in the December 2 issue of Nature.

February 2000—President Clinton signs an Executive Order to prevent genetic discrimination in the federal workplace.

March 2000—Public consortium of scientists and a private company release a substantially complete genome sequence of the fruitfly Drosophila melanogaster. The Journal Science publishes the findings.
April 2000—The NHGRI, the NIH Office of Rare Disease Research and the Don and Linda Carter Foundation sponsor the first NIH Conference on Holoprosencephaly.

May 2000—Scientists in Japan and Germany report in Nature that they have unraveled the genetic code of human chromosome 21, already known to be involved with Down syndrome, Alzheimer’s disease, Usher syndrome and Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease.

June 2000—The HGP announces a major milestone: It has assembled 85 percent of the sequence of the human genome—the genetic blueprint for a human being.

August 2000—Scientists discover a genetic “signature” that may help explain how malignant melanoma, a deadly form of skin cancer, can spread to other parts of the body. Findings are reported in the journal Nature.

October 2000—The NHGRI, the Wellcome Trust and three private companies collaborate to form the Mouse Sequencing Consortium to accelerate the sequencing of the mouse genome.

October 2000—The HGP is the recipient of the American Society of Human Genetics’ Allan Award to honor the hundreds of scientists involved in deciphering the human genetic code.

November 2000—NHGRI hosts its second annual “Consumer Day.”

January 2001—The ELSI Research Programs of NHGRI and the U.S. Department of Energy cosponsor a conference to celebrate a decade of research and consider the impact of the new science on genetic research, health and policy.

February 2001—The HGP publishes a series of scientific papers in the journal Nature. The papers, provide the first analysis of the human genome sequence, describing how it is organized and how it evolved. The analysis reveals that the human genome only contains 30,000 to 40,000 genes, far fewer than the 100,000 previously estimated.

February 2001—NHGRI scientists use microarray technology to develop a gene test that differentiates hereditary and sporadic breast cancer types. The New England Journal of Medicine publishes the findings.

March 2001—NHGRI and HGP-funded scientists find a new tumor suppressor gene on human chromosome 7 that is involved in breast, prostate and other cancers. A single post-doc, using the “working draft” data, is able to pin the gene down in weeks. In the past, the same work would have taken several years and contributions from many scientists.

May 2001—The Mouse Genome Sequencing Consortium announces it has achieved three-fold coverage of the mouse DNA sequence. The publicly available data represents 95 percent of the mouse sequence, and can be used to uncover human genes by comparing the genomes of mouse and human to each other.


September 2001—NHGRI creates the Centers for Excellence in Genomic Sciences (CEGS) program, which supports the formation of interdisciplinary research teams that develop innovative genomic research projects using the data sets and technologies developed by the HGP. The initial CEGS grants are awarded to the University of Washington and Yale University.

November 2001—NHGRI co-sponsors a forum, entitled The Human Genome Project: The Challenges and Impact of Human Genome Research for Minority Communities, to inform the public, students and healthcare providers in minority communities about the scientific advances and the ethical, legal and societal impacts of the HGP.

December 2001—NHGRI holds a planning conference, called Beyond the Beginning: The Future of Genomics, at the Airlie Conference Center in Warrenton, VA, to develop a broad vision for the future of genomics research.

January 2002—NHGRI scientists and collaborators at Johns Hopkins Medical Institutions in Baltimore and The Cleveland Clinic identify a gene on chromosome 1 that is associated with an inherited form of prostate cancer in some families. Nature Genetics publishes the findings.

February 2002—NHGRI and the NIH Office of Rare Diseases launch a new information center to provide accurate, reliable information about genetic and rare diseases to patients and their families.

May 2002—The Mouse Genome Sequencing Consortium releases a working draft assembly of the mouse genome, which is made freely available in public databases.

May 2002—NHGRI prioritizes the next set of model organisms to sequence as capacity becomes available. They include chicken, chimpanzee, several species of fungi, a sea urchin, the honeybee and a microscopic animal commonly used in laboratory studies called Tetrahymena.

July 2002—NHGRI awards two new Centers for Excellence in Genomic Sciences grants to Stanford University and the Molecular Sciences Institute, Berkeley, CA.

June 2002—NHGRI launches a redesigned Web site, www.genome.gov, which provides improved usability and easy access to new content for a wide range of users.

September 2002—NHGRI adds the cow, the dog and the ciliate Oxytricha to its list of prioritized model organisms to sequence as capacity becomes available.
September 2002—An international team of researchers led by NHGRI pinpoints the gene defect responsible for a form of the devastating brain disorder microcephaly, found for nine generations in infants among the Old Order Amish. *Nature Genetics* publishes the results, which may shed new light on normal brain development.


October 2002—NHGRI, in cooperation with five other NIH institutes, awards a grant to combine three of the world’s current protein databases into a single global resource called UniProt.

October 2002—NHGRI launches the International HapMap Project, a $100 million public-private effort to create a new type of genome map that will chart genetic variation among human populations. The HapMap will serve as a tool to speed the search for the genes involved in common disorders such as asthma, diabetes, heart disease and cancer.

November 2002—NHGRI selects Eric D. Green, M.D., Ph.D., as its new scientific director.

November 2002—NHGRI names William A Gahl, M.D., Ph.D., as its new intramural clinical director.

December 2002—The Mouse Genome Sequencing Consortium announces the publication of a high-quality draft sequence of the mouse genome.

March 2003—NHGRI launches the Encyclopedia Of DNA Elements (ENCODE) pilot project to identify all functional elements in human DNA.

April 2003—NHGRI celebrates the successful completion of the HGP two years ahead of schedule and under budget. The event coincides with, the 50th anniversary of the description of DNA's double helix and the 2003 publication of the vision document for the future of genomics research.

April 2003—NHGRI researchers identify the gene that causes the premature aging disorder progeria. The findings were released online in the journal *Nature*.

June 2003—NHGRI researchers make discoveries that may lead to safer methods of gene therapy.

June 2003—A detailed analysis of the sequence of the human Y chromosome is published in *Nature*.

July 2003—A detailed analysis of the sequence of chromosome 7, carried out by a multinational team of scientists led by the Washington University School of Medicine, uncovers structural features that appear to promote genetic changes that can cause disease. The findings were reported in the Journal *Nature*.

August 2003—A team of researchers led by NHGRI compares the genomes of 13 vertebrate animals. The results, published in *Nature*, suggest that comparing a wide variety of species’ genomes will illuminate genomic evolution and help to identify functional elements in the human genome.

October 2003—NHGRI announces the first grants in a three-year, $36 million scientific reconnaissance mission—called ENCODE—aimed at discovering all parts of the human genome that are crucial to biological function.

November 2003—NHGRI selects five centers to carry out a new generation of large-scale sequencing projects designed to maximize the promise of the HGP and dramatically expand understanding of human health and disease.

December 2003—NHGRI announces the formation of a new branch—the Social and Behavioral Research Branch—within its Division of Intramural Research.

December 2003—NHGRI announces the first draft version of the chimpanzee genome sequence and its alignment with the human genome.

December 2003—The International HapMap Consortium publishes a paper that sets forth the scientific rationale and strategy behind its effort to create a map of human genetic variation.

January 2004—NHGRI announces that the first draft version of the honey bee genome sequence has been deposited into free public databases.

January 2004—NHGRI and other scientists successfully create transgenic zebra fish using sperm genetically modified and grown in a laboratory dish, an achievement with implications for wide ranging research, from developmental biology to gene therapy. The study was published in the *Proceedings of the National Academy of Sciences*.

February 2004—The Genetic and Rare Disease Information Center established by NHGRI and the NIH Office of Rare Diseases, announces it has expanded its efforts to enable healthcare workers, patients and families who speak Spanish to take advantage of its free services.

February 2004—NHGRI's Large-Scale Sequencing Research Network announces it will begin sequencing the genome of the first marsupial, the gray short-tailed South American opossum, and more than a dozen other model organisms to further understanding of the human genome.

March 2004—NHGRI announces that the first draft version of the chicken genome sequence has been deposited into free public databases.

March 2004—NHGRI researchers and other scientists find variants in a gene that may predispose people to type 2 diabetes, the most common form of the disease.

March 2004—NHGRI announces that the International Sequencing Consortium has launched a free online resource, where scientists and the public can view the latest information on sequencing projects for animal, plant and eukaryotic genomes.

March 2004—The International Rat Genome Sequencing Project Consortium announces the publication of a high-quality draft sequence of the rat genome.
June 2004—NHGRI and the Melbourne-based Australian Genome Research Facility, Ltd. announce a partnership to sequence the genome of the tammar wallaby, a member of the kangaroo family.

June 2004—NHGRI announces it has established two new Centers of Excellence in Genomic Science at Harvard Medical School in Boston and the Johns Hopkins University School of Medicine in Baltimore.

July 2004—NHGRI announces that the first draft version of the dog genome sequence has been deposited into free public databases.

July 2004—NHGRI launches the NHGRI Policy and Legislative Database, an online resource that will enable researchers, health professionals and the general public to more easily locate information on laws and policies related to a wide array of genetic issues.

July 2004—NHGRI scientists and an interdisciplinary consortium of researchers from 11 universities and institutions discover a possible inherited component for lung cancer, a disease normally associated with external causes, such as cigarette smoking.

August 2004—NHGRI's Large-Scale Sequencing Research Network announces a comprehensive strategic plan to sequence 18 additional organisms, including the African savannah elephant, domestic cat and orangutan, to help interpret the human genome.

August 2004—NHGRI launches four interdisciplinary Centers for Excellence in Ethical, Legal and Social Implications Research to address some of the most pressing questions raised by recent advances in genetic and genomic research.

October 2004—NHGRI announces that the first draft version of the bovine genome sequence has been deposited into free public databases.

October 2004—NHGRI awards more than $38 million in grants to develop new sequencing technologies to accomplish the near-term goal of sequencing a mammalian-sized genome for $100,000 and the longer-term challenge of sequencing an individual human genome for $1,000 or less.

October 2004—NHGRI announces the election of two of its medical geneticists, Alan Guttmacher and Robert Nussbaum, to the Institute of Medicine of the National Academies.

October 2004—The International Human Genome Sequencing Consortium, led in the United States by NHGRI and the Department of Energy (DOE), publishes its scientific description of the finished human genome sequence. The analysis, published in Nature, reduces the estimated number of human protein-coding genes from 35,000 to only 20,000-25,000, a surprisingly low number for our species.

October 2004—The ENCODE Consortium publishes a paper in Science that sets forth the scientific rationale and strategy behind its quest to produce a comprehensive catalog of all parts of the human genome crucial to biological function.

November 2004—NHGRI partners with the Office of the U.S. Surgeon General to launch a free computer program, My Family Health Portrait, which the public can use to record important information about their family health history.

December 2004—NHGRI and the international Chicken Genome Sequencing Consortium publish in Nature an analysis comparing the chicken and human genomes. It is the first bird to have its genome sequenced and analyzed.

February 2005—NHGRI establishes an Office of Ethics, appointing Barbara Fuller as Deputy Ethics Counselor.

March 2005—NIH applauds the first comprehensive analysis of the sequence of the human X chromosome. The analysis, published in Nature, provides sweeping new insights into the evolution of sex chromosomes and the biological differences between males and females.

August 2005—NHGRI awards grants totaling more than $32 million to advance the development of innovative sequencing technologies intended to reduce the cost of DNA sequencing and expand the use of genomics in biomedical research and health care.

August 2005—In a surprising development, a research team led by NHGRI finds that a class of experimental anti-cancer drugs shows promise in laboratory studies for treating the fatal genetic disorder that causes premature aging. The results are published in the Proceedings of the National Academy of Sciences.

August 2005—The first comprehensive comparison of the genetic blueprints of humans and chimpanzees is published in the journal Nature, showing our closest living relatives share perfect identity with 96 percent of our DNA sequence.

October 2005—The NIH awards contracts that will give researchers unprecedented access to two private collections of knockout mice, providing valuable models for the study of human disease and laying the groundwork for a public, genome-wide library of knockout mice.

October 2005—The International HapMap Consortium publishes a comprehensive catalog of human genetic variation. This landmark achievement, published in Nature, serves to accelerate the search for genes involved in common diseases, such as asthma, diabetes, cancer and heart disease.

November 2005—As part of the U.S. Surgeon General's Family Health Initiative, an updated version of the computerized tool designed to help families gather their health history information is unveiled.

December 2005—NHGRI and the National Cancer Institute (NCI) launch The Cancer Genome Atlas (TCGA), a comprehensive effort to accelerate understanding of the molecular basis of cancer through the application of genome analysis technologies.

March 2006—A multi-institution team of experts, coordinated by geneticists from NHGRI, supports efforts to identify more than 70 bodies still unidentified in the aftermath of Hurricane Katrina.
July 2006—Researchers at the NIH Chemical Genomics Center (NCGC) -- a trans-NIH center administered by NHGRI -- develop a new screening approach that can profile compounds in large chemical libraries more accurately and precisely than standard methods. This advance speeds the production of data that can be used to probe biological activities and identify leads for drug discovery.

August 2006—NHGRI awards grants totaling $54 million over five years to establish one new Center of Excellence in Genomic Science at the California Institute of Technology in Pasadena, Calif. and continue support for two existing centers.

September 2006—NHGRI and NCI choose the first three cancers to be studied in the pilot phase of The Cancer Genome Atlas. The cancers to be studied in the TCGA Pilot Project are lung, brain (glioblastoma) and ovarian.

October 2006—NHGRI awards grants totaling more than $13 million to further speed the development of innovative sequencing technologies that reduce the cost of DNA sequencing and expand the use of genomics in medical research and health care.

April 2007—In the most comprehensive look at genetic risk factors for type 2 diabetes to date, NHGRI researchers, working in close collaboration with two other scientists, identify at least four new genetic variants associated with increased risk of diabetes and confirm existence of another six. All three reports are published in Science.

May 2007—NHGRI and NCI team with Group Health Cooperative in Seattle and Henry Ford Health System in Detroit to launch the Multiplex Initiative. The effort will explore the interest level of healthy, young adults in receiving genetic testing for eight common conditions.

July 2007—As part of the TCGA pilot, NCI and NHGRI award eight two-year grants totaling $3.4 million to support the development of innovative technologies for exploring the genomic underpinnings of cancer.

August 2007—Looking ahead to a future in which each person's genome can be sequenced as a routine part of medical research and health care, NHGRI awards more than $15 million in grants to support development of innovative technologies with the potential to dramatically reduce the cost of DNA sequencing.

August 2007—NHGRI establishes Genomic Healthcare Branch, headed by William Gregory Feero to promote the effective integration of genomic discoveries into healthcare.

August 2007—NHGRI awards grants of $30 million to establish a new Center of Excellence in Genomic Science at the Dana Farber-Cancer Institute and to continue support of the center at Stanford University.

August 2007—NHGRI establishes the Office of Population Genomics, headed by Teri Manolio.

October 2007—NHGRI awards grants totaling more than $80 million over the next four years to expand the ENCODE project, which in its pilot phase yielded provocative new insights into the organization and function of the human genome.

October 2007—NHGRI establishes two new centers at the University of North Carolina, Chapel Hill and University of Pennsylvania, Philadelphia, to address the most critical ethical, legal and social questions faced by researchers and patients involved in genetic and genomic research.

October 2007—The NIH Intramural Sequencing Center (NISC), a trans-NIH center administered by NHGRI, celebrates its 10th anniversary with a day-long symposium.

November 2007—An international team of scientists, supported in part by NHGRI, announces that its systematic effort to map the genomic changes underlying lung cancer has uncovered a critical gene alteration not previously linked to any form of cancer. The results are published in Nature.

November 2007—In a White House Ceremony, NHGRI Director Francis S. Collins is awarded the Presidential Medal of Freedom by President George W. Bush.

December 2007—To better understand the role that bacteria, fungi and other microbes play in human health, the NIH launches the Human Microbiome Project. The human microbiome is the collective genomes of all microorganisms present in or on the human body. NHGRI, the National Institute of Allergy and Infectious Diseases, and the National Institute of Dental and Craniofacial Research lead the project on behalf of NIH.

January 2008—An international research consortium announces the 1000 Genomes Project. This ambitious effort will involve sequencing the genomes of at least a thousand people from around the world to create the most detailed and medically useful picture to date of human genetic variation. NHGRI is a major funder of the 1000 Genomes Project.

February 2008—NHGRI and the National Institute of Environmental Health Sciences (NIEHS) collaborate with the U.S. Environmental Protection Agency to begin testing the safety of chemicals, ranging from pesticides to household cleaners. The initiative uses the NIH Chemical Genomics Center's (NCGC) high-speed, automated screening robots to test suspected toxic compounds using cells and isolated molecular targets instead of laboratory animals.

March 2008—NIH announces the establishment of the NIH Intramural Center for Research on Genomics and Global Health (CRGGH), a new venue for research about the way populations are impacted by diseases, including obesity, diabetes and hypertension. CRGGH will employ a genomics approach, collecting and analyzing genetic, clinical, lifestyle and socio-economic data to study a range of clinical conditions that have puzzled and troubled public health experts for decades. CRGGH is part of the NIH Office of Intramural Research and administered by NHGRI.

May 2008—The first analysis of the genome sequence of the duck-billed platypus, reveals clues about how genomes were organized during the early evolution of mammals. The research, published in Nature, was supported in part by NHGRI.
May 2008—President Bush signs into law the Genetic Information Nondiscrimination Act (GINA) that will protect Americans against discrimination based on their genetic information when it comes to health insurance and employment. The bill had passed the Senate unanimously and the House by a vote of 414 to 1.

May 2008—Francis S. Collins announces his intention to step down as NHGRI director on August 1 to explore writing projects and other professional opportunities.

August 2008—Alan E. Guttmacher is named Acting Director of NHGRI.

September 2008—NIH funds a network of nine centers across the country that will use high tech screening methods to identify small molecules for use as biological probes and targets for drug development. The NIH Chemical Genomics Center, administered by NHGRI, is funded as part of the network.

September 2008—The TCGA Research Network reports the first results of its large-scale, comprehensive study of the most common form of brain cancer, glioblastoma. In a paper published in *Nature*, the TCGA team describes the discovery of new genetic mutations and other types of DNA alterations with potential implications for the diagnosis and treatment of glioblastoma.

September 2008—The NIH Genes, Environment and Health Initiative, managed by NHGRI and NIEHS, awards grants, estimated to be up to $5.5 million over two years, for six studies aimed at finding genetic factors that influence the risks for stroke, glaucoma, high blood pressure, prostate cancer and other common disorders.

October 2008—A team of researchers from NHGRI and the National Heart, Lung, and Blood Institute (NHLBI) reports in *Proceedings of the National Academy of Sciences* that they have discovered an experimental anti-cancer drug can prevent—and even reverse—potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging.

October 2008—NIH announces the first awards for its Human Microbiome Project, which will lay a foundation for efforts to explore how complex communities of microbes interact with the human body to influence health and disease.

October 2008—NHGRI researchers help to identify a protein that plays matchmaker between two key types of white blood cells, T and B cells, enabling them to interact in a way that is crucial to establishing long-lasting immunity after an infection. The results are published in *Nature*.

October 2008—The NIH Human Microbiome Project collaborates with scientists around the globe to announce the International Human Microbiome Consortium (IHMC), an effort that will enable researchers to characterize the relationship of the human microbiome in the maintenance of health and in disease.

October 2008—a multi-institution team, funded by NHGRI, reports results in *Nature* of the largest effort to date to chart the genetic changes involved in the most common form of lung cancer, lung adenocarcinoma.

December 2008—An international consortium including NHGRI researchers, in search of the genetic risk factors for obesity, identifies six new genetic variants associated with BMI, or body mass index, a measurement that compares height to weight. The results, funded in part by NIH, are published online in the journal *Nature Genetics*.

February 2009—an NIH study that includes NHGRI researchers reveals surprising new insights into the process used to initially identify an experimental drug now being tested in people with cystic fibrosis and muscular dystrophy. In a paper published in *Proceedings of the National Academies of Sciences*, researchers from the NIH Chemical Genomics Center, suggest more work may be needed to make sure the screening process to select promising agents was not flawed by its effects on a firefly enzyme used as a marker.

February 2009—in a large-scale study and an upcoming clinical trial, scientists supported in part by NHGRI, use information from thousands of genetically and geographically diverse patients to develop a way to use genetic information from patients that could help doctors better determine optimal warfarin doses. The analysis is reported in *The New England Journal of Medicine*.

March 2009—an international team that includes NHGRI investigators reports in the journal *Pediatrics* that children born to women who have low blood levels of vitamin B12 shortly before and after conception may have an increased risk of a neural tube defect.

March 2009—Researchers from the NIH and NHGRI find a new way of detecting functional regions in the human genome. The novel approach involves looking at the three-dimensional shape of the genome’s DNA and not just reading the sequence of the four-letter alphabet of its DNA bases. The results are published online in *Science*.

March 2009—a team led by NHGRI scientists identifies a gene that suppresses tumor growth in melanoma, the deadliest form of skin cancer. The finding is reported in the journal *Nature Genetics* as part of a systematic genetic analysis of a group of enzymes implicated in skin cancer and many other types of cancer.

April 2009—Scientists identify a previously unknown connection between two genetic variants and an increased risk of stroke, providing strong evidence for the existence of specific genes that help explain the genetic component of stroke. The research is funded by NHLBI and several other NIH institutes and centers including NHGRI.

April 2009—NHGRI announces the release of the first version of PhenX, a free online toolkit aimed at standardizing measurements of research subjects’ physical characteristics and environmental exposures. The tools give researchers more power to compare data from multiple studies, accelerating efforts to understand the complex genetic and environmental factors that cause cancer, heart disease, depression and other common diseases.

April 2009—the U.S. Department of Agriculture and the NIH announce that an international consortium of researchers has completed an analysis of the genome of domestic cattle, the first livestock mammal to have its genetic blueprint sequenced and analyzed. The landmark research, which received major support from NHGRI, bolsters efforts to produce better beef and dairy products and lead to a better understanding of the human genome.

National Human Genome Research Institute - Organization - The NIH Almanac - Nationa... Page 7 of 9
May 2009—An international research team identifies a number of unsuspected genetic variants associated with systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension (high blood pressure), suggesting potential avenues of investigation for the prevention or treatment of hypertension. The work is supported in part by NHGRI.

May 2009—The NIH launches the first integrated drug development pipeline to produce new treatments for rare and neglected diseases. The $24 million program, whose laboratory operations are managed by NHGRI at the NIH Chemical Genomics, jumpstarts a trans-NIH initiative called the Therapeutics for Rare and Neglected Diseases program, or TRND.

May 2009—NHGRI researchers studying the skin's microbiome publish an analysis in the journal Science revealing that our skin is home to a much wider array of bacteria than previously thought. The study, done in collaboration with other NIH researchers, also shows the bacteria that live under your arms likely are more similar to those under another person's arm than they are to the bacteria that live on your forearm.

June 2009—The NIH's Human Microbiome Project awards more than $42 million to expand its exploration of how the trillions of microscopic organisms that live in or on our bodies affect our health.

July 2009—An NIH research team led by NHGRI researchers finds that a single evolutionary event appears to explain the short, curved legs that characterize all of today's dachshunds, corgis, basset hounds and at least 16 other breeds of dogs. In addition to what it reveals about short-legged dogs, the unexpected discovery provides new clues about how physical differences may arise within species and suggests new approaches to understanding a form of human dwarfism. The results are reported in the journal Science.

July 2009—NIH researchers report in the online issue of PLoS Genetics the discovery of five genetic variants related to blood pressure in African-Americans, findings that may provide new clues to treating and preventing hypertension. This effort, which includes NHGRI researchers, marks the first time that a relatively new research approach, called a genome-wide association study, has focused on blood pressure and hypertension in an African-American population.

August 2009—Researchers, supported in part by NHGRI, generate massive amounts of DNA sequencing data of the complete set of exons, or "exomes", from the genomes of 12 people. The findings, which demonstrate the feasibility of this strategy to find rare genetic variants that may cause or contribute to disease, are published online in the journal Nature.

August 2009—A team of NIH researchers, led by NHGRI, discover variants in just three genes acting in different combinations that account for the wide range of coat textures seen in dogs from the poodle's tight curls to the beagle's stick-straight fur. These findings can be found in the advance online issue of the journal Science.

August 2009—NHGRI researchers lead a study that identifies a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma. This discovery, published in Nature Genetics, is particularly encouraging because some of the mutations, which were found in nearly one-fifth of melanoma cases, reside in a gene already targeted by a drug approved for certain types of breast cancer.

September 2009—NHGRI announces grants expected to total approximately $45 million to establish new Centers of Excellence in Genomic Science at the Medical College of Wisconsin and University of North Carolina, Chapel Hill as well as to continue support of existing centers at Johns Hopkins University and the University of Southern California.

October 2009—NHGRI launches the next generation of its online Talking Glossary of Genetic Terms. The glossary contains several new features, including more than 100 colorful illustrations and more than two dozen 3-D animations that allow the user to dive in and see genetic concepts in action at the cellular level.

October 2009—An NHGRI-led research team finds that carriers of a rare, genetic condition called Gaucher disease face a risk of developing Parkinson's disease more than five times greater than the general public. The findings are published in the New England Journal of Medicine.

November 2009—After an extensive national search, NIH Director Francis S. Collins, M.D., Ph.D., announces the appointment of Eric D. Green, M.D., Ph.D., to be director of the NHGRI. It is the first time an institute director has risen to lead the entire NIH and subsequently picked his own successor.

BIографical Sketch of NHGRI Director, Eric D. Green, M.D., Ph.D.

Eric D. Green, M.D., Ph.D., was named to be the third director of the National Human Genome Research Institute (NHGRI), effective at the end of November 2009. Prior to this appointment, he was the Scientific Director of NHGRI, a position he has held since 2002. In addition, he served as chief of the NHGRI Genome Technology Branch (since 1996) and director of the NHGRI Intramural Sequencing Center (NISC) (since 1997). Born and raised in Saint Louis in December 1959, Dr. Green comes from a scientific family. His father, Maurice Green, Ph.D., is chairman of the Institute for Molecular Virology at Saint Louis University School of Medicine, and his brother Michael Green, M.D., Ph.D., is a molecular biologist at the University of Massachusetts at Worcester, where he directs the Program in Gene Function and Expression and is an investigator of the Howard Hughes Medical Institute.

Dr. Green received a Bachelor of Science in bacteriology from the University of Wisconsin at Madison in 1981 and both a Ph.D. in cell biology and an M.D. in 1987 from Washington University in Saint Louis. From 1987 to 1992, he was a resident in laboratory medicine in the departments of pathology and internal medicine at the Washington University School of Medicine, serving as chief resident in laboratory medicine from 1990 to 1992.

For his Ph.D., Dr. Green studied sugar molecules that are attached to proteins. But the scientific debate about the possibility of a Human Genome Project raging in the late 1980s coupled with his clinical interests in laboratory-based diagnostics prompted him to switch scientific fields. Dr. Green became a postdoctoral research fellow in the laboratory of Maynard V. Olson, Ph.D., then at the Washington University School of Medicine genetics department and a pioneer in developing approaches for studying whole genomes.
In 1992, Dr. Green was appointed assistant professor of pathology, genetics, and internal medicine at the Washington University School of Medicine, as well as a co-investigator in the Human Genome Center at Washington University, which made substantial contributions to the early successes of the Human Genome Project.

Dr. Green was recruited to join the newly formed NHGRI Division of Intramural Research in 1994. Two years later, he earned tenure at the National Institutes of Health (NIH), rising to the rank of a senior investigator; that same year, he was also appointed chief of the Genome Technology Branch. The next year, he became the founding director of NISC.

In 2002, Dr. Green was named NHGRI scientific director and director of the NHGRI Division of Intramural Research.

Honors given to Dr. Green include a Helen Hay Whitney Postdoctoral Research Fellowship (1989-1990), a Lucille P. Markey Scholar Award in Biomedical Science (1990-1994), Induction into the American Society for Clinical Investigation (2002), the Lillian M. Gilbreth Lectureship for Young Engineers at the National Academy of Engineering (2001), an Alumni Achievement Award from Washington University School of Medicine (2005), and Induction into the American Association of Physicians (2007). He is a Founding Editor of the Journal Genome Research (1995-present) and a Series Editor of Genome Analysis: A Laboratory Manual (1994-1998), both published by Cold Spring Harbor Laboratory Press. He is also Co-Editor of Annual Review of Genomics and Human Genetics (since 2005). Dr. Green has authored and co-authored over 240 scientific publications.

**NHGRI DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>James D. Watson</td>
<td>1989</td>
<td>April 10, 1992</td>
</tr>
<tr>
<td>Michael Gottesman (Acting)</td>
<td>April 10, 1992</td>
<td>April 1993</td>
</tr>
<tr>
<td>Francis S. Collins</td>
<td>April 1993</td>
<td>August 2008</td>
</tr>
<tr>
<td>Alan E. Guttmacher (Acting)</td>
<td>August 2008</td>
<td>December 2009</td>
</tr>
<tr>
<td>Eric D. Green</td>
<td>December 2009</td>
<td>Present</td>
</tr>
</tbody>
</table>

**MAJOR PROGRAMS**

**Office of the Director**

The Office of the Director oversees general operations, administration and communications for the National Human Genome Research Institute (NHGRI). The director's office provides overall leadership; sets policies; develops scientific, fiscal and management strategies; assists in governing the ethical behavior of its employees; and coordinates genomic research for the NIH with other federal, private and international programs.

The office also supports international meetings, workshops and other activities essential to the efficient international coordination and exchange of data.

**Division of Extramural Research**

The Division of Extramural Research (DER) supports and administers the role of the NIH in genomic research. In consultation with the broader genomic community, the DER supports grants for research and for training and career development at sites nationwide.

Three branches perform the work of this division. The Extramural Programs Branch administers and supports grants for extramural research, institutional training, fellowships, career awards and minority awards in support of genomic research; plans and supports activities that advance genomics; and directs the Ethical, Legal and Social Implications (ELSI) Research Program, which explores the ethical and policy issues raised by genetic research. The Scientific Review Branch plans and conducts the initial peer review of most of the research applications to NHGRI. The Grants Administration Branch oversees the fiscal aspects of NHGRI grant programs.

The DER also provides administrative management for three chartered advisory committees whose members review NHGRI's intramural and sponsored research.

**Division of Intramural Research**

The Division of Intramural Research (DIR) at the NHGRI plans and conducts a broad program of laboratory and clinical research to translate genome research into a greater understanding of human genetic disease. The DIR acts as a focal point at the NIH for genome research and maintains core facilities that serve as a resource for the entire NIH intramural research community. It evaluates research efforts and establishes intramural program priorities; allocates funds, space and personnel ceilings to ensure maximum utilization of available resources in the attainment of NHGRI objectives; and integrates new research activities into the program structure.

The DIR also collaborates with other NIH Institutes, centers and external research institutions; maintains an awareness of national and international research efforts in relevant program areas; and advises the director and staff on areas of science and intramural research programs of interest to NHGRI.
MISSION

Since 1974, the mission of the National Institute on Aging (NIA) has been to improve the health and well-being of older Americans through biomedical, social, and behavioral research.

The Institute conducts and supports research on aging through extramural and intramural programs, focusing on aging processes, age-related diseases, and special problems and needs of the aged. The extramural program funds research and training at universities, hospitals, medical centers, and other public and private organizations nationwide. The intramural program conducts basic and clinical research in Baltimore and on the NIH campus in Bethesda, Maryland. NIA also has a broad information program to communicate about research and health with older people, their families, health professionals, researchers, policymakers, and others.

IMPORTANT EVENTS IN NIA HISTORY

December 2, 1971—The White House Conference on Aging recommends the creation of a separate National Institute on Aging.

May 31, 1974—Public Law 93-296 authorizes the establishment of a National Institute on Aging and mandates the Institute develop a national comprehensive plan to coordinate the U.S. Department of Health, Education, and Welfare (succeeded by the Department of Health and Human Services) involvement in aging research.

October 7, 1974—The National Institute on Aging is established.

April 23, 1975—First meeting of the National Advisory Council on Aging is held.

1984—NIA funds Alzheimer's Disease Centers, where researchers at medical institutions nationwide focus on prevention and treatment while improving care and diagnosis.

1986—Per congressional direction, NIA funds the Federal Forum on Aging-Related Statistics, a coordinating organization made up of more than 35 Federal agencies.

November 14, 1986—P.L. 99-660, section 501-503, authorizes NIA's Alzheimer's Disease Education and Referral (ADEAR) Center as part of a broad program to conduct research and distribute information about Alzheimer's disease to health professionals, patients and their families, and the general public.

November 4, 1988—P.L. 100-607 establishes the Geriatric Research and Training Centers, renamed the Claude D. Pepper Older American Independence Centers in 1990 and charged with conducting research on diseases that threaten independent living.

1991—NIA sets up the Alzheimer's Disease Cooperative Study, an ongoing consortium of academic medical centers and others to facilitate clinical trials research.

1992—NIA and the University of Michigan begin the Health and Retirement Study, which follows more than 20,000 people at 2-year intervals, providing data from pre-retirement to advanced age to allow multidisciplinary study of the causes and course of retirement.

1993—The first Edward Roybal Centers for Research on Applied Gerontology are authorized, focusing on translational research to convert basic and clinical findings into programs that improve the lives of older people and their families.

NIA launches the Longevity Assurance Genes initiative, an interactive network of funded researchers looking for genetic clues to longevity, using a variety of organisms such as C. elegans, Drosophila, and yeast.

1994—The first Demography of Aging Centers are funded to provide research on health, economics, and aging and to make more effective use of data from several national surveys of health, retirement, and long-term care.

The Study of Women's Health Across the Nation (SWAN) is launched to characterize in diverse populations the biological and psychosocial influences related to the transition to menopause.

1995—Nathan Shock Centers of Excellence in Basic Biology of Aging are established to further the study of the basic processes of aging.

1997—The Resource Centers for Minority Aging Research (RCMAR) are funded to investigate the variability of health differences experienced across racial and ethnic groups, as well as the mentoring of new scholars in health disparities research.

2000—The Institute distributes established mouse cDNA microarray/clone set containing more than 15,000 unique genes to 10 designated academic centers worldwide.

2001—In a unique private-public partnership, NIA joins the Osteoarthritis Initiative to bring together resources and commitment to the search for biological markers of osteoarthritis.

NIA and the Icelandic Heart Association announce collaboration on a vast study on the interactions of age, genes, and the environment. The collaboration extends 34 years of data on the health of 23,000 Icelandic residents into the new millennium.

2003—NIA and the National Library of Medicine (NLM) launch NIHSeniorhealth.gov, a website designed to encourage older people to use the Internet.

NIA, joined by the Alzheimer's Association, expands the Alzheimer's Disease Genetics Initiative to create a large bank of genetic materials and cell lines for study to speed up the discovery of risk-factor genes for late-onset Alzheimer's disease.

NIA and the American Federation for Aging Research—in collaboration with the John A. Hartford Foundation, the Atlantic Philanthropies, and the Staff Foundation—establish a public-private partnership to support clinically trained junior faculty to pursue careers in aging research.

2004—NIA launches the Longevity Consortium, a network of investigators from several large-scale human cohort studies working in collaboration with individual basic biological aging researchers to facilitate the discovery, confirmation, and understanding of genetic determinants of healthy human longevity.

NIA, in conjunction with other Federal agencies and private companies and organizations through the Foundation for the National Institutes of Health, leads the Alzheimer's Disease Neuroimaging Initiative.

NIA launches Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS), a multidisciplinary community-based, longitudinal, epidemiologic study examining the influences and interaction of race and socioeconomic status on the development of age-associated health disparities among socioeconomically diverse African Americans and whites in Baltimore.

2006—NIA leads the NIH conference "AD: Setting the Research Agenda a Century after Auguste D.," a conclave assessing the state of current Alzheimer's disease research and the most promising routes to progress.

2007—U.S. Secretary of State Condoleezza Rice sponsors the Summit on Global Aging in collaboration with NIA to call attention to challenges and opportunities worldwide from population aging.

2008—A Biology of Aging Summit convenes to review NIA's research portfolio, identify areas of opportunity, and facilitate formulation of comprehensive research plans for the future.

NIA celebrates the 50th anniversary of the Baltimore Longitudinal Study of Aging.

2009—NIA collaborates with HBO Documentary Films on THE ALZHEIMER'S PROJECT, an Emmy Award winning, multi-platform (television, web, DVD, and print) public health series.

**BIOGRAPHICAL SKETCH OF NIA DIRECTOR RICHARD J. HODES, M.D.**

Richard J. Hodes, M.D., directs the research program of the National Institute on Aging (NIA) at the National Institutes of Health. A leading immunologist, Dr. Hodes was named Director of the NIA in 1993, to oversee studies of the basic, clinical, epidemiological, and social aspects of aging.

Under Dr. Hodes's stewardship, the NIA budget has surpassed $1 billion, reflecting increased public interest in aging as America and the world grow older. Dr. Hodes has devoted his tenure to the development of a strong, diverse, and balanced research program, focusing on the genetics and biology of aging; basic and clinical studies aimed at reducing disease and disability, including Alzheimer's disease and age-related cognitive change; and investigation of the behavioral and social aspects of aging. Ultimately, these efforts have one goal—improving the health and quality of life for older people and their families.

Dr. Hodes is a Diplomate of the American Board of Internal Medicine. In 1995, he was elected as a member of The Dana Alliance for Brain Initiatives; in 1997, he was elected a Fellow of the American Association for the Advancement of Science; and in 1999, he was elected to membership in the Institute of Medicine of the National Academy of Sciences.

Dr. Hodes is a graduate of Yale University and received his M.D. from Harvard Medical School. He completed training in Internal Medicine at Massachusetts General Hospital and in Oncology at the National Cancer Institute. As an author of more than 250 research papers, he is an influential scientist in and contributor to the field of immunology.

**NIA DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office From</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norman Kretchmer</td>
<td>October 1974</td>
<td>July 1975</td>
</tr>
<tr>
<td>Richard C. Greulich</td>
<td>July 1975</td>
<td>April 1976</td>
</tr>
</tbody>
</table>
RESEARCH PROGRAMS

Intramural Research

The goal of NIA’s Intramural Research Program (IRP) is to support a broad-based research program centered on critical issues regarding the general biology of aging and age-associated diseases and disabilities.

The specific areas of study on the biology of aging focus on 1) characterization of normal aging, 2) cell cycle regulation and programmed cell death, 3) stress response, 4) DNA damage and repair, 5) genetics, and 6) immunology. Age-associated disease and disabilities research includes the study of 1) Alzheimer’s disease; 2) cancer; 3) osteoporosis, osteoarthritis, and frailty; 4) cardiovascular disease and hypertension; and 5) diabetes. In addition, researchers at NIA’s IRP continue to develop and/or test different intervention strategies—e.g., pharmacotherapy, gene therapy, and behavioral or lifestyle changes—to treat many age-associated diseases.

The NIA’s IRP comprises 10 scientific laboratories, a clinical branch, a research resources support branch, and 2 sections. Most of NIA’s intramural research is conducted in Baltimore at the NIH Biomedical Research Center and the Gerontology Research Center. Clinical research resources are located at Harbor Hospital in Southeast Baltimore. Two laboratories and one scientific research section are located in Bethesda. IRP laboratories provide a stimulating environment for age-related research. The IRP also offers many excellent training opportunities in both laboratory research and clinical medicine for investigators at all stages of their careers. To read more about the NIA’s Intramural Program, go to www.grc.nia.nih.gov.

IRP Laboratories

Laboratory of Cardiovascular Science (LCS)
The overall goals of LCS are: 1) to identify age associated changes that occur within the cardiovascular system and to determine the mechanisms for these changes; 2) to determine how aging of the heart and vasculature interacts with chronic disease states to enhance the risk for CV diseases in older persons; 3) to study basic mechanisms in excitation-contraction coupling and how these are modulated by surface receptor signaling pathways in cardiac cells; 4) to elucidate mechanisms of pacemaker activity in sinoatrial nodal cells; 5) to elucidate mechanisms that govern cardiac and vascular cell survival; and 6) to establish the potentials and limitations of new therapeutic approaches such as changes in lifestyle, novel pharmacologic agents or gene or stem cell transfer techniques in aging or disease states.

Laboratory of Molecular Biology and Immunology (LMBI)
The unifying theme of LMBI’s research program is to uncover molecular mechanisms that are pertinent to understanding and ameliorating age-associated disabilities and diseases, with particular emphasis on changes in the immune system. Programs cover fundamental biological questions such as: 1) the study of transcriptional and post-transcriptional gene regulatory mechanism that mediate cellular responses to developmental signals, immune activation and stress stimuli, 2) the contribution of dys-regulated gene expression in the development of cancer and tissue-specific responses to oncogenes, 3) the examination of oxidative DNA damage and repair mechanisms in cancer, 4) induction of effective immune responses, including the mechanisms of class switch recombination and somatic hypermutation, and generation and maintenance of memory, 5) the role of telomere length and telomerase activity in lymphocyte function and aging, and 6) cellular and molecular dynamics involved in thymic involution and regeneration. LMBI programs contain a strong translational component, including 1) the study and use of biological response modifiers to optimize leukocyte trafficking, organ engraftment and vaccine efficacy in normal aging hosts, and 2) the study of the molecular and cellular basis of tumor metastasis. A wide variety of in vitro and in vivo models are employed to approach these issues. LMBI programs also share a close working relationship with the Baltimore Longitudinal Study of Aging that enable direct application of molecular parameters to the human condition.

Laboratory of Clinical Investigation (LCI)
The LCI seeks to: 1) gain fundamental understanding of age- and disease-related changes in islet cell differentiation and insulin secretion, insulin receptor function, molecular and cellular changes in osteoarthritis, and genetic features of tumorigenesis; 2) carry out translational research in each of these areas in order to take hypotheses generated from fundamental studies and apply them to humans in health and disease; 3) identify therapeutic targets in each of these areas and in other laboratories across the NIA IRP; and 4) develop therapeutic agents for the identified targets and carry out preclinical and clinical studies for proof of principle for the targets. To meet these objectives, studies are performed at the molecular, cellular, animal model, and human levels.

Laboratory of Epidemiology, Demography, and Biometry (LEDB)
Research in LEDB aims to investigate the causes and consequences of disease and function-specific outcomes that are highly prevalent in the population. We take a multi-modality and multi-disciplinary approach that is applied in large population-based cohorts developed by LEDB scientists in collaboration with other intramural and with extra-mural investigators. Studies are designed to integrate knowledge and identify common pathways of disease and function in the cardiovascular, neuro-cognitive, musculoskeletal, body composition and metabolic systems. Common mechanisms of interest include inflammation, glycemic control, increase in visceral fat and decrease in muscle mass, elevated blood pressure and atherosclerosis. Genetic contributions and their interactions with behavioral and physiologic factors are studied in the context of genome wide association study consortia. Efforts also focus on translation to clinical trials of our findings based on observational studies. In addition, we actively investigate state-of-the-art objective measures that can be applied to population-based samples.

Laboratory of Experimental Gerontology (LEG)
The LEG conducts basic research aimed at defining the mechanisms of age-related decline, and the development of effective interventions. One line of
investigation uses calorie restriction as a key experimental manipulation for identifying the basis of improved healthspan across a wide range of species, from worms and flies to rats and monkeys. Related efforts focus on neurocognitive aging, using molecular, neuroanatomical and electrophysiological approaches to understand the basis of successful and impaired trajectories. A primary objective is the preclinical development of epigenetic, pharmacological, and nutritional interventions that enable optimally healthy outcomes in aging.

**Laboratory of Genetics (LG)**

The LG views aging as an integrated extension of human development, with important genes influencing the course of aging even in embryonic and fetal life. The long-term goal is to prevent or ameliorate problems of aging tissues by understanding the coordinated action of genes in the normal pathways and genetic disorders that affect development, and in stem cells that may help to regenerate tissues. The programs include extensions to 1) an initiative to look for biomarkers of aging, disease progression, and gene function using novel pattern recognition algorithms and image informatics systems; and 2) investigation of mechanisms of DNA damage response, chromatin remodeling, and their connections with genome instability diseases and cancer.

**Laboratory of Molecular Gerontology (LMG)**

The LMG investigates processes and mechanisms such as genomic instability, DNA repair, DNA replication, and transcription with special attention to examining the role of DNA damage accumulation in senescence as the major molecular change with aging. The Oxidative DNA Damage Processing and Mitochondrial Functions Unit investigates the basis for the mitochondrial hypothesis of aging which states that accumulation of DNA damage with aging leads to the phenotypical changes that are observed in senescence and age-associated disease. The Repair of Endogenous DNA Damage Section investigates the mechanism involved in base excision repair and the function of individual DNA repair proteins and their interaction. The Telomere Maintenance and DNA Repair Unit studies the proteins and functions involved in maintenance of the chromosome ends, telomeres, processes of genome stability to reveal the genes or pathways that are important in telomere length regulation and maintenance and genomic stability. The Gene Targeting Unit is developing oligonucleotides that can form a three-stranded DNA structure called a triple helix. Eventually this approach will be used to modulate genomic sequences with targeted gene knockout as a specific application. The Section on DNA Helicases focuses on the roles of DNA helicases in genomic stability.

**Laboratory of Neurogenetics (LNG)**

The LNG studies neurodegenerative diseases based on a resolution of their genetic etiology. The Molecular Genetics Section is focused on finding genes for neurodegenerative disease; the Cell Biology & Gene Expression Section seeks to develop an understanding of the effects of mutant genes on cell physiology; the Transgenic Unit examines the pathogenesis of neurodegenerative disorders in whole animals and to test potential treatments for the diseases; and the Neuromuscular Disease Research Group works toward an understanding of the genetic basis of neuromuscular disorders. Underpinning this structure are 3 groups: a Clinical Core whose role is to identify patients with neurological disorders and facilitate collaborations with clinical investigators from around the world, a Computational Biology Core whose role is to facilitate the analysis of laboratory data in the broad context of the wealth of information available through the Human Genome Project and related endeavors, and a Genomic Technologies Group whose role is to to leverage and support the most recent genomic approaches.

**Laboratory of Neurosciences (LNS)**

The LNS seeks to understand the cellular and molecular mechanisms of neural plasticity during aging and to develop novel interventions for the prevention and treatment of neurodegenerative conditions such as Alzheimer’s, Parkinson’s, and Huntington’s diseases, as well as stroke. The LNS has a particular focus on signal transduction pathways that control the development and plasticity of nerve cell circuits, and how these pathways are altered in aging and neurological disorders. Examples include: neurotrophic factor signaling; adaptive stress response pathways, cellular calcium homeostasis; and pathways that modify energy metabolism and oxidative stress. Using animal models, LNS investigators are discovering how factors such as dietary energy intake and exercise affect the brain during aging, and they are developing and testing novel drugs that preserve or enhance brain function using animal models.

**Laboratory of Behavioral Neuroscience (LBN)**

The LBN conducts basic and clinical research on individual differences in cognition, personality, and affect; investigates the neural contribution to these individual differences; studies the influence of age on these traits and states, and their reciprocal influence on cognitive and mental health, well-being, and adaptation; examines predictors and modifiers of age-related neurodegenerative diseases and age-associated changes in behavior, predispositions, and brain-behavior associations; identifies early markers of Alzheimer’s disease and cognitive decline; and examines factors that promote the maintenance of cognitive health. Laboratory investigators employ a variety of methods, including experimental longitudinal, epidemiological, neuroimaging, biomarker, neuropathological, and genetic methods in the analyses of psychological and biological aspects of aging.

**Clinical Research Branch (CRB)**

The overall goals of CRB are: 1) to conduct major longitudinal studies of aging including the Baltimore Longitudinal Study on Aging (BLSA) and the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) studies; and 2) to support and carry out translational research in the major areas of clinical research focus of the IRP laboratories including longitudinal studies and intervention trials with a focus on cardiology, neurology, and endocrinology disease areas. To accomplish these goals, the branch: 1) provides the infrastructure needed to promote high quality clinical research and to ensure patient safety including: protocol review, clinic infrastructure, nursing and physician support, clinical informatics, data and safety management; 2) monitors and maintains quality assurance of the intramural clinical research program; 3) develops and implements clinical program priorities, allocates clinical resources; 4) integrates the established research themes and projects with clinical relevance from various IRP laboratories and branches; 5) evaluates program effectiveness and represents the IRP in management and scientific decision-making meetings within the Institute; 6) coordinates the credentialing of health care providers within the Institute; 7) coordinates and provides clinical research training for NIA staff and fellows; and 8) develops novel approaches for carrying out translational research in an efficient and cost-effective manner.

**Extramural Research**

**Division of Extramural Activities (DEA)**

DEA manages NIA's grants and training policies and procedures, including oversight of grants and contract administration, scientific review, and committee management functions. It serves as primary liaison for NIA with the NIH Office of Extramural Research and with other Institutes that share research interests. NIA's
extramural training programs, career development programs, small business initiatives, and other special programs are managed by DEA. The Division handles scientific integrity and ethical questions in research and manages the National Advisory Council on Aging.

The Scientific Review Branch (SRB) conducts initial peer review of specific research applications assigned to the NIA. These include applications for Centers, program projects, scientific meetings, and training and career development as well as applications responding to initiatives published by NIA. External peer reviewers selected from the grant community conduct reviews.

The Grants and Contracts Management Branch (GCMB) works with scientists and institutional research administrators to issue, manage, and close out awards. The branch has legal responsibility for the fiscal management of the Institute's extramural grants and contracts.

National Advisory Council on Aging (NACA)

Congress created the National Advisory Council on Aging (NACA) to provide advice on programmatic and policy matters; specifically, “to advise, consult with, and make recommendations to the Secretary, HHS, the Assistant Secretary for Health; the Director, NIH; and the Director, NIA on matters relating to the conduct and support of biomedical, social, and behavioral research, training, health information dissemination, and other programs with respect to the aging process and the diseases and other special problems and needs of the aged.”

The NACA consists of 18 members appointed by the HHS Secretary and 5 non-voting ex officio members. Of the 18 appointed members, 12 are leading representatives of the health and scientific disciplines and are leaders in the fields of public health and the behavioral or social sciences relevant to the activities of the NIA, particularly with respect to biological and medical sciences relating to aging and public health. Six of the members are leaders from the general public in the fields of public policy, law, health policy, economics, and management. The NACA meets 3 times each year.

Division of Aging Biology (DAB)

The DAB plans and supports molecular, cellular, and genetic research on the mechanisms of aging and age-related conditions through various NIH grant mechanisms and contracts. It also supports resource facilities that provide aged animals and banked tissues for use in aging research. The DAB includes the following programs:

Animal Models supports research to identify and develop new vertebrate and invertebrate animal models, for aging research. Current models include rats, mice, birds, fish, rabbits, nonhuman primates, insects, nematodes, and yeast, with rodent models of particular interest.

Biological Resources supports management of biological resources through contracts. It coordinates the aged non-human primate resources and the aging Intervention Testing Program (ITP), a multi-institutional study conducting research, on non-genetic interventions to delay aging, using a genetically heterogeneous mouse model.

Cardiovascular Biology supports investigations on the molecular and cellular changes that lead to age-related declines in cardiac and vascular function. Aging is itself the major factor for heart disease, the main cause of death in older people.

Cell Biology supports research on the age-related changes in signaling mechanisms; extracellular matrix, microenvironments, cellular senescence, apoptosis, autophagy, cancer; and protein modifications that might contribute to aging phenotypes, including integrative systems biology approaches and studies on cell-autonomy of aging.

Endocrinology supports basic research into the causes and effects of age-related changes in the endocrine system. Studies on aging-dependent changes in cellular responses to endocrine factors are also supported.

Genetics supports studies to identify and characterize genes and pathways affecting longevity; genome stability; telomere biology; genomics; epigenomics; and progeroid syndromes, all in relation to healthy aging.

Immunology supports studies on changes in the immune systems of older people that may contribute to the increased incidence of infection. Research supported includes regulation of lymphocyte proliferation; immune specificity; autoimmune disease and other immunopathologies; endocrine control of immune function; and interventions to retard and/or correct age-related decline in immune function.

Metabolic Regulation supports research on nutrition and metabolism in relation to aging. Areas of focus include age-related changes in mitochondrial (dys) function; mechanisms of lifespan extension by caloric restriction; and generation of free radicals and oxidative stress.

Musculoskeletal Biology supports studies on muscle, bone and cartilage that may have negative effects on health of the elderly (e.g., causes of osteoporosis or sarcopenia), thereby encouraging development of preventative and interventional strategies to extend healthy aging.

Stem Cells supports research on changes in stem cells and stem cell niches during aging. Two areas of emphasis are identification of factors altering stem cell function with aging, and determination of the roles of stem cells both in normal tissue homeostasis and as a result of injuries.

Tissue Physiology supports investigation of age-related changes that affect the function of the liver, digestive, renal, and pulmonary systems.

Division of Behavioral and Social Research (BSR)

This division supports basic research and research training on the processes of aging at both the individual and societal level. It focuses on how people change over the adult life course and on the societal impact of the changing age-composition of the population. BSR fosters research that reaches across disciplinary boundaries, from the genetic to comparisons across national populations, and at stages from basic through translational.
BSR has 2 branches, with substantial interactions between them:

**Individual Behavioral and Processes Branch** supports research and training on health and behavior, cognitive and emotional functioning, technology and human factors, and integrative approaches to the study of social, psychological, genetic, and physiological influences on health and well-being over the life course.

**Behavioral Medicine and Interventions** focuses on the dynamic interrelationships among aging, health, and behavior, expanding traditional studies in behavioral medicine by adding an aging perspective as well as behavioral emphasis on the influence of the socio-cultural environment on the development and maintenance of a wide range of health and illness behaviors.

**Behavioral Genetics of Aging** examines links among social, psychological, and behavioral processes with health and well-being over the life course through the study of gene-environment interplay. This includes the study of epigenetics, gene by environment interaction and gene-environment correlation.

**Cognitive Aging** supports studies on changes in cognitive functioning over the life. Research also explores the role of individual differences in cognitive functioning (e.g., motivation, self-efficacy, beliefs about aging, emotions, sensory limitations, experience, and expertise) and health disparities, collaborating with the NIA Division of Neuroscience to encourage research at the intersection of behavior and neurocognition.

**Psychological Development and Integrative Science** applies an integrative approach to the study of personality, emotion, subjective well-being, motivation, self-regulation, social behaviors and social environments, social relationships, social cognition, stress and coping, resilience, and vulnerability to stress over the life course.

**Population and Social Processes Branch** supports research and training on the causes and consequences of changes in social, demographic, economic, and health characteristics of the older population. Research on the effects of public policies, social institutions, and health care settings on the health, well-being, and functioning of people—both over the life course and in later years—is supported. International and comparative studies are encouraged, as are interconnections with individual behavioral processes. Interdisciplinary and multi-level research is especially promoted.

**Demography and Epidemiology** fosters research on trends in functioning, disability, morbidity, and mortality; age trajectories of health; life expectancy and active life expectancy; causes and consequences of changes in the age-structure of populations; interactions between health and socioeconomic status over time and across generations; the effect on health of social networks and social contexts; interrelationships between work, family, and health; and cohort analyses of aging. Epidemiologic studies include studies of the incidence, prevalence, and dynamics of disability and frailty, and the identification and evaluation of strategies and interventions to promote health.

**Labor and Retirement Economics** concentrates on implications of aging on wealth, poverty, productivity, human capital development, and economic development, and their relationship to health. Topics include: implications of population aging for public and private retirement and health insurance programs and for income security of future retirees; allocation of family resources across generations; determinants of retirement, family labor supply, and saving; evaluations of the impact of changes in Medicaid, Medicare and Social Security policies.

**Health Economics** concentrates on the economic costs of health care, health insurance, and disability in aging. Topics include consequences of retirement for health and functioning; effects of psychological factors and mental health characteristics on economic behaviors; health insurance and health care expenditures; interrelationships between health and economic status, the economic costs of disability; and cost-effectiveness of interventions to improve the health and well-being of the elderly.

**Health and Social Institutions** encourages research on the impact of formal health care and long-term care systems and settings on the health and well-being of older persons. The emphasis is on how older people and their families deal with multiple services, often for multiple conditions, not on the efficacy or effectiveness of treatments for particular conditions. This section supports research on the long-term care system; health services and health care financing for older people with multiple chronic conditions; hospital-level and regional differences in health expenditures, services, and outcomes for older persons; and U.S. and comparative cross-national studies.

**Population Genetics** explores the integration of genetic methods into population-based research, population genetics of aging, and the interplay between genes and environment on a population level.

**Division of Geriatrics and Clinical Gerontology (DGCG)**

The DGCG supports research on health and disease in older people and research on aging over the human lifespan, including its relationships to health outcomes. DGCG comprises 3 major research areas, divided into 3 division branches—Geriatrics, Clinical Gerontology, and Clinical Trials. Program-wide emphases include research training and career development to attract new investigators to the field of aging and to further the development of active investigators in clinical medicine and biomedical research, and the application of new technologies to expand opportunities for clinical aging research.

**Geriatrics** focuses on health issues regarding older people. Research emphases include multifactorial geriatric syndromes such as falls, frailty, and various types of disability; effects of comorbidity and polypharmacy; effects of age-related changes on clinical or functional disease outcomes or treatment responses; effects of physical activity on disease and disability in older persons; and the elucidation, diagnosis, and treatment of previously unappreciated pathologic changes in old age (e.g., sarcopenia, vascular stiffening, diastolic dysfunction). The Geriatrics Branch supports the Claude D. Pepper Older Americans Independence Centers (OAICs). The OAICs conduct basic and clinical research to enhance the ability of older people to maintain their independence.

**Clinical Gerontology** focuses on clinically related research on aging changes over the lifespan. Research emphases include healthy aging across the lifespan (including exceptional longevity); protective factors against multiple age-related conditions; determinants of rates of progression of age-related changes that affect disease risk, particularly those for multiple age-related conditions; menopause and mid-life aging changes; translational human research to follow up findings from basic research on aging; long-term effects of current or new interventions that may be administered over a large part of the lifespan; and long-term effects of physical activity throughout the lifespan.
Clinical Trials plans and administers clinical trials on age-related issues. Research emphases include interventions to prevent or treat "geriatric syndromes," disability, and complications of comorbidity or polypharmacy; trials to detect age- or comorbidity-related differences in responses to interventions against conditions found in middle age and old age; interventions for problems associated with menopause and other mid- and late-life changes; interventions that may affect rates of progression of age-related declines in function in early and mid-life; and interventions with protective effects against multiple age-related conditions, including intervention studies on the effects of androgens in older men.

Division of Neuroscience (DN)

Organized into 3 separate branches, this division fosters and supports extramural and collaborative research and training to further the understanding of neural and behavioral processes associated with the aging brain. Research on dementias of old age—in particular Alzheimer's disease—is one of the division's highest priorities. The division supports a number of resources and initiatives: The Alzheimer's Disease Centers (www.alzheimers.org/adcc.htm) and the National Alzheimer's Coordinating Center (www.alz.washington.edu/); the National Cell Repository for Alzheimer's Disease, the Alzheimer's Disease Genetics Initiative (http://ncrd.iu.edu/); the NIA Genetics of Alzheimer's Data Storage Site (http://alois.med.upenn.edu/niagads/); the Alzheimer's Disease Neuroimaging Initiative (www.adni-info.org); the Alzheimer's Disease Drug Translational Initiative—R21 and U01 mechanisms, respectively (http://grants.nih.gov/grants/guide/PA-files/PAS-10-151.html) and (http://grants.nih.gov/grants/guide/PA-files/PA-10-205.html); the Alzheimer's Disease Cooperative Study (http://adcs.org/); on behalf of the NIH Blueprint for Neuroscience Research: the NIH Toolbox for Neurological and Behavioral Function (http://www.nihtoolbox.org) and along with NINDS and NIMH, the Cognitive and Emotional Health Project (http://trans.nih.gov/CEHP/).

The Neurobiology of Aging Branch fosters research aimed at understanding how the nervous system is affected by normal as well as pathological aging. Fundamental Neuroscience supports studies on age-related structural and functional changes in brain, cell death mechanisms and selective vulnerability to aging effects, molecular genetics of brain aging bioenergetic processes, systemic metabolism, the cerebrovascularity, neural plasticity, glia, neural stem cells, and neurogenesis. In integrative Neurobiology, the focus is on age-related research on neural mechanisms underlying changes between organ systems and the CNS, in endocrine and immune functions, and neurodegenerative diseases associated with infectious agents including prions. Sleep and Biological Rhythm encompasses age-related studies of epidemiology, etiology, pathogenesis, diagnosis, treatment, and prevention of sleep disorders of older people; sleep-wake cycles/disordered biorhythmicity and behavioral effects in the aged.

The Dementias of Aging Branch supports studies on etiology, pathophysiology, genetics, epidemiology, clinical course, diagnosis and functional assessment, drug discovery and development, behavioral management, and clinical trials in the dementias of later life, especially Alzheimer's disease. In Basic Research, it supports examination of molecular, cellular, systemic, and systems aspects involved in the etiology of Alzheimer's disease and other dementias of aging; animal models; genetics; hormonal factors; and cerebrovascular factors. Population Studies are supported in the epidemiology of cognitive decline, mild cognitive impairment (MCI), and Alzheimer's disease including prevalence, incidence, and risk and protective factors. A Clinical Studies focus on the diagnosis, treatment, and management of patients with cognitive decline, MCI, or Alzheimer's disease is also important. Here, research on diagnosis is aimed at the development and evaluation of reliable and valid multidimensional procedures and instruments for diagnosis, progression, and response to treatment. The maintenance of a research infrastructure is critical, and the Research Centers component of this branch supports Alzheimer's Disease Research Centers and Alzheimer's Disease Center Core programs, that provide a multifaceted approach to research, training, and educational activities on Alzheimer's disease. It also supports the National Alzheimer's Coordinating Center and several multi-center collaborative research projects.

The Behavioral and Systems Neuroscience Branch emphasizes research on the neural and psychological mechanisms underlying age-related changes in cognition, emotions, sensory and motor function, from the level of gene to the whole organism, as well as epidemiological studies of populations. Studies of molecular, structural, and dynamic brain changes, including research on adaptation or plasticity, are of particular interest, as well as therapeutics to maintain or gain function in older age. A focus on Sensory Processes supports studies on mechanisms of normal aging and disease-related alterations in visual, auditory, somatosensory, vestibular, chemosensory functions, and pain. In an effort to understand Motor Function, research is supported on proprioception, postural control, sensory motor integration, vestibular, and movement disorders in aging, including Parkinson's disease. Efforts in Cognitive and Affective Neuroscience look at cognitive processes, including learning, memory, attention, and language. Studies of age-related changes in emotion also are supported. An emphasis is placed on understanding and treating age-related cognitive decline and the investigation of its relationship to cognitive dysfunction typical of Alzheimer's disease and other dementias. The Division of Neuroscience and this branch, in particular, interact and collaborate with the Division of Behavioral and Social Research where behavioral science and cognitive neurosciences converge.
MISSION

The mission of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) is to provide leadership in the national effort to reduce alcohol-related problems by:

- Conducting and supporting research in a wide range of scientific areas including genetics, neuroscience, epidemiology, health risks and benefits of alcohol consumption, prevention, and treatment;
- Coordinating and collaborating with other research institutes and Federal Programs on alcohol-related issues;
- Collaborating with international, national, state, and local institutions, organizations, agencies, and programs engaged in alcohol-related work; and
- Translating and disseminating research findings to health care providers, researchers, policymakers, and the public.

The Institute’s efforts to fulfill its mission are guided by the NIAAA vision to support and promote, through research and education, the best science on alcohol and health for the benefit of all by:

- Increasing the understanding of normal and abnormal biological functions and behavior relating to alcohol use;
- Improving the diagnosis, prevention, and treatment of alcohol use disorders; and
- Enhancing quality health care.

Research opportunities to increase our understanding of why, how, and when people drink, and why and how some people develop alcohol use disorders, are set forth in the NIAAA Strategic Plan for Research, available on the NIAAA Web site at www.niaaa.nih.gov.

IMPORTANT EVENTS IN NIAAA HISTORY

1970—The Comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment, and Rehabilitation Act was passed, establishing NIAAA as part of the National Institute of Mental Health (NIMH). Senator Harold E. Hughes of Iowa played a pivotal role in sponsoring the legislation, which recognized alcohol abuse and alcoholism as major public health problems.

1971—The First Special Report to the U.S. Congress on Alcohol and Health was issued in December, part of a series of triennial reports established to chart the progress made by alcohol research toward understanding, preventing, and treating alcohol abuse and alcoholism.

1974—NIAAA became an independent institute within the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), which also housed NIMH and the National Institute on Drug Abuse (NIDA).

1977—NIAAA organized the first national research workshop on fetal alcohol syndrome (FAS), which reviewed the state of the research on FAS.

1980—NIAAA staff contributed to the development of the Report to the President and the Congress on Health Hazards Associated with Alcohol and Methods to Inform the General Public of these Hazards; this report influenced the following year’s publication of the U.S. Surgeon General’s Advisory on Alcohol and Pregnancy of 1981 (updated in 2005 [http://www.surgeongeneral.gov/pressreleases/sg02222005.html])

1989—NIAAA launched the Collaborative Studies on Genetics of Alcoholism with the goal of identifying the specific genes underlying vulnerability to alcoholism as well as collecting clinical, neuropsychological, electrophysiological, and biochemical data, and establishing a repository of immortalized cell lines.

1991—NIAAA began the National Longitudinal Alcohol Epidemiologic Survey, designed to study drinking practices, behaviors, and related problems in the general public.

1995—NIAAA celebrated its 25th anniversary.

1996—NIAAA established the Mark Keller Honorary Lecture Series. The series pays tribute to Mark Keller, a pioneer in the field of alcohol research, and features a lecture each year by an outstanding alcohol researcher who has made significant and long-term contributions to our understanding of alcohol’s effects on the body and mind. View Image.

1999—NIAAA organized the first National Alcohol Screening Day, created to provide public education, screening, and referral for treatment when indicated. The program was held at 1,717 sites across the United States, including 499 college sites.
NIH reorganized its drug addiction, treatment, and recovery programs. Additionally, on October 4, 2010, the Institute hosted a special symposium, recognizing the 40th anniversary. At this symposium, leaders in the field discussed the ways in which alcohol research has evolved over the past 40 years, as well as NIAAA's role in this progress.

BIOGRAPHICAL SKETCH OF NIAAA DIRECTOR KENNETH R. WARREN, PH.D. (ACTING)

Kenneth R. Warren, Ph.D., a nationally-recognized expert on alcohol and pregnancy, and a long-time senior administrator at the National Institute on Alcohol Abuse and Alcoholism (NIAAA) became Acting Director of NIAAA on November 1, 2008, following the retirement of Ting-Kai Li, M.D. on October 31, 2008. Dr. Li had served as acting director of the institute's Office of Science Policy and Communications.

Dr. Warren was named NIAAA Deputy Director in February 2008. He joined NIAAA in 1976 as a staff member of the then Division of Research. He later became chief of the Biomedical Research Branch, and then deputy director of the Division of Extramural Research. From 1984 to 2005 he directed the Office of Scientific Affairs, whose responsibilities included peer review, grants management, committee management, scientific communications, and activities of the NIAAA National Advisory Council and Extramural Advisory Board. From 2002 to 2007, Dr. Warren served as Associate Director for Basic Research, and over the past year he has also served as acting director of the institute's Office of Science Policy and Communications.
A graduate of the City College of New York, Dr. Warren earned his doctorate degree in Biochemistry from Michigan State University in 1970. He subsequently undertook postdoctoral positions at the University of California, Los Angeles and at University of Michigan Mental Health Research Institute before joining the Federal government in a research position at the Walter Reed Army Institute of Research in 1974.

Dr. Warren has maintained an active interest in all areas of alcohol and health and in past years often served as the editor of the triennial Reports to Congress on Alcohol and Health. He has been particularly active in research on the effects of alcohol use during pregnancy, including fetal alcohol syndrome (FAS) and fetal alcohol spectrum disorders (FASD). Dr. Warren initiated NIAAA's research program on FAS over 30 years ago. He currently chairs the government-wide Interagency Coordinating Committee on FAS.

Dr. Warren has received numerous honors, including a superior service award from the Public Health Service in 1982 for his work in development of the first Surgeon General's Advisory on FAS. In 1994, Dr. Warren received the Seixas Award from the Research Society on Alcoholism (RSA). In 2002, he received the Henry Rosett Award from the Fetal Alcohol Syndrome Study Group of RSA. In 2007, the National Organization on Fetal Alcohol Syndrome (NOFAS) honored Dr. Warren by placing his name into its Tom and Linda Daschle FASD Hall of Fame, and awarded him the NOFAS Excellence Award in 2008.

NIAAA DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morris E. Chafitz</td>
<td>1972</td>
<td>September 1, 1975</td>
</tr>
<tr>
<td>Ernest P. Noble</td>
<td>February 1976</td>
<td>April 1978</td>
</tr>
<tr>
<td>Loran Archer (Acting)</td>
<td>April 1978</td>
<td>April 1979</td>
</tr>
<tr>
<td></td>
<td>November 1981</td>
<td>July 1982</td>
</tr>
<tr>
<td></td>
<td>January 1986</td>
<td>October 1986</td>
</tr>
<tr>
<td>John R. DeLuca</td>
<td>May 1979</td>
<td>October 1981</td>
</tr>
<tr>
<td>Robert G. Niven</td>
<td>August 1983</td>
<td>December 1985</td>
</tr>
<tr>
<td>Enoch Gordis</td>
<td>November 1986</td>
<td>January 2002</td>
</tr>
<tr>
<td>Raynard Kington (Acting)</td>
<td>January 2002</td>
<td>November 2002</td>
</tr>
<tr>
<td>Ting-Kai Li</td>
<td>November 2002</td>
<td>October 2008</td>
</tr>
<tr>
<td>Kenneth R. Warren (Acting)</td>
<td>November 2008</td>
<td>Present</td>
</tr>
</tbody>
</table>

DIVISIONS AND OFFICES

Office of the Director

The Office of the Director leads the Institute by setting research and programmatic priorities and coordinating cross-cutting initiatives. The Office includes the Office of Extramural Activities; the Office of Resource Management; and the Office of Science Policy and Communications.

Intramural Research

The overall goal of NIAAA's Division of Intramural Clinical and Biological Research is to understand the mechanisms by which alcohol produces intoxication, dependence, and damage to vital body organs, and to develop tools to prevent and treat those biochemical and behavioral processes. Areas of study include identification and assessment of genetic and environmental risk factors for the development of alcoholism; the effects of alcohol on the central nervous system, including how alcohol modifies brain activity and behavior; metabolic and biochemical effects of alcohol on various organs and systems of the body; noninvasive imaging of the brain structure and activity related to alcohol use; development of animal models of alcoholism; conducting epidemiologic research on alcohol use, abuse, and dependence; and the diagnosis, prevention, and treatment of alcoholism and associated disorders.

NIAAA uses a combination of clinical and basic research facilities, which enable a coordinated interaction between basic research findings and clinical applications in pursuit of these goals. An inpatient unit and an outpatient program are located in the NIH Clinical Research Center in Bethesda, Maryland.

NIAAA intramural researchers investigate a number of areas, including:

- genetic studies investigating, identifying, and characterizing genes that contribute to individual susceptibility to alcoholism and alcohol-related behaviors;
- studies seeking a better understanding of the underlying factors of alcoholic liver disease;
- national surveillance activities to collect, analyze, and report epidemiological data on alcohol use, abuse, and dependence, and their associated disabilities;
- behavioral and neurophysiological studies to understand the mechanisms of the motivation to drink; and
- studies to determine how alcohol interacts with nerve cells and the brain's signaling system to improve our understanding of the molecular basis of alcohol dependence and lead to development of treatments and prevention strategies.

Extramural Research
Division of Epidemiology and Prevention Research

NIAAA's Division of Epidemiology and Prevention Research (DEPR) seeks to reduce alcohol-related mortality and morbidity and other alcohol-related problems and consequences through the integration and application of epidemiology and prevention science by setting research priorities; stimulating and supporting research, training, and career development; conducting research and publishing in the scientific literature; promoting dialogue and collaboration between DEPR and other organizations; contributing to alcohol-related surveillance; and disseminating scientific information.

Two major areas of focus for the Division are:

1. the epidemiology of alcohol use and alcohol-related problems, a broad area that includes the study of the following:
   - the etiology (investigating the origins and causes, including risk factors and protective factors) and the course of alcohol-related problems, including alcohol use disorders (AUDs);
   - the relationship of alcohol consumption and AUDs to unintentional and intentional injuries and other diseases and disorders (such as co-occurring psychiatric disorders as well as diabetes, cardiovascular disease, cancer, liver disease, and other chronic diseases), alcohol's relationship to HIV/AIDS and other sexually transmitted diseases; the potential health benefits of alcohol consumption; and alcohol-related consequences (including mortality and morbidity, violence, risky and unprotected sex, compromised academic/vocational achievement, and the economic costs of alcohol).

2. the prevention of alcohol-related problems, a broad area that includes the study of the following:
   - the efficacy and effectiveness of screening and brief interventions, family-, school-, and employment-based prevention interventions, as well as comprehensive/community prevention interventions and drinking-driving countermeasures; and
   - the impact of public policy, the media, and alcohol marketing and promotion.

Division of Metabolism and Health Effects

Chronic alcohol use affects every organ and system of the body. It also can lead to medical disorders (e.g., fetal alcohol syndrome, liver disease, cardiomyopathy, and pancreatitis) throughout the lifespan—from early development to adolescence and adulthood—and contribute to the suppression of immune and endocrine functions. Heavy alcohol use is also an important factor for co-morbid conditions, such as hepatitis C, osteoporosis, obesity, type 2 diabetes, and certain cancers.

NIAAA's Division of Metabolism and Health Effects (DMHE) supports a wide range of research to elucidate the genetic, metabolic, and immunologic mechanisms of alcohol-induced tissue injury that contribute to the initiation and progression of these disorders.

DMHE supports metabolic research on enzymes, proteins, substrates, substrate adducts, co-factors, vitamins, nucleic acids, sugars, and other metabolites that may be affected by alcohol or alcohol by-products. Other basic investigations seek to identify biomarkers for the early stages of disease using genomic, proteomic, and metabolomic approaches that will facilitate early identification and treatment before diseases become irreversible. DMHE also supports research to elucidate the mechanism of alcohol's potential beneficial effects, including studies related to cardiovascular disease, diabetes, and certain inflammatory diseases.

Division of Neuroscience and Behavior

The Division of Neuroscience and Behavior (DNB) promotes research on ways in which neuronal and behavioral systems are influenced by genetic, developmental, and environmental factors in conjunction with alcohol exposure to engender alcohol abuse and alcoholism. A primary goal is to support investigations into neural and behavioral processes promoting the initiation and maintenance of drinking, as well as enduring changes in the brain resulting from long-term alcohol exposure that drive excessive alcohol drinking. The program includes studies on basic mechanisms of alcohol action on intracellular signaling pathways, neuronal membrane structure and function, ion channels and receptors, and the physiology of neurotransmission. Another goal is to identify and characterize the neural and cognitive consequences of acute, binge, and chronic alcohol exposure.

To address these goals, DNB supports three major collaborative multidisciplinary programs. The Collaborative Study of the Genetics of Alcoholism (COGA) seeks to identify the role of genes in susceptibility to (or protection from) developing alcohol dependence and related phenotypes. The ultimate goal is to understand the functional effects of variation at genes identified in these studies, including effects on expression, at the molecular and cellular level. The Integrative Neuroscience Initiative on Alcoholism (INIA), a consortium investigating the mechanisms that underlie neuroadaptation to alcohol, integrates neurobiological, behavioral, and molecular genetic research and provides opportunities for scientific collaboration. Major themes explored in this program include the role of stress in phenotypes related to alcohol dependence and the identification of druggable targets for potential pharmacotherapies. The Neurobiology of Adolescent Drinking in Adulthood (NADIA) supports a consortium of highly integrated multidisciplinary research efforts across different research institutions to elucidate persistent changes in complex brain function-behavior relationships following adolescent alcohol exposure using animal models.

In addition to these collaborative programs, DNB supports research on the molecular, genetic, cellular, and neural mediators of alcohol dependence, tolerance, sensitization, withdrawal, and relapse. This research includes developing animal models that will increase our understanding of the acute and chronic effects of alcohol exposure. DNB’s preclinical medication research program seeks to identify compounds that reduce alcohol drinking or alleviate adverse conditions prompting relapse. The goal of this program is to test the potential therapeutic efficacy of new and existing compounds and discover their therapeutic mechanism of action. In addition, DNB supports basic behavioral research that applies concepts from psychological science to understanding alcohol dependence and related problems.

Areas of particular interest include:
Examples of communications products include: NIAAA maintains a communications program aimed at informing health care practitioners, researchers, policy makers, and the general public about findings from supported research programs. Examples of communications products include:

- Helping Patients Who Drink Too Much—A Clinician's Guide, and other resources for health professionals
- Alcohol Research & Health, a quarterly peer-reviewed journal
- the Alcohol Alert series, quarterly bulletins on research findings for health professionals

Communications and Outreach Activities

NIAAA maintains a communications program aimed at informing health care practitioners, researchers, policy makers, and the general public about findings from supported research programs. Examples of communications products include:

- Helping Patients Who Drink Too Much—A Clinician's Guide, and other resources for health professionals
- Alcohol Research & Health, a quarterly peer-reviewed journal
- the Alcohol Alert series, quarterly bulletins on research findings for health professionals

Another priority is to develop medications that diminish the craving for alcohol and reduce risk of relapse. Alcohol dependence is a complex disorder involving many neurotransmitters and neuromodulators. Thus, the division is exploring a range of medications to improve treatment outcomes. Several medications are at various stages of development, ranging from preclinical research to clinical application, for the treatment of alcohol dependence.

Health services research is also an important focus for the division. Current priorities include health economics research, research on stigma and help-seeking behavior, and research on implementation of evidence-based practices and quality improvement in treatment settings.

Trans-Divisional Program Activity

NIAAA's Division of Treatment and Recovery Research supports research to better understand the natural history of heavy drinking and alcohol use disorders and factors associated with positive change. One priority is to better understand mechanisms of change, both for change occurring naturally as well as within the context of mutual help groups and professional treatment. There is also a need to develop and test models of disease management for chronic alcohol use disorders, especially for people who also have serious medical or mental disorders.

Another priority is to develop medications that diminish the craving for alcohol and reduce risk of relapse. Alcohol dependence is a complex disorder involving many neurotransmitters and neuromodulators. Thus, the division is exploring a range of medications to improve treatment outcomes. Several medications are at various stages of development, ranging from preclinical research to clinical application, for the treatment of alcohol dependence.

International Programs

NIAAA intramural and extramural staff engage in cross-cutting program activities to address the inherently interdisciplinary nature of alcohol research. NIAAA's Trans-Divisional Research Emphasis and Resource Development teams, working groups, and committees focus on biomarkers; centers and training programs; fetal alcohol spectrum disorders; gene-environment studies; HIV/AIDS; health disparities and minority research; informatics and computational/systems biology; international research; mechanisms of behavioral change; medications development; research resources and technology; and underage drinking.

Examples of cross-institute activity include the following:

Fetal Alcohol Spectrum Disorders Research

NIAAA is the lead Federal agency for research on how alcohol consumption during pregnancy results in adverse consequences for the fetus, the most serious of which is fetal alcohol syndrome. This developmental disorder is characterized by reduced growth; facial abnormalities; and neurological, cognitive, and behavioral impairment. NIAAA chairs the Interagency Coordinating Committee on Fetal Alcohol Syndrome, created in 1996 in response to an Institute of Medicine report. In 2003, NIAAA launched the Collaborative Initiative on Fetal Alcohol Spectrum Disorders, a cooperative agreement program to improve diagnosis and develop effective treatment approaches through highly integrated, multidisciplinary research projects at both domestic and international sites. Also in 2003, NIAAA and the National Institute on Child Health and Human Development established the Prenatal Alcohol, SIDS, and Stillbirth (PASS [http://www.nichd.nih.gov/research/supported/pass.cfm]) Research Network to determine the underlying causes of sudden infant death syndrome (SIDS) and stillbirth and the role played by prenatal alcohol exposure.

Trans-Divisional Program Activity

NIAAA intramural and extramural staff engage in cross-cutting program activities to address the inherently interdisciplinary nature of alcohol research. NIAAA's Trans-Divisional Research Emphasis and Resource Development teams, working groups, and committees focus on biomarkers; centers and training programs; fetal alcohol spectrum disorders; gene-environment studies; HIV/AIDS; health disparities and minority research; informatics and computational/systems biology; international research; mechanisms of behavioral change; medications development; research resources and technology; and underage drinking.

Examples of cross-institute activity include the following:

Fetal Alcohol Spectrum Disorders Research

NIAAA is the lead Federal agency for research on how alcohol consumption during pregnancy results in adverse consequences for the fetus, the most serious of which is fetal alcohol syndrome. This developmental disorder is characterized by reduced growth; facial abnormalities; and neurological, cognitive, and behavioral impairment. NIAAA chairs the Interagency Coordinating Committee on Fetal Alcohol Syndrome, created in 1996 in response to an Institute of Medicine report. In 2003, NIAAA launched the Collaborative Initiative on Fetal Alcohol Spectrum Disorders, a cooperative agreement program to improve diagnosis and develop effective treatment approaches through highly integrated, multidisciplinary research projects at both domestic and international sites. Also in 2003, NIAAA and the National Institute on Child Health and Human Development established the Prenatal Alcohol, SIDS, and Stillbirth (PASS [http://www.nichd.nih.gov/research/supported/pass.cfm]) Research Network to determine the underlying causes of sudden infant death syndrome (SIDS) and stillbirth and the role played by prenatal alcohol exposure.
Public service announcements, videos, posters, brochures, pamphlets, fact sheets, Web pages, and other materials for the general public.

Online resources—available on the NIAAA Web site, including:

- [www.rethinkingdrinking.niaaa.nih.gov](http://www.rethinkingdrinking.niaaa.nih.gov), a drinking pattern "checkup" worksheets for weighing pros and cons, making a change plan, and selecting strategies for cutting down or quitting; and calculators for estimating alcohol calories and spending, and the alcohol content of cocktails;
- [www.spectrum.niaaa.nih.gov](http://www.spectrum.niaaa.nih.gov), an online webzine featuring the latest alcohol research news from within NIAAA and throughout the field;
- [www.collegedrinkingprevention.gov](http://www.collegedrinkingprevention.gov), statistics, factsheets, and reports about college drinking the health consequences of alcohol misuse, campus alcohol policies, and other information for college students, administrators, and parents;
- [www.TheCoolSpot.gov](http://www.TheCoolSpot.gov), quizzes, games, and graphics featuring messages about the risks of underage drinking and ways to resist peer pressure for middle school audiences;
- the [Alcohol Policy Information System (APIS)](http://apis.niaaa.nih.gov/), state-by-state data on a wide variety of alcohol-related policies; and
- [NIAAA Clinical Trials](http://www.niaaa.nih.gov/ClinicalTrials.htm), links guiding patients and clinicians to NIAAA-sponsored research trials conducted at the NIH Clinical Center in Bethesda, Maryland, and at research centers across the country.

These sites and other resources can be found at [www.niaaa.nih.gov](http://www.niaaa.nih.gov).

This page last reviewed on January 3, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

"NIH...Turning Discovery into Health" is a trademark of the U.S. Department of Health and Human Services.
The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.

Following is a brief description of the major areas of investigation.

- **Acquired Immune Deficiency Syndrome (AIDS).** NIAID conducts and supports research on HIV/AIDS from basic research through clinical evaluation of treatment and prevention modalities, including vaccines and topical microbicides. Since the beginning of the epidemic, NIAID's comprehensive research program has been at the forefront in the fight against HIV/AIDS. NIAID supports a broad array of domestic and international HIV/AIDS research programs and collaborates with more than 40 countries through investigator-initiated research grants and multicenter vaccine, therapeutics, micobiode, and prevention clinical research networks. With a number of research programs and initiatives, NIAID is poised to tackle new global research challenges as well as the changing demographics of the HIV/AIDS epidemic.

- **Asthma and Allergic Diseases.** NIAID supports programs to examine the causes, pathogenesis, diagnosis, treatment, and prevention of asthma and allergic diseases. Examples of such programs include the Inner-City Asthma Consortium, the Consortium of Food Allergy Research, and the Asthma and Allergic Diseases Cooperative Research Centers. NIAID operates a pediatric allergy clinic at the NIH Clinical Center that serves as a focal point for translational research conducted in collaboration with NIAID intramural laboratories and clinical trials of novel therapies. In addition, NIAID is the lead agency within HHS for research on food allergies.

- **Biodefense.** To meet the challenges posed by biodefense, NIAID conducts and supports research on basic microbiology of and host response to pathogens as well as development of medical countermeasures for potential agents of bioterrorism and naturally emerging infectious diseases. These countermeasures include (1) rapid, accurate diagnostics for natural and bioengineered microbes; (2) effective antimicrobials, antivirals, and immunotherapeutics to treat those individuals affected; and (3) prophylactic and post-exposure vaccines. NIAID also supports biodefense and emerging infectious disease research through training programs and enhancement of research infrastructure and capacity, and by providing needed research resources and reagents to the scientific community. Basic research provides the essential underpinnings for the other research areas. The program embraces the concept that bioterrorism and emerging infectious diseases are related public health issues.

- **Emerging and Re-emerging Infectious Diseases.** New diseases are arising worldwide, and old diseases are re-emerging as infectious agents evolve or spread and as changes occur in ecology, socioeconomic conditions, and population patterns. NIAID conducts and supports basic research on influenza, severe acute respiratory syndrome (SARS), West Nile virus, malaria, hepatitis C, tuberculosis, and other emerging and re-emerging diseases, as well as translational research to develop new and improved diagnostics, treatments, and vaccines.

- **Enteric Diseases.** The global burden of enteric disease is second only to respiratory infection as a cause of sickness and death. Enteric diseases range from persistent, low-grade infections to severe, acute epidemic cholera. An additional burden of disease occurs because enteric infection greatly exacerbates the pathogenicity of diseases such as malaria and HIV/AIDS. Multi-drug resistance is a major problem, making Salmonella, *Clostridium difficile*, and cholera particularly difficult to treat in the settings where it is most likely to develop a fatal outcome. One of the most severe enteric infections is cholera, the most rapidly killing bacterial disease. Cholera is endemic in over 50 countries, and has recently been responsible for explosive epidemics in Africa and Asia. NIAID has been involved in many of the most important advances against cholera and other enteric diseases, including supporting the development of oral rehydration therapy, considered to be one of the most important medical advances of the 20th century. Presently, NIAID supports a robust research program of basic and applied research investigating how enteric pathogens cause illness, and developing appropriate diagnostics, vaccines, and therapeutics to prevent infection and to treat patients.

- **Fundamental Immunology.** NIAID oversees investigator-initiated grants and solicited research programs whose goals are to support a strong program in basic immunobiology and biodefense. Because immune-mediated diseases cross many clinical specialties, a more profound understanding of the normal human immune system and its role in disease are needed to improve the clinical management of people with these disorders. NIAID-supported research has yielded a wealth of new information leading to extraordinary growth in the conceptual understanding of the immune system.

- **Genetics and Transplantation.** NIAID's basic immunology and genetics research seeks to define the effects of gene expression on immune function and to determine the manner in which the products of gene expression control the immune response to foreign substances, such as transplanted organs and cells. NIAID supports studies to further develop methods and reagents needed for precise tissue typing to ensure that transplant recipients receive the best-matched donor organs available. Research programs in genetics and transplantation include HLA Region Genetics in Immune-Mediated Diseases, the Genomics of Transplantation, and Clinical Trials in Organ Transplantation.

- **Immune-Mediated Diseases.** NIAID conducts and supports basic, preclinical, and clinical research on immune-mediated diseases, autoimmune disorders, primary immunodeficiency diseases, and the rejection of transplanted organs, tissues, and cells. Efforts are underway to evaluate the safety and efficacy of tolerance induction strategies for treating immune-mediated diseases, as well as clinical trials to assess the efficacy of hematopoietic stem cell transplantation for treating severe autoimmune disorders. Programs include the Autoimmunity Centers of Excellence, the Immune Tolerance Network (http://immunetolerance.org), Autoimmune Diseases Prevention Centers, Clinical Trials in Organ Transplantation, the Primary Immunodeficiency Diseases Consortium (http://www.idealnet.org/), and the Clinical Islet Transplantation Consortium. NIAID chairs the NIH Autoimmune Diseases Coordinating Committee (ADCC). *Malaria and Other Tropical Diseases.* Each year, millions of people worldwide are disabled or killed by tropical diseases such as malaria, filariasis, schistosomiasis, leishmaniasis, trypanosomiasis (e.g., Chagas disease and African sleeping sickness), leprosy, and dengue. NIAID supports basic research on the microbes and parasites that cause tropical diseases, as well as the interactions of these organisms with their human hosts and with animal/invertebrate vectors involved in disease transmission. NIAID also supports translational and clinical research to develop new and
improved diagnostics, drugs, vaccines, and vector management strategies for tropical diseases. These efforts are conducted by U.S. and foreign investigators receiving Institute support and by NIAID intramural scientists and their collaborators around the world. In addition, the International Centers for Excellence in Research (ICER) program promotes and sustains research programs in developing countries through partnerships with local scientists. The current ICER sites are located in Mali, India, and Uganda. While the ICER program is focused on clinical research in infectious diseases such as malaria and filariasis, each center has the capability to address the research and training needs of greatest relevance to the local population. Clinical research on tropical diseases is largely dependent upon access to populations of patients, vectors, and pathogens/parasites in countries where these diseases are endemic; thus, an important complementary objective of NIAID's program is to strengthen international research capacity through research resources and support, scientific collaborations, and research training.

**Influenza.** NIAID has supported a focused research program on influenza infections for many years. In response to the emergence and spread of highly pathogenic avian influenza H5N1 and the persistent threat of pandemic influenza, NIAID greatly expanded its influenza program. A broad range of research activities are supported through individual grants and contracts, collaborations with industry partners and investigators in several research networks, including the Vaccine and Treatment Evaluation Units (VTEUs) for the clinical evaluation of candidate products, including several 2009 H1N1 influenza vaccines. NIAID also supports the Centers of Excellence in Influenza Research and Surveillance Network. This program conducts animal influenza surveillance domestically and internationally and focuses on basic research to enhance our understanding of influenza pathogenesis, transmission, evolution, and host response. NIAID also supports activities to develop the next generation of diagnostics, vaccines, and therapeutics and antivirals. NIAID resources and services are available to support early stage development of new vaccine and therapeutic candidates to help advance them through the product development pipeline. Ongoing projects include research to develop a 'common epitope' influenza vaccine and therapeutics that protect against all medically important influenza strains; systems biology approaches to identify host factors required for influenza infection to expand the number of potential targets for new drug development; and clinical research.

**Pathogen Genomics.** NIH is working to sequence the entire genomes of microbial pathogens and invertebrate vectors of infectious diseases. Efforts to sequence pathogen genomes are enabling scientists to identify genes that may lead to potential new vaccine candidates and drug targets so that infectious diseases can be prevented or be accurately diagnosed and treated. Furthermore, knowing a pathogen's genetic sequence will help researchers better understand how mechanisms of pathogenesis and pathogen mutations contribute to drug resistance. In addition to supporting sequencing projects, NIAID provides genomics, bioinformatics, and proteomics resources and tools to the scientific community.

**Sexually Transmitted Infections (STIs).** More than 15 million Americans each year acquire infectious diseases other than AIDS through sexual contact. STIs such as gonorrhea, syphilis, chlamydia, genital herpes, and human papillomavirus can have devastating consequences, particularly for young adults, pregnant women, and newborn babies. NIAID-supported scientists in STI Cooperative Research Centers, NIAID laboratories, and other research institutions are developing better diagnostic tests, improved treatments, and effective vaccines for STIs.

**Vaccine Development.** Effective vaccines have contributed enormously to improvements in public health in the United States during the last century. Research conducted and supported by NIAID has led to new or improved vaccines for a variety of serious diseases, including rabies, meningitis, whooping cough, hepatitis A and B, chickenpox, and pneumococcal pneumonia, to name a few. NIAID supports vaccine evaluation units for the clinical testing of new vaccines and vaccine technologies at a number of U.S. medical centers. Many vaccines are currently under development in NIAID labs, including vaccines to prevent AIDS, pandemic influenza, childhood respiratory diseases, dengue, and malaria.

**Drug Research and Development.** The development of therapies to treat infectious and immunologic diseases is a key component of NIAID's mission. In collaboration with industry, academia, non-profits, and other government agencies, NIAID has established research programs to facilitate drug development, including screening programs to identify compounds with potential for use as therapeutic agents, facilities to conduct preclinical testing of promising drugs, and clinical trials networks to evaluate the safety and efficacy of drugs and therapeutic strategies in humans.

**Antimicrobial Resistance.** NIAID funds a diverse portfolio of grants and contracts to study antimicrobial resistance in major viral, bacterial, fungal, and parasitic pathogens. Projects include basic research on the disease-causing mechanisms of pathogens, host-pathogen interactions, and the molecular mechanisms responsible for drug resistance, as well as translational research to develop and evaluate new or improved products for disease diagnosis, intervention, and prevention. NIAID supports clinical trials that assess new and existing antimicrobials and new vaccines relevant to drug-resistant infections through NIAID-targeted initiatives and clinical trial networks, which include the Collaborative Antiviral Study Group, the Adult AIDS Clinical Trials Groups, and the Vaccine and Treatment Evaluation Units.

**Minority and Women's Health.** Some of the diseases studied by NIAID disproportionately affect women and minority populations. The Institute remains committed to the inclusion of minorities and women in every aspect of its scientific agenda, from recruitment of special populations into clinical studies to the conduct of biomedical research by minority researchers. NIAID's Office of Special Populations and Research Training sponsors activities aimed at eliminating the continuing health disparities among these populations. Through the Office's efforts, activities are developed to encourage scientific advances in sex and gender differences research. The Office also develops innovative training initiatives to increase the number of minority scientists by supporting undergraduate, graduate, and postgraduate research training in immunologic and infectious diseases. NIAID research results are disseminated to underserved minority communities through the Institute's outreach activities, which have focused on HIV/AIDS, asthma, sexually transmitted infections, and autoimmune diseases.

**IMPORTANT EVENTS IN NIAID HISTORY**

1948–The National Microbiological Institute was established November 1. The Rocky Mountain Laboratory and the Biologics Control Laboratory, both dating to 1902, were incorporated into the new institute, together with the Division of Infectious Diseases and the Division of Tropical Diseases of NIH.

1951–An institute-supported grants program was initiated, and a branch was established to administer research, training, and fellowship grants. Grant applications were reviewed by the National Advisory Health Council until 1956.

1953–The Clinical Research Branch was renamed the Laboratory of Clinical Investigation.

1955–The National Microbiological Institute became the National Institute of Allergy and Infectious Diseases on December 29. The Biologics Control Laboratory was detached from the institute and expanded to division status within NIH.

1956–The first meeting of the National Advisory Allergy and Infectious Diseases Council was held March 7-8.

1957–The Laboratory of Immunology was established in January to meet the growing need for research on the mechanisms of allergy and immunology.
The Middle America Research Unit was established in the Canal Zone jointly by NIAID and the Walter Reed Army Institute of Research as a temporary field station, made permanent in 1961. Important tropical diseases studies were done there for 15 years. NIAID transferred its part of the program to the Gorgas Memorial Institute in 1972.

1959—The Laboratory of Parasitic Diseases was established, formerly a part of the Division of Tropical Diseases.

1962—A collaborative research program funded mainly by contracts was established within the institute to plan, coordinate, and direct nationwide projects on infectious diseases, vaccine development, transplantation immunology, research reagents, and antiviral substances.

1967—The Laboratory of Viral Diseases was established.

1968—With the dissolution of NIH’s Office of International Research (OIR) and creation of the Fogarty International Center on July 1, 1968, programs formerly managed by OIR were transferred to NIAID to be administered by the Geographic Medicine Branch. These included the U.S.-Japan Cooperative Medical Science Program—initiated in 1965 by the President and the Japanese Prime Minister to explore the health problems of Asia—and the International Centers for Medical Research and Training, a 1960 congressional initiative to advance the status of U.S. health sciences through international research.

1971—The first 7 Allergic Disease Centers were established to translate basic concepts of the biomedical sciences into clinical investigations.

1974—The first centers for the study of sexually transmitted diseases and of influenza were established.

1977—The NIAID Extramural Research Program was reorganized into 3 areas: Microbiology and Infectious Diseases; Immunology, Allergic and Immunologic Diseases; and Extramural Activities. An intramural Laboratory of Immunogenetics was formed.

1978—The first maximum containment facility (P4) for recombinant DNA research was opened in Frederick, Md. International program project grants and international exploratory/development research grants programs were established. Centers were created for interdisciplinary research on immunologic diseases.

1979—The Office of Recombinant DNA Activities was transferred from the National Institute of General Medical Sciences to NIAID. The International Collaboration in Infectious Diseases Research Program superseded the International Centers for Medical Research and Training established in 1960.

The Rocky Mountain Laboratory was reorganized into the Laboratory of Persistent Viral Diseases, to deal with both host and viral mechanisms leading to slow or persistent viral infections; the Laboratory of Microbial Structure and Function, directed at bacterial diseases, particularly sexually transmitted diseases; and an Epidemiology Branch.

1980—The Laboratory of Immune Regulation was established to provide a means for applying new knowledge in immunology to the clinical diagnosis and treatment of patients with immunological disorders.

1981—The Laboratory of Molecular Microbiology was created to exploit new techniques in recombinant DNA methodology and other molecular studies to expand the institute’s interests in both bacterial and viral pathogenesis and virulence.

1984—The Office of Tropical Medicine and International Research (OTMIR) was established to coordinate NIAID’s intramural and extramural research activities in tropical medicine and other international research. OTMIR works with other Federal agencies and international organizations active in these areas.

1985—The Laboratory of Immunopathology was established. At Rocky Mountain Laboratories, the Epidemiology Branch was renamed the Laboratory of Pathology.

1986—An Acquired Immunodeficiency Syndrome (AIDS) Program was established in January to coordinate the institute’s extramural research efforts in HIV/AIDS.

1987—The Laboratory of Cellular and Molecular Immunology was established.

1988—The Immunology, Allergic and Immunologic Diseases Program was reorganized and renamed the Allergy, Immunology, and Transplantation Program.

The Office of Recombinant DNA Activities transferred from NIAID to the NIH Office of the Director.

1989—NIAID’s programs became divisions: Intramural Research; Microbiology and Infectious Diseases; Allergy, Immunology, and Transplantation; Acquired Immunodeficiency Syndrome; and Extramural Activities.

1990—At Rocky Mountain Laboratories, a section of the Laboratory of Microbial Structure and Function became the Laboratory of Intracellular Parasites. The name of the Laboratory of Pathobiology was changed to the Laboratory of Vectors and Pathogens.

1991—The Laboratory of Host Defenses was established.

1994—The Laboratory of Allergic Diseases was established.

The Office of Research on Minority and Women’s Health was created.

At Rocky Mountain Laboratories, the Laboratory of Vectors and Pathogens was renamed the Microscopy Branch.

1999—The Dale and Betty Bumpers Vaccine Research Center was launched—a research program jointly funded by NIAID, NCI, and the NIH Office of AIDS Research.

2000—The Children’s Health Act of 2000 (P.L. 106-310) codified the NIH Autoimmune Diseases Coordinating Committee in law. ADCC is chaired by NIAID.

2001—Malaria Vaccine Development Unit was dedicated.
2002—Laboratory of Parasitic Diseases was reorganized; Laboratory of Malaria and Vector Research was established.

The Office of Biodefense Research Affairs was established within the Division of Microbiology and Infectious Diseases (DMID) to coordinate the planning, implementation, and evaluation of DMID-wide biodefense research.

NIAID awarded its first Partnership grants to support collaboration between private industry, academia, and government to accomplish critical infectious disease and biodefense research goals.

2003—NIAID established an intellectual and physical infrastructure for biodefense research through awards to support National and Regional Biocontainment Laboratories (NBLs and RBLs) and Regional Centers of Excellence (RCEs) for Biodefense and Emerging Infectious Diseases.

2004—The Laboratory of Molecular Immunology was established.

2005—The Laboratory of Zoonotic Pathogens was established.

The Laboratory of Bacterial Diseases was established.

NIAID made its first awards using authorities granted under Project Bioshield legislation to support development of new therapeutics and vaccines against some of the most deadly agents of bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox, and tularemia.

2006—The Division of Clinical Research was established.

The Laboratory of Virology was established.

The C.W. Bill Young Center for Biodefense and Emerging Infectious Diseases (Building 33) was launched to carry out NIAID's mission in emerging infectious disease research, including the development of medical countermeasures for biodefense.

NIAID LEGISLATIVE CHRONOLOGY

November 1, 1948—The National Microbiological Institute was established under authority of section 202 of the Public Health Service (PHS) Act, as implemented by General Circular No. 55, Organization Order No. 20, dated October 8, 1948.

December 29, 1955—NIAID was established (replacing the National Microbiological Institute) under authority of the Omnibus Medical Research Act (P.L. 81-692, 64 Stat. L. 443) as implemented by PHS Briefing Memorandum of November 4, 1955, from the Surgeon General to the Secretary of Health, Education, and Welfare.

November 4, 1988—NIAID was provided with additional authorities under title II of the Health Omnibus Programs Extension Act of 1988 (P.L. 100-607), the first major law to address AIDS research, information, education, and prevention.

August 14, 1991—The PHS act (P.L. 102-96), the "Terry Beirn Community Based AIDS Research Initiative Act of 1991" reauthorized NIAID's Community Programs for Clinical Research on AIDS (CPCRA) for another 5 years.

June 10, 1993—The PHS act was amended by P.L. 103-43, the National Institutes of Health Revitalization Act of 1993. This comprehensive legislation required NIAID to include research on tropical diseases in its mission statement and directed the U.S. Secretary of Health and Human Services (HHS) to ensure that individuals with expertise in chronic fatigue syndrome or neuromuscular diseases are appointed to appropriate NIH advisory committees.

December 14, 1993—The Preventive Health Amendments of 1993 were passed, which included provisions requiring the Director of NIAID to conduct or support research and research training regarding the cause, early detection, prevention, and treatment of tuberculosis. (The institute already had authority to conduct such research under its authorities in Title IV, PHS act.)

October 7, 1998—Rep. Anne Northup (Ky.), on behalf of herself and Rep. Bill Young ( Fla.), introduced H.C.R. 335, a resolution recognizing NIAID's 50th anniversary. On October 9, Sen. Richard Durbin (Ill.), on behalf of himself and Sen. Connie Mack (Fla.), introduced a companion measure, S.C.R. 127. Both pieces of legislation were submitted to "demonstrate the support of the U.S. Congress for the NIAID, the NIH and all of the dedicated professionals who have devoted their lives to improving the quality of the Nation's health."

October 17, 2000—The Children's Health Act (P.L. 106-310) required the Directors of NIAID and the National Institute of Arthritis and Musculoskeletal and Skin Diseases to expand and intensify the activities of their Institutes with respect to research and related activities concerning juvenile arthritis and related conditions.

November 13, 2000—The Public Health Improvement Act (P.L. 106-505) authorized the NIAID Director to establish a program of clinical research and training awards for sexually transmitted diseases.

July 21, 2004—The Project BioShield Act (P.L. 108-276) authorized the NIAID Director to provide grants for the modernization and construction of biomedical and behavioral research facilities and increased the Federal share of such NIAID-funded projects. The law also authorized the HHS Secretary to employ other procedures to respond to pressing needs in the research and development of countermeasures against biological, chemical, radiological, and nuclear threats, including expediting peer review procedures in certain instances, contracting with experts or consultants, and appointing professional and technical employees to positions at NIH.

July 30, 2008—The Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008 (P.L. 110-293) authorized the NIAID Director, acting through the head of the Division of AIDS and in accordance with the NIH peer-review process, to carry out research on, and development of, safe and effective methods for use by women to prevent the transmission of HIV, which may include microbicides.
BIOGRAPHICAL SKETCH OF NIAID DIRECTOR ANTHONY S. FAUCI, M.D.

Anthony S. Fauci, M.D., became the Director of NIAID in 1984. He received his undergraduate degree from Holy Cross College in 1962 and his medical degree from Cornell University Medical College in 1966. He completed his internship and residency at The New York Hospital Cornell Medical Center and joined NIAID in 1968 as a clinical associate in the Laboratory of Clinical Investigation. In 1980, Dr. Fauci became Chief of the Laboratory of Immunoregulation, a post he continues to hold. Dr. Fauci serves as one of the key advisors to the White House and Department of Health and Human Services on global AIDS issues, and on initiatives to bolster medical and public health preparedness against emerging infectious disease threats such as pandemic influenza.

Dr. Fauci has made many contributions to basic and clinical research on the pathogenesis and treatment of immune-mediated and infectious diseases, including human immunodeficiency virus (HIV) disease. In 2003, an Institute for Scientific Information study indicated that in the 20-year period from 1983 to 2002, Dr. Fauci was the 13th most-cited scientist among the 2.5 to 3 million authors in all disciplines throughout the world who published articles in scientific journals during that time frame. Dr. Fauci was the world’s 10th most-cited HIV/AIDS researcher in the period 1996 to 2006.

Dr. Fauci has received 35 honorary doctorate degrees from universities in the United States and abroad, as well as the Presidential Medal of Freedom, the National Medal of Science, the Mary Woodard Lasker Award for Public Service, and other major awards. A member of the National Academy of Sciences and many other professional organizations, Dr. Fauci is the author, coauthor, or editor of more than 1,100 scientific publications, including several textbooks.

DIRECTORS OF NIAID

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Victor H. Haas</td>
<td>November 1, 1948</td>
<td>April 1957</td>
</tr>
<tr>
<td>Justin M. Andrews</td>
<td>April 1957</td>
<td>October 1, 1964</td>
</tr>
<tr>
<td>Dorland J. Davis</td>
<td>October 1, 1964</td>
<td>August 1975</td>
</tr>
<tr>
<td>Richard M. Krause</td>
<td>August 1975</td>
<td>July 1984</td>
</tr>
<tr>
<td>Anthony S. Fauci</td>
<td>November 1984</td>
<td>Present</td>
</tr>
</tbody>
</table>

RESEARCH PROGRAMS

NIAID is composed of 7 research divisions: the Division of Acquired Immunodeficiency Syndrome; the Division of Allergy, Immunology, and Transplantation; the Division of Clinical Research; the Division of Extramural Activities; the Division of Intramural Research; the Division of Microbiology and Infectious Diseases; and the Dale and Betty Bumpers Vaccine Research Center. NIAID scientists conduct intramural research in laboratories located in Bethesda, Rockville, and Frederick, Maryland, and in Hamilton, Montana. More information on NIAID programs, committees, and initiatives can be found on NIAID’s web site at www.niaid.nih.gov.

Division of Acquired Immunodeficiency Syndrome

The Division of Acquired Immunodeficiency Syndrome (DAIDS) was formed in 1986 to develop and implement the national research agenda to address the HIV/AIDS epidemic. Today, with the ever-changing demographics of the epidemic, DAIDS is expanding its focus to a more global research agenda with an emphasis on an integrated prevention and therapeutics agenda. The mission of DAIDS is to help ensure an end to the HIV/AIDS epidemic. DAIDS accomplishes its mission through planning, implementing, managing, and evaluating programs in (1) fundamental basic research; (2) discovery, development, and optimization of therapies and treatment strategies for HIV infection and its complications and co-infections; and (3) discovery and development of preventive vaccines, topical microbicides, and other biomedical prevention strategies. Carl W. Difffenbach, Ph.D., Director.

Division of Allergy, Immunology, and Transplantation

The Division of Allergy, Immunology, and Transplantation (DAIT) promotes and supports a broad range of research that seeks to further our understanding of the immune mechanisms underlying immune-mediated diseases and translating this basic knowledge to clinical applications that will benefit individuals affected by these diseases. DAIT supports preclinical and clinical development of new tolerogenic and immunomodulatory approaches for the treatment and prevention of many immune-mediated diseases, and is the lead NIH component for research on transplantation. The ultimate goal of DAIT’s research program is the development of effective approaches for the treatment and prevention of immune-mediated diseases. Daniel Rotrosen, M.D., Director.

Division of Clinical Research

The Division of Clinical Research (DCR) plays an integral role in facilitating the efficient and effective performance of NIAID research programs on both the domestic and the international level. This is accomplished through a multi-faceted approach to the provision and support of services vital to the research infrastructure that include oversight and management of intramural clinical research, program planning and management, regulatory monitoring and compliance, statistical consultation and research methodology, and clinical research capacity building. H. Clifford Lane, M.D., Director.

Division of Extramural Activities

The Division of Extramural Activities (DEA) serves NIAID’s extramural research community and the Institute in several key areas: overseeing policy and management for grants and contracts; managing NIAID’s research training, small business, and international programs; and conducting initial peer review for funding mechanisms with Institute-specific needs. In addition to providing broad policy guidance to Institute management, DEA also oversees all of NIAID’s chartered committees, including the National Advisory Allergy and Infectious Diseases Council; disseminates information to its extramural community through its large Internet site; and develops extramural staff training and communications through the NIAID intranet. Marvin Kalt, Ph.D., Director.
Division of Intramural Research

The Division of Intramural Research (DIR) is composed of 20 laboratories and 4 branches that conduct biomedical research programs covering a wide range of disciplines relating to immunology, allergy, and infectious diseases. This includes the subdisciplines of virology, microbiology, biochemistry, parasitology, epidemiology, mycology, molecular biology, immunology, immunopathology, and immunogenetics. In addition, DIR supports a large clinical effort to conduct patient-centered research in allergy, immunology, and infectious diseases. Kathryn C. Zoon, Ph.D., Director.

Division of Microbiology and Infectious Diseases

The Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by virtually all human infectious agents, including bacterial, viral, parasitic, and prion diseases, but not HIV. DMID supports a wide variety of projects spanning the spectrum from basic biology of human pathogens and their interaction with human hosts, through translational and clinical research toward the development of new and improved diagnostics, drugs, and vaccines for infectious diseases. DMID's Biodefense Research Program supports basic research on organisms on the NIAID Category A to C list of priority pathogens for biodefense and emerging infectious diseases, as well as translational and clinical research to develop medical countermeasures for diseases caused by these agents. Carole A. Hellman, Ph.D., Director.

Dale and Betty Bumpers Vaccine Research Center

The Vaccine Research Center (VRC) conducts research that facilitates the development of effective vaccines for human disease. The primary focus of activities at the VRC is the development of an effective HIV/AIDS vaccine. In addition to its work on HIV, the VRC has expanded the scope of its activities to include research on developing improved smallpox vaccines; effective vaccines for Ebola and other viral hemorrhagic fevers; vaccines for West Nile virus and for SARS (severe acute respiratory syndrome)-associated coronavirus; and improved influenza vaccines protective against both seasonal influenza and avian influenza strains with the potential for pandemic outbreaks. Goals of the VRC include (1) determining whether a T-cell based vaccine can protect against acquisition of HIV-1 infection or delay disease progression; (2) developing an HIV-1 vaccine candidate that elicits neutralizing antibodies to circulating viral isolates and advancing such a vaccine into clinical trials; (3) identifying improved T-cell vaccines that optimize HIV-1-specific immunity and are independent of anti-vector immunity; and (4) advancing vaccine candidates into efficacy trials for Ebola, Marburg, and influenza viruses. Gary Nabel, M.D., Ph.D., Director.
MISSION

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) was established in 1986. The mission of NIAMS is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal, and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.

The Institute also conducts and supports basic research on the normal structure and function of bones, joints, muscles, and skin. Basic research involves a wide variety of scientific disciplines, including immunology, genetics, molecular biology, structural biology, biochemistry, physiology, virology, and pharmacology. Clinical research includes rheumatology, orthopaedics, dermatology, metabolic bone diseases, heritable disorders of bone and cartilage, inherited and inflammatory muscle diseases, and sports and rehabilitation medicine.

IMPORTANT EVENTS IN NIAMS HISTORY

November 20, 1985—The Health Research Extension Act of 1985 (P.L. 99-158) authorized the establishment of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).

April 8, 1986—NIAMS was established.

February 18, 1987—The first meeting of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council was held.

April 15, 1996—NIAMS held a 10th anniversary symposium: “Progress and Promise in Chronic Disease.”

April 2006—NIAMS celebrated its 20th anniversary.

NIAMS LEGISLATIVE CHRONOLOGY

August 1950—An arthritis program was established within the National Institute of Arthritis and Metabolic Diseases under Public Law 81-692.

May 1972—P.L. 92-305 renamed the Institute the National Institute of Arthritis, Metabolism, and Digestive Diseases.

1973—Senator Alan Cranston introduced legislation that would eventually lead to the National Arthritis Act. Companion legislation was introduced in the House by Congressman Paul Rogers.

January 1975—The National Arthritis Act (P.L. 93-640) established the National Commission on Arthritis and Related Musculoskeletal Diseases to study the problem of arthritis in depth and to develop an arthritis plan. The act also established the position of associate director for arthritis and related musculoskeletal diseases and authorized an interagency arthritis coordinating committee; community demonstration project grants; an arthritis data bank; an information clearinghouse; and comprehensive centers for research, diagnosis, treatment, rehabilitation, and education.

April 1976—After a year of study and public hearings, the commission issued a comprehensive plan aimed at diminishing the physical, economic, and psychosocial effects of arthritis and musculoskeletal diseases. It laid the groundwork for a national program encompassing research, research training, education, and patient care.

October 1976—The Arthritis, Diabetes, and Digestive Diseases Amendments of 1976 (P.L. 94-562) established the National Arthritis Advisory Board to review and evaluate the implementation of the Arthritis Plan, prepared in response to the National Arthritis Act (P.L. 93-640).

December 1980—P.L. 96-538 changed the name of the Institute to the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases. 1982—The U.S. Department of Health and Human Services (HHS) conferred bureau status on the Institute, resulting in creation of the Division of Arthritis, Musculoskeletal, and Skin Diseases and the appointment of a division director.

November 1985—The Health Research Extension Act of 1985, P.L. 99-158, established the National Institute of Arthritis and Musculoskeletal and Skin Diseases to bring increased emphasis to research on these disorders. The legislation provided for the development of a plan for a national arthritis and musculoskeletal...
Dermatology at the Uniformed Services University of the Health Sciences in Bethesda, MD. On August 1, 1995, he was appointed Director of the NIAMS.

Dr. Katz has also served on the editorial boards of most clinical and investigative dermatology journals and many immunology journals. He has authored or coauthored more than 200 scientific articles and 60 book chapters and edited several conference proceedings and books.

In 1974, he joined the National Institutes of Health (NIH) as a senior investigator in the Dermatology Branch of the National Cancer Institute (NCI), becoming acting chief in 1977 and chief from 1980 to 2001. He is still an active senior investigator. From 1989 to 1995, he also served as Marion B. Sulzberger Professor of Dermatology at the University of Miami School of Medicine, FL; military service at Walter Reed General Hospital in Washington, DC; and postdoctoral work at the Royal College of Surgeons of England.

In 1974, he joined the National Institutes of Health (NIH) as a senior investigator in the Dermatology Branch of the National Cancer Institute (NCI), becoming acting chief in 1977 and chief from 1980 to 2001. He is still an active senior investigator. From 1989 to 1995, he also served as Marion B. Sulzberger Professor of Dermatology at the Uniformed Services University of the Health Sciences in Bethesda, MD. On August 1, 1995, he was appointed Director of the NIAMS.

Dr. Katz's studies of Langerhans cells and epidermally derived cytokines have demonstrated that skin is a critical component of the immune system both in its normal function and as a target in immunologically mediated diseases. He has also made seminal discoveries in the field of inherited and acquired blistering skin diseases.

At NCI, he leads a program of investigations in fundamental biological and clinical problems in neoplastic and inflammatory diseases of the skin. He has trained a large number of immunodermatologists from the United States and abroad. These individuals are now leading their own independent research programs.

Dr. Katz has received many Government and private-sector honors and awards, including the Lifetime Achievement Award from the American Skin Association, the Presidential Distinguished Rank Award, Presidential Executive Meritorious Rank Award, Public Health Service Superior Service Award, NIH Director's Award, Sulzberger Lecture Award from the American Academy of Dermatology, Martin Carter Mentor Award from the American Skin Association, Alfred Marchionini Gold Medal, Outstanding Alumnus Award of Tulane University School of Medicine, Stephen Rothman Memorial Award of the Society for Investigative Dermatology (SID), Inflammatory Skin Disorders Research Award, Scleroderma Foundation's Messenger of Hope Award, International Pemphigus Foundation's Excellence in Leadership Award, Arthritis Foundation’s Marriott Lifetime Achievement Award, honorary membership in many international dermatologic societies, and election to the Institute of Medicine of the National Academy of Sciences.

He has served many scientific organizations in leadership positions such as president of SID, membership on the board of directors of SID and of the Association of Professors of Dermatology, secretary-general of the World Congress of Dermatology, and secretary-treasurer of the Clinical Immunology Society. In addition, he was named president of the International League of Dermatological Societies in 1997, for a 5-year term.

Dr. Katz has also served on the editorial boards of most clinical and investigative dermatology journals and many immunology journals. He has authored or coauthored more than 200 scientific articles and 60 book chapters and edited several conference proceedings and books.

BIOGRAPHICAL SKETCH OF NIAMS DIRECTOR STEPHEN I. KATZ, M.D., PH.D.

Dr. Katz earned a B.A. degree cum laude in history from the University of Maryland, College Park; an M.D. degree cum laude from Tulane University Medical School, New Orleans, LA; and a Ph.D. degree in immunology from the University of London, England. He completed a medical internship at Los Angeles County Hospital, CA; a residency in dermatology at the University of Miami School of Medicine, FL; military service at Walter Reed General Hospital in Washington, DC; and postdoctoral work at the Royal College of Surgeons of England.

Dr. Katz's studies of Langerhans cells and epidermally derived cytokines have demonstrated that skin is a critical component of the immune system both in its normal function and as a target in immunologically mediated diseases. He has also made seminal discoveries in the field of inherited and acquired blistering skin diseases.

At NCI, he leads a program of investigations in fundamental biological and clinical problems in neoplastic and inflammatory diseases of the skin. He has trained a large number of immunodermatologists from the United States and abroad. These individuals are now leading their own independent research programs.

Dr. Katz has received many Government and private-sector honors and awards, including the Lifetime Achievement Award from the American Skin Association, the Presidential Distinguished Rank Award, Presidential Executive Meritorious Rank Award, Public Health Service Superior Service Award, NIH Director's Award, Sulzberger Lecture Award from the American Academy of Dermatology, Martin Carter Mentor Award from the American Skin Association, Alfred Marchionini Gold Medal, Outstanding Alumnus Award of Tulane University School of Medicine, Stephen Rothman Memorial Award of the Society for Investigative Dermatology (SID), Inflammatory Skin Disorders Research Award, Scleroderma Foundation's Messenger of Hope Award, International Pemphigus Foundation's Excellence in Leadership Award, Arthritis Foundation’s Marriott Lifetime Achievement Award, honorary membership in many international dermatologic societies, and election to the Institute of Medicine of the National Academy of Sciences.

He has served many scientific organizations in leadership positions such as president of SID, membership on the board of directors of SID and of the Association of Professors of Dermatology, secretary-general of the World Congress of Dermatology, and secretary-treasurer of the Clinical Immunology Society. In addition, he was named president of the International League of Dermatological Societies in 1997, for a 5-year term.

Dr. Katz has also served on the editorial boards of most clinical and investigative dermatology journals and many immunology journals. He has authored or coauthored more than 200 scientific articles and 60 book chapters and edited several conference proceedings and books.

NIAMS DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lawrence E. Shulman, M.D., Ph.D.</td>
<td>April 1986</td>
<td>October 1994</td>
</tr>
</tbody>
</table>
RESEARCH PROGRAMS

The NIAMS supports a multidisciplinary program of basic, clinical, and translational investigations; epidemiologic research; research centers; and research training for scientists within its own facilities as well as grantees at universities and medical schools nationwide. It also supports the dissemination of research results and information through the National Institute of Arthritis and Musculoskeletal and Skin Diseases Information Clearinghouse and through the NIH Osteoporosis and Related Bone Diseases-National Resource Center.

The NIAMS Extramural Program supports research via grants and contracts in two Divisions: the Division of Skin and Rheumatic Diseases and the Division of Musculoskeletal Diseases. A wide array of basic, translational, and clinical research and research training in the fields of rheumatology, muscle biology, orthopaedics, bone and mineral metabolism, and dermatology is being pursued through these programs.

The Intramural Research Program of the NIAMS conducts innovative basic, translational, and clinical research relevant to the health concerns of the Institute and provides training for investigators interested in careers in these areas. The ultimate goals are: 1) to provide new insights into the normal function of bones, joints, muscles, and skin, and diseases that affect them; and 2) to generate a cadre of well-trained investigators to continue toward a complete understanding of these structures and the disease conditions that affect them adversely.

Extramural Research Program

Known as “extramural” research, most funding for the NIAMS supports investigators involved in a wide spectrum of basic, clinical, epidemiologic, training, and other programs in universities, medical schools, academic health centers, and small business concerns. The NIAMS Extramural Program’s three Divisions—the Division of Extramural Research Activities, the Division of Skin and Rheumatic Diseases, and the Division of Musculoskeletal Diseases—are as follows:

Division of Extramural Research Activities

This Division manages the NIAMS grants policies and procedures, including oversight of grants and contract administration, scientific review, and clinical research functions. It serves as the primary liaison for the NIAMS with the NIH Office of Extramural Research and with other Institutes that share research interests. The Division handles scientific integrity and ethical questions in research and manages the NIAMS Council, a congressionally mandated second tier of the NIH peer review system.

The Scientific Review Branch (SRB) conducts initial peer review of specific research applications assigned to the NIAMS. These include applications for Centers, program projects, multi-site clinical trials, scientific meetings, and training and career development, as well as applications responding to initiatives published by the NIAMS. External peer reviewers selected from the grant community conduct reviews.

The Grants Management Branch (GMB) works with scientists and institutional research administrators to issue, manage, and close out awards. The branch has legal responsibility for the fiscal management of the Institute’s extramural grants and contracts.

Division of Skin and Rheumatic Diseases

The mission of this Division is to promote and support basic, translational, and clinical studies of the skin in normal and disease states; and research leading to the prevention, diagnosis, and cure of rheumatic and related diseases. Research is managed under two main areas:

Arthritis and Rheumatic Diseases. The overall goals of the programs in this area are to advance high-quality basic, translational, and clinical biomedical and biopsychosocial research to treat, cure, and prevent arthritis and rheumatic diseases. This includes work that advances the understanding of the natural history of these disorders, as well as mechanisms of disease susceptibility and development. The programs support research in rheumatoid arthritis; adjuvant and chemically induced inflammatory arthritis; systemic lupus erythematosus; systemic sclerosis; spondyloarthropathies; dermatomyositis and polymyositis; vasculitis; fibromyalgia; juvenile arthritis and general autoimmunity; gout; Lyme disease; and infection-related arthritis. An important dimension of these programs involves taking advantage of new insights in the fields of genetics, genomics, proteomics, and imaging related to arthritis and rheumatic diseases. NIAMS is committed to pursuing new opportunities that identify risk factors for these disorders, enhance disease prediction, and advance prevention strategies.

Skin Biology and Diseases. The programs in these areas support a broad portfolio of basic and translational research in skin. These efforts include work on the developmental and molecular biology of skin, the study of skin as an immune organ, and the genetics of skin diseases. Areas of particular emphasis include: investigations of stem cells found in skin; studies related to wound healing and fibrosis; heritable disorders of connective tissue (such as Marfan’s syndrome); studies related to itch; metabolic studies of skin, such as the effects of hormones and interactions with enzymes; and immunologically mediated cutaneous disorders, such as atopic dermatitis, contact dermatitis, and vasculitis. Research is underway to better understand keratinizing disorders such as psoriasis and ichthyosis; disorders of pigmentation such as vitiligo; and bullous diseases such as pemphigus, pemphigoid, and epidermolysis bullosa. Other studies encompass the physiologic activity of the sebaceous glands, as well as disorders of the hair, such as alopecia areata. Tremendous opportunities exist in the field of skin diseases research, from work toward a deeper understanding of the basic biology of skin, to new approaches for developing artificial skin, to advances in imaging technologies for diagnosis and tracking of skin disease progression. NIAMS is committed to pursuing these and other avenues of research to improve health outcomes for patients with skin diseases.

Division of Musculoskeletal Diseases

The musculoskeletal system is comprised of the skeleton, which provides mechanical support and determines shape; the muscles, which power movement; and connective tissues such as tendon and ligament, which hold the other components together. The cartilage surfaces of joints and the intervertebral discs of the spine allow for movement and flexibility.
The Division of Musculoskeletal Diseases supports research aimed at improving the diagnosis, treatment, and prevention of diseases and injuries of the musculoskeletal system and its component tissues. Key public health problems addressed by this research include osteoporosis, osteoarthritis, and muscular dystrophy. Research is conducted at every level, from fundamental biology to clinical intervention. Research is managed under three main areas:

**Bone Biology and Diseases.** The programs in these areas cover a broad spectrum of research to better understand genetic and cellular mechanisms involved in the buildup and breakdown of bone. Research areas include: regulation of bone remodeling; mechanisms of bone formation, bone resorption, and mineralization; and effects of hormones, growth factors, and cytokines on bone cells. The programs emphasize the application of fundamental knowledge of bone cell biology to the development of drug and gene therapies for bone diseases, especially osteoporosis. This program area supports several large epidemiologic cohorts for the characterization of the natural history of osteoporosis and for the identification of genetic and environmental risk factors that contribute to bone disease. Like other cohort studies supported by the NIAMS, the ultimate goals are to contribute to the development of better diagnostic tools, treatments, and prevention strategies.

**Muscle Biology and Diseases.** The programs in these areas support a wide range of basic, translational, and clinical research projects in skeletal muscle biology and diseases. They focus on the fundamental biology of muscle development, physiology, and muscle imaging. Particular interests include the basic biology of satellite and muscle stem cells, excitation-contraction coupling, muscle metabolism, and adaptation of muscle to exercise. The programs address a need for translational research to develop discoveries that enhance treatment and improve management of muscle and musculoskeletal diseases and disorders. The overarching objective is to advance the understanding of—and ultimately prevent and treat—muscular dystrophies, inflammatory myopathies, muscle ion channel diseases, and muscle disorders such as disuse atrophy and age-related loss of muscle mass.

**Cartilage Biology and Orthopaedics.** The programs in these areas focus on understanding the fundamental biology of tissues that constitute the musculoskeletal system, and on translating this knowledge to a variety of diseases and conditions. Research includes the study of the causes and treatment of acute and chronic injuries—including carpal tunnel syndrome, repetitive stress injury, and low back pain—and clinical and epidemiological studies of osteoarthritis. The programs support the development of new technologies such as methods for imaging bone and cartilage to improve the diagnosis and treatment of skeletal disorders, or to facilitate the repair of damage caused by trauma to otherwise healthy musculoskeletal tissue. Therapeutic approaches of interest in the programs include drugs, nutritional interventions, joint replacement (including biomaterials and implant science), bone and cartilage transplantation, and gene therapy.

**Intramural Research Program**

The NIAMS Intramural Research Program (IRP) consists of 17 main components: Office of the Scientific Director, Office of the Clinical Director, Rheumatology Fellowship and Training Branch, Community Research and Care Branch, Office of Science and Technology, Arthritis and Rheumatism Branch, Autoimmunity Branch, Cartilage Biology and Orthopaedics Branch, Molecular Immunology and Inflammation Branch, Laboratory of Skin Biology, Laboratory of Structural Biology Research, Protein Expression Laboratory, Clinical Trials and Outcomes Branch, Pediatric Translational Research Branch, Laboratory of Muscle Stem Cells and Gene Regulation, Laboratory of Molecular Immunogenetics, and Career Development and Outreach Branch.

The **Office of the Scientific Director** is responsible for the development of broad decisions concerning program planning, budget and policy formulation, and resource allocation of the intramural program. The Scientific Director represents the NIAMS in discussions of NIH-wide intramural policies and programs, and serves as a vital member of the senior staff of the Institute. The Scientific Director serves as the principal advisor to the Director of the NIAMS concerning all ongoing and projected intramural research programs.

The **Office of the Clinical Director** implements innovative clinical research programs that relate to the broad field of rheumatologic, musculoskeletal, and skin disorders. Through specific programs in translational research, rheumatology fellowship training, and health partnerships, the Office of the Clinical Director plays an important role in establishing innovative therapeutic paradigms, in providing medical education in the field of rheumatology, and in reaching out to the community to reduce health care disparities and to improve the understanding of rheumatic and related diseases.

- **Rheumatology Fellowship and Training Branch.** The Branch is dedicated to the clinical and research training of physicians wishing to pursue careers in biomedical or translational research related to rheumatic diseases. The fellowship program is two years in duration, with extensions available for individuals interested in advanced research training. The program is accredited by the Accreditation Council for Graduate Medical Education (ACGME), and graduates are eligible to sit for the certifying examination in the subspecialty of rheumatology.

- **Community Research and Care Branch.** The NIAMS Community Health Center is a health information and medical center, carrying out research and providing health care services to people affected by arthritis, lupus, and other rheumatic diseases. The health center offers patient care with access to a specialist, health information and education programs, and referral to clinical investigations for the prevention and treatment of rheumatic diseases. The health center is located in upper northwest Washington, DC.

The **Office of Science and Technology** encompasses an infrastructure of research and support facilities designed to enhance the research capabilities of all IRP scientists. In addition, staff members advise the Scientific Director, Laboratory and Branch Chiefs, and other key officials on collaborative and cooperative activities, training programs, and proper use of laboratory animals. Staff members also negotiate and facilitate scientific collaborations that involve trans-institute and trans-NIH initiatives and agreements. The Office includes the following:

- **The Flow Cytometry Section** provides state-of-the-art multiparameter analytic and sorting capabilities for IRP investigators.

- **The Laboratory Animal Care and Use Section** supports all IRP branches and laboratories using animals.

- **The Light Imaging Section** functions as a core facility, offering IRP scientists access to state-of-the-art light imaging equipment and expertise in light imaging techniques.

- **The Biostatistics and Discovery Section** assesses the scientific computing needs of IRP scientists, develops strategies, and designs computational support for researchers.

- **The Translational Immunology Section** provides NIAMS investigators with services, consultative advice, and in-depth instructions in a variety of immunologic methods to facilitate interpretation of immunoassays.
The Arthritis and Rheumatism Branch conducts a variety of basic and clinical investigations. The historical focus of the branch has been the study of the autoimmune rheumatic diseases, particularly rheumatoid arthritis, systemic lupus erythematosus, and myositis. Current studies focus on inflammatory and genetic diseases affecting the musculoskeletal system.

The Autoimmunity Branch conducts basic and clinical research on the pathophysiology and treatment of autoimmune diseases. Signal transduction pathways that differentiate normal and pathological immune responses are studied in mouse models and human tissue samples to gain insights into how these processes drive autoimmune diseases and how therapies can best be developed for these diseases that minimize generalized immune suppression. The TNF-family of cytokines and their receptors are a current focus of interest in the branch, from basic investigation of the trafficking and signaling by these molecules to the study of human diseases involving TNF-family cytokines and their receptors.

The Cartilage Biology and Orthopaedics Branch conducts basic and clinical research on the pathogenesis and treatment of musculoskeletal diseases relevant to the field of orthopaedic surgery. Current investigations are focused on the genetic, cellular, and molecular events involved in the development of heterotopic ossification (HO). Specific attention is paid to progenitor cells obtained from human tissue samples and their trophic and differentiation properties involved in tissue repair and regeneration.

The Molecular Immunology and Inflammation Branch conducts basic and clinical investigations on the molecular mechanisms underlying immune and inflammatory responses in rheumatic and autoimmune diseases. A major focus is the study of receptor-mediated signal transduction and how these processes link to the regulation of genes involved in inflammatory responses. Included in the branch are the Lymphocyte Cell Biology, Genomic Integrity, and Molecular Inflammation Sections.

The Laboratory of Skin Biology conducts research on the regulation of epidermal differentiation, skin barrier formation, and inflammatory responses associated with barrier dysfunction studied in mouse models. A major focus is basic investigation on ectodermal appendage development and the study of human ectodermal dysplasias.

The Laboratory of Structural Biology Research conducts research into the structural basis of the assembly and functioning of macromolecules and their complexes (such as viruses and cytoskeletal proteins), and the mechanisms and proteins that control their assembly. These studies make extensive use of cryo-electron microscopy and three-dimensional image processing in studies of virus infection and replication; renewal of the epidermis, with maintenance of barrier function; prionogenesis (structural transitions of infectious proteins called prions); and intracellular protein quality control by energy-dependent proteases.

The Protein Expression Laboratory plans and conducts research on the expression, purification, and structural characterization of human immunodeficiency virus (HIV) and HIV-related proteins. Laboratory scientists also collaborate with NIH intramural researchers studying the structure and function of HIV and HIV-related proteins. The lab serves as a support and resource group for the expression and purification of these proteins.

The Clinical Trials and Outcomes Branch conducts research on the health outcomes of patients with rheumatic diseases and orthopaedic conditions. Studies focus on the development and testing of measures of health and disease, identification of predictors of good and poor health outcomes, examination of treatment effectiveness, and investigations of socioeconomic and ethnic disparities in health outcomes.

The Pediatric Translational Research Branch, which includes the Translational Autoinflammatory Disease Section, conducts basic, translational, and clinical research to dissect the pathways involved in the pathogenesis of immune-mediated inflammatory diseases. The mechanisms by which specific gene mutations and polymorphisms predispose to inflammation, and how they contribute to unique phenotypic manifestations of individual diseases, are being investigated using a variety of approaches.

The Laboratory of Muscle Stem Cells and Gene Regulation investigates the cellular and molecular mechanisms that regulate specification, differentiation, and regeneration of skeletal muscle in physiological and pathological conditions. The ultimate goal of these studies is to provide a conceptual, as well as practical, framework for the diagnosis and treatment of human diseases affecting skeletal muscle.

The Laboratory of Molecular Immunogenetics (LMI) conducts research on genetic and molecular regulation of normal and abnormal immune cell processes and on how these events control immune system regulation and disease. The LMI studies the role of key immune genes in controlling immunoglobulin class switching, DNA repair, immune cell activation, recruitment and function, and regulation of gene expression. The goal is to understand the molecular underpinnings on how inflammation is regulated in both health and disease. This is essential for developing targeted therapeutic agents that can ameliorate immune system disorders with minimal side effects.

The Career Development and Outreach Branch advises the Scientific Director, Lab and Branch Chiefs, and other key officials within the NIAMS IRP on current and potential training programs; coordinates resources available for NIAMS fellows and their sponsors; and works in partnership with existing NIAMS and NIH components to ensure that the NIAMS continues to attract the highest caliber of trainees at the postdoctoral, postbaccalaureate, and graduate student levels. The Branch enables NIAMS fellows to become leaders in the biomedical research community and provides trainees with a genuine growth experience, enhancing their ability to compete for independent research or other science-related careers in government or the private sector. In addition, the Branch leads institute career outreach activities, administers the summer internship program, and supports the annual Intramural Retreat.

Communications

The NIAMS Office of Communications and Public Liaison (OCPL) leads the Institute's health education and public affairs efforts to disseminate accurate, timely, and reliable science-based information on the broad range of diseases and conditions of the bones, joints, muscles, and skin. Specifically, the OCPL:

- Provides easy access to current, evidence-based, and audience-appropriate health information.
- Increases awareness of NIAMS-funded research, opportunities, and results.
- Increases awareness among scientists and students about careers and training opportunities in biomedical research fields within the NIAMS mission, particularly in underrepresented communities.
- Engages the public and encourages participation and input in NIAMS and NIH activities.
- Increases awareness of the NIAMS as the leading resource for research-based information on diseases and conditions of the bones, joints, muscles, and skin.
- Oversees two congressionally mandated information clearinghouses, the NIAMS Information Clearinghouse and the NIH Osteoporosis and Related Bone Diseases – National Resource Center.
MISSION

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care. This is achieved through: research and development of new biomedical imaging and bioengineering techniques and devices to fundamentally improve the detection, treatment, and prevention of disease; enhancing existing imaging and bioengineering modalities; supporting related research in the physical and mathematical sciences; encouraging research and development in multidisciplinary areas; supporting studies to assess the effectiveness and outcomes of new biologics, materials, processes, devices, and procedures; developing technologies for early disease detection and assessment of health status; and developing advanced imaging and engineering techniques for conducting biomedical research at multiple scales.

IMPORTANT EVENTS IN NIBIB HISTORY

December 29, 2000—The National Institute of Biomedical Imaging and Bioengineering Establishment Act (H.R. 1795) is signed into law by President William Jefferson Clinton.

2001—The NIBIB Establishment Plan is approved by the U.S. Secretary of Health and Human Services, Mr. Tommy G. Thompson.

Dr. Donna J. Dean is named as Acting Director of NIBIB.

The National Advisory Council for Biomedical Imaging and Bioengineering is established.

NIBIB assumes administration of the NIH's Bioengineering Consortium (BECON).

The NIBIB website is launched.

2002—A working group is established to review and recommend the transfer of grants to NIBIB.

NIBIB receives its first budget appropriation (FY 2002) in the amount of $112 million.

NIBIB announces its first 2 Requests for Applications.

The NIBIB announces the award of its first research grants.

Dr. Roderic Pettigrew, professor of radiology, medicine (cardiology), and bioengineering, and director of the Emory Center for MR Research, Emory University School of Medicine, assumes the position of Director of NIBIB.

Dr. Donna Dean becomes the first Deputy Director of NIBIB.

2003—The National Advisory Council for Biomedical Imaging and Bioengineering meets for the first time in Bethesda, Maryland.

A new NIBIB organization is announced by Dr. Roderic Pettigrew.

The NIBIB Special Emphasis Panel is established.

Dr. Belinda Seto is named the Deputy Director of NIBIB.

2004—NIBIB initiates its Strategic Planning process.

NIBIB and the Center for Devices and Radiological Health, FDA, sign an interagency agreement establishing the Joint Laboratory for the Assessment of Medical Imaging Systems.

NIBIB hosts a Blue Ribbon Panel on Intramural Research to provide recommendations on the planning and development of an Intramural research program.

NIBIB and Howard Hughes Medical Institute (HHMI) announce a partnership to support the HHMI/NIBIB Interfaces Initiative for Interdisciplinary Graduate Research Training.
The Positron Emission Tomography (PET) Radiochemistry Group joins the Institute as the NIBIB Intramural Research Program.

NIBIB and the National Science Foundation sponsor a conference on “Research at the Interface of the Life and Physical Sciences: Bridging the Sciences.”

2005—NIBIB issues a draft Strategic Plan and invites public comment.

NIBIB holds its first Regional Grantsmanship Seminar in Troy, New York. The seminars are intended to provide an overview of NIBIB funding opportunities and NIH application, review, and grant-making processes and policies.

NIBIB launches re-designed website.

2006—NIBIB awards its first Quantum Grant to Baylor College of Medicine.

NIBIB names Dr. Richard Leapman as Scientific Director of the Intramural Sciences Program.

NIBIB publishes its first strategic plan, Strategic Plan I, following a year-long process of input from the public, staff, and groups of outside experts. This plan is designed to (1) define key goals, (2) optimize the use of resources, and (3) install tools and processes for smart management in order to help NIBIB achieve its mission and realize its vision.

NIBIB website wins Award of Distinction from The Communicator Awards.

2007—NIBIB celebrates its 5-year anniversary with a commemorative scientific symposium on technological innovation in medicine entitled, “Changing the World’s Healthcare through Biomedical Technologies.” View Image.

NIBIB presents the first NIBIB Landmark Achievement Award to Dr. Paul Lauterbur (posthumously), 2003 Nobel Laureate, Physiology or Medicine, for his vision and fundamental discoveries in the development of magnetic resonance imaging. View Image.

The Division of Bioengineering and Physical Science is transferred from the NIH Office of Research Services to the NIBIB intramural research program.

NIBIB awards Quantum Grants to Wake Forest University Health Sciences, the University of Michigan at Ann Arbor, the Cleveland Clinic Lerner College of Medicine-CWRU, and Massachusetts General Hospital.

NIBIB and the Department of Biotechnology of the Ministry of Science and Technology, Republic of India, sign a bilateral agreement to develop low-cost healthcare technologies aimed at the medically underserved. View Image.

2008—NIBIB enters into a cooperative agreement with the U.S. Department of Defense and the Office of Naval Research to support and manage the Armed Forces Institute of Regenerative Medicine (AFIRM). Over the next 5 years, AFIRM will provide $8.5 million per year for research in the field of regenerative medicine.

NIBIB holds the first Quantum Grantees’ meeting.

NIBIB’s Point-of-Care Technologies Network holds a first-year meeting to discuss progress and future plans.

Dr. Roderic I. Pettigrew, NIBIB Director, participates in the 2008 South Africa Ph.D. Project Conference.

NIBIB and the Department of Biotechnology of the Ministry of Science and Technology, Republic of India, hold a 2-day workshop entitled “Low-Cost Diagnostic and Therapeutic Medical Technologies,” in Hyderabad, India, aimed at promoting U.S./Indian scientific collaborations in the development of low-cost diagnostics and therapeutics.

2009—NIBIB hosts the first in a series of forums on Technology Translation. The first forum focused on the role of public-private partnerships in the development and translation of in-vitro diagnostic technologies.

NIBIB provides support for the RSNA RadLex Ontology Project, which will provide a uniform source of terms and concepts for indexing and retrieving imaging information sources.

The Neuroimaging Tools and Resources Clearinghouse (NITRC) wins the 2009 Excellence in Government Award from the American Council for Technology. NITRC is supported by the NIH Blueprint for Neuroscience Research and managed by NIBIB. View Image.

NIBIB awards ten grants in Phase II of the NIBIB-HHMI Interfaces Initiative for Interdisciplinary Graduate Research Training.

**BIOGRAPHICAL SKETCH OF NIBIB DIRECTOR RODERIC I. PETTIGREW, PH.D., M.D.**

Roderic I. Pettigrew, Ph.D., M.D., is the first Director of the National Institute of Biomedical Imaging and Bioengineering at the NIH. Prior to his appointment at the NIH, he was professor of radiology, medicine (cardiology) at Emory University and Bioengineering at the Georgia Institute of Technology and director of the Emory Center for MR Research, Emory University School of Medicine, Atlanta.

Dr. Pettigrew is known for his pioneering work at Emory University involving 4-dimensional imaging of the heart using magnetic resonance imaging (MRI). Dr. Pettigrew graduated cum laude with a B.S. in physics from Morehouse College, where he was a Merrill Scholar; has an M.S. in nuclear science and engineering from Rensselaer Polytechnic Institute; and a Ph.D. in applied radiation physics from the Massachusetts Institute of Technology, where he was a Whitaker Harvard-MIT Health Sciences Scholar. Subsequently, he received an M.D. from the University of Miami School of Medicine in an accelerated 2-year program, did an internship...
and residency in internal medicine at Emory University and completed a residency in nuclear medicine at the University of California, San Diego. Dr. Pettigrew then spent a year as a clinical research scientist with Picker International, the first manufacturer of MRI equipment. In 1985, he joined Emory as a Robert Wood Johnson Foundation Fellow with an interest in noninvasive cardiac imaging.

Dr. Pettigrew's awards include membership in Phi Beta Kappa, the Bennie Award (Benjamin E. Mays) for Achievement, and being named the Most Distinguished Alumnus of the University of Miami. In 1989, when the Radiological Society of North America celebrated its 75th diamond anniversary scientific meeting, it selected Dr. Pettigrew to give the keynote Eugene P. Pendergrass New Horizons Lecture. He has also served as chairman of the Diagnostic Radiology Study Section, Center for Scientific Review, NIH. He has been elected to membership in the Institute of Medicine and fellowship in the American Heart Association, American College of Cardiology, American Institute for Medical and Biological Engineering, International Society for Magnetic Resonance in Medicine, and the Biomedical Engineering Society.

**NIBIB DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donna J. Dean (Acting)</td>
<td>April 26, 2001</td>
<td>September 22, 2002</td>
</tr>
<tr>
<td>Roderic I. Pettigrew</td>
<td>September 23, 2002</td>
<td>Present</td>
</tr>
</tbody>
</table>

**NIBIB PROGRAMS**

**Extramural Research**

The NIBIB extramural research program brings together the research communities of biomedical imaging, bioengineering, the physical sciences, and the life sciences to advance human health by improving quality of life and reducing the burden of disease. The extramural research program is organized into 3 divisions: Discovery Science and Technology, Applied Science and Technology, and Inter-Disciplinary Training.

The Institute supports basic research and research training through investigator-initiated grants, contracts, program project and center grants, and career development and training awards.

**Intramural Research**

The NIBIB Intramural Research Program plays a key role in advancing the Institute's mission. Specifically, the program advances knowledge in imaging and bioengineering research using a combination of basic, translational, and clinical science. The intramural research program has also developed several unique training opportunities in these and related fields.

The Intramural Research Program has expertise that spans technologies ranging in scale from near-atomic resolution to intact organisms. Current research areas include: molecular imaging probe development; nano theranostics; cardiovascular imaging; high resolution optical imaging; biophotonics; supramolecular structure and function; dynamics of macromolecular assembly; complex biological systems; immunochemical nanoscale analysis and diagnostics; pharmacokinetics and drug delivery; and non-invasive optical imaging.

NIBIB's Intramural Research Program offers training opportunities at several educational levels:

- Imaging Sciences Training Program — a joint NIBIB/NIH Clinical Center program for MDs and PhDs seeking research careers in clinical, translational, and basic imaging research. [www.cc.nih.gov/drd/training/index.html](http://www.cc.nih.gov/drd/training/index.html)
- Biomedical Engineering Summer Internship Program — for college students completing their junior year in a bioengineering program. [www.nibib.nih.gov/Training/UndergradGrad/besip/home](http://www.nibib.nih.gov/Training/UndergradGrad/besip/home)

This page last reviewed on October 12, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

The mission of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is to ensure that every person is born healthy and wanted, that women suffer no harmful effects from the reproductive process, that all children have the chance to fulfill their potential to live healthy and productive lives free from disease or disability, and to ensure the health, productivity, independence, and well-being of all people through optimal rehabilitation.

In pursuit of this mission, the NICHD conducts and supports laboratory research, clinical trials, and epidemiological studies that explore health processes; examines the impact of disabilities, diseases, and defects on the lives of individuals; and sponsors training programs for scientists, doctors, and researchers to ensure that NICHD research can continue.

NICHD research programs incorporate the following concepts:

- **Events that happen prior to and throughout pregnancy, as well as during childhood, have a great impact on the health and well-being of children and adults.** The Institute supports and conducts research to: advance knowledge of pregnancy, fetal development, and birth for developing strategies that prevent maternal, infant, and childhood mortality and morbidity; identify and promote the prerequisites of optimal physical, mental, and behavioral growth and development through infancy, childhood, and adolescence; and contribute to the prevention and amelioration of mental retardation and developmental disabilities.

- **Human growth and development is a life-long process that has many phases and functions.** Much of the research in this area focuses on cellular, molecular, and developmental biology to build understanding of the mechanisms and interactions that guide a single fertilized egg through its development into a multi-cellular, highly organized adult organism.

- **Learning about the reproductive health of women and men and educating people about reproductive practices is important to both individuals and societies.** Institute-supported basic, clinical, and epidemiological research in the reproductive sciences seeks to develop knowledge that enables women and men to overcome problems of infertility, and to regulate their fertility in ways that are safe, effective, and acceptable for various population groups. Institute-sponsored behavioral and social science research in the population field strives to understand the causes and consequences of reproductive behavior and population change.

- **Developing medical rehabilitation interventions can improve the health and well-being of people with disabilities.** Research in medical rehabilitation seeks to develop improved techniques and technologies, with respect to the rehabilitation of individuals with physical disabilities resulting from diseases, disorders, injuries, or birth defects.

The Institute also supports research training across all its programs, with the intent of adding to the cadre of trained professionals who are available to conduct research in areas of critical public health concern. In addition, an overarching responsibility of the NICHD is to disseminate information that emanates from Institute research programs to researchers, practitioners, other health care professionals, and the public.

IMPORTANT EVENTS IN NICHD HISTORY

**January 12, 1961**—The report of the Task Force on Health and Social Security calls for the establishment, by administrative action of the U.S. Surgeon General, of a National Institute of Child Health within the National Institutes of Health (NIH).

**January 30, 1961**—The U.S. Department of Health, Education, and Welfare (DHEW) general counsel declares that existing legislation (enacted in 1950) limited the creation of new Institutes to those focusing on a disease or group of diseases, and that new legislation would be required to establish the Institute called for in the Task Force report.

**February 17, 1961**—The Surgeon General establishes a Center for Research in Child Health in the Division of General Medical Sciences.

**October 17, 1961**—Public Law 87-838 authorizes the establishment of the NICHD.

**January 30, 1963**—Secretary of DHEW Anthony J. Celebrezze approves the establishment of the NICHD, with a provision that the Center for Research in Child Health and the Center for Research in Aging (established in 1956) be transferred from the Division of General Medical Sciences to the new Institute.

**May 1963**—The Surgeon General appoints members of the National Advisory Child Health and Human Development (NACHHD) Council.

**November 14, 1963**—The NICHD holds the first meeting of the NACHHD Council.
December 1965—A major NICHD reorganization, approved by the Surgeon General, emphasizes four program areas: reproduction, growth and development, aging, and mental retardation.

April 1967—A second reorganization of the NICHD, approved by the Surgeon General, acknowledges the Institute's intramural research programs by separating responsibility for intramural and extramural research and creating seven intramural laboratories. The reorganization brings the NICHD administrative structure into line with that of other NIH Institutes.

August 9, 1968—The DHEW Secretary establishes the Center for Population Research within the NICHD. The Center is responsible for contract and grant programs in population and reproduction research and is designated by the president as the federal agency primarily responsible for population research and training.

1970—The NICHD’s Epidemiology and Biometry Branch, created during the Institute’s second reorganization in 1967, becomes the Epidemiology and Biometry Research Program. The change allows the Program to conduct epidemiologic, behavioral, and biometric studies relating to reproductive, maternal, and child health.

May 27, 1975—The federal government establishes the Center for Research for Mothers and Children within the NICHD as the focal point for research and research training on the special health problems of mothers and children. The Center also has responsibility for increasing knowledge about pregnancy, infancy, childhood, adolescence, and adulthood, and for administering grant and contract programs related to these areas.

June 30, 1975—The Adult Development and Aging Branch and the Gerontology Research Center, with their programs for support and conduct of research in the field of aging, are transferred from the NICHD to the newly established National Institute on Aging (NIA).

1978—NICHD intramural researchers become the first to successfully clone a mammalian gene, a critical first step in obtaining large amounts of medically important proteins.

December 1983—NICHD grantees Ralph Brinster and Richard Palmiter become the first to transplant human genes into animals. Their accomplishment, transplanting the gene for human growth hormone into mice, provides an important new means to study the function of human genes, as well as the foundation of the new biotechnology industry.

1985—The NICHD forms research networks of Neonatal Intensive Care Units and Maternal-Fetal Medicine Units. The networks, which perform large clinical trials, provide the Institute with a faster, more effective system of evaluating neonatal intensive care and maternal-fetal treatments.

December 1989—The NICHD announces the establishment of the country’s first research centers that combine the biomedical and behavioral sciences to focus specifically on learning disabilities.

September 1990—The Institute begins a congressionally initiated national program of Child Health Research Centers. The goal is to expedite the application of findings from basic research to the care of sick children.

November 16, 1990—Congress establishes the National Center for Medical Rehabilitation Research within the NICHD to conduct and support programs for the rehabilitation, health, and well being of individuals with physical disabilities.

1991—The NICHD expands its Epidemiology and Biometry Research Program to create the Division of Epidemiology, Statistics, and Prevention Research, part of its intramural research component. The Division’s portfolio includes research in the fields of reproduction and maternal and child health.

1994—The NICHD launches the Back to Sleep campaign, a program designed to teach parents and caregivers the importance of putting babies on their backs to sleep, to help reduce the risk of sudden infant death syndrome (SIDS).

January 1994—In response to the need for appropriate drug therapy for pediatric patients, the NICHD establishes the Pediatric Pharmacology Research Unit Network. The Network’s mission is to facilitate and promote pediatric labeling of new drugs or drugs already on the market, to ensure the safe and effective use of drugs in children.

September 1996—Two NICHD scientists, Drs. John Robbins and Rachel Schneerson, receive the 1996 Albert Lasker Clinical Medical Research Award for the landmark development of a polysaccharide-protein conjugate vaccine for Hemophillus influenzae type b (Hib). Also in 1996, Robbins and Schneerson receive the World Health Organization Children’s Vaccine Initiative Pasteur Award for Recent Contributions in Vaccine Development for their Hib vaccine breakthrough.

1997—The NICHD launches the Milk Matters calcium education campaign, designed to educate people about the importance of getting enough calcium during the childhood and teenage years to help prevent osteoporosis and fragile bones in adulthood.

June 1997—The NICHD and the National Institute on Deafness and Other Communication Disorders (NIDCD) establish the Network on the Neurobiology and Genetics of Autism, composed of 10 Collaborative Programs of Excellence in Autism (CPEAs). The CPEA Network is a multi-million dollar, international effort that seeks to solve the puzzle of autism through research.

September 1997—The NICHD initiates the first phase of its National Longitudinal Study of Adolescent Health (called the Add Health Study). The study’s main premise is that social context—such as relationships with families, friends, and peers—influences the health-related behaviors of young people, and that understanding this context is essential to guide efforts to modify health behaviors.

March 1998—Using sophisticated brain imaging technology, NICHD-funded researchers reveal a brain map of the physical basis of dyslexia. This finding may provide the basis for screening techniques that will help identify dyslexia, allowing treatment to start earlier in a person’s development.
June 1998—In the largest, most comprehensive analysis of its kind, NICHD-funded research finds that pregnant women who are infected with HIV can reduce the risk of transmitting the virus to their infants by about 50% if they deliver by elective Cesarean section before they have gone into labor and before their membranes have ruptured.

July 1998—The Food and Drug Administration approves an NICHD-developed DTaP (diphtheria-tetanus-acellular pertussis) vaccine for use in immunization against these diseases.

September 1999—NICHD-funded researchers announce the discovery of the gene for Rett syndrome, a disorder in which healthy infant girls gradually lose their language capabilities, mental functioning, and ability to interact with others.

2000—NICHD researchers demonstrate that inhaled nitric oxide is an effective therapy for respiratory failure in critically ill term infants in whom aggressive conventional therapy had failed. The findings, which resulted from the first definitive, randomized clinical trial of nitric oxide use in human neonates, may further reduce the long-term costs of caring for such children and improve their quality of life by reducing their risk for chronic respiratory insufficiency and central nervous system ischemia.

2000—NICHD researchers evaluating data from the Fels Longitudinal Study, the oldest and largest growth study in the world, find that obesity in childhood tracks from age three years onward, into adulthood, and that obesity in adolescence is more likely to lead to adult obesity than obesity earlier in childhood. Data from the study, supported by NICHD since 1974, may allow researchers to ascertain the segregation of growth patterns over three generations, to detect linkage of candidate genes to various phenotypes of growth, and to permit the discovery of new descriptors of normal growth and underlying genetic mechanisms.

January 2000—The Bill and Melinda Gates Foundation joins the NICHD in developing and supporting an international research network to improve the health of women and children throughout the world. The NICHD will match the Foundation's $15 million to help the network establish self-sustaining, international, and medical research institutions, which are urgently needed to address many of the world's health concerns.

April 2000—The National Reading Panel, established by the NICHD, releases findings of the largest, most comprehensive, evidence-based review ever conducted of research related to how children learn to read. The independent panel concludes that the most effective way to teach children to read is through instruction that includes a combination of methods and addresses alphabets (phonemic awareness and phonemic instruction), reading fluency, reading comprehension, teacher education, and computer technology.

October 2000—An NICHD-funded study, conducted by researchers from Thailand, France, and the United States, shows that transmission of HIV from a mother to her child can be reduced nearly as effectively with shorter treatments of the drug AZT, as with longer AZT treatments. The findings may allow women in developing countries to better afford the treatment that can reduce their babies' chances of contracting AIDS.

October 2000—An NICHD grantee, Dr. James J. Heckman of the University of Chicago, is 1 of 2 NIH researchers to receive the Bank of Sweden Prize in Economic Sciences in memory of Alfred Nobel. Dr. Heckman is awarded the Nobel Prize in Economics for his pioneering work in accounting for unknown factors affecting statistical samples. Much of his work has been applied to understanding how early life events contribute to individuals' later earning potential and economic standing.

February 2001—The NICHD establishes three fragile X research centers to conduct and support research related to improving the diagnosis and treatment of, and finding a cure for, fragile X and fragile X syndrome. This initiative was mandated under Public Law 106-310, the Children's Health Act, passed in October 2000.

April 2001—A typhoid vaccine developed by NICHD scientists showed a 91.5% effectiveness rate, the highest reported for any typhoid vaccine, in clinical trials done in Vietnam. More than 16 million people worldwide are affected by typhoid every year. This highly effective vaccine could prevent the more than 600,000 deaths that result annually from typhoid fever around the world.

February 2002—NICHD scientists, in conjunction with the biologics firm Nabi, develop the first vaccine against Staphylococcus aureus, a major cause of infection and death in hospital patients. S. aureus—which can cause illness ranging from minor skin infections to life-threatening pneumonia, meningitis, and infections of the heart—attacks people whose immune systems are compromised. This new vaccine provides a powerful new way to prevent these infections, a finding which could save thousands of lives every year.

June 2002—Findings from the NICHD’s Women's Contraceptive and Reproductive Experiences Study (Women's CARE) reveal no association between oral contraception use and an increased risk of breast cancer. The study, which focuses on women age 35 to 64 because they are more likely to develop breast cancer than younger women, provides scientific evidence that past or present oral contraception use does not significantly increase breast cancer risk.

2003—In a first-of-its-kind collaboration, the NICHD, National Coalition of 100 Black Women, the Women in the NAACP, and Alpha Kappa Alpha Sorority, Inc., embark on a year-long program to spread the safe sleep message in African American communities. At regional summits held in Tuskegee, Los Angeles, and Detroit, the partners conduct SIDS risk-reduction training and activities to equip members and community leaders with educational techniques, strategies, and promotional materials so they can conduct outreach activities to reduce the risk of SIDS among African American infants.

June 2003—The NICHD establishes the Center for Developmental Biology and Perinatal Medicine. The Center strives to advance fundamental and clinical knowledge about maternal health and problems of child development, such as preterm birth, mental retardation and developmental disabilities, congenital defects and genetic disorders, fetal growth restriction, and other conditions.

April 2004—NICHD-supported researchers demonstrate that effective reading instruction not only improves reading ability, but also changes the functioning of the brain so that it reads more efficiently. The scientists used functional magnetic resonance imaging (fMRI) to observe brain functions in children during reading. With fMRI, the researchers could see that the brains of once-poor readers, as they overcame their reading disabilities, began to function like the brains of good readers. The findings show that the brain systems involved in reading respond to effective reading instruction and show increased activity in a part of the brain that recognizes words.
June 2004—Reorganization within the NICHD's Center for Research for Mothers and Children establishes the Obstetric and Pediatric Pharmacology Branch to meet the increased demand for research leadership and support of legislation passed to ensure the safety of drugs used to treat children. The new Branch includes the NICHD Pediatric Pharmacology Research Units Network, the Obstetric-Fetal Pharmacology Research Network, and NICHD Best Pharmaceuticals for Children Act activities. The Branch provides a focus for managing efforts across the U.S. Department of Health and Human Services (HHS) to address this important topic.

November 2004—The NICHD and its partner agencies announce the 96 recruitment locations for the National Children's Study, a national, longitudinal study of environmental influences on child health mandated in the Children's Health Act of 2000. The study, led by a consortium of federal agencies—including HHS (the NICHD and the National Institute of Environmental Health Sciences [NIEHS] within NIH, as well as the Centers for Disease Control and Prevention) and the U.S. Environmental Protection Agency—will be the largest and most comprehensive of its kind.

December 2004—Researchers in the NICHD Maternal-Fetal Medicine Units (MFMU) Network find that the risks from vaginal delivery after a prior Cesarean delivery are low, and are only slightly higher than for a repeat Cesarean delivery, thus clarifying the safety of vaginal birth after Cesarean. The largest, most comprehensive study of its kind indicated that, although complications (such as rupture of the uterus and infection of the uterine lining) were possible, the risk of these complications was very low. Further, the researchers noted that repeat Cesarean carries its own risks, including infection and surgical complications, and that the procedure may complicate future births. The MFMU Network allows researchers to conduct large clinical trials quickly, by recruiting from multiple sites and using one protocol, providing a faster, more effective system of evaluating maternal-fetal treatments.

January 2005—NICHD-supported researchers identify a substance—placental growth factor (PIGF)—in the urine of pregnant women that can be measured to predict the later development of preeclampsia, the leading cause of maternal and fetal death in the United States. This finding sets the stage for the development of a test to screen women for risk of preeclampsia. Such foreknowledge will help physicians to better care for the women, possibly taking steps to prolong the pregnancy to allow the fetus to develop more, while closely monitoring them for signs that the fetus should be delivered, even prematurely, if necessary.

April 7, 2005—World Health Day—the Global Network for Women's and Children's Health Research, funded by the NICHD and the Bill and Melinda Gates Foundation, initiates the First Breath Project to treat newborn asphyxia, a major cause of infant death, in resource-poor settings. The new project seeks to determine if training midwives and other traditional birth attendants in standard infant resuscitation practices commonly used in the United States can reduce the death and disability from newborn asphyxia in seven Global Network sites located in South Asia, Africa, and Latin America. The project will include nearly 80 communities and 40,000 births per year during the course of the study.

October 2006—As part of a decades-long research effort on SIDS, NICHD-funded researchers announce findings that infants who died of SIDS had abnormalities in the brainstem, a part of the brain that helps control heart rate, breathing, blood pressure, temperature, and arousal. The finding supports the concept that SIDS risk may greatly increase when an underlying predisposition combines with an environmental risk at a developmentally sensitive time in early life. Modifiable factors, such as sleep position, may provide the greatest protection against SIDS for infants with the brain abnormality.

December 2006/February 2007—NICHD researchers discover two genetic defects that lead to forms of Osteogenesis Imperfecta (OI), a disorder that weakens bones and may cause frequent fractures. The first gene discovery—a recessive form that requires two copies of the affected gene to show the trait—was implicated in a previously unexplained but fatal form of OI; the second was related to other previously unexplained forms of the disorder. Although there is no treatment for the disorder, the finding allows clinicians to test families who have lost a child to OI for the presence of the defective gene. Couples with a child affected by these forms of OI could be apprised of their risk for conceiving another child with the disorder.

June 2007—At the recommendation of the Blue Ribbon Panel Review and the Board of Scientific Counselors, the NICHD Division of Intramural Research was reorganized from 22 laboratories and branches to 10 programs, along with three branches, two sections, and three core facilities. (Please see the Division of Intramural Research (DIR) section of this document for more information.)

August 2007—The NIH initiates the Autism Centers of Excellence (ACE) Program, a consolidation of two existing programs, the Studies to Advance Autism Research and Treatment (START) and Collaborative Programs of Excellence in Autism (CPEA), into a single research effort. The ACE Program seeks to expand on earlier discoveries made by research previously supported by the NIH. Funding and resources for the Program are provided by the NICHD, along with NINDS, NIEHS, the National Institute of Mental Health, and the National Institute of Neurological Disorders and Stroke.

September 2007—The National Children's Study, led by the NICHD and a consortium of federal agencies, awards contracts to 22 new study centers, which will manage participant recruitment and data collection in 26 additional communities across the United States. Congress appropriated $69 million in fiscal year 2007 for the new Study centers and the Study's initial phase. The National Children's Study is the largest study to be conducted on the effects of environmental and genetic factors on child and human health in the United States.

January 2008—The NIH, led by the NICHD, releases a research plan to advance understanding of Down syndrome and speed development of new treatments for the condition, which is the most frequent genetic cause of mild to moderate intellectual disability and associated medical problems. The plan sets research goals for the next 10 years that build upon earlier research advances fostered by the NIH. Among the plan elements are the need for increased research on the medical, cognitive, and behavioral conditions that occur in people with Down syndrome and the need to study whether aging has a greater impact on mental processes in people with Down syndrome than in people who do not have Down syndrome.

April 2008—The NIH announces recipients of grants from the Autism Centers of Excellence (ACE) program. These grants will support studies covering a broad range of autism research areas, including early brain development and functioning, social interactions in infants, rare genetic variants and mutations, associations between autism-related genes and physical traits, possible environmental risk factors and biomarkers, and a potential new treatment. The ACE program encompasses research centers and research networks, which both rely on collaborations among teams of autism researchers working together on a single research question.

June 2008—The NICHD serves as the scientific lead for the Surgeon General's Conference on the Prevention of Preterm Birth. The aim of the conference was to establish an agenda for activities in both the public and private sectors to speed the identification of, and treatments for, the causes of and risk factors for preterm labor and delivery. The agenda calls for a national system to better understand the occurrence of preterm birth and a national education program to help
women reduce their chances of giving birth prematurely. The agenda also calls for improved methods for estimating the age of the fetus, and studies to identify biomarkers which would signal the beginning of preterm labor.

**July 2009**—The NIH, led by the NICHD, releases a research plan to advance the understanding of Fragile X syndrome and its associated conditions, Fragile X-associated Tremor/Ataxia Syndrome and Fragile X-associated Primary Ovarian Insufficiency. The plan sets research priorities for each condition and includes investigating the biological processes underlying all three disorders and how to better diagnose and treat them. Other priorities are studying how widespread the gene variations are in the population and how the three conditions affect families.

**September 2009**—After more than 40 years with the NICHD, Director Duane Alexander, M.D. announces his departure. Dr. Alexander will serve as a senior scientific advisor to the Director of the NIH's Fogarty International Center on the NIH's role in a White House initiative to reduce maternal and infant mortality and morbidity in the developing world. Dr. Alexander's tenure at the NICHD saw a myriad of scientific accomplishments, ranging from the development of a vaccine against *Hemophilus influenzae* type b (Hib) meningitis, thereby eliminating it as a major cause of acquired intellectual and developmental disability, to the dramatic decrease in the rate of mother-to-child HIV transmission in the U.S., from 27 percent to less than 2 percent. Susan Shurin, M.D., Deputy Director of the National Heart, Lung, and Blood Institute (NHLBI), becomes Acting NICHD Director on October 1, 2009.

**October 2009**—The NICHD and NIH communities joined members of the newborn screening research community and the Hunter's Hope community—the foundation started by National Football League Pro Football Hall-of-Fame quarterback Jim Kelly and his wife Jill after their son Hunter was diagnosed with a rare, degenerative, fatal genetic disease—in inaugurating the Hunter Kelly Newborn Screening Research Program. The Program aims to identify new screening technologies and research management strategies for the conditions that such screening can detect.

**December 1, 2009**—The NIH Director appoints Alan E. Guttmacher, M.D. as the Acting Director of the NICHD. Dr. Guttmacher replaces Susan B. Shurin, M.D. Dr. Shurin, Deputy Director of NHLBI, returns to that Institute to become its Acting Director. Dr. Guttmacher is the Deputy Director of the National Human Genome Research Institute (NHGRI) and served as that Institute's Acting Director from 2008 to 2009. As Deputy and Acting Director of NHGRI, Dr. Guttmacher oversaw that Institute's efforts to advance genome research, integrate the benefits of genome research into health care, and explore the ethical, legal, and social implications of human genomics.

**NICHD LEGISLATIVE CHRONOLOGY**

**October 17, 1962**—Public Law 87-838 authorizes the U.S. Surgeon general, with approval of the Secretary of the DHEW, to “establish in the Public Health Service (PHS) an Institute for the conduct and support of research and training relating to maternal health, child health and human development, including research and training in the special health problems and requirements of mothers and children and in the basic sciences relating to the processes of human growth and development, including prenatal development.”

**October 31, 1963**—Public Law 88-164 provides grants to support the construction of research centers for mental retardation and related disabilities. The NICHD remains closely associated with some 12 centers installed prior to June 30, 1967, when the authority expires.

**December 24, 1970**—Public Law 91-572 adds Title X to the PHS Act to authorize grants and contracts for research and research training in family planning and population problems. The DHEW Secretary delegates the authority to the NICHD, where the program is administered by the Center for Population Research.

**April 22, 1974**—Public Law 93-270 assigns the task of conducting research on SIDS and reporting on it to the Congress to the DHEW Secretary and, ultimately, to the NICHD.

**July 29, 1975**—Title II of Public Law 94-63, the Family Planning and Population Research Act of 1975, amends Title X of the PHS Act. Thereafter the PHS can conduct and support population research. Title X becomes the sole authority for population research appropriations.


**November 20, 1985**—The Health Extension Act of 1985 directs the NICHD to appoint an Associate Director for Prevention, "to coordinate and promote the programs in the Institute concerning the prevention of health problems of mothers and children."

**November 16, 1990**—Section 3 of the NIH Amendments of 1990, Public Law 101-613, establishes the National Center for Medical Rehabilitation Research. The Center will conduct and support programs with respect to the rehabilitation of individuals with physical disabilities that result from congenital defects, diseases, or disorders of the neurological, musculoskeletal, cardiovascular, pulmonary, or any other physiological system.

**June 10, 1993**—The NIH Revitalization Act of 1993, Public Law 103-43, mandates the NICHD to do the following: 1) establish contraception research centers to improve methods of contraception; establish infertility research centers to improve methods of diagnosis and treatment of infertility; and establish an educational loan repayment program for extramural and intramural health professionals who agree to conduct contraception or infertility research; 2) establish and maintain an intramural laboratory and clinical research program in obstetrics and gynecology within the Institute; 3) establish and support a program of Child Health Research Centers; and 4) undertake a national prospective, longitudinal study of adolescent health and well-being.

**October 17, 2000**—President Clinton signs Public Law 106-310, the Children's Health Act, which designates the NICHD as the lead organization on a number of research initiatives, including establishment of a pediatric research initiative, expansion of autism-related and fragile X syndrome research activities, and authorization for the NICHD to lead other federal agencies in conducting a national longitudinal study of environmental influences on child health.

**December 18, 2001**—President George W. Bush signs Public Law 107-84, the Muscular Dystrophy Community Assistance, Research and Education Amendments of 2001, which directs the NIH Director, in coordination with the National Institute of Neurological Disorders and Stroke, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the NICHD, to expand research activities at NIH pertaining to various types of muscular dystrophy. This expansion is to
include the formation of an inter-agency coordinating committee and the establishment of centers of excellence to conduct research. The law also mandates a contract with the Institute of Medicine to study and report on the impact of and need for centers of excellence at the NIH.

January 4, 2002—The Best Pharmaceuticals for Children Act (Public Law 107-109) seeks to improve the safety and efficacy of pharmaceuticals for children. The law authorizes funding for the NIH to conduct testing of drugs already on the market, including at federally funded facilities, such as the NICHD's Pediatric Pharmacology Research Units.

January 8, 2002—President Bush signs the No Child Left Behind Act (Public Law 107-110). Among the education legislation's many provisions is authorization for programs that build upon the reading readiness research funded by the NICHD, as well as on findings from the National Reading Panel, established and supported by the NICHD.

December 3, 2003—The President authorizes the Pediatric Research Equity Act (Public Law 108-155), which codifies a policy of requiring pharmaceutical companies to test new drugs in pediatric populations, if the drugs are likely to be used to treat children, and to provide the data to the federal government. This law complements the Best Pharmaceuticals for Children Act, in which the NICHD plays a central role.

December 3, 2004—The President signs the Individuals with Disabilities Education Improvement Act (IDEA) of 2004 (Public Law 108-446). Among the many provisions in this reauthorization of IDEA activities, the Act also amends the section of the Children's Health Act of 2000 specific to the National Children's Study. This amendment requires the U.S. Department of Education to be formally included as a partner in planning and implementing the Study; the Department is already a member of the federal consortium that leads the Study, but was not named in the original legislation. The Act also requires that the National Children's Study comply with federal education law concerning the use of school records for research purposes.

December 9, 2006—The Prematurity Research Expansion and Education for Mothers who Deliver Infants Early Act ("PREEMIE") passes, with provisions authorizing an Interagency Coordinating Council on Prematurity and Low Birthweight, and directing the U.S. Surgeon General to convene a meeting on preterm birth. The NICHD will assist the Surgeon General's Office in planning and holding the meeting in June 2008.

December 19, 2006—The Combating Autism Act becomes law, requiring the NIH and other federal agencies to expand their activities related to research on possible causes, diagnostics, and treatments for autism spectrum disorders. The Act also requires the NIH to develop and update an annual strategic plan for autism-related research, expand the Autism Centers of Excellence, and reauthorize the Interagency Autism Coordinating Committee.

September 27, 2007—Best Pharmaceuticals for Children/Pediatric Devices Act becomes law as part of the Food and Drug Administration Amendments Act of 2007. The Act reauthorizes the Best Pharmaceuticals for Children Act, extending additional patent exclusivity for drugs that are being tested for pediatric use, and makes improvements to the research program being supported by NICHD. The Act establishes a new program, for Pediatric Medical Device Safety and Improvement, requiring NIH to collaborate with the FDA and the Agency for Healthcare Research and Quality to develop a research plan for expanding medical device research and development focused on devices for children. NICHD is leading the trans-NIH effort to develop the research plan for studies of pediatric medical devices.

December 21, 2007—The President signs the bill renaming the NICHD as the "Eunice Kennedy Shriver National Institute of Child Health and Human Development." The bill and renaming honors Mrs. Shriver's work in both supporting the establishment of the Institute and her ongoing efforts on behalf of the intellectually disabled and lauds the NICHD's research efforts in reducing SIDS, maternal HIV transmission, and development of vaccines, among others.

April 24, 2008—The Newborn Screening Saves Lives Act (P.L. 110-204) renames the NICHD's program as the Hunter Kelly Newborn Screening Research Program after the son of National Football League Pro Football Hall-of-Fame quarterback Jim Kelly and his wife Jill; Hunter Kelly had Krabbe disease, one of the classic leukodystrophies (a rare, degenerative, fatal muscular and nervous-system disease), and died at age eight in 2005. The Act also authorizes the NIH, through the NICHD, to develop systematic methods for identifying additional conditions for newborn screening, develop and test innovative treatments and strategies to improve outcomes, educate providers about newborn screening, create and implement communication systems for newborn screening, and sponsor research and research training programs.

April 28, 2008—The Traumatic Brain Injury (TBI) Act (P.L. 110-206) becomes law, reauthorizing funding for TBI research, treatment, surveillance, and education activities through 2012 at the NIH, CDC, and HRSA. Among its provisions, the Act requires a report to Congress on activities that can improve the collection and dissemination of epidemiological studies on the incidence and prevalence of TBI in persons formerly in the military and charges the NIH and CDC to conduct studies identifying common therapeutic interventions for TBI rehabilitation and those that can prevent secondary neurologic conditions, and to develop practice guidelines for the rehabilitation of TBI.

October 8, 2008—The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education (MD-CARE) Amendments of 2008 (P.L. 110-361) become law. The Act names the muscular dystrophy centers of excellence (several of which are funded by NICHD) as the Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. In addition, the Muscular Dystrophy Interagency Coordinating Committee, on which the NICHD Director sits, is authorized to give special consideration to enhancing the clinical research infrastructure to test emerging therapies for the various forms of muscular dystrophy. The same day, Congress signs the Prenatally and Postnatally Diagnosed Conditions Act (P.L. 110-374) to increase the provision of information, referrals, and support services to families of patients who receive a diagnosis of Down syndrome or other prenatally or postnatally (up to one year after birth) diagnosed conditions. The Act also requires HHS to support coordination of "up-to-date and evidence-based" information regarding such services.

BIOGRAPHICAL SKETCH OF NICHD ACTING DIRECTOR ALAN E. GUTTMACHER, M.D.

Alan E. Guttmacher, M.D., assumed the duties of NICHD Acting Director on December 1, 2009. A pediatrician and medical geneticist, Dr. Guttmacher came to the NIH in 1999 to work at the National Human Genome Research Institute (NHGRI), where he has served in a number of roles, including Deputy Director since 2002, and Acting Director from 2008 to November 30, 2009. In those roles, he oversaw that Institute's efforts to advance genome research, integrate that research into health care, and explore the ethical, legal, and social implications of human genomics.
Born in Baltimore, Maryland, Dr. Guttmacher explains that he went into medicine because, as a middle school teacher, he became interested in the etiology and treatment of pediatric learning disorders. He received an A.B. degree from Harvard College in 1972 and an M.D. from Harvard Medical School in 1981. After completing his internship and residency in pediatrics at Children's Hospital Boston, Dr. Guttmacher earned a two-year National Research Service Award from the U.S. Public Health Service as a fellow in medical genetics at Children's Hospital Boston and Harvard Medical School.

Dr. Guttmacher became director of the Vermont Regional Genetics Center at the University of Vermont College of Medicine in 1987. While there, he launched a series of public health genetics programs, directed the Vermont Cancer Center's Familial Cancer Program and the Vermont Newborn Screening Program, and founded Vermont's only pediatric intensive care unit. He also directed the nation's first statewide effort to involve the general public in discussion of the Human Genome Project's (HGP) ethical, legal, and social implications—an initiative funded by NIH. He also developed a busy practice in clinical genetics, conducted research, and was a tenured associate professor of pediatrics and medicine at the University of Vermont.

In 1999, he joined the NHGRI as Senior Clinical Advisor to the Director. In that role, Dr. Guttmacher established a dialogue with health professionals and the public about the health and societal implications of the HGP. He played a pivotal role in guiding the establishment of the National Coalition for Health Professional Education in Genetics, a non-profit coalition that promotes health-professional education and access to information about advances in human genetics. He has given hundreds of talks to physicians, consumer groups, students and the lay public about genetics and its impact on health, health care and society. Among his research interests have been dysmorphology, syndrome identification and delineation, and hereditary hemorrhagic telangiectasia.

Dr. Guttmacher became Deputy Director of NHGRI in 2002. In 2003, he and Dr. Francis Collins (now NIH Director) co-edited Genomic Medicine, a series about the application of advances in genomics to medical care for The New England Journal of Medicine. He will be co-editing another series on genomics in medicine that will appear in the same journal starting in 2010. Dr. Guttmacher also oversaw the NIH's involvement in the U.S. Surgeon General's Family History Initiative, an effort to encourage all Americans to learn about and use their families' health histories to promote personal health and prevent disease. He previously served in volunteer leadership positions for several regional and national nonprofit organizations involved with reproductive health. He is a Fellow of the American Academy of Pediatrics, a Fellow of the American College of Medical Genetics, and a member of the Institute of Medicine.

DIRECTORS OF NICHD

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert A. Aldrich</td>
<td>March 1, 1963</td>
<td>October 1964</td>
</tr>
<tr>
<td>Donald Harting</td>
<td>July 8, 1965</td>
<td>1966</td>
</tr>
<tr>
<td>Gerald D. LaVeck</td>
<td>October 9, 1966</td>
<td>September 1, 1973</td>
</tr>
<tr>
<td>Gilbert L. Woodside (Acting)</td>
<td>September 1, 1973</td>
<td>September 1, 1974</td>
</tr>
<tr>
<td>Norman Kretchmer</td>
<td>September 1, 1974</td>
<td>September 30, 1981</td>
</tr>
<tr>
<td>Mortimer B. Lipsett</td>
<td>July 1, 1982</td>
<td>January 7, 1985</td>
</tr>
<tr>
<td>Duane Alexander</td>
<td>February 5, 1986</td>
<td>September 30, 2009</td>
</tr>
<tr>
<td>Susan Shurin (Acting)</td>
<td>October 1, 2009</td>
<td>November 30, 2009</td>
</tr>
<tr>
<td>Alan Guttmacher (Acting)</td>
<td>December 1, 2009</td>
<td>July 21, 2010</td>
</tr>
<tr>
<td>Alan Guttmacher</td>
<td>July 22, 2010</td>
<td>Present</td>
</tr>
</tbody>
</table>

ORGANIZATION

The NICHD's major components include both extramural programs, which support research via grants and contracts, and intramural programs, which conduct research at various laboratories, branches, units, and sections. The Division of Scientific Review provides additional support for NICHD activities. Descriptions of the major components and their functions are outlined below.

For more information on the NICHD, its mission, its components, and its research, please visit www.nichd.nih.gov.

Center for Population Research (CPR)

The CPR is the federal government's focal point for population research. Through grants and contracts, the Center supports: fundamental biomedical research on reproductive processes that influence human fertility and infertility; development of better methods for regulating fertility and for preventing the spread of sexually transmitted diseases, including HIV; evaluation of the safety and effectiveness of contraceptive methods now in use; and behavioral and social science research on the reproductive behavior of individuals, sexual transmission of HIV, and the causes and consequences of population change.

The Center also supports an extensive training program for individuals interested in all aspects of reproduction and population research through its 3 branches:

- Contraception and Reproductive Health Branch
- Demographic and Behavioral Sciences Branch
Reproductive Sciences Branch

Center for Developmental Biology and Perinatal Medicine (CDBPM)

The CDBPM provides support for basic, clinical, and applied research and research training in maternal, fetal, and infant health, and disorders of human development. The Center seeks to advance fundamental and clinical knowledge about maternal health and problems of child development, such as preterm birth, mental retardation and developmental disabilities, congenital and genetic disorders, fetal and infant morbidity and mortality (including fetal growth restriction, stillbirth, SIDS, fetal therapy, and disorders of the high risk neonate), and other conditions. Areas of emphasis include, but are not limited to: biology of high-risk pregnancies and premature birth; low birth weight; mental retardation and developmental disabilities, including autism and fragile X syndrome; heritable diseases; birth defects; prenatal and neonatal screening; immunodeficiencies; and mechanisms and factors in teratogenesis and developmental biology, including basic studies of processes in embryonic development and the development and use of animal models to study developmental processes and genetic diseases.

The Center achieves its mission through the efforts of 3 branches:

- Developmental Biology, Genetics, and Teratology Branch
- Intellectual and Developmental Disabilities Branch
- Pregnancy and Perinatology Branch

Center for Research for Mothers and Children (CRMC)

The CRMC is a major source of research and research training in child health and in the health of mothers. The Center and its programs focus on maximizing growth and development, preventing transmission of HIV/AIDS in various populations, and improving knowledge about children's behavior and behavioral outcomes. Areas of emphasis include, but are not limited to: behavioral, social, and emotional adaptation from infancy through adolescence and early adulthood; learning disabilities; nutrition; endocrine disorders and growth retardation; and preconceptional, prenatal, and postnatal infectious diseases and HIV/AIDS. In addition, the CRMC plays a lead role in the following initiatives: the Global Network for Women's and Children's Health, the activities of the Best Pharmaceuticals Act for Child and Pediatric Pharmacology Research Unit Network, examinations of reading and math outcomes and how to improve them, and accident and injury prevention.

The Center achieves its mission through the efforts of its branches:

- Endocrinology, Nutrition, and Growth Branch
- Child Development and Behavior Branch
- Pediatric, Adolescent, and Maternal AIDS Branch
- Obstetric and Pediatric Pharmacology Branch

National Center for Medical Rehabilitation Research (NCMRR)

The NCMRR funds research training and projects to develop the scientific knowledge needed to promote the health, productivity, independence, and quality of life for people with disabilities. A primary goal of the Center is to bring the health-related problems of people with disabilities to the attention of the nation's best scientists, to capitalize upon the myriad advances occurring in the biological, behavioral, and engineering sciences.

The NCMRR supports a number of research programs:

- Behavioral Sciences and Rehabilitation Engineering Technology Program
- Biological Sciences and Career Development Program
- Pediatric Critical Care and Rehabilitation Program
- Traumatic Brain Injury and Stroke Rehabilitation Program
- Spinal Cord and Musculoskeletal Disorders and Assistive Technology Program

Division of Epidemiology, Statistics, and Prevention Research (DESPR)

DESPR, an intramural research program, provides the Institute with skills in 4 disciplines: biostatistics, epidemiology, computer sciences, and prevention research. DESPR relies solely on contracts—not grants—to fund its research. Within DESPR are 3 branches:

- Biostatistics & Bioinformatics Branch
- Epidemiology Branch
- Prevention Research Branch

In 2001, in response to the Children's Health Act of 2000, DESPR initiated the planning phase of the National Children's Study, a national, longitudinal study of environmental influences on child health. The study, led by a consortium of federal agencies, including HHS (the NICHD and NIEHS within NIH, as well as the Centers for Disease Control and Prevention) and the U.S. Environmental Protection Agency, will span more than 2 decades and will follow approximately 100,000 children. In 2008-2009, the National Children's Study was moved organizationally to reside within the NICHD Office of the Director. The Study continues to progress and began recruiting participants in 2009.

Division of Intramural Research (DIR)
The DIR is broadly concerned with the biological and neurobiological, medical, and behavioral aspects of normal and abnormal human development. The Division's clinical research projects admit a limited number of research patients under guidelines established by the Director of the NIH Clinical Center. In addition to clinical research and training programs in the areas of genetics, endocrinology, and maternal-fetal medicine, a diverse range of developmental models are under study in research laboratories and branches. For more information about the DIR, visit [http://dir2.nichd.nih.gov/](http://dir2.nichd.nih.gov/).

At the recommendation of the Blue Ribbon Panel Review and the Board of Scientific Counselors, the DIR reorganized itself from 22 laboratories and branches to 10 Programs along with 3 Branches, 2 Sections, and 3 Core Facilities. The Programs, Branches, Sections, and Core Facilities include the following:

- Cell Biology and Metabolism Program (CBMP)
- Program in Cellular Regulation and Metabolism (PCRM)
- Program in Developmental and Molecular Immunity (PDMI)
- Program in Developmental Endocrinology and Genetics (PDEGEN)
- Program in Developmental Neuroscience (PDN)
- Program in Genomics of Differentiation (PGD)
- Program in Molecular Medicine (PMM)
- Program in Perinatal Research and Obstetrics (PPRO)
- Program in Physical Biology (PPB)
- Program in Reproductive and Adult Endocrinology (PRAE)
- Administrative Management Branch (AMB)
- Bone and Extracellular Matrix Branch (BEMB)
- Research Animal Management Branch (RAMB)
- Section on Nervous System Development and Plasticity (SN SDP)
- Section on Physical Biochemistry (SPB)
- Imaging Core
- Mass Spectrometry Core
- Unit on Biologic Computation (UBC) Core

**Division of Scientific Review (DSR)**

The DSR is responsible for a broad range of functions related to the review of grant applications for research and training, and of contract proposals for research. The Division also provides policy direction and coordination for planning and conducting initial scientific and technical merit reviews of applications for numerous types of grant applications, including small research grants, program projects, centers, institutional training grants, career development, and conference grants. In addition, the DSR coordinates and conducts the review of grant applications that are received by the NICHD in response to requests for applications, which are published with the aim of fostering work in a research area of particular relevance to the mission of the Institute. The Division also manages the technical evaluation of contract proposals that arrive in response to requests for proposals issued by the Institute.

To review grant applications, the DSR relies on subcommittees of the Child Health and Human Development (CHHD) Initial Review Group (IRG) or, where appropriate, a Special Emphasis Panel that is convened for its expertise in a specific area of science. The CHHD IRG includes subcommittees on the following scientific areas: pediatrics; developmental biology; biobehavioral and behavioral sciences; population sciences; obstetrics and maternal-fetal biology; reproduction, andrology, and gynecology; and function, integration, and rehabilitation sciences. In addition to managing the subcommittees, scientific review administrators also recruit extramural scientists to serve as peer-reviewers while maintaining oversight of all aspects of the peer-review process. Further, Special Emphasis Panels, which are convened as technical evaluation groups, also evaluate contract proposals.

**National Institute of Child Health and Human Development—Appropriations: Grants and Direct Operations**

[Amounts in thousands of dollars]

<table>
<thead>
<tr>
<th>Fiscal Year</th>
<th>Total Grants</th>
<th>Direct Operations</th>
<th>Total $</th>
</tr>
</thead>
<tbody>
<tr>
<td>1966</td>
<td>32,800</td>
<td>1,200</td>
<td>34,000</td>
</tr>
<tr>
<td>1965</td>
<td>38,906</td>
<td>3,790</td>
<td>42,695</td>
</tr>
<tr>
<td>1966</td>
<td>49,725</td>
<td>5,299</td>
<td>55,024</td>
</tr>
<tr>
<td>1967</td>
<td>55,710</td>
<td>9,212</td>
<td>64,922</td>
</tr>
<tr>
<td>1968</td>
<td>56,795</td>
<td>11,826</td>
<td>68,621</td>
</tr>
<tr>
<td>1969</td>
<td>57,363</td>
<td>15,763</td>
<td>73,126</td>
</tr>
<tr>
<td>1970</td>
<td>59,135</td>
<td>18,057</td>
<td>77,192</td>
</tr>
<tr>
<td>1971</td>
<td>64,151</td>
<td>30,609</td>
<td>94,760</td>
</tr>
<tr>
<td>Year</td>
<td>R&amp;D Grants</td>
<td>Intramural Research</td>
<td>Total</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>---------------------</td>
<td>-------</td>
</tr>
<tr>
<td>1972</td>
<td>78,356</td>
<td>38,477</td>
<td>116,833</td>
</tr>
<tr>
<td>1973</td>
<td>89,114</td>
<td>41,315</td>
<td>130,429</td>
</tr>
<tr>
<td>1974</td>
<td>87,955</td>
<td>42,309</td>
<td>130,254</td>
</tr>
<tr>
<td>1975</td>
<td>97,848</td>
<td>44,587</td>
<td>142,435</td>
</tr>
<tr>
<td>1976</td>
<td>95,518</td>
<td>40,886</td>
<td>136,404</td>
</tr>
<tr>
<td>1977</td>
<td>100,717</td>
<td>44,826</td>
<td>145,543</td>
</tr>
<tr>
<td>1978</td>
<td>115,471</td>
<td>50,919</td>
<td>166,390</td>
</tr>
<tr>
<td>1979</td>
<td>143,951</td>
<td>54,039</td>
<td>197,630</td>
</tr>
<tr>
<td>1980</td>
<td>149,052</td>
<td>59,901</td>
<td>208,953</td>
</tr>
<tr>
<td>1981</td>
<td>164,233</td>
<td>56,395</td>
<td>220,628</td>
</tr>
<tr>
<td>1982</td>
<td>167,221</td>
<td>59,088</td>
<td>226,309</td>
</tr>
<tr>
<td>1983</td>
<td>188,948</td>
<td>65,376</td>
<td>254,324</td>
</tr>
<tr>
<td>1984</td>
<td>208,511</td>
<td>67,535</td>
<td>276,046</td>
</tr>
<tr>
<td>1985</td>
<td>236,547</td>
<td>76,211</td>
<td>312,758</td>
</tr>
<tr>
<td>1986</td>
<td>237,299</td>
<td>70,912</td>
<td>308,211</td>
</tr>
<tr>
<td>1987</td>
<td>281,413</td>
<td>85,238</td>
<td>366,651</td>
</tr>
<tr>
<td>1988</td>
<td>295,537</td>
<td>101,047</td>
<td>396,584</td>
</tr>
<tr>
<td>1989</td>
<td>318,567</td>
<td>106,701</td>
<td>425,268</td>
</tr>
<tr>
<td>1990</td>
<td>323,156</td>
<td>118,799</td>
<td>441,955</td>
</tr>
<tr>
<td>1991</td>
<td>351,031</td>
<td>127,916</td>
<td>478,947</td>
</tr>
<tr>
<td>1992</td>
<td>375,522</td>
<td>144,055</td>
<td>519,577</td>
</tr>
<tr>
<td>1993</td>
<td>380,059</td>
<td>147,708</td>
<td>527,767</td>
</tr>
<tr>
<td>1994</td>
<td>385,700</td>
<td>172,136</td>
<td>557,836</td>
</tr>
<tr>
<td>1995</td>
<td>397,494</td>
<td>172,815</td>
<td>570,309</td>
</tr>
<tr>
<td>1996</td>
<td>422,865</td>
<td>170,286</td>
<td>593,151</td>
</tr>
<tr>
<td>1997</td>
<td>454,374</td>
<td>176,991</td>
<td>631,365</td>
</tr>
<tr>
<td>1998</td>
<td>486,527</td>
<td>185,565</td>
<td>672,092</td>
</tr>
<tr>
<td>1999</td>
<td>551,845</td>
<td>196,793</td>
<td>748,638</td>
</tr>
<tr>
<td>2000</td>
<td>642,873</td>
<td>214,519</td>
<td>857,392</td>
</tr>
<tr>
<td>2001</td>
<td>738,441</td>
<td>237,140</td>
<td>975,581</td>
</tr>
<tr>
<td>2002</td>
<td>839,365</td>
<td>271,049</td>
<td>1,110,414</td>
</tr>
<tr>
<td>2003</td>
<td>892,243</td>
<td>313,684</td>
<td>1,205,927</td>
</tr>
<tr>
<td>2004</td>
<td>906,889</td>
<td>341,088</td>
<td>1,247,977</td>
</tr>
<tr>
<td>2005</td>
<td>903,027</td>
<td>359,263</td>
<td>1,262,290</td>
</tr>
<tr>
<td>2006</td>
<td>890,228</td>
<td>364,541</td>
<td>1,254,769</td>
</tr>
<tr>
<td>2007</td>
<td>898,923</td>
<td>355,221</td>
<td>1,254,144</td>
</tr>
<tr>
<td>2008</td>
<td>898,000</td>
<td>361,439</td>
<td>1,259,439</td>
</tr>
<tr>
<td>2009</td>
<td>915,059</td>
<td>377,892</td>
<td>1,292,951</td>
</tr>
</tbody>
</table>

1 Includes R&D contracts, intramural research, and research management support.
2 Excludes enacted administrative reduction of $338.
3 Reflects 1% transfers by HHS and NIH noncomparable to fiscal year 2000.
4 Updated since the 1999 NIH Almanac.
5 Includes comparable adjustments for program transfers as reflected in the FY 2009 Congressional Justification.
6 Excludes American Recovery and Reinvestment Act funds.
MISSION

The National Institute on Deafness and Other Communication Disorders (NIDCD) conducts and supports research and research training on disorders of hearing and other communication processes, including diseases affecting hearing, balance, smell, taste, voice, speech, and language through:

- Research performed in its own laboratories and clinics
- A program of research grants, individual and institutional research training awards, career development awards, center grants, conference grants, and contracts to public and private research institutions and organizations
- Cooperation and collaboration with professional, academic, commercial, voluntary, and philanthropic organizations concerned with research and training that is related to deafness and other communication disorders, disease prevention and health promotion, and the special biomedical and behavioral problems associated with people having communication impairments or disorders
- The support of efforts to create devices that substitute for lost and impaired sensory and communication functions
- Ongoing collection and dissemination of information to health professionals, patients, industry, and the public on research findings in these areas.

IMPORTANT EVENTS IN NIDCD HISTORY

October 28, 1988—Public Law 100-553 authorized the formation of the National Institute on Deafness and Other Communication Disorders.

April 1989—The NIDCD published and released its first National Strategic Research Plan (NSRP). The NSRP was developed by one hundred distinguished scientists and clinicians charged with writing both a three year and a long-range research plan for deafness and other communication disorders.

June 26, 1989—The NIDCD Advisory Board held its first meeting.

September 18, 1989—The Advisory Council of NIDCD convened for the first time.

February 11, 1990—James B. Snow, Jr., M.D., was appointed as the first Director of NIDCD.


December 5, 1990—The Division of Intramural Research established labs and branches within the division.

December 6, 1990—The Information Systems Branch was created.

April 4, 1991—The Board of Scientific Counselors of NIDCD held its first meeting.

November 19, 1991—The Deafness and Other Communication Disorders Interagency Coordinating Committee met for the first time.

December 29, 1991—David J. Lim, M.D., was appointed as Scientific Director.


August 21, 1992—NIDCD/Department of Veterans Affairs directors signed a Memorandum of Understanding that established a collaboration to expand and intensify hearing aid research and development.

October 23, 1992—NIDCD/National Aeronautics and Space Administration (NASA) established a formal scientific collaboration to enhance basic knowledge and understanding of vestibular function in both clinical and normal states and provide investigators access to NASA's unique ground-based research facilities and to space flight.

March 1-3, 1993—Consensus Development Conference, “Early Identification of Hearing Impairment in Infants and Young Children,” evaluated current research and provided recommendations regarding hearing assessment from birth through 5 years of age.

January 18, 1994—The Division of Communication Sciences and Disorders established the Hearing and Balance/Vestibular Sciences Branch and the Voice, Speech, Language, Smell, and Taste Branch.

May 1994—The NIDCD Advisory Board held its final meeting.

August 5, 1994—The Division of Communication Sciences and Disorders was changed to the Division of Human Communication.

February 14, 1995—The Partnership Program’ began, designed to maximize opportunities for underrepresented students to participate in fundamental and clinical research in the NIDCD research areas, with 4 academic centers: Morehouse School of Medicine; University of Puerto Rico School of Medicine; University of Alaska System, Fairbanks; and Gallaudet University.

March 1, 1995—James F. Battey, Jr., M.D., Ph.D., was appointed as Director of the Division of Intramural Research.

May 15-17, 1995—Consensus Development Conference, “Cochlear Implants in Adults and Children,” summarized current knowledge about the range of benefits and limitations of cochlear implantation.

September 11-13, 1995—First biennial conference, “Advancing Human Communication: An Interdisciplinary Forum on Hearing Aid Research and Development,” was held.

September 4-5, 1997—The NIDCD Working Group on Early Identification of Hearing Impairment held its first workshop and made recommendations on acceptable protocols for use in state-wide Universal Newborn Hearing Screening Programs.

September 13, 1997—James B. Snow, Jr., M.D., retired as the first Director of NIDCD. James F. Battey, Jr., M.D., Ph.D., became Acting Director of NIDCD.

September 22-24, 1997—The second biennial hearing aid research and development conference took place.

February 10, 1998—James F. Battey, Jr., M.D., Ph.D., was appointed as the new Director of NIDCD.

March 13, 1998—The NIDCD Working Group on Early Identification of Hearing Impairment’s second workshop identified research opportunities offered by neonatal hearing screening programs, specifically in diagnostic strategies for characterizing hearing impairment and in the intervention strategies for remediating hearing impairment.

August 13-14, 1998—The Working Group on Single and Multiple Project Grants held its first meeting.

December 8, 1998—The NIDCD Working Group for Developing and Implementing Genetic Diagnostic Tests for Hereditary Hearing Impairment and Other Communication Disorders met and made recommendations for an organization of a consortium of investigators studying genes in communication disorders to permit the rapid pooling of information; support for laboratories, protocols, and carefully designed studies to address the issues of inclusion of individuals with hearing impairments and individuals who are deaf as well as related organizations representing the spectrum of involved communities of deaf or hearing-impaired people in the formulation and establishment of guidelines and future recommendations regarding genetic testing.

December 20, 1998—Robert J. Wenthold, Ph.D., was appointed as Scientific Director.

January - February 1999—The NIDCD convened a group of distinguished scientists and members of the public to provide recommendations for a Strategic Plan [http://www.nidcd.nih.gov/about/plans/strategic/].


2000—NIDCD created the Hearing Health Objectives to improve the hearing health of the Nation through prevention, early detection, treatment, and rehabilitation that were tracked in the joint Vision and Hearing Chapter of Healthy People 2010 initiative.

September 19, 2000—The third workshop of the NIDCD Working Group on Early Identification of Hearing Impairment identified critical research needs in the area of early identification of hearing impairment. The workshop was designed to provide advice to the NIDCD for identifying research to be supported through the Federal government grant and contract processes.

November 29-30, 2000—NIDCD sponsored a workshop titled “Otitis Media: New Approaches for Analysis, Treatment, and Prevention” to report on the state of the art of otitis media research and to make recommendations regarding potential new approaches for analysis, intervention, and prevention of otitis media.

December 11, 2000—NIDCD signed a Memorandum of Understanding with the Center for Comparative and Evolutionary Biology of Hearing, University of Maryland, College Park, to establish a program for training graduate students in the hearing sciences.

March 22-23, 2001—The Division of Intramural Research, NIDCD, held its first retreat at St. Michael’s, Md.

May 24, 2001—Dr. Battey unveiled the Institute’s new logo at the Advisory Council meeting.
December 12-13, 2006—The Third workshop of the NIDCD Working Group on Early Identification of Hearing Impairment convened to examine and develop recommendations for health care professionals on communicating follow-up of infants who do not return for a re-examination after an initial assessment of hearing impairment has been made.

August 1, 2001—NIDCD Auditory/Stem Cell Workshop was held to discuss and identify potential areas of the auditory and vestibular systems that might be good candidates for applications being used in other reparative medicine systems, one being the potential use of stem cell biology.

March 19-20, 2002—NIDCD Workshop on Congenital Cytomegalovirus Infection (CMV) and Hearing Loss convened to present the current research in related fields of congenital CMV infection and hearing loss; to better determine the degree to which congenital CMV infection contributes to hearing loss in children; and to facilitate a discussion among experts in order to develop a set of recommendations for future research in the area of congenital CMV infection and hearing loss.

May 13, 2002—The NIDCD workshop, "The Role of Neuroimaging in the Study of Aphasia Recovery and Rehabilitation: Research Needs and Opportunities" was held to identify research opportunities for the application of neuroimaging methods to the study of aphasia recovery and rehabilitation; to identify and address particular methodological challenges of imaging research focusing on the issue of aphasia recovery and rehabilitation; and to develop strategies to encourage collaborative efforts among researchers with expertise in functional neuroimaging, language processing and aphasia rehabilitation.

August 22, 2002—Auditory/Vestibular Cell Lineage and Development Workshop met to discuss the present and future state of cell lineage and development research in the auditory and vestibular systems.

September 2002—Dr. Battey was appointed as Chair of the NIH Stem Cell Task Force by NIH Director Dr. Elias Zerhouni. In March 2007, Dr. Battey began serving as Vice Chair.

October 21, 2002—NIDCD hosted the first NIH lecture on health literacy, “Babel Babble: What is the Doctor Saying? What is the Patient Understanding?” for health communication professionals who develop health materials and communication strategies for a range of diverse audiences.

June 12, 2003—Dr. Battey opened the First NIH Symposium on Human Embryonic Stem Cells, Bethesda, Md.

September 12, 2003—NIDCD convened the “Human Temporal Bone Research Workshop: Laboratory and Training Support” to identify the funding issues and requirements involved in sustaining human temporal bone research laboratories and the training of qualified researchers in the United States; and to develop recommendations for action(s) NIDCD might take to address the identified issues and requirements.

December 2003—NIDCD's WISE EARS!® national campaign to prevent noise-induced hearing loss turned 5 years old. The campaign is a coordinated effort among NIDCD, the National Institute on Occupational Safety and Health (NIOSH), and a coalition of organizations who care about hearing.

April 27-28, 2004—NIDCD sponsored the workshop "Translational Research (TR) in Hearing and Balance" to discuss translational research as related to hearing and balance, identify barriers to and opportunities in translational research, and articulate activities that could be initiated by the NIDCD in order to increase the translation of scientific accomplishments from the laboratory to the research clinic and beyond to impact clinical practice and public health.

April 30-May 2, 2004—NIDCD and the NIH Office of Rare Diseases co-sponsored a workshop on “Universal Reporting Parameters for the Speech of Individuals with Cleft Palate” to further develop and refine the common approach in describing and reporting clinical speech outcomes of individuals born with cleft palate, regardless of the language spoken by the individual.

October 2004—NIDCD-funded investigator Dr. Linda Buck won the 2004 Nobel Prize in Physiology or Medicine.

March 29-30, 2005—NIDCD sponsored a Workshop on Epidemiology of Communication Disorders to report on current epidemiologic knowledge in the field; suggest ways to encourage more epidemiologic research; describe the importance of population-based research studies for understanding the burden of communication disorders in society and recommend priority topics where more epidemiologic research would be valuable.

May 21-23, 2005—NIDCD held “State of the Science Conference: Developmental Stuttering” conference to enable the cross-disciplinary discussion that will help to focus NIDCD initiatives for stuttering research and treatment.

June 23-24, 2005—NIDCD co-sponsored the first Workshop on Spasmodic Dysphonia Research to develop a roadmap for SD research.

September 7, 2005—NIDCD held a workshop “Report of the Molecular Therapies for Auditory/Vestibular Disease” to discuss the current and future state of molecular therapy development in auditory and vestibular disease. The purpose of the workshop was to discuss and identify research opportunities that will advance/translate targeted molecular approaches into clinical treatments.

December 5-6, 2005—NIDCD sponsored a Workshop on Epidemiology of Communication Disorders to report on current epidemiologic knowledge in the field; suggest ways to encourage more epidemiologic research; describe the importance of population-based research studies for understanding the burden of communication disorders in society and recommend priority topics where more epidemiologic research would be valuable.

May 21-23, 2005—NIDCD held "State of the Science Conference: Developmental Stuttering" conference to enable the cross-disciplinary discussion that will help to focus NIDCD initiatives for stuttering research and treatment.

June 23-24, 2005—NIDCD co-sponsored the first Workshop on Spasmodic Dysphonia Research to develop a roadmap for SD research.

September 7, 2005—NIDCD held a workshop "Report of the Molecular Therapies for Auditory/Vestibular Disease" to discuss the current and future state of molecular therapy development in auditory and vestibular disease. The purpose of the workshop was to discuss and identify research opportunities that will advance/translate targeted molecular approaches into clinical treatments.

December 5-6, 2005—The NIDCD Tinnitus Research Workshop was held to bring together key people currently doing clinical and basic research in central mechanisms and treatments in tinnitus and others who are outside the field of tinnitus research, but who do work that might be relevant to the field.

May 26-27, 2006—NIDCD and the NIH Office of Rare Diseases sponsored a workshop to evaluate the potential for brain-computer interfaces (BCI) to provide a means for speech synthesis and control of other forms of assistive technology that support communication in patients who are locked-in.


December 12-13, 2006—NIDCD/NHI sponsored a workshop on "Outcomes Research in Children with Hearing Loss" to determine and prioritize research needs and discuss design considerations unique to outcomes research in children with hearing loss.
May 9-10, 2007—NIDCD sponsored a workshop “Clinical Research/Clinical Trials in Otology: Setting the Research Agenda for Development of an Intervention” to bring together leaders in otology and clinical trials to focus on what it would take to develop interventions in otology. The goal was to encourage cross and multidisciplinary science towards the development or establishment of evidence-based treatments for otologic conditions/disorders, and to determine, on the basis of available data regarding epidemiology and stage of science, a prioritization of otologic conditions for which intervention-oriented research may be ready.

May 6, 2008—Dr. Battey provided closing remarks at the NIH stem cell symposium, “Challenges & Promises of Cell-Based Therapies.”

July 22-23, 2008—NIDCD Workshop on Immune Mediated Ear Disease/Hearing Loss met to obtain updates on the current status of immune mediated ear disease research; to identify research gaps; and to get expert recommendations regarding research needs that will aid our understanding of this complex form of hearing loss and ultimately lead to diagnostics and therapies that preserve natural hearing.

September 23, 2008—The NIDCD Workshop on Exploring International Collaborative Research in Deafness & Other Communication Disorders met to explore international collaborative research and to stress the need to educate researchers and reviewers about the opportunities for scientific discovery through international collaborative research.

October 2008—NIDCD launched a new health education campaign called It’s a Noisy Planet. Protect Their Hearing. The Noisy Planet campaign is designed to increase awareness among parents of children ages 8 to 12 (“tweens”) about the causes and prevention of NIHL. [View Image.]

October 23, 2008—NIDCD celebrated two decades of research accomplishments with a one day symposium. The symposium included three scientific sessions representing NIDCD’s primary areas of research: hearing and balance; smell and taste; and voice, speech, and language. [View Image.]

August 13-14, 2009—NIDCD Workshop on Tinnitus met to evaluate central nervous system mechanisms of tinnitus in civilian, military and veteran populations and to stimulate new neural prosthetic and other treatments for chronic severe tinnitus.

April 1, 2009—Andrew Griffith, M.D., Ph.D., was appointed as the Director of the Division of Intramural Research.

August 25-27, 2009—NIDCD sponsored a working group on Accessible and Affordable Hearing Health Care for Adults with Mild to Moderate Hearing Loss to develop a research agenda to increase accessibility and affordability of hearing health care for adults, including accessible and low cost hearing aids.

2010—NIDCD expanded the Hearing Health Objectives of HP 2010 to include all mission areas of NIDCD. The new chapter in HP 2020 is now called “Hearing and Associated Sensory or Communication Disorders.” [http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=20]

April 13-14, 2010—NIDCD sponsored a workshop on Nonverbal School-Aged Children with Autism to address clinical needs and research opportunities regarding this population.

NIDCD LEGISLATIVE CHRONOLOGY

October 28, 1988—Public Law 100-553 authorized the formation of the National Institute on Deafness and Other Communication Disorders.

February 15, 1989—Section 406 of the Public Health Service Act, Public Law 92-463, NIDCD Advisory Council was established to advise the Secretary of the U.S. Department of Health and Human Services (HHS); the NIH Director; and the Director of NIDCD on matters relating to the conduct and support of research and research training, health information dissemination, and other programs with respect to disorders of hearing and other communication processes.

January 25, 1991—Section 402(b)(6) of the Public Health Service Act, Public Law 92-463, NIDCD Board of Scientific Counselors advises the Director, Division of Intramural Research, NIDCD, on the quality of the intramural research programs and the research of tenured and tenure-track scientists of the Division, through periodic reviews.

March 1, 1991—Public Law 100-553 Section 464(b), The NIDCD Information Clearinghouse was established to facilitate and enhance, through the effective dissemination of information, knowledge and understanding of disorders of hearing and other communication processes.

November 29, 1999—Public Law 106-113. As a part of the Consolidated Appropriations Act for Fiscal Year 2000, the Newborn Infant Hearing Screening and Intervention Act of 1999 was signed into law by President Bill Clinton. The legislation authorized three years of funding to the Health Resources and Services Administration (HRSA), the Centers for Disease Control and Prevention (CDC), and the NIDCD to aid in the development of newborn infant hearing screening programs.

December 22, 2010—Public Law 111-337. The Early Hearing Detection and Intervention Act of 2010 was signed into law by President Barack Obama. The bill reauthorized Public Law 106-113 for Fiscal Years 2011-2015 and expands the program to include diagnostic services among the services provided to newborns and infants.

BIOGRAPHICAL SKETCH OF NIDCD DIRECTOR JAMES F. BATTEY, JR., M.D., PH.D.

Dr. Battey became the new NIDCD director on February 10, 1998. He served as acting director since the retirement of the Institute's first director in September 1997. He is responsible for the planning, implementation, and evaluation of Institute programs to conduct and support biomedical and behavioral research, research training, and public health information in human communication.

He received his education at the California Institute of Technology, where he earned his B.S. with honors in physics. He earned his M.D. and Ph.D. in biophysics at Stanford University, where he had residency training in pediatrics. His postdoctoral fellowship at Harvard Medical School was under the direction of the eminent scientist Dr. Philip Leder. While working with Dr. Leder, Dr. Battey was part of a team that cloned the genes encoding the IgE immunoglobulin constant region...
domains. In addition, he isolated and characterized the human c-myc gene, a key growth regulatory nuclear proto-oncogene that contributes to cancer formation when inappropriately expressed.

Dr. Battey has been with NIH since 1983, first on the staff of the National Cancer Institute (NCI), where he rose from senior staff fellow to senior investigator. In his work at the NCI-Navy Medical Oncology Branch, he collaborated in the isolation and characterization of human N-myc and L-myc, two additional members of the human myc gene family, important in human neoplasms. He became interested in neuropeptides and their receptors at this time because of their dual function as growth factors and regulatory peptides. His group isolated cDNA and genomic clones for mammalian bombesin-like peptides, key regulators of secretion, growth and neuronal firing.

In 1988 he moved to the National Institute of Neurological Disorders and Stroke as chief of the molecular neuroscience section in the Laboratory of Neurochemistry. In 1992 he returned to the NCI to head the molecular structure section of the Laboratory of Biological Chemistry, where his laboratory cloned and characterized the genes for 3 subtypes of mammalian receptors for bombesin-like peptides. His team at NCI's Laboratory of Biological Chemistry was among the first to clone the gene encoding cdK5, a member of the cyclin-dependent kinase family, where important proteins are involved in cell cycle control. Dr. Battey was appointed as director of the Intramural Research Program for NIDCD in 1995 by Dr. Snow, the first NIDCD director. The PHS has honored him with its PHS Commendation Medal in 1990 and the Outstanding Service Medal in 1994. He is author or co-author of over 130 research articles and is co-author with Leonard Davis and Michael Kuehl of Basic Methods in Molecular Biology.

NIDCD DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>James B. Snow, Jr.</td>
<td>February 11,1990</td>
<td>September 15, 1997</td>
</tr>
<tr>
<td>James F. Battey, Jr.</td>
<td>September 14, 1997</td>
<td>Present</td>
</tr>
</tbody>
</table>

RESEARCH PROGRAMS

NIDCD supports and conducts research and research training in the normal and disordered processes of hearing, balance, smell, taste, voice, speech, and language through a program of grants and contracts in basic, clinical, and translational research. They are conducted in public and private institutions across the country and around the world and within the laboratories and clinics at the National Institutes of Health in Bethesda, Md.

The Division of Intramural Research conducts basic and clinical research in human communication disorders. Research objectives include: studies of electromechnanical processes responsible for fine tuning in the cochlea; identification, characterization, and cloning of genes responsible for hereditary hearing impairment; electromotility of the outer hair cell; molecular bases of mechanosensory transduction mechanisms in the organ of Corti; molecular bases for G-protein signaling with emphasis on sensory signaling processes in the chemical senses; development of vaccines for otitis media; molecular mechanisms underlying the development and function of the mammalian taste system; mechanisms responsible for the development of the inner ear; molecular mechanisms underlying auditory system function with emphasis on neurotransmission and neuromodulation; identification of genes associated with neoplasms affecting human communication; identification of the genetic component of stuttering; neuroimaging of brain function in physiologic and pathophysiologic states; pathophysiology and etiology of voice and speech disorders; and epidemiological and biometric research studies of communication disorders.

The Division of Extramural Activities provides leadership and advice in developing, implementing, and coordinating extramural programs and policies. It represents the Institute on NIH committees on extramural program policies and oversees compliance with such policies within the NIDCD. The Division provides grant management and processing services for all of the Institute's grants and conducts initial scientific merit review of a large array of grant mechanisms and R&D contract proposals. In addition, the Division coordinates the Institute's committee activities, research integrity activities, and Certificates of Confidentiality, and manages the meetings of the National Deafness and Other Communication Disorders Advisory Council. The Division has 2 components: Grants Management Branch and Scientific Review Branch.

- **Grants Management Branch (GMB)**—focal point for all business-related activities associated with the negotiation, award, and administration of grants and cooperative agreements within the NIDCD. GMB plays a critical role of bridging among the various NIH offices (review, program, financial management, and policy), institutional offices of sponsored programs, and principal investigators.
- **Scientific Review Branch (SRB)**—coordinates the initial scientific peer review of applications for the following mechanisms of support: research project grants, clinical center and core center grants, research training and career development grants, multi-site clinical trials, conference grants, and cooperative agreements, as well as all proposals for research and development contracts. SRB also coordinates receipt and referral issues with the Center for Scientific Review, represents NIDCD on trans-NIH committees, as well as NIH's overall committee for review policies, and manages all aspects of NIDCD's peer review process.

The Division of Scientific Programs of NIDCD is responsible for coordinating a broad range of activities and functions to assure sound and efficient management of NIDCD's extramural activities that include a program of research grants, career development awards, individual and institutional research training awards, center grants, and contracts to public and private research institutions and organizations. The Division also plans and directs a program of grant and contract support for research and research training in the normal processes and diseases and disorders of hearing, balance, smell, taste, voice, speech, and language to insure maximum utilization of available resources in attainment of the Institute's objectives; assesses needs for research and research training in program areas; establishes program priorities and recommends funding levels for programs to be supported by grants; and sets priorities and funding levels for research to be supported by contracts.

Hearing
Decades of cellular and molecular approaches have identified numerous genes and proteins important to hearing function. A multitude of genes for syndromic and nonsyndromic forms of hearing impairment including autosomal dominant and recessive, X-linked and mitochondrial modes of transmission have been located in specific regions of the human genome. In addition, clinically relevant genes essential for normal auditory development and/or function have been identified and cloned at a rapid pace. Other cochlear-specific genes have been isolated from enriched membranous labyrinth cDNA libraries. Development of detailed maps using numerous approaches, including expressed sequence tags (EST) coupled with the use of inner ear specific cDNA libraries, exon trapping, and cDNA library enrichment procedures, have facilitated gene cloning.

The use of mouse models of hereditary hearing impairment have been instrumental in mapping and cloning many deafness genes. Because of the utility of the mouse for such studies, additional mouse models of deafness are being created through mutagenesis and screening programs as well as targeted mutation of deafness genes found in man. In addition, mouse models are being used to study the function of the proteins encoded by deafness genes and to test therapeutic approaches. These advances offer researchers many opportunities to study the characteristics of deafness, hereditary factors involved in hearing loss, and genes that are critical for the development and maintenance of the human ear. Great strides are being made in the study of properties of auditory sensory cells and of characteristics of the inner ear's response to sound.

Other less obvious model systems have also proven invaluable to hearing technology. With the difficulty to hear conversations in the midst of a crowded, noisy room using current hearing aids, NIDCD-supported researchers have continued to work towards revolutionizing the technology of directional microphones. The technology is based on the ears of a parasitic fly, Ormia ochracea. Despite the small size of the insect's ears and the short distance between them, Ormia's ears are able to rapidly pinpoint the location from which the sound of a potential host—a cricket—is coming, even in a noisy environment. The intriguing mechanism that enables Ormia to accomplish this feat has provided a model for scientists and engineers to use in developing miniature directional microphones for hearing aids that can better focus on speech in a single conversation, even when surrounded by other voices.

Scientific advances have also been translated into cochlear implants. Research has verified that despite the variability in the performance of children who have received cochlear implants, most demonstrate marked improvements in speech perception and production. Cochlear implants also positively influence children's receptive and expressive language skills. The earlier children are implanted and the longer children use their implants, the greater their language ability. To achieve the most benefit from their implants, however, children generally need extensive oral-auditory training following implantation and also benefit from periodic audiological assessments. Cochlear implants have benefited children who are congenitally deaf as well as those who are postlingually deaf. The vast majority of adult implant recipients derive substantial benefit in conjunction with speechreading, and most can communicate effectively by telephone. Clinical treatment paradigms are continually advancing and now include simultaneously implanting bilateral (both ears) cochlear implants in pediatric and adult populations. Most recently, a new shortened electrode is being studied, with hopes of improving the ability of cochlear implant recipients to understand speech in noise. This electrode, which makes use of still-functioning sensory cells in the inner ear combined with an electronic speech processor, may also allow some hearing aid users who are not benefiting from their hearing aids to become cochlear implant candidates.

Neural prosthesis development efforts are continuing to seek improved device design elements and novel algorithms for operation. These activities are primarily based on animal studies that allow new concepts for selective stimulation of neural tissue to be tested quantitatively and any risks for safe operation identified through both neurophysiologic and histologic studies. Microstimulation delivered through electrodes that penetrate the neural tissue and infrared optical stimulation are 2 examples of novel device elements currently under development. Other research projects are assessing novel signal processing and stimulation algorithms which could be provided to the current generation cochlear implant recipients, if they are proven to extend user performance limits.

It is estimated that about 25 million Americans experience tinnitus each year that lasts 5 minutes or longer. Of these, about 12 million have tinnitus severe enough to seek medical attention. Many learn to ignore the sounds and experience no major effects. However, about 2 million patients are so seriously debilitated that they cannot function normally, finding it difficult to hear, work, or sleep. For many years, it was believed that structures in the inner ear produced tinnitus, but more recent evidence suggests that for many people, tinnitus is generated in the central nervous system. The recent FDA-cleared Neuromonics Tinnitus Treatment is a therapy that addresses the underlying neurological issues of tinnitus by changing or creating new neurological connections in the brain. These new auditory pathways assist the brain in filtering out the symptoms of tinnitus. Though research is providing more evidence for the causes and treatments of tinnitus, there is no real understanding of the biological bases of tinnitus.

Valuable progress has been made in understanding the structure and function of efferent feedback pathways to the inner and middle ear. There is now evidence that this system may aid in the detection of signals in noisy environments and serve to protect the ear from acoustic injury.

Our knowledge of the mechanisms of neural plasticity (the ability of the brain to change or adapt) has increased tremendously over the past decade. In contrast, our knowledge of the mechanisms that regulate and instruct plasticity remains primitive. The calibration of the auditory system's map of space by the visual system is a well-characterized example of supervised learning. In an animal model, the site in the auditory pathway where visual signals exert their effects, and the structural and functional changes they cause, have been determined. However, the properties of the instructive signals themselves, and the mechanisms by which they exert their effects, remain unknown. Research is ongoing to understand these mysteries, which will allow us to better understand learning and learning problems.

In the aging auditory system, discoveries have been made demonstrating changes in the regulation of fluid composition and autoregulation of cochlear blood flow which may underlie some of the biologic effects of aging on auditory function. The role of the stria vascularis in maintaining cochlear homeostasis has now been shown to be a component in the loss in hearing accompanying aging. Improved behavioral and electrophysiological techniques for measuring auditory function are providing more accurate assessments of the peripheral and central components of age-related hearing impairment.

Recent development of animal models for bacterial and viral infections hold promise for new diagnostic and therapeutic approaches to sensorineural hearing loss caused by infections. Antiviral drugs may find rapid application in the treatment for these conditions with the advent of suitable animal models in which to test efficacy. In addition, models will allow a greater understanding of why and to what degree infants and children are susceptible to ototoxic drugs used in the treatment of infections.

Otitis media continues to be a significant focus of research because of its prevalence and cost to society. Important risk factors have been identified. Studies of the eustachian tubes have provided new information on tubal mechanics, surfactant-like (fluid) substances and middle ear pressure regulation. The role of...
bacterial biofilms in chronic otitis media is a new and promising area of investigation. State-of-the-art molecular, genetic and genomic techniques are being used to identify genes that may predispose an individual to chronic otitis media. These techniques are also being used to define the specific molecular changes that allow viral and bacterial infection of the middle ear as well as the host/pathogen interactions that facilitate the disease process. The EarPopper (developed with support from the Small-Business Innovation Research Program) is a safe, simple, non-surgical, non-drug related prescription device for treating such common conditions as otitis media with effusion, aerotitis/barotitis (caused by rapid elevation changes), and eustachian tube dysfunction in children and adults.

Balance

NIDCD supports research on balance and the vestibular system. Balance disorders affect a large proportion of the population, particularly the elderly. The vestibular system, with its receptor organs located in the inner ear, plays an important role in the control of balance while the body is immobile and in motion, the maintenance of one's orientation in space, and visual fixation of objects during head movement. Vestibular disorders can therefore yield symptoms of imbalance, vertigo (the illusion of motion), disorientation, instability, falling, and visual blurring (particularly during motion). Deficits in vestibular function result from diverse disease processes, including infection, trauma, toxicity, impaired blood supply, autoimmune disease, impaired metabolic function, and tumors.

The cellular motion detectors of the vestibular system are mechanosensory hair cells, activated by movements of fluids and masses in the inner ear. New technologies are being used with NIDCD support to visualize and understand the micromechanical motions and the biophysical mechanisms that lead to the neural signals carried from the inner ear to the brain.

Investigators supported by the NIDCD also use molecular and biochemical approaches to characterize cellular biochemical pathways essential to normal development and function in the vestibular system. The genetic bases of several human-inherited cerebellar syndromes of imbalance and incoordination are currently being investigated.

NIDCD-supported studies suggest that, in addition to its role in the stabilization of gaze and balance, the vestibular system plays an important role in regulating respiratory muscles as well as autonomic functions, including blood pressure. These studies hold potential clinical relevance for the understanding of certain kinds of breathing problems, and management of orthostatic hypotension (lowered blood pressure related to a change in body posture).

The Institute supports research to develop and refine tests of balance and vestibular function. Computer-controlled systems have been developed and validated for clinical use to measure eye movement and body postural responses activated by stimulating specific parts of the vestibular sense organ and nerve. Also, tests of functional disability and physical rehabilitative strategies currently being applied in clinical and research settings will have important implications for refining the rehabilitation of patients with balance and vestibular disorders.

For the first time, a prosthesis for balance disorders has been implanted in a human. In the United States, more than 150,000 individuals are estimated to suffer from severe to profound bilateral vestibular deficiency, and a prosthesis of this type potentially could help many of these people, as well as patients with disabling episodes of vestibular dysfunction such as from Ménière’s disease. NIDCD funding helped support development of the device and preclinical animal testing for its use in the treatment of balance disorders.

Smell and Taste

NIDCD investigators study the chemical senses of olfaction (smell) and gustation (taste) to enhance our understanding of how individuals sense their environment and make discriminating food choices. Smell and taste perception play important roles in preferences and aversions for aromas, specific foods, and flavors. Sweet-tasting substances are generally consumed and contribute to caloric intake and proper nutrition; bitter-tasting substances are typically avoided because bitterness is often associated with toxic compounds that cause illness. NIDCD is supporting research on the development of bitter-taste blockers and artificial sweeteners in an effort to identify compounds that can mask the bitter taste of essential medications and reduce the caloric impact of sugars, especially in children.

Both the olfactory and gustatory systems offer special approaches for the understanding of the fundamental mechanisms of neural plasticity. NIDCD scientists have found that smell and taste receptor cells are continually replaced and have the further capacity to replace themselves rapidly in response to injury. With every hard sneeze and with every burnt tongue from a hot cup of coffee, olfactory and taste receptor cells are destroyed and then replaced. In addition, chronic rhinosinusitis and nasal polyps can affect olfactory function, and a variety of prescription medications can harm taste receptors. Smell and taste receptor cells are the only known mammalian sensory cells with this native regenerative capability, and the olfactory system is now used as a model system in the study of the biology of multipotent stem cells. Unfortunately, the plasticity of the olfactory system declines with age, with important consequences to the health of the increasingly aged population. The perceived quality of foods moves toward blandness in the elderly and this affects food intake, diet and overall nutrition, and health status. Prevention of this age-related decline in olfactory sensitivity is being studied by NIDCD investigators.

Advances in molecular and cellular biology, biophysics and biochemistry of the olfactory and gustatory systems are paving the way for improved diagnosis, prevention and treatment of chemosensory disorders. The vertebrate olfactory receptor neuron has become an important model system in molecular and cellular biology. The olfactory receptor gene family has been described in several mammalian species, including humans, and may contain as many as 1,000 members. NIDCD scientists are presently characterizing genetic mechanisms of olfaction, which will provide the opportunity to study the molecular pharmacology of the process of smell. More recently, a family of about 80 taste receptor genes has been identified by NIDCD investigators. Interestingly, both olfactory and sweet and bitter taste receptors are structurally related and activate similar second messenger signal transduction cascades, which ultimately generate neural activity in the central nervous system. The characterization of these receptor genes was greatly facilitated by the genetic database provided by the NIH's human and mouse genome projects.

The molecular biological studies of olfactory and taste receptor cells have provided essential information about the sensitivities of the chemical senses at the first level of neural integration. The coding of odors and tastants by the central nervous system begins at the level of the receptor cell. In addition, in both the olfactory and gustatory systems, odor and taste quality coding is further refined by a synthetic computational process of the central nervous system. NIDCD-funded projects are examining the nature of the central coding. In the olfactory system, odor coding appears very complex because of the numerous types of structurally diverse odors that must be detected and because of the complicated neuroanatomical organization of the olfactory system. We are just beginning to understand the nature of the olfactory code. On the other hand, in the taste system, significant progress has been made in our understanding of how the 4 taste qualities of
sweet, salty, sour, and bitter are coded centrally. Recent work suggests a fifth taste quality, umami, which is familiar to many as the taste of monosodium glutamate (MSG). The nature of the gustatory code and the high degree of central processing makes the gustatory system very resistant to damage. Consequently, the taste system is less often affected by injury and aging in comparison to the olfactory system.

NIDCD-supported research has shown that an individual's preference and sensitivity to certain odors and taste compounds has a genetic basis. Simply stated: different people like different foods. Since genetic factors play a role in one's food choices and overall diet, any level of smell and taste dysfunction will have an adverse impact on nutrition. Altered nutritional status can lead to emotional, cardiovascular and gastrointestinal complications. The NIDCD supports research to study the health risks associated with compromised smell and taste function.

**Voice, Speech, and Language**

Studies in the voice and speech program focus on determining the nature, causes, treatment, and prevention of a variety of disorders of motor speech production throughout the lifespan. Research is being conducted on disorders such as stuttering, speech-sound acquisition disorders, childhood apraxia of speech, voice disorders, and swallowing disorders. When oral speech communication may not be a realistic option for individuals with severe dysarthria, alternative and augmentative communication (AAC) devices and strategies are used. Substantial progress has been made in the development of augmentative communication devices to facilitate the expressive communication of persons with severe communication disabilities. An investigation of performance by young users of augmentative communicative devices is in progress. By providing access to computers, including a brain-computer interface communication prothesis, individuals with disabilities can immediately use personal computer software programs and speech synthesizers for augmentive communication. NIDCD-funded investigators are actively working to provide locked-in individuals with a direct means of producing speech to allow rapid communication between the individual and caregivers. The individual's control of computers will be enabled through development of a direct brain-to-speech generator that uses a person's neural signals.

NIDCD-funded investigators are studying a variety of treatments interventions for voice and speech disorders. One study is comparing behavioral treatments for voice disorders in school teachers. Basic research is laying the groundwork for translational research towards creating a more successful treatment of laryngeal paralysis and other peripheral nerve injuries. Others are studying the limbic and motor system interaction in laryngeal function using an animal model to better understand mechanisms of voice disorders and speech disorders and their recovery.

Language research continues to expand our knowledge of the role played by each brain hemisphere in communication and language, early specialization of the brain, and the recovery process following brain damage. This research will further our understanding of the neural bases of language and language disorders. Research on acquisition, characterization, and utilization of American Sign Language is expanding knowledge of the language used by many people who are deaf.

Language researchers supported by NIDCD are also exploring the genetic bases of child speech and language disorders, as well as characterizing the linguistic and cognitive deficits in children and adults with language disorders. Researchers are developing effective diagnostic and intervention strategies for children who are autistic, or have specific language impairment, as well as adults with aphasia.

**Epidemiology and Statistics**

NIDCD supports epidemiological (clinical) and population-based research studies in all seven mission areas of the Institute: hearing, balance, smell, taste, voice, speech, and language. Studies assess impairments of hearing and other communication disorders across the lifespan, including risks associated with other health conditions as well as behavioral, demographic, environmental, and genetic factors. The research studies supported include longitudinal cohort studies, population-based health interview or examination cross-sectional surveys, and case-control studies, such as community-based and nationally-representative health interview and examination surveys to advance knowledge of the prevalence and determinants of communication disorders. The program maintains research collaborations on national health interview and examination surveys with other Federal agencies and with academic and private sector organizations via research contracts or interagency agreements. NIDCD epidemiologists have contributed to the analysis and interpretation of trends for the Hearing Health Promotion, Office of the Secretary, Department of Health and Human Services, and the development of Healthy People 2020, which incorporates health objectives for all seven mission areas of the NIDCD. Consultation on the design and analysis of studies of therapeutic interventions, disease prevention or progression, and environmental or genetic causes are provided as well as statistical methods that are developed and data systems are supported for the purposes of tracking prevalence rates and estimation of relative and attributable risks.
Until October 21, 1998, the National Institute of Dental Research

MISSION

The mission of the National Institute of Dental and Craniofacial Research (NIDCR) is to improve oral, dental, and craniofacial health through research, research training, and the dissemination of health information. We accomplish our mission by:

- Performing and supporting basic and clinical research;
- Conducting and funding research training and career development programs to ensure an adequate number of talented, well-prepared, diverse investigators;
- Coordinating and assisting relevant research and research-related activities among all sectors of the research community;
- Promoting the timely transfer of knowledge gained from research and its implications for health to the public, health professionals, researchers, and policymakers.

IMPORTANT EVENTS IN NIDCR HISTORY

1931—The U.S. Public Health Service created a Dental Hygiene Unit at NIH and designated Dr. H. Trendley Dean as the first dental research worker. His primary function was to apply principles of epidemiology to a series of community studies on the oral disease known as mottled enamel. His research on fluoride showed not only its relation to mottled enamel, but also its influence on tooth decay.

1945—Following fluoridation of the water supply in Grand Rapids, Michigan, annual examinations of children were begun to study the effects of fluoride on the development of dental caries.

1948—On June 24, Public Law 80-755, the National Dental Research Act created the National Institute of Dental Research (NIDR) and the National Advisory Dental Research Council. On September 16, the institute was established.

1949—The first meeting of the National Advisory Dental Research Council was held on January 10. The institute-supported grants program was initiated, and the first grants and fellowships were awarded.

1954—Results of the first 10 years of the Grand Rapids study firmly established water fluoridation as a safe, effective, and economical procedure for the control of dental caries.

1958—The Laboratory of Biochemistry was established to conduct research studies on the chemistry and structure of collagen, elastin, and other proteins. President Dwight D. Eisenhower signed the appropriations bill, which included provisions to finance the construction of a building for the dental institute.

1960—On September 21, the cornerstone was laid for the dental institute building (Building 30) at NIH.


1962—The first grant for a multidisciplinary study of cleft palate was awarded to the University of Pittsburgh Health Center.

1963—Fifteen years of scientific accomplishment by NIDR were cited by scientists, administrators, and health educators on June 14 in a special anniversary observance.

1966—A reorganization of the institute's extramural programs was implemented to more adequately plan and support research and training programs designed to attack the major dental diseases and disorders—dental caries, periodontal disease, and oral-facial anomalies.

1967—An NIDR program of grant support was initiated for the development of several dental research institutes/centers in university environments. This program was designed to utilize all of the appropriate resources of the parent universities to create ideal research and training environments, fostering interdisciplinary approaches to the complex problems of oral diseases and disorders.
1971—The National Caries Program was launched utilizing funds specifically earmarked to accelerate development of preventive methods to reduce tooth decay.

1973—The Laboratory of Oral Medicine was established to conduct both clinical and laboratory research on the cause, prevention, and treatment of diseases of the soft tissue of the oral cavity.

On June 28-29, a scientific conference commemorating the silver anniversary of NIDR was convened in Washington, D.C.

1974—To encompass the expanded research studies conducted by the laboratory of Microbiology, the Laboratory of Microbiology and Immunology was established. Laboratory programs involve the role of host factors in periodontal diseases, autoimmune diseases, and allergic disorders.

To emphasize anesthesia-analgesia dental problems, the NIDR reorganized its intramural program to form a Neurobiology and Anesthesiology Branch composed of the neural mechanism section and the anesthesiology section. The branch collaborates closely with the extramural programs concerned with pain control and behavioral studies.

1975—Having established the safety and efficacy of several caries preventive measures, the NIDR initiated selected school demonstration projects through its National Caries Program.

1977—The institute established its first 2 specialized clinical research centers in periodontal diseases.

In June, Dr. Marie U. Nylen was named director of intramural research, the first woman to hold such a position at NIH.

1978—NIDR sponsored its first consensus development conference, Dental Implants—Benefit and Risk, to examine available data, suggest future research, and draft guidelines for implant therapy.

1980—The Diagnostic Systems Branch was created to pursue research and development of noninvasive diagnostic techniques, and analysis of the functional development of the oral and pharyngeal region.

The Clinical Investigations and Patient Care Branch was established to emphasize the integral association between the Institute's patient treatment and clinical dental research programs.

1982—The Laboratory of Biological Structure and the Laboratory of Biochemistry were replaced by the Laboratory of Oral Biology and Physiology and a Mineralized Tissue Research Branch. The Laboratory of Oral Biology and Physiology conducts research on the cell biology of secretory tissues and the chemical modification of proteins. Skeletal development, regulation, and disorders are under investigation in the Mineralized Tissue Research Branch.

1983—On March 21, the NIDR opened the first multidisciplinary pain clinic in the U.S. devoted exclusively to research. The clinic provides an opportunity for all NIH researchers and clinicians to pool their knowledge and exchange ideas about the pathophysiology and treatment of pain.

The Institute initiated an annual honorary lecture to recognize outstanding scientific accomplishment in basic and clinical research and to honor distinguished scientists who have made important contributions in areas of research directly related to the interests of NIDR.

1984—NIDR inaugurated the Dentist Scientist Award Program designed to provide opportunities for dentists to develop into independent biomedical investigators in the oral health research field.

The Institute completed its Long-Range Research Plan FY 1985-89 entitled Challenges for the Eighties. Under the direction of NIDR Director Dr. Harald Loe, a coordinating committee prepared this 5-year plan and summary of progress in the oral sciences and in disease prevention, diagnosis, and treatment. The document pinpoints 14 emphasis areas for NIDR's oral health research.

NIDR established 3 new specialized caries research centers in university environments to continue research investigations into the cause, treatment, and prevention of dental decay.

An NIDR reorganization disbanded the National Caries Program and created the Epidemiology and Oral Disease Prevention Program (EODPP). The EODPP is devoted to research on the etiology, incidence, and prevalence of dental caries, periodontal diseases, and other oral diseases and disorders.

A realignment of the administrative offices within the Office of the Director was completed and established the Office of Planning, Evaluation and Communications (OPEC).

An NIDR annual lecture series was named for a former institute director. The "Seymour J. Kreshover Lecture" is given each September at NIH.

1985—NIDR convened a meeting at NIH of over 160 deans and senior officials from almost every U.S. and Canadian dental school to explore key issues in dental research and education. The conference, first of its kind in NIDR history, was designed to strengthen the relationship between the institute and universities.

1986—NIDR completed its first nationwide survey on the dental health of American adults—the most comprehensive survey of its kind ever done, and the first to look at the prevalence of root caries and periodontal disease in detail.

1988—NIDR celebrated its 40th anniversary with a year-long agenda of commemorative activities.

NIDR funded 4 new oral biology research centers.

The institute released findings of its second National Caries Prevalence Study. Data show half of all American schoolchildren have no tooth decay.
NIDR held its second consensus development conference on dental implants. According to the summary statement, the use of dental implants has increased fourfold from 1983 to 1987.

NIDR and the Fogarty International Center launched an international oral health research study to identify oral health issues that would benefit most from international collaborative research.

The institute launched the 'Research and Action Program to Improve the Oral Health of Older Americans and Other Adults at High Risk.' The goal is to eliminate toothlessness and prevent further deterioration of oral health in individuals who have compromised dentition.

1990—The institute completed the NIDR Long-Range Research Plan for the Nineties: Broadening the Scope, the blueprint for research in this decade. The plan establishes major initiatives geared to 'special care patients' whose oral health is affected by systemic diseases or treatments and to older Americans. The ultimate goal of these initiatives is to eliminate toothlessness among future generations and prevent further deterioration of the oral health of people with compromised dentition.


The institute sponsored a technology assessment conference on the effects and side effects of dental restorative materials.

1992—The Epidemiology and Oral Disease Prevention Program reorganized to expand the scope of EODPP activities. The program now consists of 4 branches: Molecular Epidemiology and Disease Indicators; Disease Prevention and Health Promotion; Analytical Studies and Decision Systems; and Health Assessment. EODPP is the Federal focus for research in orofacial epidemiology and disease prevention.

A reorganization of the Extramural Program (EP) established the Program Development Branch, consisting of 7 categorical programs and an Office of Policy and Coordination. This office comprises manpower development and training activities and the Program Operations Unit, which includes the Scientific Review Office, the Grants Management Office, and the Contracts Management Office. EP provides grant and contract funds for research and research training.

NIDR hosted a second meeting of the leadership from the nation's dental schools, dental professional organizations and industry to explore ways to enhance the research capacity of dental schools.

1993—The National Oral Health Information Clearinghouse was established as a centralized resource for patients, health professionals, and the public seeking information on the oral health of special care patients.

1994—The intramural, extramural, and epidemiology organizational components of NIDR were redefined from programs to divisions, establishing the Division of Intramural Research, the Division of Extramural Research, and the Division of Epidemiology and Oral Disease Prevention (DEODP).

The DEODP was streamlined from 4 to 3 branches: Analytical Studies and Health Assessment; Disease Prevention and Health Promotion; and Molecular Epidemiology and Disease Indicators.

1995—NIDR sponsored "Partnerships in Communication: A Meeting of Dental Editors," which brought together for the first time at NIH more than 30 editors and executive directors of dental organizations to enhance communication among the group.

The institute met with a diverse group of representatives from pharmaceutical, biotechnology, manufacturing, and other industries to develop ways to accelerate the transfer of research findings into application.

NIDR conducted more than 30 focus groups with professional organizations, NIDR staff, specialty groups, and the public toward the development of a new institute strategic plan.

1996—The first community conference in the institute's history was held in May for employees to review the NIDR strategic planning process to date and to discuss the NIDR mission, vision, situation audit, strategic initiatives, management principles, and plans for the future.

The NIDR sponsored a technology assessment conference on the management of temporomandibular disorders.

The institute's intramural, extramural, and epidemiology organizational components were reorganized into the Division of Intramural Research and the Division of Extramural Research.

NIDR launched its World Wide Web page on the Internet, making all pertinent information available to the public and the research community.

1997—The NIDR's first strategic plan, Shaping the Future, was released in July. Focusing on areas of research opportunities, research capacity, and health promotion, the document serves as a critical structure for multiple institute initiatives.

The institute celebrated its 50th anniversary.

A reorganization within the Office of the Director created the Office of International Health, the Office of Science Policy and Analysis, and the Office of Communications and Health Education. The Office of Planning, Evaluation, and Communications was eliminated.

1998—The institute changed its name to National Institute of Dental and Craniofacial Research to accurately reflect its research base. NIDCR became official on October 21, 1998, with the Omnibus Consolidated and Emergency Supplemental Appropriations Act, H.R. 4128.
1999—NIDCR introduced its Strategic Plan to Reduce Racial and Ethnic Health Disparities. The plan is designed to support research leading to the reduction and prevention of health disparities, including those in the oral cavity, and to provide research opportunities to increase the diversity of the scientific workforce.

The Office of Information Technology was established within the NIDCR Office of the Director.

2000—The institute hosted the first "NIDCR Patient Advocates Forum." The conference, attended by patient advocates from 15 organizations, was designed to enhance communication between patient liaison groups and NIDCR and to bring the patient perspective to Institute planning and research.

NIDCR served as lead agency for the preparation and publication of Oral Health In America: A Report of the Surgeon General, released on May 25th. The report—commissioned by U.S. Department of Health and Human Services Secretary Donna Shalala and released by Surgeon General David Satcher—is the first of its kind to be dedicated solely to oral health.

The institute supported the first-ever national, multidisciplinary meeting on children and oral health, "Face of a Child," held June 12-13 in Washington, D.C.

2001—The Division of Extramural Research was reorganized into 3 components: Division of Basic and Translational Sciences, Division of Population and Health Promotion Sciences, and Division of Extramural Activities.

NIDCR sponsored a consensus development conference on the “Diagnosis and Management of Dental Caries Throughout Life.”

The institute released its strategic plan to eliminate craniofacial, oral, and dental health disparities.

NIDCR funded 5 new Centers for Research to Reduce Oral Health Disparities.

2003—NIDCR released its Strategic Plan for FY 2003-2008. The plan addresses the myriad diseases and conditions that affect the oral cavity and craniofacial structures by outlining a course for the Institute to follow in the areas of research, research training, and communication of research results.

The Institute was a lead agency in preparing A National Call to Action to Promote Oral Health, released April 29, 2003, by U.S. Surgeon General Richard Carmona.

2005—NIDCR awarded 3 major grants that establish regional “practice-based” research networks to investigate with greater scientific rigor everyday issues in the delivery of oral health care.

Two extramural research programs were reorganized into 4 centers focusing on craniofacial research, infectious diseases and immunology, clinical research, and health promotion and behavioral research.

2006—NIDCR integrated its extramural programs into 2 centers—the Center for Integrative Biology and Infectious Diseases and the Center for Clinical Research—and a Biotechnology and Innovation Program.

2007—NIDCR reorganized its extramural program to better reflect the current NIH extramural model. The Center for Integrative Biology and Infectious Diseases was renamed the Division of Extramural Research (DER); the Center for Clinical Research is now part of the DER.

2008—NIDCR celebrated its 60th anniversary. View Images.

2009—NIDCR released its 2009-2013 Strategic Plan. The plan provides a guide for the institute’s funding decisions and defines areas to monitor for key developments and innovations that can be applied to oral, dental, and craniofacial health. View Image.

The institute launched the FaceBase Consortium, a 5-year initiative that will compile the biological instructions to build the middle region of the human face and precisely define the genetics underlying its common developmental disorders, such as cleft lip and palate. View Image.

2010—On August 19, NIH Director Francis S. Collins appointed NIDCR Director Lawrence Tabak as Principal Deputy Director, NIH. Dr. Tabak had been director of NIDCR since September 2000. He was acting principal deputy NIH director from November 2008 to August 2009, and had also served as acting director of the Division of Program Coordination, Planning, and Strategic Initiatives. Dr. Collins named Dr. Isabel Garcia Acting Director, NIDCR. View Image

NIDCR completed its commitment of American Recovery and Reinvestment Act (ARRA) funds. The Institute’s two-year Recovery Act funding totaled $101.8 million and provided support for 141 new or competing two-year research and research training grants, 128 administrative supplements to scientists with active NIDCR grants, and research projects in 33 states. The ARRA funds allowed NIDCR to make strategic investments in virtually all areas of dental, oral, and craniofacial research. View Image

The NIDCR-sponsored Attack of the S. mutans! was featured in the NIH pavilion at the October 23-24 USA Science & Engineering Expo on the National Mall in Washington, D.C. Attack of the S. mutans! is a 3-D interactive game that aims to advance understanding of the tooth decay process, including the role of a bacterium known as S. mutans. The game was developed with funding from NIDCR and NIH’s National Center on Minority Health and Health Disparities. View Image

**NIDCR LEGISLATIVE CHRONOLOGY**

June 24, 1948—Public Law 80-755 established NIDR to conduct, support, and foster research investigations on the causes, treatment, and prevention of dental diseases and conditions.

August 1, 1958—President Eisenhower signed an HEW appropriation bill that included provisions to finance construction of laboratory facilities to house NIDR.
BIOGRAPHICAL SKETCH OF DIRECTOR MARTHA J. SOMERMAN, D.D.S., PH.D.

Martha J. Somerman, D.D.S., Ph.D. became the eighth director of the National Institute of Dental and Craniofacial Research, a component institute within the National Institutes of Health, on August 29, 2011. In this position, Dr. Somerman oversees an extensive research portfolio and leads the Institute’s team of more than 400 scientists and administrators.

A widely respected periodontist and researcher, Dr. Somerman most recently served as the dean of the University of Washington School of Dentistry, a post she held starting in 2002 while continuing to teach in the school’s Department of Periodontics, and as an adjunct professor in the Department of Oral Biology. Under her leadership, the School of Dentistry stepped up its efforts to attract students from diverse backgrounds who were committed to giving back to underserved communities. She was a strong and vocal supporter of the school’s Dental Education in Care of Persons with Disabilities (DECOD) program, which for more than three decades has been one of the few dental care resources available to Washington residents with developmental or acquired disabilities. She also served on the medical staff of the Seattle Cancer Care Alliance and as a member of the associate medical staff of the University of Washington Medical Center and the Harborview Medical Center.

Prior to her work at the University of Washington, Dr. Somerman was on the faculty of the University of Michigan School of Dentistry from 1991 to 2002 and the Baltimore College of Dental Surgery from 1984 to 1991. At Michigan, she served as chair of the Department of Periodontics, Prevention and Geriatrics, and held the William K. and Mary Anne Najjar Endowed Professorship, and also served as professor in the Department of Pharmacology in the University of Michigan School of Medicine from 1995 to 2002. In Baltimore, she was a professor in the departments of periodontics and pharmacology. Her own research has focused particularly on understanding tooth root development and on the application of that understanding to periodontal regeneration.

Dr. Somerman is a diplomate of the American Board of Periodontology and a past president of the American Association for Dental Research. She has received numerous honors and awards, including the 2011 Paul Goldhaber Award from the Harvard School of Dental Medicine, the Geis Award from the American Academy of Periodontology and the Distinguished Scientist Award for Research in Oral Biology from the International Association for Dental Research (IADR). In 2010, she was a co-winner of the first IADR/Strataumann Award in Regenerative Periodontal Medicine. She is also a fellow of the American Association for the Advancement of Science, the International College of Dentists, and the American College of Dentists.

Along with her D.D.S from New York University, Dr. Somerman holds an M.S. in environmental health from Hunter College and a Ph.D. in pharmacology from the University of Rochester, along with a certificate in periodontics from Eastman Dental Center in Rochester, NY.

RIDC DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. Trendley Dean</td>
<td>September 17, 1948</td>
<td>March 31, 1953</td>
</tr>
<tr>
<td>Francis A. Arnold, Jr.</td>
<td>April 1, 1953</td>
<td>February 1966</td>
</tr>
<tr>
<td>Seymour J. Kreshover</td>
<td>February 1966</td>
<td>June 30, 1975</td>
</tr>
<tr>
<td>Clair L. Gardner (Acting)</td>
<td>July 1, 1975</td>
<td>December 31, 1975</td>
</tr>
<tr>
<td>David B. Scott</td>
<td>January 1, 1976</td>
<td>December 31, 1981</td>
</tr>
<tr>
<td>John F. Goggins (Acting)</td>
<td>January 1, 1982</td>
<td>December 31, 1982</td>
</tr>
<tr>
<td>Harald Löe</td>
<td>January 1983</td>
<td>June 1, 1994</td>
</tr>
<tr>
<td>Dushanka V. Kleinman (Acting)</td>
<td>June 1994</td>
<td>June 1995</td>
</tr>
<tr>
<td>Harold C. Slavkin</td>
<td>July 1995</td>
<td>July 14, 2000</td>
</tr>
<tr>
<td>Lawrence A. Tabak</td>
<td>September 2000</td>
<td>August 19, 2010</td>
</tr>
<tr>
<td>A. Isabel Garcia (Acting)</td>
<td>August 19, 2010</td>
<td>August 28, 2011</td>
</tr>
<tr>
<td>Martha J. Somerman, D.D.S., Ph.D.</td>
<td>August 29, 2011</td>
<td>Present</td>
</tr>
</tbody>
</table>

RESEARCH PROGRAMS

Division of Extramural Research

Through its Division of Extramural Research, the institute provides research funds outside its intramural laboratories and clinics in Bethesda, Maryland. These funds are made available in the form of grants, cooperative agreements, and contracts, which support scientists working in institutions throughout the U.S. and in foreign countries. These scientists conduct basic, translational, patient-oriented and demonstration research to increase understanding of fundamental processes in health and disease, and to promote timely transfer and community adoption of research findings. The institute also supports research training and career development to ensure an adequate pool of research personnel.

The Division of Extramural Research comprises 3 branches and 1 center:
The Core facilities include the Clinical Research Core, DNA Sequencing Core, Gene Targeting Core, Scientific Systems Core, Technology Transfer, and Veterinary Resources.

Bone marrow, tendons, and ligaments. Emphasis is placed on genetic and acquired disorders through basic, clinical, and translational research, including studies on craniofacial tissue development, function, and health.

Other cell interaction systems in embryonic development and function. Research focuses on such areas as normal and abnormal embryonic development of connective tissues and the immune system. Studies also focus on the role of bacteria and viruses in oral disease, genetic and acquired disorders of the craniofacial region, tumors of the oral cavity, the causes and treatment of acute and chronic pain, and the development of new and improved methods to diagnose oral disease. The division has approximately 300 employees and guest researchers in 30 laboratories and 6 laboratory and clinical support facilities. These support facilities include the Clinical Research Core, DNA Sequencing Core, Gene Targeting Core, Scientific Systems Core, Technology Transfer, and Veterinary Resources Core.

The Clinical Research Core supports the research efforts of NIDCR and other NIH Institutes by providing dental medicine expertise for clinical studies and dental consult services to the unique patient populations at the NIH Clinical Center.

The Craniofacial and Skeletal Diseases Branch studies development and structure of hard tissues—bones, teeth, and cartilage—and associated soft tissues, such as bone marrow, tendons, and ligaments. Emphasis is placed on genetic and acquired disorders through basic, clinical, and translational research, including studies on adult stem cells and their biological activities; and composition, synthesis, and destruction of extracellular matrices—the major components of most tissues and critical in craniofacial tissue development, function, and health.

The Laboratory of Cell and Developmental Biology explores the roles and gene regulation of the extracellular matrix, a key component of connective tissue, and other cell interaction systems in embryonic development and function. Research focuses on such areas as normal and abnormal embryonic development of craniofacial and other tissues, processes involved in tissue repair and cancer, and replacement or regeneration of defective or damaged tissues.

The Laboratory of Sensory Biology investigates fundamental mechanisms of various types of sensation including taste, somatosensation (touch, pressure, temperature), and pain. Using a range of laboratory techniques, scientists are exploring how sensory stimuli are detected and processed—some of this information is used to develop and test novel therapeutic strategies to combat pain.

The Molecular Physiology and Therapeutics Branch pursues a comprehensive bench-to-bedside program to understand the molecular basis of salivary gland function and dysfunction and to develop strategies for the diagnosis, prevention, and management of salivary gland diseases. Clinical and translational studies focus on mechanisms of, and therapies for, salivary gland dysfunction caused by head and neck irradiation and diseases such as Sjögren’s syndrome.

The Oral and Pharyngeal Cancer Branch explores several aspects of cancer cell biology to identify the faulty molecular mechanisms underlying the development of oral malignancies and their metastatic spread. Investigators are using this knowledge to identify early diagnostic markers and develop novel therapeutic approaches for the prevention and treatment of oral cancer.
The **Oral Infection and Immunity Branch** conducts research on the causes, diagnosis, treatment, and prevention of infectious and inflammatory diseases. Studies are focused on gaining a better understanding of the functional and molecular organization of infectious organisms in an effort to identify ways to disarm them. Research is also under way on the basic mechanisms of inflammatory and immune host response to these harmful organisms, which may ultimately lead to novel interventions and strategies for therapy.

The **Developmental Mechanisms Unit** investigates mechanisms of cell differentiation in early embryos of sea urchins, an important model for research in developmental biology. Current studies focus on elucidating: the gene regulatory network underlying development of the anterior nervous system, which includes many relatives of genes expressed in the vertebrate forebrain; the mechanisms that restrict the developmental capacities of cells within the endomesoderm of early embryos to either endoderm or mesoderm; and the mechanism that embryos use to mount a morphological response to changes in food availability. Because the essential features of gene regulatory networks are highly conserved in evolution, relatively quick and inexpensive experiments in sea urchin embryos may provide a shortcut to understanding similar processes in higher vertebrates, including man.

The **Secretory Mechanisms and Dysfunction Section** investigates the molecular nature and function of the ion transport mechanisms involved in the fluid and electrolyte secretion process in the exocrine salivary gland. Scientists are probing the structure-function relationships of cotransporter, exchanger, and channel proteins using a combination of molecular biology, gene modification, proteomics, and functional studies in mouse and human salivary glands. Investigators are using a high-throughput approach to catalogue the human saliva proteome, to identify salivary biomarkers for human diseases, and to compile a comprehensive list of the plasma membrane proteins expressed in salivary glands.

The **Section on Biological Chemistry** conducts basic research on biosynthesis, structure, and function of glycoproteins, placing a special emphasis on mucin-type O-glycans. As glycans cannot be readily altered directly, studies are focusing on modulating the activity of the family of glycosyltransferases that initiate mucin-type O-glycosylation (the UDP GaINAc polypeptide:N-Acetylgalactosaminyltransferases) as a means of probing O-glycan function.

The **Immunopathology Section** explores the modulation of human monocyte functions that may contribute to connective tissue damage associated with inflammatory diseases such as cancer, rheumatoid arthritis and periodontal disease. These functions include the regulation of certain enzymes and inhibitors that play a major role in the destruction and remodeling of connective tissue in the human monocyte, a major cell at sites of inflammation.
MISSION

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) conducts and supports research on many of the most serious diseases affecting public health. The Institute supports much of the clinical research on the diseases of internal medicine and related subspecialty fields, as well as many basic science disciplines.

The Institute's Division of Intramural Research encompasses the broad spectrum of metabolic diseases such as diabetes, obesity, inborn errors of metabolism, endocrine disorders, mineral metabolism, digestive and liver diseases, nutrition, urology and renal disease, and hematology. Basic research studies include biochemistry, biophysics, nutrition, pathology, histochemistry, bioorganic chemistry, physical chemistry, chemical and molecular biology, and pharmacology.

NIDDK extramural research is organized into 4 divisions: Diabetes, Endocrinology, and Metabolic Diseases; Digestive Diseases and Nutrition; Kidney, Urologic, and Hematologic Diseases; and Extramural Activities.

The Institute supports basic and clinical research through investigator-initiated grants, program project and center grants, and career development and training awards. The Institute also supports research and development projects and large-scale clinical trials through contracts.

IMPORTANT EVENTS IN NIDDK HISTORY

August 15, 1950—President Harry S. Truman signed the Omnibus Medical Research Act into law establishing the National Institute of Arthritis and Metabolic Diseases (NIAMD) in the U.S. Public Health Service. The new Institute incorporated the laboratories of the Experimental Biology and Medicine Institute and expanded to include clinical investigation in rheumatic diseases, diabetes, and a number of metabolic, endocrine, and gastrointestinal diseases.

November 15, 1950—The National Advisory Arthritis and Metabolic Diseases Council held its first meeting and recommended approval of NIAMD's first grants.

November 22, 1950—U.S. Surgeon General Leonard Scheele established NIAMD.

1959—Dr. Arthur Kornberg, former chief of the Institute's enzyme and metabolism section, won the Nobel Prize for synthesizing nucleic acid. The Institute initiated an intramural research program in gastroenterology and launched an intramural research program in cystic fibrosis with the establishment of the Pediatric Metabolism Branch.

1961—Laboratory-equipped, mobile trailer units began an epidemiological study of arthritis among the Blackfeet and Pima Indians in Montana and Arizona, respectively.

October 16, 1969—The Nobel Prize was awarded to Dr. Marshall W. Nirenberg of the National Heart Institute, who reported his celebrated partial cracking of the genetic code while an NIAMD scientist (1957-1962).

November 1970—The Institute celebrated its 20th anniversary. U.S. Secretary of Defense Melvin R. Laird addressed leaders in the department, representatives from voluntary health agencies and professional biomedical associations, as well as past and present Institute National Advisory Council members.

May 19, 1972—The Institute name was changed to the National Institute of Arthritis, Metabolism, and Digestive Diseases.

October 1972—Christian B. Anfinsen, chief of the Institute's Laboratory of Chemical Biology, shared a Nobel Prize with 2 other American scientists for his demonstration of one of the most important simplifying concepts of molecular biology, that the 3-dimensional conformation of a native protein is determined by the chemistry of its amino acid sequence. A significant part of this research cited by the award was performed while with NIH.

September 1973—The Institute's diabetes centers program was initiated with the establishment of the first Diabetes-Endocrinology Research Centers.

November 1975—After 9 months of investigation into the epidemiology and nature of diabetes mellitus and public hearings throughout the United States, the National Commission on Diabetes delivered its report, the Long-Range Plan to Combat Diabetes, to Congress. Recommendations encompassed expansion and
coordination of diabetes and related research programs; creation of a diabetes research and training centers program; acceleration of efforts in diabetes health care, education, and control programs; and establishment of a National Diabetes Advisory Board.

April 1976—After a year of study and public hearings, the National Commission on Arthritis and Related Musculoskeletal Diseases issued The Arthritis Plan—its report to Congress. The report called for increased arthritis research and training programs, multipurpose arthritis centers, epidemiologic studies and data systems in arthritis, a National Arthritis Information Service, and a National Arthritis Advisory Board.

October 1976—Dr. Baruch Blumberg was awarded the Nobel Prize in Physiology or Medicine for research on the hepatitis B virus protein, the “Australia antigen,” which he discovered in 1963 while at the Institute. This advance has proven to be a scientific and clinical landmark in detection and control of viral hepatitis and led to the development of preventive measures against hepatitis and liver cancer.

April 19, 1977—The NIH Director established a trans-NIH program for diabetes, with lead responsibility in NIAMDD.

September 1977—Over $5 million in grants was awarded to 5 institutions to establish Diabetes Research and Training Centers.

October 1977—In response to the recommendation of the National Commission on Diabetes, the National Diabetes Data Group was established within the Institute to collect, analyze, and disseminate data on this disorder to scientific and public health policy and planning associations.

December 1977—Institute grantees Dr. Roger C.L. Guillemin and Dr. Andrew V. Shally shared the Nobel Prize in Physiology or Medicine with a third scientist, Dr. Rosalyn S. Yalow. Guillemin and Shally’s prizes were for discoveries related to the brain’s production of peptide hormones.

December 1978—A study of cystic fibrosis focused on the need for future research activities, including increased support for clinical and basic research, expansion of specialized cystic fibrosis research resources, emphasis on training of scientific personnel, and coordination of public and private cystic fibrosis research activities.

January 1979—Following 2 years of study and public hearings, the National Commission on Digestive Diseases issued its report, The National Long-Range Plan to Combat Digestive Diseases. Recommendations to Congress included the establishment of a National Digestive Diseases Advisory Board, an information clearinghouse, and increased emphasis on educational programs in digestive diseases in medical schools.


September 1980—Dr. Joseph E. Rall, director of NIAMDD intramural research, became the first person at NIH to be named to the distinguished executive rank in the Senior Executive Service. President Jimmy Carter presented the award in ceremonies at the White House on September 9.

October 15, 1980—NIAMDD celebrated its 30th anniversary with a symposium, “DNA, the Cell Nucleus, and Genetic Disease,” and dinner at the National Naval Medical Center. Dr. Donald W. Seidlin, chairman of the department of internal medicine, University of Texas Southwestern Medical School, Dallas, was guest speaker.

June 23, 1981—The Institute was renamed National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases.

April 1982—U.S. Department of Health and Human Services (HHS) Secretary Richard S. Schweiker elevated NIADDK’s programs to division status, creating 5 extramural divisions and the Division of Intramural Research.

November 1982—Dr. Elizabeth Neufeld received a Lasker Foundation Award. She is cited, along with Dr. Roscoe E. Brady of NINCDS, for “significant and unique contributions to the fundamental understanding and diagnosis of a group of inherited diseases called mucopolysaccharide storage disorders (MPS).”

November 1984—Grants totaling more than $4 million were awarded to 6 institutions to establish Silvio O. Conte Digestive Disease Research Centers. The research centers investigate the underlying causes, diagnoses, treatments, and prevention of digestive diseases.

April 8, 1986—The Institute’s Division of Arthritis, Musculoskeletal and Skin Diseases became the core of the new National Institute of Arthritis and Musculoskeletal and Skin Diseases. The NIADDK was renamed the National Institute of Diabetes and Digestive and Kidney Diseases.

June 3, 1986—The National Kidney and Urologic Diseases Advisory Board was established to formulate the long-range plan to combat kidney and urologic diseases.

August 1, 1987—Six institutions were funded to establish the George M. O’Brien Kidney and Urological Research Centers.

December 25, 1987—In response to congressional language on the FY 1988 appropriation for the NIDDK, the institute established a program of cystic fibrosis research centers.

September 16, 1990—NIDDK celebrated its 40th anniversary. Dr. Daniel E. Koshland, Jr., editor of Science, was guest speaker.

June, 1991—The NIDDK Advisory Council established the National Task Force on the Prevention and Treatment of Obesity to synthesize current science on the prevention and treatment of obesity and to develop statements about topics of clinical importance that are based on critical analyses of the literature.

September 30, 1992—Three Obesity/Nutrition Research Centers and an animal models core to breed genetically obese rats for obesity and diabetes research were established.

October 12, 1992—Drs. Edwin G. Krebs and Edmond H. Fischer were awarded the Nobel Prize in Physiology or Medicine for their work on “ reversible protein phosphorylation.” They have received grant support from NIDDK since 1955 and 1956, respectively.
October 30, 1992—In response to congressional language on the Institute's FY 1993 appropriation, the NIDDK initiated a program to establish gene therapy research centers with emphasis on cystic fibrosis.

November 1, 1993—The functions of the NIH Division of Nutrition Research Coordination, including those of the NIH Nutrition Coordinating Committee, were transferred to NIDDK.

October 10, 1994—Dr. Martin Rodbell and Dr. Alfred G. Gilman received the Nobel Prize in Physiology or Medicine for discovering G-proteins, a key component in the signaling system that regulates cellular activity. Dr. Rodbell discovered the signal transmission function of GTP while a researcher in the National Institute of Arthritis and Metabolic Diseases, now NIDDK.

June 22, 1997—Led by NIDDK, NIH and the U.S. Centers for Disease Control and Prevention (CDC) announce the National Diabetes Education Program (NDEP) at the American Diabetes Association annual meeting in Boston. The NDEP's goals are to reduce the rising prevalence of diabetes, the morbidity and mortality of the disease, and its complications.

June 2000—In an effort to reduce the disproportionate burden of many diseases in minority populations, NIDDK initiated an Office of Minority Health Research Coordination.

November 16, 2000—NIDDK celebrated its 50th Anniversary. Professional societies in 8 U.S. locations and Canada sponsored scientific symposia and hosted an NIDDK exhibit. 'A New Century of Science. A New Era of Hope' was published to highlight research supported and conducted by NIDDK and concluded the year with a joint scientific symposium at the Society for Cell Biology's 40th Anniversary meeting in December.

June 13, 2003—To avoid confusion with the newly-established NIH Obesity Research Task Force, NIDDK changed the name of its National Task Force on Prevention and Treatment of Obesity, established in 1991, to the Clinical Obesity Research Panel (CORP).

June 2003—The Report on Progress and Opportunities: Special Statutory Funding for Type 1 Diabetes Research described recent achievements and major projects that address unmet research needs in type 1 diabetes. From fiscal year 1998 through fiscal year 2008, the special funding program provides a total of $1.14 billion in research funds to supplement other funds for type 1 diabetes research provided through the regular appropriations process.

NIDDK LEGISLATIVE CHRONOLOGY

December 11, 1947—Under section 202 of Public Law 78-410, the Experimental Biology and Medicine Institute was established.

August 15, 1950—P.L. 81-692, the Omnibus Medical Research Act, authorized establishment of NIAMDD to “…conduct researches relating to the cause, prevention, and methods of diagnosis and treatment of arthritis and rheumatism and other metabolic diseases, to assist and foster such researches and other activities by public and private agencies, and promote the coordination of all such researches, and to provide training in matters relating to such diseases. . . .” Section 431 also authorized the U.S. Surgeon General to establish a national advisory council.

May 19, 1972—President Richard M. Nixon signed P.L. 92-305 to bring renewed emphasis to research in digestive diseases by changing the name of the Institute to NIAMDD and by designating a digestive diseases committee within the Institute's National Advisory Council.

August 29, 1972–The National Cooley's Anemia Control Act (PL 92-414) authorized research in the diagnosis, treatment, and prevention of this debilitating inherited disease, also known as thalassemia, occurring largely in populations of Mediterranean and Southeastern Asian origin.

July 23, 1974—P.L. 93-354, the National Diabetes Mellitus Research and Education Act, was signed. The National Commission on Diabetes, called for by this act, was chartered on September 17, 1974. Members were appointed by the Secretary of the U.S. Department of Health, Education and Welfare (HEW). The Act called for centers for research and training in diabetes and establishment of an intergovernmental diabetes coordinating committee, including NIAMDD and 6 other NIH institutes.

January 1975–The National Arthritis Act of 1974 (P.L. 93-640) was signed into law to further research, education, and training in the field of the connective tissue diseases. The HEW Secretary appointed the mandated National Commission on Arthritis and Related Musculoskeletal Diseases, June 2. The Act required centers for research and training in arthritis and rheumatic diseases and the establishment of a data bank, as well as an overall plan to investigate the epidemiology, etiology, control, and prevention of these disorders.

October 1976—P.L. 94-562, the Arthritis, Diabetes, and Digestive Diseases Amendments of 1976, established the National Diabetes Advisory Board charged with advising Congress and the HEW Secretary on Implementation of the "Long-Range Plan to Combat Diabetes," developed by the National Commission on Diabetes. The law also established the National Commission on Digestive Diseases to deal with many problems, including investigation into the incidence, duration, mortality rates, and social and economic impact of digestive diseases.

The National Arthritis Advisory Board, established by the same law, reviews and evaluates the implementation of the Arthritis Plan, formulated by the Arthritis Act of 1974. The board advises Congress, the HHS Secretary, and heads of Federal agencies with respect to the plan and other Federal programs relating to arthritis.

December 1980—Title II of the Health Programs Extension Act of 1980, P.L. 96-538, changed the institute's name to the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases. The Act also established the National Digestive Diseases Advisory Board. The law authorized the National Diabetes Information Clearinghouse, the Diabetes Data Group, and the National Digestive Diseases Information and Education Clearinghouse. In addition, it reauthorized advisory boards for arthritis and diabetes research.

November 20, 1985–The Health Research Extension Act of 1985, P.L. 99-158, changed the Institute name to the National Institute of Diabetes and Digestive and Kidney Diseases. The act also established the National Kidney and Urologic Diseases Advisory Board. The law gave parallel special authorities to all Institute...
operating divisions, including authorization of the National Kidney and Urologic Diseases Information Clearinghouse; National Kidney, Urologic, and Hematologic Diseases Coordinating Committee; National Kidney and Urologic Diseases Data System; National Digestive Diseases Data System; kidney and urologic diseases research centers; and digestive diseases research centers.

June 10, 1993—The NIH Revitalization Act of 1993, P.L. 103-43, established NIDDK as the lead institute in nutritional disorders and obesity, including the formation of a research and training centers program on nutritional disorders and obesity.

It also provided for the directors of the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute on Aging, National Institute of Dental Research, and the NIDDK to expand and intensify programs with respect to research and related activities concerning osteoporosis, Paget's disease, and related bone disorders.


August 1997—The Balanced Budget Act of 1997 (P.L. 105-33) established a Special Statutory Funding Program for Type 1 Diabetes Research. The program provided $30 million per year for fiscal years 1998 through 2002. This funding program augmented regularly appropriated funds that HHS received for diabetes research through the Labor-HHS-Education Appropriations Committees. The NIDDD, through authority granted by the HHS Secretary, has a leadership role in planning, implementing, and evaluating the allocation of these funds.

October 17, 2000—The Children's Health Act of 2000 (P.L. 106-310) amended the Public Health Service Act with respect to children's health. Title IV, entitled "Reducing Burden of Diabetes Among Children and Youth," section 402, specified that NIH conduct long-term epidemiology studies, support regional clinical research centers, and provide a national prevention effort relative to type 1 diabetes.

December 2000—The Fiscal Year 2001 Consolidated Appropriations Act (P.L. 106-554) extended and augmented the Special Statutory Funding Program for Type 1 Diabetes Research in amount and time, allocating an additional $70 million for Fiscal Year 2001 (for a total of $100 million for Fiscal Year 2001), an additional $70 million for Fiscal Year 2002 (for a total of $100 million for Fiscal Year 2002), and $100 million for Fiscal Year 2003.

October 2002—NIH issued a detailed progress report, Conquering Diabetes: Highlights of Program Efforts, Research Advances, and Opportunities, on NIH-funded diabetes research. The report describes research achievements and initiatives since 1999, when the Diabetes Research Working Group published its 5-year plan. The Congressionally established Group made scientific recommendations in 5 areas of extraordinary research opportunity: the genetics of diabetes, autoimmunity and the beta cell, cell signaling and cell regulation, obesity, and clinical research and clinical trials. The Group also made recommendations regarding the microvascular and macrovascular complications of diabetes, the special populations most affected by diabetes, and resource and infrastructure needs to further diabetes research.

December 17, 2002—President Bush signed into law H.R. 5738, a bill that will increase and extend funding for the Special Diabetes Program (formerly P.L. 105-33). The bill provides $750 million for type 1 diabetes research over a period of 5 years (FY 04-FY 08).

December 2002—The Public Health Service Act Amendment for Diabetes (P.L. 107-360) extended and augmented the Special Statutory Funding Program for Type 1 Diabetes Research in time and amount, allocating $150 million per year for fiscal years 2004 through 2008.

December 8, 2003—The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (P.L. 108-173). Title VII, Subtitle D, Section 733 of this law, entitled "Payment for pancreatic islet cell investigational transplants for Medicare beneficiaries in clinical trials," specifies that the Secretary, acting through NIDDK, conduct a pancreatic islet transplantation clinical trial that includes Medicare beneficiaries, and that Medicare cover the routine costs, the transplantation, and appropriate related items and services for the Medicare beneficiaries enrolled in the trial.

October 25, 2004—The Pancreatic Islet Cell Transplantation Act of 2004 (P.L. 108-362) amended the Public Health Service Act for the purposes of increasing the supply of pancreatic islet cells for research, and providing for better coordination of Federal efforts and information on islet cell transplantation. A provision of this law specified that the annual reports prepared by the Diabetes Mellitus Interagency Coordinating Committee, which is led by the NIDDK, include an assessment of the Federal activities and programs related to pancreatic islet transplantation.

September 2004—The reports accompanying the FY 2005 Senate and House Labor, HHS, Education appropriations bills (reports 108-345 and 108-636, respectively) called on the NIH and HHS to establish a national commission on digestive diseases to review the burden of digestive diseases in the United States and develop a long-range research plan to address this burden. The NIH Director subsequently established the National Commission on Digestive Diseases, under NIDDK leadership, in August 2005. Commission activities included public meetings, review of a report by the Digestive Diseases Interagency Coordinating Committee on the burden of digestive diseases in the United States, and the development of a Long-Range Plan for Digestive Diseases Research.

**BIOGRAPHICAL SKETCH OF NIDDK DIRECTOR GRIFFIN P. RODGERS, M.D., M.A.C.P.**

Dr. Griffin P. Rodgers was named Director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)—one of the National Institutes of Health (NIH)—on April 1, 2007. He had served as NIDDK's Acting Director since March 2006 and had been the Institute's Deputy Director since January 2001. Dr. Rodgers also has been chief of the Molecular and Clinical Hematology Branch since 1998; the branch is now administratively managed by NIH's National Heart, Lung and Blood Institute.

Dr. Rodgers received his undergraduate, graduate, and medical degrees from Brown University in Providence, R.I. He performed his residency and chief residency in internal medicine at Barnes Hospital and the Washington University School of Medicine in St. Louis. His fellowship training in hematology/oncology was in a joint...
program of the NIH with George Washington University and the Washington Veterans Administration Medical Center. In addition to his medical and research training, he earned a master's degree in business administration, with a focus on the business of medicine, from Johns Hopkins University in 2005.

As a research investigator, Dr. Rodgers is widely recognized for his contributions to the development of the first effective-and now FDA approved-therapy for sickle cell anemia. He was a principal investigator in clinical trials to develop therapy for patients with sickle cell disease. He also performed basic research that focused on understanding the molecular basis of how certain drugs induce gamma-globin gene expression. He was honored for his research with numerous awards including the 1998 Richard and Hinda Rosenthal Foundation Award, the 2000 Arthur S. Fleming Award, the Legacy of Leadership Award in 2002, and a Mastership from the American College of Physicians in 2005.

Dr. Rodgers has been an invited professor at medical schools and hospitals in France, Italy, China, Japan, and Korea. He has been honored with many named lectureships at American medical centers and has published over 150 original research articles, reviews, and book chapters and has edited 4 books and monographs.

Dr. Rodgers served as Governor to the American College of Physicians for the U.S. Department of Health and Human Services from 1994 to 1997. He is a member of the American Society of Hematology, the American Society of Clinical Investigation, and the Association of American Physicians, among others. He is the chair of the Hematology Subspecialty Board and is a member of the American Board of Internal Medicine Board of Directors.

**NIDDK DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Henry Sebrell, Jr.</td>
<td>August 15, 1950</td>
<td>October 1, 1950</td>
</tr>
<tr>
<td>Russell M. Wilder</td>
<td>March 6, 1951</td>
<td>June 30, 1953</td>
</tr>
<tr>
<td>Floyd S. Daft</td>
<td>October 1, 1953</td>
<td>May 3, 1962</td>
</tr>
<tr>
<td>Lester B. Salans</td>
<td>June 17, 1982</td>
<td>June 30, 1984</td>
</tr>
<tr>
<td>Mortimer B. Lipsett</td>
<td>January 7, 1985</td>
<td>September 4, 1986</td>
</tr>
<tr>
<td>Phillip Gorden</td>
<td>September 5, 1986</td>
<td>November 14, 1999</td>
</tr>
<tr>
<td>Allen M. Spiegel</td>
<td>November 15, 1999</td>
<td>March 3, 2006</td>
</tr>
<tr>
<td>Griffin P. Rodgers</td>
<td>April 1, 2007</td>
<td>present</td>
</tr>
</tbody>
</table>

**RESEARCH PROGRAMS**

**Division of Intramural Research**

The Division of Intramural Research conducts research and training within the Institute’s laboratories and clinical facilities in Bethesda, Maryland, and at the Phoenix Epidemiology and Clinical Research Branch in Arizona.

The Division has 12 Branches and 10 Laboratories that cover a wide range of research areas. In addition, there is a section on veterinary sciences, a section on biological chemistry, the Office of Technology Transfer, the Office of Fellow Recruitment and Career Development, and an Administrative Management Branch. Six core laboratories provide scientific support services to investigators.

The Intramural Branches engage in both basic and clinical research on diabetes, bone metabolism, endocrinology, obesity, hematology, digestive diseases, kidney diseases, kidney transplantation, and genetics. Additionally, the Phoenix Branch develops and applies epidemiologic and genetic methods to the study of diabetes and obesity. The tenth branch addresses mathematical modeling of biological problems.

The Laboratories are engaged in fundamental research related to the Institute’s mission in the fields of molecular biology, structural biology, chemistry, cell biology, pharmacology, chemical physics, biochemistry, neuroscience, developmental biology, and mathematical modeling of biological problems.

The Laboratory Animal Science section provides research animal support and collaboration for Institute research programs. The 6 core laboratories provide services to interested NIDDK scientists in the areas of proteomics and mass spectrometry, microarray, chemical biology, mouse metabolism/transgenic support, biotechnological support, and knockout mice.

**Division of Diabetes, Endocrinology and Metabolic Diseases**

The DEMD supports research and research training related to diabetes mellitus, endocrinology, and metabolic diseases, including cystic fibrosis. In addition, the Division leads the administration of the Trans-NIH Diabetes Program and coordinates federally supported diabetes-related activities.

**Diabetes Research Programs**
The Adipocyte Biology Research Program encompasses research that addresses the development and physiology of the adipocyte cell. Specific areas of support include studies on the properties of transcription factors that regulate adipocyte differentiation; research on the consequences of insulin action on adipocyte physiology; and use of animal and tissue culture models to understand adipocyte biology.

The Autoimmunity/Viral Etiology of Type 1 Diabetes Research Program emphasizes support of investigator-initiated basic and clinical research relating to autoimmune endocrine diseases, including type 1 diabetes and autoimmune thyroid disease (AITD). Applications that address the etiology and pathogenesis of type 1 diabetes, immunology, and viral etiology of diabetes are included. Studies utilizing animal models to further our understanding of type 1 diabetes are of continuing interest to this program. Studies that emphasize autoimmune thyroid disease, including Graves' disease, Hashimoto's thyroiditis, and their complications, are included. Humanized animal models ofAITD are also included.

The Behavioral/Prevention Research Program encompasses individual, family, and community-based strategies aimed at prevention of diabetes and its complications through lifestyle modifications, education, and other behavioral interventions. Particular emphasis is placed on development of culturally sensitive, lifestyle interventions to prevent or treat diabetes in diverse high-risk populations including African Americans, Hispanic Americans, and Native Americans. Specific areas of research include the link between behavior and physical health as it relates to diabetes and complications; approaches to improving health-related behaviors and to enhancing diabetes self-management; and other aspects of diabetes care.

The Beta Cell Therapy Research Program focuses on research to develop alternative cell or tissue sources, as well as an understanding of the basic mechanisms that support regeneration or neogenesis of pancreatic islets. This program supports research in the following areas:

- Developing methods to expand pancreatic islets or beta cells for transplantation
- Optimizing growth conditions for islet cell proliferation and differentiation
- Deriving pancreatic islets from stem/precursor cells
- Assessing alternative cell or tissue sources by transplantation
- Animal models of islet regeneration and neogenesis.

The Clinical Inlet Transplantation Consortium develops and implements a program of single- and/or multi-center clinical studies, accompanied by mechanistic studies, in islet transplantation with or without accompanying kidney transplantation, for the treatment of type 1 diabetes.

The Clinical Research in Type 2 Diabetes Program will focus on patient-oriented research (i.e., clinical studies and small clinical trials) related to:

- Pharmacologic interventions and/or lifestyle interventions to prevent or treat type 2 diabetes, including studies relevant to new drug development
- Development of surrogate markers for use in clinical trials for the prevention or treatment of type 2 diabetes
- Cellular therapies for the treatment of type 2 diabetes
- Improving the care of patients with type 2 diabetes

The Complications of Diabetes Research Program encompasses basic and clinical research related to acute (e.g., ketoacidosis and hyperosmolar coma) and chronic complications of type 1 and type 2 diabetes. Chronic complications include the vascular complications of diabetes and the effects of diabetes on any organ system. Clinical studies supported under this program include strategies to prevent or treat the complications of diabetes. Supported basic research examines the molecular and cellular mechanisms by which hyperglycemia mediates its adverse effects and the interrelationships among the mechanisms potentially involved in the pathogenesis of complications, including increased polyol pathway flux, alteration of intracellular redox state, oxidative stress, glycation of structural and functional proteins, altered expression of growth factors, enhanced activity of PKC, impaired synthesis of nitric oxide and other vasoactive substances, and altered metabolism of fatty acids.

The Developmental Biology Research Program supports research related to developmental genetic screens for identifying mutations that affect the formation of tissue such as bone, adipose, endocrine pancreas, or pituitary. Specific areas of support also include signals, signaling pathway components, and transcriptional factors that regulate pattern formation in the embryo, or control the fate, specifications, proliferation, and differentiation of cells in the formation of tissues and organs.

The Diabetes Centers Program administers 2 types of center awards, the Diabetes Endocrinology Research Centers (DERC) and the Diabetes Research and Training Centers (DRTC). An existing base of high-quality diabetes-related research is a primary requirement for establishment of either type of center. While not directly funding major research projects, both types of center grants provide core resources to integrate, coordinate, and foster the interdisciplinary cooperation of a group of established investigators conducting research in diabetes and related areas of endocrinology and metabolism. The 2 types of centers differ in that the DERC focuses entirely on biomedical research, while the DRTC has an added component in training and translation.

The Diabetes Mellitus Interagency Coordinating Committee (DMICC), established in 1974 and chaired by the DDEM Director, includes representatives from all Federal departments and agencies whose programs involve health functions and responsibilities relevant to diabetes mellitus and its complications. Functions of the DMICC include coordinating the research activities of NIH and those activities of other Federal programs that are related to diabetes mellitus and its complications; ensuring the adequacy and soundness of these activities; and providing a forum for communication and exchange of information necessary to maintain coordination of these activities.

The Drug Discovery Program supports:

- Interdisciplinary activities and resources that increase understanding of physiological and pathophysiological processes relevant to therapeutic development in diabetes, endocrine, and metabolic disorders
- Research that seeks to elucidate molecular structures or biological pathways that may lead to the identification and validation of targets that can be potentially manipulated by ligands/inhibitors. “Druggable” molecular targets/pathways
Studies of the potential bioavailability of compounds, the ability to modulate selectively the function of drug discovery targets, and the ability to translate biological endpoints of preclinical research to the clinic showing high potential for success in later stage drug development.

Development of high-throughput assays based on biologic pathways likely involved in the pathogenesis of diabetes and its complications that could be used to screen molecular libraries for novel therapeutic agents.

Research that seeks to discover new mechanisms of action for therapeutics used for diabetes, endocrine, and metabolic disorders, and the development and validation of disease models to evaluate novel therapeutics for these disorders.

The Endocrine Pancreas Research Program includes projects to elucidate the basic biology of the endocrine cells of the pancreas, which include alpha, beta, and delta cells within the islet. These include insulin or other hormone synthesis and secretion; coupling of nutrient sensing to insulin secretion; cell interactions; role of incretins, cytokines, other hormones, and enervation; studies of apoptosis and cell turnover in the adult organ; metabolism, basic signal transduction, and regulation of gene transcription, especially as these areas relate to beta cell and islet function. This program also contains studies in cell culture to bioengineer glucose-responsive hormone-secreting cells or islets for eventual treatment of diabetes.

The Environmental Determinants of Diabetes in the Young (TEDDY) Program is a multi-center, multi-national, epidemiological study to identify infectious agents, dietary factors, or other environmental exposures that are associated with increased risk of autoimmunity and type 1 diabetes.

The Genetics of Type 1 Diabetes Research Program seeks to identify the genes that predispose to the development of type 1 diabetes and studies to determine their mechanism. Specific areas of support include:

- Studies of animal models of type 1 diabetes such as the NOD mouse and the BB rat to identify genes responsible for the development of type 1 diabetes.
- Studies of the HLA region that contains the major genetic determinant for type 1 diabetes to understand its contribution to the development of diabetes.
- Studies of immune regulatory regions that may contribute to both type 1 diabetes as well as other autoimmune disorders.
- Development of genetic resources and patient samples for studies of type 1 diabetes.
- Creation of animal models for therapeutic trials.

The Genetics of Type 2 Diabetes Research Program seeks to identify genes that contribute to the development of type 2 diabetes mellitus. Specific areas of support include using animal models to identify diabetes genes; studies using quantitative statistical methods to identify diabetes genes in human populations; and development of genetic resources, patient samples, and methods for studying genetic linkage for diabetes.

The Glucose Sensors Research Program will contain projects aimed at developing or implementing glucose sensors that can determine glucose concentration in the plasma, interstitial fluid, or other appropriate space in diabetic patients continuously or in repeated samples. This program also includes development of the necessary components of glucose sensors (such as biocompatible materials or fluorescent glucose ligands, new sampling systems, etc.), software, mathematical algorithms and circuitry designed for calibration or insulin pump control, and devices that combine these sensors with insulin delivery systems in a "closed-loop" artificial pancreas.

The Hypoglycemia in Diabetes Research Program encompasses clinical and basic studies on the pathogenesis, prevention, treatment, and sequelae (including hypoglycemia unawareness) of hypoglycemia in both type 1 and type 2 diabetes. Specific areas of research include studies to identify the neuronal and hormonal systems involved in recognition and response to hypoglycemia; examine the interplay of counterregulatory endocrine responses; and ascertain the regulatory mechanisms for glucose homeostasis and the cells involved in this regulation.

The Insulin Receptor/Structure/Function/Action Research Program encompasses studies of the structure, function, and action of the insulin receptor. Specific areas of support include:

- Molecular analysis of ligand binding to receptor.
- Activation of the tyrosine kinase.
- Subsequent insulin receptor function in signal transduction by serving as a platform for the attachment of downstream signaling molecules involved in insulin action.
- Insulin Receptor Signaling proteins (IRS)-1,2,3,4, and other proteins containing Src Homology Domains (e.g., SH2).

The Islet Transplantation Research Program encompasses studies of therapeutic or preclinical approaches to treat diabetes. Specific areas include:

- Transplantation of pancreas, pancreatic endocrine cells (islets or beta cells), beta cells in culture or other insulin-producing cells in humans or animal models (including procedures to enhance tolerance, encapsulate/immunoisolate islets or other means to improve transplant survival). The program also includes gene therapy or other approaches to manipulate islets to improve viability, durability, or other aspects of transplantation.

The Molecular and Functional Imaging Program comprises projects that employ novel molecular and functional imaging techniques to visualize various aspects of diabetes and obesity, endocrinology, metabolism, and metabolic diseases. The emphasis will be on in vivo techniques (PET, MRI, Ultrasound, CT, optical tomography, etc.), with applications serving to tag tissues and cells of interest; study biological processes in vivo; diagnose disease; or monitor progress during therapy. These will be studies either to monitor physiological or metabolic processes, rate of metabolism, blood flow, sites of hormone action, etc., using imaging and spectroscopic techniques or to identify cell types using molecular imaging probes. Another application might be the technology to develop a probe to identify in vivo the sites within the hypothalamus that control satiety.

The Mouse Metabolic Phenotyping Program contains a consortium of centers with the purpose of phenotyping mouse models of diabetes and its complications, obesity, or other chronic metabolic diseases. It will include the development of new tests for phenotyping mice, adaptation or miniaturization of existing tests, as well as the performance of these tests to more fully characterize new or existing models of disease. Emphasis is placed on noninvasive or minimally invasive technologies that can be used for longitudinal studies, but this program also includes high-throughput metabolic screens. Examples include glucose and insulin...
clamps; miniaturized assays for hormones, cytokines, nutrients, or intermediary metabolites; kinetic measures of metabolic processes; immunological parameter; measurements of energy balance, body composition, and activity; measures for metabolic, behavioral, and physiologic abnormalities during disease progression.

The National Diabetes Data Group (NDDG) serves as the major Federal focus for the collection, analysis, and dissemination of data on diabetes and its complications. Drawing on the expertise of the research, medical, and lay communities, the NDDG initiates efforts to:

- Define the data needed to address the scientific and public health issues in diabetes
- Foster and coordinate the collection of these data from multiple sources
- Identify important data sources on diabetes, and analyze and promulgate the results of these analyses to the scientific and lay public
- Promote the timely availability of reliable data to scientific, medical, and public organizations and individuals
- Modify data reporting systems to identify and categorize more appropriately the medical and socioeconomic impact of diabetes
- Promote the standardization of data collection and terminology in clinical and epidemiologic research
- Stimulate development of new investigator-initiated research programs in diabetes epidemiology.

The National Diabetes Education Program (NDEP), co-sponsored by the NIDDK and the CDC, is focused on improving the treatment and outcomes for people with diabetes, promoting early diagnosis, and ultimately preventing the onset of diabetes. The goal of the program is to reduce the morbidity and mortality associated with diabetes through public awareness and education activities targeted to the general public, especially those at risk for type 2 diabetes, people with diabetes and their families, health care providers, and policy makers and payers. These activities are designed to:

- Increase public awareness that diabetes is a serious, common, costly, and controllable disease that has recognizable symptoms and risk factors
- Encourage people with diabetes, their families, and their social support systems to take diabetes seriously and to improve practice of self-management behaviors
- Reduce disparities in health care in racial and ethnic populations disproportionately affected by diabetes
- Alert health care providers to the seriousness of diabetes, effective strategies for its control, and the importance of a team care approach to helping patients manage the disease. Toward these ends, the NDEP is developing partnerships with organizations concerned about diabetes and the health care of its constituents.

The Prevention of Type 1 Diabetes Research Program includes studies on drug development and cellular therapy that are being proposed to prevent type 1 diabetes. Areas of particular interest are:

- Studies on drug development for type 1 diabetes treatment or prevention
- Studies including the creation of animal models for therapy trials or humans to maintain normal blood glucose levels
- Tolerance induction for prevention of type 1 diabetes
- Immune intervention
- "Humanized" mouse model (development of transgenic NOD with human HLA molecules on the T cells) for type 1 diabetes
- Development of therapies for prevention of impaired Glucose Tolerance (IGT) or interventions to prevent conversion of IGT to type 1 diabetes
- Drugs designed to enhance peripheral glucose metabolism or reduce hepatic glucose production of type 1 diabetes
- Therapies designed to increase insulin sensitivity of type 1 diabetics.

The Type 1 Diabetes Clinical Trials Program supports large, multi-center clinical trials conducted under cooperative agreements or contracts. One primary prevention trial has concluded. The Diabetes Prevention Trial Type 1 (DPT-1) [http://www.niddk.nih.gov/patient/dpt_1/dpt_1.htm] was aimed at determining whether it was possible to prevent or delay the onset of type 1 diabetes in individuals determined to be at immunologic, genetic, and/or metabolic risk. It also supported future clinical trials of the Type 1 Diabetes TrialNet, which will conduct intervention studies to prevent or slow the progress of type 1 diabetes, and natural history and genetics studies in populations screened for or enrolled in these studies. The program also supports the Epidemiology of Diabetes Interventions and Complications (EDIC) study, an epidemiologic follow-up study of the subjects previously enrolled in the Diabetes Control and Complications Trial (DCCT) [http://www.niddk.nih.gov/health/diabetes/pubs/dcct/dcct.htm].

The Type 2 Diabetes Clinical Trials Program supports large, multi-center clinical trials conducted under cooperative agreements or contracts. One primary prevention trial is underway. The Diabetes Prevention Program (DPP) is focused on testing lifestyle and pharmacological intervention strategies in individuals at genetic and metabolic risk for developing type 2 diabetes to prevent or delay the onset of this disease.

The Type 2 Diabetes in the Pediatric Population Research Program encompasses research on the pathophysiology, prevention, and treatment of type 2 diabetes in children. Specific areas of support include studies:

- To describe the epidemiology (incidence, prevalence, risk factors) of type 2 diabetes and its complications in children
- To develop diagnostic criteria to distinguish type 1 and type 2 diabetes in children
- To define the metabolic abnormalities (and the natural history of such abnormalities) in children with type 2 diabetes
- To develop practical, effective strategies for the prevention and/or treatment of type 2 diabetes in children
- To understand the basis for race/ethnic disparities in the incidence of type 2 diabetes in the pediatric population.
The **Bone and Mineral Metabolism Research Program** encompasses basic and clinical research on the hormonal regulation of bone and mineral metabolism in health and disease. Specific areas of support include:

- Endocrine aspects of disorders affecting bone, including osteoporosis, Paget's disease, renal osteodystrophy, and hypercalcemia of malignancy
- Pathogenesis, diagnosis, and therapy of parathyroid disorders, including primary or secondary hyperparathyroidism;
- Effects of parathyroid hormone, parathyroid hormone-related protein, calcitonin, vitamin D, estrogen, retinoic acid, growth factors (e.g., IGF-I), glucocorticoids, thyroid hormone, and other systemic or local-acting hormones and their receptors on bone metabolism
- Bone active cytokines (e.g., TGF-b, BMPs, CSF-1)
- Studies of calcium homeostasis, absorption, metabolism, and excretion, including the calcium-activated receptor
- Basic and clinical studies of vitamin D
- Bone morphogenesis, including the roles of developmental factors in bone formation (e.g., hedgehogs, Hox genes)

The **G-Protein Coupled Receptors Program** encompasses studies on the G-protein coupled receptor superfamily. Specific areas of support include:

- Cell surface, or 7-transmembrane domain, receptors coupled to GTP-binding (“G”)-proteins for signal transduction (e.g., beta-adrenergic receptor)
- Receptor structure
- Receptor down-regulation (homologous desensitization)
- Role(s) of mutated receptors in disease
- Coupling of signaling through the receptor to other membrane-bound effectors and or regulators, such as adenylyl cyclase, ion channels, protein phosphatases or kinases, and other receptors.

Signal transduction through GPCRs also includes mechanisms of regulation of gene expression through nuclear proteins such as the Cyclic Nucleotide Response Element Binding Protein (CREB) and the CREB-binding protein.

The **Integrative Biology of Obesity Program** supports both basic and clinical research investigating the neural and endocrine mechanisms contributing to obesity and the pathophysiological consequences of obesity, particularly type 2 diabetes. Also included are studies that explore the neuronal and peptidergic pathways regulating food intake and other behaviors influencing body adiposity. Thus, proposals encompassed by this program will take an integrative approach to the goal of elucidating the physiological and behavioral factors contributing to the etiology of obesity. Clinical studies that expand on basic research findings and/or explore basic mechanisms involved in human obesity are encouraged. Examples of areas of interest include: Neurobiology of human obesity and behavior, neuropeptides and their receptors involved in the regulatory pathways controlling feeding behavior, satiety and energy expenditure, intrauterine and neonatal environment in the development of obesity, and imaging of neural pathways involved in the regulation of food intake.

The **Intracellular Signal Transduction Research Program** encompasses research aimed at understanding the structure and function of intracellular signal-transducing molecules. Specific areas of support include:

- Intracellular kinases, phosphatases, and anchoring proteins
- Signaling mechanisms that have altered activity in response to protein phosphorylation, calcium, and cAMP
- Approaches to solving the 3-dimensional structure of signaling proteins including crystallography and NMR
- Functional analysis of these proteins, including comparison of wild-type and naturally occurring or synthetic, mutant proteins, or expression of dominant-negative forms of the proteins
- Microscopic techniques to localize these proteins within cells
- Identification of substrates for these signaling proteins
- Analysis of crosstalk among distinct signal transduction pathways

The **Neuroendocrinology Research Program** encompasses research on neuropeptides of the hypothalamus. Specific areas of research support include:

- Physiological response to stress through the hypothalamic-pituitary-adrenal axis
- Neuropeptides and neuropeptide receptor signaling pathways
- Gene regulation in the hypothalamus and pituitary gland
- Diseases of the pituitary including neoplasia
- Hypopituitary dwarfism
- Identification and characterization of novel hypothalamic or pituitary hormones
- Tissue-specific and developmental expression of pituitary and hypothalamic genes
- Pituitary hormone receptors and actions on target tissues (e.g., GH IGF-1 axis)
- Neuropeptide receptors in diagnosis and treatment of disease
- Neuroendocrine-immune interactions

The **Nuclear Receptor Superfamily Program** encompasses basic and clinical research on members of the steroid hormone superfamily (also known as the nuclear receptor superfamily). The program includes structure/function studies and the role in signal transduction and regulation of gene expression of:
- Steroid hormones, including glucocorticoids, mineralocorticoids, progesterone, estrogens, androgens (testosterone), and DHEA
- Nuclear receptors, including thyroid hormone, vitamin D, retinoids (RAR, RXR, vitamin A), PPARs, and orphan receptors (LXR, Nur77, COUP-TF, and others).

Topics covered include receptor structure, interaction with cytoplasmic chaperones (e.g., Hsp90, Hsp70, etc.), interaction with ligand, nuclear translocation, binding to hormone response elements, interaction with nuclear accessory proteins (e.g., SRC-1, N-CoR, CBP, histone acetylase/deacetylase, GRIP1, etc.), and regulation of gene expression.

The **Regulation of Energy Balance and Body Composition Research Program** encompasses research on regulation of body composition by the hypothalamus and circulating factors. Specific areas of support include:

- Endocrinology of body composition, including interactions between nutrition, exercise, and anabolic hormones
- Neuropeptides and their receptors involved in regulatory pathways controlling feeding behavior, satiety, and energy expenditure
- Interactions between hypothalamic-pituitary adrenal axis and peripheral metabolic signals (e.g., insulin), leptin, and glucocorticoids
- Hormones and cytokines involved in wasting syndromes (e.g., cancer, AIDS)
- Endocrine regulation of energy balance via uncoupling proteins
- Hypothalamic integration of peripheral endocrine and metabolic signals

**Metabolic Diseases Research Programs**

The **Functional Metabolomics Program** includes grants focused on the application of technology used to measure large-scale integrated metabolism of cells, tissues, and organ systems. These studies can be done in vivo, in isolated tissue, or in cell culture. They have a focus on applying novel technology advancements in measuring and identifying many metabolites within multiple pathways. Emphasis is on discovering new, potentially mechanistic relationships between changes in metabolite profile and the etiology or pathology of specific metabolic diseases or syndromes that fall within NIDDK's scope of research. Important goals include in vivo and translational potential of technology to rapidly analyze and interpret large networks of pathways and fluxes to gain a more complete view of metabolome dynamics.

The **Gene Therapy and Cystic Fibrosis Centers Program** supports 3 types of centers: Gene Therapy Centers (P30), Cystic Fibrosis Research Centers (P30), and Specialized Centers for Cystic Fibrosis Research (P50). Gene Therapy Centers provide shared resources to a group of investigators to facilitate development of gene therapy techniques and to foster multidisciplinary collaboration in the development of clinical trials for the treatment of cystic fibrosis and other genetic metabolic diseases. Cystic Fibrosis Research Centers and Specialized Centers for Cystic Fibrosis Research provide resources and support research on many aspects of the pathogenesis and treatment of cystic fibrosis.

The **Cystic Fibrosis Research Program** supports investigator-initiated research grants encompassing both fundamental and clinical studies of the etiology, molecular pathogenesis, pathophysiology, diagnosis, and treatment of cystic fibrosis and its complications. Particular areas of emphasis of the program include:

- Characterization of the cystic fibrosis gene, its mutations, and the molecular mechanisms by which mutations cause dysfunction
- Studies of the cystic fibrosis transmembrane regulator (CFTR) protein encoded by the cystic fibrosis gene, including its processing, trafficking, and folding, and the mechanisms by which mutations alter CFTR trafficking and structure/function
- Elucidation of the pathways of electrolyte transport in affected epithelia and the relationship between CFTR and other epithelial ion channels
- Elucidation of the potential roles of CFTR in the transport of molecules other than chloride, posttranslational processing of mucins and other proteins, exocytosis and recycling of cell membranes, subcellular organelle function, and other cellular processes
- Studies of the relationship between genotype and phenotype in cystic fibrosis and identification of genetic or environmental factors that explain the variable clinical presentations and severity of disease
- Delineation of the mechanisms underlying the inflammation and infection characteristic of cystic fibrosis. Analysis of how mutations in the cystic fibrosis gene and alterations in CFTR function result in inflammation and infection
- Research on other clinical manifestations of cystic fibrosis, including the pathophysiologic mechanisms underlying malnutrition and growth failure, impaired fertility, liver disease, and overall physical and psychosocial development. Investigation of approaches to ameliorate the complications of cystic fibrosis
- Development of potential therapeutic approaches to modulating the transport defect in cystic fibrosis and to stabilize mutant CFTR and enhance its targeting and integration into the cell membrane
- Development of safe and effective methods for gene therapy
- Development of animal or cell models useful for studying cystic fibrosis and its therapy
- Evaluation of therapeutic interventions in cystic fibrosis in clinical studies or animal models

The **Gene Therapy Research Program** encompasses research aimed at developing basic and applied gene therapy for genetic metabolic diseases. Specific areas of support include:

- Pilot and feasibility studies (R21) to improve gene delivery systems
- Studies of the basic science of AAV, adenovirus, retrovirus, and lentivirus vectors
- Studies of non-viral methods of gene transfer such as liposomes or DNA-conjugates
- Studies to target gene delivery to specific cell types
- Gene therapy of stem cells to treat a genetic metabolic disease
The *Genomic Resource and Technology Development Program* supports projects that take advantage of recent development in genetic analysis, genomic-based technologies, and systems biology to propose innovative ways of understanding the biological networks behind diseases of interest to NIDDK, such as metabolic disease. Emphasis will be put on assembling a community of researchers to propose integrated approaches and develop new tools to solve complex problems that are difficult to tackle in a traditional laboratory setting and that require multi-disciplinary teams. Areas of interest include:

- Genome-wide analysis of transcriptional regulatory networks in health and disease
- Tissue development and regeneration
- Functional genomics in disease-relevant organs under normal and pathological conditions
- Forward and reverse chemical genetics to explore regulatory networks involved in disease biology
- Development of high-throughput, cell-based screening platforms to interrogate basic and disease biology
- Development of partnerships and integrated research projects between physicians, geneticists, computational scientists, biochemists, and others, to better identify the underlying causes of complex diseases

The *Inborn Errors of Metabolism Research Program* encompasses research in the pathophysiology and treatment of genetic metabolic diseases. Specific areas of support include:

- Studies of etiology, pathogenesis, prevention, diagnosis, pathophysiology, and treatment of these diseases
- Characterization of the genes, gene defects, and regulatory alterations that are the underlying causes of these diseases
- Studies of the mutant enzyme and its effect on the structure and function of the protein
- Development of animal models for genetic disease
- Development and testing of dietary, pharmacologic, and enzyme replacement therapies
- Development of stem cell transplantation both prenatally and postnatally as a treatment for metabolic diseases

The *Integrative Metabolism and Insulin Resistance Program* comprises grants that study intermediary metabolism and physiology on the whole-body, organ, and cell level. These studies can be done in vivo, in isolated tissues, or in cell culture. They focus on flux and regulation of either a single metabolic pathway, interacting pathways in a cell or organ, or interactions between organs in the whole body. Especially important are in vivo measurements of whole-body flux, such as glucose production or turnover, or blood flow. Examples of important goals for these studies include an understanding of insulin resistance, regulation of gluconeogenesis and glucose disposal, protein turnover rate and regulation, cellular and whole-body lipid fluxes, interaction between carbohydrate and lipid metabolism, rate of tricarboxylic acid cycle flux and energy production in the cell, transcriptional regulation of important flux regulating enzymes or transporters for a given pathway, etc.

The *Metabolomics Technology Development Roadmap Program* promotes development of novel technologies to study cellular metabolites, such as lipids, carbohydrates, and amino acids. Knowledge gained from these studies will be used to understand more precisely the role of metabolites in the context of cellular pathways and networks.

The *Protein Trafficking/Secretion/Processing Research Program* encompasses research aimed at understanding the mechanisms that account for the fate of proteins after their initial translation. Specific areas of support include:

- Protein folding
- Post-translational modifications and the enzymes that catalyze them
- Movement of proteins in vesicles from the endoplasmic reticulum through the Golgi and endosomes and their ultimate secretion
- Mechanisms that account for vesicle formation (pinching off) and vesicle fusion, which are paramount to understanding trafficking
- Movement of proteins in the direction opposite of secretion, including endocytosis and retrograde transport
- Proteins and small molecules that regulate protein trafficking
- Proteasomes, ubiquitin conjugation, and the N-end rule

The *Proteomics in Diabetes, Endocrinology, and Metabolic Diseases Program* comprises grants that study the structure, mechanism, kinetics, and regulation of isolated purified proteins. This would include x-ray crystallography, mass spectroscopy, electron microscopy, nuclear magnetic resonance, and mutational studies of structure. It also includes studies of subunit interactions and interactions with small regulatory ligands, substrates, intermediates, and products. Of special interest are new technologies for structure determination (especially membrane proteins), crystallization, identification of interacting molecules and proteins, and assignment of function to unknown gene products of interest to the fields of diabetes, endocrinology, and metabolic diseases. High-throughput methods are highlighted. All informatics associated with the field of proteomics are included.

**Division of Digestive Diseases and Nutrition**

This Division supports research related to liver and biliary diseases; pancreatic diseases; gastrointestinal diseases, including neuroendocrinology, motility, immunology, and digestion in the GI tract; nutrient metabolism; obesity; eating disorders; and energy regulation. The Division provides leadership in coordinating activities related to digestive diseases and nutrition throughout the NIH and with various other Federal agencies.

**Gastrointestinal Disease Programs**
Investigators supported by the Gastrointestinal Motility Program focus their research on the structure of gastrointestinal muscles, the biochemistry of contractile processes and mechanochanical energy conversion relations between metabolism and contractility in smooth muscle, the extrinsic control of digestive tract motility, and the fluid mechanics of gastrointestinal flow. Other studies and areas of interest include the actions of drugs on gastrointestinal motility; intestinal obstruction; and diseases such as irritable bowel syndrome (functional digestive disorders), colonic diverticular disease, swallowing disorders, and gastroesophageal reflux.

The research emphasis of the Gastrointestinal Mucosa and Immunology Program focuses on intestinal immunity and inflammation. Areas of interest include: ontogeny and differentiation of gut-associated lymphoid tissue; migratory pathways of intestinal lymphoid cells; humoral antibody responses; cell-mediated cytotoxic reactions and the role of cytotoxic effector cells in chronic intestinal inflammation; genetic control of the immune response at the mucosal surface; immune response to enteric antigens in both intestinal and extra-intestinal sites; granulomatous inflammation; lymphokines and cellular immune regulation; leukotriene/prostaglandin effects on intestinal immune responses; T-cell mediated intestinal cell injury; the intestinal mast cell and its role in intestinal inflammation; approaches to optimal mucosal immunoprophylaxis, including viral, bacterial, and parasitic diseases; diseases such as gluten-sensitive enteropathy, inflammatory bowel disease, and gastritis; malabsorption syndromes; diarrhea; gastric and duodenal ulcers; disease of the salivary glands (excluding cystic fibrosis); the effects of prostaglandins and other treatment modalities on the gastrointestinal tract; and the possible role of prostaglandins or other agents in the pathogenesis and treatment of digestive diseases.

The Gastrointestinal Neuroendocrinology Research Program supports basic and clinical studies on normal and abnormal function of both the enteric nervous system and the elements within the central nervous system that control the enteric nervous system. Neuroendocrine studies include histochemical and biochemical analyses of the enteric nervous system, electrical properties of enteric ganglia, chemical neurotransmission, neural control of effector function, and extrinsic nervous input. This program places emphasis on gastrointestinal hormones and peptides, including their structure, biological actions, structure-activity relationships, receptors, distribution, quantitation, metabolism, release, correlation with physiological events, deficiency, and the role of time variation in the data collected in the above studies. In addition, the program supports studies on disease conditions associated with excessive or inadequate secretion of neuropeptides.

The Gastrointestinal Transport and Absorption Program supports research on the process of food digestion, and absorption and transport in the gastrointestinal tract, including the synthesis and assembly of digestive enzymes; the transport of water, ions, sugars, amino acids, peptides, lipids, vitamins, and macromolecules; and the formation, structure, and function of chylomicrons. Other areas of research focus on the regulation of gene expression in the gastrointestinal tract; the structure and function of the gut mucosa; the cytoskeletal structure and contractility in brush borders; the growth and differentiation of gastrointestinal cells in normal and disease states; intestinal transplantation, storage, and preservation; and gastrointestinal tissue injury, repair, and regeneration. Also supported are studies on gastrointestinal diseases such as maldigestion and malabsorption syndromes.

The Acquired Immunodeficiency Syndrome Program encourages research into the characterization of intestinal injury, mechanism of maldigestion, and intestinal mucosal functions, as well as hepatic and biliary dysfunction in AIDS. In addition, studies are supported on mechanisms of nutrient dysfunction, deficiencies of various micronutrients, nutritional management of the wasting syndrome, and other aspects of malnutrition related to AIDS.

The Clinical Trials in Digestive Diseases Program supports patient-oriented clinical research focusing on digestive diseases. Small clinical studies (pilot), planning grants or phase III clinical trials may be appropriate to this program. The small clinical studies should focus on research that is innovative and/or potentially of high impact. They should lead to full scale clinical trials. Please see the current program announcement for small grants for clinical trials [http://grants1.nih.gov/grants/guide/pa-files/PAR-01-056.html]. Phase III clinical trials usually are multi-center and involve several hundred human subjects that are randomized to 2 or more treatments, 1 of which is usually a placebo. The aim of the trial is to provide evidence for support of, or a change in, health policy or standard of care. The interventions/treatments may include pharmacologic, nonpharmacologic, and behavioral interventions given for disease prevention, prophyaxis, diagnosis, or therapy. Areas of emphasis include: Helicobacter pylori; inflammatory bowel disease; functional bowel syndrome and constipation; non-ulcer dyspepsia; celiac disease; intestinal failure, short-gut syndrome, and small bowel transplantation.

The Digestive Diseases Research Core Centers Program provides a mechanism for funding shared resources (core facilities) that serve to integrate, coordinate, and foster interdisciplinary cooperation between groups of established investigators who conduct programs of high quality research that are related to a common theme in digestive disease research. An existing base of high-quality digestive disease-related research is a prerequisite for the establishment of a center. The research emphases of centers in this program presently focus on liver diseases, gastrointestinal motility, absorption and secretion processes, inflammatory bowel disease, structure/function relationships in the gastrointestinal tract, neuropeptides and gut hormones, and gastrointestinal membrane receptors. Due to a restriction on the number of core center grants that can be supported, new center grant proposals will be accepted only in response to a Request for Applications (RFA) announced in the NIH Guide for Grants and Contracts.

The Pancreas Program encourages research into the structure, function, and diseases (excluding cancer and cystic fibrosis) of the exocrine pancreas. Research efforts focus on:

- Neurohormonal factors involved in the regulation of pancreatic exocrine function in response to pathophysiological stimuli
- Studies on receptor and function of intra-cellular signal transducing molecules, coupling to downstream effectors
- Compartmentalization of enzymes, substrates, and their effectors
- Understanding post-translational mechanisms that account for the fate of proteins, including folding, trafficking, and secretion
- Understanding the properties and functions of intracellular and extracellular filamentous suprastructures that are involved in hormone signaling and exocrine pancreatic function
- Studies on the biochemistry, etiology, pathogenesis, genetics, epidemiology, diagnosis, treatment, and prevention of disorders of the exocrine pancreas
- Development of experimental models
- Studies relating to development of the exocrine pancreas, including the growth and differentiation factors involved in this process and the characterization, isolation, production, and uses of pancreatic stem cells
In this trial, non-responders to previous treatment with interferon, interferon and ribavirin, or peginterferon were retreated initially with peginterferon alfa-2a.

The NIDDK’s HALT-C study is a multi-center, randomized controlled study designed to determine if long-term treatment with peginterferon in previous non-responders with advanced hepatic fibrosis can prevent cirrhosis and reduce the risk of developing end-stage liver disease and hepatocellular carcinoma. Antiviral therapy with peginterferon and ribavirin leads to a sustained virological response in approximately half of patients with chronic hepatitis C. Patients who achieve a sustained loss of hepatitis C virus (HCV) usually have marked improvements in liver histology. Lesser but important degrees of improvement in liver histology also occur in interferon-treated patients who fail to achieve a virological response. Furthermore, data from a recent controlled study suggest that continuing interferon in non-responder patients can maintain the histological improvements. Interferon therapy may also reduce the incidence of hepatocellular carcinoma and improve survival in patients with cirrhosis.

In this trial, non-responders to previous treatment with interferon, interferon and ribavirin, or peginterferon were retreated initially with peginterferon alfa-2a (Pegasys, Roche Pharmaceuticals) in a dose of 180 mcg/week and ribavirin in a dose of 1,000 to 1,200 mg/day for 24 weeks (the lead-in phase). Those who became HCV RNA negative were continued on treatment for 48 weeks, whereas those who remained HCV RNA positive entered the formal protocol and were randomly assigned either to continue treatment with peginterferon alfa-2a alone (90 mcg/week) for an additional 42 months or be followed without treatment. Patients are followed with outpatient visits and blood tests every three months. Liver biopsies are performed at baseline and after 2 and 4 years of treatment.

The study goal to randomize 900 patients into the controlled phase was achieved in June 2003. This sample size will provide 90% power to detect a decrease in the annual rate of development of cirrhosis or its complications from 6% per year among controls to 3% per year in those treated.
Primary outcome variables to be assessed in the 2 groups of patients include progression to cirrhosis on liver biopsy, development of hepatic decompensation, development of hepatocellular carcinoma, and death.

Secondary outcomes include quality of life and serious adverse events.

The study is being conducted at 10 clinical centers in the United States, with the support of a virology laboratory and a data-coordinating center. The study is also supported by a clinical research and development agreement with Roche Pharmaceuticals and is cosponsored by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Center on Minority Health and Health Disparities.

**NASH Clinical Research Network**—Nonalcoholic fatty liver disease is one of the most common causes of liver disease in the United States, and its prevalence appears to be increasing. In surveillance studies of chronic liver disease, nonalcoholic fatty liver disease is the third most common diagnosis, accounting for 10% of new cases. The spectrum of nonalcoholic fatty liver disease includes simple steatosis, steatosis with inflammation, and what is currently referred to as nonalcoholic steatohepatitis (NASH). The differentiation of simple steatosis from NASH requires liver biopsy, as there are no laboratory tests for this distinction. The diagnosis of NASH requires the presence of fat, inflammation, and centrolobular (zone 3) ballooning degeneration with either pericellular fibrosis or Mallory bodies. This distinction is important because NASH is believed to be a progressive liver disease that can lead to cirrhosis and even hepatocellular carcinoma, whereas simple steatosis or fatty liver is usually non-progressive and benign. In some cases, however, patients with steatosis alone are later found to develop full-blown NASH. Clinical features, serum aminotransferase elevations, and hepatic imaging studies showing changes suggestive of fatty liver are not adequate alone or in combination to distinguish simple steatosis from NASH. These considerations make it difficult to evaluate the natural history and course of nonalcoholic fatty liver disease or better define the need for therapy or intervention. The causes of NASH are not well defined, but it typically occurs in association with obesity, insulin resistance or type 2 diabetes, and hyperlipidemia, suggesting that fatty liver and NASH are hepatic manifestations of the dysmetabolic syndrome, and might better be referred to as metabolic steatohepatitis (MESH). The lack of clear understanding of the pathogenesis of NASH, its natural history, prognostic features, and treatment all underscore the need for clinical and basic research into this important liver disease.

In response to these needs, NIDDK initiated a request for applications (RFA) to create a multicenter study on the natural history, pathogenesis, and therapy of NASH. The RFA was published in February 2002, and 8 clinical centers and a data coordinating center were awarded in September 2002. Cofunding to allow for expansion of the pediatric component was provided by the National Institute of Child Health and Development (NICHD). The NASH Network will create both a prospective and retrospective database of adult and pediatric cases of nonalcoholic fatty liver disease that will be evaluated and followed prospectively in a standardized fashion. A pathology committee has proposed a standardized system for histological grading and staging and has initiated studies of its reliability and reproducibility. The Network has also developed plans to conduct randomized controlled trials of promising therapies of NASH, both in children and in adults. These studies will focus initially on use of insulin-sensitizing agents and vitamin E. Endpoints of therapy will be based on histological improvements using the standardized grading and staging systems that are currently being refined. An important component of the NASH Clinical Research Network is to develop a cohort of patients and a collaborative group of clinical and basic researchers to generate hypotheses and develop ancillary studies using the resources of the database. These ancillary studies may be in the area of laboratory research or clinical investigation and will focus on pathogenesis and determinants of progression and severity.

**Biliary Atresia Clinical Research Consortium**—Neonatal liver disease affects 1 in 2,500 live births, and its major cause is biliary atresia. At present, biliary atresia is the single most common reason for liver transplantation in children and is a major challenge for early detection, diagnosis, and management. At the same time, the underlying cause of biliary atresia is unclear. The disease is congenital but does not appear to be familial or inherited. Various hypotheses have been advanced to explain the occurrence of biliary atresia, but none have proven to be true or to lead to a practical means of early detection, diagnosis, treatment, or prevention. Because biliary atresia and other forms of neonatal liver disease are rare, no single referral center in North America cares for enough new patients each year to allow for intensive analysis of etiology and risk factors or to critically assess novel means of diagnosis or treatment. For these reasons, NIDDK established a Biliary Atresia Clinical Research Consortium (BARC). The consortium is charged with establishing and maintaining the infrastructure for accruing sufficient numbers of biliary atresia and neonatal hepatitis patients to perform adequately powered clinical studies. The overall goal of this consortium is to gather clinical and biochemical data and adequate numbers of serum, tissue, and DNA samples in a prospective manner to facilitate research and generate new hypotheses and test existing hypotheses on the pathogenesis and optimal diagnostic and treatment modalities of these disorders. It is also hoped that the establishment of this consortium and the serum and tissue bank will stimulate other scientists to develop an interest in investigating the etiology and pathogenesis of these disorders and collaborate with the consortium, with serum and tissue being made available for appropriate studies. The study is funded by NIDDK and the Office of Rare Disorders. At present, BARC consists of 9 liver disease Clinical Centers and a Data Coordinating Center.

**Adult-to-Adult Living Donor Liver Transplantation Cohort Study**—Liver transplantation is now the standard of care for patients with end-stage liver disease. At present, more than 4,500 liver transplants are done yearly. Unfortunately, more than 18,000 patients await liver transplantation, and in recent years, the waiting list has continued to grow. As a consequence, the numbers of patients dying on the liver transplant waiting list has grown. The introduction of the MELD system was designed to assign livers to the patients in most critical need for transplantation and, thereby, decrease the waiting list mortality. While this approach may have been partially successful, the continued shortage of cadaveric livers and continued growth of demand for liver transplantation will mean that the mortality rate on the waiting list will continue to be high.

Among possible remedies to the shortage of cadaveric livers for transplantation, living donor liver transplantation is perhaps the most practicable, but also the most controversial. Living donor liver transplantation has become widely accepted for pediatric patients. For children, the left lobe of an adult liver is adequate for transplantation, and left-lobe living donor liver transplantations (particularly from parent to child) have been done successfully for more than a decade. For adults, transplantation of a left lobe of the liver (approximately 20-30% of the liver mass) is usually inadequate to support life, particularly in a patient already suffering from end-stage liver disease. Transplantation of the right lobe (50-60% of the liver mass) can be successful in adults, but the donor operation is accordingly more extensive and more life-threatening. Adult-to-adult living donor liver transplantation was first accomplished in the late 1990s and was introduced into the United States in 1997 and now accounts for approximately 5% of all liver transplants done in the United States. Nevertheless, the donor operation in adult-to-adult liver transplantation is challenging and potentially dangerous.

To address the issues of proper use, relative risks, and potential benefits of adult-to-adult living donor liver transplantation, NIDDK established a multicenter clinical cohort study. The “Adult-to-Adult Living Donor Liver Transplantation Cohort Study” (AZALL) consists of 9 liver transplant centers experienced in performing
living donor liver transplantation and a data coordinating center responsible for directing and maintaining an infrastructure of a clinical database on patients. The primary goal of A2ALL will be to provide valuable information on the outcomes of living donor liver transplantation. The cohort study will follow both donors and recipients before and after the liver transplant operation to assess clinical outcomes and quality of life. This information is needed to aid decisions made by physicians, patients, and potential donors.

**Hepatotoxicity Network**—Liver injury due to medications is one of the most common causes of acute liver disease and jaundice. Importantly, the mortality rate of hepatic idiosyncratic drug reactions is quite high, and over half of cases of acute liver failure in the United States are due to medications. Elucidation of the mechanisms of hepatic drug injury, however, is often difficult. Drug-induced liver disease is typically unpredictable, idiosyncratic, and rare. Most of the medications that cause acute liver injury in humans do not produce injury in experimental animals. Attribution of acute liver injury to a medication is frequently difficult: the patient with hepatotoxicity often has multiple other risk factors for liver disease, may be on many potentially hepatotoxic drugs, and may not present until the injury resolved. Drug-induced liver injury is also quite variable in clinical expression. Patterns of injury mimic virtually all other forms of liver disease, including acute viral hepatitis, autoimmune liver disease, biliary cholestasis, mixed cholestatic-hepatic syndromes, acute cholangitis, microvascular steatosis with lactic acidosis, alcohol-like steatohepatitis, and venoocclusive disease. Finally, drugs that cause hepatotoxicity are usually withdrawn from use and are no longer available for study.

Despite the clinical significance of drug-induced liver injury, this form of liver disease is a relatively unstudied area of research. Part of the difficulty in studying drug-induced liver disease is the absence of a sufficient cohort of well-characterized patients in whom to carry out clinical, genetic, immunological, and biochemical investigation. To help develop a prospective database on drug-related hepatotoxicity, NIDDK has established a Hepatotoxicity Clinical Research Network. The Network consists of 5 interactive clinical centers and a data coordinating center. The objective of the Network is to develop standardized definitions and instruments to identify and characterize bone fide cases of drug-induced liver injury. Researchers could then analyze the epidemiology and clinical spectrum of hepatotoxicity and identify cases of medication-induced liver disease prospectively. They could also collect biological samples to study the pathogenesis of hepatotoxicity using biochemical, serological, and genetic techniques. The Network will be expected to collaborate with other investigators in the areas of hepatocyte biology and cell injury as well as pharmacokinetics and pharmacogenetics. A repository will be established for storage of serum, tissue, and DNA samples. The Network will be funded as a pilot phase (3 years) which, if successful, will be extended by future RFAs.

**Obesity Research Programs**

The Bariatric Surgery Clinical Research Consortium will provide infrastructure for and facilitate coordinated clinical, epidemiological, and behavioral research in the field of bariatric surgery through the cooperative development of common clinical protocols and a bariatric surgery database. The Consortium will also provide the preliminary data and background for further investigator-initiated research. Consortium goals include a greater understanding of the risks and benefits of bariatric surgery as a treatment; the standardization of definitions and data collection instruments to enhance the ability to provide meaningful evidence-based recommendations for patient evaluation, selection, and follow-up care; basic and clinical studies to explore the mechanisms by which surgery affects obesity-related co-morbid conditions, energy expenditure, nutrient partitioning, appetitive behaviors, and psychosocial factors. Four to six clinical centers and a data coordinating center were funded in September 2003.

The Program on Genetics and Genomics of Obesity supports research to identify genes that influence obesity and related anatomical, physiological, and behavioral traits such as body fat composition and distribution, metabolic rate, energy balance, food consumption and preference, and physical activity levels, as well as research on patterns of gene expression associated with these traits, and mechanisms of regulation of these patterns. The Program supports research on humans as well as model organisms, encouraging both genome-wide and candidate-gene based approaches exploiting naturally occurring genetic variation as well as artificially induced mutations. Typical approaches include genetic linkage, association, and linkage-disequilibrium studies, QTL mapping, phenotype- and gene-driven mutagenesis screens, and macro- and microarray-based surveys of gene expression.

The Obesity and Eating Disorders Program emphasizes support of investigator-initiated basic and clinical research relating to biomedical and behavioral aspects of obesity and eating disorders, particularly binge eating disorder and its relationship to obesity. Areas of research interest include investigations of factors that affect food choices, food intake, eating behavior, appetite, satiety, body composition, nutrient partitioning, physical activity, and energy regulation. The roles of neural and hormonal factors from the molecular to the whole-animal/human level are encompassed within this program if the primary goal of the investigations is to examine their role in the development or maintenance of obesity. The physiological and metabolic consequences of weight loss or weight gain, the effects of exercise and diet composition on appetite and weight control, and the individual variability in energy utilization and thermogenesis are contained within the specific research interests of this program. Investigations incorporating improved methods for assessment of body composition, examination of health risk factors with specific degrees of obesity or body composition, and determination of the effect of exercise on body composition also are supported.

The Obesity Prevention and Treatment Program supports research that focuses on the prevention and treatment of overweight and obesity in humans. Prevention includes primary and secondary approaches to prevent the initial development of overweight/obesity through control of inappropriate weight gain and increases in body fat, weight maintenance among those at risk of becoming overweight, and prevention of weight regain once weight loss has been achieved. Treatment includes clinical trials evaluating approaches to lose weight or maintain weight loss, including but not limited to behavioral, pharmacologic, and surgical approaches. This program also includes environmental, policy-based, and population-based approaches to the prevention and treatment of obesity.

**Look AHEAD: Action for Health in Diabetes** is a clinical trial recruiting 5,000 obese individuals with type 2 diabetes into an 11.5-year study that will investigate the long-term health consequences of interventions designed to achieve and sustain weight loss. The primary outcome of the trial is cardiovascular events: heart attack, stroke, and cardiovascular death. The study also will examine the impact of interventions on cardiovascular risk factors, diabetes control, cost effectiveness, quality of life, and a number of additional measures. The Obesity Special Projects program also administers ancillary studies to Look AHEAD. Recruitment for Look AHEAD was expected to end at most centers by the end of 2003.

As a means of encouraging a multidisciplinary approach to obesity and nutrition research, the Division supports Obesity/Nutrition Research Centers (ONRC). The goal of an ONRC is to help coordinate and strengthen support for research activities primarily by providing funds for core facilities and associated staff that serve the various projects on a shared basis. This approach ensures that an ONRC has multiple sponsors, both Federal and non-Federal, and thereby reduces the likelihood that the ONRC will become unduly dependent on any one source of funds for its continued operation. The specific objectives of an ONRC include efforts to:
Nutrition Sciences Programs

The **Nutrient Metabolism Program** supports basic and clinical studies related to the requirement, bioavailability, and metabolism of nutrients and other dietary components at the organ, cellular, and subcellular levels in normal and diseased states. Specific areas of research interest include:

- Understanding the physiologic function and mechanism of action/interaction of nutrients within the body
- Nutrient influence on gene regulation and expression
- Metabolism and function of nutrient antioxidants
- Effects of environment, heredity, stress, drug use, toxicants, and physical activity on problems of nutrient imbalance and nutrient requirements in health and disease
- Specific metabolic considerations relating to alternative forms of nutrient delivery and use, such as total parenteral nutrition
- Research to improve methods of assessing nutritional status in health and disease

The **Clinical Trials in Nutrition Program** supports clinical research on nutrition and eating disorders, focusing on metabolic and/or physiologic mechanisms. Small clinical studies (pilot), planning grants, or phase III clinical trials may be appropriate to this program. The small clinical studies should focus on research that is innovative and/or potentially of high impact. They should lead to full-scale clinical trials. Please see the current program announcement [http://grants1.nih.gov/grants/guide/pa-files/PAR-01-056.html](http://grants1.nih.gov/grants/guide/pa-files/PAR-01-056.html) for small grants for clinical trials. Phase III clinical trials usually are multi-center and involve several hundred human subjects that are randomized to two or more treatments, one of which is a placebo. The aim of the trial is to provide evidence for support of, or a change in, health policy or standard of care.

**Clinical Nutrition Research Unit (CNRU)** is an integrated array of research, educational, and service activities focused on human nutrition in health and disease. It serves as the focal point for an interdisciplinary approach to clinical nutrition research and for the stimulation of research in areas such as improved nutritional support of acutely and chronically ill persons, assessment of nutritional status, effects of disease states on nutrient needs, and effects of changes in nutritional status on disease. Funding for the CNRU program, which began in 1979, is provided through the core center grant mechanism. Due to a restriction in the number of core center grants that can be supported, new center grant proposals will be accepted only in response to a Request for Applications (RFA) announced in the NIH Guide for Grants and Contracts.

**Other Programs**

- Small Business Innovation Research (SBIR) [http://www2.niddk.nih.gov/Funding/SmallBusiness/NIH_SBIR_STTR+Program.htm]
- Small Business Technology Transfer (STTR) [http://www2.niddk.nih.gov/Funding/SmallBusiness/NIH_SBIR_STTR+Program.htm]
- Training [http://www2.niddk.nih.gov/Funding/TrainingCareerDev/]
- Career Development

**Division of Kidney, Urologic, and Hematologic Diseases**

The Division supports research on diseases of the kidney, genitourinary tract, and blood and blood-forming organs, and on the fundamental biology relevant to these organ systems. It funds training and professional development of investigators in disciplines critical for research in these areas.

**Kidney Research**

The **Basic Renal Biology Program** supports research on normal development, structure, and function of the kidney. Areas of emphasis include glomerular function and cell biology, transport physiology and structure-function analysis of transport proteins, and integrated regulation of solute and water excretion. The program supports investigation of adverse effects of nephrotoxic drugs and environmental toxins and mechanisms of hypoxic renal cell injury.

A major area of strength is studies examining intracellular signal transduction for renal hormones and growth factors. In addition to study on mammalian systems, investigation is supported on transport function and development and genomic analysis of membrane transport proteins using simple systems such as bacteria, *C. elegans*, and zebrafish.

The **Chronic Renal Diseases Program** supports basic and clinical studies on the etiology, prevention, diagnosis, and treatment of chronic renal diseases. Disease categories receiving particular emphasis include analgesic nephropathy, polycystic kidney disease, diabetic nephropathy, glomerulonephritis and other immune
disorders of the kidney, hypertensive nephrosclerosis, and HIV nephropathy. A major interest in this program is renal diseases that affect children and the effects of chronic renal insufficiency on growth and development of children.

The End-Stage Renal Disease Program supports investigation on the pathogenesis of the uremic state, on end-stage renal disease treatment by peritoneal and hemodialysis, and on nutrition in renal disease. Investigation on renal transplantation is supported with particular emphasis on nonimmunological renal injury and on methods of increasing organ availability, particularly in minority populations.

The Diabetic Nephropathy Program supports investigation into the pathogenesis, prevention, and treatment of the kidney disease associated with diabetes mellitus. One major area of emphasis is the identification of genes associated with familial clustering of diabetic kidney disease, through sponsorship of the FIND consortium.

The Pediatric Nephrology Program supports basic and clinical research on the causes, treatments, and prevention of kidney diseases of children. Research efforts focus on inherited and congenital renal diseases; kidney disease of diabetes mellitus; IgA nephropathy; and kidney disease and hypertension, which starts in early childhood.

The Renal Epidemiology Program supports investigation into the incidence and prevalence of renal diseases, the factors associated with increased mortality and co-morbidity, and cost-benefit assessment of prevention and treatment strategies.

The U.S. Renal Data System (USRDS), an information resource for the epidemiology of end-stage renal disease, is supported through this program. USRDS investigation of cost factors in dialysis care is co-funded with the Centers for Medicare and Medicaid Services, formerly known as the Health Care Financing Administration.

Urology Research

The Basic Urology Program supports basic research on the normal and abnormal development, structure, and function of the genitourinary tract. A major area of interest is investigation of the biology of bladder cells, including studies on transport properties, effects of obstruction on patterns of protein expression, and examination of interactions between urinary pathogens and cells of the urinary tract. The program on prostate biology has particular strengths in investigation of prostate cell growth and mechanisms of growth factor signal transduction.

The Clinical Urology Program focuses on research that will increase the knowledge of etiology, diagnosis, pathophysiology, therapy, and prevention of major pediatric and adult urological disorders. Non-malignant disorders of the bladder and prostate, including benign prostatic hyperplasia, interstitial cystitis, urinary tract infections, urinary incontinence, and urolithiasis are areas of emphasis, as are the effects of systemic diseases such as diabetes mellitus, spinal cord injury, and multiple sclerosis on these organs. In addition, the program supports studies of diagnostic and therapeutic modalities such as shock-wave and laser lithotripsy, urolithiasis inhibitors, bladder substitution procedures and devices, and prostate growth inhibitor and reduction therapies.

The Urologic Diseases Epidemiology Program has a major emphasis on developing a source of epidemiological information that may further understanding of natural history, risk factors, and health resource utilization for urologic conditions. Plans are to collect and analyze new and existing data on incidence, prevalence, morbidity, mortality, and health resource utilization associated with various urologic conditions of high public health importance. The information will be presented in a planned publication tentatively titled "Urologic Diseases in America."

Hematology Research

The Hematology Program supports research into the fundamental processes underlying the normal and pathologic function of blood cells and the reticuloendothelial system. Major areas of interest include:

- Genetic regulation of hemoglobin and other proteins of the blood
- Acquired and inherited anemias
- Cell membrane composition and regulatory processes
- Iron metabolism, storage, and transport
- Hematopoiesis and its regulation by growth factors, including erythropoietin
- Transcription and signaling factors such as the JAK/STAT pathway involved in hematopoietic cell differentiation
- Immunohematology
- Hematopoiesis, hematopoietic stem cell biology, and the expression of differentiation potential of hematopoietic stem cells
- Stem cell plasticity and the cellular, molecular, and genetic mechanisms that allow cells to express plasticity

Emphasis is on the application of fundamental knowledge to current issues such as gene transfer therapy and bone marrow transplantation, and disorders such as sickle cell anemia, thalassemia, hemochromatosis, iron deficiency anemia, thrombocytopenia, and hemolytic anemia.

The Chelator Therapy Program supports development of new iron chelating drugs for the treatment of transfusion iron overload, such as in Cooley's anemia, sickle cell disease, and other instances of iron overload. A safe and inexpensive orally active iron chelator that effectively promotes iron excretion is needed urgently, since the only currently available drug, desferrioxamine B, is expensive and is painful and cumbersome to administer, leading to widespread non-compliance among the young adult patient population. Pre-clinical toxicity studies of potential iron chelating drugs are performed under the contract mechanism. Grant support is offered for basic research on the kinetics of iron chelation, the identity of the iron pools addressed, and ways to enhance the chelating activity and reduce the toxicity of known iron chelators.
The Hematopoietic Lineage Genomics Anatomy Program—This program has been initiated to merge the fields of hematopoietic cell biology, including erythroid cell physiology, with bioinformatics. The combination of these two fields will: 1) advance the ability to catalog and monitor genes that are expressed during normal and variant hematopoietic cell differentiation, 2) facilitate a more comprehensive understanding of the dynamics of molecular events that occur during differentiation, and most importantly, 3) develop a quantitative model that incorporates known gene expression data into a description of a red blood cell. This model could then be used to test novel expression patterns as they are discovered and also be used as a scaffold from which to devise models for other tissue and organ development.

Genomics Research

The Genomics Research Program encompasses research on genomics and related technologies in the study of kidney, genitourinary tract, and blood and blood-forming organs. This program also supports model organism genomics research, including the development of genetic tools for high-throughput functional genomics studies. One major programmatic area is the leadership of a major trans-NIH initiative to develop genomics of zebrafish, Danio rerio.

Division of Extramural Activities

The Division of Extramural Activities (DEA) [http://www.niddk.nih.gov/fund/divisions/DEA/DEAintro.htm] is responsible for coordinating the receipt, referral and scientific review of extramural research applications and proposals before funding, and for the processing of awards for grants, cooperative agreements and contracts. It logs in, assigns and internally distributes all extramural applications and proposals received by the NIDDK, and conducts scientific and technical peer review for grant applications and contract proposals requiring special programmatic consideration. The DEA also manages an acquisitions and general contracting service center that services NIDDK and several other NIH Institutes and Centers as well. The DEA also coordinates the Institute’s Committee Management Activities [http://www.niddk.nih.gov/fund/divisions/DEA/committee.htm] and the meetings of the National Diabetes and Digestive and Kidney Diseases Advisory Council [http://www.niddk.nih.gov/fund/divisions/DEA/Council/councildesc.htm]. Finally, the DEA performs and coordinates programmatic analysis and evaluation activities. Organizationally the Division has 3 primary functional components:

- The Grants Management Branch [http://www2.niddk.nih.gov/Funding/Grants/GrantsManagement.htm] is the focal point for all business-related activities associated with the negotiation, award, and administration of grants and cooperative agreements within the NIDDK.

- The Scientific Review Branch [http://www2.niddk.nih.gov/Funding/Grants/GrantReview/] coordinates the initial scientific peer review of applications submitted in response to Request for Applications (RFAs), training and career awards, program projects, multi-center clinical trials and research contracts, including Loan Repayment Program applications. Most R01s, R21s, Fellowship and SBIR grant applications are reviewed in the Center for Scientific Review [http://cms.csir.nih.gov/].

- The Office of Acquisitions [http://www.niddk.nih.gov/fund/divisions/DEA/Amb/AMBintro.htm] plans, organizes, directs, awards, and administers a comprehensive acquisition program for three Institutes and one Center: NIDDK, the National Institute of Child Health and Human Development (NICHD); the National Institute on Alcohol Abuse and Alcoholism (NIAAA); and the John E. Fogarty International Center (FIC).

NIDDK Office of the Director

The NIDDK director created the Office of Minority Health Research Coordination to address the burden of diseases and disorders that disproportionately impact the health of minority populations. The OMHRC will help implement the Institute’s strategic plan for health disparities and build on the strong partnership with the National Center on Minority Health and Health Disparities at NIH.

The NIDDK Office of Obesity Research is responsible for coordination of obesity-related research within NIDDK, and carries out its functions through the NIDDK Obesity Research Working Group. The Office is located organizationally under the auspices of the Office of the Director, NIDDK, and its co-directors represent the two divisions with primary responsibility for obesity-related extramural research, the Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM) and the Division of Digestive Diseases and Nutrition (DDN) and the Division of Diabetes, Endocrinology, and Metabolic Diseases (DEM). The Obesity Research Working Group consists of representatives of DDN, DEM, the Division of Kidney, Urologic, and Hematologic Diseases (KUH), the NIDDK Review Branch, the Office of Scientific Program and Policy Analysis (OSPPA), and the Division of Nutrition Research Coordination (DNRC). The responsibilities of the NIDDK Obesity Research Working Group are: 1) to provide a forum for sharing and coordination of trans-NIDDK and trans-NIH obesity research activities; 2) to assist the Director, NIDDK in identifying research opportunities, initiatives, and advances; 3) to identify and plan appropriate workshops and conferences; and 4) to assist in the preparation of obesity-related reports and inquiries.

Under the auspices of the NIDDK Advisory Council, the National Task Force on Prevention and Treatment of Obesity was established in June 1991. In June 2003, the name was changed to the Clinical Obesity Research Panel (CORP). The mission of the CORP is to synthesize current scientifically based information on the prevention and treatment of obesity and to develop statements about topics of clinical importance that are based on critical analyses of the literature. It is composed of leading obesity researchers and clinicians who advise the Institute on research needs and sponsor workshops on topics related to the prevention and treatment of obesity. The CORP serves in an advisory capacity to the Weight-control Information Network (WIN).

Health Information and Education Services

National Diabetes Information Clearinghouse (NDIC)
National Digestive Diseases Information Clearinghouse (NDDIC)
National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC)

The 3 clearinghouses serve as information resources for patients, the public, and health professionals concerned with diabetes, digestive diseases, and kidney and urologic diseases. Each was authorized by Congress to increase knowledge and understanding about these areas through the effective dissemination of information. The NDIC was authorized by Congress in 1976, the NDDIC in 1980, and the NKUDIC in 1987.
The clearinghouses answer inquiries; develop, print and distribute publications; and work closely with professional and patient-advocacy organizations and U.S. Government agencies to coordinate informational resources about diabetes, digestive diseases, and kidney and urologic diseases.

The clearinghouses also develop and maintain a free, online bibliographic database of reference materials, audiovisuals, educational materials, and “fugitive” literature in its Reference Collection, as well as an image library of free non-copyrighted images, and linkages to relevant interactive resources.

The clearinghouses provide 2 campaigns to increase awareness and action for people with underdiagnosed or undertreated conditions: celiac disease (www.celiac.nih.gov) and bladder control issues in women (www.kidney.niddk.nih.gov/kudiseases/pubs/bladdercontrol/index.htm).

Addresses are:
- NDIC, 1 Information Way, Bethesda, Maryland 20892-3560, phone: 1-800-860-8747;
- NDDIC, 2 Information Way, Bethesda, Maryland 20892-3570, phone: 1-800-891-5389;
- NKUDIC, 2 Information Way, Bethesda, Maryland 20892-3580, phone: 1-800-891-5390.

National Diabetes Education Program (NDEP)

The NDEP, co-sponsored by the NIDDK and the Centers for Disease Control and Prevention (CDC), is focused on improving the treatment and outcomes for people with diabetes, promoting early diagnosis, and ultimately preventing the onset of diabetes. The goal of the program is to reduce the morbidity and mortality associated with diabetes through public awareness and education activities targeted to the general public, especially those with at risk for type 2 diabetes, people with diabetes and their families, health care providers, and policy makers and payers. These activities are designed to 1) increase public awareness that diabetes is a serious, common, costly, and controllable disease that has recognizable symptoms and risk factors; 2) encourage people with diabetes, their families, and their social support systems to take diabetes seriously and to improve practice of self-management behaviors; 3) reduce disparities in health in racial and ethnic populations disproportionately affected by diabetes and 4) alert health care providers to the seriousness of diabetes, effective strategies for its prevention and control, and the importance of a team care approach to helping patients manage the disease. Toward these ends, the NDEP develops partnerships with organizations concerned about diabetes and the health care of its constituents.

NDEP publications are available through the NDEP home page at http://ndep.nih.gov. The mailing address is 1 Diabetes Way, Bethesda, Maryland 20892-3600, phone 800-438-5383.

National Kidney Disease Education Program (NKDEP)

The NKDEP addresses the growing problem of kidney disease in this country and aims to reduce the morbidity and mortality caused by kidney disease and its complications. The program is dedicated to raising awareness of the seriousness of kidney disease and its risk factors, the importance of testing those at high risk, and the availability of treatment to prevent or slow the progression of kidney disease to kidney failure.

NKDEP publications are available through the NKDEP home page at www.nkdep.nih.gov. Contact information for the program is as follows:

National Kidney Disease Education Program
3 Kidney Information Way
Bethesda, MD 20892
Toll free 1-866-4-KIDNEY (1-866-454-3639)
Fax: 301-402-8182
E-mail: nkdep@info.niddk.nih.gov

Weight-control Information Network (WIN)

The WIN is a national information service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH). WIN was established in 1994 to provide health professionals and consumers with science-based information on obesity, weight control, and nutrition. WIN has also developed the Sisters Together: Move More, Eat Better Media program that encourages Black women 18 and over to maintain a healthy weight by becoming more physically active and eating healthier foods. For more information, contact WIN at:

The Weight-control Information Network
1 WIN Way, Bethesda, Maryland 20892-3665
Toll-free number: 1-877-946-4627
Fax: 202-828-1028
Email: win@info.niddk.nih.gov
Internet: www.win.niddk.nih.gov

This page last reviewed on January 3, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892
“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

The mission of the National Institute on Drug Abuse (NIDA) is to lead the Nation in bringing the power of science to bear on drug abuse and addiction. In this regard, NIDA addresses the most fundamental and essential questions about drug abuse—from detecting and responding to emerging drug abuse trends and understanding how drugs work in the brain and body to developing and testing new approaches to treatment and prevention. NIDA also supports research training, career development, public education, and research dissemination efforts. Through its Intramural Research Program, as well as grants and contracts to investigators at research institutions around the country and overseas, NIDA supports research and training on:

- The genetic, neurobiological, behavioral, and social mechanisms underlying drug abuse and addiction;
- The causes and consequences of drug abuse, including the impact on society and morbidity and mortality in selected populations (e.g., ethnic minorities, youth, and women);
- The relationship of drug abuse to other mental illnesses and to psychosocial outcomes such as unemployment, low socioeconomic status, and violence;
- Effective prevention and treatment approaches, including a broad research program designed to develop new medications and behavioral therapies for drug addiction;
- The relationship of drug abuse to cultural and ethical issues such as health disparities; and
- The relationship of drug abuse to the acquisition, transmission, and clinical course of HIV/AIDS, tuberculosis, and other diseases, as well as the development of effective prevention/intervention strategies.

IMPORTANT EVENTS IN NIDA HISTORY

1935—A research facility is established in Lexington, KY, as part of a U.S. Public Health Service (USPHS) hospital. It became the Addiction Research Center in 1948.

1972—Drug Abuse Warning Network and National Household Survey on Drug Abuse are initiated under the Special Action Office for Drug Abuse Prevention.

1974—NIDA is established as the Federal focal point for research, treatment, prevention, training, services, and data collection on the nature and extent of drug abuse.

National Drug and Alcohol Treatment Unit Survey begins to identify the location, scope, and characteristics of public and private drug prevention and treatment programs.

1975—The Monitoring the Future Survey, also known as the High School Senior Survey, is initiated to measure prevalence and trends of non-medical drug use and related attitudes of high school seniors and young adults.

NIDA begins its “Research Monograph Series.” Each monograph contains scientific papers that discuss a variety of subjects including drug abuse treatment and prevention research.

1976—NIDA establishes the Community Epidemiology Work Group, made up of state and local representatives meeting semiannually with NIDA staff to assess recent drug abuse trends and to identify populations at risk.

1979—The clinical research program moves from Lexington, KY, to the campus of the Francis Scott Key Medical Center (later Johns Hopkins Bayview Medical Center) in Baltimore, MD. The basic science program follows in 1985.

NIDA sponsors the Treatment Outcome Prospective Study (TOPS), which continues through 1987 to evaluate the overall effectiveness of treatment and to identify certain factors as important determinants of drug abuse treatment success, such as length of time in treatment.

1985—NIDA publishes the first issue of its bimonthly newsletter, NIDA Notes.

1986—The dual epidemics of drug abuse and HIV/AIDS are recognized by Congress and the Administration, resulting in a quadrupling of NIDA funding for research on both major diseases.

1987—NIDA initiates the National AIDS Demonstration Research projects to study and change the high-risk behaviors of injection drug users not enrolled in drug treatment and their sex partners.
1990—NIDA establishes the Medications Development Program, focusing on developing new medications for treating addiction.

1991—The Monitoring the Future Survey is expanded to include 8th and 10th graders.

NIDA begins data collection for the Drug Abuse Treatment Outcome Study (the successor to TOPS) to assess the effectiveness of treatment in reducing drug abuse and to identify predictors of drug abuse treatment success.

NIDA holds its first research technology transfer conference in Washington, DC: “National Conference on Drug Abuse Research and Practice: An Alliance for the 21st Century.”

1992—NIDA joins the National Institutes of Health (NIH).

1993—The Institute obtains approval from the U.S. Food and Drug Administration (FDA) for levomethadyl acetate (LAAM), the first medication approved in a decade for the treatment of opioid addiction. Although the FDA approval was an important milestone in medications development, subsequent findings revealed more effective treatment options for opioid abuse, resulting in a consensus that the use of LAAM should be discontinued.

1995—NIDA researchers clone the dopamine transporter, cocaine's primary site of action in the brain.

The Institute holds the first “National Conference on Marijuana Use: Prevention, Treatment, and Research” in Arlington, VA.

1996—NIDA dedicates the Regional Brain Imaging Center located at the Institute's intramural research center in Baltimore.

1997—NIDA releases Preventing Drug Use Among Children and Adolescents: A Research-Based Guide, which describes the most successful concepts for preventing drug abuse among young people.

The Institute sponsors “Heroin Use and Addiction: A National Conference on Prevention, Treatment, and Research,” in Washington, DC.

NIDA launches the annual PRISM awards for accurate depiction of drugs, alcohol, and tobacco in feature films and television productions.

1998—NIDA launches the “NIDA Goes to School” initiative to provide middle school students with accurate information on how drugs affect the brain. As a part of this initiative, more than 18,000 middle schools across the country received a compilation of resource materials.

1999—In collaboration with the National Cancer Institute (NCI) and the Robert Wood Johnson Foundation, NIDA creates the Transdisciplinary Tobacco Use Research Centers for studying tobacco use and new ways to combat it and its consequences.

NIDA launches its National Drug Abuse Treatment Clinical Trials Network, to rapidly and efficiently test the effectiveness of behavioral and pharmacological treatments in real-life settings.


NIDA launches the “NIDA Goes to School” initiative to provide middle school students with accurate information on how drugs affect the brain. As a part of this initiative, more than 18,000 middle schools across the country received a compilation of resource materials.


2001—The Institute launches the National Prevention Research Initiative to stimulate research that will fill critical gaps in the knowledge and use of science-based drug abuse prevention strategies in communities across the country.

2002—The Institute launches the new peer-reviewed journal Science and Practice Perspectives to encourage more collaboration between researchers and practitioners.

The FDA approves buprenorphine for the treatment of opioid dependence. NIDA, in collaboration with industry, supported the development of this medication. It is the first form of opioid treatment to be given in a physician’s office.

With support from 8 partner agencies in the U.S. Department of Health and Human Services (HHS) and the Department of Justice, NIDA launches a major research initiative called the Criminal Justice Drug Abuse Treatment Studies (CJ-DATS). The goal of CJ-DATS is to establish a research infrastructure to develop and test models for an integrated approach to the treatment of incarcerated individuals with drug abuse or addictive disorders.

NIDA releases a new elementary school curriculum Brain Power! The NIDA Junior Scientist Program, for use in second- and third-grade classrooms.

NIDA teams with Scholastic, a leading provider of educational materials for children and teachers, in launching a project to bring science-based information about drug abuse to millions of U.S. school children.

NIDA releases Principles of HIV Prevention in Drug-Using Populations: A Research-Based Guide, to help communities prevent the spread of HIV.

2003—NIDA releases its newly updated publication, Preventing Drug Use among Children and Adolescents: A Research-Based Guide for Parents, Educators, and Community Leaders, Second Edition, which reflects NIDA's expanded research program and knowledge base in the area of drug abuse prevention.
2004—NIDA collaborates with the Drug Enforcement Administration and other Federal agencies to design a traveling museum exhibit, which debuted in New York City. This exhibit draws attention to the social, economic, and medical consequences associated with drug abuse.

2005—NIDA expands efforts to understand how drugs of abuse influence brain development through new NIDA research initiatives and collaborations with other NIH Institutes on pediatric neuroimaging studies.

NIDA launches an HIV/AIDS campaign to raise awareness regarding the link between drug abuse and HIV transmission. As a part of this effort NIDA develops a public service announcement that is aired across the Nation and displayed in Washington DC's Metro system. NIDA also develops a dedicated website, creates a "Research Report," and holds a scientific meeting on drug abuse and HIV/AIDS. A Spanish version of the public service announcement is developed for distribution the following year.

2006—NIDA launches its Principles of Drug Abuse Treatment for Criminal Justice Populations: A Research-Based Guide, summarizing proven components for successfully treating drug abusers who have entered the criminal justice system.

2007—NIDA, in collaboration with the Substance Abuse and Mental Health Services Administration (SAMHSA), releases 5 Blending Team products to facilitate the adoption of effective research-based treatment by community practitioners. Products include education and training materials on: treatment protocols using buprenorphine, motivational interviewing, motivational incentives, and the Addiction Severity Index for treatment planning.

NIDA releases its first plain-language booklet explaining the science behind addiction. Drugs, Brains, & Behavior—The Science of Addiction discusses the reasons people take drugs, why some people become addicted while others do not, how drugs work in the brain, and how addiction can be prevented and treated. View Image.

NIDA joins with the Robert Wood Johnson Foundation, the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and HBO to produce the Emmy Award-winning documentary titled "Addiction," which explores many elements of drug and alcohol addiction through the eyes of those who are addicted and features the insights of scientific experts working to better understand and treat this devastating disease.

NIDA holds the first national Drug Facts Chat Day. High school students in schools from 49 states, the District of Columbia, Puerto Rico, the Virgin Islands, and Guam submitted over 36,000 questions on a wide range of drug abuse-related topics. View Images.

2008—NIDA launches its Avant Garde Award program. This award is designed to support HIV/AIDS-focused investigators of exceptional creativity who propose bold and highly innovative research approaches that have the potential to produce a major impact on treatment and/or prevention of HIV/AIDS among drug users.

NIDA launches the first annual Addiction Science award, with Scholastic as co-sponsor (and in subsequent years with Friends of NIDA), at the Intel International Science and Engineering Fair (ISEF), the world's largest science competition for high school students. Three Addiction Science awards were given to talented high school scientists to foster their interest in addiction research.

2009—NIDA launches its first comprehensive Physicians Outreach Initiative, NIDAMED, which gives medical professionals tools and resources to screen their patients for tobacco, alcohol, illicit, and nonmedical prescription drug use.

NIDA unveils a series of new teaching tools, through its Centers of Excellence for Physician Information Program (NIDA CoEs). The new NIDA CoE curriculum resources provide scientifically accurate information on substance abuse, addiction and its consequences to help meet the educational needs of medical students, residents and medical school faculty.

NIDA sponsors its first virtual town hall meeting, bringing together representatives from key federal agencies involved in preventing and combating substance abuse in the United States. Participants were linked via satellite from Washington, DC to Camden, Maine where members of five local communities, as well as community leaders from Freeport, Illinois and Quincy, Washington, talked about their success in implementing the Communities That Care (CTC) system aimed at keeping youth safe from drugs.

NIDA-funded research, published in the October issue of Archives of General Psychiatry, shows promise for treating cocaine addiction. The study is the first successful, placebo-controlled demonstration of a vaccine against an illicit drug of abuse.

NIDA’s director, Dr. Nora Volkow, was awarded the International Prize from the French Institute of Health and Medical Research (INSERM) for her pioneering work in brain imaging and addiction science.

2010—NIDA collaborates with the Department of Veteran Affairs and two NIH institutes to award 11 research institutions in 11 states more than $6 million in federal funding to support research on substance abuse and associated problems among U.S. military personnel, veterans, and their families.

NIDA launches its Avant-Garde Medications Development Research Award program designed to support researchers whose innovative approaches could have a major impact on the development of addiction medications. The newly launched research competition is an extension of NIDA’s successful Avant-Garde Award for Innovative HIV/AIDS Research, now in its third year.

NIDA launches its “NIDA Goes Back to School” campaign and “NIDA for Teens” website in an effort to keep parents, teachers, and teenagers informed about the science behind drug abuse.

NIDA seeks to address the gap that exists in the drug abuse treatment field between clinical practice and basic scientific investigation through the establishment of its “Blending” series of meetings. The 2003 meeting was titled “Blending Clinical Practice and Research: Forging Partnerships in the Rocky Mountain States to Enhance Drug Addiction Treatment.”

In 2001, NIDA launched its first national “Drug Facts Chat Day.” High school students in schools from 49 states, the District of Columbia, Puerto Rico, the Virgin Islands, and Guam submitted over 36,000 questions on a wide range of drug abuse-related topics. View Images.
Two developments in the treatment of opioid addiction herald important advances for addressing this worldwide epidemic: The FDA approves Vivitrol, a long-acting injectable form of naltrexone, for opioid dependence, which could address compliance issues of oral naltrexone by allowing for once a month dosing. Similarly, a study reported in the Journal of the American Medical Association shows promising findings for a long-acting implantable formulation of buprenorphine (Probuphine). NIDA is supporting further research on the clinical efficacy of Probuphine.

NIDA launches three new curriculum resources for NIDAMED’s Centers of Excellence for Physician Information Program: an objective structured clinical exam on opioid risk management; a lecture presentation on how to talk to patients about sensitive subjects, including drug/alcohol abuse, intimate partner violence, and sexual history/concerns; and a methamphetamine lecture and interclerkship that introduces learners to methamphetamine abuse and dependence.

NIDA launches its first annual National Drug Facts Week (NDFW) [http://drugfactsweek.drugabuse.gov/index.php], a health observance week for teens aimed to shatter the myths about drugs. Through community-based events around the country and activities on the Web, on TV and through music, NIDA encouraged teens to get factual answers from scientific experts about drugs and drug abuse. Efforts included a collaboration with MusiCares® and the GRAMMY Foundation® to create the Teen Substance Abuse Awareness through Music Contest; the development of a new booklet “Drug Facts: Shatter the Myths” as well as numerous media outreach efforts that reached millions nationwide.

NIDA launches pages on Facebook and Twitter, two widely viewed social networking websites. NIDA posts on both platforms highlight a variety of topics, including press releases, program initiatives, drug facts, research updates and other news of interest.

NIDA LEGISLATIVE CHRONOLOGY

1966—P.L. 89-793, the Narcotic Addict Rehabilitation Act, provided for increased Federal efforts in the rehabilitation and treatment of narcotic addicts (limited to opiate abusers).

1970—P.L. 91-513, the Comprehensive Drug Abuse Prevention and Control Act, replaced the USPHS Act's definition of “narcotic addict” with a definition of “drug dependent person” to authorize treatment for both narcotic addicts and other persons with drug abuse problems.

1972—P.L. 92-255, the Drug Abuse Office and Treatment Act, created a Special Action Office for Drug Abuse Prevention (SAODAP) in the Executive Office of the President, and authorized the establishment of NIDA within the Department to become operational in 1974. In cooperation with other Federal agencies, especially the National Institute of Mental Health’s (NIMH) Division of Narcotic Addiction and Drug Abuse (DNADA), SAODAP established a national network of multi-modality drug abuse treatment programs.

1974—P.L. 93-282, the Comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment, and Rehabilitation Act Amendments, created the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA), which was charged with supervising and coordinating the functions of NIMH, NIDA, and NIAAA. Programs and responsibilities of DNADA and SAODAP were moved to NIDA.

1979—P.L. 96-181, the Drug Abuse Prevention, Rehabilitation, and Treatment Act, mandated that at least 7% in FY 1980 and 10% in FY 1981 of NIDA’s Community Programs budget be spent on prevention.

1981—P.L. 97-35, the Omnibus Budget Reconciliation Act, repealed NIDA’s formula grants and Community Programs project grants and contracts authorities, and established the Alcohol, Drug Abuse, and Mental Health Services (ADMS) Block Grant program, giving more control of treatment and prevention services to the states.

1986—P.L. 99-570, the Anti-Drug Abuse Act of 1986, increased the Block Grant and created a substance abuse treatment enhancement. The Act also provided increased funds for all NIDA research, particularly AIDS research.

Executive Order 12564 mandated a drug-free Federal workplace program. NIDA became the lead agency, creating its Office of Workplace Initiatives.


1988—P.L. 100-690, the Anti-Drug Abuse Act of 1988, established the Office of National Drug Control Policy (ONDCP) in the Executive Office of the President and authorized funds for Federal, state, and local law enforcement, school-based drug prevention efforts, and drug abuse treatment with special emphasis on injection drug abusers at high risk for AIDS.

1989 and 1990—P.L. 101-166 and P.L. 101-517, the Departments of Labor, HHS, and Education Appropriations Acts for FY 1990 and 1991, contained identical prohibitions precluding the use of funds provided under these enactments to carry out any program of distributing sterile needles.

1992—P.L. 102-321, the ADAMHA Reorganization Act, transferred NIDA to NIH; earmarked 15% of the Institute's research appropriation for health services research; established a Medication Development Program within NIDA; provided authority to designate Drug Abuse Research Centers for interdisciplinary research on drug abuse and related biomedical, behavioral, and social issues; and created an Office on AIDS at NIDA.

P.L. 102-394, the Departments of Labor, HHS, and Education FY 1993 Appropriations Act, provided that up to $2 million of NIDA research funds be available to carry out section 706 of P.L. 102-321, which required the HHS Secretary, acting through NIDA, to request a National Academy of Sciences study of U.S. programs that provide both sterile hypodermic needles and bleach.

1993—P.L. 103-112, the Department of Labor, HHS and Education FY 1994 Appropriations Act, prohibited the use of funds under the Act for any further implementation of section 706 of P.L. 102-321 (see above) and any program for distributing sterile needles.
1994 and 1996—P.L. 103-333, the Departments of Labor, HHS, and Education Appropriations Act for FY 1995; P.L. 104-134, the Omnibus Consolidated Rescissions and Appropriations Act for FY 1996; and P.L. 104-208, the Omnibus Consolidated Appropriations Act for FY 1997—each prohibited use of any funds provided in the enactments to carry out any program of distributing sterile needles. 

1997—P.L. 105-78, the Departments of Labor, HHS, and Education Appropriation Act for FY 1998, continued prior restrictions on needle-exchange programs through March 31, 1998, permitting funding thereafter of those programs meeting certain statutory requirements including criteria of the HHS Secretary. 

1998—P.L. 105-277, the Omnibus Consolidated and Emergency Supplemental Appropriations Act-1999, restored the general prohibition on funds for needle exchange programs; statutorily reestablished ONDCP in the Executive Office of the President with significantly expanded authority over drug control agencies; and required ONDCP to conduct a 4-year (Fy's 1999-2002) national anti-drug media campaign aimed at youth. 

1999—P.L. 106-113, the Consolidated Appropriations Act-2000, continued the ban on funding of sterile needle and syringe exchange programs; prohibited use of appropriated funds for promotion of legalization of any Schedule I controlled substance; and postponed termination of NIDA's triennial report until 5/15/2000. 

2000—P.L. 106-554, the Consolidated Appropriations Act-2001, authorized the Director of NIH to negotiate a long-term lease for research facilities at Baltimore's Bayview Campus, and continued prior prohibitions on funding of sterile needle/syringe exchange programs and on promotion of legalization of Schedule I controlled substances. 

P.L. 106-310, the Children's Health Act of 2000, repealed the Narcotic Addict Rehabilitation Act of 1966 (P.L. 89-793); waived certain requirements of the Controlled Substances Act to permit qualified physicians to engage in office-based treatment of opiate dependence; and authorized expansion of NIDA research on methamphetamine and increased emphasis on ecstasy research. 

2001—P.L. 107-116, the Departments of Labor, HHS, and Education FY 2002 Appropriations Act, continued prior prohibitions on funding of sterile needle and syringe exchange programs and on legalization of Schedule I controlled substances. 

2002—Title II of P.L. 107-273, the Drug Abuse Education, Prevention, and Treatment Act of 2002, authorized NIDA expansion of interdisciplinary research and clinical trials with treatment centers of the National Drug Abuse Treatment Clinical Trials Network; and required a NIDA study on development of medications for amphetamine/methamphetamine addiction. 

2003—Division G of P.L. 108-7, the Departments of Labor, HHS, and Education FY 2003 Appropriations Act, continued prior prohibitions on funding of sterile needle and syringe exchange programs and on legalization of Schedule I controlled substances. 

2004—P.L. 108-358, the Anabolic Steroids Control Act of 2004, significantly expanded the list of anabolic steroids classified as controlled substances; required a review of Federal sentencing guidelines; and authorized $15 million, for each of the next fiscal years through 2009, for educational programs in schools to highlight the dangers of steroids, with preference given to programs deemed effective by NIDA. 

2005—P.L. 109-56 amended the Controlled Substances Act to lift the patient limitations imposed on medical practitioners in group practices regarding the prescribing of drug addiction treatments. Section 2013 of P.L. 109-59, the Safe, Accountable, Flexible, Efficient Transportation Equity Act, directs the Secretary of Transportation to advise and coordinate with other Federal agencies to address driving under the influence of controlled substances. 

2006—P.L. 109-469, the U.S. Office of National Drug Control Policy (ONDCP) Reauthorization Act of 2006, in section 1102, amended the Controlled Substances Act to further relax the patient limitations on provision of drug addiction treatments, allowing medical practitioners to notify the HHS Secretary of need and intent to treat up to 100 patients. Section 1120 required the ONDCP Director to consult with NIH (NIDA) and the National Academy of Sciences in making policy relating to syringe exchange programs. 

2008—P.L. 110-199, Second Chance Act of 2007, reauthorizes and rewrites provisions of the 1968 Omnibus Crime Control and Safe Streets Act to expand reentry services for offenders. Requires the Attorney General (1) to consult with NIDA (and SAMHSA) regarding performance outcome measures and data collection related to substance abuse and mental health services [sec. 101 (k)]; and (2) in consultation with NIDA to conduct a study on the use and effectiveness of funding aftercare services for offenders completing substance abuse programs while incarcerated [sec. 102 (c)]. Permits the U.S. Attorney General in consultation with NIDA to make research grants to evaluate the effectiveness of depot naltrexone for treatment of heroin addiction [sec. 244 (a)]. 

2009—P.L. 111-117, the Consolidated Appropriations Act, changes federal law regarding potential funding for syringe exchange programs. The Act states: “None of the funds contained in this Act may be used to distribute any needle or syringe for the purpose of preventing the spread of blood borne pathogens in any location that has been determined by the local public health or local law enforcement authorities to be inappropriate for such distribution.” Thus, syringe exchange for this purpose is allowed unless public health or law enforcement authorities choose, at the local level, to prevent it. This change could result in additional research proposals, and thus funding, for syringe exchange-related research projects. 

**BIOGRAPHICAL SKETCH OF NIDA DIRECTOR, NORA D. VOLKOW, M.D.**

Nora D. Volkow, M.D., became Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health in May 2003. NIDA supports most of the world’s research on the health aspects of drug abuse and addiction. 

Dr. Volkow’s work has been instrumental in demonstrating that drug addiction is a disease of the human brain. As a research psychiatrist and scientist, Dr. Volkow pioneered the use of brain imaging to investigate the toxic effects of drugs and their addictive properties. Her studies have documented changes in the dopamine system affecting the actions of frontal brain regions involved with motivation, drive, and pleasure and the decline of brain dopamine function with age. She has also made important contributions to the neurobiology of obesity, attention deficit hyperactivity disorder (ADHD), and the behavioral changes that occur with aging.
Dr. Volkow was born in Mexico, attended the Modern American School, and earned her medical degree from the National University of Mexico in Mexico City, where she received the Premio Robins award for best medical student of her generation. Her psychiatric residency was at New York University, where she earned the Laughlin Fellowship Award as one of the 10 Outstanding Psychiatric Residents in the USA.

Dr. Volkow spent most of her professional career at the U.S. Department of Energy's Brookhaven National Laboratory in Upton, NY, where she held several leadership positions including Director of Nuclear Medicine, Chairman of the Medical Department, and Associate Director for Life Sciences. In addition, Dr. Volkow was a professor in the Department of Psychiatry and Associate Dean of the Medical School at the State University of New York (SUNY)—Stony Brook.

Dr. Volkow has published more than 440 peer-reviewed articles and more than 75 book chapters and non-peer-reviewed manuscripts, and has also edited three books on the use of neuroimaging in studying mental and addictive disorders.

During her professional career, Dr. Volkow has been the recipient of multiple awards, including her selection for membership in the Institute of Medicine in the National Academies and the International Prize from the French Institute of Health and Medical Research for her pioneering work in brain imaging and addiction science. She was recently named one of Time magazine’s “Top 100 People Who Shape our World” and was included as one of the 20 people to watch by Newsweek magazine in its “Who’s Next in 2007” feature. She was also included in Washingtonian Magazine’s 2009 list of the “100 Most Powerful Women” and named “Innovator of the Year” by U.S. News & World Report in 2000.

**NIDA DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert L. DuPont</td>
<td>1973</td>
<td>1978</td>
</tr>
<tr>
<td>William Pollin</td>
<td>1979</td>
<td>1985</td>
</tr>
<tr>
<td>Charles R. Schuster</td>
<td>1986</td>
<td>1992</td>
</tr>
<tr>
<td>Richard A. Millstein (Acting)</td>
<td>1992</td>
<td>1994</td>
</tr>
<tr>
<td>Alan I. Leshner</td>
<td>1994</td>
<td>2001</td>
</tr>
<tr>
<td>Glen R. Hanson (Acting)</td>
<td>2001</td>
<td>2003</td>
</tr>
<tr>
<td>Nora D. Volkow</td>
<td>2003</td>
<td>Present</td>
</tr>
</tbody>
</table>

**DIVISIONS AND OFFICES**

**Office of the Director**

The Office of the Director (OD) leads the Institute by setting research and programmatic priorities. In order to help coordinate key OD functions, a position of Director of Program Integration at NIDA was created in 2008. This position is designed to facilitate collaboration across NIDA’s Divisions, Offices, and Centers as well as across the NIH with an emphasis on program development. Further, cross-cutting initiatives are coordinated through special offices within the Office of the Director.

The Special Populations Office has two goals: (1) to address the research training and career development needs of underrepresented minorities and others (women, individuals with disabilities, etc.) in drug abuse research and (2) to ensure that minority issues in drug abuse research are adequately represented in the work supported by NIDA.

The AIDS Research Program office provides direction and leadership for the development of a progressive HIV/AIDS research portfolio that addresses the unique dimensions of drug abuse as it relates to HIV/AIDS. The development and implementation of this research program is guided by several factors including, but not limited to, the epidemiology of the HIV/AIDS pandemic, the evolution of HIV/AIDS diagnoses and treatment, and the role of drug abuse and related behaviors in the spread and progression of HIV/AIDS.

The NIDA International Program fosters international cooperative research and the exchange of scientific information by drug abuse researchers around the globe. NIDA’s international objectives include promoting international research activities; supporting research training and exchange opportunities globally; communicating and disseminating science-based information on drug abuse; and supporting international research collaboration.

NIDA’s Women and Sex/Gender Differences Research Program promotes the conduct, translation, and dissemination of drug abuse research on sex/gender differences and issues specific to women. Research on women and gender differences is supported in all of NIDA’s programmatic branches and is grouped into four major program areas: Etiology, Consequences, Prevention, and Treatment and Services.

**Division of Epidemiology, Services, and Prevention Research**

The Division of Epidemiology, Services, and Prevention Research plans, stimulates, develops, and supports a broad extramural research program to study: (1) the nature, patterns, and consequences of drug use among general, special, and community-based populations; (2) innovative sampling, data collection, and analytic methodologies designed to support epidemiology and prevention and early intervention and services research; (3) prevention of drug use and addiction, and services research including the prevention of medical/social/psychological sequelae of drug use; (4) behavioral and social science research in the context of communities and defined populations, including the consequences of drug use such as delinquency and violence; (5) services research on the impact of the organization, financing, and management of treatment programs and services systems on quality, cost, access, and outcomes of care; and (6) economic modeling and configuration of the treatment system.
Division of Basic Neuroscience and Behavioral Research

The primary goal of the Division of Basic Neuroscience and Behavioral Research is to support an extramural program of research in the basic biomedical and behavioral sciences that relates to the public health problem of drug abuse and addiction. The supported research provides an understanding of the neurobiological and behavioral effects of drugs of abuse. Research focuses on the molecular, neurobiological, and genetic mechanisms of addiction, drug craving, effects of drugs on behavior and cognition, long-term chronic effects of drugs, and drug metabolism. Basic research concerned with understanding the complex interrelationship between HIV/AIDS progression and transmission and drug abuse is also supported. The research supported by the Division provides important fundamental information for developing prevention and treatment interventions for drug abuse and addiction.

Division of Clinical Neuroscience and Behavioral Research

The Division of Clinical Neuroscience and Behavioral Research supports a broad range of research focused on translating addiction science related to brain, behavior, and health through an integrated research program in clinical neuroscience, development, and behavioral treatment, including HIV/AIDS-related factors. This division has three research branches that develop and administer national research and research training programs:

The Clinical Neuroscience Branch (CNB) advances a clinical research and research training program focused on understanding the neurobiological substrates of drug abuse and addiction processes, including the etiology of drug use and transition from drug use to addiction. A major focus of this program is on the characterization of how abused drugs affect the structure and function of the human central nervous system and the behavioral processes subserved by neural circuits. Another major emphasis of this program is on individual differences in neurobiological, genetic, and neurobehavioral factors that underlie increased risk for and/or resilience to drug abuse, addiction, and drug-related disorders.

The Behavioral and Brain Development Branch (BBDB) supports a spectrum of research and research training programs that addresses relationships among drug use/addiction, social/physical environment factors, and human development, with emphasis on neurodevelopmental, cognitive, and behavioral mechanisms that underlie these relationships. Studies cover the full developmental time course from prior to conception through adulthood and into senescence, and utilize a variety of behavioral and neuroscience research methods.

The Behavioral and Integrative Treatment Branch (BITB) supports research directed toward the development and improvement of drug abuse treatment and intervention for associated problems. The Branch encourages a staged approach to treatment and intervention development, supporting activities required to translate findings from basic science, other areas of health, or clinical observation, into researchable interventions; supporting the full-scale testing of promising or established interventions; and supporting the development of clinical training and supervision methods, streamlining of interventions, and other activities that prepare an intervention for dissemination.

Center for the Clinical Trials Network

The Center for the Clinical Trials Network (CTTN) was established in 1999 with the goal to improve Substance Use Disorders (SUD) treatment by accelerating the pace of translating basic discoveries into clinical practice, fostering and mentoring of emerging scientists and physicians, and communicating research advances to the public. The CTTN is an expansive enterprise that brings together providers from more than two hundred hospitals, clinics, treatment centers, private practices and scientists from fifty-seven affiliated universities in an organization of thirteen Regional Research Training Centers (RRTCs) funded through cooperative agreements. The network serves a NIDA-wide mission to identify gaps in knowledge, develop community based health care system oriented approaches to increase the use of evidence-based addiction treatment by individuals, communities, health care providers, public institutions, and especially by populations that experience a disproportionate disease burden.

Division of Pharmacotherapies and Medical Consequences of Drug Abuse

The Division of Pharmacotherapies and Medical Consequences of Drug Abuse plans and directs studies necessary to identify, evaluate, develop, and obtain FDA marketing approval for medications to treat substance use disorders (SUDs). The Division develops and administers a program of basic and clinical research to develop innovative pharmacological (both chemical and biological) approaches to treat SUDs. This program is implemented through collaborations with academia, industry (pharmaceutical and biotechnology companies), and other government institutions (e.g., the Veterans Administration and the FDA). The Division also coordinates and provides leadership in the area of medical conditions associated with SUDs, including but not limited to HIV/AIDS.

Intramural Research Program

NIDA's Intramural Research Program is located in Baltimore, MD. Originally known as the Addiction Research Center, the Intramural Research Program conducts multidisciplinary research on basic biological and behavioral mechanisms that underlie drug abuse and addiction, including its causes and adverse consequences. Research is also supported on treatments for drug addiction and HIV transmission of injection drug users. Studies range from molecular to laboratory research with legislative efforts; responds to congressional inquiries; and analyzes legislative proposals for the NIDA Director; (7) advises the Director on national drug abuse...
Policy issues; (8) conducts relevant public affairs activities and collaborates with a variety of public and private entities to enhance knowledge and awareness of NIDA's program and findings; (9) provides liaison with scientific and professional groups and private organizations; and (10) develops and disseminates publications designed to communicate the current science regarding drug abuse.

Office of Extramural Affairs

NIDA's Office of Extramural Affairs (1) provides advice and guidance to the NIDA Director regarding the Institute's peer review process and extramural policy; (2) provides scientific analyses of the Institute's extramural research program, assessing the breadth and scope of the Institute's research activities; (3) administers the peer review of extramural grant applications; (4) administers contract concept reviews and peer review of all contract proposals; (5) administers the National Advisory Council on Drug Abuse second level review of extramural support mechanisms and advises on overall NIDA program and policy manners; (6) coordinates and assures the development of program policies and rules relating the Institute's extramural activities, including Institute responsibility for inquiries and investigations into misconduct in science; (7) coordinates Institute activities under the Privacy Act; (8) manages issuance of Confidentiality Certificates; and (8) administers the Institute's committee management function under the National Advisory Council Act.

Office of Management

The Office of Management (1) provides all administrative and management support services to the Institute in such areas as: financial planning, analysis, and management; administrative services; personnel management; information resources management; grants and contracts management; and management analysis; (2) develops, implements, and monitors administrative management policies, procedures, and guidelines; (3) develops and monitors the implementation of program policies and plans, and evaluates progress in meeting established Institute objectives; (4) develops data requirements pertinent to short- and long-range program planning and develops the Institute's program evaluation policy; (5) administers the Institute's program evaluation system for all Institute employees; and (6) maintains responsibility for all management and administrative policy studies, reports, analyses, and program objectives.
MISSION

The mission of the National Institute of Environmental Health Sciences (NIEHS) is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease. Achieving this mission depends on a set of core values that apply to all activities of the Institute:

- Research excellence (innovation; discovery of new scientific knowledge and technology);
- Management excellence; and
- Community outreach, education, and involvement.

At NIEHS and the National Toxicology Program, we engage in a special form of public service—producing scientific knowledge that promotes individual and public health. Our Institute is uniquely positioned to help prevent disease and transform new scientific knowledge into improvements in human health. There are many opportunities before us to build and expand the contributions of the NIEHS:

- Foster research on environmental triggers of disease;
- Communicate advances in environmental health sciences to the public;
- Foster training and development of emerging young environmental health scientists and practitioners;
- Enhance translation of knowledge from research to disease prevention; and
- Foster safety assessment research on chemicals and other environmental factors.

The fulfillment of this mission requires the partnership and effort of everyone in the environmental health sciences communities.

IMPORTANT EVENTS IN NIEHS HISTORY

June 7, 1960—A study group on the U.S. Public Health Service (PHS) mission and organization states that environmental health problems require increased public and private effort, and predicts that a central laboratory facility would be needed.

November 1, 1961—The Committee on Environmental Health Problems recommends to PHS that a national center be established to undertake integrated research and other activities related to environmental health.

September 1964—In the wake of the best-selling book by Rachel Carson, *Silent Spring*—which forecast the deaths of birds and possibly people from the use of persistent chemicals—Congress authorizes funds to plan a central environmental health research facility.

January 7, 1965—The U.S. Surgeon General announces the establishment of the Division of Environmental Health Sciences as a part of the National Institutes of Health.

September 26, 1967—A deed for 509.25 acres within Research Triangle Park, N.C., is presented to the Surgeon General for a permanent site for the Division of Environmental Health Sciences.

January 12, 1969—The Secretary of the then-Department of Health, Education, and Welfare (HEW) elevates the division to Institute status—as the National Institute of Environmental Health Sciences.

April 1972—The first edition of *Environmental Health Perspectives*, an NIEHS scientific journal, is issued.

April 1977—Construction begins on NIEHS' $65.7 million facility.

November 15, 1978—HEW Secretary Joseph Califano announces the establishment of the National Toxicology Program.

July 14, 1981—U.S. Department of Health and Human Services (HHS) Secretary Richard Schweiker approves the reorganization of NIEHS, transferring the National Cancer Institute's Division of Cancer Cause and Prevention bioassay program to NIEHS.
October 5, 1981—The National Toxicology Program is made a permanent activity of HHS.

November 20, 1985—NIEHS is established in law by the Health Research Extension Act of 1985 (Public Law 99-158).


October 10, 1994—Martin Rodbell, NIEHS scientist emeritus and former scientific director, is named co-recipient of the 1994 Nobel Prize in Physiology or Medicine for his work in discovering G-proteins, which transmit signals between cells. View Image.

May 12, 1995—NIEHS announces isolation and cloning of a gene that suppresses the spread of prostate cancer.

December 6, 1995—Experiments conducted by NIEHS researchers show that phenolphthalein, a widely used laxative, causes ovarian and other cancers in laboratory rats and mice.

February 6, 1996—NIEHS scientists report that people who are missing the gene GST11 are more likely to get myelodysplastic syndrome, or MDS—a serious, often fatal, bone marrow disease.

July 2, 1996—NIEHS researchers find that women who douche more than once a week are about 30% less likely to conceive in a given month than those who do not.

October 29, 1996—The newly completed 4-story laboratory 'F Module' is dedicated on the celebration of NIEHS' 30th anniversary.

October 17-18, 1997—NIEHS Environmental Genome Project is announced to an international audience of scientists. The project is described as one to explore the gene variations (called "polymorphisms," which means "many forms") that influence people's susceptibility to environmental exposures that cause disease in some people, none in others.


August 10, 1998—NIEHS and the Environmental Protection Agency jointly fund the creation of 8 Children's Environmental Health Research Centers.

June 22, 1999—The new Interagency Coordinating Committee on the Validation of Alternative Methods—a group formed by NIEHS, the National Toxicology Program (which is headquartered at NIEHS), and other health and regulatory agencies—for the first time concludes that, in many chemical tests, a non-animal test can replace the use of laboratory animals in a key test of whether a chemical is likely to burn or corrode human skin. Acceptance of this alternative test is followed on December 28, 1999 by acceptance by regulatory agencies of the Murine Local Lymph Node Assay for products causing allergic contact dermatitis, which greatly reduced the number of guinea pigs used in testing.

May 9, 2000—The First National Allergen Survey, led by NIEHS scientists in collaboration with the U.S. Department of Housing and Urban Development, finds more than 45% of U.S. housing stock has bedding with dust mite allergen concentrations that exceed 2 micrograms per gram of dust, a level associated with the development of allergies.

December 14, 2000—NIEHS-supported researchers at The Johns Hopkins University School of Public Health publish research findings showing a strong correlation between exposure to particulate matter air pollution and death from all causes including cardiovascular and respiratory illnesses. These analyses provide evidence that particulate matter pollution continues to cause adverse health outcomes and strengthens the argument for maintaining air quality standards for this pollutant.

January 2001—Grantees from the University of Southern California publish reports showing modest increases in ambient ozone concentration are associated with increases in school absenteeism.

September 2001—NIEHS-supported grantees in and around New York City joined forces to monitor exposures and advise clean-up crews and residents exposed to hazardous working and living conditions resulting from the terrorists attacks on the World Trade Center. Air monitoring stations were established, and many research studies were begun to determine possible adverse health effects. Grantees from the NIEHS Worker Safety and Education Program were on-site immediately following the collapse of the buildings to provide advice and assistance for protecting the health of the clean-up crews.

November 5, 2001—NIEHS awards $37 million to 5 academic research organizations to form a Toxicogenomics Research Consortium with the Institute's own National Toxicogenomics Center. Building a library of known toxins and the genes they turn "on" or "off," the Center seeks to use an array of cloned genes to review chemicals for toxicity. Further down the road, the technology may be used on individual patients to tailor preventive, diagnostic and treatment methods.

July 3, 2002—An NIEHS analysis of data from 7 European cities suggests that healthy young couples need not jump into expensive reproductive assistance too soon. The study showed that better than 90% of the couples who failed to achieve a pregnancy in their first year of unprotected intercourse achieved conception before a second year was out—without medical assistance.

August 29, 2002—NIEHS-supported researchers at the University of California at San Diego discover that B. anthracis evades the host immune system, using a toxin called lethal factor (LF) to destroy macrophages and spread throughout the body. These results may explain why anthrax infections proceed nearly undetected until the patient is very sick and near death.

April 17, 2003—NIEHS grantees at the Cincinnati-Children's Hospital Medical Center and the University of Rochester Medical Center find that IQ scores for children with blood lead levels at 10 micrograms/dl were 7.4 points lower than for children at 1 microgram/dl. Surprisingly, the study also concludes that as blood lead increased from 10 to 30 micrograms/dl, there was a more modest decline in IQ scores, indicating that more damage occurs at lower levels for any given exposure. These results emphasize the importance of prevention and add further evidence that there is indeed no safe level of lead exposure.
October 9, 2007—Inhalation exposure. The new findings show that it can also cause cancer in animals when administered orally.

December 10, 2004—Grantees at the Harvard School of Public Health and Brigham and Women's Hospital demonstrate that lifetime lead exposure may increase the risk of developing cataracts, the leading cause of blindness. Men with high levels of lead in the tibia, the larger of the 2 leg bones below the knee, had a 2.5-fold increased risk for cataracts.

May 2005—a comparison study across 7 different laboratories demonstrates how scientists can get more consistent and reliable results when using gene chips, or microarray technologies. Microarrays allow researchers to see which genes are active in both normal and diseased cells. In the past, scientists have had trouble comparing microarray data from different sources. The new study shows that using a standardized process and commercially manufactured microarrays (rather than microarrays made in-house by each lab) leads to the best reproducible results.

May 10, 2005—NIEHS releases 'A National Toxicology Program for the 21st Century: A Roadmap for the Future.' The Roadmap outlines a plan to strategically position the National Toxicology Program at the forefront of providing scientific data and for guiding the interpretation of those data to maximize their impact on public health. A meeting was held at the National Academy of Sciences to reflect on the history of the National Toxicology Program and its impact on public health since its establishment in 1978 and unveil the plans and directions for the program's future.

June 1, 2005—NIEHS brings together national and community leaders with researchers to sort out how a child's environment increases the risk for obesity and to identify ways the environment can be changed to address this health epidemic. More than 700 people gathered for a 2-day conference, "Environmental Solutions to Obesity in America's Youth."

February 8, 2006—Two NIH Initiatives launch intensive efforts to determine genetic and environmental roots of common diseases. One initiative boosts NIH funding for a multi-institute effort to identify the genetic and environmental underpinnings of common illnesses. The other initiative creates a public-private partnership between NIH, the Foundation for the National Institutes of Health, and major pharmaceutical and biotechnology companies, especially Pfizer Global Research & Development of New London, CT, and Affymetrix Inc. of Santa Clara, CA, to accelerate genome association studies to find the genetic roots of widespread sicknesses.

May 1, 2006—the NIEHS Director unveils a new strategic plan aimed at challenging and energizing the scientific community to use environmental health sciences to understand the causes of disease and to improve human health. The plan, New Frontiers in Environmental Sciences and Human Health, fundamentally changes the way NIEHS approaches research. The new strategy emphasizes research focused on complex human disease, and calls for inter-disciplinary teams of scientists to investigate a broad spectrum of disease factors, including environmental agents, genetics, age, diet, and activity levels.

October 25, 2006—a teleconference with the NIEHS Director, leading scientific experts, and the media preceded a 2-day meeting at which researchers announce they have successfully sequenced the DNA of 15 mouse strains most commonly used in biomedical research. More than 8.3 million genetic variations, or single nucleotide polymorphisms (SNPs), were discovered among the genomes of the 15 mouse strains, and the data are now available on a public website.

May 16, 2007—Researchers announce that there is strong evidence a chemical referred to as hexavalent chromium, or chromium 6, causes cancer in laboratory animals when it is consumed in drinking water. The 2-year study conducted by the National Toxicology Program shows that animals given hexavalent chromium developed malignant tumors. Earlier studies had shown that hexavalent chromium causes lung cancer in humans in certain occupational settings as a result of inhalation exposure. The new findings show that it can also cause cancer in animals when administered orally.

October 9, 2007—a report issued by the National Academies of Sciences recognizes the importance of toxicogenomics in predicting effects on human health and recommends the integration of toxicogenomics into regulatory decision making. Toxicogenomic technologies provide tools to better understand the mechanisms through which environmental agents initiate and advance disease processes. They can also provide important information to help identify individuals who are more susceptible to disease risks posed by certain environmental agents than the general population.

February 14, 2008—NIEHS and the National Toxicology Program form a formal collaboration with NIH's National Human Genome Research Institute and the U.S. Environmental Protection Agency to improve the safety testing of chemicals. The collaboration creates a toxicity testing process using state-of-the-art robotic technologies that rely less on animals and more on cell-based tests and will generate data that are specifically applicable to humans.

September 3, 2008—The National Toxicology Program releases its final report on Bisphenol-A (BPA), a high-production volume chemical used primarily in the production of polycarbonate plastics and epoxy resins. The report found current human exposure to BPA to be of "some concern" for effects on development of the prostate gland and brain and for behavioral effects in fetuses, infants, and children. The National Toxicology Program uses a 5-level scale ranging from negligible to serious, with "some concern" being the midpoint.

BIographiesketch of NIEHS Director Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S.

Dr. Linda S. Birnbaum is director of the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health, and the National Toxicology Program. As director of NIEHS and the National Toxicology Program, Dr. Birnbaum oversees a $730 million budget that funds multidisciplinary biomedical research programs, prevention, and intervention efforts that encompass training, education, technology transfer, and community outreach. The NIEHS supports more than 1,240 research grants.

Dr. Birnbaum has received numerous awards, including the Women in Toxicology Elsevier Mentoring Award, the Society of Toxicology Public Communications Award, the U.S. Environmental Protection Agency (EPA) Health Science Achievement Award and Diversity Leadership Award, and 12 Science and Technology Achievement Awards. She is the author of more than 600 peer-reviewed publications, book chapters, abstracts, and reports. Dr. Birnbaum received her M.S. and Ph.D. in microbiology from the University of Illinois, Urbana. A board-certified toxicologist, Dr. Birnbaum has served as a federal scientist for nearly 29 years—19 years with the EPA Office of Research and Development, and the first 10 years at NIEHS as a senior staff fellow at the National Toxicology Program, then as a principal investigator and research microbiologist, and finally as a group leader for the institute's Chemical Disposition Group.
NIEHS DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paul Kotin</td>
<td>November 1, 1966</td>
<td>February 28, 1971</td>
</tr>
<tr>
<td>David P. Rall</td>
<td>March 1, 1971</td>
<td>October 1, 1990</td>
</tr>
<tr>
<td>David G. Hoel (Acting)</td>
<td>October 1990</td>
<td>June 1991</td>
</tr>
<tr>
<td>Kenneth Olden</td>
<td>June 18, 1991</td>
<td>May 21, 2005</td>
</tr>
<tr>
<td>David A. Schwartz</td>
<td>May 22, 2005</td>
<td>August 19, 2007</td>
</tr>
<tr>
<td>Linda S. Birnbaum</td>
<td>January 16, 2009</td>
<td>Present</td>
</tr>
</tbody>
</table>

PROGRAMS

The NIEHS provides additional oversight and program development in the following areas:

**Exposure Biology Program of the NIH Genes and Environment Initiative**

The NIEHS leads the Exposure Biology Program, one of the two main components of the NIH Genes and Environment Initiative. The Exposure Biology Program focuses on the development of innovative technologies to measure environmental exposures, diet, physical activity, psychosocial stress, and addictive substances that contribute to the development of disease.

**National Children's Study**

National Children's Study (http://www.nationalchildrensstudy.gov/) is designed to examine the effects of environmental influences on the health and development of more than 100,000 children across the United States. NIEHS plays a lead role in this program.

**NIH Roadmap Epigenomics Program**

The goals of the NIH Roadmap Epigenomics Program are to create an international committee; develop standardized platforms, procedures, and reagents for epigenomics research; conduct demonstration projects to evaluate how epigenomes change; develop new technologies for single-cell epigenomic analysis and in vivo imaging of epigenetic activity; and create a public data resource to accelerate the application of epigenomics approaches.

**Education and Biomedical Research Development**

NIEHS is committed to establishing goals and developing programs to assure minority participation and success in NIEHS research and training programs. Included in these activities are K-12 environmental health sciences education programs, minority health research and training programs, environmental health research and training programs at minority institutions, and research and training programs that address low-income and underserved populations.

**NanoHealth Enterprise Initiative**

NIEHS is engaged in efforts to establish an NIH NanoHealth Enterprise. This broad-based initiative is designed to investigate the fundamental physico-chemical interactions of engineered nanomaterials with biological systems and the use of nanotechnology research as a tool for exploring cellular and molecular structure function relationships. The initiative outlines an integrated, interdisciplinary program that draws upon the expertise and interests of the NIH Institutes and Centers, along with other public and private partners to address critical research needs for the safe development of nanoscale materials and devices.

**Standing Committee on Identifying and Quantifying Environmental Health Risks**

NIEHS has asked the National Academies (NAS) to facilitate communication among government, industry, environmental groups, and the academic community about scientific advances that may be used in the identification, quantification, and control of environmental impacts on human health. The NAS Standing Committee on Use of Emerging Science for Environmental Health Decisions will, on an ongoing basis for a 5-year period, examine issues on the use of new discoveries, new tools, and new approaches for guiding environmental health decisions.

**Implementation of the National Toxicology Program Vision and Roadmap**

The NIEHS is engaged in a long-term collaboration with the National Toxicology Program to assist in efforts to achieve the program's Vision and Roadmap of future activities, particularly contributing to the development of new tools for high-throughput screening and new animal models of genetic susceptibility.

**Institute of Medicine Roundtable on Environmental Health Sciences, Research, and Medicine**

The NIEHS was instrumental in establishing the National Academy of Sciences Institute of Medicine Roundtable on Environmental Health Sciences, Research, and Medicine, and continues to sponsor the panel with the NIEHS acting director as a member. The Roundtable was created to provide a mechanism for parties interested in environmental health from the academic, industrial, and federal research perspectives to meet and discuss sensitive and difficult issues of mutual interest in a neutral setting. The purpose is to foster dialogue and discussion among sectors and institutions and to illuminate issues, not resolve them. Among the
MISSION

The National Institute of General Medical Sciences (NIGMS) primarily supports research that lays the foundation for advances in disease diagnosis, treatment, and prevention. The Institute's research training programs help provide the next generation of scientists.

Each year, NIGMS-supported scientists make many advances in understanding fundamental life processes. In the course of answering basic research questions, these investigators increase our knowledge about the mechanisms and pathways involved in certain diseases. Institute grantees also develop important new tools and techniques, some of which have medical applications. In recognition of the significance of their work, a number of NIGMS grantees have received the Nobel Prize [http://www.nigms.nih.gov/Publications/factsheet_NIGMSNobelists.htm] and other high scientific honors.

NIGMS is organized into divisions and a center that support research [http://www.nigms.nih.gov/Research/] and research training [http://www.nigms.nih.gov/Training/] in a range of scientific fields. One division has the specific mission of increasing the diversity of the biomedical and behavioral research workforce.

NIGMS was established in 1962. In fiscal year 2010, the Institute's budget was $2.048 billion. The vast majority of this money goes into local economies through grants to scientists at universities, medical schools, hospitals, and other research institutions throughout the country. At any given time, NIGMS supports over 4,500 research grants [http://www.nigms.nih.gov/Research/Mechanisms/]—about 10% of the grants funded by NIH as a whole. NIGMS also supports approximately 25% of the trainees who receive assistance from NIH.

The Institute places great emphasis on supporting investigator-initiated research grants. It funds a limited number of research center grants in selected fields, including structural genomics, trauma and burn research, and systems biology. In addition, NIGMS supports several important scientific resources, including the NIGMS Human Genetic Cell Repository and the Protein Data Bank.

In recent years, NIGMS has launched initiatives in structural genomics (the Protein Structure Initiative) [http://www.nigms.nih.gov/Initiatives/PSI/], pharmacogenetics [http://www.nigms.nih.gov/Initiatives/PGRN/], and computational modeling of infectious disease outbreaks [http://www.nigms.nih.gov/Initiatives/MIDAS/]. The Institute also has several "glue grants" [http://www.nigms.nih.gov/Initiatives/Collaborative/GlueGrants/] that promote the collaborative approaches increasingly needed to solve complex problems in biomedical science. NIGMS participates in the NIH Common Fund [http://nihroadmap.nih.gov/], a series of far-reaching initiatives designed to transform the nation's medical research capabilities and speed the movement of research discoveries from the bench to the bedside.

NIGMS research training programs recognize the interdisciplinary nature of biomedical research today and stress approaches that cut across disciplinary and departmental lines. Such experience prepares trainees to pursue creative research careers in a wide variety of areas.

Certain NIGMS training programs address areas in which there are particularly compelling needs. One of these, the Medical Scientist Training Program [http://www.nigms.nih.gov/Training/InstPredoc/PredocDesc-MSTP.htm], produces investigators who hold the combined M.D.-Ph.D. degree and are well trained in both basic science and clinical research. Other programs train scientists to conduct research in rapidly growing areas like biotechnology [http://www.nigms.nih.gov/Training/InstPredoc/PredocDesc-Biotechnology.htm] and at the interfaces between fields such as chemistry and biology [http://www.nigms.nih.gov/Training/InstPredoc/PredocDesc-Chemistry.htm] and behavioral and biomedical sciences [http://www.nigms.nih.gov/Training/InstPredoc/PredocTrainingDescription.htm#behavioral].

NIGMS also has a Pharmacology Research Associate Program [http://www.nigms.nih.gov/Training/PRAT.htm], in which postdoctoral scientists receive training in pharmacology in NIH or the Food and Drug Administration laboratories.

IMPORTANT EVENTS IN NIGMS HISTORY


October 17, 1962—Congress authorized establishment of the National Institute of General Medical Sciences.

January 30, 1963—The HEW Secretary approved establishment of NIGMS.

October 8, 1963—The National Advisory General Medical Sciences Council held its first meeting.
October 13, 1982—NIGMS celebrated its 20th anniversary by establishing the DeWitt Stetten, Jr., Lecture. Dr. David S. Hogness, Stanford University, gave the first lecture.

October 1, 1989—Administration of the Minority Biomedical Research Support Program was transferred to NIGMS from the NIH Division of Research Resources.

May 14, 2001—NIGMS created the Center for Bioinformatics and Computational Biology.

NIGMS LEGISLATIVE CHRONOLOGY

October 17, 1962—Public Law 87-838 authorized the U.S. Surgeon General to establish an institute to conduct and support research and research training in the general or basic medical sciences and in related natural or behavioral sciences that have significance for two or more other institutes of NIH, or that lie outside the general areas of responsibility of any other institute.

BIOGRAPHICAL SKETCH OF NIGMS ACTING DIRECTOR JUDITH H. GREENBERG, PH.D.

Judith H. Greenberg, Ph.D., became acting director of the National Institute of General Medical Sciences on July 8, 2011.

In this position, she oversees the Institute’s $2 billion budget, which mainly funds basic research in the areas of cell biology, biophysics, genetics, developmental biology, pharmacology, physiology, biological chemistry, bioinformatics and computational biology. NIGMS supports more than 4,500 research grants—about 10 percent of the grants funded by NIH as a whole—as well as a substantial amount of research training and programs designed to increase the diversity of the biomedical and behavioral research workforce.

A developmental biologist by training, Greenberg has directed the NIGMS Division of Genetics and Developmental Biology since 1988. In Fiscal Year 2010, the division’s budget was $566 million.

Since 1984, Greenberg has been the project officer for the Human Genetic Cell Repository, which provides cell lines and DNA samples to scientists studying genetic diseases. She has been instrumental in overseeing the evolution of the collection to anticipate and meet the needs of the human genetic research community.

She served as NIGMS acting director once before, from May 2002 to November 2003.

Greenberg’s other leadership roles at NIGMS include overseeing the development of the Institute’s strategic plan issued in 2008 and its strategic plan for research training issued in 2011. She now chairs the implementation committee for the training strategic plan.

Her strong interest in bioethical issues related to genetics led Greenberg to hold the First Community Consultation on the Responsible Collection and Use of Samples for Genetic Research in September 2000. In addition, she chaired an NIH working group on community consultation in genetic research, which issued a document entitled “Points to Consider When Planning a Genetic Study that Involves Members of Named Populations.” She currently serves on the NIH Bioethics Task Force.

Greenberg has also advised NIH on human embryonic stem cells and gene therapy. She has served as principal leader of the NIH Director’s Pioneer Award program since 2004 and of the NIH Director’s New Innovator Award program since its inception in 2007.

Greenberg was the NIH program representative to the Federal Demonstration Partnership from 1991 to 1998 and was a member of its executive committee from 1996 to 1998.

Prior to joining NIGMS as a program administrator in 1981, Greenberg conducted research in the intramural program of what is now the NIH’s National Institute of Dental and Craniofacial Research. Her focus was on cell migration and differentiation in early embryonic development.

Greenberg’s honors include a Public Health Service Special Recognition Award in 1991 and a Presidential Meritorious Executive Rank Award in 1999. Her leadership of the Pioneer and New Innovator Award programs was recognized with NIH Director’s Awards in 2006 and 2008, respectively.

Greenberg earned a B.S. degree in biology from the University of Pittsburgh, an M.A. degree in biology from Boston University and a Ph.D. degree in developmental biology from Bryn Mawr College.

NIGMS DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinton C. Powell</td>
<td>July 1962</td>
<td>July 1964</td>
</tr>
<tr>
<td>Frederick L. Stone</td>
<td>August 1964</td>
<td>April 1970</td>
</tr>
<tr>
<td>DeWitt Stetten, Jr.</td>
<td>October 1970</td>
<td>August 1974</td>
</tr>
<tr>
<td>Ruth L. Kirschstein</td>
<td>September 1974</td>
<td>July 1993</td>
</tr>
<tr>
<td>Marvin Cassman (Acting)</td>
<td>July 1993</td>
<td>August 1996</td>
</tr>
<tr>
<td>Marvin Cassman</td>
<td>August 1996</td>
<td>May 2002</td>
</tr>
<tr>
<td>Judith H. Greenberg (Acting)</td>
<td>May 2002</td>
<td>November 2003</td>
</tr>
<tr>
<td>Jeremy M. Berg</td>
<td>November 2003</td>
<td>July 2011</td>
</tr>
</tbody>
</table>
MAJOR PROGRAMS

Division of Cell Biology and Biophysics

The Division of Cell Biology and Biophysics seeks greater understanding of the structure and function of cells, cellular components, and the biological macromolecules that make up these components. The research it supports ranges from studies of single molecules [http://www.nigms.nih.gov/Initiatives/SingleMolecule/] to work in structural genomics and proteomics. The long-term goal of the division is to find ways to prevent, treat, and cure diseases that result from disturbed or abnormal cellular activity. The division has 3 components: the Biophysics Branch, the Cell Biology Branch, and the Structural Genomics and Proteomics Technology Branch.

Biophysics Branch

This branch supports studies in the areas of biophysics, a discipline that uses techniques derived from the physical sciences to examine the structures and properties of biological substances. Areas of emphasis in biophysical research include the determination of the structures of proteins and nucleic acids; studies of the structural features that determine macromolecular conformation; the structural analysis of macromolecular interactions and of ligand-macromolecular interactions; bioinformatics as it relates to protein and nucleic acid structure; the development of physical methodology for the analysis of molecular structure; and the development and use of theoretical methods to investigate biological systems. Other research interests include the development and refinement of instruments needed to conduct research in the areas described above. These include nuclear magnetic resonance spectroscopy, X-ray crystallography and other scattering techniques, optical spectroscopy and other forms of microscopy. This branch also supports the development of new bioanalytical methods and biomaterials.

Cell Biology Branch

This branch supports general studies on the molecular and biochemical activities of cells and subcellular components, as well as on the role of cellular dysfunction in disease. Emphasis is placed on research with applications to more than one cell type, model system, or disease state, as well as research that does not fall within the disease-oriented mission of another NIH component. Representative studies include those on plasma and intracellular membranes, receptors, and signal transduction mechanisms; the structure and function of the cytoskeleton; cell motility; the regulation of protein and membrane synthesis and activation of cell growth; subcellular organelles; cell division; and lipid biochemistry.

Structural Genomics and Proteomics Technology Branch

This branch supports studies that take a genomics or computational approach to determining protein structures and functions. Such research includes the development of high-throughput methods for protein structure determination, bioinformatics as it relates to the analysis of protein structures en masse, and the development of mass spectroscopy and other tools for the rapid analysis of biological molecules. The branch is responsible for monitoring the research centers and research grants associated with the NIGMS Protein Structure Initiative (PSI) [http://www.nigms.nih.gov/Initiatives/PSI/]. This responsibility also includes developing a database of model structures and a repository for the distribution of materials resulting from the PSI.

Division of Genetics and Developmental Biology

The Division of Genetics and Developmental Biology supports studies directed toward gaining a better understanding of the cellular mechanisms that underlie inheritance and development. The results of these studies form the foundation for advances in diagnosing, preventing, treating, and curing human genetic and developmental disorders. Most of the projects supported by the division make use of model organisms [http://www.nigms.nih.gov/Initiatives/Models/], which speed advances in understanding human biological processes.

The division consists of the Genetic Mechanisms Branch and the Developmental and Cellular Processes Branch. The 2 branches are closely linked and share substantial regions of overlap. Areas under active investigation are: chromosome organization and mechanics; developmental biology and genetics; DNA replication, recombination, and repair; epigenetics; extrachromosomal inheritance; mechanisms of mutagenesis; neurogenetics and the genetics of behavior; population genetics and evolution; the genetics of complex traits; protein synthesis; regulation of cell growth, cell division, cell death, and differentiation; RNA transcription and processing; and stem cell biology.

Along with its research and research training activities, the division supports the Human Genetic Cell Repository [http://www.nigms.nih.gov/Initiatives/HGCR/], which maintains and distributes cell lines and DNA samples—from people with and without genetic disorders—to research scientists.

Division of Minority Opportunities in Research

The Division of Minority Opportunities in Research (MORE) administers research and research training programs aimed at increasing the number of minority biomedical and behavioral scientists. Support is available at the undergraduate, graduate, postdoctoral, and faculty levels, as well as for education and research infrastructure improvements.

The division has 3 branches: Minority Access to Research Careers (MARC), Minority Biomedical Research Support (MBRS), and MORE Special Initiatives.

MARC Branch

MARC programs seek to increase the number of highly-trained underrepresented biomedical and behavioral scientists in leadership positions to significantly impact the health-related research needs of the nation. MARC meets this objective by supporting two institutional programs, MARC Undergraduate Student Training in
**MBRS Branch**

MBRS programs are aimed at increasing the number of faculty, students, and investigators who are members of minority groups that are underrepresented in the biomedical sciences. MBRS grants are awarded to 2- or 4-year colleges, universities, and health professional schools with 50% or more student enrollment from underrepresented minority groups to support research by faculty members, strengthen the institutions’ biomedical research capabilities, and provide opportunities for students to work as part of a research team.

**MORE Special Initiatives Branch**

This branch develops and launches new research and research training programs and other activities designed to enhance the research and research training capabilities of institutions with substantial enrollments of individuals from underrepresented groups.

**Division of Pharmacology, Physiology, and Biological Chemistry**

The Division of Pharmacology, Physiology, and Biological Chemistry supports a broad spectrum of research and research training aimed at improving the molecular-level understanding of fundamental biological processes and discovering approaches to their control. Research supported by the division takes a multifaceted approach to problems in pharmacology, physiology, biochemistry, and biorelated chemistry that are either very basic in nature or that have implications for more than one disease area. The goals of supported research include an improved understanding of drug action and mechanisms of anesthesia; pharmacogenetics/pharmacogenomics and mechanisms underlying individual responses to drugs; new methods and targets for drug discovery; advances in natural products synthesis; an enhanced understanding of biological catalysis; a greater knowledge of metabolic regulation and fundamental physiological processes; and the integration and application of basic physiological, pharmacological, and biochemical research to clinical issues in anesthesiology, clinical pharmacology [http://www.nigms.nih.gov/Training/InstPostdoc/PostdocOverview-ClinPharm.htm], and trauma and burn injury. The division also supports quantitative studies of complex systems involving areas within its scope. There are 2 components in this division: the Biochemistry and Biorelated Chemistry Branch and the Pharmacological and Physiological Sciences Branch.

**Biochemistry and Biorelated Chemistry Branch**

This branch supports basic research in areas of biochemistry, such as enzyme catalysis and regulation, bioenergetics and redox biochemistry, and glycoconjugates. It also supports research in areas of biorelated chemistry, such as organic synthesis and methodology, as well as bioinorganic and medicinal chemistry. Examples of biochemical investigations include studies of the chemical basis of the regulation and catalytic properties of enzymes, intermediary metabolism, the chemical and physical properties of the cellular systems for electron transport and energy transduction, and the biosynthesis and structure of carbohydrate-containing macromolecules. Examples of chemical investigations include the development of strategies for natural products synthesis, studies of the structure and function of small molecules, the chemistry of metal ions in biological systems [http://www.nigms.nih.gov/Initiatives/Metals/], the development of novel medicinal agents or mimics of macromolecular function, and the creation of new synthetic methodologies. The branch also supports studies in biotechnology. This work focuses on the development of biocatalysts, including living organisms, for the production of useful chemical compounds, medicinal or diagnostic agents, or probes of biological phenomena.

**Pharmacological and Physiological Sciences Branch**

This branch supports research in pharmacology, anesthesiology, and the physiological sciences. Studies range from the molecular to the organismal level, and can be clinical in nature. In the pharmacological sciences and anesthesiology, important areas being studied are the effects of drugs on the body and the body's effects on drugs, as well as how these effects vary from individual to individual. This includes traditional investigations of the absorption, transport, distribution, metabolism, biotransformation, and excretion of drugs, as well as drug delivery strategies and determinants of bioavailability. It also includes a newer focus on pharmacogenetics/pharmacogenomics, linking phenotype to genotype in drug action. Understanding the mechanisms of drug interactions with receptors and signal transduction mechanisms is another major focus of this section. This includes studies of soluble and membrane-bound receptors and channels, secondary and tertiary messenger systems, mediator molecules, and their regulation and pharmacological manipulation. Examples of studies in the physiological sciences include basic and clinical investigations directed toward improving understanding of the total body response to injury, including the biochemical and physiological changes induced by trauma. Research supported in this section includes studies on the etiology of post-traumatic sepsis and the mechanisms of immunosuppression, wound healing, and hypermetabolism following injury. This section also supports research in basic molecular immunobiology which focuses on using cells of the immune system to study fundamental cellular and molecular mechanisms.

**Division of Extramural Activities**

The Division of Extramural Activities is responsible for the grant-related activities of the Institute, including the receipt, referral, and advisory council review of applications as well as grant funding and management. It maintains an overview of the Institute's scientific and financial status and advises the NIGMS director and other key staff on policy matters and on the planning, development, and scientific administration of Institute research and training programs. The division recommends budget allocations for the various NIGMS programs. It also acts as a liaison with other NIH components for activities relating to grant application assignments and foreign grants.

**Center for Bioinformatics and Computational Biology**

The Center for Bioinformatics and Computational Biology supports research and research training in areas that join biology with the computer sciences, engineering, mathematics, and physics. Toward this end, the center develops and manages programs in computational biology, such as the generation of mathematical models of biological networks, the development of modeling and simulation tools, the conduct of basic theoretical studies related to network
organization and dynamic processes, and the development of methods for the analysis and dissemination of computational models. The center also defines the Institute's needs for database development and applications, and it collaborates with other NIH components and Federal agencies in developing policies in this area. Other center activities include the support of multidisciplinary collaborations and of workshops, courses, and specialized meetings. The center oversees NIH's Biomedical Information Science and Technology Initiative (BISTI) through its management of the BISTI Consortium (BISTIC). The goal of this initiative is to make optimal use of computer science and technology to address problems in biology and medicine. BISTIC is composed of senior-level representatives from the NIH Institutes and Centers and representatives of other Federal agencies concerned with bioinformatics and computer-based applications.
MISSION

The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure.

For the Institute to continue fulfilling this vital public health mission, it must foster innovative thinking and ensure that a full array of novel scientific perspectives are used to further discovery in the evolving science of brain, behavior, and experience. In this way, breakthroughs in science can become breakthroughs for all people with mental illnesses.

In support of this mission, NIMH will generate research and promote research training to fulfill the following 4 objectives:

- Promote discovery in the brain and behavioral sciences to fuel research on the causes of mental disorders
- Chart mental illness trajectories to determine when, where, and how to intervene
- Develop new and better interventions that incorporate the diverse needs and circumstances of people with mental illnesses
- Strengthen the public health impact of NIMH-supported research

To reach these goals, NIMH divisions and programs are designed to emphasize translational research spanning bench, to bedside, to practice.

IMPORTANT EVENTS IN NIMH HISTORY

1946—On July 3 President Harry Truman signed the National Mental Health Act, which called for the establishment of a National Institute of Mental Health. The first meeting of the National Advisory Mental Health Council was held on August 15. Because no federal funds had yet been appropriated for the new institute, the Greentree Foundation financed the meeting.

1947—On July 1 the U.S. Public Health Service (PHS) Division of Mental Hygiene awarded the first mental health research grant (MH-1) entitled “Basic Nature of the Learning Process” to Dr. Winthrop N. Kellogg of Indiana University.

1949—On April 15 NIMH was formally established; it was 1 of the first 4 NIH institutes.

1955—The Mental Health Study Act of 1955 (Public Law 84-182) called for “an objective, thorough, nationwide analysis and reevaluation of the human and economic problems of mental health.” The resulting Joint Commission on Mental Illness and Health issued a report, Action for Mental Health, that was researched and published under the sponsorship of 36 organizations making up the Commission.

1961—Action for Mental Health, a 10-volume series, assessed mental health conditions and resources throughout the United States “to arrive at a national program that would approach adequacy in meeting the individual needs of the mentally ill people of America.” Transmitted to Congress on December 31, 1960, the report commanded the attention of President John F. Kennedy, who established a cabinet-level Interagency committee to examine the recommendations and determine an appropriate Federal response.

1963—President Kennedy submitted a special message to Congress—the first Presidential message to Congress on mental health issues. Energized by the President’s focus, Congress quickly passed the Mental Retardation Facilities and Community Mental Health Centers Construction Act (P.L. 88-164), beginning a new era in Federal support for mental health services. NIMH assumed responsibility for monitoring the Nation’s community mental health centers (CMHC) programs.

1965—During the mid-1960s, NIMH launched an extensive attack on special mental health problems. Part of this was a response to President Johnson’s pledge to apply scientific research to social problems. The Institute established centers for research on schizophrenia, child and family mental health, and suicide, as well as crime and delinquency, minority group mental health problems, urban problems, and later, rape, aging, and technical assistance to victims of natural disasters. A provision in the Social Security Amendments of 1965 (P.L. 89-97) provided funds and a framework for a new Joint Commission on the Mental Health of Children to recommend national action for child mental health.

Also in this year, staffing amendments to the CMHC act authorized grants to help pay the salaries of professional and technical personnel in federally funded community mental health centers.
Alcohol abuse and alcoholism did not receive full recognition as a major public health problem until the mid-1960s, when the National Center for Prevention and Control of Alcoholism was established as part of NIMH; a research program on drug abuse was inaugurated within NIMH with the establishment of the Center for Studies of Narcotic and Drug Abuse.

1967—NIMH separated from NIH and was given Bureau status within PHS by reorganization effective January 1. However, NIMH's intramural research program, which conducted studies in the NIH Clinical Center and other NIH facilities, remained at NIH under an agreement for joint administration between NIH and NIMH.

On August 13 U.S. Department of Health, Education, and Welfare (HEW) Secretary John W. Gardner transferred St. Elizabeth's Hospital, the Federal government's only civilian psychiatric hospital, to NIMH.

1968—NIMH became a component of PHS's Health Services and Mental Health Administration (HSMDA).

1970—Dr. Louis Sokoloff, an NIMH researcher, won the Nobel Prize in Physiology or Medicine for research into the chemistry of nerve transmission for "discoveries concerning the humoral transmitters in the nerve terminals and the mechanisms for their storage, release, and inactivation." He found an enzyme that stopped the action of the nerve transmitter noradrenaline—a critical target of many antidepressant drugs—in the synapse.

In a major development for people with manic-depressive illness (bipolar disorder), the U.S. Food and Drug Administration (FDA) approved the use of lithium as a treatment for mania, based on NIMH research. The treatment led to sharp drops in inpatient days and suicides among people with this serious mental illness and to immense reductions in the economic costs associated with bipolar disorder.

Also during this year, the Comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment, and Rehabilitation Act (P.L. 91-616) established the National Institute of Alcohol Abuse and Alcoholism within NIMH.

1972—The Drug Abuse Office and Treatment Act established a National Institute on Drug Abuse within NIMH.

1973—NIMH went through a series of organizational moves. The Institute temporarily rejoined NIH on July 1 with the abolishment of HSMHA. Then, the HEW secretary administratively established the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA)—composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and NIMH—as the successor organization to HSMHA.

1974—ADAMHA was officially established on May 4 when President Nixon signed P.L. 93-282.

1975—The community mental health centers program was given added impetus with the passage of the CMHC amendments of 1975.

1977—President Jimmy Carter established the President's Commission on Mental Health on February 17 by Executive Order No. 11973. The commission was charged to review the mental health needs of the Nation, and to make recommendations to the President as to how best to meet these needs. First Lady Rosalyn Carter served as the Honorary Chair of the commission.

1978—The 4-volume Report to the President from the President's Commission on Mental Health was submitted.

1980—The Epidemiologic Catchment Area (ECA) study, an unprecedented research effort that entailed interviews with a nationally representative sample of 20,000 Americans, was launched. The field interviews and first-wave analyses were completed in 1985. Data from the ECA provided an accurate picture of rates of mental and addictive disorders and services usage.

The Mental Health Systems Act—based on recommendations of the President's Commission on Mental Health and designed to provide improved services for persons with mental disorders—was passed. NIMH also participated in development of the National Plan for the Chronically Mentally Ill, a sweeping effort to improve services and fine-tune various Federal entitlement programs for those with severe, persistent mental disorders.

1981—President Ronald Reagan signed the Omnibus Budget Reconciliation Act of 1981. This act repealed the Mental Health Systems Act and consolidated ADAMHA's treatment and rehabilitation service programs into a single block grant that enabled each State to administer its allocated funds. With the repeal of the community mental health legislation and the establishment of block grants, the Federal role in services to the mentally ill became one of providing technical assistance to increase the capacity of State and local providers of mental health services.

Dr. Louis Sokoloff, an intramural NIMH researcher, received the Albert Lasker Award in Clinical Medical Research for developing a new method of measuring brain function that contributed to basic understanding and diagnosis of brain diseases. His technique, which measures the brain's use of glucose, made possible exciting new applications to positron emission tomography, or PET scanning, the first imaging technology that permitted scientists to "observe" and obtain visual images of the living, functioning brain.

Dr. Roger Sperry, a longtime NIMH research grantee, received the Nobel Prize in Medicine or Physiology for discoveries regarding the functional specialization of the cerebral hemispheres, or the "left" and "right" brain.

1983—NIMH-funded investigator Fernando Nottebohm discovered the formation of new neurons in brains of adult song-birds; this evidence of "neurogenesis" opened an exciting and clinically promising new line of research in brain science. It was 15 years, however, before investigators reported finding evidence for continued neurogenesis in the brains of adult human subjects.

1987—Administrative control of St. Elizabeth's Hospital is transferred from the NIMH to the District of Columbia. NIMH retained research facilities on the grounds of the hospital.

1989—Congress passed a resolution, subsequently signed as a proclamation by President George Bush, designating the 1990s as the "Decade of the Brain."
The NIMH Neuroscience Center and the NIMH Neuropsychiatric Research Hospital, located on the grounds of St. Elizabeth's Hospital, were dedicated on September 25.

1992—Congress passed the ADAMHA Reorganization Act (P.L. 102-321), abolishing ADAMHA. The research components of NIAAA, NIDA, and NIMH rejoined NIH, while the services components of each institute became part of a new PHS agency, the Substance Abuse and Mental Health Services Administration (SAMHSA). The return to NIH and the loss of services functions to SAMHSA necessitated a realignment of the NIMH extramural program administrative organization. New offices are created for research on Prevention, Special Populations, Rural Mental Health, and AIDS.

1993—NIMH established the Silvio O. Conte Centers program to provide a unifying research framework for collaborations to pursue newly formed hypotheses of brain-behavior relationships in mental illness through innovative research designs and state-of-the-art technologies.

NIMH established the Human Brain Project to develop—through cutting-edge imaging, computer, and network technologies—a comprehensive neuroscience database accessible via an international computer network.

1994—Intramural Research Program Revitalization—The House Appropriations Committee mandated that the director of NIH conduct a review of the role, size, and cost of all NIH intramural research programs. NIMH and the National Advisory Mental Health Council initiated a major study of the NIMH Intramural Research Program. The planning committee recommended continued investment in the Intramural Research Program and recommended specific administrative changes; many of these were implemented upon release of the committee's final report. Other changes—for example, the establishment of a major new program on Mood and Anxiety Disorders—have been introduced in the years since.

1996—NIMH, with the National Advisory Mental Health Council, initiated systematic reviews of several areas of its research portfolio, including the genetics of mental disorders; epidemiology and services for child and adolescent populations; prevention research; clinical treatment; and services research. At the request of the NIMH director, the Council established programmatic groups in each of these areas. NIMH continued to implement recommendations issued by these work groups.

NIMH increased the priority placed on research on childhood mental disorders and clinical neuroscience and initiated efforts to expand research in these areas.

NIMH expanded its efforts to safeguard and improve the protections of human subjects who participate in clinical mental health research.

1996-1998—NIMH initiated planning for integration of the Institute's peer review system for neuroscience, behavioral and social science, and AIDS research applications into the overall NIH peer review system.

1997—NIMH realigned its extramural organizational structure to capitalize on new technologies and approaches to both basic and clinical science, as well as immense changes to health care delivery systems, while retaining the Institute's focus on mental illness. The new extramural organization resulted in 3 research divisions: Basic and Clinical Neuroscience Research; Services and Intervention Research; and Mental Disorders, Behavioral Research, and AIDS.

1997-1999—NIMH refocused career development resources on early careers and added new mechanisms for clinical research.

1999—The NIMH Neuroscience Center/Neuropsychiatric Research Hospital was relocated from St. Elizabeth's Hospital in Washington, DC to the NIH Campus in Bethesda, MD, in response to the recommendations of the 1996 review of the NIMH Intramural Research Program by the IRP Planning Committee.

The first White House Conference on Mental Health, held June 7 in Washington, DC, brought together national leaders, mental health scientific and clinical personnel, patients, and consumers to discuss needs and opportunities. NIMH developed materials and helped organize the conference.

NIMH convened its fourth rural mental health research conference in August. "Mental Health at the Frontier: Alaska," was held in Anchorage, with visits by researchers and program representatives to several towns and villages. The aim was to solicit assistance in the development of a research agenda focusing on mental health issues for people who live in rural or frontier areas, with a focus on the needs of Alaska Natives.

NIMH hosted "Dialogue: Texas," which was the first in a series of mental health forums to solicit input from the public on the direction of future research at NIMH and to highlight current research. Held in San Antonio, the forum provided Texas consumers, researchers, care providers, and policymakers the opportunity to discuss mental health issues of greatest concern. The meeting focused on Latino and Hispanic populations.

U.S. Surgeon General David Satcher released The Surgeon General's Call To Action To Prevent Suicide, in July, and the first Surgeon General's Report on Mental Health, in December. NIMH, along with other Federal agencies, collaborated in the preparation of both of these landmark reports.

In the late 1990s, NIMH began to strengthen its efforts to include the public in its priority setting and strategic planning processes, instituting a variety of approaches to ensure increased public participation.

The NIMH expanded and revitalized its public education and prevention information dissemination programs, including information on suicide, eating disorders, and panic disorder, in addition to the ongoing Institute educational program, Depression: Awareness, Recognition, and Treatment (D/ART).

NIMH also launched an initiative to educate people about anxiety disorders, to decrease stigma and trivialization of these disorders, and to encourage people to seek treatment promptly.

NIMH included members of the public on its scientific review committees reviewing grant applications in the clinical and services research areas.

2000—NIMH created the Council Work Group on Training for Diversity in February to ensure adequate opportunities for minorities to pursue research careers, and to track the success of related Institute programs.
NIMH launched a 5-year communications initiative in March called the Constituency Outreach and Education Program, enlisting nationwide partnerships with state organizations to disseminate science-based mental health information to the public and health professionals, and increase access to effective treatments.

In March, NIMH assisted First Lady Hillary Rodham Clinton in conducting a meeting on the Safe Use of Medication to Treat Young Children.

NIMH co-hosted 2 town meetings in Chicago on the mental health needs of minority youth and related research. The first meeting, held in April, focused on behavioral, emotional, and cognitive disorders; the impact of violence; the criminalization of youth with treatment needs; service system issues; barriers to treatment; and barriers to research. The July 2000 meeting addressed the prevention of sexually transmitted diseases, such as HIV, and the role of the family and society in stemming the spread of HIV, as well as the increase in violence. Members of the general public, parents, teachers, school officials, guidance counselors, and professionals in the health, family assistance, social services, and juvenile justice fields attended the meetings.

NIMH organized the 14th International Conference on Challenges for the 21st Century: Mental Health Services Research, held in Washington, DC in July, to address how to meet mental health service needs nationwide most effectively, reduce health disparities, and provide equitable treatments in an era of managed care.

Dr. Eric Kandel and Dr. Paul Greengard, each of whom has received NIMH support for more than 3 decades, shared the Nobel Prize in Physiology or Medicine with Sweden's Dr. Arvid Carlsson. Dr. Kandel received the prize for his elucidating research on the functional modification of synapses in the brain. Initially using the sea slug as an experimental model but later working with mice, he established that the formation of memories is a consequence of short- and long-term changes in the biochemistry of nerve cells. Further, he and his colleagues showed that these changes occur at the level of synapses. Dr. Greengard was recognized for his discovery that dopamine and several other transmitters can alter the functional state of neuronal proteins. These findings made it clear that signaling between neurons could alter their function not only in the short term but also in the long term. Also, he learned, such changes could be reversed by subsequent environmental signals.

Dr. Nancy Andreasen, a psychiatrist and long-time NIMH grantee, receives the National Medal of Science for her groundbreaking work in schizophrenia and for joining behavioral science with neuroscience and neuroimaging. The Presidential Award is one of the nation's highest awards in science.

2001—In Pittsburgh, NIMH convened more than 150 clinical and basic scientists with expertise relevant to the study of mood disorders to help develop a Research Strategic Plan for Mood Disorders. A public forum held in conjunction with the meeting focused on the frequent co-occurrence of depression with general medical illnesses.

NIMH launched several long-term, large-scale, multi-site, community-based clinical studies to determine the effectiveness of treatment for bipolar disorder (also called manic-depressive illness); depression in adolescents; antipsychotic medications in the treatment of schizophrenia, and management of psychotic symptoms and behavioral problems associated with Alzheimer's disease; and subsequent treatment alternatives to relieve depression.

The Surgeon General released a Report on Children's Mental Health indicating that the nation is facing a public crisis in the mental health of children and adolescents. The National Action Agenda outlines goals and strategies to improve services for children and adolescents with mental and emotional disorders. NIMH, along with other Federal agencies, collaborated in the preparation of this report.

2002—NIMH published a national conference report entitled 'Mental Health and Mass Violence: Evidence-Based Early Psychological Intervention for Victims/Survivors of Mass Violence: A Workshop to Reach Consensus on Best Practices.' While most people recover from a traumatic event in a resilient fashion, the report indicates that early psychological intervention guided by qualified mental health caregivers can reduce the harmful psychological and emotional effects of exposure to mass violence in survivors. NIMH and the Department of Defense, along with other Federal agencies and the Red Cross, collaborated in the preparation of this report.

2003—Real Men. Real Depression campaign launched to raise awareness about depression in men and create an understanding of the signs, symptoms, and available treatments. The campaign was designed to inspire other men to seek help after hearing from real men talking about their experiences with depression, treatment, and recovery.

NIMH, in collaboration with the University of New Mexico, hosted a regional public outreach meeting, Dialogue Four Corners, in April that focused on the Four Corners area of New Mexico, Arizona, Colorado, and Utah. Over 350 stakeholders— including consumers and their families, health care providers, policy makers, advocates, and researchers—gathered to discuss the impact of mental illness on American Indian and Hispanic populations living in rural communities and to help NIMH shape its future research agenda on issues relevant to the region.

2004—The Treatment of Adolescent Depression Study (TADS), one of NIMH's 4 large-scale practical clinical trials, yielded important first phase results. The clinical trial of 439 adolescents with major depression [http://www.nimh.nih.gov/health/topics/depression/depression-in-children-and-adolescents.shtml] found a combination of medication and psychotherapy to be the most effective treatment over the course of the 12-week study. The study compared cognitive-behavioral therapy with fluoxetine, currently the only antidepressant approved by the FDA for use in children and adolescents.

2005—Results from the first phase of the Clinical Antipsychotic Trials of Intervention Effectiveness research program (CATIE), the second of NIMH's 4 large-scale practical clinical trials, provided, for the first time, detailed information comparing the effectiveness and side effects of 5 medications—both new and older medications—that are currently used to treat people with schizophrenia. Overall, the medications were comparably effective but were associated with high rates of discontinuation due to intolerable side effects or failure to control symptoms adequately. Surprisingly, the older, less expensive medication used in the study generally performed as well as the newer medications. The NIMH-funded study included more than 1,400 people.

NIMH and the National Alliance for Research on Schizophrenia and Depression (NARSAD) collaborated to help launch the Schizophrenia Research Forum, an online resource—www.schizophreniaforum.org—that aims to advance research in schizophrenia and related diseases. NARSAD is one of the largest donor-supported organizations that funds research on the brain and behavioral disorders.
In the first few weeks after Hurricane Katrina, and later Hurricane Rita, staff from NIMH traveled to the southern Gulf Coast region to provide immediate mental health treatment and prevention services to storm survivors and emergency response staff serving affected communities. In total, NIMH sent 26 scientists, clinicians, nurses, and social workers. Staff provided care to city police and fire squads, allowing these men and women to continue to perform vital services to the city. Others provided treatment assessment and evaluation for children and adolescents who were evacuated from the Mississippi Gulf area.

2006—NIMH launched the inaugural edition of Inside NIMH, a new electronic newsletter designed to be published three times each year following meetings of the National Advisory Mental Health Council. The e-newsletter provides the latest news on funding opportunities and policies at NIMH, as well as highlights of research breakthroughs, new tools for mental health research, and public education efforts.

At the open session of the September meeting of NIMH’s National Advisory Mental Health Council, Dr. John March, principal investigator of NIMH’s TADS program, provided the latest findings of the study, which suggested that even after 18 weeks, the combination of medication and psychotherapy continued to provide the fastest, most effective outcome. Psychotherapy alone could be a viable option for adolescents unable to take medication, but required 6 extra months to achieve the same improvement as treatments involving medication.

Results from the first phase of NIMH’s CATIE study focused on Alzheimer’s disease yielded evidence that commonly prescribed antipsychotic medications used to treat Alzheimer’s patients with delusions, aggression, hallucinations, and other similar symptoms can benefit some patients, but they appear to be no more effective than a placebo when adverse side effects are considered. The study provided the first real-world test of antipsychotic medications prescribed for these patients.

Results from the NIMH-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) research program, the nation’s largest clinical trial for depression (and the third of NIMH’s 4 practical clinical trials), reported a series of results over the course of the year. The program included 2,876 participants. Phase 1 results, which used flexible adjustment of dosages based on quick and easy-to-use clinician ratings of symptoms and patient self-ratings of side effects, helped clinicians to track ‘real world’ patients who became symptom-free and to identify those who were resistant to the initial treatment over the course of 14 weeks. Phase 2 results showed that 1 in 3 depressed patients who previously did not achieve remission using an antidepressant became symptom-free with the help of an additional medication and 1 in 4 achieved remission after switching to a different antidepressant. Phases 3 and 4 together showed that patients with treatment-resistant depression had a modest chance of becoming symptom-free when they tried different treatment strategies after 2 or 3 failed treatments.

Dr. Aaron T. Beck—professor emeritus of psychiatry at the University of Pennsylvania, the founder of cognitive therapy, and a long-time NIMH grantee—was named the recipient of the prestigious Lasker Award for Clinical Medical Research.

2007—Building on previous research, several studies in the NIMH Intramural Research Program have shown that the drug ketamine relieves depression within hours and helped to clarify a possible mechanism behind this finding. While ketamine itself probably won’t come into use as an antidepressant because of its side effects, the new results move scientists considerably closer to understanding how to develop faster-acting antidepressant medications. Current medications to treat depression can take weeks to have an effect.

Findings from another NIMH clinical study—The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)—revealed that people receiving medication treatment for bipolar disorder are more likely to get well faster and stay well if they also receive intensive psychotherapy.

A simulation study, conducted by Dr. Philip Wang of Harvard University (currently at NIMH) and colleagues, revealed that providing a minimal level of enhanced care for employees’ depression would result in a cumulative savings to employers of $2,898 per 1,000 workers over 5 years. Savings from reduced absenteeism and employee turnover and other benefits of the intervention began to exceed the costs of the program by the second year, yielding a net savings of $4,633 per 1,000 workers.

2008—NIMH began implementation of a new Strategic Plan (View Image.) with 4 major objectives:

- Promote discovery in the brain and behavioral sciences to fuel research on the causes of mental disorders [http://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml#strategic-objective1]
- Chart mental illness trajectories to determine when, where, and how to intervene [http://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml#strategic-objective2]
- Develop new and better interventions that incorporate the diverse needs and circumstances of people with mental illnesses [http://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml#strategic-objective3]
- Strengthen the public health impact of NIMH-supported research [http://www.nimh.nih.gov/about/strategic-planning-reports/index.shtml#strategic-objective4]

NIMH’s Dr. Linda Brady, director of the Division of Neuroscience and Basic Behavioral Science, received the first Individual Roadmap Compass Award on October 24, 2008, for her leadership and coordination of the Molecular Libraries [http://nihroadmap.nih.gov/molecularlibraries/] Working Group.

NIMH and the U.S. Army entered into a memorandum of agreement (MOA) to conduct research that will help the Army reduce the rate of suicides. The MOA allows for a $50 million, multi-year study on suicide [http://www.nimh.nih.gov/health/topics/suicide-prevention/index.shtml] and suicidal behavior among soldiers, across all phases of Army service. It will be the largest single study on the subject of suicide that NIMH has ever undertaken. (View Image.)

Twelve NIMH staff members received the 2008 Hubert H. Humphrey Award for Service to America for their work in addressing the mental health needs of returning veterans. In an effort to address pressing scientific and public health needs related to the ongoing wars, these staff developed a new research initiative [http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-09-070.html] seeking grants designed to describe and evaluate national, state and local programs that address the mental health needs of returning service members and their families.

2009—Using the unprecedented additional funding made available through the American Recovery and Reinvestment Act, NIMH supported an additional $196 million in research in fiscal year 2009. Included in this amount was $33 million for research on autism. Approximately 240 additional projects were supported.
Following up to the MOU that was signed in 2008 and with $50 million in funding from the U.S. Army, NIMH launched the Army Study to Assess Risk and Resilience in Service Members (Army STARRS). Army STARRS is the largest study of suicide and mental health among military personnel ever undertaken and will identify modifiable risk and protective factors related to mental health and suicide.

**NIMH LEGISLATIVE CHRONOLOGY**

1929—P.L. 70-672 established 2 Federal "narcotics farms" and authorized a Narcotics Division within PHS.

1930—P.L. 71-357 redesignated the PHS Narcotics Division to the Division of Mental Hygiene.


1946—P.L. 79-487, the National Mental Health Act, authorized the Surgeon General to improve the mental health of U.S. citizens through research into the causes, diagnosis, and treatment of psychiatric disorders.

1949—NIMH was established April 15.

1953—Reorganization plan No. 1 assigned PHS to the newly created U.S. Department of Health, Education, and Welfare.

1955—P.L. 84-182, the Mental Health Study Act, authorized NIMH to study and make recommendations on mental health and mental illness in the U.S. The act also authorized the creation of the Joint Commission on Mental Illness and Health.

1956—P.L. 84-830, the Alaska Mental Health Enabling Act, provided for territorial treatment facilities for mentally ill individuals in Alaska.

1963—P.L. 88-164, the Mental Retardation Facilities and Community Mental Health Centers Construction Act, provided for grants for assistance in the construction of community mental health centers nationwide.

1965—P.L. 89-105, amendments to P.L. 88-164, provided for grants for the staffing of community mental health centers.


1967—P.L. 90-31, Mental Health Amendments of 1967, separated NIMH from NIH and raised it to bureau status in PHS.

1968—NIMH became a component of the newly created Health Services and Mental Health Administration.

P.L. 90-574, The Alcoholic and Narcotic Addict Rehabilitation Amendments of 1968, authorized funds for the construction and staffing of new facilities for the prevention of alcoholism and the treatment and rehabilitation of alcoholics.

1970—P.L. 92-211, Community Mental Health Centers Amendments of 1970, authorized construction and staffing of centers for 3 more years, with priority on poverty areas.

P.L. 91-513, Comprehensive Drug Abuse Prevention and Control Act of 1970, expanded the national drug abuse program by extending the services of federally funded community treatment centers to non-narcotic drug abusers as well as addicts.

P.L. 91-616, Comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment, and Rehabilitation Act, authorized the establishment of a National Institute on Alcohol Abuse and Alcoholism within NIMH.

1972—P.L. 92-255, Drug Abuse Office and Treatment Act of 1972, provided that a National Institute on Drug Abuse be established within NIMH.

1973—NIMH rejoined NIH.

NIMH later became a component of the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA).

1974—P.L. 93-282, authorized the establishment of ADAMHA.


1979—P.L. 96-88, the Department of Education Organization Act, created the Department of Education and renamed HEW the Department of Health and Human Services (HHS).

1980—P.L. 96-398, the Mental Health Systems Act, reauthorized the community mental health centers program.

1981—P.L. 97-35, the Omnibus Reconciliation Act, repealed P.L. 96-398 and consolidated ADAMHA’s treatment and rehabilitation programs into a single block grant that enabled each State to administer allocated funds.


1984—P.L. 98-509, Alcohol Abuse, Drug Abuse, and Mental Health Amendments, authorized funding for block grants for fiscal years 1985 through 1987, as well as extending the authorizations for Federal activities in the areas of alcohol and drug abuse research, information dissemination, and development of new treatment methods.

1992—P.L. 102-321, the ADAMHA Reorganization Act, abolished ADAMHA, created the Substance Abuse and Mental Health Services Administration, and transferred NIMH research activities to NIH.

2000—P.L. 106-310, The Children’s Health Act of 2000, Title I Autism, instructed the Director of NIH to carry out this section through the Director of NIMH and in collaboration with other agencies that the Director determined appropriate. The Act expands, intensifies, and coordinates activities of the NIH with respect to research on autism, including the establishment of not less than 5 centers of excellence that conduct basic and clinical research into autism. The Act also mandated that the Secretary, DHHS establish an Interagency Autism Coordinating Committee (IACC) to coordinate autism research and other efforts within the Department. Authority to establish the IACC was delegated to the NIH. The NIMH was designated the NIH lead for this activity.

2006—P.L. 109-416, the Combating Autism Act of 2006, authorized expanded activities related to autism spectrum disorder (ASD) related research, surveillance, prevention, treatment, and education. Specifically, the Act authorizes research under NIH to address the entire scope of ASD; authorizes a review of regional centers of excellence for autism research and epidemiology; authorizes activities to increase public awareness, improve use of evidence-based interventions, and increase early screening for autism; and calls on the Interagency Autism Coordinating Committee to enhance information sharing.

2010—P.L. 111-148, the Patient Protection and Affordable Care Act, contains a section encouraging NIMH to continue relevant research, as well as a “Sense of the Congress” authorizing the Director of NIMH to conduct a longitudinal study of the relative mental health consequences for women of resolving a pregnancy.

BIOGRAPHICAL SKETCH OF NIMH DIRECTOR, THOMAS INSEL, M.D.

Thomas R. Insel, M.D., is Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health charged with generating the knowledge needed to understand, treat, and prevent mental disorders. With a budget of over $1.4 billion, the NIMH leads the nation’s research on disorders that affect an estimated 44 million Americans, including 1 in 5 children.

Immediately prior to his appointment as Director, which marks his return to NIMH after an 8-year hiatus, Dr. Insel was professor of psychiatry at Emory University. There, he was founding director of the Center for Behavioral Neuroscience, one of the largest science and technology centers funded by the National Science Foundation and, concurrently, director of an NIH-funded Center for Autism Research. From 1994 to 1999, he was director of the Yerkes Regional Primate Research Center in Atlanta. While at Emory, Dr. Insel continued the line of research he had initiated at NIMH studying the neurobiology of complex social behaviors in animals. Early in his NIMH research career, which extended from 1979 to 1994, Dr. Insel conducted clinical research on obsessive-compulsive disorder (OCD), conducting some of the first treatment trials for OCD using the selective serotonin reuptake inhibitors (SSRI) class of medications. He has published over 200 scientific articles and 4 books, including the Neurobiology of Parental Care (with Michael Numan) in 2003.

Dr. Insel has served on numerous academic, scientific, and professional committees, including 10 editorial boards. He is a member of the Institute of Medicine, a fellow of the American College of Neuropsychopharmacology, and is a recipient of several awards [A. E. Bennett Award from the Society for Biological Psychiatry, Curt Richter Prize from the International Society of Psychoneuroendocrinology, Outstanding Service Award from the U.S. Public Health Service, and a Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD)]. Dr. Insel graduated from the combined B.A.–M.D. program at Boston University in 1974. He did his internship at Berkshire Medical Center, Pittsfield, MA, and his residency at the Langley Porter Neuropsychiatric Institute at the University of California, San Francisco.

NIMH DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert H. Felix</td>
<td>1949</td>
<td>1964</td>
</tr>
<tr>
<td>Stanley F. Yolles</td>
<td>1964</td>
<td>1970</td>
</tr>
<tr>
<td>Bertram S. Brown</td>
<td>1970</td>
<td>1977</td>
</tr>
<tr>
<td>Herbert Pardes</td>
<td>1977</td>
<td>1984</td>
</tr>
<tr>
<td>Shervert H. Frazier</td>
<td>1984</td>
<td>1986</td>
</tr>
<tr>
<td>Lewis L. Judd</td>
<td>1988</td>
<td>1992</td>
</tr>
<tr>
<td>Frederick K. Goodwin</td>
<td>1992</td>
<td>1994</td>
</tr>
<tr>
<td>Steven E. Hyman</td>
<td>1996</td>
<td>2001</td>
</tr>
<tr>
<td>Richard K. Nakamura (Acting)</td>
<td>2001</td>
<td>2002</td>
</tr>
<tr>
<td>Thomas R. Insel</td>
<td>2002</td>
<td>Present</td>
</tr>
</tbody>
</table>

NIMH PROGRAMS

http://www.nimh.nih.gov/about/organization/index.shtml
Office of the Director
http://www.nimh.nih.gov/about/organization/od/index.shtml

This office coordinates all NIMH research and activities working toward a better understanding of the causes, diagnosis, treatment, and prevention of HIV/AIDS. The office also cooperates with voluntary and professional health organizations, other NIH components, and Federal agencies to identify national research needs and opportunities directed toward meeting AIDS-related public health goals.


This office oversees the NIMH’s public liaison and outreach efforts, including requesting and receiving public input on the Institute’s activities, as well as promoting and coordinating Institute interactions with patient advocacy, professional, scientific, and community-based organizations with specific interests in NIMH’s mission and programs. The office also monitors mental health-related legislation and issues, and reviews all mental health-related reports to the Congress and other Federal agencies. On request, the office develops analyses and serves as a principal point of contact for interactions with NIH and Departmental staff, as well as with senior staff of the Office of the President and other Federal agencies.

Office for Research on Disparities and Global Mental Health (ORDGMH) [http://www.nimh.nih.gov/about/organization/od/office-for-research-on-disparities-and-global-mental-health-ordgmh.shtml]

The NIMH Office for Research on Disparities and Global Mental Health (ORDGMH) coordinates the Institute’s efforts to reduce mental health disparities both within and outside of the United States. The office’s combined focus on local and global mental health disparities reflects an understanding of how the rapid movements of populations, global economic relationships, and communication technologies have created more permeable borders and new forms of interconnectedness among nations and people. These trends both require and enable researchers to address the variations in incidence, prevalence, and course of mental disorders and access to care across diverse populations using a global perspective.

ORDGMH oversees research on global mental health, health disparities, and women’s mental health. The office works in close collaboration with NIMH’s Office of Rural Mental Health Research to address the mental health needs of people living in rural areas.


This office directs the Institute’s resource allocation and management improvement processes by overseeing program planning and financial management, acquisition management, information management, management policy and procedure development, interpretation and implementation, the provision of general administrative services throughout the Institute, and personnel operations.

Office of Rural Mental Health [http://www.nimh.nih.gov/about/organization/od/office-of-rural-mental-health-research-ormhr.shtml]

This office supports research activities and provides information on conditions unique to people living in rural areas, including research on the delivery of mental health services to such areas. Also, the office coordinates related Departmental research and activities with public and nonprofit entities.


This office plans and directs a comprehensive strategic agenda for national mental health policy, including science program planning and related policy evaluation, research training and coordination, and technology and information transfer. In order to develop and assess NIMH strategic plan and portfolio management, OSPPC plans and implements portfolio analysis, scientific disease coding, and program evaluations. OSPPC also creates and implements the Institute’s communication efforts, including information dissemination, media relations, and internal communications. The office proposes and guides science education activities concerned with informing the scientific community and public about diagnosis, treatment, and prevention of mental and brain disorders. In addition, the office is responsible for managing issues related to the Freedom of Information Act (FOIA), correspondence control, and clearance services for the Institute.

Division of Neuroscience and Basic Behavioral Science (DNBBS)
http://www.nimh.nih.gov/about/organization/dnbs/index.shtml

The DNBBS supports research programs in the areas of basic neuroscience, genetics, basic behavioral science, research training, resource development, technology development, drug discovery, and research dissemination. In cooperation with other components of the Institute and the research community, the division has the responsibility of ensuring that relevant basic science knowledge is generated and then harvested improve diagnosis, treatment, and prevention of mental and behavioral disorders.

Office of Cross-Cutting Science and Scientific Technology

This office provides the programmatic lead on numerous scientific activities that cut across divisions, NIH institutes and centers, and agencies. These activities include, but are not limited to, the following: NIMH Small Business Research Program coordination; NIH Blueprint for Neuroscience Research; NIH BISTIC (Biomedical Information Science and Technology Initiative Consortium); NIH BECON (BioEngineering CONsortium); NIH Nano Task Force; and the United States-European Commission Task Force on Biotechnology. In addition, the office coordinates NIMH involvement in several NIH Roadmap Initiatives (Interdisciplinary Research, Bioinformatics and Computational Biology, and Nanomedicine). The office also supports research and development of scientific technologies related to brain and behavioral research, including software (such as informatics tools and resources), hardware (such as devices and instrumentation), and wetware (such as novel genetic methods or bioactive and molecular imaging agents).

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs [http://www.nimh.nih.gov/about/organization/dnbs/small-business-innovation-research-and-small-business-technology-transfer-programs.shtml]
The SBIR Program supports research and development by small businesses of innovative technologies that have the potential to succeed commercially or provide significant societal benefit. The STTR program has the same objectives but requires academic research involvement. In the DNBBS, the SBIR and STTR programs support research and the development of tools related to basic brain and behavioral science, genetics, and drug discovery and development relevant to the mission of NIMH.

**Office of Research Training and Career Development**

This office supports research training at the pre-doctoral, postdoctoral, and early investigator level of career development in basic neuroscience, basic behavioral science, and other areas relevant to the focus of the DNBBS. The office's primary goal is to ensure that sufficient, highly trained research investigators will be available to address basic and clinical research questions pertinent to mental health and mental illness and thereby to reduce the burden of mental and behavioral disorders.

**Genomics Research Branch** [http://www.nimh.nih.gov/about/organization/dnbb/genomics-research-branch/index.shtml]

The Genomics Research Branch plans, supports, and administers programs of research including the identification, localization, and function of genes and other genomic elements that produce susceptibility to mental disorders. Research projects use genetic epidemiological methods, population-based sampling; longitudinal cohort and extended-family study designs; and genomic approaches to identify genetic, biological, and environmental risk factors and biomarkers for diagnosis, prognosis, drug efficacy, and pharmacogenomics of mental disorders. The branch also supports the creation and distribution of research resources, including the development of novel statistical and bioinformatics tools and the NIMH Human Genetics Initiative, a repository of DNA extracted from blood and immortalized cell lines and associated clinical information for use in genetic studies of mental disorders.

**Molecular, Cellular, and Genomic Neuroscience Research Branch**

This branch plans and administers research programs that elucidate the genetic, molecular, and cellular mechanisms underlying brain development, neuronal signaling, synaptic plasticity, circadian rhythmicity, and the influence of hormones and immune molecules on brain function. Other supported activities include drug discovery, identification of novel drug targets, development of functional imaging ligands, development of imaging probes as potential biomarkers, testing of models for assessing novel therapeutics, and studies of mechanisms of action of therapeutics in animals and humans.

**Behavioral Science and Integrative Neuroscience Research Branch**

This branch supports innovative research—including empirical, theoretical, and modeling approaches—on cognitive, affective, social, motivational, and regulatory systems and their development across the lifespan in humans, in nonhuman primates, and in other animals. Relevant reduced and model systems approaches are also supported. Basic research in these areas provides a foundation for new insights into the nature and origins of mental and behavioral disorders and for the development of improved treatment and prevention interventions.


This program provides infrastructure support and coordination for the NIH Roadmap Molecular Libraries Screening Centers Network and for related technology development projects. The program supports research on biological assay implementation, high-throughput screening to identify active compounds, synthetic chemistry and probe development, and informatics.

**Division of Adult Translational Research and Treatment Development (DATR)**

[http://www.nimh.nih.gov/about/organization/datr/index.shtml]

The DATR supports programs aimed at understanding the pathophysiology of adult and late-life mental illness and hastening the translation of behavioral science and neuroscience advances into innovations in clinical care. The division supports a broad research portfolio, which includes studies of the phenotypic characterization and risk factors for major psychiatric disorders; clinical neuroscience to elucidate etiology and pathophysiology of these disorders; and psychosocial, psychopharmacologic, and somatic treatment development.

**SBIR and STTR Programs**

The SBIR program supports research and development by small businesses of innovative technologies that have the potential to succeed commercially or to provide significant societal benefits; the STTR program has the same objectives but requires academic research involvement. In the DATR, the SBIR and STTR programs support research aimed at facilitating the validation and commercialization of new methods of assessing psychopathology, measuring treatment response to therapeutic agents or approaches, and the clinical development of novel psychopharmacological or psychosocial approaches to the treatment of adult and late life mental illness.

**Research Training and Career Development Program**

This program supports research training at the pre-doctoral, post-doctoral, and early-investigator levels of career development in areas relevant to the DATR. These areas include adult psychopathology and psychosocial interventions, clinical neuroscience, geriatrics, translational research focusing on adults, and experimental therapeutics and treatment mechanisms related to mental illness. The program's primary goal is to ensure that sufficient numbers of highly trained, independent investigators will be available to address the complexities of adult psychopathology and translational research.

**Traumatic Stress Research Program**

This program is the DATR/NIMH point of contact for disaster/terrorism/biodefense-related research, supporting studies on biopsychosocial risk/protective factors for psychopathology after traumatic events and on interventions for post-traumatic stress disorder (PTSD) in adults. The program also oversees research spanning
and integrating basic science, clinical practice, and health care system factors, including interventions and service delivery, regarding the effects of mass trauma and violence (e.g., war, terrorism, and natural and technological disaster) on children, adolescents, and adults.

**Adult Psychopathology and Psychosocial Intervention Research Branch**

This branch promotes translational research that is directed toward an understanding of how the development, onset, and course of adult psychopathology may be studied in terms of dysfunction in fundamental biobehavioral mechanisms such as emotion, cognition, motivational processes, and interpersonal relationships. The branch emphasizes studies that combine approaches from neuroscience and behavioral science to elucidate the role of psychosocial factors in the alterations of brain functioning associated with mental disorders and to produce integrative models of risk, disorder, and recovery.

**Clinical Neuroscience Research Branch**

This branch supports research, training, and resource development programs aimed at understanding the neural basis of mental disorders. Specifically supported are human and animal studies on the molecular, cellular, and systems level of brain function designed to elucidate the pathophysiology of mental disease and to translate these findings to clinical diagnosis, treatment, and prevention strategies.

**Geriatrics Research Branch**

This branch supports research in the etiology and pathophysiology of mental disorders of late life (such as Alzheimer’s disease and related dementias, neuroregulatory and hemostatic disorders, and menstrual cycle disorders), the treatment and recovery of persons with these disorders, and the prevention of these disorders and their consequences. The program encourages collaborative multidisciplinary research programs using the tools of molecular neuroscience, cognitive sciences, and social and behavioral sciences to facilitate the translation of basic science and preclinical research to clinical research.

**Experimental Therapeutics Branch**

This branch also engages in cross-Institute activities to identify specific bottlenecks in the development of novel treatments for mental disorders and collaborates with academic, industry, and regulatory agencies to develop programmatic approaches to hasten the availability of better treatments to reduce the burden of mental illness.

**Division of Developmental Translational Research (DDTR)**


The DDTR supports programs of research and research training with the ultimate goal of preventing and curing mental disorders that originate in childhood and adolescence. Relevant disorders include mood disorders, anxiety, schizophrenia, autism, attention deficit hyperactivity disorder, conduct disorder, eating disorders, obsessive compulsive disorder, and Tourette syndrome. The division stimulates and promotes an integrated program of research across basic behavioral/psychological processes, environmental processes, brain development, genetics, developmental psychopathology, and therapeutic interventions.

**SBIR and STTR Programs**

The SBIR program supports research and development by small businesses of innovative technologies that have the potential to succeed commercially or to provide significant societal benefits; the STTR program has the same objectives but requires academic research involvement. In the DDTR, the SBIR and STTR programs support research aimed at the development and validation of new methods and techniques to advance understanding, prevention, and treatment of child psychopathology.

**Research Training and Career Development Program**

This program supports research training at the pre-doctoral, post-doctoral, and early investigator level of career development in areas relevant to the DDTR. The program's primary goal is to ensure that sufficient numbers of highly trained, independent investigators will be available to address the complexities of developmental psychopathology that inform the trajectories and mechanisms of mental disorders.

**Developmental Trajectories of Mental Disorders Branch**

This branch supports research that identifies trajectories of mental disorders by looking across time (e.g., across developmental stages) at sequential and integrative relationships among genetic, neural, behavioral, and experiential/environmental factors leading to psychopathology or to recovery. Emphasis is on developmental progressions and the identification of early signs, risk factors, predictors, and biological mediators/moderators of continuity or change. The branch also supports prevention and treatment trials and testing of personalized interventions. The branch strongly encourages cross-disciplinary research collaborations. Studies of humans and non-human animals are supported.

**Neurobehavioral Mechanisms of Mental Disorders Branch**

This branch supports research that identifies mechanisms responsible for mental disorders by looking across levels of analysis to specify genetic, neural, behavioral, and environmental components that interact to define etiology of childhood-onset mental disorders. Cognitive, emotional, sensorimotor, and biobehavioral processes that are often shared across disorders, and the neurobiological mechanisms underlying them, are of particular interest to this branch. Also of interest is research leading to the identification of biomarkers and novel pharmacologic agents, as well as the development of novel mechanism-based cognitive or behavioral interventions for childhood-onset mental disorders. This branch encourages cross-disciplinary research collaborations. Studies involving human and non-human animals are supported.
Division of AIDS Health and Behavior Research (DAHBR)

http://www.nimh.nih.gov/about/organization/dahbr/index.shtml

The DAHBR supports research programs that focus on developing and disseminating behavioral interventions that prevent HIV/AIDS transmission, clarifying the pathophysiology and alleviating the neuropsychiatric consequences of HIV/AIDS infection, and using a public health model to reduce the burden of mental illness from medical co-morbidities, non-adherence to treatment, societal stigma, health disparities, and unhealthy behaviors.

SBIR and STTR Programs

The SBIR program supports research and development by small businesses of innovative technologies that have the potential to succeed commercially or to provide significant societal benefits. The STTR program has the same objectives but requires academic research involvement. In the DAHBR, the SBIR and STTR programs support research aimed at changing risky behaviors, promoting strategies to reduce AIDS transmission, elucidating the pathophysiology of HIV-related neuropsychiatric dysfunction, and investigating processes that influence adherence to treatment in individuals with HIV.

Research Training and Career Development Program

This program supports research training at the pre-doctoral, post-doctoral, and early-investigator level of career development in areas relevant to the DAHBR, such as research on treatment adherence and behavior change in patients with mental disorders. The program's primary goal is to ensure that sufficient numbers of highly trained independent investigators will be available to address the complexities of health behaviors involved in mental illness.

Center for Mental Health Research on AIDS

This center supports domestic and international studies to develop behavior change and prevention strategies to reduce the transmission of HIV and other sexually transmitted diseases. To accomplish this goal, the center oversees research in developing and testing interventions to reduce the neuropsychiatric morbidity associated with HIV infection, clarifying the pathophysiology of HIV infection of the central nervous system (CNS) and associated motor/cognitive disturbances, developing therapeutic agents to prevent or reverse the effects of HIV on the CNS, improving the effectiveness and efficiency of mental health services relevant to HIV infection and people living with HIV and co-occurring mental illness, and other related areas.

Health and Behavioral Research Branch

This branch supports research on a range of health behaviors in people with mental disorders, such as identifying potent, modifiable risk and protective factors for mental disorders that may guide the development and initial testing of theory-driven interventions. Interventions may comprise prevention, treatment, or rehabilitation and include biological, pharmacological, behavioral, psychosocial, or environmental components. Examples of supported research areas include adherence to interventions for mental disorders, ethics in mental disorders research, and functional assessment in people with mental disorders.

Division of Services and Intervention Research (DSIR)

http://www.nimh.nih.gov/about/organization/dsir/index.shtml

The DSIR supports 2 critical areas of research: intervention research to evaluate the effectiveness of pharmacologic, psychosocial (psychotherapeutic and behavioral), somatic, rehabilitative, and combination interventions on mental and behavior disorders; and mental health services research on organization, delivery (process and receipt of care), related health economics, delivery settings, clinical epidemiology, and the dissemination and implementation of evidence-based interventions into service settings. The division also provides biostatistical analysis and clinical trials operations expertise for research studies; analyzes and evaluates national mental health needs and community research partnership opportunities; and supports research on health disparities.

SBIR and STTR Programs

The SBIR program supports research and development by small businesses of innovative technologies that have the potential to succeed commercially or to provide significant societal benefits. The STTR program has the same objectives but requires academic research involvement. In the DSIR, the SBIR and STTR programs support research and development of tools related to clinical trials (including preventive, treatment, and rehabilitative interventions alone or in combination), clinical epidemiology, services research, effectiveness research, health disparities (including rural populations), and the dissemination of evidence-based treatments and research into services and clinical practice in areas directly related to the mission of NIMH.

Office of Research Training and Career Development

This office supports research training at the pre-doctoral, post-doctoral, and early-investigator levels of career development in areas relevant to the DSIR. Areas of emphasis include research related to clinical trials (including preventive, treatment, and rehabilitative interventions alone or in combination) and adapting interventions and demonstrating their utility in broad populations (e.g., ethnic and racial groups, co-morbidities) for various service settings (e.g., primary care, schools, public sector). The office's primary goal is to ensure that sufficient, highly trained research investigators will be available to address interventions and services research questions pertinent to mental health and mental illness and thereby to reduce the burden of mental and behavioral disorders.

Clinical Trials Operations and Biostatistics Unit

This unit serves as the operations focal point for collaborative clinical trials on mental disorders in adults and children. The unit is responsible for overseeing both contract-supported and cooperative agreement-supported multisite clinical trial protocols, as well as special projects undertaken by NIMH. In addition, the unit manages overarching matters related to clinical trials operations, such as the coordination of the ancillary protocols across the large trials and the implementation of NIMH policy for dissemination of public access datasets. The unit also consults Institute staff and grantees/contractors on biostatistical matters related to appropriateness of study design, determination of power and sample size, and approaches to statistical analysis of data from NIMH-supported clinical trials.
Adult Treatment and Preventive Intervention Research Branch

This branch supports research evaluating therapeutic (acute, maintenance, and preventive) and adverse effects of psychosocial, psychopharmacologic, and somatic interventions of proven efficacy in the treatment of mental disorders in adult populations. For example, the branch has administered trials evaluating modified or adapted forms of interventions for use with special populations (such as women, or specific ethnic or racial groups), in new settings (public sector, primary care, workplace, other non-academic sites), through new methods of treatment delivery (e.g., web or computer-based). Studies look beyond symptom reduction to include short- and long-term assessment of functioning and other outcome measures that can help identify disorder subgroups more likely to benefit from treatment, to determine the optimal length of treatment, and to evaluate the long-term impact of interventions.

Child and Adolescent Treatment and Preventive Intervention Research Branch

This branch plans, supports, and administers research programs to evaluate the effectiveness of mental health preventive, treatment, and rehabilitative interventions (alone or in combination) for children and adolescents. The branch also supports research addressing the long-term effectiveness of known successful interventions, including their role in preventing relapse and recurrence of mental disorders. Types of intervention research supported by the branch include the full range of behavioral, psychotherapeutic, pharmacologic, and non-pharmacologic somatic or complementary/alternative approaches for which acute efficacy has been demonstrated, as well as as rehabilitation or other adjunctive interventions.

Services Research and Clinical Epidemiology Branch

This branch administers programs of research, training, and infrastructure development, across the lifespan, on all mental health services research issues, including but not limited to: services organization, delivery (process and receipt of care), and related health economics at the individual, clinical, program, community, and systems levels in specialty mental health, general health, and other delivery settings (such as the workplace); interventions to improve the quality and outcomes of care, including diagnostic, treatment, preventive, and rehabilitation services; enhanced capacity for conducting services research; clinical epidemiology of mental disorders across all clinical and service settings; and dissemination and implementation of evidence-based interventions into service settings.

Division of Extramural Activities (DEA)
http://www.nimh.nih.gov/about/organization/dea/index.shtml

The DEA provides leadership and advice in developing, implementing, and coordinating extramural programs and policies; represents the Institute on extramural program and policy issues within HHS and with outside organizations; provides scientific and technical peer and objective review of applications for grants, cooperative agreements, and contracts; provides information and guidelines for grant applications; oversees National Advisory Mental Health Council activities and provides committee management services.

Division of Intramural Research Programs (DIRP)
http://intramural.nimh.nih.gov/

The DIRP is the internal research division of the NIMH. Intramural scientists conduct research ranging from studies into mechanisms of normal brain function—conducted at the behavioral, systems, cellular, and molecular levels—to clinical investigations into the diagnosis, treatment, and prevention of mental illness. Major disease entities studied throughout the lifespan include mood disorders and anxiety, schizophrenia, obsessive-compulsive disorder, attention deficit hyperactivity disorder, and pediatric autoimmune neuropsychiatric disorders. Because of its outstanding resources, unique funding mechanisms, and location in the nation's capital, the DIRP is viewed as a national resource, providing unique opportunities in mental health research and research training.

This page last reviewed on January 5, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

The National Institute on Minority Health and Health Disparities (NIMHD) promotes minority health and leads, coordinates, supports, and assesses the NIH effort to reduce and ultimately eliminate health disparities. The NIMHD works independently and in partnership with the NIH Institutes and Centers and with other Federal agencies, and other non-federal groups and organizations to improve health and address the disparities in health status. To achieve its mission, the NIMHD:

- Conducts and supports basic, clinical, social sciences, and behavioral research on health disparities;
- Promotes infrastructure development and training;
- Fosters emerging programs;
- Disseminates information; and
- Reaches out to minority and other health disparity communities.

VISION

The NIMHD envisions an America in which all populations will have an equal opportunity to live long, healthy and productive lives.

IMPORTANT EVENTS IN NIMHD HISTORY

1990—The Office of Minority Programs (OMP) was established in the NIH Office of the Director, at the request of then Secretary of the U.S. Department of Health and Human Services, Dr. Louis Sullivan. Dr. John Ruffin was appointed Associate Director of Minority Programs to direct the OMP.

1991—The OMP convened an advisory Fact-Finding Team (FFT) to conduct three regional conferences with grassroots constituencies. The FFT issued a report with 13 recommendations from the community that guided the initial efforts of the OMP.

1992—The Minority Health Initiative (MHI), the centerpiece of the OMP agenda, was launched in response to the FFT’s recommendations, and initially funded at $45 million. This multi-year biomedical and behavioral research and research training program is a partnership with the NIH Institutes and Centers. The OMP co-funded various projects including: 1) interventions to improve prenatal health and reduce infant mortality; 2) studies of childhood and adolescent lead poisoning; HIV infection and AIDS; 3) alcohol and drug use studies; 4) research in adult populations focused on cancer, diabetes, obesity, hypertension, cardiovascular diseases, mental disorders, asthma, visual impairments, and alcohol abuse; and 5) training for faculty and for students at all stages of the educational pipeline – from precollege and undergraduate through graduate and postdoctoral levels.

1992—The OMP initiated a study with the National Academy of Sciences designed to present an overview of NIH extramural research training programs for minority students and to assess the feasibility of conducting a trans-NIH assessment of these programs.

1993—Public Law 103-43, the Health Revitalization Act of 1993, established the Office of Research on Minority Health (ORMH) in the Office of the Director, NIH. Dr. John Ruffin was appointed as the Associate Director for Research on Minority Health.

1994—The National Conference on Minority Health Research and Research Training was held in Chicago.

1996—Conferences were held in Honolulu, Hawaii; Miami, Florida; and Puerto Rico to inform ORMH constituencies of the progress made, to solicit feedback on those achievements, and to obtain information on the needs of minority populations.

1997—The Advisory Committee on Research on Minority Health was established to provide advice to the Director, ORMH, and to the Director, NIH, regarding research and research training with respect to minority health issues.

1998—The first meeting of the Advisory Committee on Minority Health was held.

2000—The ORMH celebrated its 10th anniversary with a conference entitled Closing the Minority Health Gap: 10 Years of Progress and Challenge in Eliminating Health Disparities.
2000—The National Center on Minority Health and Health Disparities (NCMHD) was established by the passage of the Minority Health and Health Disparities Research and Education Act of 2000, Public Law 106-525, which was signed by the President of the United States, William Jefferson Clinton, on November 22, 2000. The bill was introduced into the Congress by Senator Edward Kennedy of Massachusetts.

2001—Dr. John Ruffin was sworn in as the first director of the National Center on Minority Health and Health Disparities.

2001—Programs mandated by Congress were implemented to expand the infrastructure of institutions committed to health disparities research and to encourage the recruitment and retention of highly qualified minority and other scientists in the fields of biomedical, clinical, behavioral, and health services research: (1) the Endowment Program, (2) the Loan Repayment Program for Health Disparities Research, and (3) the Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds.

2002—The Congressionally mandated program, Centers of Excellence program was launched, referred to as Project EXPORT - Partnerships for Community Outreach, Research on Health Disparities and Training.

2002—The first meeting of the National Advisory Council on Minority Health and Health Disparities (NACMHD) was convened.

2002—The NCAMHD assumed responsibility for the Research Infrastructure in Minority Institutions Program (RIMI), which was established by its predecessor ORMH, in partnership with the National Center for Research Resources.

2003—The first NIH Strategic Research Plan and Budget to Reduce and Ultimately Eliminate Health Disparities was issued.

2005—The NCMHD assumed responsibility for the Minority International Research Training Program (MIRT) which was established by its predecessor ORMH in partnership with Fogarty International Center (FIC). The program was renamed to be more consistent with the mission of the NCMHD to the Minority Health and Health Disparities International Research Training Program (MHIRT).

2005—The NCMHD Community Based Participatory Research (CBPR) program was established. This program supports community-based participatory research intervention studies to reduce health disparities caused by diseases or conditions affecting minority and other health disparity communities. NCMHD is currently funding 25 CBPR three-year planning grants.

2005—The National Research Council of the National Academies released the report Assessment of NIH Minority Research and Training Programs: Phase 3. The report was the culmination of a series of assessments and analyses of the NIH minority research and training programs initiated by the ORMH, the predecessor to the NCMHD. This report examined the effectiveness of the programs and provided recommendations for improvement.

2006—The Institute of Medicine of the National Academies issued the report Examining the Health Disparities Research Plan of the National Institutes of Health: Unfinished Business. The NCMHD requested this report to assess the adequacy of the NIH Health Disparities Strategic Plan in achieving the goals and objectives; to evaluate the adequacy of coordination among the NIH Institutes and Centers in developing the strategic plan; and to obtain recommendations to help NIH achieve the objectives of the strategic plan.

2007—The NCMHD Centers of Excellence in Partnerships for Community Outreach, Research on Health Disparities and Training (Project EXPORT), was re-competed for the first time. The program was also renamed the NCMHD Centers of Excellence program.

2008—NCMHD hosted the first NIH Science of Eliminating Health Disparities summit on December 16-18, 2008. The summit attracted more than 4,000 participants including scientists, health care practitioners, and policy makers, community leaders, and students who work or have an interest in eliminating health disparities. Acclaimed poet Maya Angelou spoke at the opening ceremony.

2008—NIH Director, Dr. Elias Zerhouni approved an Intramural Research Program (IRP) for the NCMHD. Acting NIH Director, Dr. Raynard Kington announced the creation of the NCMHD IRP at the NIH Science of Eliminating Health Disparities summit.

2009—NCMHD launched its Health Disparities Research on Minority and Underserved Populations program. This Research Project Grant (R01), funds original and innovative research addressing elements that support the advancement of research to eliminate health disparities.

2009—NCMHD launched the NIH Health Disparities Seminar Series in July 2009. The monthly lecture series brings national and international health disparities experts including NIH and federal agency partners to the NIH to share information about advances, gaps, and current issues related to health disparities research.

2009—The NCMHD Disparities Research and Education Advancing our Mission (DREAM) program was launched as a component of the NCMHD Intramural Research Program.

2009—The Research Infrastructure in Minority Institutions Program (RIMI) was renamed the Building Research Infrastructure and Capacity (BRIC) program, to be more consistent with the mission of NCMHD.

2009—NCMHD partnered with the NIH Office of Intramural Research to sponsor the 2009 NIH J. Edward Rall Cultural Lecture as part of the NIH Wednesday Afternoon Lecture Series, featuring Dr. Maya Angelou,

2010—NIMHD was re-designated to the National Institute on Minority Health and Health Disparities (NIMHD) with the passing of the Patient Protection and Affordable Care Act. In addition, the Research Endowment program was expanded to include NIMHD Centers of Excellence as eligible institutions.

JOHN RUFFIN, PH.D., NIMHD DIRECTOR

2010—NIMHD launched a Faith-based Initiative on Health Disparities and a Social Determinants of Health Initiative.

NCMHD LEGISLATIVE HISTORY


2000—P.L. 106-525, Minority Health and Health Disparities Research and Education Act of 2000, established the National Center on Minority Health and Health Disparities. It also called for the development of a NIH comprehensive strategic research plan and budget for health disparities research. It authorizes the NCMHD Director and the Director of the Agency for Health Care Research Quality (AHRQ) to define health disparity populations. The law also requires the NCMHD to maintain communications with all Public Health Service agencies and other Departments of the Federal government to disseminate health disparities research information.

2010—On March 23, 2010, the Patient Protection and Affordable Care Act (Public Law 111-148) passed and re-designated the NCMHD to an Institute, the National Institute on Minority Health and Health Disparities (NIMHD). The law gave the NIMHD authority to plan, review, coordinate, and evaluate the minority health and health disparities research activities and conducted supported by the NIH Institutes and Centers. In addition, it transferred all of the responsibilities of the NCMHD to the NIMHD, and expanded the eligibility criteria for the Research Endowment program to include institutions with an active NIMHD Center of Excellence.

BIOGRAPHICAL SKETCH

Dr. John Ruffin is the Director of the National Institute on Minority Health and Health Disparities (NIMHD). He oversees the NIMHD budget of approximately $211 million. In addition, he provides leadership for the minority health and health disparities research activities of the National Institutes of Health (NIH) which constitutes an annual budget of approximately $2.8 billion.

He is a well-respected leader and visionary in the field of minority health and health disparities. As an academician and a scientist, he has devoted his professional career to improving the health status of racial and ethnic minorities and other medically underserved populations in the United States. He has an impressive track record of developing and supporting programs to increase the cadre of minority scientists, physicians, and other health professionals, as well as attract a diverse group of researchers to the health disparities field.

His success has been due in large part to his ability to motivate others and gain the support of key individuals and organizations, as well as to his expertise in strategic planning, administration, and the development of numerous collaborative partnerships. For the past 20 years, he has led the transformation of the NIH minority health and health disparities research agenda from a programmatic concept to an institutional reality. Under his leadership the NIH Office of Minority Programs was established to address the health of minorities around the country. That Office later transitioned to the Office of Research on Minority Health, which later became the National Center on Minority Health and Health Disparities in 2000, and in March 2010 the Patient Protection and Affordable Care Act re-designated it the National Institute on Minority Health and Health Disparities.

As the NIH federal official for minority health disparities research, through multi-faceted collaborations, Dr. Ruffin has planned and brought to fruition the largest biomedical research program in the nation to promote minority health and other health disparities research and training. In his quest to eliminate health disparities, the hallmark of his approach is to foster and expand strategic partnerships in alliance with the NIH Institutes and Centers, various Federal and state agencies, community organizations, academic institutions, private sector leaders, and international governments and non-governmental organizations. Under his leadership, the NIH convened its first summit on health disparities, “The NIH Science of Eliminating Health Disparities Summit” in December 2008. The summit showcased the work, progress, and challenges of the NIH Institutes and Centers and many of their federal and non-federal government partners involved in minority health and health disparities research around the theme of Integrating Science, Practice, and Policy. The summit attracted more than 4000 individuals from around the world representing various disciplines and sectors.

Dr. Ruffin is committed to conceptualizing, developing and implementing innovative programs that create new learning opportunities and exposure for individuals, communities, and academic institutions interested in eliminating health disparities. His efforts have impacted local, regional, national and international communities. He has established and continues to expand a growing portfolio of research, training, and capacity building programs to train health professionals and scientists from health disparity populations; conduct cutting-edge health disparities research; build the capacity at academic institutions and within the community to support a promising health disparities research enterprise.

His life-long commitment to academic excellence, improving minority health and promoting training and health disparities research, has earned him distinguished national awards. Dr. Ruffin has received an honorary doctor of science degree from Spelman College, Tuskegee University, the University of Massachusetts in Boston, North Carolina State University, Morehouse School of Medicine, Meharry Medical College, Tulane University and Dillard University. He has been recognized by various professional, non-profit, and advocacy organizations including: the National Medical Association, the Society for the Advancement of Chicanos and Native Americans in Science; the Association of American Indian Physicians, the Hispanic Association of Colleges and Universities; the Society of Black Academic Surgeons; and the National Science Foundation. The John Ruffin Scholarship Program is an honor symbolic of his legacy for academic excellence bestowed by the Duke University Talent Identification Program. He has also received the Martin Luther King Jr., Legacy Award for National Service, the Samuel L. Kountz Award for his significant contribution to increasing minority access to organ and tissue transplantation; the NIH Director’s Award; the National Hispanic Leadership Award; Beta Beta Beta Biological Honor Society Award; the Department of Health and Human Services’ Special Recognition Award; and the U.S. Presidential Merit Award.

Dr. Ruffin received a B.S. in Biology from Dillard University, a M.S. in Biology from Atlanta University, a Ph.D. in Systematic and Developmental Biology from Kansas State University, and completed post-doctoral studies in biology at Harvard University.
PROGRAMS

Three official organizational components comprise NIMHD:

The Office of the Director (OD)

The Office of the Director provides overall leadership and direction to the programs, plans, and activities of the NIMHD. It determines the goals and priorities of the Institute, serves as the focal point for the coordination of the NIH minority health and health disparities research programs as authorized, and develops and directs new and special scientific programs of the Institute. The OD leads the Institute’s coordination of programs and strategic partnerships with the NIH Institutes and Centers, Federal agencies, and other stakeholders; provides management and administrative services to the Center; oversees the Institute’s ethics program; and plans and directs the Institute’s communications activities, including developing and disseminating information on minority health and health disparities research.

Division of Extramural Activities and Scientific Programs (DEASP)

This division serves as the focal point for planning, directing, implementing and managing the NIMHD extramural research programs. The DEASP provides leadership for the NIMHD’s legislatively mandated extramural research programs and other NIMHD research, research training, research capacity building, career development, and community outreach programs. It also directs the scientific peer review and grants management activities for all NIMHD programs ensuring that all awards are made in accordance with applicable policies, statutes and regulations.

Division of Scientific Strategic Planning and Policy Analysis (DSSPPA)

This division provides leadership for scientific strategic planning, evaluation, knowledge management, reporting, legislative affairs, and policy activities relative to the mission of NIMHD. The DSSPPA serves as the focal point for coordinating reports including the development of the legislatively mandated trans-NIH Health Disparities Strategic Plan, and monitoring and assessment of the trans-NIH minority health/health disparities research programs. It also advises the NIMHD staff on policy matters that support program development, science policy formulation, and overall program direction and decision-making activities.

NIMHD Leading Programs:

The Centers of Excellence Program (COE) is congressionally mandated by Public Law 106-525. The program was established to develop novel programs in the U.S. that would make significant advances and contributions to easing the health burden in underserved populations and in reducing and ultimately eliminating health disparities in several priority diseases and conditions. This strategy helps to increase the pool of investigators from health disparity populations through research training and faculty development. In addition, the collaborations help disseminate health information to underserved populations and increase the participation of health disparity populations in clinical trials. The program has funded studies on numerous diseases/conditions including breast, prostate, and pancreatic cancers; human papillomavirus, HIV, and cardiovascular disease.

The Research Endowment Program is congressionally mandated by Public Law 106-525. The program was established to provide endowments to eligible academic institutions to support minority health and health disparities research. The educational institutions must use interest from the grants to a) build the capacity for research or research training which may include renovating facilities, improving technology or updated equipment; b) recruit and develop a diverse faculty, as well as create courses concerning health disparities research methodology; and c) advance recruitment and training of students from underrepresented and socio-economically disadvantaged populations who plan to pursue scientific careers.

The Loan Repayment Program (LRP)

NIMHD offers two types of loan repayment programs. The Health Disparities Research Loan Repayment Program is mandated by the Congress to increase the pool of extramural researchers who conduct health disparities research. The Extramural Clinical Research Loan Repayment Program extends to health professionals from disadvantaged backgrounds who engage in clinical research. Eligible candidates are health professionals with post doctoral degrees who are not federally employed and interested in conducting basic, clinical, behavioral, social sciences or health services research addressing health disparities.

The Community Based Participatory Research Program (CBPR) is designed to promote collaborative research between scientific researchers and members of their community through the joint design and implementation of intervention research projects targeting health disparities in underserved populations including racial and ethnic minorities, rural populations, and individuals of low socio-economic status.

The ultimate goal is to foster sustainable efforts at the community level that will accelerate the translation of research advances to health disparity populations and eliminate health disparities. The CBPR Initiative has three phases. It starts with a three year planning grant, followed by a competitive five year intervention grant and concludes with a competitive three year information dissemination grant. This is a long term commitment by the NIMHD with potential funding for up to eleven years in individual CBPR projects.

The Minority Health and Health Disparities International Research Training Program (MHIRT) supports young scientists conducting scientific research abroad. It offers short-term international training opportunities in health disparities research for undergraduate and graduate students in the health professions who are from health disparity populations. Grantees work with international health investigators in countries around the world including Mexico, Uganda, Ghana, Australia, Peru, Spain and South Africa.

The Building Research Infrastructure and Capacity (BRIC) Program supports the development of sustainable research programs at non-research intensive institutions of higher education. The primary goal is to build, strengthen, and/or enhance the research infrastructure and research training capacity of non-research intensive institutions.

The Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Program is a highly competitive federal program mandated by the Congress as a part of the Small Business Development Act. Each year designated federal departments and agencies award a reserved portion of their research and
development funds to small businesses and to partnerships between small businesses and nonprofit research institutions to bring innovative technologies to market. The NCMHD SBIR/STTR Programs give high priority to research activities designed to empower health disparity communities to achieve health equity through health education, disease prevention, and community-based, problem driven research.

The Health Disparities Research on Minority and Underserved Populations Program, a NIH Research Project Grant (R01) program, supports original and innovative research addressing elements that eliminate health disparities. It also supports the study of diseases/conditions that contribute to poor health outcomes or disproportionately impact racial and ethnic minority populations, rural and urban poor, and other health disparity populations.

Disparities Research and Education Advancing Mission (DREAM) Career Transition Award is the NCMHD’s first intramural program. It facilitates the transition of early stage investigators involved in health disparities research from the mentored stage of career development to become independent investigators. DREAM grants provide an opportunity for investigators to develop solid research skills during the initial period of up to two years of study and research within the NIH Intramural Research Programs located on the NIH campus. The award may also include a follow-on period of up to three years of salary and mentored research support at the candidate’s current institution or organization or an academic or research grantee institution of the candidate’s choice. This period of extramural support will facilitate the transition to independence as a researcher in health disparities research.
National Institute of Neurological Disorders and Stroke

Originally National Institute of Neurological Diseases and Blindness. Name changed 1968 to National Institute of Neurological Diseases and Stroke; March 1975 to National Institute of Neurological and Communicative Disorders and Stroke; and October 1988 to present name.

MISSION

Created by the U.S. Congress in 1950, the National Institute of Neurological Disorders and Stroke (NINDS) has occupied a central position in the world of neurosciences for nearly 60 years.

The mission of NINDS is to reduce the burden of neurological disease—a burden borne by every age group, every segment of society, and people all over the world.

To accomplish this goal, the Institute supports and conducts basic, translational, and clinical research on the healthy and diseased nervous system; fosters the training of investigators in the basic and clinical neurosciences; and seeks better understanding, diagnosis, treatment, and prevention of neurological disorders.

The Institute's extramural program supports thousands of research project grants and research contracts at institutions across the country. Institutional training grants and individual fellowships support hundreds of scientists in training and provide career awards that offer a range of research experience and support for faculty members at various levels. Scientists in the Institute's laboratories and clinics in Bethesda, Maryland, conduct research in the major areas of neuroscience and on many of the most important and challenging neurological disorders. NINDS staff researchers also collaborate with scientists in several other NIH Institutes.

This is a time of accelerating progress and increasing hope in the battle against brain disease. Advances in understanding the nervous system are beginning to pay off in the form of treatments for previously intractable problems such as spinal cord injury, acute stroke, multiple sclerosis, epilepsy, and Parkinson's disease, to name a few. It is fortunate that scientific progress is matched by unprecedented public commitment to research. NINDS is aware that increased public support and funding require visionary leadership and effective stewardship of the resources entrusted to the Institute.

The NINDS vision is:

- To lead the neuroscience community in shaping the future of research and its relationship to brain diseases.
- To build an intramural program that is the model for modern collaborative neuroscience research.
- To develop the next generation of basic and clinical neuroscientists through inspiration and resource support.
- To seize opportunities to focus our resources to rapidly translate scientific discoveries into prevention, treatment, and cures.
- To be the first place the public turns to for authoritative neuroscience research information.

IMPORTANT EVENTS IN NINDS HISTORY

1950—On August 15 President Harry S. Truman signed Public Law 81-692, establishing the National Institute of Neurological Diseases and Blindness (NINDB).

1951—NINDB received its first budget of $1,232,253.

1953—The NINDB budget became a line item in the NIH budget.

1953-54—An intramural program of clinical investigation was initiated, including medical neurology, surgical neurology, and electroencephalography. Training programs in neurology and ophthalmology were initiated.

1955—Basic science training grants were initiated.

1956—The intramural clinical investigations program was expanded to include work in ophthalmology.

1957—Training programs in otolaryngology and pediatric neurology began.

Field investigations involving collaborative and cooperative clinical studies began and the initial phase of the Collaborative Perinatal Project was started.

1960—The joint intramural basic research program of NINDB and the National Institute of Mental Health (NIMH) was divided and organized into 2 basic research laboratory programs.
1961—First program projects and clinical research centers in stroke and communicative disorders were supported.

1962—Funds were appropriated for professional and technical information assistance. Training grants in neurosurgery and neuroradiology were initiated.

1963—Developmental graduate training grants were initiated.

1965—A head injury research program was established.

1966—The stroke research program was expanded; additional grants for clinical research centers were awarded. An antiepileptic drug testing program began.

1967—Vision outpatient research centers were established. A program of research in neural control mechanisms and prostheses was initiated.

1968—The Institute was renamed the National Institute of Neurological Diseases and Stroke. The NINDS blindness program became the nucleus of the National Eye Institute.

1969—Research Building 36—dedicated by the U.S. Department of Health, Education, and Welfare (HEW) Secretary Robert H. Finch—was occupied by NINDS and NIH research laboratories.

1971—Programs in applied neurological research (epilepsy, head injury), infectious diseases, and biometry were added to the Collaborative and Field Research Division.

1973—Two new communicative disorders programs began with establishment of an intramural Laboratory of Neuro-Otolaryngology and a section on communicative disorders in the Collaborative and Field Research Division.

1974—Laboratories for neuroimmunology and neuropharmacology were established.

1975—NINDS was renamed the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS).

The Institute reorganized into 6 units for intramural research, fundamental neurosciences, communicative disorders, neurological disorders, stroke and trauma, and extramural activities.

1976—Dr. D. Carleton Gajdusek, chief, Laboratory of Central Nervous System Studies, was awarded the Nobel Prize in Physiology or Medicine for work on atypical slow viruses.

1979—A neuroepidemiology section and a section of neurotoxicology were established within the Intramural Research Program. NINCDS substantially expanded extramural support of research studies using positron emission tomography.

1982—The Institute's Neurological Disorders Program was replaced by 2 new program units: convulsive, developmental, and neuromuscular disorders and demyelinating, atrophic, and dementing disorders.

1984—NINCDS established the Senator Jacob Javits Neuroscience Awards, which provide research grant support for up to 7 years in the basic and clinical neurosciences and communicative sciences.

A Laboratory of Neurobiology and a Laboratory of Experimental Neuropathology were established within the Intramural Research Program.

1986—A Laboratory of Neural Regeneration and Implantation was established within the Intramural Research Program.

1987—NINCDS programs were renamed divisions, reflecting major areas of research interest: communicative and neurosensory disorders; convulsive, developmental, and neuromuscular disorders; demyelinating, atrophic, and dementing disorders; fundamental neurosciences; stroke and trauma; extramural activities; and intramural research.

A Clinical Neuroscience Branch was established within the Division of Intramural Research.

1988—The communicative disorders program became the nucleus of the National Institute of Deafness and Other Communication Disorders. NINCDS was renamed the National Institute of Neurological Disorders and Stroke.

1989—On July 25 President George H.W. Bush signed P.L. 101-58, declaring the 1990s the "Decade of the Brain."

1990—A Stroke Branch was established within the Division of Intramural Research.

1998—NINDS formed 7 planning panels comprising neuroscience leaders. Panel members outlined opportunities for research investment.


2000—The Parkinson's Disease Research Agenda was developed.

2001—NINDS celebrated its 50th anniversary with a 2-day scientific symposium, "Celebrating 50 Years of Brain Research: New Discoveries, New Hope."

The Stroke Progress Review Group was created.
The Research Agenda for Epilepsy was developed.


2004—The new National Neuroscience Research Center opened.

2007—The NINDS launched a new strategic planning process, in which it convened external panels on basic, translational, and clinical research and on neurological diseases.

2008—The NINDS Division of Extramural Research created an Office of Translational Research and an Office of Clinical Research, each led by an Associate Director.

2009—As part of the American Recovery and Reinvestment Act of 2009, NIH received $10.4 billion to stimulate biomedical research over a 2-year period. NINDS’s share ($400 million) was used to fund existing and peer-reviewed projects, and to support trans-NIH programs that solicited innovative ideas and research projects. (For more details visit www.ninds.nih.gov/recovery/overview.htm)

2010—The new NINDS Strategic Plan: ‘Priorities and Plans for the National Institute of Neurological Disorders and Stroke’ was released.

NINDS LEGISLATIVE CHRONOLOGY

August 15, 1950—Public Law 81-692 established NINDB ‘for research on neurological diseases (including epilepsy, cerebral palsy, and multiple sclerosis) and blindness.’

August 16, 1968—Public Law 90-489 renamed the NINDB the National Institute of Neurological Diseases.

October 24, 1968—Public Law 90-636 changed the name of the Institute to the National Institute of Neurological Diseases and Stroke.

October 25, 1972—Public Law 92-564 established a temporary National Commission on Multiple Sclerosis supported by NINDS.

March 14, 1975—Part 8 of a HEW Statement of Organization, Functions, and Delegations of Authority was amended to change the title of NINDS to the National Institute of Neurological and Communicative Disorders and Stroke.

July 29, 1975—Public Law 94-63 established 2 temporary commissions to be supported by NINCDS: Commission for the Control of Epilepsy and Its Consequences, and Commission for the Control of Huntington's Disease and Its Consequences.

October 28, 1988—Public Law 100-553 changed the name of NINCDS to the National Institute of Neurological Disorders and Stroke.

June 10, 1993—Public Law 103-43 added language on Multiple Sclerosis research to the legislative mandate of the NINDS.

November 13, 1997—Public Law 105-78, the Morris K. Udall Parkinson's Disease and Research Act, added language authorizing increased Parkinson’s disease research and training, including research centers.

November 17, 2000—Public Law 106-310, the Children’s Health Act of 2000, amended the Public Health Service Act with regard to a wide range of issues affecting children's health. Specifically relevant to the NINDS mission were authorizing provisions for the expansion of autism research, including research centers of excellence, and the establishment of an Interagency Autism Coordinating Committee; the establishment of a Pediatric Research Initiative; the development of a pediatric research loan repayment program; the conduct of a national longitudinal study of environmental influences on children’s health and development; the study of risk factors for childhood cancers, including malignant tumors of the central nervous system; the support of research with respect to cognitive disorders and neurobehavioral consequences arising from traumatic brain injury; and the expansion and coordination of muscular dystrophy research.

December 18, 2001—Public Law 107-084, the Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2001, or the “MD-CARE Act,” amended the Public Health Service Act to provide for the expansion and coordination of research with respect to various forms of muscular dystrophy, including the establishment of research centers of excellence and an interagency coordinating committee.

December 19, 2006—Public Law 109-416, the Combating Autism Act of 2006, amended the Public Health Service Act to expand and coordinate research activities with respect to autism spectrum disorders through the Centers of excellence and to establish the Interagency Autism Coordinating Committee.

November 8, 2008—Public Law 110-361, the Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments of 2008, reauthorizes programs at NIH with regard to muscular dystrophy, and designates the previously established research centers of excellence as Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers.

March 30, 2009—Public Law 111-11, the Omnibus Public Land Management Act of 2009, which includes text of the Christopher and Dana Reeve Paralysis Act, authorizes the NIH Director to: coordinate paralysis research and rehabilitation activities at the NIH; establish consortia in paralysis research; and establish networks of clinical sites that will collaborate to design clinical rehabilitation intervention protocols and outcome measures on paralysis.

BIOGRAPHICAL SKETCH OF NINDS DIRECTOR STORY C. LANDIS PH.D.

Dr. Landis has been Director of the National Institute of Neurological Disorders and Stroke since September 1, 2003. As Director, she oversees an annual budget of more than $1.6 billion and a staff of more than 900 scientists, physician-scientists, and administrators.
Dr. Landis received her B.A. in biology from Wellesley College in 1967 and her master's degree (1970) and her Ph.D. (1973) from Harvard University. She held postdoctoral fellowships at the National Institute of Mental Health and Harvard Medical School and also held faculty positions at Harvard Medical School and Case Western Reserve University. At Case Western Reserve, she was responsible for the creation of a Department of Neurosciences. Under 5 years of her leadership, the program achieved worldwide acclaim and a reputation for excellence. In 1995, Dr. Landis joined NINDS as Scientific Director and was responsible for the direction and excellence of research conducted in the Institute's intramural program. In 2007 Dr. Landis was named Chair of the NIH Stem Cell Task Force.

Dr. Landis' own research is aimed at understanding how functional connections form in the developing nervous system. She has received distinction as an Established Investigator of the American Heart Association, a Javits Neuroscience Investigator, and a McKnight Senior Investigator, and as an elected Fellow of the American Academy of Arts and Sciences and the American Association for the Advancement of Science. Dr. Landis has served on numerous scientific advisory committees, including selection and review committees for the NIH and the Howard Hughes Medical Institute. In 2002, she was named the President-Elect of the Society for Neuroscience. She was elected to the Institute of Medicine in 2009.

NINDS DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pearce Bailey</td>
<td>1951</td>
<td>1959</td>
</tr>
<tr>
<td>Richard L. Masland</td>
<td>1959</td>
<td>1968</td>
</tr>
<tr>
<td>Edward F. MacNichol, Jr.</td>
<td>September 1, 1968</td>
<td>1973</td>
</tr>
<tr>
<td>Donald B. Tower</td>
<td>May 31, 1974</td>
<td>February 1, 1981</td>
</tr>
<tr>
<td>Murray Goldstein</td>
<td>December 23, 1982</td>
<td>October 1, 1993</td>
</tr>
<tr>
<td>Patricia A. Grady (Acting)</td>
<td>September 1993</td>
<td>August 31, 1994</td>
</tr>
<tr>
<td>Zach W. Hall</td>
<td>September 1, 1994</td>
<td>December 31, 1997</td>
</tr>
<tr>
<td>Audrey S. Penn (Acting)</td>
<td>January 1, 1998</td>
<td>July 31, 1998</td>
</tr>
<tr>
<td>Gerald D. Fischbach</td>
<td>August 1, 1998</td>
<td>January 31, 2001</td>
</tr>
<tr>
<td>Audrey S. Penn (Acting)</td>
<td>February 1, 2001</td>
<td>August 31, 2003</td>
</tr>
<tr>
<td>Story C. Landis</td>
<td>September 1, 2003</td>
<td>Present</td>
</tr>
</tbody>
</table>

MAJOR DIVISIONS

The Institute is organized into a division of extramural research and a division of intramural research.

Division of Extramural Research

The Division of Extramural Research funds grants, cooperative agreements, and contracts to support research, research training, and career development. The Division is organized into work groups known as “program clusters.” The clusters were organized around critical, cross-cutting scientific topics that hold great promise for advancing knowledge and reducing the burden of neurological disease. The current scientific clusters are: Repair and Plasticity; Systems and Cognitive Neuroscience; Channels, Synapses, and Circuits; Neurogenetics; Neural Environment; and Neurodegeneration. In addition, the Extramural Division includes the Office of International Activities, the Office of Training and Career Development, the Office of Minority Health and Research, the Office of Clinical Research and the Office of Translational Research.

The Division monitors developments in these program areas; assesses the national need for research on the cause, prevention, diagnosis, and treatment of disorders of the brain and nervous system; and pursues technological development, the application of research findings, and research training and career development. The Division also (a) determines program priorities, (b) collaborates with other institutes of the NIH on specific research efforts, (c) prepares reports and analyses of national needs to assist NINDS staff and advisory groups in carrying out their responsibilities and in developing new areas of emphasis, and (d) consults with extramural scientists, voluntary health organizations, and professional associations in identifying research needs and developing programs to meet these needs.

The Division coordinates training of young investigators in all basic and clinical neurological research areas. This includes institutional and individual training programs as well as support through research career development awards and clinical investigator development awards.

Repair and Plasticity

http://www.ninds.nih.gov/funding/areas/repair_and_plasticity/index.htm

Mission:

- To encourage and support research on higher brain functions and the neural systems that mediate them, including learning, memory, language, cognition, emotion, movement, attention, regulation of the wakefulness-sleep cycle, food intake, body weight, sensory perception, and neuropathic pain.
- To support the understanding of the homeostatic regulation of cyclic and appetitive behaviors such as sleep, feeding, and drinking.
- To support the understanding of peripheral and central mechanisms of neuropathic pain and pain perception, and the development of strategies to alleviate chronic pain.
To support and evaluate non-invasive functional imaging research such as PET (positron emission tomography) and fMRI (functional magnetic resonance imaging).

To support and investigate the neural mechanisms of sensory and motor circuits that can be compromised by disease or injury.

To support and evaluate novel tools and methodologies for system approaches.

To support translational research of rehabilitative strategies and technology-driven therapeutics for neural dysfunction.

**Systems and Cognitive Neuroscience**
http://www.ninds.nih.gov/funding/areas/systems_and_cognitive_neuroscience/index.htm

**Mission:**

- To encourage and support research on higher brain functions and the neural systems that mediate them, including learning, memory, language, cognition, emotion, movement, attention, regulation of the wakefulness-sleep cycle, food intake, body weight, sensory perception, and neuropathic pain.
- To support the understanding of the homeostatic regulation of cyclic and appetitive behaviors such as sleep, feeding, and drinking.
- To support the understanding of peripheral and central mechanisms of neuropathic pain and pain perception, and the development of strategies to alleviate chronic pain.
- To support and evaluate non-invasive functional imaging research such as PET (positron emission tomography) and fMRI (functional magnetic resonance imaging).
- To support and investigate the neural mechanisms of sensory and motor circuits that can be compromised by disease or injury.
- To support and evaluate novel tools and methodologies for system approaches.
- To support translational research of rehabilitative strategies and technology-driven therapeutics for neural dysfunction.

**Channels, Synapses, and Circuits**
http://www.ninds.nih.gov/funding/areas/channels_synapses_and_circuits/index.htm

**Mission:**

- To initiate and support basic and translational research on ion channels, transporters, and pumps implicated in neuronal function and disease.
- To advance basic and translational research in mechanisms of synaptic transmission, development, and plasticity, including research on function and dysfunction of the neuromuscular junction.
- To support basic, translational, and clinical studies in epilepsy and epileptogenesis.
- To implement the epilepsy benchmarks (http://www.ninds.nih.gov/funding/research/epilepsyweb/index.htm).
- To support research on the pathogenesis and treatment of inherited/acquired neuropathies, muscular dystrophies, and other neuromuscular disorders, including myasthenia gravis.
- To promote the development of new methodologies for basic research, including genetic models, high-resolution structural studies of membrane proteins, optical recording, neuroimaging, and neuroinformatics tools.

**Neurogenetics**
http://www.ninds.nih.gov/funding/areas/neurogenetics/index.htm

**Mission:**

- To promote efforts to identify genes and susceptibility loci for neurological diseases.
- To promote investigation of the mechanisms by which genetic variants cause or contribute to risks for neurological disease.
- To develop gene-based assays, diagnostics, and therapeutics for neurological disorders.
- To develop cutting-edge tools and resources for neurogenetic research.
- To promote basic and translational research in neurogenetics and genomics.
- To investigate the genetic basis of normal neural development, function, and perturbations that can lead to neurological disorders.
- To promote and assist in the training of neuroscientists in molecular medicine.
- To educate the scientific and lay communities in the ethical, legal, and social issues in neurogenetics.
- To engage patient voluntary and advocacy groups in partnerships to promote research in neurogenetics.

**Neural Environment**

**Mission:**

- To encourage studies on the role of diverse cell populations of the nervous system and mechanisms of cell-cell interaction responsible for the normal function and maintenance of the nervous system as an organ, including the function of glial cells, brain blood supply, and flow of cerebrospinal fluid (CSF).
- To encourage research on infectious, immune, and inflammatory mechanisms in nervous system disorders such as multiple sclerosis, prion diseases, stroke, brain tumors, and neuroAIDS.
To encourage studies to identify the molecular mechanisms of cell injury and death in the nervous system.

To foster studies on vascular mechanisms of neurological disorders; vascular development in the central nervous system (CNS); and the role of microvascular endothelia, extracellular matrix, and cells of hematopoietic origin within the CNS.

To promote the development of diagnostics and of therapies that will prevent, arrest, or reverse autoimmune neurological disorders such as multiple sclerosis.

To expand studies on the mechanisms of blood-brain and brain-CSF barrier functions and of cell migration (and/or trafficking) into the CNS in stroke, immune disorders, brain tumors, and CNS infections.

To encourage the development of animal models for infectious and immune disorders, CNS and peripheral nervous system (PNS) tumors, and stroke (e.g., transgenic or knockout/in models, viral models).

To encourage the study of normal glial or progenitor/stem cell populations and their role in the development or treatment of CNS and PNS tumors.

To promote the study of biomarkers for vascular, tumorigenic, and immune diseases of the nervous system.

To strongly encourage bi-directional translational research that transfers insights gained from basic research and clinical investigations.

**Neurodegeneration**

http://www.ninds.nih.gov/funding/areas/neurodegeneration/index.htm

**Mission:**

- To stimulate basic, translational and clinical research on the mechanisms of neuron death and neurodegeneration underlying a wide range of neurodegenerative disorders including Parkinson's disease and parkinsonian disorders, Alzheimer's disease, vascular cognitive impairment, amyotrophic lateral sclerosis and related motor disorders, Huntington's disease, frontotemporal dementia, and essential tremor.

- To promote the development of representative models of human neurodegenerative diseases to support gene and drug discovery research.

- To encourage gene discovery and population-based genetic and epidemiological studies of neurological disorders in order to elucidate the natural history of neurodegeneration and to identify biomarkers for neurodegenerative disorders.

- To promote the development of advanced research technologies necessary for achieving new breakthroughs in neurodegeneration research.

- To encourage the development and testing of therapeutics for the treatment and cure of neurodegenerative diseases in collaboration with the NINDS Office of Translational Research.

- To support the rigorous testing of candidate therapies in controlled clinical trials in conjunction with the NINDS Office of Clinical Research.

**Office of International Activities**


**Mission:**

- To identify significant global health issues as they relate to neurological disorders and stroke.

- To develop creative approaches that promote international research in the neurosciences.

- To stimulate international activities with other NIH Institutes and Centers, other domestic and foreign government agencies, and non-governmental organizations.

- To encourage international neuroscience collaborations, training, and capacity building through grants, short-term travel supplements, and international conferences.

- To coordinate bilateral and multilateral activities under agreements between the U.S. and other countries.

**Office of Training and Career Development**

http://www.ninds.nih.gov/funding/areas/training_and_career_development/index.htm

The Training Office provides support for the research training and career development of outstanding young investigators during the predoctoral, postdoctoral, and early faculty phases of their careers. Future discoveries that will lead to a reduction in the burden of neurological disorders will require an outstanding cadre of scientists in basic, clinical, and translational research. Thus, support for training in all of these realms is a high priority at NINDS.

**Office of Minority Health and Research**

www.ninds.nih.gov/funding/areas/office_of_minority_health_and_research/index.htm

**Mission:**

- To assist in the overall development of state-of-the-art neuroscience research programs at minority-serving institutions.

- To foster innovative and effective partnerships and collaboration between minority-serving institutions and established neuroscience laboratories at Federal and non-Federal research institutions.

- To provide support to develop and sustain competitively funded neuroscience research projects and programs at minority-serving institutions.

- To create, support, and maintain a stimulating academic and intellectual milieu to inspire and prepare diverse students and fellows to pursue research careers in neuroscience. To enhance the diversity of the biomedical research workforce through supporting individuals from underrepresented ethnic/racial minority groups or disadvantaged backgrounds, individuals with disabilities, and individuals re-entering the research workforce.

- To aid the Institute in achieving its goals of decreasing health disparities in neurological disorders.
Office of Clinical Research
www.ninds.nih.gov/funding/areas/clinical_trials/index.htm

Mission:
- To promote the development of clinical interventions for neurological disorders and stroke.
- To stimulate the translation of findings in the laboratory to clinical research and clinical interventions.
- To ensure measures for protection of human subjects and safety monitoring.
- To encourage innovation in clinical research methodology.
- To support the development of neurology clinical researchers with training in biostatistics, epidemiology, and clinical trial methodology.

Office of Translational Research
http://www.ninds.nih.gov/funding/areas/technology_development/index.htm

Mission:
- To facilitate the preclinical discovery and development of new therapeutics or diagnostics for neurological disorders.
- To support research on promising candidate therapeutics and medical devices required to secure Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications to the U.S. Food and Drug Administration (FDA).
- To design, implement, and manage research infrastructure activities that support translational research.
- To support translational neuroscience projects by small businesses.
- To support ongoing trans-NIH translational research programs including those within the NIH Roadmap, the NIH Blueprint, and NIH Biodefense programs.

Division of Intramural Research

A full description of the NINDS Division of Intramural Research can be found at http://intra.ninds.nih.gov.

Additional information on NIH neuroscience programs, including programs sponsored by the NINDS, is available at http://neuroscience.nih.gov.
MISSION

The mission of the National Institute of Nursing Research (NINR) is to promote and improve the health of individuals, families, communities, and populations. NINR supports and conducts clinical and basic research and research training on health and illness across the lifespan. NINR seeks to extend nursing science by integrating the biological and behavioral sciences, employing new technologies to research questions, improving research methods, and developing the scientists of the future.

The nursing research supported by NINR develops knowledge to:
- build the scientific foundation for clinical practice,
- prevent disease and disability,
- manage and eliminate symptoms caused by illness, and
- enhance end-of-life and palliative care.

NINR supports research relevant to its mission, in order to provide a sound scientific basis for changes in clinical practice. In keeping with the importance of nursing practice in various settings, NINR's major emphasis is on clinical research.

NINR programs overseen by the Division of Extramural Activities are conducted primarily through the provision of research grants to investigators across the country. On the NIH campus, the laboratories of NINR's Division of Intramural Research focus primarily on research into symptom management and pain mechanisms.

NINR places great emphasis on research training to cultivate the next generation of nurse scientists, as well as other biobehavioral researchers whose work advances nursing science. NINR-supported opportunities for research training are available for students beginning their research careers, as well as for scientists seeking to expand their research expertise. Among these opportunities, NINR provides support for trainees from underrepresented and disadvantaged backgrounds.

NINR fosters collaborations with many other disciplines in areas of mutual interest such as long-term care for older adults, the special needs of women across the lifespan, genetic testing and counseling, biobehavioral aspects of the prevention and treatment of infectious diseases, and the impact of environmental influences on risk factors for chronic illnesses.

The NINR Strategic Plan: An Overview

Developed with the input of scientists, clinicians, experts in health care and public policy, other stakeholders, and members of the public, the NINR Strategic Plan for 2006-2010 [http://www.ninr.nih.gov/AboutNINR/NINRMissionandStrategicPlan/] provides a blueprint for continuing to elevate the contributions of nursing research within the health care sciences.

Nursing science offers a rich mix of topic areas for research that can be viewed in the context of diseases and disorders, phases of the lifespan, and population groups. To address current health care needs of the nation, the Strategic Plan lists 4 key, cross-cutting areas of research emphasis:
- promoting health and preventing disease;
- improving quality of life through self-management, symptom management, and caregiving;
- eliminating health disparities; and
- taking the lead in end-of-life research.

The Strategic Plan also outlines 4 objectives to advance science:
- integrating biological and behavioral science;
- adopting, adapting, and generating new technologies;
- improving methods for future scientific discoveries; and
- developing scientists for today and tomorrow.
Central to the themes of nursing research and practice are the important roles of the patient, the family, formal and informal caregivers, and the community in promoting health and managing disease.

IMPORTANT EVENTS IN NINR HISTORY

November 10, 1985—Public Law 99-158, the Health Research Extension Act of 1985, became law, overriding a presidential veto. Among other provisions, the law authorized the National Center for Nursing Research (NCNR) at NIH.

April 18, 1986—The U.S. Department of Health and Human Services (HHS) Secretary announced the establishment of NCNR at NIH.

December 3, 1986—Members of the NCNR Advisory Council were appointed by the HHS Secretary.

February 17, 1987—The first meeting of the NCNR Advisory Council was held.

May 30, 1988—The NCNR Advisory Council was renamed the National Advisory Council for Nursing Research.

June 10, 1993—P.L. 103-43, the NIH Revitalization Act of 1993, became law. Among other provisions, it elevated NCNR to full status as an NIH Institute.

June 14, 1993—The HHS Secretary signed the Federal Register notice establishing the National Institute of Nursing Research (NINR).

1997—The NIH Director designated NINR as the lead NIH institute to coordinate collaborative research on end-of-life palliative care.

Summer 2000—NINR held its first Summer Genetics Institute.

2003—NINR Director Dr. Patricia A. Grady named co-chair of the Interdisciplinary Research component of the NIH Roadmap for Medical Research, and co-chair of the NIH Pain Consortium.

2004—NINR Director Dr. Grady named co-chair of NIH Public Trust Initiative.

2004—NINR launched a new pilot training project, the Graduate Partnerships Program (GPP) in Biobehavioral Research.

December 2004—NINR co-sponsored the NIH State of the Science conference, Improving End-of-Life Care, bringing together almost 1,000 health care practitioners from around the world.

2005—NINR celebrated its 20th anniversary at NIH.

2008—NINR Director Dr. Grady named co-chair, Science of Behavior Change Roadmap Initiative.

2008—NINR published new brochure, “Research Training Grants and Opportunities.”

2009—NINR published new patient information brochure, “Palliative Care: The Relief You Need When You’re Experiencing the Symptoms of Serious Illness.”

2009—NINR, in a joint effort with the Bravewell Collaborative and the NIH Clinical Center, conducted a post-doctoral training program for research in integrative medicine, the BNC Fellowship.

2010—The NINR Summer Genetics Institute transitioned to a new format, overseen by the Foundation for Advanced Education in the Sciences (FAES).

2010—NINR held the first Methodologies Boot Camp, focusing on pain research.


2010—NINR celebrates its 25th anniversary at NIH.

2011—New NINR Director’s Lecture series launched, designed to bring the nation’s top nurse scientists to the NIH campus to share their work and interests with a trans-disciplinary audience.

NINR LEGISLATIVE CHRONOLOGY

November 10, 1985—P.L. 99-158, the Health and Research Extension Act of 1985, became law. Its provisions included the establishment of NCNR to support research and research training related to patient care.


June 10, 1993—NCNR was redesignated as an NIH institute under a provision in P.L. 103-43, the NIH Revitalization Act of 1993.
2010—U.S. Senate resolution, S. Res. 642, congratulated NINR on a quarter century of achievement in science and public service. The resolution was introduced by Senator Daniel Inouye (D-Hawaii) and cosponsored by Senator Susan Collins (R-Maine).

BIOGRAPHICAL SKETCH OF NINR DIRECTOR PATRICIA A. GRADY, PH.D., R.N.

Dr. Patricia A. Grady was appointed Director, NINR, on April 3, 1995. She earned her undergraduate degree in nursing from Georgetown University in Washington, DC. She pursued her graduate education at the University of Maryland, receiving a master's degree from the School of Nursing and a doctorate in physiology from the School of Medicine.

An internationally recognized researcher, Dr. Grady's scientific focus has primarily been in stroke, with emphasis on arterial stenosis and cerebral ischemia. She was elected to the Institute of Medicine in 1999 and is a member of several scientific organizations, including the Society for Neuroscience, the American Academy of Nursing, and the American Neurological Association. She is also a fellow of the American Heart Association Stroke Council.

In 1988, Dr. Grady joined NIH as an extramural research program administrator in the National Institute of Neurological Disorders and Stroke (NINDS) in the areas of stroke and brain imaging. Two years later, she served on the NIH Task Force for Medical Rehabilitation Research, which established the first long-range research agenda for the field of medical rehabilitation research. In 1992, she assumed the responsibilities of NINDS Assistant Director. From 1993 to 1995, she was Deputy Director and Acting Director of NINDS. Dr. Grady served as a charter member of the NIH Warren Grant Magnuson Clinical Center Board of Governors.

Before coming to NIH, Dr. Grady held several academic positions and served concurrently on the faculties of the University of Maryland School of Nursing and School of Medicine.

Dr. Grady has authored or co-authored numerous articles and papers on hypertension, cerebrovascular permeability, vascular stress, and cerebral edema. She is an editorial board member of the major stroke journals. Dr. Grady lectures and speaks on a wide range of topics, including future directions in nursing research, developments in the neurological sciences, and Federal research opportunities.

Dr. Grady has been recognized with several prestigious honors and awards for her leadership and scientific accomplishments, including the first award of the Centennial Achievement Medal from Georgetown University School of Nursing and Health Sciences, being named the inaugural Rozella M. Schlotfeld distinguished lecturer at the Frances Payne Bolton School of Nursing at Case Western Reserve University, and receiving the honorary degree of Doctor of Public Service from the University of Maryland. In 2005, Dr. Grady received Doctor of Science, Honoris Causa degrees from the Medical University of South Carolina and Thomas Jefferson University, and Columbia University School of Nursing honored her with its prestigious Second Century Award for Excellence in Health Care. In 2008, Dr. Grady received a Doctor of Science, Honoris Causa degree from the State University of New York Downstate Medical Center. View Image.

Dr. Grady is a past recipient of the NIH Merit Award and received the Public Health Service Superior Service Award for her exceptional leadership.

NINR DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Doris H. Merritt (Acting)</td>
<td>April 18, 1986</td>
<td>June 1987</td>
</tr>
<tr>
<td>Ada Sue Hinshaw</td>
<td>June 6, 1987</td>
<td>June 30, 1994</td>
</tr>
<tr>
<td>Suzanne S. Hurd (Acting)</td>
<td>July 1, 1994</td>
<td>April 2, 1995</td>
</tr>
<tr>
<td>Patricia A. Grady</td>
<td>April 3, 1995</td>
<td>Present</td>
</tr>
</tbody>
</table>

MAJOR PROGRAMS

Division of Extramural Activities

The Division of Extramural Activities consists of the Office of Extramural Programs, the Office of Grants Management, and the Office of Review.

The Office of Extramural Programs (OEP) [http://www.ninr.nih.gov/ResearchAndFunding/DEA/OEP/] manages the funding activities of NINR that occur outside of NIH, in research institutions across the country and around the world. A major program priority is the integration of biological and behavioral research. The NINR OEP is organized into 4 sections:

- Neuroscience, Genetics, & Symptom Management
- Child & Family Health, & Health Disparities
- Immunology, Infectious Disease, & Chronic Disorders
- Acute & Long-Term Care, End-of-Life, & Training.

The Office of Grants and Contracts Management (OGCM) [http://www.ninr.nih.gov/ResearchAndFunding/DEA/OGCM/] is the central point of contact for all business-related activities associated with the negotiation, award, and administration of grants and cooperative agreements within NINR.

The Office of Review (OR) [http://www.ninr.nih.gov/ResearchAndFunding/DEA/OR/] provides policy direction and coordination for the planning and execution of initial scientific and technical reviews conducted within NINR. The reviews conducted by the office are considered to be first level reviews, and involve panels of
career transition, contingent on securing an independent research position. Award recipients will be expected to compete successfully for independent R01 career. The PI Award provides up to 5 years of support consisting of 2 phases: 1-2 years of mentored support, followed by up to 3 years of independent support for

This training mechanism, investigators have addressed such issues as serious developmental problems in Mexican migrant infants; culturally appropriate community-level suicide prevention programs for American Indian rural youth; improvement of awareness of prostate cancer screening among African American men; and ways to identify triggers or markers for increased risk for sudden death in Asian heart failure patients.

NINR continues to build its campus-based Division of Intramural Research (DIR) [http://www.ninr.nih.gov/ResearchAndFunding/DivisionofIntramuralResearch/default.htm] to help the nursing science community take full advantage of the resources, infrastructure, and mentoring opportunities available at NIH. The DIR seeks to understand the underlying biological mechanisms of a range of symptoms, their effect on patients, and how patients respond to interventions. It comprises 2 major activities: the Symptoms Management Branch and Research Training.

Recent scientific efforts in the Symptoms Management Branch have included evaluating the efficacy of novel interventions for managing symptoms associated with cancer treatment and exploring the molecular and genetic mechanisms that influence an individual’s response to analgesic treatment for acute pain. NINR laboratories leverage the benefits of the highly collaborative research environment of the NIH intramural research community, wherein fruitful scientific partnerships can be readily established.

Under DIR Research Training activities, training is provided through several mechanisms.

Post-baccalaureate training positions are available that allow BSN-prepared nurses interested in exploring a career in research to spend a year engaged in biomedical investigation in the DIR laboratories. Pre- and postdoctoral fellowship positions, as well as summer internships, are also available.

Another training opportunity, the NINR Career Transition Award (K22) [http://grants.nih.gov/grants/guide/pa-files/PAR-08-148.html], provides up to 3 years of support for research training in an NINR or NIH intramural laboratory, followed by 2 years of support for an independent program of research in an extramural institution. It is anticipated that awardees will subsequently obtain a research project grant to support the continuation of their work.

The DIR also supports the Graduate Partnerships Program (GPP) [http://www.ninr.nih.gov/Training/TrainingOpportunitiesIntramural/GraduatepartnershipprogFile/]. The NINR GPP is a doctoral fellowship training program that combines the academic environment of a university with the breadth and depth of research resources available at NIH. The NINR GPP is open only to students...
currently enrolled in or accepted to schools with an NINR-funded T32 Institutional Training grant. NINR celebrated its first 2 graduates from the GPP in 2008. The GPP has been a very successful program, and those who have completed it exemplify how NINR is working to prepare the nurse scientists of the future. View Image.

Through the DIR, NINR sponsors the Summer Genetics Institute (SGI) [http://www.ninr.nih.gov/Training/TrainingOpportunitiesIntramural/SummerGeneticsInstitute/], an intensive research training program held at NIH. The SGI provides a foundation in molecular genetics for use in research and clinical practice and features both lecture and hands-on laboratory training. The purpose of the SGI is to increase the research capability among graduate students and faculty, and develop and expand the basis for clinical practice in genetics among clinicians. The program awards eight hours of graduate-level college credit. SGI graduates are making a difference in their communities in many ways. They are successfully building programs of research in genetics related to nursing; disseminating findings through publications and scientific conference presentations; and integrating genetics content into nursing school curricula across the country.

The NIH DIR also participates in the new NIH Lasker Clinical Research Scholar (Lasker Scholar) program. The Lasker Scholar program will support a small number of exceptional clinical researchers in the early stages of their career to promote their development to fully independent scientists. It combines a period of research experience as a tenure-track Principal Investigator in the NIH Intramural Research Program (IRP) with an opportunity for additional years of independent financial support, either within the IRP or at an extramural (outside of NIH) research institution.

In addition, an online research training workshop, "Developing Nurse Scientists [http://www.ninr.nih.gov/Training/OnlineDevelopingNurseScientists/]," targets doctorally prepared nurses and provides them with knowledge and skill development needed for submitting competitive grant applications to NIH for research funding.


**Leadership in End-of-Life Research**

In recent years, many factors have converged to increase public and professional interest in issues surrounding the end of life.

The 1997 report from the Institute of Medicine, *Approaching Death: Improving Care at the End of Life*, found widespread dissatisfaction with end-of-life care and many gaps in our scientific knowledge of this phase of life. In response, NINR sponsored a workshop on the symptoms of terminal illness. Later that year, the NIH Director designated NINR as the lead Institute within NIH for end-of-life research. NINR studies on the management of pain and other symptoms, family decision-making, caregiving, advance planning, and the maintenance of the health and function of the elderly and the critically ill provided an important base of knowledge on which to build. NINR has sponsored several community events to gather input on concerns related to end-of-life issues.

In December 2004, NINR co-sponsored the NIH State of the Science conference, *Improving End-of-Life Care*, bringing together almost 1,000 health care practitioners from around the world. This conference served to evaluate the current state of the science in end-of-life care and to determine future directions for research. It also highlighted the interactions among patients, caregivers, and the health system, and their effects on outcomes. The consensus statement from this conference is available here [http://consensus.nih.gov/2004/2004EndOLifeCare50S024main.htm].

The NINR Spotlight on End-of-Life Research [http://www.ninr.nih.gov/ResearchAndFunding/Spotlight-%E2%80%93on-End-of-Life-%E2%80%93Research.htm] web page provides information related to EOL research at NINR and across the NIH.

In 2009, NINR published an article, “Improving palliative care and communication in the ICU,” [http://www.americannursetoday.com/Article.aspx?id=4514&fid=4474] in *American Nurse Today*, the official journal of the American Nurses Association. This article described some of the current research supported by NINR related to palliative care, end-of-life planning, and clinician-family communication in hospital intensive care units.

Also in 2009, NINR released a patient information brochure entitled: "Palliative Care: The Relief You Need When You're Experiencing the Symptoms of Serious Illness." [http://www.ninr.nih.gov/NR/rdonlyres/01CC4F1-04B6-468A-BD9F-3AB727A381D2/0/NINR_PalliativeCare_Brochure_50BC.pdf] This brochure is copyright free and may be downloaded and reproduced without charge. To order print copies (up to 25), please email info@ninr.nih.gov or call 301-496-0207. (Please inquire about the process for orders greater than 25).

NINR participates as a member of the NIH End of Life and Palliative Care Special Interest Group (EOL PC SIG). Membership is open to anyone with a shared interest in EOL PC science, including researchers across NIH ICs, academia, fellows/trainees, clinicians, students, and interested professionals and non-scientists. The NIH EOL PC SIG serves as an important source for ideas and inter-institute discussions of ongoing activities in end-of-life and palliative care research, and provides a forum to foster career development, investigator training, and opportunities to collaborate in new initiatives. In 2010, NINR hosted a kick-off lecture for the new NIH EOL PC SIG, “Learning from elders about meeting the challenges of the last phase of life,” given by Dr. Eva Kahana of Case Western Reserve University.

Supported by a trans-NIH organizing committee from NCI, NINR, NHLBI, NCCAM, NIA, and the NIH Clinical Center, the NIH EOL PC SIG meets four times a year (October, January, April, and July) on the NIH campus. Lectures and discussions reflect emerging scientific issues such as challenging research methodologies, new technologies, interventions, treatments, resources, and training. The group also has an active listserv that exchanges EOL PC research information, grant opportunities, news items, and educational events.

For more information or to subscribe to the listserv, please visit the NIH EOL PC SIG web site at: http://sigs.nih.gov/eolpc.

**End-of-Life and Palliative Care Evaluation Project**

In 2010, NINR was awarded funds from the NIH OD Evaluation Set-Aside Program to conduct an evaluation project, titled *End-of-Life and Palliative Care Science: A Needs Assessment of Federal and Private Research Funding Trends, Project Grants, and National Research Priorities*. NINR received letters of support from four NIH Institutes/Centers: NCCAM, NCI, NIA, and NIAID.
The project will derive comprehensive analytic data that will be used to identify historical national funding trends in end-of-life and palliative care (EOL PC) research. The evaluation will:

- Describe the nature and extent of funded EOL PC research conducted since the 1997 IOM report, Approaching death: improving care at the end of life;
- Review and analyze EOL PC funding trends supported by the NIH, other Federal agencies, and philanthropic and non-profit organizations;
- Analyze factors that led to solicitations for EOL PC research in both public and private sectors;
- Identify and examine the scientific needs and interests of research funding organizations in these areas; and
- Evaluate critical issues related to EOL PC funding sustainability.

As the number of persons with life-limiting conditions in the United States increases, there is a growing need to provide patients, their loved ones, and their providers with the highest quality of evidence-based end-of-life and palliative care. This project will serve to strengthen and stimulate research capability and scholarship in EOL PC science and permit the unique opportunity to specify benchmarks for advancing research, create opportunities for future collaborations, and guide strategic planning to build a national commitment to research in this important field.

A final report summarizing the results of this project will be available in 2012.

**NINR and trans-NIH Initiatives**

NINR plays an active role in several trans-NIH initiatives, including:

- The NIH Roadmap for Medical Research
- The NIH Public Trust Initiative
- The NIH Pain Consortium
- The NIH Neuroscience Blueprint
- The NIH Science of Behavior Change Roadmap initiative
- The NIH OppNet

The NIH Roadmap is based on the idea that bringing new disciplines together holds the best promise of opening up new and currently unimagined scientific avenues of inquiry. Under the Roadmap theme of Research Teams for the Future, NINR Director Dr. Grady co-chairs the Interdisciplinary Research Working Group. The goal of this initiative is to lower institutional barriers that impede research progress and to challenge individual disciplines to work together to provide new ways of solving complex problems in the biomedical sciences. Nursing science's experience and expertise in collaborative research will be a benefit to all of NIH as this initiative continues to move forward. In addition, Dr. Grady co-chairs the Roadmap Science of Behavioral Change committee. NINR also participates in the Clinical Research Training initiatives, toward the goal of training a highly skilled workforce of investigators who have strong backgrounds in multidisciplinary clinical research.

Dr. Grady serves as the co-chair of the NIH Public Trust Initiative (PTI). The goal of the PTI is to improve the public's health by promoting trust in biomedical and behavioral research. In 2007, the PTI launched the Partners in Research (PIR) program to develop partnerships between scientific or research institutions and community organizations, which were intended to:

- facilitate discussion of the health care needs and interests of the community,
- develop and implement research programs that address these needs,
- study methods to engage and inform the public regarding health science,
- improve public understanding of the benefits of publicly funded research, and
- communicate the results of this research.

The PIR grant program was administered by NINR and the National Institute of Child Health and Human Development on behalf of the NIH.

NINR is a key member of the NIH Pain Consortium, which Dr. Grady co-chairs. The consortium promotes collaboration among the many NIH Institutes and Centers that conduct or fund pain research. NINR is also a member of the NIH Neuroscience Blueprint, which is designed to develop resources (i.e., people, tools, methods, knowledge bases) for the advancement of research in neuroscience. NINR involvement in these areas opens further avenues of research to NINR-supported investigators.

NINR is a co-sponsor of the Science of Behavior Change (SOBC) Roadmap initiative, and Dr. Grady serves as an SOBC Roadmap Development co-chair. Advancing the science of behavior change has been identified as a top priority for NIH-wide research efforts, and this initiative is focused on developing new and innovative approaches to enhance health-related behavior change.

In 2009, NIH launched the Basic Behavioral and Social Science Opportunity Network (OppNet) [http://oppnet.nih.gov/index.asp], a trans-NIH initiative to expand the agency’s funding of basic behavioral and social sciences research (b-BSSR). Basic-BSSR studies mechanisms and processes that influence behavior at the individual, group, community and population level. Research results lead to new approaches for reducing risky behaviors and improving the adoption of healthy practices. All NIH Institutes and Centers (ICs) share the mission of supporting b-BSSR. Representatives for NINR are involved in the OppNet Steering Committee and other working groups and initiatives. OppNet will also develop a plan for focused multi-year programs across ICs to advance priority topics within b-BSSR.
For more information about NINR, nursing research, and research training opportunities, please visit the NINR web site at: [www.ninr.nih.gov](http://www.ninr.nih.gov).

This page last reviewed on January 5, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

Celebrating its 175th anniversary in 2011, the National Library of Medicine (NLM), in Bethesda, Maryland, is a part of the National Institutes of Health, U.S. Department of Health and Human Services (HHS). Since its founding in 1836 as the library of the U.S. Army Surgeon General, NLM has played a pivotal role in translating biomedical research into practice. It is the world's largest biomedical library and the developer of electronic information services that deliver trillions of bytes of data to millions of users every day. Scientists, health professionals, and the public in the United States and around the globe search the Library's online information resources more than 1 billion times each year.

The Library is open to all and has many services and resources—for scientists, health professionals, historians, and the general public. NLM has over 17 million books, journals, manuscripts, audiovisuals, and other forms of medical information on its shelves, making it the largest health-science library in the world.

In today's increasingly digital world, NLM carries out its mission of enabling biomedical research, supporting health care and public health, and promoting healthy behavior by:

- Acquiring, organizing, and preserving the world's scholarly biomedical literature;
- Providing access to biomedical and health information across the country in partnership with the 5,800-member National Network of Libraries of Medicine [http://nnlm.gov/ (NN/LM®)];
- Serving as a leading global resource for building, curating and providing sophisticated access to molecular biology and genomic information, including those from the Human Genome Project [http://www.genome.gov/10001772] and NIH Common [http://nihroadmap.nih.gov/] Fund;
- Creating high-quality information services relevant to toxicology and environmental health, health services research, and public health;
- Conducting research and development on biomedical communications systems, methods, technologies, and networks and information dissemination and utilization among health professionals, patients, and the general public;
- Funding advanced biomedical informatics research and serving as the primary supporter of pre- and post-doctoral research training in biomedical informatics at 18 U.S. universities.

IMPORTANT EVENTS IN NLM HISTORY


1865—John Shaw Billings, M.D., appointed to supervise Surgeon General's Library, which he developed into a national resource of biomedical literature. He served as director until 1895.

1879—First volume of Index Medicus published.

1880—First volume of Index-Catalogue published.


1952—Army Medical Library renamed Armed Forces Medical Library.

1956—Act of Congress moved Armed Forces Medical Library to U.S. Public Health Service (PHS) and rechristened it the National Library of Medicine (NLM).

1961—New Library building, #38 (at 8600 Rockville Pike, Bethesda, Maryland, on the NIH campus), dedicated.


1965—Medical Library Assistance Act gave NLM responsibility of helping the nation's medical libraries through a grant program, and created the Regional Medical Library Network (now the National Network of Libraries of Medicine [http://www.nlm.nih.gov/pubs/factsheets/nnlm.html]).

1967—Toxicology Information Program established at NLM in response to recommendations of the President's science advisory committee.

1968—NLM became a component of NIH. The Lister Hill National Center for Biomedical Communications [http://www.nlm.nih.gov/pubs/factsheets/lister_hill.html], NLM's research and development component, was created by Congress.
1971—MEDLINE ("MEDLARS Online") was initiated to provide online access to a subset of references in the MEDLARS database.


1980—NLM's Lister Hill National Center for Biomedical Communications building, #38A, was dedicated. The new structure, adjacent to the Library, houses NLM's research and development components.

1986—Grateful Med—PC-based, user-friendly software for accessing MEDLARS—was introduced to the health community.

1988—The National Center for Biotechnology Information (NCBI) was created by Congress as a national resource for molecular biology information.

1993—National Information Center on Health Services Research and Health Care Technology [http://www.nlm.nih.gov/nichsr/] was created by Congress as a national resource for health services research and evidence-based practice guidelines.


1994—The Visible Human Male [http://www.nlm.nih.gov/pubs/factsheets/visible_human.html], a large computer dataset of images based on a cadaver, was introduced. The Visible Human Female appeared 1 year later.


1998—MedlinePlus [http://www.medlineplus.gov/] created to provide access to consumer health information.

2000—ClinicalTrials.gov [http://www.clinicaltrials.gov], an online resource designed to give the public easy access to information about research studies, was launched.

2006—NIH MedlinePlus magazine launched, to provide Americans with reliable, up-to-date health information in a consumer-friendly format. The Spanish-English version, Salud, followed two years later.


2010—Emergency Access Initiative (EAI) launched. This collection of over 200 biomedical journals and more than 65 reference books was provided free of charge for persons responding to the January earthquake in Haiti. A partnership of the National Network of Libraries of Medicine and members of the Professional & Scholarly Publishing division of the Association of American Publishers and other publishers. The EAI would be activated again later in the year, in response to severe flooding in Pakistan and the cholera outbreak in Haiti.

2010—Vocabulary standards supported or developed by NLM (LOINC, RxNorm, SNOMED CT) included in rule specifying certification criteria for electronic health record systems that Medicare and Medicaid providers must use to be eligible for “meaningful use” incentives included in the American Recovery and Revitalization Act of 2009.

NLM LEGISLATIVE CHRONOLOGY

August 3, 1956—An amendment to Title III of the Public Health Service Act, the National Library of Medicine Act, placed the Armed Forces Medical Library under the PHS, and renamed it the National Library of Medicine (Public Law 84-941).

October 22, 1965—The Medical Library Assistance Act of 1965 (Public Law 89-291) was signed into law, authorizing NLM's extramural programs of grant assistance to help expand and improve the nation's medical library and health communications resources, technology, and professional staff for service to the health community.

August 3, 1968—Public Law 90-456 authorized the designation of the Lister Hill National Center for Biomedical Communications.

November 4, 1988—Public Law 100-607 authorized the establishment of the National Center for Biotechnology Information at NLM.

June 10, 1993—Public Law 103-43 authorized the establishment of the National Information Center on Health Services Research and Health Care Technology at NLM.

November 21, 1997—The Food and Drug Administration Modernization Act (Public Law 105-115) called for the creation of the centralized, consumer-friendly online listing of clinical trials that would become ClinicalTrials.gov [http://www.clinicaltrials.gov].

BIOGRAPHICAL SKETCH OF NLM DIRECTOR DONALD A.B. LINDBERG, M.D.

Donald A.B. Lindberg, M.D., a scientist who has been a pioneer in applying computer technology to health care since 1960 at the University of Missouri, in 1984 was appointed Director of the National Library of Medicine, the world's largest biomedical library (FY 2009 annual appropriation of $331 million and 731 FTE).
From 1992 to 1995, he served in a concurrent position as founding Director of the National Coordination Office for High Performance Computing and Communications (HPCC) in the Office of Science and Technology Policy, Executive Office of the President. In 1996 he was named by the HHS Secretary to be the Coordinator for the G-7 Global Health Applications Project.

In addition to an eminent career in pathology, Dr. Lindberg has made notable contributions to information and computer activities in medical diagnosis, artificial intelligence, and educational programs. Before his appointment as NLM Director, he was Professor of Information Science and Professor of Pathology at the University of Missouri-Columbia. He has current academic appointments as Clinical Professor of Pathology at the University of Virginia and Adjunct Professor of Pathology at the University of Maryland School of Medicine.

Dr. Lindberg was elected the first President of the American Medical Informatics Association (AMIA). As the country's senior statesman for medicine and computers, he has been called upon to serve on many boards including the Computer Science and Engineering Board of the National Academy of Sciences, the National Board of Medical Examiners, and the Council of the Institute of Medicine of the National Academy of Sciences.

Dr. Lindberg is the author of 3 books (The Computer and Medical Care; Computers in Life Science Research; and The Growth of Medical Information Systems in the United States), several book chapters, and more than 200 articles and reports. He has served as editor and editorial board member of 9 publications including the Journal of the American Medical Association.

Dr. Lindberg graduated Magna cum Laude from Amherst College and received his M.D. from the College of Physicians and Surgeons, Columbia University. Among the honors he has received are Phi Beta Kappa, Simpson Fellow of Amherst College, Markle Scholar in Academic Medicine, Surgeon General's Medallion, recipient of the First AMA Nathan Davis Award for outstanding Member of the Executive Branch in Career Public Service, the Walter C. Alvarez Memorial Award of the American Medical Writers Association, the Presidential Senior Executive Rank Award, Founding Fellow of the American Institute of Medical and Biological Engineering, the Outstanding Service Medal of the Uniformed Services University of the Health Sciences, Federal Computer Week's Federal 100 Award, Computers in Healthcare Pioneer Award, Association of Minority Health Professions Schools Commendation, RCI High Performance Computing Industry Recognition Award, U.S. National Commission on Libraries and Information Science Silver Award, Council of Biology Editors Meritorious Award, HHS Meritorious Service Award, Medical Library Association President's Award, American College of Medical Informatics Morris F. Collen, M.D. Award of Excellence, Johns Hopkins University School of Medicine Ranice W. Crosby Distinguished Achievement Award, New York Academy of Medicine Information Frontier Award, Cosmos Club Award, American Medical Women's Association Lila A. Wallis Women's Health Award, U.S. Medicine Frank Brown Berry Prize, and Fellow of the American Association for the Advancement of Science and the New York Academy of Medicine. He has also received honorary doctorates from Amherst College, the State University of New York at Syracuse, the University of Missouri-Columbia, and the Universities for Health Sciences, Medical Informatics and Technology, Innsbruck, Austria.

### NLM DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leon Lloyd Gardner</td>
<td>1945</td>
<td>1946</td>
</tr>
<tr>
<td>Joseph Hamilton McNinch</td>
<td>1946</td>
<td>1949</td>
</tr>
<tr>
<td>Frank Bradway Rogers</td>
<td>1949</td>
<td>1963</td>
</tr>
<tr>
<td>Martin Marc Cummings</td>
<td>1964</td>
<td>1984</td>
</tr>
<tr>
<td>Donald A.B. Lindberg</td>
<td>1984</td>
<td>Present</td>
</tr>
</tbody>
</table>

### MAJOR DIVISIONS

**Division of Extramural Programs**

http://www.nlm.nih.gov/ep/

The Extramural Programs (EP) Division provides grants to organizations and individuals for applying computers and telecommunications for improving storage, retrieval, access and use of biomedical information.

EP provides research support via grants on a wide range of basic and applied biomedical informatics research topics.

It awards resource grants to support improved dissemination, managements, and use of biomedical information in real settings.

The Extramural Programs Division also offers career development support in the form of early career transition awards, to assist recent Ph.D.s and M.D.s who are establishing their initial research careers in informatics.

To ensure an adequate national pool of informaticians and health information scientists, NLM supports research training in biomedical informatics at 18 educational institutions throughout the U.S. These programs offer graduate education and postdoctoral research experiences in a wide range of areas, including health care informatics, bioinformatics, and computational biology.

Grants are also made to U.S. small businesses that seek to undertake informatics research and development leading to commercialization. Critical research areas include: representation of medical knowledge in computers; organization and retrieval issues for image databases; and enhancement of human intellectual capacities through virtual reality, dynamic modeling, artificial intelligence, and machine learning.
Division of Library Operations


The Bibliographic Services Division (BSD), a part of Library Operations at NLM, fosters expanded access of health information to health professionals and the general public by creating MEDLINE®, NLM’s premier citation database to biomedical literature references. Its responsibilities include:


- The Index Section [http://www.nlm.nih.gov/bsd/indexhome.html]: creates and maintains the MEDLINE [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed] database containing references to current articles from over 5,000 of the world’s biomedical journals; coordinates the data entry, indexing, and commentary contracts; and conducts research leading to more efficient forms of indexing and data entry.

- The MEDLARS Management Section (MMAS) [http://www.nlm.nih.gov/bsd/mmshome.html] is responsible for coordinating the overall development and management activities for MEDLINE/PubMed, the UMLS, and other NLM projects and services.

Division of Specialized Information Services (SIS)


SIS creates information resources and services in toxicology, environmental health, chemistry, and HIV/AIDS. Another component of SIS, the Outreach and Special Populations Branch [http://sis.nlm.nih.gov/outreach.html] (OSPB), seeks to improve access to quality and accurate health information by underserved and special populations.


Some SIS products help to address the toxicology and environmental health information needs of the general public. One such resource is Tox Town® [http://toxtown.nlm.nih.gov/], an interactive guide to toxic chemicals and environmental health issues in everyday locations. It is a companion to the extensive information in the TOXNET collection of databases. Tox Town also offers some resources in Spanish [http://toxtown.nlm.nih.gov/espanol]. The Household Products Database [http://householdproducts.nlm.nih.gov/] is a consumer’s guide that provides information on the potential health effects of chemicals contained in more than 7,000 common household products used inside and around the home. This database allows consumers, scientists, and health professionals to investigate ingredients in brand-name products.


The Outreach and Special Populations Branch [http://sis.nlm.nih.gov/outreach.html] manages and develops programs in an effort to eliminate disparities in accessing health information by providing community outreach support, training of health professionals to use NLM’s health information databases, and designing special population Web sites [http://sis.nlm.nih.gov/outreach.html] that address specific concerns in various racial and ethnic groups. SIS is also taking the lead in NLM’s disaster preparedness efforts, through its Disaster Information Management Research Center. DIMARC was created to aid the nation’s disaster management efforts and is tasked with the effective collection, organization, and dissemination of health information for natural, accidental, or deliberate disasters.

Lister Hill National Center for Biomedical Communications


The Lister Hill Center performs research in developing Next Generation electronic health records to facilitate patient-centered care and advancing clinical decision support systems. It conducts and supports research in natural language processing to extract usable and meaningful information from biomedical text. It also performs extensive research and development in the capture, storage, processing, retrieval, transmission, and display of biomedical documents and medical imagery. Areas of active investigation include image compression, image enhancement, image recognition and understanding, image transmission, and user interface design. LHC conducts extensive research in developing advanced computer technologies to facilitate the access, storage, and retrieval of biomedical information. In addition, it performs extensive research in developing and advancing infrastructure capabilities such as high-speed networks, nomadic computing, network management, and improving the quality of service, security, and data privacy. This research center also performs extensive research and development in...
the capture, storage, processing, retrieval, transmission, and display of multimedia biomedical data. Multimedia products include high quality-video, audio, imaging, and graphics materials.

**National Center for Biotechnology Information (NCBI)**


NCBI conducts research on fundamental biomedical problems at the molecular level using mathematical and computational methods.

It maintains collaborations with several NIH Institutes, academia, industry, and other governmental agencies.

NCBI also fosters scientific communication by sponsoring meetings, workshops, and lecture series. In addition, it supports training on basic and applied research in computational biology for postdoctoral fellows through the NIH Intramural Research Program.

NCBI engages members of the international scientific community in informatics research and training through the Scientific Visitors Program.

It develops, distributes, supports, and coordinates access to a variety of databases and software for the scientific and medical communities. Finally, NCBI develops and promotes standards for databases, data deposition and exchange, and biological nomenclature.

**Office of Computer & Communications Systems (OCCS)**


OCCS provides efficient, cost-effective computing and networking services, technical advice, and collaboration in informational sciences in support of the research and management programs offered through NLM.

OCCS develops and provides the NLM backbone computer networking facilities, and supports, guides, and assists other NLM components in local area networking. The Division provides professional programming services and computational and data processing facilities to meet NLM program needs; operates and maintains the NLM Computer Center; designs and develops software; and provides extensive customer support, training courses and seminars, and documentation for computer and network users.

OCCS helps to coordinate, integrate, and standardize the vast array of computer services available throughout all of the organizations comprising NLM. The Division also serves as a technological resource for other parts of the NLM and for other Federal organizations with biomedical, statistical, and administrative computing needs.

The Division promotes the application of High Performance Computing and Communication to biomedical problems, including image processing.

The OCCS staff develops computer-based systems for information retrieval applications, conducts computer science and engineering research and development, and consults and collaborates in the area of advanced electronic office automation facilities. They support software systems to perform these services, and conduct research and evaluations for best fit solutions to information access needs.

This page last reviewed on January 5, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

The Center for Information Technology's (CIT) mission is to provide, coordinate, and manage information technology and to advance computational science.

CIT supports NIH's research and management programs with efficient, cost-effective administrative and high-powered scientific computing, software development, networking, and telecommunications services. CIT also provides bioinformatics support through its scientists, engineers, and mathematicians. Among its activities, the CIT:

- engages in collaborative research and provides collaborative support to NIH investigators in the area of computational bioscience
- provides efficient, cost-effective information systems and networking services
- provides state-of-the-art scientific and administrative computing facilities
- identifies new computing technologies with innovative applications to biomedical research
- creates, purchases, and distributes software applications
- provides NIH staff with computing information, expertise, and training
- provides data-processing and high-performance computing facilities, integrated telecommunications data networks, and services to the U.S. Department of Health and Human Service (HHS) and other Federal agencies
- serves as a data center to HHS and other Federal agencies
- develops, administers, and manages NIH systems and provides consulting services to NIH Institutes and Centers in support of administrative and business applications

IMPORTANT EVENTS IN CIT HISTORY

1954—A central data-processing facility is established in the NIH Office of the Director under Dr. Harold Dorn, combining EAM (punched card) equipment and biometric expertise.

1956—The biometric facility becomes the Biometrics Branch in the new Division of Research Services (DRS).

May 1956–The NIH Director establishes a committee on electronic data processing and computers.

1958—NIH installs its first electronic digital computer as an experimental device.

March 1960–The U.S. Surgeon General approves the establishment of a Computation and Data Processing Branch in DRS.

October 1961–NIH installs its first "second generation" computer.

April 1963–The NIH Director appoints a steering committee to undertake a comprehensive study of data-processing activities at NIH.

The NIH steering committee recommends the establishment of a Division of Computer and Information Sciences, subsequently changed to the Division of Computer Research and Technology (DCRT), including provision for the transfer of the Computation and Data Processing Branch, DRS, to the new organization.

1964–DCRT is established, with James King as Interim Acting Director.

1966–Dr. Arnold W. Pratt is named DCRT's first Director.

April 1966–Components of the "third-generation" computer system are installed.

April 1969–NIH research community receives the first time-sharing computers.

June 1969–Minicomputers designed by DCRT are installed in NIH laboratories.

August 1969–DCRT introduces WYLBUR, an innovative software that eliminates the need for punch cards and provides new computing capabilities to the administrative and scientific communities.

1981—DCRT designs and implements NIH Extended WYLBUR, providing text-editing capabilities used for NIH publications, grants guidance and summary statements, and research papers.

April 1983—The Personal Workstation Project is founded to determine how effectively NIH personnel can use personal computers.

February 1984—NIH opens the Personal Computer User Resource Center (URC). The URC, a joint effort between the DCRT, Division of Personnel Management, and the Division of Management Policy, serves as an NIH resource for obtaining assistance with personal computer usage and houses the first hands-on personal computer training facility at NIH.

1988—The Convex Unix-based supermini-computer is installed, and the network task group is created.

1990—Extensive networking (NIHnet) is installed at NIH, providing connectivity for 60 local area networks.

March 1992—HHS Secretary Lewis Sullivan, in a letter to Congress, commits to creating a new office to improve management and coordination of NIH's information resources.

June 1992—The NIH Director approves creation of the Office of Information Resources Management (OIRM) in the NIH Office of the Director. Dr. Francis W. Hartel is selected as the NIH Senior IRM official and the Director of OIRM.

September 1993—The Information Systems Security Officers committee is established to handle NIH IT security issues.

January 1994—DCRT celebrates its 30th anniversary.

February 1994—DCRT establishes the Technical Assistance and Support Center (TASC) to help customers obtain computer-related information and support.

October 1994—OIRM sponsors the first NIH Internet conference on legal and policy issues related to the increased use of Internet resources.

May 1995—DCRT sponsors Internet Expo Day to help NIH staff discover the World Wide Web and its enormous potential to disseminate and exchange information.

June 1995—The NIH Director approves a revised charter for the IRM Council and increases its role in providing management leadership on NIH-wide information technology (IT) initiatives.

July 1995—OIRM, the National Science Foundation, and the World Wide Web Federal Consortium sponsor a Federal Webmaster workshop on legal, ethical, and security issues related to increased Web use by Federal agencies.

August 1995—The first NIH electronic store is established to provide efficient acquisition of personal computers, hardware, software, and online components to NIH personnel.

1996—A telecommunications committee is established to provide the IRM Council with advice about crosscutting telecommunication issues affecting a large number of NIH staff. Issues include telephone features and services, pagers, cellular services, video teleconferencing, remote access, audio conferencing, and switchboard operator services.

Responsibilities are shared by DCRT and the Telecommunications Branch located in NIH's Office of Research Services. DCRT introduces a subscription-based program for the acquisition and distribution of brand-name software to NIH and HHS personnel, with the result of significant cost reduction for software licensing.

The NIH Director names Anthony Itteilag, the NIH Deputy Director for Management, to serve as interim NIH CIO.

Dona R. Lenkin is appointed to serve as OIRM Acting Director and alternate NIH CIO.

May 1996—the IRM Council establishes the NIH Year 2000 Work Group (Y2K) to provide NIH with leadership and direction on initiatives modifying computer systems and applications to accommodate problems related to a 2-digit date field.

June 1996—NIHs Computer Center is designated as a major HHS data center.

July 1996—the NIH Data Warehouse, which provides a one-stop-shop graphical user interface to NIH administrative and accounting information, is introduced to NIH.

August 1996—the Information Technology Management Reform Act of 1996 (ITMRA, also known as the Clinger-Cohen Act) becomes effective. ITMRA assigns overall responsibility for the acquisition and management of government IT resources to the Director, Office of Management and Budget. Additionally, ITMRA gives authority to heads of executive agencies to acquire IT resources and directs agencies to appoint a Chief Information Officer (CIO) to provide advice to each agency on the effective management of IT investments.

September 1996—the NIH Director's leadership forum on the management of IT at NIH forms an IT Central Committee (ITCC) to provide recommendations on improving the management of NIH IT resources.
December 1996—A final ITCC report is submitted to the NIH Director. The report recommends appointing a CIO and combining DCRT, OIRM, and the Telecommunications Branch into a single organizational structure.

1997—A review of NIH’s administrative structure, conducted in response to a request from Congressman John Porter (Ill.), is completed. The report recommends that the NIH implement the ITCC recommendations by appointing a permanent CIO and establishing a CIO organization.

NIH’s first electronic magazine, LiveWire, is launched by DCRT. The online magazine offers easy access to key services and computer information.

July 1997—DCRT introduces the NIH Human Resources Information and Benefits System, a Web service that gives employees easy access to personnel data, including benefits, salary, awards, leave, savings, performance, and retirement.


October 1997—Vice President Albert Gore awards OIRM staff the National Performance Review “Hammer” Award for the development of an automated security risk assessment tool for networks.

November 1997—DCRT inaugurates SILK (Secure Internet-Linked) technology to provide Web access to enterprise data.

February 1998—The Center for Information Technology (CIT) is formed, combining the functions of the DCRT, OIRM, and the Telecommunications Branch.

March 1998—Alan S. Graeff is named NIH’s first CIO and Director of the newly formed CIT.

April 1998—CIT’s OIRM sponsors an IT security conference to provide IT security officers and others with essential information for moving toward the 21st century.

CIT renames its original acquisition and distribution project to the Software Distribution Project (SDP). The SDP provides software to more than 24,000 customers, including more than 80% of all NIH personnel.

October 1998—The NIH IT Board of Governors is established to advise the NIH and the NIH CIO on NIH-wide IT management and to make recommendations on IT activities and priorities.

January 1999—CIT completes development of the predecessor to the TELESYNERGY(TM) Medical Consultation WorkStation, a multimedia, medical imaging workstation. This system provides an electronic imaging environment, utilizing a prototype Asynchronous Transfer Mode (ATM) telemedicine network. The TELESYNERGY environment includes a scientific workstation as the computing platform that transmits simultaneous high-resolution images to all sites participating in a medical consultation.

May 1999—The Information Technology Management Committee (ITMC) is formed to develop and communicate recommendations and decisions at the NIH Institute and Center level, provide a forum for building consensus across the NIH, and serve as an umbrella organization to the NIH IT process management and technical committees.

December 1999—NIH successfully prepares for the Year 2000, thus bringing to fruition 4 years of effort preparing for the largest information management project in history. The NIH strategy of aggressive renovation and validation of information systems, biomedical equipment, facilities, utilities, and telecommunications provides a smooth transition that ensures the integrity of the NIH mission.

2000—CIT renames the Software Distribution Project (SDP) to the Information Systems Designated Procurement (ISDP) to acquire and deliver brand-name software, hardware, and services to NIH and HHS personnel. The ISDP takes advantage of large-volume purchasing agreements to provide significantly discounted prices to its customers. The ISDP also saves its participants time and money by eliminating the need to search for the best information systems deals. ISDP provides major software titles, hardware, and services to more than 54,000 customers, including 84% of HHS personnel and all of NIH.

January 2000—CIT joins forces with the National Cancer Institute (NCI) in a pioneering TELESYNERGY collaboration to reach out to distant community hospitals. Patients in remote areas are now able to participate in selected NCI phase I and phase II protocols. Collaborating sites, with TELESYNERGY Systems either installed or under construction, include hospitals in Fort Lauderdale, Florida; Wheeling, West Virginia; Belfast, Northern Ireland, United Kingdom; and Dublin, the Republic of Ireland.

2001—The NIH Incident Response Team is the first civilian Federal agency to receive the prestigious Office of Personnel Management Guardian Award for exceptional contributions in ensuring the confidentiality, availability, and integrity of NIH information resources.

2002—Dr. John F. (Jack) Jones, Jr., joins CIT as Chief IT Architect for NIH, to focus on NIH enterprise systems critical to the mission of NIH and lead Enterprise Architecture.

CIT takes a leadership role in forging NIH’s strategy for common services, including hosting the improved and expanded NIH Portal.

CIT supports the development and staged implementation of the NIH Portal as a single, user-friendly customizable Web interface by which data and documents can be readily accessed by NIH staff and associated personnel.

CIT successfully implements the NIH Administrative Restructuring Advisory Committee (ARAC) recommendations for IT Consolidation (Phase I).
The NIH Information Technology Working Group (ITWG), established by the NIH Director as part of the NIH Steering Committee, provides governance and oversight on NIH IT management issues. As an advisory group to the NIH Director, NIH Steering Committee, and NIH CIO on IT management, the ITWG establishes governance over the 5 IT Domain Areas below, representing the areas where decisions need to be made at the intersection of business and information technology.

- **IT Principles Domain**—includes alignment of IT to the NIH mission, corporate policies, and oversight of the use of IT, and determination of ownership of IT initiatives
- **IT Infrastructure Strategies Domain**—includes the IT “public utility” and secure, robust, and manageable common services
- **IT Architecture Domain**—includes data standards and application standards
- **Business Application Needs Domain**—includes all enterprise, non-scientific administrative, grants/extramural, and Intramural IT systems
- **IT Investment and Prioritization Domain**—includes funding mechanisms and priorities

The CIT help desk is formally established as the NIH IT Help Desk.

**2004**—CIT successfully implements the NIH ARAC recommendations for IT Consolidation Phase II; CIT continues to implement and oversee NIH enterprise-wide applications like:

- Integrated Time and Attendance System (ITAS)
- NIH Enterprise Common Services (NECS), including NIH Login and NIH Portal
- NIH Intramural Data Base (NIDB)
- Contractor Performance System (CPS)
- Vulnerability Tracking System (VTS)
- Human Resources Data Base (HRDB)

**2005**—Dr. Jones assembles domain teams from across NIH to examine the technology and standards needs of areas that are about to undergo significant consolidation, such as e-mail systems and wireless networks.

**2006**—Al Whitley is named Deputy Director of CIT.

CIT becomes the technical owner of the NIH Enterprise Ethics System (NEES), the comprehensive automation of the NIH Ethics Program. NEES provides the means to submit, review, track, and report on all ethics-related reports and requests along with supporting documentation. Because of the size and complexity of the overall system, the product is delivered in phases. The first release of NEES is implemented in FY 2006 and focuses on the Public Financial Disclosure Report, referred to as the SF-278.

**2007**—CIT implements NIH NEES Release 1.5, which enables all remaining functions required for the review and certification of the SF-278 Public Financial Disclosure Report.

CIT designs a new system for the helix.nih.gov general purpose scientific platform that hosts applications in response to technology needs of the NIH research community. This includes introducing 1024 new processors for the Biowulf cluster and completing plans to upgrade the Helix shared memory system. Forty-eight additional nodes are integrated into the Infiniband network of the Biowulf cluster, thus reducing queue times for the most demanding parallel molecular dynamics applications. In addition, new hardware to replace helix.nih.gov is delivered and applications are installed, configured, and tested.

CIT accomplishes the closure of a multi-year project to federate with the HHS’s consolidated and outsourced email system. As part of this Federation task (which is a requirement on the Performance Management Appraisal Program of the NIH Director and NIH CIO for 2007), the NIH successfully provides for a synchronized email directory service, a synchronized calendar service, email vaulting services, email disaster recovery services, and the doubling of the default mailbox size at the NIH from 100 to 200 MB.

CIT establishes a framework and develops policies, procedures, and templates for the multiple phases of a process improvement software development life cycle and 2 phases on the software management life cycle. During the fiscal year, a suite of project management practices is established. Processes, tools, and artifacts align the DECA PM Methodology with the HHS Enterprise Performance Life Cycle (EPLC) Framework. Quality Assurance (QA) and Configuration Management (CM) functions are established.

In April 2007, the NIH Data Town interface is retired and a new nVision interface is implemented to create a single, central Web site—the nVison Data Warehouse Portal. Data Warehouse business areas and reporting tools, such as Budget and Finance, Human Resources, Research Contracts and Grants, Staff Training and Development, Budget Tracking, Manager’s Desktop Assistant, and Workforce Planning Trends that were previously housed on Data Town are co-located with the nVision business areas to form the new nVision Data Warehouse portal page.

**January 2008**—On January 7, 2008, the Office of the Chief Information Officer (OCIO) is established, transferring the functions of the Chief Information Officer (CIO), formerly part of CIT, to the NIH Office of the Director. The NIH CIO advises the NIH Director on the strategic direction and management of significant NIH IT program and policy activities.

**February 2008**—CIT celebrates its 10th anniversary.

**June 2008**—CIT deploys the NIH Federated Authentication Identity Service (NIH Federated Login). This service facilitates access by NIH and non-NIH collaborators to specific, publicly available NIH research applications, databases, and scientific information. To log in to these resources, authorized collaborators from Government agencies, national laboratories, universities, hospitals, and pharmaceutical and biotechnology medical research centers can use the same user name,
password, or other personal identification from their home agency, institution, or organization. By providing an easy-to-use login, online information and web-based resources can be shared to promote collaboration for enhanced worldwide research in support of scientific and medical research.

August 2008—CIT announces the first online Service Catalog, providing customers with a single, online authoritative source of service information. The new catalog combines the wide range of CIT services into customer friendly categories, making information easier to find. The catalog lists 120 services in such areas as telecommunications, application development, computer systems, and customer support. Key catalog components include service description, customer benefits, hours of operation, contact information, customer market, and related links. The catalog design focuses on Information Technology Infrastructure Library (ITIL), an internationally recognized set of best practices for IT Service Management, and was developed in recognition of the growing dependency on IT to satisfy business needs.

September 2008—CIT Training marks 40 years of computer training to the NIH community. In the fall of 1968, DCRT began offering courses to assist NIH programmers, analysts, and managers to make more effective use of computers and software. A total of 18 courses were offered, with 261 course completions. CIT Training now offers more than 220 courses with seminars designed for those interested in scientific applications, web development, networking, computer security, statistics, grants, and personal computing. Over 10,000 course completions are recorded in FY 2008.

October 2008—CIT participates in the NIH Research Festival, presenting several collaborative initiatives, including the following:

- CIT joins forces with the National Institute of Dental and Craniofacial Research (NIDCR) to develop the Salivary Proteome Wiki as a resource for the proteomic research community. The system is one of the first in NIH to facilitate scientific collaboration and knowledge management using Web 2.0 technologies. It allows researchers to discuss ideas, perform annotation and curation, share experimental results, and discover new knowledge in a community-driven paradigm.

- In collaboration with the Molecular Libraries Program Center Network (MLPCN), CIT successfully delivers the Common Assay Reporting System (CARS), which allows center investigators and program directors to track the status of bioassay projects and related issues at each screening center within the MLPCN. The system also provides a means for collecting, sharing, and retrieving bioassay information among the screen centers and program office at NIH.

February 2009—CIT hosts a symposium highlighting recent research using the computational resources of the NIH Biowulf Cluster, one of the larger general-purpose biomedical computing clusters in the world.

February 2009—The NIH Federated Identity Service, which provides authorized collaborators worldwide with secure, single sign-on access to NIH information, is honored with the Government Information Technology Executive Council’s (GITEC) 2009 Project Management Excellence Award.

September 2009—CIT is selected as a 2009 InformationWeek Government IT Innovator in recognition of the NIH Federated Identity Service.

December 2009—The NIH IT Help Desk is transitioned to the NIH IT Service Desk, implementing enhancements to deliver more robust support to users and partners.

December 2009—CIT and the NIH Office of the CIO co-sponsor the first iTrust forum, "Identity and Trust: Enabling Collaboration in a Connected World," to focus on the effects of Open Identity and Personal Identity Verification (PIV) card technology and to examine Federal-wide efforts to foster identity management collaboration.

December 2009—NIH retires WYLBUR, the Titan editing and batch processing system, as many of its text editing functions are now performed with desktop computer tools.

February 2010—CIT deploys the website for First Lady Michelle Obama’s Let’s Move! campaign to combat the epidemic of childhood obesity. This website provides schools, families, and communities tools to help children become healthier through increased activity and better nutrition.

April 2010—CIT collaborates with the National Institute of Mental Health (NIMH) on the design of prospective PET imaging probes radiolabeled with fluorine-18.

June 2010—CIT collaborates with the National Institute of Mental Health (NIMH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Environmental Health Sciences (NIEHS) with the development of the National Database for Autism Research (NDAR) system. NDAR expands to help accelerate progress in autism research by creating a secure, web-enabled infrastructure that integrates heterogeneous datasets, providing unprecedented access to a high volume of research data relevant to autism.

June 2010—CIT adds compute nodes to the NIH Biowulf Cluster, greatly increasing compute power for a wide range of biomedical research applications, including those in genomics, imaging, molecular dynamics, and statistical analysis. At nearly 9000 processing cores, the NIH Biowulf Cluster is the largest single compute resource at the NIH, helping meet the ever increasing demand for biomedical research computing.

June 2010—CIT develops the Content Management System for, and directs the launch of, the Public Health Emergency website for the Department of Health and Human Services (HHS) Assistant Secretary for Preparedness and Response.

June 2010—CIT collaborates with the National Heart, Lung, and Blood Institute (NHLBI) to develop a system for quality control monitoring, data collection, and statistical analysis of gene expression data for thousands of samples from the Framingham Heart Study.

August 2010—CIT adds zLinux Virtual Server Hosting Service, offering Department of Health and Human Services (HHS) customers open source applications hosting, including dynamic web publishing tools and collaborative tools such as wikis. Virtualization also results in significant cost savings by promoting energy conservation and space optimization.

August 2010—CIT hosts server and web collaboration services for the Department of Health and Human Services (HHS) in support of the Health Care Reform tracking project. Users access the applications using single sign-on authentication.
October 2010—CIT deploys a data repository and website developed for Science and Technology for America’s Reinvestment: Measuring the Effect of Research on Innovation, Competitiveness and Science, or STAR METRICS, a multi-agency venture led by the NIH, National Science Foundation (NSF), and White House Office of Science and Technology Policy (OSTP). STAR METRICS provides an innovative partnership between science agencies and research institutions to document the value and outcomes of science investments to the public.

November 2010—CIT collaborates with the National Institute of Dental and Craniofacial Research (NIDCR) to develop a wiki-based platform for scientists to explore and enrich a comprehensive catalog of proteins found in human saliva. The service now extends to include researchers from industries and other governmental agencies, such as the Food and Drug Administration (FDA).

BIOGRAPHICAL SKETCH OF ACTING CIT DIRECTOR THOMAS G. MURPHY

Mr. Thomas G. Murphy was appointed Acting NIH CIO and Acting CIT Director in February 2011. Mr. Murphy has been a leader in IT for over 20 years as a CIO and IT manager, and prior to that, an avid IT practitioner and software developer. He is currently the Associate Director for Management, National Institute of Dental and Craniofacial Research (NIDCR), and in 2010 also served in a dual leadership role as the overall Program Coordinator of the NIH Financial Systems Integration project. In earlier years, Mr. Murphy served as the NIDCR CIO, where he was involved in many significant trans-NIH IT activities. Before coming to NIH in 1992, Mr. Murphy was the Director of Academic Computing Services for the College of Education at the University of Maryland, where he was also on the Educational Technology faculty. Mr. Murphy has a BA from Catholic University in Washington, DC, where he studied physics and music, and he holds an MS in IT from University of Maryland University College (UMUC).

CIT DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>James King (Acting)</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Dr. Eugene Harris (Acting)</td>
<td>N/A</td>
<td>August 1966</td>
</tr>
<tr>
<td>Dr. Arnold W. Pratt</td>
<td>August 1966</td>
<td>May 1990</td>
</tr>
<tr>
<td>Dr. David Rodbard</td>
<td>November 1990</td>
<td>April 1996</td>
</tr>
<tr>
<td>Alan S. Graeff</td>
<td>March 1998</td>
<td>November 2005</td>
</tr>
<tr>
<td>Dr. John F. Jones, Jr. (Acting)</td>
<td>November 2005</td>
<td>February 2011</td>
</tr>
<tr>
<td>Thomas G. Murphy (Acting)</td>
<td>February 2011</td>
<td>Present</td>
</tr>
</tbody>
</table>

PROGRAMS

CIT consists of the Office of the Director (OD), Division of Computational Bioscience (DCB), Division of Computer System Services (DCSS), Division of Customer Support (DCS), Division of Enterprise and Custom Applications (DECA), and Division of Network Systems and Telecommunications (DNST).

Office of the Director (OD)

The Office of the Director plans, directs, coordinates, and evaluates the Center's programs, policies, and procedures and provides analysis and guidance in the development of systems for the effective use of IT techniques and equipment in support of NIH programs.

Division of Computational Bioscience (DCB)

DCB is a research and development organization that provides scientific and technical expertise in computational science and engineering to support biomedical research activities at the NIH, including the following:

- Conducts collaborative research in biomedical instrumentation and rapid prototyping, clinical and laboratory imaging and image management, communication and processing technologies, computational statistics, genomics and proteomics, high-performance computing, high-throughput sequence analysis, human- and animal-based research systems, knowledge-based management systems, mathematical and biophysical modeling, medical and bioinformatics, molecular dynamics of biological macromolecules, molecular modeling, molecular structure determination, portfolio analysis, robotics and process automation, scientific visualization, signal transduction, data acquisition and processing, simulation of complex biological systems, systems biology, and telecollaboration and telehealth systems.
- Develops complex computational methods and tools for solving biomedical, laboratory, and clinical research problems.

Division of Computer System Services (DCSS)

DCSS plans, implements, operates, and supports centrally owned or administered computing resources for NIH enterprises use, ensuring interoperability among those resources and between them and other computing facilities owned by customer organizations. Activities include the following:

- Promotes awareness and efficient and effective use of these computing resources by customer personnel through training, presentations, consultations, and documentation.
- Investigates new and emerging computing requirements of customer programs. It conducts research and development to identify, evaluate, and adapt new computer architectures and technologies to meet identified customer requirements and to enhance current service offerings.
Division of Customer Support (DCS)

DCS provides centralized, integrated computer support services to the NIH computing community, including the following:

- Advocates customer needs to CIT management and represents services and policies to CIT's customers.
- Plays an active and participatory role in supporting desktop computing to the end-user in the areas of software and hardware, including internet, communications, and access technologies.
- Coordinates and oversees CIT's Training Program for the benefit of the NIH computing community. The training program is delivered at no charge to the user.
- Provides central account establishment and management services for access to CIT systems, manages the NIH IT Service Desk, and implements problem tracking systems.

Division of Enterprise and Custom Applications (DECA)

DECA supports the NIH enterprise business process through the development and management of transaction and decision-support environments for administrative and business applications of NIH, such as procurement, budget, accounting, and human resource activities, as well as systems that support extramural and intramural business processes. Activities include the following:

- Provides complete information systems management services to the NIH, including technical project management, systems analysis, programming, data integration and conversion, quality assurance, testing, and production support.
- Provides the NIH community with World Wide Web development, support services, and consulting services for applications development.

Division of Network Systems and Telecommunications (DNST)

DNST directs the engineering, design, implementation, and support of network infrastructure and services for the NIH-wide area network (NIHnet) to facilitate the use of scientific, administrative, and other business applications. Activities include the following:

- Manages and directs NIH telecommunications systems and technical requirements for the NIH ICs and implements telecommunications programs to meet the needs of the NIH community.
- Researches, develops, and tests next-generation networking/telecommunications technologies and develops and supports applications using new network technologies.
- Provides consulting, guidance and support to the ICs, helping them meet their network requirements.
- Improves the information infrastructure on networking/telecommunications activities by serving as liaison to the NIH ICs and other HHS components.
- Serves as a focal point for telecommunications service orders, and develops and disseminates recommended standards, policies, and procedures for the nationwide implementation and management of NIH networking and telecommunications systems.

This page last reviewed on April 5, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
MISSION

The Center for Scientific Review's (CSR's) key mission is to see that NIH grant applications receive fair, independent, expert, and timely reviews--free from inappropriate influences--so NIH can fund the most promising research.

The Center specifically:

- Serves as the central receipt point for all research and training grant applications submitted to NIH. Also receives some of the applications submitted to other components of the U.S. Department of Health and Human Services (HHS) and refers them to these components;
- Assigns all NIH applications to the appropriate NIH institutes or centers for consideration for funding and also to the scientific review groups within CSR or other institutes or centers for review;
- Provides the scientific merit review of most research grant and fellowship applications submitted to NIH;
- Provides staff support to the Office of the Director, NIH, in the formulation of grant and award policies and procedures; and
- Assists other NIH components in providing information on the NIH peer review system and information about the research grant and fellowship application process and procedures to the scientific community, Congress, other NIH staff, and the general public.

IMPORTANT EVENTS IN CSR HISTORY

1944—Public Health Service (PHS) Act (Public Law 78-410, sec. 301, July 1) authorized the Surgeon General to “make grants-in-aid to universities, hospitals, laboratories, and other public or private institutions, and to individuals for such research projects as are recommended by the National Advisory Health Council, or, with respect to cancer, recommended by the National Advisory Cancer Council.” The Act also authorized the award of fellowships in the health sciences.

1946—The Research Grants Office was established January 1 under authority of section 301 of the PHS Act to administer several research projects transferred to PHS at the end of World War II and to operate a program of extramural research grants and fellowship awards. The office was elevated to division status at the end of 1946.

The Division of Research Grants (DRG) was responsible for operating and administering a program of extramural research and training through grants-in-aid of research in the biomedical and health-related sciences. DRG retained the operating responsibility until each successive institute was established and took over the programs in its categorical fields. The National Cancer Institute, which already ran an extramural research program on its own, continued to do so.

DRG was instructed by the National Advisory Health Council to establish study sections for scientific and technical review of research grant applications, and to explore neglected areas of research in the health sciences.

1958—Responsibility for research grant and training programs in noncategorical areas, operated by the division since 1946, was transferred to the new Division of General Medical Sciences (DGMS). DRG then reorganized to concentrate on the review of research grant and fellowship applications, coordination of all extramural programs operated by the institutes and DGMS, and operation of the health research facilities program and grants management.

1961—The Grants Associates Program began recruitment and training of professional staff for the extramural branches of all PHS granting divisions, with DRG serving as a primary training focus.

1962—DRG was assigned overall responsibility for coordinating policies and practices for administration of grants and awards for all PHS extramural programs.

1965—The Civil Rights Liaison Office was established.

1966—DRG assumed additional responsibilities for review with the transfer from the institutes of the committee on scientific publications, the NCI collaborative research panel, the environmental sciences review committee, and the review functions of 6 panels of the U.S.-Japan Cooperative Medical Science program.

1968—DRG expanded the computer-based central data system, information for management planning analysis and coordination (IMPAC), to include the fellowship programs in addition to research, training grant, and research career award programs.

1969—DRG became a part of the Office of the Associate Director for Extramural Research and Training. Grants management responsibilities were transferred to the Office of Financial Management in the Office of the Associate Director for Administration.
1970—DRG coordinated the initial review of all U.S. Food and Drug Administration applications for research grants.

1971—The computer retrieval of information on scientific projects (CRISP) system was designed to provide scientific and associated grant identification information.

1978—The Extramural Associates Program was established under the Intergovernmental Personnel Act (P.L. 91-648) to promote participation of ethnic minorities and women in NIH-supported research.

1983—The Scientific Review Branch, Referral Branch, and Office of Research Manpower were consolidated into the Referral and Review Branch.

DRG became the central information source for the new Small Business Innovative Research (SBIR) Program and coordinated the scientific review of SBIR applications.

1995/96—DRG moved from the Westwood Building, where it had been since 1965, to the Rockledge Center, located near the NIH campus in Bethesda. Most of the Information Systems Branch was transferred to the Office of Extramural Research in the Office of the Director, NIH.

1997—Under a new Director, Dr. Ellie Ehrenfeld, DRG underwent a major reorganization and received a new name: the Center for Scientific Review (CSR). The name change reflected the Center’s primary mission—scientific review of grant applications—and signaled an expanded focus on developing and implementing flexible and innovative ways for referral and scientific review. The Center was divided into 3 review divisions (Molecular and Cellular Mechanisms; Physiological Systems; and Clinical and Population-based Studies) plus the Division of Receipt and Referral; the Division of Management Services; the Office of Planning, Analysis, and Evaluation; and the Office of Outreach.

CSR also began a thorough examination of its Integrated Review Groups (IRGs) and their study sections. CSR received assistance from 2 types of external advisory groups that reported to the CSR Advisory Committee: (1) IRG working groups, which were established to evaluate individual IRGs (2) the Panel on Scientific Boundaries for Review (PSBR), which was established to assess the overall structure and function of the IRGs.

The review activities of the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse, and the National Institute of Mental Health—at that time all components of the Alcohol, Drug Abuse, and Mental Health Administration—began to be integrated into CSR.

1999—The PSBR completed its Phase 1 report, which defined organizing principles for a rigorous yet fair review and provided recommendations for reconfiguring the IRGs. In addition, 8 IRG Working Groups were developed or under development to assess current IRGs.

2000—Phase 2 of the PSBR effort was initiated to implement the Panel’s recommendations. A Study Section Boundary (SSB) Team of extramural scientists with a small number of NIH and CSR staff members was formed to design the first new IRG (Hematology). A 3-year plan was developed to initiate additional SSB Teams and complete the reorganization of the 24 IRGs proposed by PSBR.

A reviewer survey was distributed to all CSR review groups to assess reviewer satisfaction and workload burdens. Ninety percent of the respondents reported that they were at least ‘satisfied’ with their service, and a majority of respondents reported that they were ‘very satisfied.’ Reviewers indicated that it takes an average of 30 hours to prepare an average of 6 written critiques and an additional 8 hours to prepare as a reader of approximately 2.5 applications.

2001—Major strides were made in completing CSR evaluation and reorganization efforts. IRG Working Group reports for nearly all existing IRGs were completed. Three SSB Teams completed the design of their IRGs: Hematology; Biology of Development and Aging; Musculoskeletal, Oral and Skin Sciences; and Cardiovascular Sciences. SSB Teams were developed to design 4 additional IRGs.

The number of CSR study sections increased to 153 with the addition of new review groups in the areas of biomedical information science and technology development, epidemiology, muscle biology, and oncological sciences. CSR also developed 12 new study sections to review fellowship applications.

2002—CSR further advanced its efforts to reorganize its IRGs. SSB Teams completed the design for 8 of the remaining 12 IRGs to be reorganized: (1) Bioengineering Sciences and Technologies; (2) Surgical Sciences, Biomedical Imaging, and Bioengineering; (3) Oncological Sciences; (4) Digestive Sciences; (5) Immunology; (6) Renal and Urological Sciences; (7) Endocrinology, Metabolism, Nutrition, and Reproductive Sciences; and (8) Infectious Diseases and Microbiology.

Strides were made in using new technologies to enhance CSR reviews. All chartered study sections were given access to the Internet Assisted Peer Review System, which allows reviewers to post their critiques and later read the critiques posted by others in their study section. In addition, the vast majority of CSR reviewers were given CDs with electronic copies of the grant applications to be considered by their review panel. The CDs are easier to transport and are bookmarked for easy navigation.

2003—Important milestones were reached in CSR’s reorganization efforts. SSB teams completed their recommendations for the last IRGs to be designed: (1) Respiratory Sciences; (2) Genes, Genomes, and Genetics, (3) Biological Chemistry and Macromolecular Biophysics; and (4) Cell Biology. CSR also implemented its first redesigned IRG—the Hematology IRG—and advanced efforts to implement other IRGs.

Dr. Ellie Ehrenfeld stepped down as CSR’s Director. Dr. Elias Zerhouni appointed CSR’s Deputy Director, Dr. Brent Stanfield, to be the new Acting Director.

A CSR-coordinated effort to develop new ways to encourage, review, and fund innovative research grant applications was advanced and incorporated into the NIH Roadmap for Medical Research initiative.

CSR restructured its 3 review divisions into 4 new divisions: (1) Division of Biologic Basis of Disease, (2) Division of Molecular and Cellular Mechanisms, (3) Division of Physiology and Pathology, and (4) Division of Clinical and Population-Based Studies.
In an effort to make the review focus of study sections more transparent, CSR gave names to study sections that were previously designated by their IRG affiliation and a number.

The Internet Assisted Review system was built into IMPAC, the grants system used by NIH. Reviewers now access the system through the NIH Commons, the venue for electronic communications between NIH and its principal investigators.

2004—The formal design stage for reorganizing CSR's scientific review groups as proposed by PSBR was completed in January 2004 after the CSR Advisory Committee endorsed the guidelines for the last groups to be reorganized. Study sections within all but 3 of the new IRGs met at least once.

CSR advanced outreach efforts to educate applicants, reviewers, and NIH staff by developing (1) an online video of a mock study section; (2) a new CSR exhibit booth, which was deployed at 6 major scientific meetings across the country; (3) CSR's first Annual Report; and (4) a new CSR logo.

All CSR study sections used the Internet-Assisted Review Peer Review system, and CSR helped advance pilot studies for the electronic submission of grant applications.

The CSR Advisory Committee held its last meeting on September 20, 2004. A new Peer Review Advisory Committee will advise the CSR and NIH on peer review issues and operations.

2005—The Peer Review Advisory Committee held its first meetings to provide comprehensive guidance to the NIH Director, CSR Director, and Deputy Director for Extramural Research on all NIH peer review policies and operations.

Dr. Antonio Scarpa assumed the responsibilities of CSR's Director on July 1, 2005.

CSR received the first electronic grant applications via grants.gov and prepared to receive most applications by October 1, 2006.

A new payment system was developed to replace the Scientific Review and Evaluation Awards system. Under the new system, reviewers attending study section meetings receive their honoraria and “flat-rate” reimbursements for meals and incidental expenses without having to submit vouchers. Reviewers will no longer need to submit vouchers for hotel expenses, which will be paid directly by NIH. All reviewer payments will be made electronically.

2006—CSR accelerated the release of summary statements to applicants and the ICs. Ninety-seven percent of its summary statements were released according to a new schedule: summary statements for new investigators submitting a R01 should be posted within 10 days of the study section meeting and all other summary statements should be released within 30 days of the study section meeting. Applicants used to receive their summary statements between 1-3 months after their study section meetings.

CSR's Scientific Review Evaluation Award Office reduced NIH travel costs by issuing reviewers nonrefundable airline tickets instead of refundable tickets. Scientists flying to CSR review meetings were allowed to make one change per trip, with NIH covering the costs. Between June and December 2006, NIH saved $5.2 million. When this practice is expanded to all CSR and NIH reviewers, NIH will save over $10 million a year.

Two Web-based electronic modes for reviewing grants were deployed by CSR to improve the recruitment of well-qualified reviewers who find it difficult to travel to review meetings: online asynchronous discussions (secure chat rooms), and video-enhanced discussions.

CSR published data that suggests slight but significant differences in the scoring of clinical and nonclinical research applications are not related to (1) the percent of clinical applications assigned for review to a review group, (2) the greater costs of clinical research, or (3) the clinical research experience of the reviewers. The findings were described in “Outcomes of NIH Peer Review of Clinical Grant Applications,” by Theodore Kotchen, et al., published in the January 2006 issue of the Journal of Investigative Medicine.

2007—As NIH expanded its ability to receive electronic grant applications, CSR responded by adjusting its administrative systems and practices. For the first time, applicants submitted their R01 grant applications electronically. In fact, most grant applications submitted to CSR in 2007 were electronic.

After the success of a pilot to shorten the review cycle for new investigators applying for an R01 grant, CSR shortened the review cycle for all new R01 grant applicants. A shorter cycle will allow some of these more than 10,000 applicants to reapply in the next review round instead of having to wait out a review cycle. The ultimate goal is to offer this opportunity to all applicants who need to revise their applications so the best science can advance more quickly.

CSR began a reorganization of its review divisions, by creating a fifth division and rearranging the review groups in its Division of Clinical and Population-Based Studies, now titled the ‘Healthcare, Population, and Behavioral Sciences Division.’ The fifth review division clusters neuroscience IRGs from 3 CSR divisions into 1 new division: the Division of Neuroscience, Development, and Aging. Consolidating CSR's neuroscience IRGs will enhance staff interactions; encourage shared recruitment of new SROs and reviewers; improve the balancing of workloads; and advance interactions with the NIH and the neuroscience community. CSR also created a new neuroscience IRG—Emerging Technologies and Training in Neurosciences—creating a home for new study sections focused on molecular neurogenetics and neurotechnology, as well as special emphasis panels to review fellowship and small business applications.

2008—CSR worked to enhance NIH peer review and help NIH identify the most promising research sooner by developing new incentives to recruit reviewers, implementing a major reorganization of study sections, preparing to assist NIH in implementing enhancements to peer review, and other measures.

CSR initiated solutions to recruit and retain high-quality reviewers, while decreasing their burden to serve the government by holding more meetings on the West Coast where many reviewers live, permitting permanent members of study sections to submit many of their applications anytime, and convening more electronic meetings that appeal to reviewers who cannot or will not travel to meetings. CSR completed a reorganization of its review divisions and added a new one to cluster similar areas of science within the newly realigned organizational units, ensuring more effective and efficient reviews of applications and helping NIH achieve the greatest public health impact. This will allow SROs who manage the review process to work together more effectively to identify and review transformative, innovative applications and share knowledge between review panels.
In an effort to increase transparency and uniformity in NIH peer review, CSR launched meetings with study section chairs to examine study section practices and ensure the most consistent and highest quality of reviews across all panels.

2009—Following recommendations by the internal and external stakeholders supporting the trans-NIH Enhancing Peer Review Initiative, CSR successfully implemented the most sweeping NIH enhancements to the NIH peer review systems: deploying a new scoring system, using new templates for reviewer critiques, permitting only one application resubmission, and clustering the review of New and Early Stage Investigator R01 and clinical research applications.

CSR simultaneously managed the receipt, assignment, and review of the largest surge in grant applications NIH has ever seen. An extra 25,000 grant applications were submitted in 2009 for American Recovery and Reinvestment Act funds, which were appropriated to NIH to advance the economy, science, and health. The bulk of these applications—over 20,000—were Challenge grant applications, which were all reviewed by 20,000 reviewers in two-stage editorial board review groups. Stage-one reviewers submitted their critiques online. Stage-two reviewers then examined the critiques and applications, focusing on the impact of the proposed research and assigning the final overall impact/priority scores.

2010—CSR helped stimulate the economy, research, and healthcare by assisting the IRS as it implemented its Qualifying Therapeutic Discovery Project program, which issued $1 billion in tax credits or grants to small businesses. CSR engaged about 120 of its scientific review officers to help the IRS determine which of the 5,600 projects submitted met qualifications, were designed to meet the goals of the program, and had a reasonable chance of success.

CSR released three new videos that scored over 45,000 views on YouTube:

- The Rocket Boys of NIH Cartoon [http://cms.csr.nih.gov/aboutcsr/csrnihhistory/nihrocketboys/rockettoon.htm]

CSR successfully implemented several NIH enhancements to peer review:

- Reviewers began reviewing shorter applications that were restructured so they are now better aligned with the review criteria to make the application and review process more efficient and transparent.
- NIH limited the types of supplemental materials applicants could send after having submitted their R01 and R21 applications. Since the majority of these supplements don’t affect review outcomes, these limits will reduce unnecessary burdens on staff and reviewers.

CSR began hosting new telepresence review meetings, which make it possible to recruit scientists who find it difficult to travel to review meetings. These meetings use customized conference rooms in hotels in Washington, San Francisco and/or New York City. Using large video screens and responsive technologies, reviewers meet and discuss applications around a virtual table.

CSR reduced the number of small and inefficient special emphasis review panels (SEPs) by pairing similar study sections and staggering their meetings so more applications can be reviewed in existing study sections. The number of small SEPs had been growing since NIH eliminated many standard due dates for applications submitted by scientists who have made a significant commitment to serve on NIH review and advisory committees.

CSR continued to honor the vital contributions of thousands of CSR reviewers by announcing the fourth winner of the Marcy Speer Outstanding CSR Reviewer Award. This year’s honoree was Dr. Alice Clark, the Vice Chancellor for Research and Sponsored Programs and the F.A.P. Barnard Distinguished Professor of Pharmacognosy at The University of Mississippi.

**BIOGRAPHICAL SKETCH OF ACTING DIRECTOR RICHARD NAKAMURA, PH.D.**

On September 18, 2011, Dr. Richard Nakamura became Acting Director of the Center for Scientific Review (CSR) at the National Institutes of Health (NIH). He leads CSR’s 450 scientists and administrative staff, overseeing their efforts to manage 80,000 incoming NIH grant applications a year and review the majority of them in CSR peer review groups. CSR holds 1,600 review meetings a year, involving about 18,000 reviewers from the scientific community.

Dr. Nakamura has had a 35-year tenure at the National Institute of Mental Health (NIMH), where he has served as both Scientific Director and Deputy Director of the institute, and he served as Acting Director from 2001 to 2002. During his time at NIMH, he received a number of leadership awards, including the Presidential Rank Award for outstanding leadership.

He came to NIMH in 1976 as a postdoctoral fellow. In the mid-80’s he coordinated NIMH’s Biobehavioral Program and later was Chief of its Integrative Neuroscience Research Branch. Between 1997 and 2007, he served as the Institute’s Deputy Director. From 2007 to 2011 he has been Institute Scientific Director. While at NIMH, he also has held other positions, including Associate Director for Science Policy and Program Planning; Chief, Behavioral and Integrative Neuroscience Research Branch; and Coordinator, ADAMHA Office of Animal Research Issues.

Dr. Nakamura earned his B.A. in psychology from Earlham College in Richmond, Indiana, his M.A. in psychology from New York University, and his Ph.D. in psychology from the State University of New York in Stony Brook. He has expertise in a number of areas, including cognitive and comparative neuroscience, science policy/funding and ethics in science. He has published 30 peer reviewed scientific journal articles, most related to neurocognition in primates.

**CSR DIRECTORS**

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cassius James Van Slyke</td>
<td>January 1946</td>
<td>December 1, 1959</td>
</tr>
<tr>
<td>Name</td>
<td>From</td>
<td>To</td>
</tr>
<tr>
<td>----------------------------</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>David E. Price</td>
<td>1948</td>
<td>1950</td>
</tr>
<tr>
<td>Ernest M. Allen</td>
<td>1951</td>
<td>1960</td>
</tr>
<tr>
<td>Dale R. Lindsay</td>
<td>1960</td>
<td>1963</td>
</tr>
<tr>
<td>Eugene A. Confrey</td>
<td>October 1963</td>
<td>1969</td>
</tr>
<tr>
<td>Stephen P. Hatchett</td>
<td>1969</td>
<td>August 1976</td>
</tr>
<tr>
<td>Carl D. Douglass</td>
<td>August 1976</td>
<td>December 1985</td>
</tr>
<tr>
<td>Jerome G. Green</td>
<td>January 1986</td>
<td>June 1, 1995</td>
</tr>
<tr>
<td>Ellie Ehrenfeld</td>
<td>January 1997</td>
<td>September 30, 2003</td>
</tr>
<tr>
<td>Brent Stanfield (Acting)</td>
<td>October 1, 2003</td>
<td>June 30, 2005</td>
</tr>
<tr>
<td>Antonio Scarpa</td>
<td>July 1, 2005</td>
<td>September 2, 2011</td>
</tr>
<tr>
<td>Richard Nakamura (Acting)</td>
<td>September 18, 2011</td>
<td>present</td>
</tr>
</tbody>
</table>
VISION
The Fogarty International Center's vision is a world in which the frontiers of health research extend across the globe and advances in science are implemented to reduce the burden of disease, promote health, and extend longevity for all people.

MISSION
The Fogarty International Center is dedicated to advancing the mission of the National Institutes of Health by supporting and facilitating global health research conducted by U.S. and international investigators, building partnerships between health research institutions in the United States and abroad, and training the next generation of scientists to address global health needs.

IMPORTANT EVENTS IN FOGARTY HISTORY
1988—The AIDS International Training and Research Program began as one of the first of a new generation of research training programs sponsored by Fogarty. It has become a model for a number of research capacity-building programs in the developing world in such areas as tropical diseases, emerging infectious diseases, environmental and occupational health, and population-related research.

1992—Focused on the potential relationships between drug development, biological diversity, and economic growth, the International Cooperative Biodiversity Groups program was initiated in a collaborative effort of NIH, the National Science Foundation, and the U.S. Agency for International Development to advance their 3 interrelated goals.

The Fogarty International Research Collaboration Award program began as small international collaborative research grants to American investigators whose research would benefit from collaboration with a partner from Latin America or Eastern Europe. Today, the scope of this program has expanded to cover developing regions everywhere.

1995—The International Training and Research in Environmental and Occupational Health program—created with the close support of NIH's National Institute of Environmental Health Sciences and other partners—focuses on training local professionals in research on workplace and environmental protection and public health and safety, with an emphasis on implementing interventions targeted to specific conditions in the home country.

2003—The Informatics Training for Global Health program was created to fund international collaborations between the United States and low- and middle-income countries to develop informatics training programs in support of global health research.

2004—The International Collaborative Trauma and Injury Research Training Program was launched to address the growing burden related to trauma and injury in the developing world. It addresses training across the range of basic to applied science, the epidemiology of risk factors, acute care and survival, rehabilitation, and long-term mental health consequences.

2005—Fogarty began its Framework Program for Global Health to provide administrative support to link diverse schools—such as engineering, business, chemistry, biology, communication, and medicine—together on the topic of global health and to develop multidisciplinary global health curricula.

October 22, 2007—In an effort to focus attention on global health, Fogarty joined with the Council of Science Editors to promote its 2007 international theme issue on poverty and human development. Fogarty, in conjunction with NIH's National Library of Medicine, hosted the event at NIH to coincide with the simultaneous publication of related research by more than 235 scientific journals in 37 countries. At least 1,000 articles were disseminated, representing research projects taking place in 85 nations.

May 6, 2008—Stephen Lewis, a former diplomat and co-founder of AIDS-Free World, delivered a passionate lecture at Masur Auditorium, as part of Fogarty International Center's 40th anniversary celebrations. Lewis described the plight of sub-Saharan countries struggling for survival, mired in a cycle of disease and despair caused by HIV/AIDS.

August 2, 2008—Fogarty recognized the 20th anniversary of its AIDS International Training and Research Program during a symposium and reception, which included current and former trainees in Mexico City, held as an affiliated event of the International AIDS Conference.
September 2, 2008—Congressman John E. Fogarty's legacy and the Center's 40th anniversary were recognized with events at Brown University. U.S. Sen. Jack Reed, Providence Mayor David Cicilline, and Fogarty family members celebrated with Center Director Dr. Roger I. Glass, who used the occasion to recognize Brown for its strong history in global health and to announce it would receive a Fogarty Framework grant to further develop its programs.

October 15, 2008—The Foundation for NIH hosted Fogarty's 40th anniversary gala dinner at the Italian embassy, which brought together leaders from Congress, federal agencies, science, advocacy groups, the diplomatic corps, and businesses with an interest in global health issues. Guests included Sen. Richard Lugar (R-IN) and Rep. Donald Payne (D-NJ), who were lauded for their global health leadership in Congress. View Image.

November 12, 2008—As part of its 40th anniversary celebrations, Fogarty held a symposium titled ‘The Role of Science in Advancing Global Health Diplomacy’ at the Georgetown University Law Center. The discussion examined the relationship between science and diplomacy and how U.S. efforts in this arena could be strengthened. View Image.

December 16, 2008—Former NIH Director Dr. Harold Varmus delivered the 2008 David E. Barmes Global Health Lecture, titled 'The U.S. Commitment to Global Health.' Fogarty co-sponsors the annual event with the National Institute of Dental and Craniofacial Research in honor of the late David E. Barmes, who was a special expert for international health at NIDCR. View Image.

March 30, 2009—Fogarty International Center and the Foundation for the National Institutes of Health (FNIH) announced the launch of MAL-ED [http://mal-ed.fnih.org/], a five-year study to investigate the linkages between malnutrition and intestinal infections and their effects on children in the developing world, funded by a grant of nearly $30 million from the Bill & Melinda Gates Foundation to the FNIH. Fogarty's Division of International Epidemiology and Population Studies serves as the Scientific Secretariat for this 8-site study located in Brazil, Peru, South Africa, Tanzania, India, Pakistan, Bangladesh and Nepal.

April 22, 2009—Jeffrey Sachs, health economist and best-selling author, visited NIH as a Fogarty scholar-in-residence and delivered a lecture to an overflow audience at Masur Auditorium. Sachs spoke about the importance of investing in global health despite the ongoing financial crisis, describing the need for systemic changes in the design, financing, management and delivery of health care around the world. The event was part of a series marking Fogarty’s 40th anniversary, sponsored by the Foundation for the National Institutes of Health. View Image.

June 2009—Fogarty became a founding member of the Global Alliance for Chronic Diseases [http://www.ga-cd.org/], a collaboration involving national health agencies of some of the biggest countries in the world, including NIH represented by the National Heart, Lung and Blood Institute and Fogarty, Australia's National Health Medical Research Council, Canadian Institutes of Health Research, China's Ministry of Health and the Chinese Academy of Medical Sciences, the Indian Council of Medical Research and the United Kingdom's Medical Research Council. Fogarty also began making initial grants in its Millennium Promise Awards program to train researchers in chronic diseases, which account for 60 percent of all deaths around the world.

July 22, 2009—Fogarty announced funding from the American Recovery and Reinvestment Act that will allow the NIH to create jobs for early career scientists and increase the ranks of researchers and clinicians working in the global health field. With $3 million in funding over an 18-month period, Fogarty will be able to support 21 additional participants in its Clinical Research Training Scholars and Fellows Program.

August 2009—Fogarty hosted a meeting of the newly created Trans-NIH Global Health Research Working Group at the Stone House. The high-level working group is the result of a two-year effort by institute and center directors to analyze global health research activities at NIH and explore better ways to coordinate efforts, both across NIH and throughout the government. NIH director Dr. Francis Collins, who attended the meeting, urged members of the working group to find better ways to leverage resources and coordinate international activities to improve human health. View Image.

September 14-15, 2009—Fogarty co-hosted the first meeting of the Consortium of Universities for Global Health [http://www.cugh.org/] at NIH’s Natcher Center. The consortium was created to increase public support and funding for new global health initiatives and build an alliance of universities to strengthen a field that students are demanding in unprecedented numbers. Guest speakers included White House health adviser Dr. Ezekiel Emanuel and U.S. Global AIDS Coordinator Dr. Eric Goosby, among others. View Images.

October 28-30, 2009—Fogarty played an instrumental role in the first mHealth Summit, a gathering of scientists, information technology developers and policymakers sponsored by the Foundation for the National Institutes of Health and Microsoft Research. The three-day event focused on the use of mobile technologies as tools and platforms for health research and health care delivery. The summit drew an overflow crowd, with about 500 attending in person and hundreds more via webcast. Fogarty Director Dr. Roger I. Glass spoke at the event, along with several prominent Fogarty grantees who had established mobile health projects in low- and middle-income countries. View Image.

January 2010—The highlights from the NIH portfolio analysis on climate change and health were released, the result of a series of meetings of the Trans-NIH Working Group on Climate Change. Convened by Fogarty, the meetings addressed the topic of climate change and its relationship to health research. The working group, chaired by Fogarty’s Dr. Josh Rosenthal, brings together scientists from other federal agencies to share information and better coordinate research efforts.

February 22, 2010—Google collaborator and guru of global health data Dr. Hans Rosling drew a capacity crowd at Masur Auditorium when he presented a lecture titled “The New Health Gap: Science for Emerging Economies vs. the Bottom Billion.” During his talk, Rosling took the audience through time to illustrate how the world has changed. A co-founder of Gapminder, a nonprofit that promotes a fact-based world view, he used his own Trendalyzer software to convert numbers into interactive graphics. Dr. Rosling visited NIH as a Fogarty International Center Scholar-in-Residence, concluding the Center’s 40th anniversary activities. View Image.

February 26, 2010—Representatives from G8 countries met at NIH with leading researchers from sub-Saharan Africa, convened by Fogarty, to discuss African research capacity and how to move forward with commitments made at the 2009 L’Aquila Summit. The G8 Leaders Declaration had pledged to address health care improvement in Africa through a variety of strategies, including developing networks of researchers and working with African partners to establish a consortium of interdisciplinary centers of health innovation. View Image.
March 17, 2010—Following the Third Annual NIH Conference on the Science of Dissemination and Implementation, Fogarty and the Office of Behavioral and Social Sciences Research convened a satellite meeting on Implementation Science and Global Health in Bethesda. The event brought together Fogarty grantees and trainees working in the field of international implementation science, research training, and curriculum development, and explored strategies to build linkages between implementation science researchers to global healthcare delivery programs.

June 2010—The Fulbright Program joined Fogarty to expand clinical research training opportunities in sub-Saharan Africa for U.S. pre-doctoral students. The Fulbright-Fogarty Fellowships program will encourage innovative evidence-based public health research training, problem-based learning and clinical preceptorships. It will also encourage collaboration among the Fulbright-Fogarty fellows, who will be mentored by U.S. and African faculty and researchers. Together, the organizations will provide up to $205,000 per year to support as many as five awards. Initially, the one-year assignments will be distributed among six sites in Botswana, Malawi, South Africa, Uganda and Zambia. View Image.

June 17, 2010—Longtime Fogarty grantee Dr. Jean ‘Bill’ Pape visited NIH to report that HIV/AIDS research has resumed in full at Haitian Group for the Study of Kaposi’s Sarcoma and Opportunistic Infections (GHERKKIO), just months after Haiti’s devastating earthquake. He addressed the NIH community while in town to accept the 2010 Gates Award for Global Health on behalf of GHESKIO-- the world’s first HIV/AIDS organization--which he founded nearly 30 years ago and still directs. View Image.

September 2010—NIH joined the Global Alliance for Clean Cookstoves, a new public-private partnership led by the United Nations Foundation. The initiative was announced by Secretary of State Hillary Rodham Clinton at the Clinton Global Initiative meeting in New York. Fogarty also continues to support research training programs to increase human capacity in low- and middle-income countries in the field of indoor air pollution and cookstove research. Half the world’s population relies on elemental stoves for cooking or heating, and the resulting indoor air pollution is estimated to take 1.9 million lives each year. NIH has committed about $25 million over the next five years to reducing this impact and improving the health of cookstove users.

September 2010—Fogarty issued its final awards under the American Recovery and Reinvestment Act. Overall, the Center awarded about 100 grants under the two-year stimulus program, totaling roughly $30 million. An additional $8 million of stimulus funding is being administered by Fogarty for a project focused on implementing novel drugs, diagnostics, and devices in low-resource settings. Fogarty’s share of Recovery Act funding was $17.4 million but its grantees successfully competed for an additional $13 million in funds from the central NIH pot. Five such applications were supported under the “Challenge” program, with $1 million of the funding coming from the central pool. Another $8 million came from the NIH Director’s fund for the new implementation science consortium and about $2 million to support “Signature Framework” awards, which emphasize hands-on problem solving, collaborative approaches and innovative, multidisciplinary team research. 2010 awards included funds to support innovative multidisciplinary research projects and enhance studies involving human subjects.

September 24-26, 2010—Several hundred alumni of the Fogarty International Clinical Research Scholars and Fellows (FICRS-F) program gathered near the NIH campus for their first-ever reunion and scientific symposium. The young scientists presented a broad range of research projects from more traditional infectious disease projects to cardiology and cancer studies. Many are also investigating novel ways to apply emerging technologies to speed up discoveries. View Image.

October 2010—The U.S. Department of Health and Human Services— including several components of the NIH— joined the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) in funding the Medical Education Partnership Initiative. The program, administered by Fogarty and the HIV/AIDS Bureau of the Health Resources and Services Administration, will invest as much as $130 million over five years to transform African medical education and dramatically increase the number of health care workers. The initiative will form a network including about 30 regional partners, country health and education ministries, and more than 20 U.S. collaborators. Grants have been awarded directly to African institutions in a dozen countries, working in partnership with U.S. medical schools and universities.

November 8-10, 2010—Fogarty participated in the second annual mHealth Summit, a gathering of scientists, information technology developers and policymakers organized by the Foundation for the National Institutes of Health. The three-day event focused on the use of wireless technologies to improve health outcomes in the U.S. and abroad. Fogarty Director Dr. Roger I. Glass gave closing remarks at the summit and several prominent Fogarty grantees who have established mobile health projects in low-and middle-income countries presented findings and shared insights. The summit drew over 2,000 attendees, hosted 149 exhibitors and included representatives from 48 countries. View Image.

LEGISLATIVE CHRONOLOGY

January 18, 1967—Rep. Melvin Laird (Wisc.) proposed that Congress establish an international research and study center at NIH as a memorial to the late Rep. John E. Fogarty (R.I.). President Lyndon B. Johnson subsequently announced that he was seeking funds to establish the John E. Fogarty International Center for Advanced Study in the Health Sciences.

February 26, 1968—Departmental approval was given to establish the Fogarty International Center.

March 16, 1968—Official notice was published in the Federal Register.

July 1, 1968—President Lyndon Johnson issued an Executive Order establishing the John E. Fogarty International Center at the National Institutes of Health. The NIH Office of International Research was abolished and several of its functions were transferred to FIC.

June 1979—The Task Force to Assess the Missions and Functions of the Fogarty International Center reported to the director, NIH, on its year-long study of the center, reaffirming FIC’s importance as the focus for international aspects of biomedical and behavioral research at NIH, and recommending specific measures for strengthening and broadening its programs.

June 1982—FIC was designated a World Health Organization Collaborating Center for Research and Training in Biomedicine.

September 1985—The first meeting of the FIC Advisory Board was held.
November 1985—FIC was established in law (Public Law 99-158, sec. 482).

BIOGRAPHICAL SKETCH OF FOGARTY DIRECTOR ROGER I. GLASS, M.D., PH.D.

Dr. Glass was named Director of the Fogarty International Center and Associate Director for International Research by NIH Director Dr. Elias A. Zerhouni on March 31, 2006. Dr. Glass formally took office on June 11, 2006.

Dr. Glass graduated from Harvard College in 1967, received a Fulbright Fellowship to study at the University of Buenos Aires in 1967, and received his M.D. from Harvard Medical School and his M.P.H. from the Harvard School of Public Health in 1972. He joined the Centers for Disease Control and Prevention (CDC) in 1977 as a medical officer assigned to the Environmental Hazards Branch. He received his doctorate from the University of Goteborg, Sweden, in 1984, and joined the National Institutes of Health Laboratory of Infectious Diseases, where he worked on the molecular biology of rotavirus. In 1986, Dr. Glass returned to the CDC to become Chief of the Viral Gastroenteritis Unit at the National Center for Infectious Diseases.

Dr. Glass’s research interests are in the prevention of gastroenteritis from rotaviruses and noroviruses through the application of novel scientific research. He has maintained field studies in India, Bangladesh, Brazil, Mexico, Israel, Russia, Vietnam, China, and elsewhere. His research has been targeted toward epidemiologic studies to anticipate the introduction of rotavirus vaccines. He is fluent and often lectures in 5 languages.

Dr. Glass has received numerous awards including the prestigious Charles C. Shepard Lifetime Scientific Achievement Award presented by the CDC in recognition of his 30-year career of scientific research application and leadership, and the Dr. Charles Merieux Award from the National Foundation for Infectious Diseases for his work on rotavirus vaccines in the developing world. Other honors include the U.S. Department of Health and Human Services (HHS) Secretary’s Award for Distinguished Service, the Outstanding Unit Citation from the National Center for Infectious Diseases, the Outstanding Service Medal from the U.S. Public Health Service, and a Commendation Medal from the U.S. Public Health Service. He is a member of the Institute of Medicine (an arm of the National Academy of Sciences), the American Academy of Microbiology, the American Society of Microbiology, the American Association for the Advancement of Science, the American Society of Virology, and the American Epidemiological Society. Dr. Glass is also a fellow in the Infectious Disease Society and the American College of Epidemiology.

Dr. Glass has co-authored more than 400 research papers and chapters. He is married to Barbara Stoll, M.D., the George W. Brumley, Jr. Professor and Chair of the Department of Pediatrics at Emory University School of Medicine and the Medical Director of the Children’s Healthcare of Atlanta at Egleston. He and his wife have 3 children.

FIC DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Milo D. Leavitt, Jr.</td>
<td>June 16, 1968</td>
<td>July 1978</td>
</tr>
<tr>
<td>Leon Jacobs</td>
<td>July 1, 1978</td>
<td>June 29, 1979</td>
</tr>
<tr>
<td>Edwin D. Becker (Acting)</td>
<td>July 1979</td>
<td>April 1980</td>
</tr>
<tr>
<td>Claude Lenfant</td>
<td>February 1981</td>
<td>July 1982</td>
</tr>
<tr>
<td>Mark S. Beaubien (Acting)</td>
<td>July 1, 1982</td>
<td>January 1984</td>
</tr>
<tr>
<td>Craig K. Wallace</td>
<td>January 1984</td>
<td>December 1987</td>
</tr>
<tr>
<td>Carl Kupfer (Acting)</td>
<td>January 1, 1988</td>
<td>July 1988</td>
</tr>
<tr>
<td>Gerald T. Keusch</td>
<td>October 1, 1998</td>
<td>December 31, 2003</td>
</tr>
<tr>
<td>Roger I. Glass, M.D., Ph.D.</td>
<td>June 11, 2006</td>
<td>Present</td>
</tr>
</tbody>
</table>

RESEARCH AND RESEARCH TRAINING PROGRAMS

Training Grants

AIDS International Training and Research Program [http://www.fic.nih.gov/Programs/Pages/hiv-aids.aspx]

This program supports HIV/AIDS-related research training to strengthen the capacity of institutions in low- and middle-income countries to conduct multidisciplinary biomedical and behavioral research to address the AIDS epidemic in the collaborating country. Grants are awarded to U.S. and developing country institutions with strong HIV-related research training experience and with HIV-related research collaborations with institutions in low- and middle-income countries. These institutions, in partnership with their foreign collaborating institutions, identify health scientists, clinicians, and allied health workers from the foreign countries to participate in their joint research training programs. Individuals from foreign nations who wish to become trainees must apply to the project director of an awarded grant.

Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award [http://www.fic.nih.gov/Programs/Pages/chronic-lifespan.aspx]
This program will support collaborative research training between institutions in the U.S. and low-and middle-income countries (LMIC), defined by the World Bank classification system. The proposed institutional research training program is expected to sustainably strengthen the research capacity of the LMIC institutions, and to train in-country experts to conduct research on chronic, non-communicable diseases and disorders, with the ultimate goal of implementing evidence-based interventions relevant to their countries. Examples of the non-communicable diseases that could be addressed include, but are not limited to, cancer, cardio- and cerebrovascular disease and stroke, chronic lung disease, diabetes, mental illness, neurological, substance abuse and developmental disorders.

NIH/Fogarty Clinical Research Training Scholars Program [http://www.fic.nih.gov/Programs/Pages/scholars-fellows.aspx]
The Fogarty International Center in collaboration with the National Institute of Allergy and Infectious Diseases, the National Center on Minority Health and Disparities, the National Cancer Institute, the National Institute on Drug Abuse, the National Institute of Nursing Research, and the National Institute of Child Health and Human Development is offering a 1-year clinical research training experience for graduate-level U.S. students in the health professions.

Fogarty International Collaborative Trauma and Injury Research Training Program [http://www.fic.nih.gov/Programs/Pages/trauma-injury.aspx]
This program addresses the research needs related to the growing burden of morbidity and mortality in the developing world due to trauma and injury. The program is supported by Fogarty, 7 NIH partners, the CDC's National Center for Injury Prevention and Control, the Pan American Health Organization, and the World Health Organization (WHO). It addresses training across the range of basic to applied science, the epidemiology of risk factors, acute care and survival, rehabilitation, and long-term mental health consequences.

Framework Programs for Global Health [http://www.fic.nih.gov/Programs/Pages/framework.aspx]
This initiative builds global health research capacity in the United States and abroad. Through the Framework Programs for Global Health, institutions create administrative frameworks to bring multiple schools (such as engineering, business, chemistry, biology, communication, public health, medicine, and environmental studies) together on the topic of global health and develop multidisciplinary global health curricula for undergraduates, graduates and professional school students. Each program leverages and enhances currently funded global health projects at the institution supported by NIH and other sponsors, as well as encourages new training opportunities, collaborations, and partnerships.

Global Infectious Disease Research Training Program [http://www.fic.nih.gov/Programs/Pages/infectious-disease.aspx]
This program enables institutions in the United States or in developing foreign countries to support current and future collaborative research-related training on infectious diseases that are predominately endemic in or impact upon people living in developing countries.

Informatics Training for Global Health [http://www.fic.nih.gov/Programs/Pages/informatics.aspx]
This initiative supports the development of informatics training programs that will contribute to global health research and informatics capacity in low- and middle-income countries in partnership with U.S. institutions.

International Research Ethics Education and Curriculum Development Award [http://www.fic.nih.gov/Programs/Pages/bioethics.aspx]
This program allows domestic or foreign institutions to develop graduate curricula and provide training in international bioethics related to performing research in developing countries.

International Clinical, Operational, and Health Services Research and Training Award [http://www.fic.nih.gov/Programs/Pages/clinical-operational.aspx]
This program supports training to facilitate collaborative, multidisciplinary, international clinical, operational, health services, and prevention science research between U.S. institutions and those in low- and middle-income nations.

International Clinical, Operational, and Health Services Research Training Award for AIDS and Tuberculosis [http://www.fic.nih.gov/Programs/Pages/clinical-operational-aids-tb.aspx]
This program supports research training to strengthen the capacity of institutions to conduct clinical, operational, and health services research. These institutions are located in low- and middle-income countries where AIDS, TB, or both are significant problems. In Phase I, one-year planning grants to support the development of full research training applications in Phase II are awarded to institutions in low- and middle-income countries with strong HIV- or TB-related research experience. In Phase II, grants to support a research training program are awarded to Phase I awardees and to their United States or other developed country institutional partner with whom they have strong HIV- or TB-related research collaborations. Individuals who wish to become trainees must apply to the project director of an awarded grant.

International Collaborative Genetics Research Training Program [http://www.fic.nih.gov/Programs/Pages/genetics.aspx]
This program supports innovative genetics research training programs in the context of existing scientific collaborations between U.S. and low- and middle-income country researchers to begin to build a critical mass of scientists, health professionals, and academics with human genetics expertise and a sustainable research environment at the collaborating foreign institution.

International Research Scientist Development Award (IRSDA) [http://www.fic.nih.gov/Programs/Pages/us-postdoc.aspx]
The purpose of the award is to provide junior U.S. scientists with an opportunity to pursue careers in research on global health, and to prepare them for independent research careers. This award is similar to other NIH K01 career development awards, but requires grantees to spend 50% of the grant period conducting research in developing countries. Two mentors are required, one in the U.S. and the other in the developing country where research is being conducted. These awards will support three- to five-years of “protected time” for mentored research and career development experiences, leading to an independent research career focused on global health. The IRSDA supports salary and some research expenses, including international travel.

International Training and Research Program in Environmental and Occupational Health [http://www.fic.nih.gov/Programs/Pages/environmental-occupational-health.aspx]
This program enables U.S. universities and non-profit research institutions to support international training and research programs for scientists from developing nations in general environmental health and occupational health. This is an institutional training grant. Applications are accepted from U.S. institutions in response to a specific request for applications which is published once every 5 years; the first awards were made in 1995. Individuals from foreign countries who wish to become trainees must apply to the project director of an awarded grant.
Global Research Training in Population Health [http://www.fic.nih.gov/Programs/Pages/population.aspx]
This program supports international research training for scientists from low- and middle-income nations in population-related sciences. This is an institutional training grant. Individuals from foreign countries who wish to become trainees must apply to the project director of an awarded grant.

Millennium Promise Awards: Non-communicable Chronic Diseases Research Training Program [http://www.fic.nih.gov/Programs/Pages/non-communicable-chronic.aspx]
This program is designed to build research capacity in low- and middle-income countries in the fields related to cancer; cerebrovascular disease including stroke, lung disease including chronic obstructive pulmonary disease and environmental factors including indoor air pollution; and obesity and lifestyle factors related to these conditions as well as the genetics of non-communicable diseases.

Medical Education Partnership Initiative [http://www.fic.nih.gov/Programs/Pages/medical-education-africa.aspx]
This program supports foreign institutions in Sub-Saharan African countries that receive PEPFAR support and their partners to develop or expand and enhance models of medical education. These models are intended to support PEPFAR’s goal of increasing the number of new health care workers by 140,000, strengthen medical education systems in the countries in which they exist, and build clinical and research capacity in Africa as part of a retention strategy for faculty of medical schools and clinical professors.

Independent Scientist in Global Health Award [http://www.fic.nih.gov/Programs/Pages/independent-scientist.aspx]
The overall objective of this program is to foster the development of outstanding independent scientists and enable them to expand their potential to make significant impact on the health related research needs of developing countries. This award provides three, four, or five years of salary and some research support. This award is similar to other NIH K02 career development awards, but requires grantees to spend 50% of the grant period conducting research in developing countries.

Research Grants

Brain Disorders in the Developing World: Research Across the Lifespan [http://www.fic.nih.gov/Programs/Pages/brain-disorders.aspx]
This program supports collaborative research and capacity building projects on brain disorders throughout life, relevant to low- and middle-income nations. Funded projects focus on neurological disorders and function (including sensory, motor, cognitive, and behavioral) and the impairment they lead to throughout life. R21 grants provide support to conduct pilot studies and to organize, plan for, prepare, and assemble an application for a more comprehensive R01 grants. R01 awards involve substantial collaboration between developed and developing country investigators and incorporate both research and capacity building.

Ecology of Infectious Diseases [http://www.fic.nih.gov/Programs/Pages/ecology-infectious-diseases.aspx]
This program funds interdisciplinary research projects that strive to elucidate the underlying ecological and biological mechanisms that govern the relationships, environmental changes, and the transmission dynamics of infectious diseases. The focus of this program is on the development of predictive models for the emergence and transmission of diseases in humans and other animals, and ultimately to facilitate the development of strategies to prevent or control them.

The Japan Society for the Promotion of Science [http://www.fic.nih.gov/Programs/Pages/japan-fellowships.aspx]
The Japan Society for the Promotion of Science, as the funding agency, provides 3 types of scientific collaboration fellowships using the NIH as a nominating authority. One type of Fellowship Program allows Japanese Biomedical and Behavioral Scientists to conduct research at NIH. The other 2 types allow U.S. (and permanent resident) scientists to participate in research with scientists from developing countries.

Fogarty International Research Collaboration Award (FIRCA) [http://www.fic.nih.gov/Programs/Pages/research-collaboration.aspx]
This program provides funds ($32,000/year direct costs) to foster international research partnerships between NIH-supported U.S. scientists and their collaborators in countries of the developing world. The FIRCA program aims to benefit the research interests of both the U.S. and foreign collaborators while increasing research capacity at the foreign site. U.S. scientists who have an eligible NIH grant may apply as Principal Investigators. Former FIRCA foreign collaborators may also apply as Principal Investigators. All areas of biomedical, behavioral, and social science research supported by NIH are eligible FIRCA research topics.

Global Research Initiative Program for New Foreign Investigators (GRIP) [http://www.fic.nih.gov/Programs/Pages/new-foreign-investigators.aspx]
This initiative promotes productive re-entry of NIH-trained foreign investigators into their home countries as part of a program to enhance the scientific research infrastructure in developing countries, to stimulate research on high priority health-related issues in these countries, and to advance NIH efforts to address health issues of global import. The GRIP provides partial salaries to the foreign researcher returning home and support for research projects.

International Cooperative Biodiversity Groups [http://www.fic.nih.gov/Programs/Pages/biodiversity.aspx]
This program integrates drug discovery from natural products with conservation of biodiversity and scientific and economic development in host countries. The program is jointly funded by the National Institutes of Health, the National Science Foundation, and the Foreign Agriculture Service of the U.S. Department of Agriculture.

International Tobacco and Health Research and Capacity Building Program [http://www.fic.nih.gov/Programs/Pages/tobacco.aspx]
This program encourages transdisciplinary approaches to the international tobacco epidemic to reduce the global burden of tobacco-related illness. The program is designed to promote international cooperation between investigators in the U.S. and other high-income nation(s) pursuing research programs on tobacco control, and scientists and institutions in low- and middle-income nation(s), where tobacco consumption is a current or anticipated public health urgency.

Stigma and Global Health Research Program [http://www.fic.nih.gov/Programs/Pages/stigma.aspx]
The purpose of this program is to stimulate interdisciplinary, investigator-initiated research on the role of stigma in health, and on how to intervene to prevent or mitigate its negative effects on the health and welfare of individuals, groups and societies world-wide.

Fogarty Organization

Division of International Relations [http://www.fic.nih.gov/About/Staff/Pages/International-Relations.aspx]
The international relations division develops new partnerships among U.S. scientists, institutions, and counterparts abroad to advance research and training in the biomedical and behavioral sciences. The division works on behalf of Fogarty and the whole of NIH to identify opportunities for collaboration with foreign science-funding agencies, the U.S. Department of State, U.S. technical agencies, and international organizations. It forms agreements with other nations to establish research collaborations and commitments for home country support for foreign researchers returning from NIH fellowships to facilitate their successful re-entry.

**Division of International Epidemiology and Population Studies** [http://www.fic.nih.gov/About/Staff/Pages/epidemiology-population.aspx]

Fogarty’s in-house scientists conduct research on the epidemiology and mathematical modeling of infectious diseases. Primary concentrations include cross-national studies of mortality patterns with special emphasis on influenza, vector-borne diseases, and vaccine-preventable diseases. Since 2000, these scientists, with collaborators in more than 24 countries, have produced research used to guide domestic and international policy in the development of countermeasures for potential bioterror agents and public health measures to control the spread of infectious diseases.

**Division of International Science Policy, Planning, and Evaluation** [http://www.fic.nih.gov/About/Staff/Policy-Planning-Evaluation/Pages/default.aspx]

The policy division provides strategic guidance to Fogarty’s director on the development, analysis and evaluation of Fogarty’s programs and on international science policy issues. The division tracks activities of international funding agencies and research trends in global health. The division also advises Fogarty’s director on legislative and partnership matters and manages the Center’s involvement in the Disease Control Priorities Project.

**Division of International Training and Research** [http://www.fic.nih.gov/About/Staff/Pages/Training-Research.aspx]

The international training and research division administers research grants, training grants and fellowship programs at sites in more than 100 countries. Fogarty programs that build the research pipeline are anchored to peer-reviewed research grants and designed to be collaborative, long term and flexible. Nearly a quarter of Fogarty awards are made directly to robust research institutions in the developing world. The remaining grants support scientists at U.S. institutions who collaborate with colleagues abroad. About one-third of Fogarty’s grants focus on scientific discovery, and two-thirds support research training.
The mission of the National Center for Complementary and Alternative Medicine (NCCAM) is to define, through rigorous scientific investigation, the usefulness and safety of complementary and alternative medicine (CAM) interventions and their roles in improving health and health care.

Vision

Scientific evidence informs decision making by the public, by health care professionals, and by health policymakers regarding use and integration of complementary and alternative medicine.

What We Do

NCCAM sponsors and conducts research using scientific methods and advanced technologies to study CAM. CAM is defined simply as a group of diverse medical and health care interventions, practices, products, or disciplines that are not generally considered part of conventional medicine.

NCCAM has four primary areas of focus:

1. Advancing Scientific Research

NCCAM funds research projects at scientific institutions across the United States and around the world. NCCAM’s primary responsibility is to conduct and support basic and clinical research using well-established tools of rigorous scientific design, conduct, and oversight. These studies involve extramural investigator-initiated and NCCAM-solicited projects, and intramural research. Examples include basic mechanistic research, translational research, clinical trials; research centers; and studies relevant to areas of CAM that show promise: mind and body interventions, practices, and disciplines and natural products. The Center carries out these activities independently and in collaboration with other NIH Institutes and Centers, other government agencies, domestic and international research institutions, and industry.

2. Training and Career Development

NCCAM supports a full spectrum of predoctoral, postdoctoral, and career awards to develop a cadre of skilled investigators from both the CAM and conventional communities. The goal is to train individuals to apply the tools of exacting science to CAM systems and modalities. Institutional awards are available to support research fellows. Mentored Research Career Development Awards provide opportunities to clinicians and research scientists to develop skills for conducting rigorous research and to pursue careers as investigators. Among special topic areas are supplements to build diversity in the research workforce and to allow qualified individuals to reenter active research careers. Limited support is also provided for research conferences.

3. Information Dissemination

Distributing reliable, scientifically based information on CAM research, practices, and findings is central to the NCCAM mission. This is accomplished through:

- Offering a Web site at http://nccam.nih.gov, that includes a portal for health care providers
- Operating the NCCAM Information Clearinghouse at http://nccam.nih.gov/health/clearinghouse/index.htm
- Producing publications, such as fact sheets, and newsletters
- Participating in social media such as Facebook, Twitter, and YouTube
- Sponsoring lectures, conferences, an online continuing education program, and other outreach activities
- Exhibiting at events around the United States
- Outreach to health care providers and the public to promote a dialogue about CAM, at http://nccam.nih.gov/timetotalk/.

4. Supporting integration of proven CAM therapies

Our research helps the public and health professionals understand which CAM therapies have been proven to be safe and effective.
IMPORTANT EVENTS IN NCCAM HISTORY

October 1991—The U.S. Congress passes legislation (Public Law 102-170) that provides $2 million in funding for fiscal year 1992 to establish an office within the National Institutes of Health (NIH) to investigate and evaluate promising unconventional medical practices. Dr. Stephen C. Groft is appointed Acting Director of the new Office of Alternative Medicine (OAM).

September 1992—A Workshop on Alternative Medicine is convened in Chantilly, Virginia, to discuss the state of the art of major areas of alternative medicine and to direct attention to priority areas for future research activities.

October 1992—Dr. Joseph J. Jacobs is appointed first Director of the OAM.

June 1993—The NIH Revitalization Act of 1993 (P.L. 103-43) formally establishes the OAM within the Office of the Director, NIH, to facilitate study and evaluation of complementary and alternative medical practices and to disseminate the resulting information to the public.

December 1993—The Alternative Medicine Program Advisory Council is established.

September 1994—Dr. Alan I. Trachtenberg is appointed Acting Director of the OAM.

January 1995—Dr. Wayne B. Jonas is appointed the second Director of the OAM.

October 1996—A Public Information Clearinghouse is established.

November 1996—The OAM is designated a World Health Organization Collaborating Center in Traditional Medicine.

October 1998—NCCAM is established by Congress under Title VI, Section 601 of the Omnibus Appropriations Act of 1999 (P.L. 105-277). This bill amends Title IV of the Public Health Service Act and elevates the status of the OAM to an NIH Center.

January 1999—Dr. William R. Harlan is named Acting Director of NCCAM.

February 1999—The U.S. Secretary of Health and Human Services (HHS) signs the organizational change memorandum creating NCCAM and making it the 25th independent component of NIH. The NCCAM Director is vested with broad decision-making authority, especially concerning financial and administrative management and fiscal and review responsibility for grants and contracts.

May 1999—The NCCAM Trans-Agency CAM Coordinating Committee (TCAMCC) is established by the NCCAM Director to foster the Center's collaboration across the HHS and other Federal agencies. This committee supersedes a trans-agency committee established by the NIH Director in 1997.


October 1999—Dr. Stephen E. Straus is appointed the first Director of NCCAM.

September 2000—NCCAM's first strategic plan is published.

February 2001—NCCAM and the National Library of Medicine launch CAM on PubMed, a comprehensive Internet source of research-based information on CAM.

May 2004—NCCAM and the National Center for Health Statistics of the U.S. Centers for Disease Control and Prevention announce findings from the largest nationally representative survey to date on Americans' use of CAM (part of the 2002 National Health Interview Survey).

January 2005—The National Academies' Institute of Medicine releases a report, Complementary and Alternative Medicine in the United States, that was requested by NCCAM and Federal partners. The report focuses on the scientific and policy implications of the widespread use of CAM.

February 2005—NCCAM publishes its second strategic plan, Expanding Horizons of Health Care: Strategic Plan 2005-2009, following a year-long process of input from the public, staff, and groups of outside experts.

November 2006—The Center's founding Director, Dr. Stephen E. Straus, steps down and becomes Senior Advisor to NIH Director Dr. Elias A. Zerhouni. Dr. Ruth L. Kirschstein is named Acting Director of NCCAM.

May 2007—NCCAM establishes a Complementary and Integrative Medicine Consult Service at the NIH Clinical Center.

January 2008—Dr. Josephine P. Briggs is named second Director of NCCAM.

June 2008—NCCAM launches "Time to Talk," an educational campaign to encourage patients and their health care providers to openly discuss the use of CAM. View Image.

December 2008—An NCCAM-supported supplement on CAM in the 2007 National Health Interview Survey yields the first nationally representative data on children's use of CAM and on trends in adult CAM use.

July 2009—The first nationally representative figures are released on how much Americans spend on CAM, from a nationwide government study cofunded by NCCAM. In 2007, they spent nearly $34 billion out-of-pocket on CAM, of which about two-thirds was for self-care.

September 2010—NCCAM launches the Clinical Digest, a monthly e-newsletter that offers evidence-based information on CAM, including scientific literature searches, summaries of NCCAM-funded research, fact sheets for patients, and more.


NCCAM LEGISLATIVE CHRONOLOGY

October 1991—Public Law 102-170 provided $2 million to the National Institutes of Health (NIH) to establish an office and advisory panel to recommend a research program that would investigate promising unconventional medical practices.

June 1993—Public Law 103-43, the NIH Revitalization Act of 1993, established the OAM within the Office of the Director of NIH. The purpose of the Office was to facilitate the evaluation of alternative medical treatment modalities and to disseminate information to the public via an information clearinghouse.

October 1998—Public Law 105-277, the Omnibus Consolidated and Emergency Supplemental Appropriations Act, elevated the status and expanded the mandate of the OAM by authorizing the establishment of NCCAM. This act amended Title IV of the Public Health Service Act.

BIOGRAPHICAL SKETCH OF NCCAM DIRECTOR JOSEPHINE P. BRIGGS, M.D.

Josephine P. Briggs, M.D., an accomplished researcher and physician, is Director of the National Center for Complementary and Alternative Medicine. Dr. Briggs brings a focus on translational research to the study of complementary and alternative medicine to help build a fuller understanding of the usefulness and safety of CAM practices.

Dr. Briggs received her A.B. cum laude in biology from Harvard-Radcliffe College and her M.D. from Harvard Medical School. She completed her residency training in internal medicine and nephrology at the Mount Sinai School of Medicine, New York, NY, where she was also chief resident in the Department of Internal Medicine and a fellow in clinical nephrology. She then held a research fellowship in physiology at Yale School of Medicine, New Haven, CT. Dr. Briggs was a research scientist for 7 years at the Physiology Institute at the University of Munich, Munich, Germany.

In 1985, Dr. Briggs moved to the University of Michigan, Ann Arbor, MI, where she held several academic positions, including associate chair for research in the Department of Internal Medicine and professorships in the Division of Nephropathology, Department of Internal Medicine and the Department of Physiology. Dr. Briggs joined the National Institutes of Health (NIH) in 1997 as director of the Division of Kidney, Urologic, and Hematologic Diseases at the National Institute of Diabetes and Digestive and Kidney Diseases where she oversaw extramural research activities. While at NIDDK, she co-chaired an NIH Roadmap Committee on Translational Core Resources. In 2006, she accepted a position as senior scientific officer at the Howard Hughes Medical Institute.

Dr. Briggs' research interests include the renin-angiotensin system, diabetic nephropathy, circadian regulation of blood pressure, and the effect of antioxidants in kidney disease. She has published more than 175 research articles, book chapters, and scholarly publications. Dr. Briggs also has served on the editorial boards of several journals (including the Journal of Laboratory and Clinical Medicine, Seminars in Nephrology, and Hypertension) and was deputy editor for the Journal of Clinical Investigation. She is an elected member of the American Association of Physicians and the American Society of Clinical Investigation and a fellow of the American Association for the Advancement of Science. She is a recipient of many awards and prizes, including the Vollhard Prize of the German Nephrological Society, the Alexander von Humboldt Scientific Exchange Award, and NIH Director's Awards for her role in the development of the Trans-NIH Type I Diabetes Strategic Plan and her leadership of the Trans-NIH Zebrafish committee. Dr. Briggs is also a member of the NIH Steering Committee, the senior most governing board at the NIH.

NCCAM DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>William R. Harlan (Acting)</td>
<td>January 1999</td>
<td>October 1999</td>
</tr>
<tr>
<td>Stephen E. Straus</td>
<td>October 1999</td>
<td>November 2006</td>
</tr>
<tr>
<td>Ruth L. Kirschstein (Acting)</td>
<td>November 2006</td>
<td>January 2008</td>
</tr>
<tr>
<td>Josephine P. Briggs</td>
<td>January 2008</td>
<td>Present</td>
</tr>
</tbody>
</table>

MAJOR OFFICES AND DIVISIONS

The Office of the Director plans, directs, coordinates, and evaluates the development of programs and activities of the Center. Within the Office:

- The Office of Policy, Planning, and Evaluation reports on NCCAM's scientific initiatives and programs, and oversees congressional testimony and the implementation of the Freedom of Information Act [http://nccam.nih.gov/about/offices/oppe/foia.htm].
The Office of Communications and Public Liaison handles activities pertaining to the dissemination of information about NCCAM and CAM. Its work includes operating the Information Clearinghouse, serving as liaison with the media, and implementing education and outreach initiatives.

The Office of Administrative Operations is responsible for financial management, administrative operations, and the design and implementation of innovative business and management systems.

The Division of Extramural Activities develops, implements, and coordinates extramural programs and policies within NCCAM. It also coordinates meetings of NCCAM’s advisory council and manages the Center’s committee management activities. Within the Division, two Offices have a specialized focus:

- The Office of Scientific Review [http://nccam.nih.gov/about/offices/osr/] coordinates the receipt, referral, and scientific review of grants, cooperative agreements, and research contracts.
- The Office of Grants Management [http://nccam.nih.gov/about/offices/ogm/] oversees the processing of grant, cooperative agreement, and contract awards.

The Division of Extramural Research is primarily responsible for scientific management of NCCAM's portfolio of federally supported research grants and fellowships. In addition, the Division:

- Provides guidance in developing research, research training, and career development programs;
- Designs and develops specific CAM research projects, announced through such mechanisms as Requests for Applications (RFAs); and
- Coordinates with other components of NIH in research endeavors.

Within the Division, 3 offices have a specialized focus:

- The Office of Special Populations oversees NCCAM’s activities pertaining to the HHS Initiative to Eliminate Racial and Ethnic Disparities in Health.
- The Office of International Health Research oversees NCCAM's global scientific research activities.
- Coordinates with other components of NIH in research endeavors.

The Office of Clinical and Regulatory Affairs helps plan, coordinate, and monitor NCCAM’s clinical trials; serves as a resource for investigators; and oversees staff and grantee compliance with all Federal guidelines pertaining to research using human subjects.

The Division of Intramural Research conducts clinical, translational, and basic research on the efficacy, safety, and mechanisms of action of diverse CAM modalities; facilitates integration of effective CAM and conventional practices into the interdisciplinary health care system at the NIH Clinical Center; and fosters development of research and training curricula that include information about safe and effective CAM and conventional practices. The Complementary and Integrative Medicine Consult Service offers clinical consultation to NIH Clinical Center staff on CAM approaches, botanical/drug interactions, and issues of credentialing for CAM practitioners, as well as a lecture series on CAM and integrative medicine.
MISSION

The National Center for Research Resources (NCRR) provides laboratory scientists and clinical researchers with the tools and training they need to understand, detect, treat and prevent a wide range of diseases. NCRR supports all aspects of clinical and translational research, connecting researchers, patients and communities across the nation. This support enables discoveries made at a molecular and cellular level to move to animal-based studies, and then to patient-oriented clinical research, ultimately leading to improved patient care. Through programs such as the Clinical and Translational Science Awards, NCRR convenes innovative research teams and equips them with essential tools and critical resources needed to tackle the nation's complex health problems.

IMPORTANT EVENTS IN NCRR HISTORY

1962—On April 13, U.S. Surgeon General Dr. Luther L. Terry announced the creation of the Division of Research Facilities and Resources (DRFR), officially established on June 15.

In June, the Regional Primate Research Centers were transferred from the National Heart Institute to DRFR.

1967—The Biotechnology Resources Program was established with the transfer of Centers for Biomedical Computing and Bioengineering to DRFR from another NIH component. BRP funded the first Centers in Mass Spectrometry and Nuclear Magnetic Resonance.

1969—DRFR, in the U.S. Public Health Service (PHS) Bureau of Health Professions Education and Manpower Training, was renamed the Division of Research Resources (DRR).

1970—DRR was removed from the Bureau of Health Professions Education and Manpower Training and became an independent NIH division.

1972—The Minority Biomedical Research Support Program was formed.

1975—The NIH Director approved a broadened mission for the division and an internal reorganization.

1979—The BRP funded the first synchrotron facility for use in X-ray crystallography by NIH investigators.


1985—The Research Centers in Minority Institutions (RCMI) program was established.

The Biological Models and Materials Research Section was created in DRR's Animal Resources Program.

1986—The only national laboratory dedicated to biomedical applications of fluorescence was funded at the University of Illinois.

1987—The Pittsburgh Supercomputer Center was funded.

1988—The Research Facilities Improvement Program began.

1989—The Biological Models and Materials Resources Section of the Animal Resources Program became the Biological Models and Materials Research Program.

The Minority Biomedical Research Support Program was transferred from DRR to NIH's National Institute of General Medical Sciences.

1990—On February 15, Louis W. Sullivan, M.D., secretary of the U.S. Department of Health and Human Services, approved the merger of the Division of Research Resources and the NIH Division of Research Services to form the National Center for Research Resources.

NCRR received appropriated funding for the Research Centers in Minority Institutions (RCMI) program, which had been previously administered by DRR but funded by the Office of the Director, NIH, since the program's inception in 1985.

1991—The Science Education Partnership Award (SEPA) program was established.

1993—NCRR began the Science Teaching Enhancement Award program, a 2-year pilot program to create a corps of master teachers to form institutional partnerships that would improve biology education at the pre-college level.
The Institutional Development Award (IDeA) program and the Research Facilities Improvement Program were established, as mandated by the NIH 1993 Revitalization Act.

1994—NCRR convened expert biomedical investigators, academic administrators, and staff to develop NCRR's first comprehensive strategic plan, NCRR: A Catalyst for Discovery, A Plan for the National Center for Research Resources.

1995—NCRR reorganized the original seven extramural programs into: Biomedical Technology, Clinical Research, Comparative Medicine, and Research Infrastructure.

The Center established the Research Centers in Minority Institutions Clinical Research Infrastructure Initiative to enable RCMI-eligible institutions with affiliated medical schools to develop their clinical research infrastructure.

Three National Gene Vector Laboratories were established with joint funding from the NCRR; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; and NIH Office of AIDS Research.

1996—An agreement was formalized between the NIH/NCRR Shared Instrumentation Grant program and the National Science Foundation's Multi-user Equipment Program to jointly review and fund single scientific instruments costing more than $500,000.

1997—NCRR's intramural programs were transferred to the NIH Division of Intramural Research Services within the NIH Office of Research Services.

The NCRR Reporter, a quarterly magazine formerly published by DRR as the Reporter, celebrated its first 20 years of publication.


NCRR established the NIH Chimpanzee Management Program.

1999—NCRR established the nation's eighth Regional Primate Research Center at the Southwest Foundation for Biomedical Research—the first center to be added to the RPRC network since the 1960s.

NCRR established the Mutant Mouse Regional Resource Centers (MMRRC) program.

Eight 'collaboratory' projects were initiated within the NCRR-supported Biomedical Technology Resource Centers to demonstrate and evaluate the efficiency and effectiveness of conducting multi-investigator research utilizing the Internet.

A full-scale biosafety level-4 (BL4) laboratory—partially funded by NCRR—was dedicated at the Southwest Foundation for Biomedical Research in Texas. It is 1 of 4 federally supported BL4 labs nationwide, but the only such facility dedicated to basic molecular studies and investigation of long-term pathogenesis of deadly microbes.

2000—As part of the IDeA program, NCRR established Centers of Biomedical Research Excellence at independent institutions located in states with historically low aggregate success rates for obtaining NIH grants. The COBRE support thematic multidisciplinary centers that augment and strengthen institutional biomedical research capacity.

2001—NCRR launched the Biomedical Informatics Research Network, a shared network of neuroimaging databases that serves as a test bed for development of hardware, software and protocols for mining data in a site-independent manner for both basic and clinical research.

The first NIH-wide High-End Instrumentation grant program was established to enable institutions to purchase instruments that cost more than $1 million.

NCRR began providing Science Education Partnership Awards (SEPA) to science centers and museums nationwide to enhance the reach of unique health-related education programs.

2002—NCRR, along with five other NIH components, issued infrastructure enhancement awards to increase the capacity for basic research using human embryonic stem cells for preclinical investigations. The awards, which support entities listed on the NIH Human Embryonic Stem Cell Registry, were designed to increase the supplies and access to self-renewing cells that are well characterized for quality controls.

A private, nonprofit organization received a contract to establish and operate a sanctuary for chimpanzees no longer needed for biomedical research. The Chimpanzee Health Improvement, Maintenance, and Protection Act of December 2000 mandated such a sanctuary.

The eight Regional Primate Research Centers were renamed as National Primate Research Centers (NPRCs) to reflect their enhanced emphasis on providing nonhuman primates and related resources to biomedical scientists nationwide.

The Rat Resource and Research Center (RRRC), established at the University of Missouri (Columbia), serves as a resource for the study of rat models for biomedical research worldwide. The RRRC imports, cryopreserves, produces, and distributes high-quality laboratory rats.

2003—To address the challenges inherent in diagnosing and treating rare diseases, NCRR and other NIH components established the Rare Disease Clinical Research Network, which consists of 7 Rare Diseases Clinical Research Centers and a Data and Technology Coordinating Center. Each research center consists of a consortium of clinical investigators partnering with patient-support groups and institutions within and outside of the United States that have agreed to work together studying a group of rare diseases.
NCRR and the NIH National Center on Minority Health and Health Disparities (NCMHD) awarded a grant to Tuskegee University to complete its National Center for Bioethics in Research and Health Care. The grant allows the university to provide research and teaching facilities for faculty, researchers, and visiting scholars for studies in bioethics, public health, and integrated bioscience programs. The Center is the nation's first bioethics institute dedicated to addressing issues that involve African Americans and other vulnerable or disadvantaged populations.

IDEANet (an Internet-based network providing connectivity for high-bandwidth science applications. IDEANet enables collaboration among institutions) began with the funding of a test-bed consortium of six IDeA states (called the Lariat Project) to provide increased connectivity for high-bandwidth science applications and facilitate collaborations among these and other institutions. IDEANet enhances IT infrastructure by providing support for staff in bioinformatics and data management cores, computer hardware and software, and Internet2 broad-bandwidth access for biomedical applications. It was intended to relieve strategic bottlenecks in connectivity entering states and to improve Internet performance at many sites throughout the IDeA states.

The Division of Comparative Medicine funded 3 new resource centers. A Viper Resource Center was established at Texas A&M University in Kingsville, Texas, to provide a resource of more than 400 venomous snakes. A National Swine Research and Resource Center was established at the University of Missouri-Columbia to serve as a national repository and distribution center for genetically modified swine. The Drosophila Genomics Resource Center, housed at the Center for Genomics and Bioinformatics at Indiana University in Bloomington, Ill, was created to assist researchers in applying genomics in the model organism Drosophila by assuring economical access to quality-controlled genomics materials.

Three new resources were developed to integrate technologies that enhance the study of proteomics and glycomics, two emerging fields that seek to identify and uncover the structures, functions, and interactions of the thousands of proteins (proteomics) or carbohydrates (glycomics) found in cells. The new resources were the Proteomics Research Resource for Integrative Biology at Pacific Northwest National Laboratory, Integrated Technology Resource for Biomedical Glycomics at the University of Georgia, and the Integrated Proteome Technologies for Pathway Mapping resource at the University of Michigan, which houses a high-throughput robotic analysis system.

Tulane University, in New Orleans, established a center for the preparation, quality testing, and distribution of adult stem cells. Using standardized protocols, the center prepares and distributes a continuous supply of marrow stromal cells derived from adult human and rat bone marrow.

2004—A comprehensive five-year strategic plan, 2004-2008 Strategic Plan: Challenges and Critical Choices, was published, based on the input of biomedical investigators, senior administrators in research organizations, scholarly organizations and NIH senior program staff. The Strategic Plan guided NCRR's priorities for investments, including local and national networks, research resources, technology development, instrumentation, biological models, and biomedical informatics tools to facilitate research intended to prevent, alleviate, or treat human disease.

Using existing resources and centers, NCRR began serving as a significant partner in many NIH Roadmap initiatives, including those under the theme of Re-engineering the Clinical Research Enterprise. NCRR was the lead Center partnering with other NIH components to support Exploratory Centers for Interdisciplinary Research. NCRR was also the lead NIH component supporting National Technology Centers for Networks and Pathways. Additionally, NCRR supports the National Centers for Biomedical Computing Initiative.

Comprehensive Centers on Health Disparities were established to systematically address one or more of the health disparities that negatively impact racial and ethnic minority populations served by the grantee institutions. The new centers are: Meharry Medical College in Nashville; Charles R. Drew University of Medicine and Science in Los Angeles; and the Puerto Rico consortium, which consists of the 3 accredited medical schools in Puerto Rico (the University of Puerto Rico School of Medicine, the Universidad Central del Caribe School of Medicine, and the Ponce School of Medicine.) The health disparities to be studied include a variety of cancers (breast, prostate, and colorectal); diabetes mellitus; renal disease; infant mortality; AIDS; and cerebrovascular and cardiovascular diseases.

2005—The Research Centers in Minority Institutions program celebrated its 20th anniversary. Launched in 1985 with Congressional support, the RCMI program fosters environments that are conducive to excellence in basic, clinical and behavioral research. Through training and career development opportunities, the RCMI program also establishes a critical mass of scientists that more closely reflect the growing ethnic and cultural diversity of the U.S. population.

The WiCell Research Institute in Wisconsin was awarded $16.1 million over four years to fund a National Stem Cell Bank. The Bank will consolidate many of the federally funded eligible human embryonic stem cell lines in one location, reduce the costs that researchers have to pay for the cells, and maintain quality control over the cells. The Stem Cell Bank provides scientists affordable and timely access to federally approved human embryonic stem cells and other technical support that will make it easier for scientists to obtain the cells lines currently listed on the NIH Human Embryonic Stem Cell Registry.

Chimp Haven, the first federally funded chimpanzee sanctuary, opened on October 28, 2005. The sanctuary, funded by an NCRR contract, provides lifetime care for federally owned or supported chimpanzees that are no longer needed for biomedical research. NCRR also awarded construction grants so that Chimp Haven could develop and build a state-of-the-art facility that closely resembles the chimpanzees' natural habitat. The sanctuary was established in response to the Chimpanzee Health Improvement, Maintenance, and Protection Act of December 2000, which authorized $30 million in federal dollars for the sanctuary.

2006—The Clinical and Translational Science Awards program was launched to form a national consortium of research institutions that work together to transform the discipline of clinical and translational science. Led by NCRR, the CTSA Consortium was initiated through funding to 12 academic health centers located throughout the nation. An additional 52 awardees received planning grants to help them prepare applications to join the consortium. When fully implemented, the consortium will support approximately 60 CTSA's. CTSA Consortium members share a common vision to reduce the time it takes for laboratory discoveries to become treatments for patients, to engage communities in clinical research efforts, and to train a new generation of clinical and translational researchers.

By encouraging collaboration across disciplines, CTSA consortium members use innovative approaches to tackle research challenges and train clinical and translational researchers. As a direct result of the CTSA program, researchers are working together in new ways to advance medical research across many disease areas and conditions, including cancer, neurological disorders, cardiovascular disease, diabetes and obesity. The CTSA Consortium's Web site (CTSAWeb.org) helps to ensure access to CTSA resources, to enhance communications and to encourage information sharing.
The Rare Diseases Clinical Research Network, an initiative of the NIH Office of Rare Diseases and NCRR—in collaboration with many NIH Institutes, facilitates clinical research of rare diseases. More than 20 studies opened at approximately 50 sites across the United States and in several other countries including the United Kingdom, Japan, and Brazil. The network has received five-year funding awards totaling $71 million.

NIH also awarded a set of cooperative agreements, totaling up to $52 million over five years, to launch the Knockout Mouse Project. The goal of this program was to build a comprehensive and publicly available resource of knockout mutations in the mouse genome. NCRR was one of the 19 NIH Institutes, Centers and Offices contributing to the Knockout Mouse Project.

2007—In April, NIH Director Elias A. Zerhouni, M.D., named Barbara Alving, M.D., M.A.C.P., as the director of NCRR. Dr. Alving joined NIH in 1999. She previously served as acting director of NCRR as well as NHLBI.

In September, NCRR expanded the CTSA consortium from 12 to 24 academic health centers. The consortium's major goal is to speed the translation of laboratory discoveries into treatments for patients. Currently, the CTSA consortium is working to address three major priorities: standardizing clinical research informatics, streamlining institutional review board processes, and developing national curricula for clinical and translational science. When fully implemented in 2012, 60 institutions will be linked together to energize the discipline of clinical and translational science. View Image.

Scientists have now added a third primate to the list of sequenced genomes: the rhesus macaque, Macaca mulatta. This old-world monkey is the nonhuman primate most widely used in biomedical research focusing on major diseases, such as AIDS and diabetes. Its genome sequence is reported in the April 13, 2007, issue of Science [http://www.sciencemag.org/science/ma...]. The sequencing, funded by NIH's National Human Genome Research Institute, was performed at the Baylor College of Medicine Human Genome Sequencing Center in Houston; the Genome Sequencing Center at Washington University in St. Louis; and the J. Craig Venter Institute in Rockville, Md. It was based on the DNA from a single individual—a female rhesus macaque housed at the NCRR-funded NPRC at the Southwest Foundation for Biomedical Research in San Antonio. The California, Oregon and Yerkes NPRCs, also funded by NCRR, contributed additional biological samples used in the study. View Image.

NCRR provided $9.5 million over three years to launch a Translational Research Network that will increase the opportunity for multi-site clinical and translational research among minority and other collaborating institutions throughout the nation. Investigators at these institutions are focused on cancer, diabetes, renal disease, infant mortality, HIV/AIDS and cardiovascular diseases—all of which disproportionately affect minority populations.

Researchers at the Oregon Health and Science University's NPRC—funded by NCRR—made a significant breakthrough in efforts to develop human stem cell therapies to combat devastating diseases. For the first time, scientists successfully derived embryonic stem cells by reprogramming the genetic material of skin cells from rhesus macaque monkeys. Related future studies will have the potential to accelerate progress in regenerative medicine.

A team of University of Wisconsin-Madison researchers led by Dr. James Thomson reported the genetic reprogramming of human skin cells to create cells apparently indistinguishable from embryonic stem cells. This alternative to the embryo-based cloning technique shows that human skin cells can be reprogrammed into so-called induced pluripotent stem (iPS) cells that look and act like embryonic stem cells. These iPS cells could be used to generate patient-specific stem cells. Using this new reprogramming technique (inserting viral genes into adult human skin cells), the Wisconsin group developed eight new stem cell lines.

NCRR released a multimedia presentation—Harnessing Innovation to Advance Human Health [http://videocast.nih.gov/podcast/ncrr/nccr...m_web.mov]—that provides an overview of the Center's mission, grant programs and resources.

2008—The NCRR Strategic Plan 2009-2013: Translating Research from Basic Discovery to Improved Patient Care [http://www.nccr.nih.gov/strategic_plan/online_version/contents.asp], was published. This comprehensive five-year strategic plan reflects extensive discussions and advice from a broad spectrum of individuals, including biomedical scientists, senior administrators in research institutions, members of professional organizations, and NIH senior program staff. Implementation of the plan requires that NCRR continue to develop and explore creative ways to partner with other federal government agencies and additional organizations, both public and private. NCRR also will continue to enlist the help of researchers and administrators across the biomedical research community to ensure successful implementation of the plan and its continued evolution in response to new challenges and discoveries.

Fourteen academic health centers in 11 states became the newest members of the National Institutes of Health's CTSA consortium [http://www.ctsaweb.org/]. These 14 centers joined 24 others announced in 2006 and 2007. Creating a unique network of medical research institutions across the nation, the consortium works to reduce the time it takes for laboratory discoveries to become treatments for patients and to engage communities in clinical research efforts. The 2008 CTSA grants expanded state representation in the consortium from Alabama, Colorado, Indiana, Massachusetts and Utah. They also supported pediatric research at 13 dedicated children's hospitals, expanded research in genetics and genomics, enhanced research in behavioral immunology and infection risk, and increased outreach into local communities. View Image.

CTSA institutions have formed regional networks within the national consortium. Such networks have formed on the West Coast, in the Midwest, and on the East Coast, improving collaboration between CTSA institutions in these areas. These regional alliances also provide opportunities to cultivate equitable and collaborative partnerships between regional communities and the CTSA institutions, create new ways to disseminate information about research findings, and conduct research that leads to measurable improvements in community health.

CTSA networks also are building partnerships with other NCRR programs—such as the Institutional Development Awards and the Research Centers in Minority Institutions programs—through research collaborations, visiting professorships, working groups, and sharing and leveraging resources and infrastructure. The goal is to extend the CTSA philosophy of interdisciplinary interactions and connectivity to generate partnerships and collaboration beyond the consortium to organizations involved with health care throughout the nation. These partnerships enable scientists to expand research opportunities and to share their expertise and resources to further advance clinical and translational research.

Scientists developed the first genetically altered monkey model that replicates some symptoms observed in patients with Huntington's disease, according to a new study funded by NCRR. Researchers are now able to better understand this complex, devastating and incurable genetic disorder affecting the brain. This advance,
Through the Research Centers in Minority Institutions (RCMI) program, NCRR awarded $75 million to support four institutions over the next five years. Three of the four institutions also serve unique populations—such as rural and medically underserved communities—in these states.

NCRR awarded $8.5 million through 18 grants to 17 CTSA institutions to support studies of pharmaceutical treatments for children. The funding supports studies that focus on three areas critical to health (pediatric cardiology, neonatology and pediatric neurology) and is part of NIH's continuing efforts in studying drugs for use in pediatric populations.

Researchers at the Center for Functional Imaging Technologies at Massachusetts General Hospital—an NCRR-supported Biomedical Technology Research Center (BTRC)—created a powerful MRI brain-scanning instrument that it can detect the tiniest of lesions, even those as small as blood vessels. The instrument uses dozens of overlapping coils that pick up the MRI signal, all built into a helmet that fits closely to the patient's head. The Center for Functional Imaging Technologies is one of more than 50 NCRR-funded BTRCs across the United States that enable researchers to develop and distribute new technologies and methodologies.

NCRR's support of its Institutional Development Award program in 2009 included $274 million over the next five years for IDeA Networks of Biomedical Research Excellence (INBRE) in 16 IDeA-eligible states. In addition, NCRR granted $137.4 million for its IDeA Centers of Biomedical Research Excellence (COBRE) program, including $20.4 million for two new COBRES in Rhode Island and South Carolina. The INBRE program is designed to improve the competitiveness of investigators in states that historically have not been successful in obtaining federal research awards. The INBRE program also serves unique populations such as rural and medically underserved communities in these states.

NCRR awarded an estimated total of $19.2 million along with nearly $1.4 million in funding from the National Institute of Environmental Health Sciences to fund 17 Science Education Partnership Awards. The awards provide two to five years of support to stimulate scientific curiosity and encourage hands-on science education among students in kindergarten through 12th grade. The grants support partnerships among scientists, educators, museums and community organizations to encourage choosing science as a career path and to improve public understanding of NIH-funded biomedical research.

NCRR awarded $8.5 million through 18 grants to 17 CTSA institutions to support studies of pharmaceutical treatments for children. The funding supports studies that focus on three areas critical to health (pediatric cardiology, neonatology and pediatric neurology) and is part of NIH's continuing efforts in studying drugs for use in pediatric populations.

NCRR's support of its Institutional Development Award program in 2009 included $274 million over the next five years for IDeA Networks of Biomedical Research Excellence (INBRE) in 16 IDeA-eligible states. In addition, NCRR granted $137.4 million for its IDeA Centers of Biomedical Research Excellence (COBRE) program, including $20.4 million for two new COBRES in Rhode Island and South Carolina. The INBRE program is designed to improve the competitiveness of investigators in states that historically have not been successful in obtaining federal research awards. The INBRE program also serves unique populations such as rural and medically underserved communities in these states.

NCRR awarded an estimated total of $19.2 million along with nearly $1.4 million in funding from the National Institute of Environmental Health Sciences to fund 17 Science Education Partnership Awards. The awards provide two to five years of support to stimulate scientific curiosity and encourage hands-on science education among students in kindergarten through 12th grade. The grants support partnerships among scientists, educators, museums and community organizations to encourage choosing science as a career path and to improve public understanding of NIH-funded biomedical research.

NCRR awarded $8.5 million through 18 grants to 17 CTSA institutions to support studies of pharmaceutical treatments for children. The funding supports studies that focus on three areas critical to health (pediatric cardiology, neonatology and pediatric neurology) and is part of NIH's continuing efforts in studying drugs for use in pediatric populations.

NCRR's support of its Institutional Development Award program in 2009 included $274 million over the next five years for IDeA Networks of Biomedical Research Excellence (INBRE) in 16 IDeA-eligible states. In addition, NCRR granted $137.4 million for its IDeA Centers of Biomedical Research Excellence (COBRE) program, including $20.4 million for two new COBRES in Rhode Island and South Carolina. The INBRE program is designed to improve the competitiveness of investigators in states that historically have not been successful in obtaining federal research awards. The INBRE program also serves unique populations such as rural and medically underserved communities in these states.

NCRR awarded an estimated total of $19.2 million along with nearly $1.4 million in funding from the National Institute of Environmental Health Sciences to fund 17 Science Education Partnership Awards. The awards provide two to five years of support to stimulate scientific curiosity and encourage hands-on science education among students in kindergarten through 12th grade. The grants support partnerships among scientists, educators, museums and community organizations to encourage choosing science as a career path and to improve public understanding of NIH-funded biomedical research.

NCRR awarded $8.5 million through 18 grants to 17 CTSA institutions to support studies of pharmaceutical treatments for children. The funding supports studies that focus on three areas critical to health (pediatric cardiology, neonatology and pediatric neurology) and is part of NIH's continuing efforts in studying drugs for use in pediatric populations.

NCRR's support of its Institutional Development Award program in 2009 included $274 million over the next five years for IDeA Networks of Biomedical Research Excellence (INBRE) in 16 IDeA-eligible states. In addition, NCRR granted $137.4 million for its IDeA Centers of Biomedical Research Excellence (COBRE) program, including $20.4 million for two new COBRES in Rhode Island and South Carolina. The INBRE program is designed to improve the competitiveness of investigators in states that historically have not been successful in obtaining federal research awards. The INBRE program also serves unique populations such as rural and medically underserved communities in these states.

NCRR awarded an estimated total of $19.2 million along with nearly $1.4 million in funding from the National Institute of Environmental Health Sciences to fund 17 Science Education Partnership Awards. The awards provide two to five years of support to stimulate scientific curiosity and encourage hands-on science education among students in kindergarten through 12th grade. The grants support partnerships among scientists, educators, museums and community organizations to encourage choosing science as a career path and to improve public understanding of NIH-funded biomedical research.

NCRR awarded $8.5 million through 18 grants to 17 CTSA institutions to support studies of pharmaceutical treatments for children. The funding supports studies that focus on three areas critical to health (pediatric cardiology, neonatology and pediatric neurology) and is part of NIH's continuing efforts in studying drugs for use in pediatric populations.

NCRR's support of its Institutional Development Award program in 2009 included $274 million over the next five years for IDeA Networks of Biomedical Research Excellence (INBRE) in 16 IDeA-eligible states. In addition, NCRR granted $137.4 million for its IDeA Centers of Biomedical Research Excellence (COBRE) program, including $20.4 million for two new COBRES in Rhode Island and South Carolina. The INBRE program is designed to improve the competitiveness of investigators in states that historically have not been successful in obtaining federal research awards. The INBRE program also serves unique populations such as rural and medically underserved communities in these states.

NCRR awarded an estimated total of $19.2 million along with nearly $1.4 million in funding from the National Institute of Environmental Health Sciences to fund 17 Science Education Partnership Awards. The awards provide two to five years of support to stimulate scientific curiosity and encourage hands-on science education among students in kindergarten through 12th grade. The grants support partnerships among scientists, educators, museums and community organizations to encourage choosing science as a career path and to improve public understanding of NIH-funded biomedical research.

NCRR awarded $8.5 million through 18 grants to 17 CTSA institutions to support studies of pharmaceutical treatments for children. The funding supports studies that focus on three areas critical to health (pediatric cardiology, neonatology and pediatric neurology) and is part of NIH's continuing efforts in studying drugs for use in pediatric populations.

NCRR's support of its Institutional Development Award program in 2009 included $274 million over the next five years for IDeA Networks of Biomedical Research Excellence (INBRE) in 16 IDeA-eligible states. In addition, NCRR granted $137.4 million for its IDeA Centers of Biomedical Research Excellence (COBRE) program, including $20.4 million for two new COBRES in Rhode Island and South Carolina. The INBRE program is designed to improve the competitiveness of investigators in states that historically have not been successful in obtaining federal research awards. The INBRE program also serves unique populations such as rural and medically underserved communities in these states.

NCRR awarded an estimated total of $19.2 million along with nearly $1.4 million in funding from the National Institute of Environmental Health Sciences to fund 17 Science Education Partnership Awards. The awards provide two to five years of support to stimulate scientific curiosity and encourage hands-on science education among students in kindergarten through 12th grade. The grants support partnerships among scientists, educators, museums and community organizations to encourage choosing science as a career path and to improve public understanding of NIH-funded biomedical research.
resonance spectrometer; and $215,000 to investigators at the University of Washington, Seattle, to develop a multicolor total internal reflection fluorescence microscope, enabling them to examine cell division in greater detail.

The North East Cyberinfrastructure Consortium, established in part with NCRR Recovery Act funding, began work on determining the genome sequence of the little skate (Leucoraja erinacea) – one of 11 non-mammalian organisms strategically selected for sequencing by an NIH National Human Genome Research Institute advisory panel because the skate shares characteristics with the human immune, circulatory and nervous systems.

In addition to its Recovery Act grants, NCRR made Clinical and Translational Science Awards (CTSAs) to nine academic health centers, increasing the CTSA consortium membership to 55 institutions. This national network of medical research institutions works to reduce the time it takes for laboratory discoveries to become treatments for patients, to engage communities in clinical research efforts, and to train clinical and translational researchers. The 2010 CTSA expanded consortium representation to new areas including New Mexico, Virginia and the District of Columbia.

A website created by University of Washington researcher Eric Chudler, with funding from an NCRR Science Education Partnership Award (SEPA), won the Science Prize for Online Resources in Education. The prize recognizes exceptional online materials that are available free of charge to science educators. The website, "Neuroscience for Kids," provides some 150 million file downloads each year.

With pilot funding from the Northwestern University Clinical and Translational Sciences Institute, supported through the CTSA program, researchers studied sticky proteins produced by the foot of the common mussel (Mytilus edulis). Northwestern University researcher Phillip Messersmith developed synthetic materials mimicking these proteins that can stick to different surfaces even in wet environments. Messersmith tested these mussel-based “glues” to repair tears that occur in amniotic sacs, a complication of some pregnancies. View Image.

At NCRR-funded Biomedical Technology Research Centers, interdisciplinary teams created unique, transformative technologies and promoted their widespread use. During the past decade, University of California, Irvine, biomedical engineering professor Bruce Tromberg has been developing a device that uses thousands of colors of low-energy light to look at breast cancers in a new way. This noninvasive device, called a Laser Breast Scanner, conducts noninvasive, functional imaging of breast tumors and may help to improve cancer treatment while also lowering health care costs.

Researchers led by Chris Johnson at the University of Utah's NCRR-supported Center for Integrative Biomedical Computing developed an iPhone application that is changing how and where doctors practice medicine. The ImageVis3D Mobile visualization program enables them to retrieve and view high-resolution 3-D medical images on their mobile phones. View Image.

NCRR also funded the development of genetically engineered rodents and research rodent colonies. A research team led by Qi-Long Ying at the University of Southern California demonstrated that a gene-targeting mutation in rat embryonic stem cells can be transmitted through the germline to produce rats with the same mutation, providing a powerful new approach for creating models to study gene function relevant to human diseases. View Image.

At the University of Wisconsin, Madison, NCRR veterinary career development participant Rebecca Johnson studied rat models of diseases that affect myelin, such as Multiple Sclerosis. Severely affected MS patients often suffer from complications in breathing, but the cause is unclear. By studying rats that lack myelin in the brain and spinal cord, Johnson discovered that these animals have abnormalities in central nervous system signals that cause the diaphragm to contract and draw air into the lungs, which in turn may explain relationships between myelin disorders and breathing control in humans. View Image.

NCRR IDeA Networks of Biomedical Research Excellence (INBRE) researchers at the National Center for Genome Resources in Santa Fe, N.M., and their collaborators from the University of California at San Francisco; Stanford Medical School, Calif.; Wayne State Medical School, Mich.; Illumina Inc.; and Genentech, integrated state-of-the-art next generation DNA sequencing and analysis technologies to compare genes, gene activity and methylation gene controls associated with Multiple Sclerosis. Their work underscored the potential significance of environmental exposures and other non-genetic factors in complex disorders.

**NCRR LEGISLATIVE CHRONOLOGY**

July 30, 1956—The Health Research Facilities Act of 1956 (Title VII of the Public Health Service act) authorized a PHS program of federal matching grants to public and nonprofit institutions for the construction of health research facilities. Congress extended title VII through 1971. No grants were made under this authority after 1969.

August 19, 1959—Congress appropriated $2 million to establish two primate research centers.

September 15, 1960—Public Law 86-798 amended the PHS act to authorize grants-in-aid to universities, hospitals, laboratories, and other public and nonprofit institutions to strengthen their programs of research and research training in sciences related to health. The act also authorized the use of funds appropriated for research or research training to be set aside by the Surgeon General in a special account for general research support grants. Passage of this law resulted in the Biomedical Research Support Program.

July 29, 1971—The Minority Biomedical Research Support Program was created with $2 million from the Senate Appropriations Committee under authority of sec. 301(c) of the amended PHS act.

October 3, 1984—The Research Centers in Minority Institutions program was created with a $5 million congressional appropriation to the NIH Office of the Director. DRR was given administrative authority for the program.

December 22, 1987—Public Law 100-202 provided $23.9 million for the “repair, renovation, modernization and expansion of existing research facilities, and for the purchase of associated equipment.” The accompanying report, H.R. 100-498, directed that the money be spent on improving AIDS research facilities. The Research Facilities Improvement Program was created in DRR in response to this legislation.
November 6, 1990—Public Law 101-613, NIH Revitalization Act of 1990, mandated new programs, specified program funding levels, and reauthorized existing activities.

June 10, 1993—Public Law 103-43, NIH Revitalization Act of 1993, provided the statutory authority to redesignate DRR as NCRR and the authority to fund construction of biomedical and behavioral research facilities, with a special provision for centers of excellence and regional centers for research utilizing nonhuman primates. It also authorized the Institutional Development Award program, which supports programs in states that historically have been unsuccessful in competing for NIH grants.

November 13, 2000—The Clinical Research Enhancement Act of 2000, which is Title II of the Public Health Improvement Act [Minibus] (P.L. 106-505), provided the NCRR director with statutory authority to award grants for the establishment of GCRCs. The bill also required the NIH director to establish a Loan Repayment Program to encourage recruitment of new clinical investigators and to award grants that will enhance clinical research career development.

November 13, 2000—The Twenty-First Century Research Laboratories Act, which is Title III of the Public Health Improvement Act [Minibus] (P.L. 106-505), authorized $250 million for FY 2001 to the NCRR director to make grants or contracts to public and nonprofit private entities to expand, remodel, renovate, or alter existing research facilities or to construct new research facilities, including centers of excellence. It also authorized such sums as necessary for FY 2002 and FY 2003. In addition, the Act created, in statute, a specific authorization for NCRR's Shared Instrumentation Grant program, authorizing $100 million for FY 2000 and such sums as necessary for subsequent fiscal years.

December 20, 2000—The Chimpanzee Health Improvement, Maintenance, and Protection Act (P.L. 106-551) required NIH to enter into a contract with a nonprofit private entity for the purpose of operating a sanctuary system for the long-term care of chimpanzees that are no longer needed in research conducted or supported by the federal government. The law provides for standards for permanent retirement of chimpanzees into the system, including prohibiting using sanctuary chimpanzees for research except in specified circumstances.

January 15, 2007—President George W. Bush signed into law the NIH Reform Act of 2006. Of specific importance to NCRR, the legislation enhances the Clinical and Translational Science Awards by requiring the establishment of a mechanism to preserve independent funding and infrastructure for pediatric clinical research centers.

December 26, 2007—President Bush signed into law P.L. 110-170, the Chimp Haven is Home Act. Provisions modified the program for the sanctuary system for surplus chimpanzees by terminating the authority for the removal of chimpanzees from the system for research purposes.

February 17, 2009—President Obama signed into law P.L. 111-5, the American Recovery and Reinvestment Act. Provisions included $1 billion for NCRR's Extramural Construction program, $300 million for NCRR's Shared Instrumentation Grant program, and approximately $300 million for NCRR's biomedical research priorities.

BIOGRAPHICAL SKETCH OF NCRR ACTING DIRECTOR LOUISE E. RAMM, PH.D.

Louise E. Ramm, Ph.D., is the acting director of the National Center for Research Resources at the National Institutes of Health. She earned her Ph.D. in microbiology at the University of Virginia. After post-doctoral training in biochemistry, also at the University of Virginia, she became a faculty member at the Johns Hopkins School of Medicine in the Microbiology Department.

In 1977, Dr. Ramm joined the Microbiology Department at the Johns Hopkins University School of Medicine, serving as research scientist. From 1982 to 1987, she served as a research associate in Hopkins' Subdepartment of Immunology.

Later in 1987, Dr. Ramm joined the Division of Research Resources, the predecessor organization of NCRR, as a health scientist administrator in the Biological Models and Materials Program and subsequently became the director of the program. She has served as the NCRR deputy director since 1994 and also has served as the director of extramural activities.

In addition, Dr. Ramm has served as the executive secretary of National Advisory Research Resources Council and in various capacities on numerous other NIH committees. She has been an invited lecturer at many biomedical research conferences. Her research in immunochemistry, particularly in the interactions and structure of the complement proteins with cell membranes, resulted in numerous peer-reviewed publications.

NCRR DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frederick L. Stone</td>
<td>July 1962</td>
<td>June 1965</td>
</tr>
<tr>
<td>Thomas J. Kennedy</td>
<td>July 1965</td>
<td>November 1969</td>
</tr>
<tr>
<td>Thomas G. Bowery</td>
<td>November 1969</td>
<td>December 1981</td>
</tr>
<tr>
<td>Betty H. Pickett</td>
<td>October 1982</td>
<td>October 1988</td>
</tr>
<tr>
<td>Judith L. Vaitukaitis</td>
<td>September 1992</td>
<td>March 2005</td>
</tr>
<tr>
<td>Barbara M. Alving (Acting)</td>
<td>April 2005</td>
<td>March 2007</td>
</tr>
<tr>
<td>Barbara M. Alving</td>
<td>April 2007</td>
<td>October 2011</td>
</tr>
</tbody>
</table>
MAJOR EXTRAMURAL PROGRAMS

Division of Biomedical Technology

Biomedical Technology Research Centers

The Division of Biomedical Technology supports the development of a broad spectrum of technologies, techniques and methods via more than 50 Biomedical Technology Research Centers (BTRCs) at academic and other research institutions nationwide. The BTRCs develop versatile new technologies and methods that help researchers who are studying virtually every human disease, each creating innovative technologies in one of five broad areas: imaging resources, informatics resources, optical and laser technology, structural biology, and systems biology. They are complemented by programs providing research project grants to individual investigators and small businesses, often focusing on high-risk, high-reward technological innovation.

These resources create critical, often unique technology and methods at the forefront of their respective fields, and apply them to a broad range of basic, translational and clinical research. This is accomplished through a synergistic interaction of technical and biomedical expertise, both within the resources and through intensive collaborations with other leading laboratories.

BTRCs serve a unique purpose in the broad context of NIH-funded research. They represent a wealth of technological and intellectual resources focused on service and training for investigators. To accelerate translational research, BTRCs actively disseminate technologies, methods and software through approaches ranging from direct distribution to commercialization. The goal of the centers is to promote widespread application of cutting-edge technological discoveries across the full spectrum of science and medicine, from bench to bedside.

Biomedical Informatics Research Network

The NCRR-funded Biomedical Informatics Research Network (BIRN) uses emerging technologies to enhance collaborative efforts that integrate data, expertise and unique technologies from research centers across the country. The collaborative infrastructure is used by BIRN test beds to create new tools and procedures that enable multi-site studies and also benefit single-laboratory research. The tools and datasets, and the underlying collaborative infrastructure, are publicly available. Collaborations within BIRN include scientists in a large number of biomedical sub-disciplines as well as computer scientists and engineers who are creating this cyberinfrastructure.

BIRN tools currently focus on neuroscience and are available to researchers worldwide as they pursue the causes and new treatments of Alzheimer's disease, schizophrenia, major depression, attention deficit hyperactivity disorder and autism. However, researchers in other medical fields, including cardiology and cancer, also can benefit from this infrastructure to support collaborative research and sharing of data and applications.

Shared Instrumentation Grant

The Shared Instrumentation Grant (SIG) program provides funding—using the S10 funding mechanism—to institutions to purchase commercially available, expensive, technologically sophisticated equipment for use by groups of NIH-supported researchers. Examples of instrumentation supported by SIG funding include nuclear magnetic resonance systems, electron and confocal microscopes, mass spectrometers, protein and DNA sequencers, biosensors, X-ray diffractometers, and cell sorters. Shared use of these high-sensitivity and high-resolution instruments, essential to understanding fundamental biological processes, optimizes this federal investment. The SIG mechanism provides between $100,000 and $600,000 for the purchase of such instruments.

High-End Instrumentation

Rapid technological development has led to the production of a new generation of advanced instruments. Instruments in this price range include structural and functional imaging systems, macromolecular NMR spectrometers, high-resolution mass spectrometers, electron microscopes and supercomputers. As the capabilities of these high-sensitivity, high-resolution instruments increases, so does their cost. To meet the investigators' needs for this advanced technology, in FY 2002, NCRR began the High-End Instrumentation (HEI) program, which allows institutions to acquire equipment that costs more than $750,000. The maximum award is $2 million. The HEI grant program complements the SIG program and also uses the S10 funding mechanism.

Division for Clinical Research Resources

The NCRR Division for Clinical Research Resources administers the Clinical and Translational Science Awards, a part of the NIH Common Fund enabling researchers to provide new treatments more efficiently and quickly to patients. The division also provides funding to biomedical research institutions to establish and maintain specialized clinical research facilities and clinical-grade biomaterials that enable clinical and patient-oriented research. It supports these resources through the following programs:

Clinical and Translational Science Awards

The Clinical and Translational Science Award program is designed to more rapidly and efficiently transfer discoveries made in the laboratory into new treatments for patients. Through the CTSAs, academic health centers are working together as a consortium to provide enriched resources to educate and develop the next generation of researchers trained in the complexities of translating research discoveries into clinical trials and ultimately into practice; design new and improved clinical research informatics tools for analyzing research data and managing clinical trials; support outreach to underserved populations, local community, and advocacy organizations and health care providers; assemble interdisciplinary teams that include biologists, clinical researchers, dentists, nurses, pharmacists, biomedical engineers, and veterinarians; and forge new partnerships with private and public health care organizations, including pharmaceutical companies,
Veterans Administration hospitals, and health maintenance organizations as well as state health agencies. Additionally, each CTSA is creating an academic home at each grantee institution for clinical and translational research.


General Clinical Research Centers

NCRR funds a national network of 19 General Clinical Research Centers (GCRCs) that provide settings for medical investigators to conduct safe, controlled, state-of-the-art, in-patient and out-patient studies of both children and adults. GCRCs also provide infrastructure and resources that support several career development opportunities. GCRC staff includes research nurses, dietitians, biostatisticians, technicians, and administrative personnel who provide a supportive environment for patients and help investigators by facilitating the day-to-day research process. The GCRC network will gradually be transformed under the new CTSA program, described above.

National Gene Vector Biorepository

The National Gene Vector Biorepository and Coordinating Center was established on March 31, 2008. The Center stores tissue products for patients who received gene therapy products, purified vectors for pre-clinical and clinical trials. It also houses a searchable pharmacology/toxicology (P/T) database, a reagent repository, educational resources, and an insertion site analysis. As of January 2010, it included 33 studies in the P/T database, archived over 70 reagents from seven sites including the NCI, stored 9,322 tissue samples with requests increasing at greater than 40 percent per 6 months, and completed testing on 67 samples for replication competent retrovirus. The site also received a 2009 American Recovery and Reinvestment Act supplement for high throughput sequencing for clonal outgrowth of vector transduced cells. The proposal requested support for the development of an alternative automated method to standard LM-PCR and LAM-PCR for cloning. The novel method required the development of a novel vector insertion site chip. The biorepository supports an information coordinating center and performs original research in gene vector toxicity. The National Gene Vector Biorepository and Coordinating Center at Indiana University serves as a critical resource for academic investigators conducting gene therapy research. It also seeks to further improve safety for research subjects through education and compliance efforts.

Islet Cell Resource Centers

In 2001, NCRR established a network of 10 Islet Cell Resource (ICR) Centers to isolate, purify and characterize human pancreatic islets for subsequent transplantation into patients with type 1 diabetes. Following competitive applications in 2006, the ICR Center Consortium was reconfigured to consist of 7 production and testing centers and an Administrative and Bioinformatics Coordinating Center—supported for 3 years—for storage and communication of data, program analysis and equitable distribution of islets to basic scientists. According to plan, the ICR program ended on July 31, 2009 with some sites remaining open for one to two years on no cost extensions, two of them as recipients of ARRA supplements. The centers purified, stored and shipped islets under good laboratory practice for investigators for clinical studies and for basic science research. The islet purification program supported the NIAID-NIDDK-sponsored Clinical Islet Transplantation Study of islet efficacy in type 1 diabetes.

Human Tissues and Organs Resource

The Human Tissues and Organs Resource Cooperative Agreement supports a procurement network within the National Disease Research Interchange—a not-for-profit organization. By collaborating with various medical centers, hospitals, pathology services, eye banks, tissue banks and organ procurement organizations, the Resource provides a wide variety of human tissues and organs—both diseased and normal—to researchers for laboratory studies. Such samples include tissues from the nervous system, pulmonary system, cardiovascular system, endocrine system, eyes, bone, and cartilage.

Science Education Partnership Award

The Science Education Partnership Award program encourages scientists to work with educators and other organizations to improve students' (K-12) and the public's understanding of health sciences. The SEPA program supports development of a variety of model projects in biomedical and behavioral science education that make it feasible for scientists, educators, media and community leaders to partner in order to promote science by increasing science literacy. Past models have included a national video education program, a traveling and fixed museum exhibit about AIDS and other health issues, biotechnology research experiences that make it feasible for scientists, educators, media and community leaders to partner in order to promote science by increasing science literacy. In addition, NCRR funds and oversees a network of eight National Primate Research Centers, which provide the animals, facilities and expertise to enable studies of nonhuman primates. In addition, the NCRR supports more specialized resources and applied research grants that help to develop specific animal colonies, technologies and reagents that are complementary to, and synergize with, the research activities at NCRR Division of Comparative Medicine

The NCRR Division of Comparative Medicine provides scientists with essential resources—including specialized laboratory animals, research facilities, training and other tools—that enable health-related discoveries. Animal models are a critical part of the biomedical research continuum to bridge the gap between basic science and human medicine. Division programs support the maintenance and distribution of primate, rodent, aquatic and comparative animal models and resources. The division also funds a unique training program aimed at providing research training for veterinarians and veterinary students.

Nonhuman Primates

Nonhuman primates are critical components in translational research because of their close physiological similarities to humans. They are used in hypothesis-based research to enable discoveries that allow investigators to relate their research findings directly to human health. Nonhuman primates also are used in pre-clinical, applied research studies to test therapeutic approaches and vaccines. NCRR funds and oversees a network of eight National Primate Research Centers, which provide the animals, facilities and expertise to enable studies of nonhuman primates. In addition, the NCRR supports more specialized resources and applied research grants that help to develop specific animal colonies, technologies and reagents that are complementary to, and synergize with, the research activities at
the rest of the NPRCs and at other sites. Key research areas include infectious diseases (particularly AIDS), neurobiology, reproductive biology, bio-defense and regenerative medicine. Finally, the Chimpanzee Sanctuary provides housing and lifetime care for chimpanzees no longer needed for research.

**Rodents**

Rodents play a central role in research that can translate into treatments for human disease. Mice share much in common with human genetics, development, physiology, behavior and disease and are used to predict promising directions in biomedical research. NCRR's laboratory rodent programs fund development of genetically engineered rodents and research rodent colonies, facilities that distribute rodents and related biological materials, and new ways to study, diagnose and eliminate laboratory rodent disease.

**Aquatics**

Some aquatic animals serve as models for studying human development, behavior and disease. With short reproductive cycles and transparent eggs that are easily observed as they develop, zebrafish are useful for research. Other aquatic models include marine slugs. NCRR's aquatic models program funds development and maintenance of critical genetic stocks, biological materials and online information for researchers.

**Comparative Models**

Comparative models that add flexibility and ease of manipulation in the early stages of the translational discovery process include fruit flies and round worms, which are genetically well characterized and inexpensive and can undergo many genetic manipulations. Results from experiments involving these less complex models can help scientists decide whether to pursue similar research with higher species. NCRR's Comparative Models program supports development and use of new and improved models that complement those more traditionally used to study human diseases.

**Genetic, Biological and Information Resources**

NCRR supports a variety of sources for genetic analysis services, array technology and databases. This program also supplies critical biological materials, such as stem cells, enzymes and proteinases, as well as online information on model organisms.

**Research Training and Career Development Programs**

Molecular and genomic studies using animal models help lay the foundation for translational research that benefits human health. Scientists with a background in veterinary medicine contribute unique expertise and important knowledge and skills to this paradigm. To address the significant shortage of trained veterinary researchers, NCRR funds National Research Science Award programs specifically aimed at biomedical research trainees with a veterinary medicine background; NCRR is the only unit within NIH to uniquely fulfill this need. These programs either introduce veterinary students to research during a summer session, allow veterinary students to immerse in a full-time pursuit of research studies for an entire academic year, or encourage graduated veterinarians to pursue biomedical research studies.

**Division of Research Infrastructure**

The Division of Research Infrastructure develops and invigorates the nation's research capacity and infrastructure at all stages of research—from basic discoveries in the laboratory to advanced treatments for patients. The division supports the following programs to enhance the competitiveness of investigators in underserved states and institutions and also provides funding to build, expand, remodel or renovate research facilities throughout the nation:

**Research Centers in Minority Institutions**

The Research Centers in Minority Institutions program develops and enhances the research infrastructure of minority institutions by expanding human and physical resources for conducting basic, clinical and translational research. The RCMI program provides grants to institutions that award doctoral degrees in the health professions or health-related sciences and have enrollments that are predominately students from minority communities underrepresented in the biomedical sciences. These communities include African Americans, Hispanics, American Indians, Alaska Natives, Native Hawaiians and Pacific Islanders. Because many RCMI investigators study diseases that disproportionately affect minority populations—such as a variety of cancers, diabetes, HIV/AIDS and cardiovascular diseases—the program serves the dual purpose of increasing the number of minority scientists engaged in biomedical research and enhancing studies on minority health.

The RCMI program supports research by: 1) providing a wide array of research resources to enhance institutional infrastructure, ranging from state-of-the-art instrumentation to outpatient clinical research facilities; 2) sponsoring faculty development, enrichment and expansion activities; 3) enhancing grants management and research development activities; 4) improving biostatistical and informatics resources and developing new technologies; 5) funding pilot projects; and 6) renovating laboratory and animal facilities.

**Institutional Development Award**

The Institutional Development Award program was initiated by Congress to broaden the geographical distribution of NIH grant funding for biomedical and behavioral research. Through the IDEA program, NCRR fosters health-related research and improves the competitiveness of investigators in states that historically have not received significant levels of competitive research funding from NIH. The program serves unique populations, such as minority, rural and medically underserved communities in these states. The IDEA program supports multidisciplinary centers or statewide networks of collaborative partnerships that increase the capacity to conduct cutting-edge biomedical research. Specifically, the IDEA program establishes Centers of Biomedical Research Excellence within institutions to explore multidisciplinary research themes and foster mentoring opportunities. It also creates IDEA Networks of Biomedical Research Excellence within a state that share multidisciplinary, thematic scientific goals. Funding for these networks supports statewide partnerships that include community colleges, tribal colleges, undergraduate and graduate/professional institutions. These networks serve as a “pipeline” for undergraduate students to continue in health research careers.
Research and Animal Facilities Improvements

Research Facilities Improvement grants increase the nation's ability to conduct state-of-the-art research by providing competitive funding to modernize repair, renovate and construct research facilities that support basic and/or clinical biomedical and behavioral research investigations. Funding has supported the construction of cancer laboratories, improved research imaging capabilities, and many more biomedical research facilities much more. Through the Animal Facilities Improvement Program, NCRR provides federal grant awards institutional funding to improve animal research facilities, including facility upgrades and the development of programs related to laboratory animal care and use.

NCRR Information Dissemination

The purpose of the NCRR Reporter magazine is to foster communication, collaboration, and resource sharing in areas of current interest to scientists and others in the biomedical field. Subscriptions to the electronic (e-mail) and print editions of the NCRR Reporter are available free of charge. Subscribe to the E-Reporter by using the NCRR Reporter subscriber page [https://list.nih.gov/cgi-bin/wa?SUBED1=ncrr-reporter&A=1] on the NIH LISTSERV website. Subscribe to the print edition by contacting the NCRR Information Officer at info@ncrr.nih.gov.

The NCRR website (http://ncrr.nih.gov) presents timely information about Center programs and activities, while providing ready access to information of interest to both current and potential grantees. The site fosters communication, collaboration and resource sharing in areas of current interest to scientists and the public, as well as other stakeholders in research, such as leaders in academia, industry, voluntary health organizations, patient advocacy groups and scientific professional societies; policy makers; and science teachers.

NCRR's Twitter page (http://ncrr.nih.gov/twitter) offers up-to-the-minute information about the Center and its grantees to websites and mobile devices. As do other Web-based social media platforms, Twitter allows users to select content they wish to view, based on relationships and common interests.

NCRR's Facebook page (http://ncrr.nih.gov/facebook) informs social media users about the work accomplished by the Center's grantees and programs and also provides a gateway to the Center's public website. It complements other NCRR Web communications efforts as well as those across NIH and other parts of the federal government.

The Clinical and Translational Science Awards consortium's website (http://ctsaweb.org) ensures broad access to CTSA resources, enhances communication and encourages information sharing.

This page last reviewed on January 5, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

"NIH...Turning Discovery into Health" is a trademark of the U.S. Department of Health and Human Services.
MISSION

The NIH Clinical Center (CC) is the clinical research hospital for the National Institutes of Health. It's the nation's largest hospital devoted entirely to clinical research. Through clinical research, clinician-investigators translate laboratory discoveries into better treatments, therapies and interventions to improve the nation's health.

About 1,500 clinical research studies currently are active at the NIH Clinical Center. About half are the first tests of new drugs or medical treatment in people. The rest are natural history studies of diseases, including many rare diseases. Clinical and laboratory research is conducted shoulder-to-shoulder at the CC and this tandem approach drives all aspects of its operations. More than 350,000 research volunteers have participated in clinical research studies at the Clinical Center since the hospital opened in 1953. In 2009 their care accounted for about 6,500 inpatient admissions and more than 90,000 outpatient visits.

At the NIH Clinical Center, clinical research participants are active partners in medical discovery, a partnership that has resulted in a long list of medical milestones, including the first cure of a solid tumor with chemotherapy, gene therapy, use of AZT to treat AIDS, and successful replacement of a mitral valve.

IMPORTANT EVENTS IN CC HISTORY

November 1948—Construction of the Clinical Center was started.

June 22, 1951—President Harry S. Truman was the honored guest for the cornerstone ceremony.

July 2, 1953—The CC was dedicated by DHEW Secretary Oveta Culp Hobby.

July 6, 1953—The first patient was admitted to the Clinical Center.

1954—The Clinical Center's diagnostic x-ray department acquires the only Schonander angiocardiographic unit in the U.S. It takes films in two planes at the rate of six films per second, permitting a graphic demonstration of contrast substances as they pass through the heart, making diagnosis faster and more accurate.

1957—The Clinical Pathology Department starts an approved residency training program and develops the first automated machine for counting red and white blood cells (until then counted manually), from which later comes the Coulter counter.

1957—The Blood Bank publishes its first research paper, delineating the post-transfusion hepatitis problem, firing the first salvo in a long but largely successful campaign.

1959—A new, circular surgical wing (10A) is built.

September 5, 1963—A new surgical wing for cardiac and neurosurgery was dedicated by Luther L. Terry, Surgeon General. Disposable surgical gloves are introduced.

1963—The Blood Bank moves to a new a new areas and blood collections begin on the NIH campus.

1964—Harvey Alter (Clinical Center) and Baruch Blumberg (NIDDK) co-discover the Australian antigen, which Blumberg later shows to be the surface coating of the hepatitis B virus, leading to the isolation of this medically important virus. Blumberg later wins Nobel Prize. Alter, who later receives the Lasker Award, does pioneering work in the causes and prevention of blood-transmitted infections, which helps lead to the discovery of the virus that causes hepatitis C and the development of screening methods that will reduce the risk of transfusion-transmitted hepatitis.

1964—John L. Doppman and associates in diagnostic radiology report the first successful imaging of the arteries that supply the spinal cord. The technique of spinal angiography makes surgical intervention possible where spinal arterial malformations, lesions, or tumors cause paralysis.

1965—Clinical Pathology acquires a Control Data 3200 computer, which fills a room the size of a small living room. Some instruments are placed online; other data are entered on key-punched cards.

1966—A Department of Nuclear Medicine is established in the Clinical Center, headed by Jack Davidson, to centralize imaging facilities for patients in any institute. Radiation Safety, Diagnostics, and the Whole Body Counter Division become part of Nuclear Medicine and the old Radiation Safety Division is abolished. President Lyndon B. Johnson visits the new department.
1966—Wanda S. Chappell, chief nurse in the Blood Bank, comes up with a simple but ingenious method for separating blood platelets (the smallest blood cells) from blood plasma, so that the platelets can be used for transfusion to leukemia patients and the rest of the blood can be used by others, including patients undergoing open heart surgery.

1966—Additions to the Clinical Center (a library, cafeteria) are begun.

1968—Diagnostic radiologist John L. Doppman develops a method for locating the parathyroid, a group of glands (each about the size of a BB pellet) that regulates calcium metabolism.

July 2, 1969—A dedication ceremony was held to name the Clinical Center's Jack Masur Auditorium.

1970—The Blood Bank switches to an all-volunteer donor system, adding a test for hepatitis B surface antigen. Those two measures alone reduce the hepatitis rate from 30 percent before 1970 to about 11 percent after. Later, when it adds more sensitive tests for hepatitis B, hepatitis B virtually disappears as a problem in the Blood Bank.

1972—Clinical Pathology's Richard B. Friedman develops a computer program to teach students to diagnose illnesses by having the computer report symptoms, inform on test availability and cost, test results, and reactions to treatment.

1972—Blood Bank scientists develop a test for the antigen associated with hepatitis. The test will be used nationally.

1974—The Clinical Center Blood Bank develops a nationally recognized program in automated blood collection (apheresis), tissue typing (HLA), and an international reputation for research studies of red cell serology and hepatitis.

1976—The electronic medical information system—one of the nation's first—is introduced.

April 1977—Construction of the ambulatory care research facility was started.

September 1977—Medicine for the Layman, a series of health seminars for the public later named Medicine for the Public, is launched.

November 1977—The Critical Care Medicine Department was established.

1977—The Blood Bank establishes therapeutic apheresis/exchange programs that for decades will improve the lifespan and welfare of patients with such illnesses as sickle cell disease, hyperlipidemia, and autoimmune disorders. It also establishes the first automated platelet-pheresis center, collecting platelets for transfusion from volunteer donors using automated instrumentation.

1980—The research hospital was renamed the Warren Grant Magnuson Clinical Center, in honor of the former chairman of the Senate Committee on Appropriations, who has actively supported biomedical research at NIH since 1937. (P.L. 96-518.)

1981—As part of the design for the new Ambulatory Care Research Facility, Clinical Pathology services (previously scattered) are brought under one roof—working together in one vast open room, except for specialized functions sequestered for safety purposes (such as the containment of radionuclides).

June 16, 1981—The first patient with the new disease, later to be named AIDS/HIV, is seen at the Clinical Center.

1981—Clinical research dietitians develop standards of care for the clinical nutrition service and devise diets with controlled intake of certain nutrients to support clinical research.

1982—A new surgical facility opens, with more space for equipment, larger operating suites, two viewing galleries, and better delivery systems. A surgical intensive care unit opens in conjunction with new surgical suites.

1982—Under Henry Masur, Critical Care Medicine plays a key role in managing treatment for the opportunistic infections that are the main threat to immuno-suppressed AIDS patients. The department becomes world-recognized in its field, first for treating Pneumocystis pneumonia and then for experimental treatments with patients in shock.

1983—Clinical Pathology creates an immunology service, reflecting growing demand for sophisticated antibody and cellular-level diagnostic services.

March 22, 1984—The first magnetic resonance imaging unit became operational for patient imaging.

October 1984—NCI's Radiation Oncology Building was dedicated.

1984—Clinical Center Blood Bank is renamed the Department of Transfusion Medicine (DTM) because its activities extend well beyond traditional blood banking. DTM achieves the first transmission of HIV (HTLV III) to a primate through transfusion and describes the HIV seronegative window.

April 13, 1985—Two cyclotrons were delivered to the underground facility operated by the Nuclear Medicine Department.

1986—as a charter member of the National Marrow Donor Program (NMDP), the Clinical Center signs an agreement to become one of the first donor centers participating in the NMDP.

November 20, 1987—The Lipsett Amphitheater in the clinic was dedicated.

September 14, 1990—A 4-year-old patient with adenosine deaminase deficiency was the first to receive gene therapy treatment.
April 8, 1991—The Department of Transfusion Medicine opened its state-of-the-art facility.

1991—A thrombosis unit is established in Clinical Pathology's hematology service to help manage patients with coagulopathies. A virology section is redeveloped within Clinical Pathology's microbiology service. The original viral diagnostic unit had long since lapsed, for lack of clinical utility, but with the development of new diagnostic methodologies and new therapies, the need for such a service has become increasingly apparent.

June 1992—The A-wing addition was completed, adding NCI and NIAID labs focusing on AIDS research.

July 1993—The hematology/bone marrow unit opened to improve transplant procedures and develop gene therapy techniques.

May 1994—First multi-institute unit designed and staffed for children opened.

1995—The course “Introduction to the Principles and Practice of Clinical Research” is first offered. It provides education in the basics of safe, ethical, and efficient clinical research.

February 1996—Details on clinical research studies conducted at the Clinical Center are made available on the World Wide Web (http://clinicalstudies.info.nih.gov/), increasing opportunities for physicians and patient volunteers to participate in NIH clinical investigations.

November 1996—A Board of Governors was appointed by the Secretary of HHS, marking a new governing system for the Clinical Center.

July 1997—Transfusion Medicine Department launches a 3,000-square feet model core [cGMP] cell processing facility, created to meet increasing investigative needs for cell products used in research into new cellular therapies such as immunotherapy, gene therapy, stem cell transplantation, and pancreatic islet cell transplantation.

July 1997—To meet increasing investigative needs for cell products used in immunotherapy, gene therapy, and stem cell transplantation, a cell processing facility was created.

November 4, 1997—Vice President Al Gore and Senator Mark O. Hatfield attend groundbreaking ceremonies for the Mark O. Hatfield Clinical Research Center, to include a new hospital and research laboratories, is scheduled to be completed in 2004.

1999—Clinical Pathology Department is renamed Department of Laboratory Medicine. A new laboratory information system is put in place for Laboratory Medicine, Transfusion Medicine, and the Pathology Lab.

1999—The Bench-to-Bedside awards program was established to speed translation of promising laboratory discoveries into new medical treatments by encouraging collaborations among basic scientists and clinical investigators.

2000—The NIDDK and the Clinical Center (in collaboration with Walter Reed Army Medical Center, the Naval Medical Research Center, and the Diabetes Research Institute of the University of Miami) launch a new kidney, pancreas, and islet transplant program. The idea is to test novel therapies that may eliminate the need for the immunosuppressive drugs patients take to keep their bodies from rejecting new transplanted organs.

2000—Clinical Center launches a new Pain and Palliative Care Consult Service.

2000—Harvey Alter, Department of Transfusion Medicine, receives the Lasker Award “for pioneering work leading to the discovery of the virus that causes hepatitis C and the development of screening methods that reduced risk associated with transfusion-associated hepatitis in the United States from 30 percent in 1970 to virtually zero in 2000.” Alter, who is also elected to the National Academy of Sciences, shares the award with Chiron's Michael Houghton.

2000—The Imaging Sciences Program takes first steps toward filmless radiology, unveiling the pilot phase of its new Picture Archiving and Communication System (PACS) and Radiology Information System (RIS).

2001—A second bone marrow transplant unit opens to support NCI protocols.

2002—DTM establishes a model program for collecting blood from subjects with hereditary hemochromatosis. This program supplies 10% of the hospital's red cell needs.

October 29, 2002—Groundbreaking ceremony was held for the Edmond J. Safra Family Lodge at NIH. Located steps away from the Mark O. Hatfield Clinical Research Center, the lodge will provide a comfortable home away from home for the families and caretakers of Clinical Center patients.

2003—The Office of Clinical Research Training and Medical Education is established to help train the next generation of clinical researchers.

2004—As recommended by the NIH Director's Blue Ribbon Panel on the Future of Intramural Clinical Research, the former Clinical Center Board of Governors assumed a new and larger identity, becoming the NIH Advisory Board for Clinical Research. The Board will oversee all intramural clinical research, while continuing its oversight of Clinical Center resources, planning and operations.

2004—The Clinical Center formalizes an emergency preparedness partnership with Suburban Hospital and the National Naval Medical Center.


2005—Radiologist Ronald M. Summers found that computer-aided software, in conjunction with a procedure commonly called virtual colonoscopy, can deliver results comparable to conventional colonoscopy for detecting the most worrisome types of polyps.

2005—Bioethics chief Ezekiel Emanuel co-authored a study suggesting that minority involvement is more a matter of access than attitude.

2005—The Department of Rehabilitation Medicine opens its clinical movement analysis lab, a joint venture with the National Institute of Child Health and Human Development.

April 2, 2005—Patients are moved into the Mark O. Hatfield Clinical Research Center and the building becomes fully operational.

May 26, 2005—An opening ceremony is held for the Edmond J. Safra Family Lodge, offering a temporary residence for families and loved ones of adult patients receiving care at the NIH Clinical Center. The Lodge opens its doors to guests on June 1.

2005—Visitors to the Clinical Center include President George W. Bush and Britain's Prince Charles and his wife, the Duchess of Cornwall. Bush came to discuss health-care alternatives. The royal couple came for a briefing on osteoporosis.

2006—the NIH Clinical Center Bench-to-Bedside program was extended to include intramural and extramural collaborations.

2006—Nursing and Patient Care Services initiated a collaboration with the Indian Health Service. The joint agenda is to increase clinical nursing research capabilities in the Indian Health Service.

2006—A study examining the feasibility of billing insurance companies for patient-care services rendered during clinical trial participation was completed. The NIH Advisory Board for Clinical Research recommended to the NIH Director that this option not be pursued at this time because of the nature of the CC's research portfolio, the relatively low projected revenue, and how collections may affect patient volunteers.

2006—The Clinical Center receives a 250-bed contingency hospital from Department of Health and Human Services in support of the Emergency Preparedness Partnership with Suburban Hospital and National Naval Medical Center. The contingency hospital comprises pre-positioned supplies and equipment ready for quick set-up within the Clinical Center.

2007—Training and education programs from the NIH Office of Intramural Research and the Clinical Center merged to form an expanded Clinical Center Office of Clinical Research Training and Medical Education.

2007—The first of 1,000 volunteers enrolled in a study led by the National Human Genome Research Institute to test the use of human genome sequencing in a clinical research study. The study will focus first on the genes connected to coronary heart disease and will follow participants for up to ten years. The Institute also opened an Immersive Virtual Environment Testing Area to conduct its first social and behavioral research students at the Clinical Center.

January 25, 2007—A ribbon-cutting ceremony is held for a new NIH metabolic clinical research unit that provides researchers from multiple institutes the opportunity to study obesity and related conditions, such as diabetes, heart disease and certain cancers. An important component of the NIH Strategic Plan for Obesity Research, the unit and work conducted there generates new knowledge regarding the physiology, prevention, and treatment of obesity.

2008—The Undiagnosed Diseases Program was established, led by the National Human Genome Research Institute, the NIH Office of Rare Diseases, and the Clinical Center.

2008—The Clinical Center’s newest computed tomography scanner installed. It captures the image of an entire organ in only one rotation take a millisecond.

2008—The Biomedical Translational Research Information System is introduced. Ultimately, it will provide researchers easy access to clinical data derived from multiple sources.

2008—Clinical Center nurses undertake a multi-year project to define the clinical research domain of practice and lead the way in establishing it as a recognized nursing specialty practice area.

2008—An adaptation of the Clinical Center course “Introduction to the Principles and Practice of Clinical Research” was presented in Beijing.

2008—The Clinical Center began partnership with the Uniformed Services University of the Health Sciences and the Department of Defense in which the Clinical Center will play a key role in clinical research studies involving military and civilian populations.

2009—Two new trans-NIH imaging resources were initiated, the Center for Interventional Oncology and the Center for Infectious Diseases Imaging.

2009—in July, BTRIS, the Biomedical Translational Research System, launched its NIH-wide intramural research data repository allowing investigators to view identified data from their active protocols. In December, intramural researchers were able to access de-identified data from clinical and research systems across the NIH intramural programs. BTRIS is designed to facilitate hypothesis generation, data gathering and analysis.

2009—The Pharmacy Department opens a state-of-the-art pharmaceutical development facility. Staff formulates and analyzes vaccines and medications not available from manufacturers. The section formulates and analyzes vaccines and medications not available from manufacturers. These products account for one-third of the drugs (including placebos and varying strengths) that the CC uses in its research protocols.

2009—Transfusion Medicine begins use of a prototype cell expansion system to automate bone marrow stomal cell expansion.
2009—Radiology and Imaging Sciences at the Clinical Center takes a significant step to further safeguard clinical research patients who are exposed to radiation during certain imaging tests while at the Clinical Center. CT and PET/CT equipment purchased by the Clinical Center will now be required to routinely record radiation dose exposure in a patient's hospital-based electronic medical record.

2009—Two Clinical Center course go global—the Introduction of the Principles and Practice of Clinical Research and Principles of Clinical Pharmacology were taken to China.

2009—President Barack Obama visits the Clinical Center “to talk about our nation's commitment to research.”

CC LEGISLATIVE CHRONOLOGY

July 1, 1944—Public Law 78-410, the Public Health Service Act, authorized establishment of the Clinical Center.

July 8, 1947—Under P.L. 80-165, research construction provisions of the Appropriations Act for FY 1948 provided funds “For the acquisition of a site, and the preparation of plans, specifications, and drawings, for additional research buildings and a 600-bed clinical research hospital and necessary accessory buildings related thereto to be used in general medical research.”

BIOGRAPHICAL SKETCH OF CC DIRECTOR JOHN I. GALLIN, M.D., MACP

Dr. John Gallin was appointed director of the NIH Clinical Center in 1994. The Clinical Center serves the clinical research needs of 17 NIH institutes and is the largest clinical research hospital in the world. During his tenure, Dr. Gallin has overseen the design and construction of a new research hospital for the Clinical Center, the Mark O. Hatfield Clinical Research Center, which opened to patients in 2005; the establishment of a new curriculum for clinical research training that has trained more than 19,000 students globally; and development of new information systems for biomedical translational and clinical research.

While serving as CC director, Dr. Gallin has continued to be an active clinician and researcher. His primary research interest is in a rare hereditary immune disorder, chronic granulomatous disease (CGD). His laboratory described the genetic basis for several forms of CGD and has done pioneering research that has reduced life-threatening bacterial and fungal infections in CGD patients.

In 2009, the National Organization for Rare Disorders presented Dr. Gallin with the National Health Leadership Award. He was the 2006 recipient of the Richard and Hinda Rosenthal Foundation Award of the American College of Physicians for “his contribution to the advancement of clinical research, to the teaching structure, to the principles of patient care, and to overall productivity of hospital programs.” Established in 1976, the Rosenthal awards are bestowed each year in two distinct categories—for contributions to improve clinical care in the field of internal medicine and for recognition of health care that improves clinical care or economics of care.

A New York native, Dr. Gallin attended public school in New Rochelle, New York, graduated cum laude from Amherst College, and earned an M.D. degree at Cornell University Medical College. After a medical internship and residency at New York University’s Bellevue Hospital Medical Center, he received postdoctoral training in basic and clinical research in infectious diseases at NIH from 1971 to 1974. He then went back to the New York University-Bellevue Medical Center as senior chief medical resident from 1974-1975 before returning to NIH.

In 1985, Dr. Gallin began a nine-year period as scientific director for intramural research activities at the National Allergy and Infectious Diseases. During this period, Dr. Gallin oversaw intramural activities for NIAID, including doubling the research budget in response to the AIDS epidemic, introduction of a modern informatics program to NIAID and revitalization of NIAIDs Rocky Mountain Laboratories in Hamilton, Montana. Dr. Gallin also was chief of Laboratory of Host Defenses, NIAID, from 1991-2003, and he continues as chief of the lab's clinical pathology section.

He has published more than 300 articles in scientific journals and has edited two textbooks—Inflammation, Basic Principles and Clinical Correlates (Lippincott, Williams, and Wilkins, 1999, now in 3rd edition) and Principles and Practices of Clinical Research (Academic Press, 2002, now in 2nd edition)

Dr. Gallin is a member of the American Society for Clinical Investigation, the Association of American Physicians, Institute of Medicine of the National Academy of Sciences and he is a Master of the American College of Physicians.

CLINICAL CENTER DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jack Masur</td>
<td>1948</td>
<td>1951</td>
</tr>
<tr>
<td></td>
<td>1956</td>
<td>1969</td>
</tr>
<tr>
<td>John A. Trautman</td>
<td>1951</td>
<td>1954</td>
</tr>
<tr>
<td>Donald W. Patrick</td>
<td>1954</td>
<td>1956</td>
</tr>
<tr>
<td>Thomas C. Chalmers</td>
<td>1970</td>
<td>1973</td>
</tr>
<tr>
<td>Robert S. Gordon, Jr.</td>
<td>1974</td>
<td>1975</td>
</tr>
<tr>
<td>Mortimer B. Lipsett</td>
<td>1976</td>
<td>1982</td>
</tr>
<tr>
<td>Saul Rosen (Acting)</td>
<td>1990</td>
<td>1994</td>
</tr>
</tbody>
</table>
MAJOR PROGRAMS

As America's research hospital, the Clinical Center leads the global effort in training today's investigators and discovering tomorrow's cures.

The Clinical Center's mission is to provide a versatile clinical research environment enabling the NIH mission to improve human health by:

- Investigating the pathogenesis and natural history of disease
- Developing state-of-the-art diagnostic, preventive, and therapeutic interventions
- Training the next generation of clinical researchers
- Ensuring that clinical research is safe, efficient, and ethical

Major components: Anesthesia and Surgical Services; Bioethics; Clinical Epidemiology and Biostatistics; Clinical Research Informatics; Clinical Research Training and Medical Education; Communications, Patient Recruitment, and Public Liaison; Credentials Services; Critical Care Medicine; Edmond J. Safra Family Lodge; Facility Management; Financial Resource Management; Hospital Epidemiology; Housekeeping and Fabric Care; Hospitality Services; Internal Medicine Consultants; Laboratory Medicine; Laboratory for Informatics Development; Management Analysis and Reporting; Materials Management; Medical Records; Nursing and Patient Care Services; Nutrition; Organizational Development; Pain and Palliative Care; Pharmacy; Purchasing and Contracts; Rehabilitation Medicine; Transfusion Medicine; Pediatric Consults; Protocol Services; Radiology and Imaging Sciences; Positron Emission Tomography; Social Work; Spiritual Ministry; Veterinary Care.
Historical Data

- **Chronology of Events**
  Significant events and major research advances in NIH history, from 1798 to the present.

- **Directors** of the NIH

- **Photo Gallery**
  High-resolution photos of past presidential visits, NIH campus buildings, scientists and more.
  
<table>
<thead>
<tr>
<th>OD</th>
<th>NHGRI</th>
<th>NIAMS</th>
<th>NIDCR</th>
<th>NIGMS</th>
<th>NLM</th>
<th>NCCAM</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCI</td>
<td>NIA</td>
<td>NIBIB</td>
<td>NIDDK</td>
<td>NIMH</td>
<td>CIT</td>
<td>NIMHD</td>
</tr>
<tr>
<td>NEI</td>
<td>NIAAA</td>
<td>NICHID</td>
<td>NIDA</td>
<td>NINDS</td>
<td>CSR</td>
<td>NCRR</td>
</tr>
<tr>
<td>NHLBI</td>
<td>NIAID</td>
<td>NIDCD</td>
<td>NEHS</td>
<td>NINR</td>
<td>FIC</td>
<td>CC</td>
</tr>
</tbody>
</table>

MORE INFORMATION:

- **Legislative Chronology**
  Federal legislation that had a major influence on the growth of the NIH, from its beginning as the Marine Hospital Service in 1798, to the present.

- **Deputy Directors** of the NIH

- **Associate Directors** of the NIH

- **Secretaries** of the Department of Health and Human Services (HHS)

- **Nobel Laureates** associated with the NIH

- **Major NIH Lectures**, highlights from the NIH

- **Budget**, Appropriations for the NIH

---

This page last reviewed on January 5, 2012

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Chronology of Events


1700

1798
The Marine Hospital Service was established with the July 16 signing by President John Adams of an act for the relief of sick and disabled seamen.

1799
An amending act of March 2 extended benefits of the Marine Hospital Service to officers and men of the U.S. Navy.

1800

1802
The admission of foreign seamen to Marine hospitals on a reimbursable basis was authorized on May 3.

1803
The first permanent Marine hospital was authorized on May 3 to be built in Boston, Mass.

1807
Dr. Benjamin Waterhouse was appointed physician in charge of the Boston Marine Hospital on November 27. He was the first to introduce interns and residents into hospitals in the United States.

1836
The Library of the Office of the Surgeon General of the Army was established (the present National Library of Medicine).

1865
John Shaw Billings, M.D., was assigned to supervise the Surgeon General's Library, which he built into a national resource of biomedical literature.

1870
A bill dated June 29 provided for administration of Marine hospitals within a Bureau of the Treasury Department with a medical officer in charge.

1871
Dr. John Maynard Woodworth was appointed supervising surgeon of the Marine Hospital Service in April, marking the beginning of central control of Marine hospitals.

1873
Regulations were approved on December 1 for appointment and promotion of physicians in the Marine Hospital Service, establishing the first career service for civilian employees in the Federal Government.

1875
A bill passed on March 3 authorized admission of Navy seamen and seamen of other government services to Marine hospitals on a reimbursable basis.

In recognition of Dr. Woodworth's progress in reorganizing the Marine Hospital Service, his title was changed by law to supervising Surgeon General on March 3.
1878
The first Federal Quarantine Act was passed April 29.
On December 21, Congress appropriated funds "for investigating the origin and causes of epidemic diseases, especially yellow fever and cholera."

1879
The National Board of Health was created by law on March 3. It represented the first organized, comprehensive, national medical research effort of the Federal Government.
Dr. John B. Hamilton was appointed Surgeon General of the Marine Hospital Service, April 3.

1884
The seamen's hospital tax was abolished on July 1. The cost of maintaining Marine hospitals was paid out of a tonnage tax, which continued until 1906.

1887
A bacteriological laboratory, known as the Laboratory of Hygiene, was established under Dr. Joseph J. Kinyoun at the Marine Hospital, Staten Island, N.Y., in August, for research on cholera and other infectious diseases (renamed Hygienic Laboratory in 1891.)

1889
The commissioned corps was authorized on January 4 establishing by law the policy of a mobile corps subject to duty anywhere upon assignment.

1890
Congress gave the Marine Hospital Service interstate quarantine authority on March 27.

1891
The Hygienic Laboratory moved from Staten Island, N.Y., to the Butler Building, Service Headquarters, Washington, D.C., in June.
Dr. Walter Wyman was appointed Surgeon General of the Marine Hospital Service on June 1.

1893
A new Quarantine Act, passed February 15, strengthened the Quarantine Act of 1878 and repealed the act establishing the National Board of Health.

1899
The Marine Hospital Service was directed by Congress on March 2 to investigate leprosy in the United States.
Dr. Milton J. Rosenau succeeded Dr. Kinyoun as director of the Hygienic Laboratory on May 1.

1900

1902
The earliest studies of Rocky Mountain spotted fever took place in Montana.
A bill approved July 1 changed the name of the Marine Hospital Service to the Public Health and Marine Hospital Service and established an advisory board for the Hygienic Laboratory. It later became the National Advisory Health Council.
The 57th Congress enacted Public Law 244 to regulate the shipment of biologics. The technical responsibilities of the program were assigned to the Hygienic Laboratory.
The Advisory Board for the Biologics Control Division was established July 1.
The Pan American Sanitary Bureau was established December 2. The Public Health and Marine Hospital Service began international health cooperation.

1904
The Hygienic Laboratory moved to a new building on a 5-acre tract at 25th and E Streets NW, Washington, D.C., on March 16.
1906

Medical care for merchant seamen and other beneficiaries of the Public Health and Marine Hospital Service began to be supported by direct congressional appropriations, with the repeal of the tonnage tax on June 30.

1909

Dr. John F. Anderson was appointed Hygienic Laboratory director on October 1.

1910

1912

Dr. Rupert Blue was appointed Surgeon General of the Public Health and Marine Hospital Service on January 13.

The name Public Health and Marine Hospital Service was changed to Public Health Service (PHS) on August 14, and the research program was expanded to include other-than-communicable diseases field investigations, navigable stream pollution, and information dissemination.

1914

Dr. Joseph Goldberger announced his views of pellagra as a dietary deficiency, emphasizing the importance of dietary deficiency diseases.

1915

Dr. George W. McCoy was appointed Hygienic Laboratory director on November 20.

1918

The Chamberlain-Kahn Act, passed July 9, provided for the study of venereal diseases. The PHS made grants to 25 institutions, establishing a precedent for the Federal Government to seek assistance of scientists through grants.

The PHS reserve corps was established by law on October 27, during the influenza pandemic, as a means of coping with the emergencies.

1920

1920

Dr. Hugh Smith Cumming was appointed PHS Surgeon General on March 3.

1921

The Rocky Mountain Spotted Fever Laboratory was established in a former school building in Hamilton, Mont., on September 20 as a recognized PHS field station.

1922

The Library of the Office of the Surgeon General (Army) was renamed the Army Medical Library in January.

A Special Cancer Investigations Laboratory was established by PHS investigators at Harvard Medical School on August 1.

1929

On January 19, the Narcotics Control Act was passed, authorizing construction of two hospitals for drug addicts, and creation of a PHS Narcotics Division.

1930

1930

On April 9, the Advisory Board for the Hygienic Laboratory became the National Advisory Health Council.

On May 26 the Ransdell Act redesignated the Hygienic Laboratory as the National Institute of Health, authorizing $750,000 for construction of two buildings for NIH, and creating a system of fellowships.

On June 14, Public Law 357 authorized creation of a separate Bureau of Narcotics in the Treasury Department and changed the PHS Narcotics Division to the Division of Mental Hygiene. The law gave the Surgeon General authority to investigate the causes, treatment, and prevention of mental and nervous diseases.
1935
A narcotic "farm" at Lexington, Ky., was completed and opened on May 29.
On August 10, Mr. and Mrs. Luke I. Wilson made a gift of 45 acres of their estate "Tree Tops" for use of the National Institute of Health in Bethesda, MD.
Title VI of the Social Security Act was passed August 14 authorizing the expenditure of up to $2 million on health grants to the states for "investigation of disease and problems of sanitation."

1936
Dr. Thomas Parran was appointed PHS Surgeon General on April 6.

1937
The Rocky Mountain Laboratory became part of the National Institute of Health in February, and was administratively made part of the Division of Infectious Diseases.
Dr. Lewis R. Thompson was appointed director of the National Institute of Health on February 1.
With the reorganization of the National Institute of Health into eight divisions, the biologics control program, previously the responsibility of the Division of Pathology and Bacteriology, NIH, was assigned to a newly established Division of Biologics Control (redesignated Biologics Control Laboratory, 1944).
The National Cancer Institute Act was signed on July 23.

1938
The National Advisory Cancer Council recommended approval of the first awards for fellowships in cancer research on January 3.
The cornerstone for Building 1 was laid June 30.
Congress approved construction of new, larger laboratory facilities, and NIH moved to Bethesda, MD., in July.
The narcotics hospital at Fort Worth, Tex., was dedicated on October 28.

1939
Under a Reorganization Act dated April 3, the PHS was transferred from the Treasury Department to the Federal Security Agency.

1940
1940
Mrs. Luke I. Wilson made a fourth gift, 11.6 acres of land, to NIH on September 27.
President Franklin D. Roosevelt dedicated the buildings and the grounds of the National Institute of Health on October 31.

1942
Dr. Rolla Eugene Dyer was appointed director of the National Institute of Health on February 1.
A final gift of land was made by Mrs. Luke I. Wilson on March 17 bringing the total to 92 acres. This was the nucleus of the present 306.4-acre reservation. Additional land was acquired through a series of purchases.

1943
NIH was given bureau status in the PHS on November 11.

1944
The PHS act was approved on July 1, consolidating and revising existing public health legislation, and giving NIH the legislative basis for its postwar program, with general authority to conduct research. Under this act NCI became a division of NIH.
1946
The Research Grants Office was created at NIH in January to administer the Office of Scientific Research and Development projects transferred to the PHS at the end of World War II and to operate a program of extramural research grants and fellowship awards.

The National Mental Health Act was passed July 3.

On August 12, the Research Grants Office became the Research Grants Division (later renamed Division of Research Grants). The division was instructed by the National Advisory Health Council to establish study sections for scientific and technical review of research grant applications, and to explore neglected areas of research in the health sciences.

The Hospital Survey and Construction Act, introduced by Senators Lister Hill and Harold H. Burton, was passed on August 13, authorizing the Hill- Burton program.

1948
Dr. Leonard A. Scheele was appointed PHS Surgeon General on April 6.

On June 16 the National Heart Act was signed. It authorized the National Heart Institute and changed the name of the National Institute of Health to National Institutes of Health.

The National Dental Research Act, passed June 24, authorized the National Institute of Dental Research.

The National Heart Institute was established August 1.

The National Institute of Dental Research was established September 16.

Construction of the Clinical Center was started in November.

The National Microbiological Institute and the Experimental Biology and Medicine Institute were established on November 1.

The Rocky Mountain Laboratory and Biologics Control Laboratory became two of the four components of the National Microbiological Institute on November 1.

1949
The purchase of 115.8 acres from the Town & Country Golf Club, Inc., for $600,000 was concluded February 11.

The purchase of 47.9 acres of land from Mr. and Mrs. G. Freeland Peter for $505,000 was concluded on February 14.

The National Institute of Mental Health was established on April 15, with the abolishment of the Division of Mental Hygiene.

The first issue of The NIH Record was published May 20.

The purchase of 50.2 acres of land from the Sisters of the Visitation for $173,058 was concluded on June 28.

Dr. Frank B. Rogers became director of the Army Medical Library in October.

1950

The Omnibus Medical Research Act, signed August 15, authorized the National Institute of Neurological Diseases and Blindness and the National Institute of Arthritis and Metabolic Diseases, the latter absorbing the Experimental Biology and Medicine Institute. The act also gave the Surgeon General authority to establish new institutes.

Dr. William H. Sebrell, Jr. was appointed NIH director on October 1.

The National Institute of Neurological Diseases and Blindness and the National Institute of Arthritis and Metabolic Diseases were established November 22.

1951

The first R. E. Dyer Lecture was given by Dr. George W. Beadle, California Institute of Technology, June 21.

President Harry S. Truman laid the Clinical Center cornerstone on June 22.

1952

The Army Medical Library was renamed Armed Forces Medical Library in April.
1953
The first NIH Lecture was given on January 21 by Dr. Severo Ochoa of New York University College of Medicine.
PHS became part of the newly created Department of Health, Education, and Welfare on April 11.
The Clinical Center was dedicated on July 2, extending the clinical dimension of PHS research programs.
The first patient was admitted to the Clinical Center on July 6.

1954
A central data processing facility was established in the Office of the Director, NIH.
The NIH Graduate School Program began on September 27.

1955
The biologics control function was placed in the newly formed Division of Biologics Standards in June. The Division of Research Services and Division of Business Operations were also formed.
The Cancer Chemotherapy National Service Center was established April 1 to coordinate the first national cancer chemotherapy program.
The Mental Health Study Act was passed July 28.
Dr. James A. Shannon was appointed NIH director on August 1.
The National Microbiological Institute became the National Institute of Allergy and Infectious Diseases (NIAID) by order of the Surgeon General on December 29.
The Biologics Control Laboratory was detached from the institute and expanded to division status within NIH.

1956
In January the biometric facility became the Biometrics Branch in the new Division of Research Services.
Dr. Leroy E. Burney was appointed PHS Surgeon General August 8.
The Armed Forces Medical Library was designated the National Library of Medicine (NLM) and placed under PHS October 1.

1957
The Center for Aging Research was established November 27 as the focal center for NIH extramural activities in gerontology.

1958
On July 16 the Division of General Medical Sciences was established by order of the Surgeon General, extending research into noncategorical areas covered until that time by the Division of Research Grants.
The Center for Aging Research was transferred from the National Heart Institute to the Division of General Medical Sciences on November 4.

1959
The Office of Administrative Management was formed July 15, consolidating the Division of Business Operations and other managerial responsibilities.
Congress appropriated $2 million for the establishment of one or two private research centers on August 19.

1960

1960
On March 8 the Surgeon General approved establishment of a Computation and Data Processing Branch in the Division of Research Services.
NIH acquired 513 acres of farmland near Poolesville, MD., on May 6. This land became the site of the NIH Animal Center.
The International Health Research Act was passed July 12, extending NIH international programs.

1961
The Surgeon General established the Center for Research in Child Health in the Division of General Medical Sciences on February 17.
Dr. Luther L. Terry was appointed PHS Surgeon General March 24.

On May 26, DHEW Secretary Abraham A. Ribicoff dedicated the new NIDR building.

The first Jules Freund Lecture was given by Dr. Merrill W. Chase of the Rockefeller Institute on November 15.

The NIH European Office was established in Paris, France, on December 18.

1962

The NIH Latin American Office was established in Rio de Janeiro, Brazil, July 1.

The Division of Research Facilities and Resources was established July 15.

Public Law 87-838, passed October 17, authorized the National Institute of Child Health and Human Development and the National Institute of General Medical Sciences.

Five acres of land for a Gerontology Research Center were donated by the City of Baltimore in December.

1963

The NIH Pacific Office was established in Tokyo, Japan, on January 1.

The National Institute of Child Health and Human Development and the National Institute of General Medical Sciences were established on January 30.

The Center for Research in Child Health and the Center for Research in Aging (established in 1956) were transferred from NIGMS to NICHD.

The surgical wing for the Clinical Center was dedicated September 5.

The first NIH International Lecture was given October 31 by Dr. Walsh McDermott of Cornell University Medical College.

1964

The Medical Literature Analysis and Retrieval System (MEDLARS) became operational at the NLM in January.

The Division of Computer Research and Technology was established on April 16.

On September 19 Congress authorized planning funds for a central environmental health research facility.

A special virus-leukemia program was initiated under a special appropriation, included in the FY 1965 appropriation signed into law on September 19.

1965

On January 7, the Surgeon General announced that the National Environmental Health Sciences Center would be located in Research Triangle Park, N.C.

The NIH Animal Center, Poolesville, MD., officially opened May 27 with 2 days of orientation for NIH employees, area residents and the press after completion of the first of three phases of an $18 million construction program.

NIH received a $20,250,000 supplemental appropriation on August 31 to intensify and expand support of research in heart disease, cancer, stroke and related diseases.

Dr. William H. Stewart, appointed PHS Surgeon General September 24, took office on October 2.

A reorganization of the DHEW provided for an expansion of the secretary's office with the creation of three new assistant secretaries, including an assistant secretary for health and scientific affairs.

Dr. Philip R. Lee was appointed to the new position of assistant secretary for health and scientific affairs on November 2.

1966

The Division of Regional Medical Programs was created on February 1 to administer grants under the Heart Disease, Cancer and Stroke Amendments of 1965. Dr. Robert Q. Marston was appointed NIH associate director for regional medical programs and chief of the division.

At a White House meeting June 27, the NIH director and institute directors discussed with the President how the benefits of research findings in health could be brought more rapidly to all the people. Later in the year, a report to the President described current NIH research efforts on the major U.S. disease problems and set forth the status of those problems, the nature of present and planned investigative efforts and the problems of and opportunities for further research.

A Division of Environmental Health Sciences was established in NIH November 1 to conduct, foster and coordinate research on the biological, chemical, and physical effects of environmental agents. Dr. Paul Kotin, scientific director for etiology, NCI, was named director of the new division.
An advisory committee to the NIH director was appointed on November 9 to provide advice on the further development of NIH research and related programs.

1967

The National Institute of Mental Health was separated from NIH and raised to bureau status in PHS by a reorganization that became effective January 1. NIMH's Division of Clinical, Behavioral and Biological Research, within the mental health Intramural Research Program, comprising activities conducted in the Clinical Center and other NIH facilities, continued here under an agreement for joint administration between the two companion bureaus. The Toxicology Information Program was established at NLM, January 1, in response to recommendations of the President's Science Advisory Committee. The program includes the entire range of chemical effects on living organisms.

The PHS Audiovisual Facility, renamed the National Medical Audiovisual Center, became an NLM component July 1.

On September 26, the deed for 509.25 acres of Research Triangle Park, N.C., to serve as a permanent site for the Division of Environmental Health Sciences, was presented to the Surgeon General.

1968

Establishment of the John E. Fogarty International Center for Advanced Study in the Health Sciences (FIC) was given departmental approval February 26. The center became operational on July 1, at which time the NIH Office of International Research was abolished and certain of its functions were transferred to FIC and NIAID.

Under a reorganization of health activities announced on April 1, NIH assumed status as a new operating agency within the department, with the NIH director reporting directly to the assistant secretary for health and scientific Affairs. Under the reorganization, the Bureau of Health Manpower and the National Library of Medicine became components of NIH.

On June 15 the four-story $7.5 million Gerontology Research Center building, located at and operated in cooperation with Baltimore City Hospitals, was officially opened.

A proposed facility to house the biomedical communications network was designated the Lister Hill National Center for Biomedical Communications by passage of P.L. 90-456 on August 3.

Established by the DHEW secretary on August 9, the Center for Population Research conducts a contract and grant program in population and reproduction research. The center was designated by the President as the primary Federal agency responsible for population research and training.

On August 16 the National Eye Institute was created to build an enlarged program based on blindness research formerly conducted in the National Institute of Neurological Diseases and Blindness. The legislation also changed the NINDB name to the National Institute of Neurological Diseases.

Dr. Robert Q. Marston was sworn in as NIH director on August 29.

A Nobel Prize in Physiology or Medicine was awarded on October 16 to Dr. Marshall W. Nirenberg, chief of NIH's Laboratory of Biochemical Genetics, for discovering the key to deciphering the genetic code. He was the first NIH Nobel laureate, and the first Federal employee to receive a Nobel Prize.

On October 24 the President signed into law (P.L. 90-639) legislation changing the name of the NIND to the National Institute of Neurological Diseases and Stroke.

The National Eye Institute was established on December 26.

1969

A further reorganization of the NIH internal structure announced January 4 renamed the Bureau of Health Manpower as the Bureau of Health Professions Education and Manpower Training and expanded it to include seven divisions, one of which was the Division of Research Resources (DRR).

The Division of Environmental Health Sciences was elevated to institute status on January 12, thus becoming the 10th NIH institute.

Dr. Roger O. Egeberg was named DHEW assistant secretary for health and scientific affairs on July 14, succeeding Dr. Lee.

On November 10, the DHEW secretary redesignated the National Heart Institute as the National Heart and Lung Institute (NHLI).

1970

A reorganization of the Bureau of Health Professions Education and Manpower Training renamed it the Bureau of Health Manpower Education on September 18. DRR was separated from the bureau and became a division within NIH.

1971

Dr. Merlin K. DuVal was appointed DHEW assistant secretary for health and scientific affairs on July 1, succeeding Dr. Egeberg.

The White House Conference on Aging recommended creating a separate National Institute on Aging on December 2.
On December 23 the President signed the National Cancer Act of 1971 initiating a National Cancer Program, establishing the President's Cancer Panel, a National Cancer Advisory Board and 15 new research, training and demonstration cancer centers.

1972

The National Institute of Arthritis and Metabolic Diseases was renamed the National Institute of Arthritis, Metabolism, and Digestive Diseases on May 19. On July 1, DBS transferred from NIH and officially became a sixth bureau, the Bureau of Biologics in the Food and Drug Administration. The bureau continues to use NIH facilities and buildings.

The DHEW secretary approved a reorganization of NHLI on July 14, elevating the institute to bureau status within NIH. A bureau-level organization was established for the National Cancer Institute on July 27.

On October 25 Public Law 92-564 established a temporary National Commission on Multiple Sclerosis (supported by NINDS).

Dr. Christian B. Anfinsen, NIAMDD, won the Nobel Prize in Chemistry for his work on ribonuclease.

1973

Dr. Charles C. Edwards was appointed DHEW assistant secretary for health on April 18, succeeding Dr. DuVal.

Dr. Robert S. Stone was sworn in as the 10th NIH director on May 29.

The Bureau of Health Manpower Education was transferred from NIH to the new Health Resources Administration on July 1 and renamed the Bureau of Health Resources Development.

The National Institute of Mental Health rejoined the National Institutes of Health on July 1. On September 25, NIMH became part of the new Alcoholism, Drug Abuse and Mental Health Administration.

1974

The Research on Aging Act of 1974, creating the National Institute on Aging, was signed into law on May 31.

On July 23, the National Cancer Act Amendments of 1974 were signed by the President to improve the National Cancer Program. It also established a President’s Biomedical Research Panel.

The National Institute on Aging was established on October 7.

The Interagency Primate Steering Committee was established by the DHEW assistant secretary for health with NIH as the lead agency.

Institutional Relations Branch was transferred on October 27 from DRG to the immediate Office of the Director, NIH, and renamed the Office for Protection From Research Risks.

1975

On March 13 the National Institute of Neurological Diseases and Stroke was renamed the National Institute of Neurological and Communicative Disorders and Stroke.

Dr. Theodore Cooper was appointed DHEW assistant secretary for health on July 1, succeeding Dr. Edwards.

Dr. Donald S. Fredrickson was sworn in as the 11th NIH director on July 1.

The Adult Development and Aging Branch and the Gerontology Research Center were separated from NICHD to become the core of the National Institute on Aging, also on July 1.

1976

On June 25, the National Heart and Lung Institute was renamed the National Heart, Lung, and Blood Institute.

Dr. D. Carleton Gajdusek, NINCDS, shared the Nobel Prize in Physiology or Medicine with Dr. Baruch Blumberg, Institute for Cancer Research. Dr. Gajdusek was honored for his research on kuru and Dr. Blumberg for his work on the Australia antigen at the National Institute of Arthritis and Metabolic Diseases (1957-1964).

1977

Construction of the Ambulatory Care Research Facility was started in April.

On July 13, Dr. Julius B. Richmond took the oath of office as DHEW assistant secretary for health and Surgeon General, becoming the first person to hold both offices simultaneously.
1978

On November 15 the DHEW secretary announced the establishment of the National Toxicology Program under the direction of NIEHS.

1979

Dr. Hans J. Muller Eberhard, Scripps Clinic and Research Foundation, delivered the first Kinyoun Lecture on April 24.

A protocol of cooperation in the exchange of information on medicine and public health between the United States and China was signed on June 22 in Beijing's historic Great Hall. The DHEW secretary signed on behalf of the United States.

On July 18 NCI and the National Naval Medical Center, Bethesda, MD., agreed to cooperate in a cancer treatment research program.

1980

1980

DHEW became the Department of Health and Human Services (DHHS) on May 14.

A separate Department of Education was established.

On May 22, the Lister Hill Center for Biomedical Communications was dedicated as part of NLM.

1981

On May 14 Dr. Edward N. Brandt, Jr., was sworn in as assistant secretary for health.

The National Institute of Arthritis, Metabolic, and Digestive Diseases was renamed the National Institute of Arthritis, Diabetes, and Digestive and Kidney diseases on June 23.

On June 30 Dr. Fredrickson stepped down as NIH director. Dr. Thomas E. Malone was appointed acting director.

The Ambulatory Care Research Facility was officially dedicated on October 22. The research hospital was renamed the Warren Grant Magnuson Clinical Center in honor of the former chairman of the Senate Committee on Appropriations. Sen. Magnuson was involved in support of biomedical research at NIH since 1937.

Dr. C. Everett Koop became PHS Surgeon General on November 16.

1982

On April 22 NIADDK was converted to bureau status, joining NCI, NHLBI, and NLM. Dr. James B. Wyngaarden, chairman of the Duke University department of medicine, was appointed NIH director on April 29.

The National Institute of Child Health and Human Development marked its 20th anniversary on September 20.

NIHMS celebrated its 20th anniversary by establishing the DeWitt Stetten, Jr., Lectureship. Dr. David S. Hogness, Stanford University, gave the first lecture, October 13.

The National Institute on Aging opened its first on-campus research unit in the NIH Clinical Center.

The NIEHS facility in Research Triangle Park, N.C., was dedicated on November 15.

Lasker Foundation Awards were presented on November 17 to three NIH scientists: Dr. Elizabeth Neufeld, NIADDK; Dr. Roscoe O. Brady, NINDS; and Dr. Robert C. Gallo, NCI.

1983

On January 18, Building 1 was officially named the James A. Shannon Building in honor of the former NIH director (1955-1968).

The first multidisciplinary pain clinic in the United States devoted exclusively to research was opened in the Clinical Center March 21 by NIDR.

NCI dedicated its R.A. Bloch International Cancer Information Center on October 2. The building houses the institute's information programs that serve health professionals and scientists.

In December, the Clinical Center celebrated its 30th anniversary of operation.

1984

NIH purchased the Convent of the Sisters of the Visitation of Washington along with about 11 acres of land for $4.5 million.
In May NCI scientists headed by Dr. Robert C. Gallo, Jr., uncovered strong evidence that variants of a human cancer virus called HTLV-III are the primary cause of acquired immunodeficiency syndrome (AIDS).

DCRT celebrated its 20th anniversary in May.

NIH and Howard Hughes Medical Institute launched a multimillion dollar cooperative program in August to help increase the vigor of American biomedical research and continue the flow of new doctors into research areas.

The former Convent was dedicated September 19 as the Mary Woodard Lasker Center for Health Research and Education.

1985

NIH and the Howard Hughes Medical Institute chose the first 25 HHMI-NIH research scholars in June.

In July the NIA celebrated its 10th anniversary.

1986

In May the National Institute of Arthritis and Musculoskeletal and Skin Diseases became a separate institute separated from its parent NIADDK - now called the National Institute of Diabetes and Digestive and Kidney Diseases. Also created was the National Center for Nursing Research.

NIH held the First Intramural Research Day on September 25 featuring symposia and poster sessions.

In June NIAID funded 14 centers to evaluate experimental drugs in the treatment of AIDS.

NIH opened its year-long centennial celebration—A Century of Science for Health—on October 16.

1987

NIH scheduled monthly events, hosted by individual components throughout the year, to commemorate its 100th anniversary.

NIAID awarded contracts to five medical centers to establish AIDS treatment evaluation units.

NIH celebrated its 20th anniversary, while NIGMS and DRR marked their 25th.

Fifty-six promising science students—one from each state and U.S. possession—were honored by NIH as centennial scholars.

On July 23 President Reagan named a 13-member Commission on the Human Immunodeficiency Virus Epidemic, which held its first meeting following the announcement.

NIH became a smoke-free agency on September 1, banning smoking in all buildings.

Hundreds of NIH alumni from the United States and abroad returned to the campus on October 15-16 to help close out the year-long celebration of the NIH centennial.

1988

Recognizing the importance of computerized information processing methods for the conduct of biomedical research, Congress establishes the National Center for Biotechnology Information (NCBI) as a division of the National Library of Medicine on November 4.

NIH was honored by Spain with the presentation of the Grand Cross of the Civil Order of Health.

The NICHD celebrated its 25th anniversary and NIAID and NIDR marked their 40th.

The Children's Inn at NIH, a temporary home away from home for NIH pediatric patients, was dedicated. A gift of $2.5 million from Merck and Co., Inc. was donated toward the construction of the building.

"Sky Horizon," a sculpture created by Louise Nevelson, was provided to the NIH on loan by Edwin C. Whitehead, founder of the Whitehead Institute of Biomedical Research.

Officials from NICHD, NINDS, and NIMH broke ground for a facility they will share—Building 49, the Child Health and Neurosciences Building.

November marked the establishment of the National Institute on Deafness and Other Communication Disorders. The parent institute was renamed the National Institute of Neurological Disorders and Stroke.

1989

On May 10, Building 31 was named the Claude Denson Pepper Bldg. to honor NIH's "legislative father."

The NIH Record marked its 40th year of publication in May.
On May 22, NIH conducted its first gene transfer in humans. A cancer patient was infused with tumor-infiltrating lymphocytes (TIL) that had been altered by insertion of a gene. This allowed scientists to track the special cancer-fighting cells in the body to increase the understanding of TIL therapy.

1990

The National Center for Human Genome Research was established in January.

DRR and DRS merged in March and named the National Center for Research Resources.

On June 21 the Children's Inn at NIH opened its doors to pediatric patients and their families. The President and Mrs. Bush attended the ceremonies.

The Recombinant DNA Advisory Committee approved the first experiments involving transfer of human genes for therapeutic purposes on July 31. The treatment was initiated on September 14 in a 4-year-old girl with adenosine deaminase deficiency.

The National Institute of Neurological Disorders and Stroke and the National Institute of Diabetes and Digestive and Kidney Diseases marked their 40th anniversaries.

It was announced in September that the gene that caused osteoarthritis was isolated by scientists supported by the National Institute of Arthritis and Musculoskeletal Diseases.

The Office of Research on Women's Health was established to strengthen NIH's efforts to improve the prevention, diagnosis and treatment of illness in women and to enhance research related to diseases and conditions that affect women.

1991

On January 29, NIH scientists treated the first cancer patients with human gene therapy. Two patients received transfusions of special cancer-killing cells removed from their own tumors and armed in the laboratory with a gene capable of producing a potent antitumor toxin, tumor necrosis factor.

Dr. Bernadine Healy was confirmed as NIH's 13th director on March 21. She was the first woman appointed to this post.

In August the National Center for Human Genome Research announced the start of a new, unified effort to develop a "framework" map of the human genome—expected to take 2 to 3 years to complete.

1992

The National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism, and National Institute of Mental Health were transferred from the Alcohol, Drug Abuse, and Mental Health Administration to become part of the NIH.

Two components—NICHD and NIGMS—celebrated their 30th anniversaries on September 21 and October 17, respectively.

1993

NIH Director Bernadine Healy stepped down to return to the Cleveland Clinic Foundation.

The Clinical Center celebrated its 40th anniversary.

Sixteen university medical programs were launch sites for the 15-year, $625 million Women's Health Initiative. About 3,000 women will be enrolled at each center to investigate women's most common causes of death and disability.

Dr. Harold Varmus was appointed NIH's 14th Director.

FIC noted its 25th anniversary.

The National Center for Nursing Research became the 16th Institute.

1994

Former director, Dr. James Shannon, died.

NHLBI scientists for the first time successfully transferred a normal cystic fibrosis gene into the cells lining a CF patient's lungs.

Researchers at NIEHS isolated the BRCA1 gene—responsible for about 5 percent of all breast cancers and 25 percent in women under age 30.

Dr. Martin Rodbell, NIEHS, shared the Nobel Prize in physiology or medicine for research on G proteins, key components of the communication system that regulates cellular activity.
1995

NLM unveiled the “Visible Man,” a detailed atlas of human anatomy created from thousands of images of a human body collected by radiographic and photographic techniques.

NIAAA celebrated its 25th anniversary.

1996

The first multicenter trial of bone marrow transplantation in children with sickle cell disease demonstrated that the procedure can provide a cure for young patients that have a matched sibling, according to NHLBI-supported scientists.

DRG celebrated its 50th anniversary and NIEHS noted its 30th.

1997

Researchers with NHGRI completed a map of chromosome 7, an important milestone within the Human Genome Project.

DRG was renamed the Center for Scientific Review and DCRT became the Center for Information Technology.

Vice President Al Gore performed an “inaugural search,” opening up free access on the world wide web to NLM’s MEDLINE.

Results from the NIH-supported Dietary and Systolic Hypertension trial indicated that blood pressure can be swiftly and significantly lowered through a diet low in fat and high in vegetables, fruits, and low-fat dairy foods.

A team led by NHGRI scientists identified a defective gene that causes some inherited cases of Parkinson’s disease.

Results from an NIH trial showed that a low-dose diuretic cuts by half the chance that an older person with high systolic blood pressure will develop heart failure. In those who had already had a heart attack, their chance of developing heart failure dropped by 80 percent.

A team led by NIH-funded scientists determined the complete genome sequence of the E. coli bacterium, a laboratory workhorse. This accomplishment gives researchers a powerful new tool for understanding fundamental questions of biological evolution and function.

On November 4, Vice President Al Gore and Senator Mark O. Hatfield attended the groundbreaking ceremonies for the new Clinical Center, which will be called the Mark O. Hatfield Clinical Research Center.

1998

Building 20, NIH’s apartment building, was carefully demolished to make way for the new Mark O. Hatfield Clinical Research Center.

NICHD’s new zebrafish facility opened. Zebrafish have become the mainstay of developmental biologists for studying the development of the vascular system and central nervous system, as well as the functional genomics of the zebrafish.

A large prevention trial conducted by NCI showed that long-term use of a moderate-dose vitamin E supplement substantially reduced prostate cancer incidence and deaths in male smokers.

In a cooperative endeavor (Neurolab) between NASA, NIH and others, astronauts on Space Shuttle Columbia conducted research on how the neurological system responds to the challenges of space flight.

Results from a NCI-sponsored clinical trial showed that women at high risk of developing breast cancer who took the drug tamoxifen had 49 percent fewer cases of breast cancer than those who didn’t. Tamoxifen was hailed as the first drug to prevent breast cancer in women at high risk for the disease.

The new NIH Intramural Sequencing Center opened in Gaithersburg. NISC is a 14-institute consortium that is dedicated to large-scale sequencing of human and animal DNA.

NIDR celebrated its 50th anniversary, with a name change to the National Institute of Dental and Craniofacial Research.

Building 16, known as the Stone House, was renamed the “Lawton Chiles International House”; it will be the locus for international activities supported by FIC and other NIH and DHHS components.

Between 1992 and 1996, the rate of Sudden Infant Death Syndrome (SIDS) dropped by 38 percent, much of that likely being due to a 66 percent decrease during the same period in the number of U.S. infants being placed to sleep on their stomachs. A national Back to Sleep Campaign—encouraging parents to put their infants to sleep on their backs - was launched in 1994 by NICHD, in partnership with HH5 and other organizations.

The complete sequence of two bacteria that are among the major causes of sexually transmitted diseases worldwide—Treponema pallidum, responsible for syphilis, and Chlamydia trachomatis, responsible for chlamydial infections—were obtained by two separate teams of scientists supported by NIAID and others.

NIDCD celebrated its 10th anniversary.
Senator John Glenn and six other astronauts spent nine days in space aboard NASA's Space Shuttle Discovery conducting about 83 scientific projects, the most research-intensive space journey yet. Glenn, NASA and others worked with NIA to develop the projects.

NIAID celebrated its 50th anniversary.

NHLBI's Framingham Heart Study celebrated its 50th anniversary.

An international team funded by NHGRI and others obtained the complete sequence of the 97-million-base genome of the roundworm, Caenorhabditis elegans. This marks the first time that scientists have spelled out the instructions for a complete animal which, like humans, has a nervous system, digests food, reproduces, and gets old, making it a very important organism in which to carry out studies that parallel human biology.

1999

The new South Entry to the Clinical Center opened, thus facilitating construction on the Mark O. Hatfield Clinical Research Center on the north face of Building 10.

A team of investigators led by an NIAID grantee discovered that a subspecies of chimpanzees native to west Africa are the origin of HIV-1, the virus responsible for the global AIDS pandemic.

Underlying vitamin D deficiency in postmenopausal women is associated with increased risk of hip fracture, according to a study supported by NIA and NCRR.

NIDA, NIMH, and NINDS moved into the new Neuroscience Center office building on Executive Boulevard, which some have dubbed “NIH North”.

A meta-analysis study, led by an NICHD researcher, found that pregnant women infected with HIV could reduce the risk of transmitting the virus to their infants by about 50 percent if they deliver by cesarean section before they go into labor and before their membranes rupture.

NIH Director Dr. Harold Varmus convened the first meeting of the Director's Council of Public Representatives (COPR). The Council will provide advice and recommendations to, and consult with, the NIH Director regarding matters related to medical research, NIH's policies and programs, and public participation in NIH's activities. COPR was chartered in November 1998.

On June 9, President Bill Clinton unveiled the cornerstone for the new Dale and Betty Bumpers Vaccine Research Center, which initially will focus on accelerating the search for a vaccine against AIDS. Earlier, Dr. Varmus named Dr. Gary Nabel as the director of the new VRC, which currently exists as a "center without walls". The VRC is funded by NIAID and NIC and spear-headed by them and NIH's Office of AIDS Research.

NLM's MEDLINE added the 10 millionth journal citation to its database.

A joint Uganda—U.S. study, funded by NIAID, demonstrated a highly effective, affordable and practical strategy for preventing transmission of HIV from an infected mother to her newborn. A single-oral dose of the antiretroviral drug nevirapine given to the HIV-infected mother while in labor and another to her baby within three days of birth reduced the transmission rate by half compared with a similar short course of AZT.

Women with preeclampsia, a potentially fatal complication of pregnancy, were found to have an imbalance of two key chemical compounds that control blood pressure, prostacyclin and thromboxane, months before their symptoms appeared, according to NICHD scientists.

NIDA celebrated its 25th anniversary.

NIH announced its plan to establish a repository called PubMed Central for free electronic distribution of primary research reports in the life sciences. The new site would be integrated with NLM's widely used bibliographic site PubMed and is intended to be one of several repositories in an international system first proposed by NIH director Dr. Harold Varmus. PubMed Central would begin receiving, storing and distributing content—including peer-reviewed articles, preprints, and other screened reports from existing journals, new journals, and reputable scientific organizations—in January 2000.

Children born to mothers with untreated hypothyroidism during pregnancy were found to score lower on IQ tests than children of healthy mothers suggesting that early detection and treatment of hypothyroidism in pregnant women may be a critical part of prenatal care, according to a study funded by NICHD and others.

In October 1999, NIH announced a major research program involving 10 laboratories, called the Mouse Genome Sequencing Network, to map and sequence the DNA in the mouse genome.

A research effort led by NIAID scientists produced the first high-resolution genetic map of Plasmodium falciparum, the deadliest malaria parasite, which is responsible for the death of more than two million people annually.

Scientists supported by NHGRI along with groups in England and Japan completed the first sequence of a human chromosome, chromosome 22. Genes on chromosome 22 have been implicated in immune system function, congenital heart disease, and several cancers including leukemia.

The National Toxicology Program, headquartered at NIEHS, announced that Federal regulatory agencies—FDA, OSHA, EPA and CPSC—would accept, for the first time, an alternative way to test chemicals for allergic contact dermatitis that could reduce by thousands the number of guinea pigs needed for such tests.

After leading NIH for 6 years, Dr. Harold Varmus left to become the President and CEO of Memorial Sloan-Kettering Cancer Center in New York City.
2000

On January 1, Dr. Ruth Kirschstein, deputy director of NIH, became the acting director.

Scientists funded by NICHD and NIAMS, along with an NCI scientist discovered that leptin, the product of the obesity gene, acts as a bone inhibitor by telling the brain to slow down the rate of bone formation, showing for the first time that the brain has a central role in controlling bone formation and density.

A team including NCI scientists and grantees used microarray technology to show that the most common form of non-Hodgkin's lymphoma (NHL), diffuse large B-cell lymphoma, is actually two distinct diseases, thus explaining why 40 percent of patients with this NHL can be cured through chemotherapy while others succumb to the disease. This is the first demonstration of a technology that promises to revolutionize cancer diagnosis as well as many other areas of research.

The NIEHS headquarters and laboratory Building 101 in Research Triangle Park, N.C., was renamed the Rall Building in honor of former NIEHS director, Dr. David Platt Rall.

NIH launched the first phase of a consumer-friendly database, ClinicalTrials.gov, with information on more than 4,000 Federal and private medical studies involving patients and others at more than 47,000 locations nationwide. The new database may be reached at http://clinicaltrials.gov/.

NIH’s Office of Research on Minority Health and the Office of Research on Women’s Health celebrated their tenth anniversaries.

An NHLBI-supported clinical trial showed that lowering the amount of salt for those who ate a “usual” American diet as well as those following the DASH diet—rich in vegetables, fruits and low-fat dairy foods and low in saturated fat, total fat and cholesterol—lowered blood pressure correspondingly for both those with and without hypertension, including African Americans.

NIAMS and the Indian Health Service announced plans to collaborate on a new program, Native American Research Centers for Health (NARCH), designed to promote, develop and support centers that will link the Native American community with organizations that conduct health research.

The information from this project has been completely, immediately, and freely released to the world with no restrictions on its use.

Researchers supported by NIGMS demonstrated that a simple and inexpensive change in basic surgical procedures—giving patients more oxygen during and immediately after surgery—can cut the rate of wound infections in half, thus saving millions of dollars in hospital costs by helping to prevent post-surgical wound infection, nausea and vomiting.

A team of scientists funded by NIAID determined the complete sequence of the genome of the bacterium—Vibrio cholerae—that causes cholera.

2001

Grantees of NIAID and NHGRI and others sequenced the entire genome of a deadly strain of E. coli, a bacterium that is emerging as a major public health threat through contaminated ground beef, milk, fruits and vegetables. By comparing the sequence of this strain with that of harmless strains of E. coli, scientists may learn why only some forms cause disease and then find ways to prevent harmful strains from causing disease.

A team of NHGRI and NCI scientists and others developed a new genetic test that can distinguish between two types of hereditary breast cancer—caused by BRCA1 and BRCA2 mutations—and sporadic breast cancer. The new approach uses microarray (gene chip) technology to analyze the activity of more than 5300 genes at once. This advance should ultimately help physicians diagnose the cause of a woman’s breast cancer and guide decisions about the most effective treatments.

A team composed of scientists from NHGRI and NINDS, grantees of NHLBI and NIA, and others demonstrated that adult stem cells isolated from mouse bone marrow could become functioning heart muscle cells when injected into a damaged mouse heart. The new cells at least partially restored the heart’s ability to pump blood.

NIH’s Office of Research on Minority Health and the Office of Research on Women’s Health celebrated their tenth anniversaries.

NIH's Office of Research on Minority Health and the Office of Research on Women's Health celebrated their tenth anniversaries.
Scientists from NICHD developed and, along with an NIDDK scientist and others, tested the first vaccine capable of protecting children ages 2 to 5 against typhoid fever. Seemingly the most effective typhoid vaccine ever developed, it is also virtually free of side effects. About 16 million people worldwide develop typhoid each year, and 600,000 die from it, mainly in developing countries without adequate sewage and sanitation.

Under a CRADA with the drug company Novartis, NCI scientists found that a new drug known as Gleevec was effective against chronic myelogenous leukemia (CML) in patients for whom standard treatments had failed. (CML is a disease in which too many white blood cells are made in the bone marrow, the spongy tissue inside the large bones in the body,) NCI funded the Iouri's share of the basic research that led to the discovery and development by Novartis of Gleevec, the first anti-cancer drug specifically developed to target the molecular problem that causes a particular type of cancer.

NHGRI scientists and others developed a method that combined microarray (gene chip) technology with a form of artificial intelligence. This enabled them to tell the difference between four childhood cancers that often look alike—neuroblastoma, Ewing's sarcoma, non-Hodgkin lymphoma (Burkitt's lymphoma) and rhabdomyosarcoma. Because the treatments for these tumors are quite different, an accurate diagnosis can be critical for a child's survival. This study should help lead to the discovery of genes that are altered in these tumors and ultimately to the development of effective new treatments.

Grantees of NHLBI and NIA found that human heart muscle cells can regenerate after a heart attack. This finding opens up the possibility of repairing heart muscle damage after a heart attack.

Animal studies by NIDA researchers found that craving for cocaine seems to increase, rather than decrease, in the days and months after drug use has stopped. This phenomenon helps explain why addiction is a chronic, relapsing disease.

People at high risk for type 2 diabetes can sharply lower their chances of getting the disease by losing weight (5 percent to 7 percent of their body weight) and by getting 30 minutes of walking or other moderate exercise every day, according to the findings of a clinical trial sponsored by NIDDK.

On August 9, President Bush announced that Federal funds could be used to support research using existing lines of human embryonic stem cells that meet certain criteria. NIH then developed a registry of the known human embryonic stem cell lines so researchers could identify in their applications for funding which sources of stem cells they plan to use.

An NEI-sponsored clinical trial showed that people at high risk of developing advanced stages of age-related macular degeneration (AMD) significantly lowered that risk by taking a high-dose combination of zinc and the antioxidants vitamin C, vitamin E and beta-carotene. These nutrients are the first effective treatment to slow the progression of AMD, a leading cause of visual impairment and blindness in Americans 65 years of age and older.

2002

NCRR-supported scientists were part of a team that cloned the world's first "knockout" pigs—ones with a particular gene removed. The gene they removed was for a molecule on the surface of the pig cells that the human immune system recognizes and attacks, leading to the failure of transplanted tissues or organs.

A team of NICHD and other scientists developed the first vaccine against Staphylococcus aureus, a major cause of infection and death among hospital patients.

People with elevated levels of homocysteine in the blood had nearly double the risk of Alzheimer's disease (AD), according to a team of scientists supported by NIA and NIINDS. The findings, in a group of participants in NHLBI's long-running Framingham Study, are the first to tie homocysteine levels measured several years before with a later diagnosis of AD and the other dementias, providing some of the most powerful evidence yet of an association between high plasma homocysteine and later significant memory loss.

NIAID released its Counter-Bioterrorism Research Agenda, a document describing an accelerated research plan for the most threatening agents of bioterrorism. The agenda outlines the research NIAID will undertake to help protect civilian populations from diseases such as smallpox, anthrax and plague should those who wish to do harm unleash them intentionally.

Results of an NIAID study indicate that the existing U.S. supply of smallpox vaccine—15.4 million doses—could successfully be diluted up to five times and retain its potency, effectively expanding the number of individuals it could protect from the contagious disease. The success of this study puts us one step closer to the goal of having enough vaccine for every American if needed to respond to a potential outbreak.

Dr. Elias Zerhouni became the 15th director of the National Institutes of Health.

The International Mouse Genome Sequencing Consortium, jointly funded by NHGRI and several NIH institutes along with the Wellcome Trust in the United Kingdom, announced that it had assembled and deposited into public databases an advanced draft sequence of the mouse genome, the genetic blueprint for the most important animal model in biomedical research. The sequence is freely available on the Internet.

Dr. Roderic I. Pettigrew was named the first director of NIH's new National Institute of Biomedical Imaging and Bioengineering.

Researchers used whole-genome sequencing technology and computational methods to genetically compare two important isolates of the anthrax bacterium; the well-known Ames strain and an isolate from the 2001 Florida anthrax attacks. These techniques will enable researchers to more accurately trace the origin of individual bacterial strains, determine if those strains have been genetically modified, and assess differences in their ability to cause disease or resist antibiotics. NIAID teamed with the Office of Naval Research, the National Science Foundation, and other agencies to fund the research.

NHLBI stopped early a major clinical trial of the risks and benefits of combined estrogen and progestin in healthy menopausal women due to an increased risk of invasive breast cancer. The large trial, a component of the Women's Health Initiative (WHI), also found increases in coronary heart disease, stroke, and pulmonary embolism in study participants on estrogen plus progestin compared to women taking placebo pills. There were some benefits of estrogen plus progestin, including fewer cases of hip fractures and colon cancer, but on balance the harm was greater than the benefit.
NIH licensed a new technology that allows physicians and researchers to make detailed, three-dimensional maps of nerve pathways in the brain, heart muscle fibers, and other soft tissues. The new imaging technology, called Diffusion Tensor Magnetic Resonance Imaging (DT-MRI), was invented by researchers now at NICHD.

A new approach to cancer treatment that replaces a patient's immune system with cancer-fighting cells can lead to tumor shrinkage. NCI researchers demonstrated that immune cells, activated in the laboratory against patients' tumors and then administered to those patients, could attack cancer cells in the body. The experimental technique, known as adoptive transfer, has shown promising results in patients with metastatic melanoma who have not responded to standard treatment.

NIAID-supported researchers proved conclusively that the malaria-causing parasite Plasmodium falciparum became resistant to the anti-malarial drug chloroquine through mutations in a single parasite gene. This finding has potentially important implications for malaria treatment and control.

An international research consortium of NHGRI, other NIH components, and other countries launched a public-private effort to create the next generation map of the human genome. Called the International HapMap Project, this new venture is aimed at speeding the discovery of genes related to common illnesses such as asthma, cancer, diabetes and heart disease.

2003

The International Human Genome Sequencing Consortium, led in the United States by NHGRI and the Department of Energy, completed the Human Genome Project more than two years ahead of schedule and for a cost substantially less than the original estimates. The international effort to sequence the three billion DNA letters is considered by many to be one of the most ambitious scientific undertakings of all time. The first draft of the human sequence was completed in June 2000. Researchers have now produced a "finished" sequence, which covers about 99 percent of the human genome's gene-containing regions, and has been sequenced to an accuracy of 99.99 percent. All of the sequence data have been deposited into public databases and made freely available to scientists around the world, with no restrictions on their use or redistribution.

The complete genetic blueprint of Bacillus anthracis—the microbe that gained notoriety during the 2001 anthrax mail attacks—has been completed by NIAID-funded researchers. This bacterium, which can cause potentially fatal inhalational anthrax, differs very little from a common soil bacterium related to it. Scientists hope that the genetic differences between these two may reveal valuable clues to its vulnerabilities.

NHLBI published new clinical practice guidelines for the prevention, detection, and treatment of high blood pressure—a major risk factor for heart disease and the chief risk factor for stroke and heart failure. The guidelines define a new blood pressure category called "prehypertension" that includes about 22 percent of American adults, or about 45 million people. Americans' lifetime risk of developing hypertension is greater than previously thought, according to the new guidelines. Medications and lifestyle changes are both crucial parts of treatment.

Researchers supported by NIMH found a gene called 5-HTT that influences whether people become depressed when faced with major life stresses such as relationship problems, financial difficulties and illness. The gene by itself does not cause depression, but it does affect how likely people are to get depressed when faced with major life stresses. Another study led by NIAAA researchers found that this same gene affects drinking habits in college students. These studies are major contributions toward understanding how a person's response to their environment is influenced by their genetic makeup.

A team led by NIDCR and NICHD researchers discovered that "baby" teeth, the temporary teeth that children begin losing around their sixth birthday, contain a rich supply of stem cells in their dental pulp. The cells, named SHED, remain alive inside the tooth for a short time after it falls out of a child's mouth. This easily accessible source of stem cells could be readily harvested for research. Scientists hope they can learn to manipulate them to repair damaged teeth, induce the regeneration of bone, and treat neural injury or disease.

Researchers supported by NICHD, NIGMS, NHLBI and NIDCR discovered how an embryo attaches to the wall of the uterus in what may be one of the earliest steps needed to establish a successful pregnancy. After an egg is fertilized, a specialized protein called L-selectin on the embryo surface binds to carbohydrates on the uterine wall. Scientists think that this interaction slows the embryo down to a complete stop so it can then attach to the wall of the uterus. The finding may lead to insights into infertility and early pregnancy loss.

An international research team funded by NIH found that filters made from old cotton saris cut the number of cholera cases in rural Bangladesh villages almost in half. Other inexpensive cloth should work just as well in other parts of the world where cholera is endemic. Cholera is a waterborne disease that causes severe diarrhea and vomiting, killing thousands of people around the world every year. This simple preventive measure has the potential to make a significant impact on a global health problem.

NIH director Dr. Elias Zerhouni names five new institute directors: Dr. Ting-Kai Li at the National Institute on Alcohol Abuse and Alcoholism; Dr. Thomas Insel at the National Institute of Mental Health; Dr. Nora Volkow at the National Institute on Drug Abuse, Dr. Jeremy Berg at the National Institute of General Medical Sciences; Dr. Story Landis at the National Institute of Neurological Disorders and Stroke.

President George W. Bush visits NIH on Feb. 3 to unveil Project BioShield, a $6 billion, 10-year effort to protect the public from various weapons of bioterrorism.

The FY 2003 appropriation for NIH completes a 5-year doubling of the NIH budget that began in 1998.

Construction begins on a new Perimeter Security System including a fence around the Bethesda campus.

Construction begins on the Bldg. 33 Complex, to include a parking garage and 150,000 gross square foot laboratory for work on infectious agents that might be used in bioterrorism.

Dr. Zerhouni announces the NIH Roadmap for Medical Research, a comprehensive plan whose purpose is to identify the major scientific opportunities and gaps in medical research that no single institute or center at NIH could tackle alone.
2004

NIH opens the Mark O. Hatfield Clinical Research Center, a 240-bed successor to the NIH Clinical Center, which opened in 1953. It is the world's largest facility dedicated to clinical research. The 870,000-square-foot addition welcomed occupants of its research wings in fall 2004, and was to admit its first patients in early January 2005.

The NIH Roadmap for Medical Research, a coordinated effort to speed the results of bench research to the patient bedside, marks its first anniversary, which includes the award of 9 grants to the inaugural class of winners of the NIH Director's Pioneer Awards.

NIH director Dr. Elias Zerhouni announces an NIH proposal to enhance public access to taxpayer-supported research by creating an online, searchable archive of all NIH-funded publications within 6 months of their appearance in journals.

NIH proposes enhancements to its rules governing potential conflicts of interest on the part of employees, thereby resolving public and congressional concerns about the outside activities of NIH staff.

NIH launches the Neuroscience Blueprint, a framework to enhance cooperative activities among 14 NIH Institutes and Centers that support research on the nervous system. The ultimate goal of the Blueprint is to accelerate neuroscience research to reduce the burden of nervous system disorders and maintain a healthy nervous system throughout life.

The Council of Public Representatives to the NIH director (COPR) holds a Public Trust Workshop aimed at increasing public participation in clinical research. COPR advocates building trust through community partnerships, building relationships with patients, building partnerships with community providers and building trust in both scientists and NIH scientific research.

An international clinical trial concluded that women should consider taking letrozole after 5 years of tamoxifen treatment to continue to reduce the risk of recurrence of breast cancer. This advance in breast cancer treatment will improve the outlook for many thousands of women. NCI supported the U.S. portion of the study, which offered one more example of the ability to interrupt the progression of a cancer using a drug that blocks a crucial metabolic pathway in the tumor cell.

As of July 2003, about 10 million American women were taking some form of hormone therapy, including approximately 6.7 million taking estrogen alone and 3.3 million taking estrogen plus progestin. A large, multi-center prevention study of estrogen-alone hormone therapy in healthy, postmenopausal women without a uterus, was stopped in February 2004 after researchers found that estrogen-alone had no effect on coronary heart disease risk, but increased the risk of stroke. The study, part of the NHLBI-sponsored Women's Health Initiative (WHI), also found that estrogen-alone therapy significantly increased the risk of deep vein thrombosis, had no significant effect on the risk of breast or colorectal cancer, and reduced the risk of hip and other fractures. In addition, among older women in the study, estrogen-alone therapy did not prevent cognitive decline.

The International Human Genome Sequencing Consortium, led in the United States by the National Human Genome Research Institute and the Department of Energy, published its scientific description of the finished human genome sequence, reducing the estimated number of human protein-coding genes from 35,000 to only 20,000-25,000, a surprisingly low number for our species.

Adding to a developing body of research examining a possible link between diabetes and cognitive decline, a long-term study supported by NIA found that diabetes mellitus was linked to a 65 percent increased risk of developing Alzheimer's disease (AD). These results are among the first to examine how certain cognitive systems, including memory for words and events, the speed of processing information, and the ability to recognize spatial patterns, decline in people with diabetes, while others do not. Further research, some currently under way, will tell researchers whether therapies for diabetes may in fact play a role in lowering risk of AD or cognitive decline.

From language to literature, from music to mathematics, a single protein, known as mBDNF, appears central to the formation of the long-term memories needed to learn these and all other disciplines. Most of what we accomplish as human beings depends on what we learn. This discovery, led by scientists at NICHD, brings the possibility of studying this protein system in people with learning and memory disorders and perhaps designing new medications that might help to compensate for these problems.

2005

People with type 1 diabetes can lower their risk of heart disease and stroke by about 50% by tightly controlling their blood glucose levels, according to a study supported by NIDDK and NCRR. The findings were based on a follow-up study of patients who took part more than a decade ago in the Diabetes Control and Complications Trial, a major clinical study funded by NIDDK and other NIH components along with Genentech, Inc. Continuing studies will reveal whether the same applies to those with type 2 diabetes, the more prevalent form of the disease.

NCI and NHGRI launched a comprehensive effort called The Cancer Genome Atlas (TCGA) to accelerate an understanding of the molecular basis of cancer using genome analysis technologies. A pilot project involves a few types of cancer chosen for their value in helping to determine the feasibility of a possible larger-scale project. The project will develop and test the complex science and technology framework needed to systematically identify and characterize genomic changes associated with cancer.

An international team supported by NHGRI published the genome sequence of the dog. Because of selective breeding over the past few centuries, modern dog breeds are a model of genetic diversity, from 6-pound Chihuahuas to 120-pound Great Danes, from high-energy Jack Russell Terriers to mild-mannered basset hounds, and from the herding instincts of Shetland sheepdogs to pointers pointing. However, selective breeding has also caused many dog breeds to be predisposed to genetic disorders including heart disease, cancer and blindness. In combination with the human genome, the dog genome sequence will help researchers identify genetic contributors to several diseases.
Prince Charles and his wife, the Duchess of Cornwall, visited NIH on November 3 for a briefing on osteoporosis. The Duchess of Cornwall's interest in osteoporosis—her mother and grandmother died as a result of the disease—spurred the visit. Sponsored by NIAMS, the meeting explored opportunities to spread the messages of the Bone Health and Osteoporosis: A Surgeon General's Report.

President George W. Bush made his fourth visit to NIH in less than 3 years on November 1 to announce the government's pandemic influenza preparations and response. His previous visit, on January 26, was for a 40-minute town hall-style meeting to emcee a discussion with five citizens on the topic "Strengthening Health Care."

NIH launched a new state-of-the-art way for applicants to submit their grant applications electronically. Beginning with the receipt date of Dec. 1, 2005, NIH is requiring all its SBIR/STTR grant applicants to electronically submit their competing grants. NIH plans to transition all of its competing grant programs from paper to electronic by May 2007.

The International HapMap Consortium, a public-private effort to chart patterns of genetic variation in the world's population, published the human haplotype map, or HapMap. With more than 1 million markers of genetic variation, the HapMap is a comprehensive catalog of human genetic variation showing "neighborhoods" of correlated genetic variation, or haplotypes, across the entire human genome. Researchers will be able to identify genetic contributions to common diseases far more efficiently using HapMap data than with traditional approaches.

NIH launched a major new program, the Institutional Clinical and Translational Science Awards (CTSAs) program, to encourage the development of clinical and translational science, so that new treatments can be developed more efficiently and delivered more quickly to patients.

An HIV/AIDS vaccine developed by scientists at NIAID's Dale and Betty Bumpers Vaccine Research Center moved into its second phase of clinical testing in October. This vaccine contains synthetic genes representing HIV subtypes found in Europe, North America, Africa and Asia that account for about 85% of HIV infections worldwide.

Rates for new cases of kidney failure stabilized after 20 years of annual increases from 5 to 10%, according to research from NIDDK. Credit likely goes to clinical strategies proven in the 1990s to significantly delay or prevent kidney failure: angiotensin-converting enzyme inhibitors (ACE-inhibitors) and angiotensin receptor blockers (ARBs), which lower protein in the urine and are thought to directly prevent injury to the kidneys' blood vessels; and careful control of diabetes and blood pressure. The launch of private and government programs to improve care and increase awareness, including NIDDK's National Kidney Disease Education Program (NKDEP), likely also had an impact.

The nation's leading cancer organizations reported in October that Americans' risk of dying from cancer continues to decline and that the rate of new cancers is holding steady. Observed cancer death rates from all cancers combined dropped 1.1% per year from 1993 to 2002. NCI announced the results in the "Annual Report to the Nation on the Status of Cancer, 1975-2002" in collaboration with the Centers for Disease Control and Prevention, the American Cancer Society, and the North American Association of Central Cancer Registries.

NIH celebrated the second anniversary of progress guided by the NIH Roadmap for Medical Research in September. In fiscal year 2005, NIH funded $235 million in new and continuing NIH Roadmap projects. Key NIH Roadmap accomplishments include:

- The establishment of advanced centers in nanomedicine.
- The Molecular Libraries Screening Center Network began work in June 2005.
- Research Teams of the Future awards were granted through fiscal year 2006 to fund 21 Exploratory Centers for Interdisciplinary Research throughout the country.
- The launch of the Re-engineering the Clinical Research Enterprise.

Within a day of Katrina's passage, NIH director Dr. Elias Zerhouni convened the first in a series of emergency meetings at which clinical directors, nursing and administrative leaders rapidly hammered out ways NIH could help. In partnership with the American Association of Medical Colleges, NIH created and activated a telemedicine brain trust for specialty medical consultations over a telephone hotline. An advance team and medical team numbering about 50 people deployed temporarily to a field hospital in Mississippi. In addition, the Clinical Center made 100 beds of "surge capacity" available for patients who might need to be transferred from the affected areas, such as young cancer patients who would need specialized services.

The Chimpanzee Sequencing and Analysis Consortium, which is supported in part by NHGRI, described its landmark analysis comparing the genome of the chimp (Pan troglodytes) with that of humans (Homo sapiens). The chimp sequence draft represents the first non-human primate genome. Our closest living relatives share 96% of our DNA sequence.

Dr. Zerhouni announced the latest and final regulations to prevent conflicts of interest at NIH on August 25. In the works since interim final regulations were published in February of 2004, the new revised standards became effective on August 31, when they appeared in the Federal Register.

Computer models developed by the NIGMS-funded Models of Infectious Disease Agent Study (MIDAS) research network found that a carefully chosen combination of public health measures, if implemented early, could stop the spread of an avian flu outbreak at its source. The researchers found that antiviral treatment is a critical component of a multi-pronged approach.

An international group of researchers working in more than 20 laboratories around the globe and funded in part by NIAID sequenced the genomes of three parasites that cause deadly insect-borne diseases: African sleeping sickness, leishmaniasis and Chagas disease. Knowing the full genetic make-up of the three parasites might lead to better ways to treat or prevent the diseases they cause.

The Women's Health Study, a long-term clinical trial funded by NHLBI and NCI, found that vitamin E supplements don't protect healthy women against heart attacks and stroke. They also had no effect on the most common cancers in women or on total cancers.
The Protein Structure Initiative (PSI) completed its first 5-year phase and moved into its second. The PSI aims to figure out the three-dimensional shapes of proteins, with the long-term goal of being able to predict most protein structures from their DNA sequences. More than 1,100 protein structures were solved in the PSI's first phase, which was dedicated to figuring out how to process proteins and determine their three-dimensional structures more efficiently. Phase 2 is the production phase, in which thousands more protein structures will be solved and put into the Protein Data Bank (http://www.rcsb.org/pdb/), a public repository with powerful tools for processing protein structure information.

NHGRI announced 13 more organisms that the Large-Scale Sequencing Research Network will target, including 9 mammals, as part of its ongoing effort to produce genomic data that will expand biological knowledge and improve human health.

The Edmond J. Safra Family Lodge opened its doors to guests on Wednesday, June 1. This new addition to the NIH campus offers a temporary residence for families and loved ones of adult patients who are receiving care at the NIH Clinical Center.

Using New BioShield Authorities, NIAID awarded 10 grants and 2 contracts totaling approximately $27 million to fund development of new therapeutics and vaccines against some of the most deadly including bioterrorism including anthrax, botulinum toxin, Ebola virus, pneumonic plague, smallpox and tularemia. Project BioShield, which was signed into law on July 21, gives federal agencies new tools to accelerate research on medical countermeasures to safeguard Americans against chemical, biological, radiological or nuclear attack.

Researchers funded by NIH were asked to begin voluntarily submitting their manuscripts on May 2, 2005 to the National Library of Medicine's PubMed Central upon acceptance for publication. "Public access" to peer-reviewed, NIH-funded research publications will enable health care providers, educators and scientists to more easily exchange and search for research results. The public will also have greater access to published material about the medical research their tax dollars support.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a long-term, multi-center trial of antihypertensive therapies funded by NHLBI, found that diuretics work better than newer therapies in treating high blood pressure and reducing the risk of heart disease in both black and non-black patients. The large study, with 33,357 participants, concluded that diuretics should be the first therapy for most patients with high blood pressure.

Three independent research teams supported by NEI found a gene, called complement factor H (CFH), that affects a person's risk of developing age-related macular degeneration (AMD), the leading cause of blindness in people over age 60. One team, which included NIH's own researchers, found that people with this variant of the CFH gene are more than seven times more likely to develop the disease.

The Heart Truth, a national awareness campaign about women's heart disease sponsored by NHLBI, hosted the Red Dress Collection 2005 Fashion Show at Olympus Fashion Week in New York City on February 4, National Wear Red Day. First Lady Laura Bush, the national ambassador for NHLBI's campaign, joined Sarah Ferguson, the Duchess of York, and NHLBI director Dr. Elizabeth Nabel at a press event at the Time Life building in New York to kick off the fashion show. Made possible by Johnson & Johnson, Celestial Seasonings and Swarovski, the show was hosted by actress Vanessa Williams and included 26 of America's most influential designers along with a star-studded cast of celebrity models. The fashion show brought to life the Red Dress, the national symbol for women and heart disease awareness. In a survey was conducted by Harris Interactive in January, 60% of all the women surveyed agree that the Red Dress makes them want to learn more about heart disease, 25% recalled the Red Dress as the national symbol for women and heart disease and 45% agreed that it would prompt them to talk to their doctor and/or get a check-up.

2006

NCI-funded research spanning nearly 2 decades helped lead to FDA approval for a vaccine to prevent cervical cancer, a disease that claims the lives of nearly 4,000 women each year in the United States. It is the first cancer vaccine approved by the FDA.

NHLBI's nearly half-century commitment to exploring innovative mechanical approaches for treating damaged hearts led to the development of the first totally implanted artificial heart, approved by FDA in September 2006.

The NIH Office of Technology Transfer announced that products and processes invented by NIH scientists generated close to $100 million in royalties in 2005, nearly double $56 million-plus earned by NIH inventions the previous year. The top royalty earner is the invention of a Taxol-coated stent, which helps more than half a million Americans each year avoid bypass surgery.

On May 2, NIH dedicated a new research facility for studying globally important infectious diseases. NIAID's new C.W. Bill Young Center for Biodefense and Emerging Infectious Diseases will house studies of naturally occurring infectious diseases, infectious agents that might be used for bioterrorism and potential vaccines.

A multicenter research team, funded in part by NHGRI, completed the draft genome sequence of the rhesus macaque monkey and deposited the information into free public databases. The macaque is the second non-human primate, after the chimpanzee, to have its genome sequenced. Overall, the macaque shares about 92-95% of its genome sequence with humans. The genome sequence will facilitate research in neuroscience, behavioral biology, reproductive physiology, endocrinology, and cardiovascular studies.

NIH announced the launch of the first clinical studies under the Rare Diseases Clinical Research Network. The network unites more than 300 investigators at dozens of research centers nationwide to study more than 40 rare diseases, most of which are difficult to diagnose and treat because they are so poorly understood. The new initiative will help move discoveries more quickly to patients.

As part of the largest hypertension clinical trial conducted to date, researchers began a comprehensive outreach program to improve high blood pressure control nationwide. About 150 physicians in 34 states and Washington, DC, have completed training to educate other physicians in their communities. Their goal is to help doctors and patients prevent and better treat high blood pressure.
The drug misoprostol was shown to provide a safe, convenient, and inexpensive way to prevent postpartum hemorrhage, a major killer of women in developing countries. In a clinical study conducted in rural villages in India, women who received the drug after birth were less likely to have serious postpartum bleeding, and had significantly lower average blood loss, than women who received placebo. The study was funded by the Global Network for Women's and Children's Health Research, a public-private partnership between NICHD and the Bill and Melinda Gates Foundation.

Leading scientists and experts on women's health joined study participants for a 2-day conference at NIH. Attendees discussed the findings, public health impact, and future directions of the Women's Health Initiative—the largest and most comprehensive study of postmenopausal women's health ever conducted in the United States.

The NIH Pathway to Independence Award program introduced a new opportunity for promising postdoctoral scientists to receive both mentored and independent research support from the same award. Announced in January, the program answers a National Academy of Sciences call for new ways to help early-career scientific investigators progress from postdoctoral studies to running their own research programs.

NIH created a plan for continuity of operations should a pandemic flu outbreak occur. The goal is to maintain critical operations and protect patients, visitors, and employees— as well as animals and ongoing research—in the event of widespread infectious disease or other emergencies.

The first comprehensive analysis of an animal's reaction to the 1918 influenza virus provided new insights into this deadly flu, which disproportionately killed young people at the prime of life. NIAID-funded scientists found that the 1918 virus triggers a hyperactive immune response that may be the key to its lethal effects. A deeper understanding of the 1918 virus will aid efforts to develop improved therapies against future influenza threats, including the H5N1 avian influenza virus.

The U.S. House of Representatives passed the National Institutes of Health Reform Act of 2006 by a vote of 414 to 2 on September 26; the U.S. Senate passed an amended version by unanimous consent on December 8. The House approved the Senate version by voice vote on December 9. The legislation—NIH's third omnibus reauthorization in history and first since 1993—affirmed the importance of NIH and its vital role in advancing biomedical research to improve the health of the Nation.

NIH Director Dr. Elias Zerhouni endorsed the conclusions of a National Academies report on women in science, which proposed that immediate, decisive action must be taken to maximize the potential of women scientists. The report found that women currently face barriers to hiring and promotion in research universities in many fields of science and engineering, which deprives the nation of an important source of talent and may reduce U.S. competitiveness in the global marketplace.

An imaging molecule known as FDDNP binds to abnormal proteins in the brain and shows promise for enabling early and reliable diagnosis of Alzheimer's disease. The molecule was developed and tested by researchers supported in part by NIA, NCRR, and NIMH. When administered to patients before a brain scan, the molecule helps to distinguish among people who are healthy, those with Alzheimer's disease, and those with mild cognitive impairment, which sometimes progresses to Alzheimer's disease.

Thirteen recipients of the 2006 NIH Director's Pioneer Award—5-Year, $2.5 million grants that support highly innovative research—were announced at the second annual Pioneer Award Symposium. Now in its third year, the award is a key component of the NIH Roadmap for Medical Research.

NIEHS-supported researchers announced that they had successfully sequenced the DNA of 15 mouse strains most commonly used in biomedical research. More than 8.3 million tiny genetic variations called single nucleotide polymorphisms (SNPs) were discovered among the 15 genomes. The new data will help researchers better understand complex genetic traits, such as why some individuals are more susceptible to certain diseases, and how environmental agents influence the development of disease.

2007

President George W. Bush visited NIH on January 17, touring a cancer research laboratory and participating in a discussion on cancer prevention. It was his fifth visit to the NIH campus in the past 4 years. The president praised the agency's work, touting the new vaccine against cervical cancer. He was briefed on the Cancer Genome Atlas Project, a 3-year, $100 million collaboration between NCI and NHGRI to create a trove of molecular data describing the genomic changes that occur in all types of cancer.

An experimental vaccine—originally created and tested over the past 2 decades by NIAID scientists—appears safe and effective in preventing hepatitis E, a sometimes-deadly viral disease prevalent in developing countries. A clinical trial involving nearly 2,000 healthy adults in Nepal, where the virus is widespread, found that the vaccine was nearly 96% effective in preventing hepatitis E during a follow-up period of about 2 years.

NINDS launched the new Neurological Emergencies Treatment Trials (NETT) network, a nationwide clinical study that will look at emergency interventions for stroke, massive seizure, brain or spinal cord injury, and other major emergencies that affect the brain and nervous system. The long-term goal of the study, conducted in ambulances and hospitals across the country, is to improve medical care in the first minutes and hours after neurological emergencies occur.

By modifying only 4 genes in human skin cells, researchers supported by NCRR and NIGMS found that they could "reprogram" the cells to give them the characteristics of embryonic stem cells. This major advance could open doors to innovative therapies in the future, where people's own cells might be reprogrammed and used to repair their damaged tissues and organs.

EUREKA, a new funding initiative to help researchers with original ideas, was launched by 5 institutes. EUREKA—exceptional, unconventional research enabling knowledge acceleration—awards seek to raise the profile of paradigm-shifting concepts that might otherwise get overlooked.

A collaborative effort by 3 international research teams uncovered new clues about why some people develop type 2 diabetes and others don't. The NIH-funded research relied on a relatively new method, called a genome-wide association study (GWAS), which rapidly and cost effectively analyzes and compares genetic differences between people with and without specific illnesses. The scientists identified 4 new genetic risk factors for type 2 diabetes.
NIH Director Dr. Elias Zerhouni established an NIH-wide working group to address the issues that surround GWAS research, which holds tremendous promise for uncovering new and more effective methods for preventing, diagnosing, and treating disease. Because GWAS science is so new, policies for collecting, storing and using GWAS data have not yet been set. The new working group will gather feedback from the public, examine important issues, and draft an NIH policy.

The International HapMap Consortium, funded in part by NHGRI, published analyses of its second-generation map of human genetic variation. The revised map contains more than 3.1 million genetic variants—3 times the number reported in the initial HapMap of 2005. The improved HapMap will help researchers find DNA variants that influence the risk of disease and other traits.

NIH Director Dr. Elias Zerhouni met with nearly 200 members of the scientific community to hear comments on NIH peer review, the process of evaluating research grant applications. Over the last 60 years, peer review has been examined several times. The current effort to revitalize the process came as federal funding had receded, the number of experienced reviewers had dwindled, and grant application volume had increased in number and complexity.

The Human Microbiome Project, part of the NIH's Roadmap for Medical Research, will explore the role of the trillions of microbes that live within or on the human body. The “human microbiome” is the collective genomes of all these organisms. By analyzing these genomes, the scientists hope to discover what microbial communities exist in different parts of the human body and explore how they change in health and disease.

With this year’s NIH Director’s Pioneer Awards and the inaugural class of NIH Director’s New Innovator Awards, the agency made a major investment in the future of science, distributing 5-year grants totaling more than $105 million to 41 investigators. This is the first group of New Innovator Awards and the fourth group of Pioneer Awards. Both programs are part of an NIH Roadmap initiative that tests new approaches to supporting research.

Scientists identified a tiny, unchanging region on an AIDS virus protein that may be the key to neutralizing the virus. A multi-site research team, including scientists from NIAID and NCI, used X-ray crystallography to take detailed 3-D snapshots of an antibody grabbing onto this stable viral region, which HIV uses to latch onto and infect T cells. Discovery of this potential viral weak spot could have a profound impact on development of an AIDS vaccine.

The Clinical and Translational Science Award (CTSA) consortium, funded by NCRR, added 12 more academic health centers to the 12 announced in 2006. When fully implemented in 2012, 60 institutions will be linked together to energize the discipline of clinical and translational science.

In a September 12 ceremony in the U.S. Capitol, NIH and NASA signed a memorandum of understanding that will help American scientists use the International Space Station to answer questions about human health and disease. NIH Director Dr. Elias Zerhouni and NASA Administrator Dr. Michael D. Griffin signed a pact to collaborate on space-related health research.

NIH research was featured in a new TV series, "Tomorrow's Medicine Today." NIH Director Dr. Elias Zerhouni served as guest-co-host of the discussion shows, taped at Montclair State University studios in New Jersey. Each episode featured interviews with NIH Institute or Center directors, who invited extramural scientists to present their research in lay terms for a general audience.

The NIH Council of Councils, a new advisory body to the NIH Director, convened for the first time on November 8. Created by the NIH Reform Act of 2006, the Council oversees Common Fund expenditures, which pay for broad, trans-NIH initiatives that need support no single institute or center could offer. Council members represent the advisory councils of all 27 Institutes and Centers plus 1 ad hoc representatives. Their mission is to advise the NIH Director about which cross-cutting initiatives to support.

NIH's Public Trust Initiative launched its Partners in Research Program, a unique opportunity for scientists to team up with community organizations. Announced in cross-cutting initiatives to support.

A draft environmental impact statement for expansion of the National Naval Medical Center (NNMC) to accommodate Walter Reed Army Medical Center's move to Bethesda was released in mid-December 2007, launching a 45-day period for public comments. Between 2,500 and 4,000 workers are expected to be added to the existing NNMC and tenant staff of 7,500, and NNMC outpatient visits are expected to double to about 4,000 per weekday, which is expected to have a major impact on traffic congestion in the area.

2008

Through legislation enacted by Congress, NICHD was renamed the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the institute's 45th anniversary celebration. In the early 1960s, Shriver persuaded her brother, President John F. Kennedy, to include the proposal for an NIH institute focusing on child health and human development in his first health message to Congress. NICHD was then established in 1963.

Two large NIH-funded clinical trials found that taking vitamin E, vitamin C, or selenium does not reduce the risk of prostate cancer or other cancers in older men, as some previous studies had suggested. The results highlight the fact that dietary supplements can sometimes seem beneficial in small observational studies, but

NIH began a new process that provides the public with detailed funding information for 215 major areas. Called Research, Condition, and Disease Categorization (RCD), the new process uses knowledge management and computerized, standardized tools to provide consistent and transparent NIH research funding information.

On May 19, NIH's Office of the Director, Office of Rare Diseases, Clinical Center, and NHGRI launched the Undiagnosed Diseases Program. A trans-NIH initiative, it will focus on the most puzzling medical cases referred to the Clinical Center by physicians across the nation.

NIH-funded scientists identified genetic variations that put people at risk for several common and complex disorders, including breast cancer, gout, lung cancer, schizophrenia, glioblastoma, and blood cholesterol and lipid levels. Their successes relied on genome-wide association studies (GWAS), which scan the genomes of large numbers of people to find genetic variations associated with a particular disease.
On June 2, U.S. Senators Barbara Mikulski (D-MD) and Benjamin Cardin (D-MD), along with NIH Director Dr. Elias Zerhouni, visited NIH's newest research facility, the Biomedical Research Center (BRC) in Baltimore. The approximately 500,000-square-foot, 2-tower BRC is a leased building on the Johns Hopkins Bayview campus, where NIA and NIDA have long conducted intramural research in other facilities.

The NIH Gateway Center—the long-awaited “front door” to the Bethesda campus at Rockville Pike and South Drive near the Medical Center Metro station—opened in July, merging the now-separate pedestrian and vehicle entrances to campus into a single welcoming point.

As of October 1, NIH no longer permitted the use of any tobacco products on the Bethesda campus. The tobacco-free policy replaces smoking regulations that were instituted at NIH in 2002, which restricted smoking to selected outdoor locations. It has long been known that tobacco use has a wide range of negative health consequences.

The Edwin Smith Papyrus, one of the world's earliest known medical documents, has been digitally transformed by NLM into a document that can be perused on a computer screen. The papyrus was written in Egyptian hieratic script around the 17th century BCE, but probably based on material from 1,000 years earlier. The papyrus is a textbook on trauma surgery and discusses anatomical observations and the examination, diagnosis, treatment, and prognosis of numerous injuries in exquisite detail.

Researchers devised a fast new technique for producing human monoclonal antibodies (mAbs) that can roam the bloodstream to target and destroy infectious microbes. Using the new method, NIH-funded scientists created fully human influenza-fighting antibodies in a matter of weeks, rather than the months typically needed to generate mAbs.

The first-ever NIH health disparities summit was held December 16-18, gathering together biomedical scientists and research administrators, public health commissioners, community health care providers, and diplomats from around the world. ‘NIH Summit: The Science of Eliminating Health Disparities’ was coordinated by NIH’s National Center on Minority Health and Health Disparities.

A study by NIH-funded scientists identified over 300 human genes that play a role in West Nile virus infection. The findings reveal several potential targets for antiviral therapies.

2009

The American Recovery and Reinvestment Act (ARRA), signed by President Barak Obama on February 17, gave NIH a one-time 34% budget increase of $10.4 billion, a sum meant both to stimulate scientific research and to create jobs. The allotment, part of a $787 billion stimulus bill, must be disbursed within 2 years, sending NIH's grant-making apparatus into high gear. At NIH, 4 big renovation projects—for the John Edward Porter Neuroscience Research Center, the NIH Clinical Center, Building 3, and NIAID’s Rocky Mountain Laboratories Building 7 in Hamilton, Montana—will receive a total of nearly $430 million in building and facilities funds from ARRA.

Three international research teams have detected many tiny and common gene variations that together could account for at least one-third of the genetic risk for schizophrenia. Although none of these variants alone significantly boosts the chances of developing schizophrenia, in combination they seem to exert a powerful effect on disease risk.

NIH released the 565-page Biennial Report of the Director, National Institutes of Health, Fiscal Years 2006 & 2007. Mandated in January 2007 by Congress as part of Public Law 109-482, the document shows how NIH's 27 institutes and centers, along with various other NIH components, work together on the nation's largest medical research enterprise.

Rhinoviruses are a major cause of the common cold and may contribute to about half of asthma flare-ups. Researchers have now completed sequencing the genomes of all the known rhinovirus types, setting the stage for the development of medications and vaccines to combat the viruses.

NIH released its final “Guidelines for Human Stem Cell Research” on July 6, after officials spent several weeks reviewing more than 49,000 public comments on the draft guidelines. Comments were received from the scientific community, patient advocacy groups, and medical and religious organizations, as well as from private citizens and many members of Congress.

Although the prostate-specific antigen (PSA) test can spot prostate cancer early, annual tests might not lead to fewer prostate cancer deaths, according to a new report. Of over 76,000 men in an NIH-funded study, half were randomly assigned to annual screening with PSA tests for 6 rounds and digital rectal exams (DRE) for 4 rounds. The other men were assigned to usual care. After up to 10 years of follow-up, the death rate from prostate cancer didn't differ significantly between the 2 groups. Follow-up of participants will continue for several more years.

On July 9, NIH hosted the White House's H1N1 Influenza Preparedness Summit, which assembled about 500 emergency managers, educators, school nurses, and public health officials from around the country to discuss how to investigate, monitor, and slow the spread of the 2009 H1N1 influenza outbreak. NIH launched the first clinical trials of 2009 H1N1 vaccine candidates on July 22.

Regular exercise—with medical supervision—is safe for heart failure patients, improves their quality of life, and may slightly lower their risk of death or hospitalization, according to an NIH-funded study of more than 2,300 patients with heart failure.

On August 17, Dr. Francis Collins was officially sworn in as the 16th director of the National Institutes of Health.
The NIH Directors

NIH DIRECTOR FRANCIS S. COLLINS, M.D., PH.D.

Francis S. Collins, M.D., Ph.D., a physician-geneticist noted for his landmark discoveries of disease genes and his leadership of the Human Genome Project, served as Director of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health from 1993-2008. Read Dr. Collins' full biosketch [http://www.nih.gov/about/director/directorbio.htm]

CHRONOLOGY OF NIH DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph J. Kinyoun¹</td>
<td>August 1887</td>
<td>April 30, 1899</td>
</tr>
<tr>
<td>Milton J. Rosenau</td>
<td>May 1, 1899</td>
<td>September 30, 1909</td>
</tr>
<tr>
<td>John F. Anderson</td>
<td>October 1, 1909</td>
<td>November 19, 1915</td>
</tr>
<tr>
<td>George W. McCoy²</td>
<td>November 20, 1915</td>
<td>May 25, 1930</td>
</tr>
<tr>
<td></td>
<td>May 26, 1930</td>
<td>Jan. 31, 1937</td>
</tr>
<tr>
<td>Lewis R. Thompson</td>
<td>February 1, 1942</td>
<td>January 31, 1942</td>
</tr>
<tr>
<td>Rolla E. Dyer³</td>
<td>February 1, 1942</td>
<td>June 15, 1948</td>
</tr>
<tr>
<td></td>
<td>June 16, 1948</td>
<td>September 30, 1950</td>
</tr>
<tr>
<td>William H. Sebrell, Jr.</td>
<td>October 1, 1950</td>
<td>July 31, 1955</td>
</tr>
<tr>
<td>James A. Shannon</td>
<td>August 1, 1955</td>
<td>August 31, 1968</td>
</tr>
<tr>
<td>Robert Q. Marston</td>
<td>September 1, 1968</td>
<td>January 21, 1973</td>
</tr>
<tr>
<td>Donald S. Fredrickson</td>
<td>July 1, 1975</td>
<td>June 30, 1981</td>
</tr>
<tr>
<td>James B. Wyngaarden</td>
<td>April 29, 1982</td>
<td>July 31, 1989</td>
</tr>
<tr>
<td>Bernadine Healy</td>
<td>April 9, 1991</td>
<td>June 30, 1993</td>
</tr>
<tr>
<td>Harold E. Varmus</td>
<td>November 23, 1993</td>
<td>December 31, 1999</td>
</tr>
<tr>
<td>Elias A. Zerhouni</td>
<td>May 2, 2002</td>
<td>October 31, 2008</td>
</tr>
<tr>
<td>Francis S. Collins</td>
<td>August 17, 2009</td>
<td>Present</td>
</tr>
</tbody>
</table>

¹ Director, Hygienic Laboratory.
² Director, National Institute of Health.
³ Director, National Institutes of Health.

BIOGRAPHICAL SKETCHES

Joseph James Kinyoun, M.D.

Founder and director of the Hygienic Laboratory, Dr. Joseph J. Kinyoun introduced scientific research into the Marine Hospital Service. His interest in bacteriology and his isolation of the cholera organism laid the groundwork for the present health research program of NIH.

Dr. Kinyoun received his M.D. degree from New York University in 1882 and did postgraduate work in Europe under the German bacteriologist, Robert Koch.
Dr. Kinyoun joined the Marine Hospital Service in 1886. In a one-room laboratory on Staten Island, N.Y., he applied new techniques he had learned in Europe, enabling him to isolate the organism that causes cholera. The Hygienic Laboratory was established in August 1887 and Dr. Kinyoun served as its director until April 30, 1899.

During his government career, Dr. Kinyoun designed the Kinyoun-Francis sterilizer, a shipboard disinfecting apparatus. In 1903 he retired from public service and, after working in private industry and as a professor at the George Washington University, he became a bacteriologist in the District of Columbia Health Department.

Milton Joseph Rosenau, M.D.

As second director of the Hygienic Laboratory, Dr. Milton J. Rosenau was responsible for expanding its scope of investigations.

After receiving his M.D. from the University of Pennsylvania, he did postgraduate work in Europe in the field of sanitation and public health. In 1890 he received his commission in the Marine Hospital Service. He became director of the Hygienic Laboratory on May 1, 1899.

A pioneer in the study of anaphylaxis, he also conducted research on yellow fever, malaria, typhoid fever, poliomyelitis, disinfectants, and the pasteurization of milk. His Preventive Medicine and Hygiene is a standard text for students of public health.

On September 30, 1909, Dr. Rosenau resigned from government service to join the staff of Harvard Medical School. In 1936 he went to the University of North Carolina where he served as director of the Public Health School.

John F. Anderson, M.D.

Dr. John F. Anderson, third director of the Hygienic Laboratory, was among the early scientists who made the Laboratory well-known in scientific circles.

After receiving his M.D. degree at the University of Virginia, he went abroad to study bacteriology. Upon returning in 1898, he joined the Marine Hospital Service and on October 1, 1909, succeeded Dr. Rosenau as director of the Hygienic Laboratory.

Throughout his career in the service, he was actively engaged in research. He studied serum and vaccine therapy, immunology, cholera, typhus, poliomyelitis, and public health and sanitation problems. He worked with Dr. Rosenau on hyper-susceptibility, anaphylaxis, and tuberculosis, and with Dr. Joseph Goldberger on the transmission of measles to monkeys, providing science with an experimental animal for that disease.

Dr. Anderson served as director of the Hygienic Laboratory until November 19, 1915, when he resigned to become director of the Research and Biological Laboratories and later vice president of E. R. Squibb & Sons.

George Walter McCoy, M.D.

Dr. George W. McCoy was, during his lifetime, the Nation's greatest authority on leprosy. For his many contributions to public health, he won the Sedgwick Memorial Medal of the American Public Health Association in 1921.

He entered the Marine Hospital Service in 1900 after graduating from the University of Pennsylvania Medical School.

During his first assignment at the Marine hospital in San Francisco, he became interested in leprosy. While heading the U.S. Plague Laboratory in San Francisco from 1908 to 1911, he discovered that the California ground squirrel was responsible for the spread of the organism causing tularemia.

On November 20, 1915, he became fourth director of the Hygienic Laboratory, renamed "National Institute of Health" in 1930. During this period he conducted important studies in influenza, poliomyelitis, smallpox, tularemia, amoebic dysentery, and pneumonia. Dr. McCoy served as director until January 31, 1937.

After conducting a nationwide survey on leprosy, Dr. McCoy retired from PHS on June 30, 1938, and joined the staff of Louisiana State University in New Orleans.

Lewis Ryers Thompson, M.D.

Dr. Lewis R. Thompson was intensely interested in research on industrial health problems and on problems of stream pollution.

He joined PHS in 1910, having graduated from Louisville Medical College. After becoming chief of the Division of Scientific Research in 1930, he administered field investigations of stream pollution, malaria, cancer, nutritional diseases, child hygiene, milk, dental problems, and industrial hygiene. When the division was merged with NIH, Dr. Thompson became director on February 1, 1937.

Dr. Thompson was largely responsible for securing the present-day site of NIH and for securing appropriations for the construction of the first six buildings. He served as director until January 31, 1942, and after retiring from PHS in 1947 became a scientific director of the international health division of the Rockefeller Foundation.
Rolla Eugene Dyer, M.D.

Dr. Rolla E. Dyer's major research contributions were in the field of infectious diseases; in particular, endemic typhus. He demonstrated how endemic typhus is spread and helped develop a vaccine to protect against the disease.

Dr. Dyer received his M.D. from the University of Texas and joined PHS in 1916.

His first assignment involved fieldwork on bubonic plague in New Orleans. Five years later he joined the staff of the Hygienic Laboratory, became chief of the Division of Infectious Diseases in 1936, and director of NIH in 1942.

As director, Dr. Dyer organized the Division of Research Grants, assisted in planning the Clinical Center, and helped establish three new institutes: the National Heart Institute, the National Institute of Dental Research, and the National Institute of Mental Health.

After retiring from active duty on September 30, 1950, Dr. Dyer served as a member of the scientific board of directors of the international health division of the Rockefeller Foundation.

William Henry Sebrell, Jr., M.D.

A leading international authority on nutrition, Dr. William H. Sebrell first recognized and described the dietary deficiency disease, riboflavinosis, and made significant contributions to knowledge of dietary needs and deficiencies.

Dr. Sebrell received his M.D. degree from the University of Virginia and joined PHS in 1926.

He began his research career under Dr. Joseph Goldberger who demonstrated that pellagra is a deficiency disease. During the 1930's, Dr. Sebrell made many important contributions to our knowledge of the anemias and the role of diet in cirrhosis of the liver.

During World War II, Dr. Sebrell was codirector of the National Nutrition Program which coordinated activities of all state agencies working in the field of nutrition. This program aided food production and the maintenance of civilian health during the war years.

In 1948 he became director of the Experimental Biology and Medicine Institute, and on October 1, 1950, was appointed director of NIH. He held this post until his retirement on July 31, 1955.

Dr. Sebrell helped formulate the first international standards of nutrition for the League of Nations, and pioneered the growing acceptance of scientific nutrition as a regular function of modern state and local health departments.

James A. Shannon, M.D.

Dr. James A. Shannon, widely recognized in the scientific world for his original research in kidney function, chemotherapy, and malaria, has throughout his career, been devoted to medical research, teaching, and public service.

He received his M.D. in 1929 and a Ph.D. in physiology in 1935 from New York University.

Following his internship at Bellevue Hospital in New York, Dr. Shannon taught in the department of physiology at New York University College of Medicine from 1931 to 1941, and directed research at the university's Goldwater Memorial Hospital from 1940 to 1945.

During periods of leave, he served as guest investigator at the physiological laboratory, University of Cambridge, England, and as a member of the staff of the Marine Biological Laboratory at Woods Hole, Mass.

During World War II, Dr. Shannon played a prominent part in malaria research activities of the National Research Council and was consultant on tropical diseases to the secretary of war. In recognition of this work, he received the Presidential Medal for Merit, the highest award at that time for civilian service in government.

Before joining PHS in 1949, he was director of the Squibb Institute for Medical Research (1946-49), and special consultant to the PHS Surgeon General.

Dr. Shannon then served as associate director in charge of research in the National Heart Institute until 1952. After holding the post of associate director, NIH, for 3 years, he became its director on August 1, 1955.

Among his many honors were the Public Welfare Medal of the National Academy of Sciences for "eminence in the application of science to the public welfare" (1962), the Rockefeller Public Service Award for Science, Technology, or Engineering (1964), and the Presidential Distinguished Federal Civilian Service Award (1966).

On retiring as NIH director (August 31, 1968), Dr. Shannon joined the NAS as special advisor to the president. In February 1970 he became professor and special assistant to the president, Rockefeller University. He retired from those positions in 1975.

Robert Q. Marston, M.D.

Dr. Robert Quarles Marston became director of NIH on September 1, 1968, after serving for 5 months as administrator of the Health Services and Mental Health Administration.
He received his B.S. degree in 1943 from the Virginia Military Institute, and his M.D. from the Medical College of Virginia in 1947. As a Rhodes scholar, he worked for the next 2 years with Nobel prizewinner Howard Florey at Oxford University, Oxford, England, earning a B.Sc. from that institution in 1949.

After an internship at Johns Hopkins Hospital and a year's residency at Vanderbilt University Hospital in Nashville, Tenn., he was stationed at NIH from 1951 to 1953 as a member of the Armed Forces Special Weapons Project, conducting research on the role of infection after whole body irradiation. He completed his residency at the Medical College of Virginia in Richmond the following year.

While a Markle fellow, he served as assistant professor of medicine at the Medical College of Virginia from 1954 to 1957, and as assistant professor of bacteriology and immunology at the University of Minnesota in Minneapolis for 1 year. He returned to the Medical College of Virginia in 1959 as associate professor of medicine and assistant dean in charge of student affairs.

In 1961, Dr. Marston became director of the University of Mississippi Medical Center and dean of the School of Medicine in Jackson, Miss., and was appointed vice chancellor there in 1965.

He became an associate director of NIH and director of the newly created Division of Regional Medical Programs on February 1, 1966.

On April 1, 1968, Dr. Marston was named administrator of the Health Services and Mental Health Administration, under a departmental reorganization.

He became acting director of the National Institute of Neurological Diseases and Stroke on January 21, 1973. He left the Federal service in April 1973 to become a scholar-in-residence at the University of Virginia. He also was named the first distinguished fellow of the Institute of Medicine, NAS.

On January 11, 1974, Dr. Marston was named president of the University of Florida at Gainesville, a position he held until 1984, after which he sat on the governing board of Virginia Military Institute while continuing his work with graduate students at the University. He retired in the late 1980s.

Robert S. Stone, M.D.

Dr. Robert S. Stone, former vice president for health services and dean of the school of medicine at the University of New Mexico, became director of NIH on May 29, 1973.

He received his B.A. in 1942 from Brooklyn College and his M.D. from the State University of New York College of Medicine in 1950. Dr. Stone was an instructor in pathology at Columbia University College of Physicians and Surgeons from 1950 to 1952.

Following his 1950-1952 internship and assistant residency in pathology at New York's Presbyterian Hospital, Dr. Stone moved to Los Angeles and joined the faculty of UCLA's School of Medicine, department of pathology.

From 1957 to 1959 as part of his academic duties he was deputy coroner at Los Angeles County, and for several years was pathologist for the Los Angeles Shriners Hospital for Crippled Children.

While on sabbatical as a visiting scientist at the Rockefeller Institute in 1959, he was credited with demonstrating by electron microscopy that the Shope papilloma virus of rabbits could be found in mature skin cells, but was undetectable, although presumed present, in younger growing cells.

Based on his observation of autopsies of atomic bomb victims in Hiroshima, Japan, Dr. Stone was one of the first researchers to suggest that radiation exposure increases the incidence of certain known diseases rather than creating new types. He served as chief of research in pathology for the Atomic Bomb Casualty Commission from 1959 to 1960.

He contributed to the concept of developing a method control population to study the normal incidence of various diseases for comparison, as was subsequently done.

It was a result of this work and his continuing interest that he was appointed to the NAS Advisory Committee on the Atomic Bomb Casualty Commission.

Dr. Stone joined the University of New Mexico School of Medicine as chairman of the department of pathology in 1963, and became dean of the school in 1968. Prior to his appointment as NIH director, he took a year's leave from the university and was a visiting professor at the Sloan School of Management, MIT.

He became dean of the School of Medicine of the University of Oregon Health Sciences Center and vice president of the Health Sciences Center in August 1975. In August of 1978, he was appointed dean of the College of Medicine at Texas A & M University in August of 1978.

Donald S. Fredrickson, M.D.

Dr. Donald S. Fredrickson, internationally known authority on lipid metabolism and its disorders, became NIH director on July 1, 1975. Immediately prior to this appointment, he had served for 1 year (1974-1975) as president of the Institute of Medicine, NAS.

His association with NIH, however, spanned more than two decades beginning in 1953 when he joined the scientific staff of the then National Heart Institute (renamed the National Heart, Lung, and Blood Institute in 1976) as a clinical associate.

During his research career in the Federal service, Dr. Fredrickson held numerous positions at NIH, several in the heart institute simultaneously. From 1955 to 1961 he was a member of the Laboratory of Cellular Physiology and Metabolism. He then served as clinical director (1961-1966), while continuing his research as head of the section of molecular diseases, Laboratory of Metabolism (1962-1966). He
was appointed institute director in 1966, serving in that capacity until 1968. He combined this executive responsibility with research as chief of the Molecular Diseases Branch (1966-1974), and as director of intramural research (1969-1974).

His earliest research interests centered on the metabolism of sterols. Later he focused on the structure of the plasma lipoproteins, their importance in the transport of fats, and the genetic factors regulating their metabolism and concentration in blood. It was during this period that he discovered two new genetic disorders: Tangier disease (absence of high density lipoproteins) and cholesteryl ester storage disease, a lysosomal enzyme deficiency.

In 1965 he and his coworkers introduced a system for identifying and classifying blood-lipid abnormalities on the basis of plasma lipoprotein patterns. From this work came recognition of new monogenic causes of hyperlipidemia: type 3 and type 5 hyperlipoproteinemia and what is called familial hypertriglyceridemia. The system received prompt acceptance by the WHO and is now used widely by laboratories around the world.

Research findings of Dr. Fredrickson and colleagues have also included the discovery of several previously unknown apolipo-proteins, and new knowledge including descriptions concerning the structure and function of various apoproteins.

He received both his B.S. (1946) and M.D. (1949) from the University of Michigan, and was certified by the American Board of Internal Medicine in 1957. He did postgraduate work at Peter Bent Brigham and Massachusetts General Hospitals and the Harvard Medical School prior to coming to NIH in 1953.

Dr. Fredrickson was a member of numerous professional societies in addition to the NAS and the American Academy of Arts and Sciences.

He resigned as NIH director on June 30, 1981 and returned to the NAS as a visiting scholar. In 1983 he joined the Howard Hughes Medical Institute (HHMI) as vice president, and became president and CEO in 1984. In 1987 he left HHMI and became a scholar at the National Library of Medicine.

James B. Wyngaarden, M.D.

Dr. James B. Wyngaarden, an internationally recognized authority on the regulation of purine biosynthesis and the genetics of gout, and a nationally respected advisor on various aspects of the administration of biomedical research, became the 12th director on April 30, 1982. Immediately prior to his appointment, he was professor and chairman of the department of medicine at Duke University School of Medicine, a position he had held since 1967.

He has had a long association with the NIH. From 1953 to 1954, he was a research associate in the Laboratory of Chemical Pharmacology of the then National Heart Institute, and from 1954 to 1956, he was a clinical associate at the then National Institute of Arthritis and Metabolic Diseases. After leaving in 1956 to become associate professor at the Duke University School of Medicine, he continued an association with NIH. He has held grants from several NIH components.

Dr. Wyngaarden has been active on various NIH study groups, evaluation committees, and review panels over the years, including a term with the board of scientific counselors of the then NIAMD (1971-1974). He also served as a consultant to the NIH as a member of study sections (1958-1960; 1967-1969).

He has also served as advisor to the broader scientific community as a member of the National Academy of Sciences since 1974, and was active from 1975 to 1982 on an NAS committee set up to study the Nation's overall need for biomedical and behavioral researchers; consultant for the President's Office of Science and Technology (1966-1972), a member of the President's Science Advisory Committee (1972-1973), and a member of the U.S. Atomic Energy Commission's Advisory Committee on Biology and Medicine.

Dr. Wyngaarden is the coauthor of Cecil Textbook of Medicine. In collaboration with former NIH director, Dr. Fredrickson, and others, he edited The Metabolic Basis of Inherited Disease. The original work was published in 1960.

He attended Calvin College there, and Western Michigan University in 1943-1944. In 1948 he graduated first in his class from the University of Michigan Medical School.

Dr. Wyngaarden trained in internal medicine at the Massachusetts General Hospital and did postdoctoral work at the Public Health Research Institute of the City of New York, under the direction of Dr. DeWitt Stetten, Jr., former NIGMS director. After serving as research associate at NIH from 1953 to 1956, he went to Duke and in 1959 became director of the medical research training program there as well as associate professor of medicine and biochemistry. In 1961 he became professor of medicine and associate professor of biochemistry.

In 1963 and 1964, he was a visiting scientist at the Institute de Biologie-Physiocochemie in Paris. Shortly after his return to this country, he left Duke to become professor and chairman of the department of medicine and professor of biochemistry at the University of Pennsylvania. He returned to Duke in 1967.

Dr. Wyngaarden has received many honorary degrees: University of Michigan (D.Sc., 1980), Medical College of Ohio (D.Sc., 1984), University of Illinois at Chicago (D.Sc., 1985), George Washington University (D.Sc., 1986), and Tel Aviv University (Ph.D., 1987).

He is a diplomate of the American Board of Internal Medicine. He has served on editorial boards of numerous professional publications.

Dr. Wyngaarden is a member of a number of professional societies including the NAS Institute of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, and is a past president of the Association of American Physicians. He is a fellow of the Royal College of Physicians of London and was elected to the Royal Academy of Sciences of Sweden in 1987.

Bernadine Healy, M.D.
Dr. Bernadine Healy became NIH director in April 1991. Shortly after her appointment, she launched the NIH Women's Health Initiative, a $500 million effort to study the causes, prevention, and cures of diseases that affect women. She also established the Shannon Award, grants designed to foster creative, innovative approaches in biomedical research and keep talented scientists in a competitive system.

Prior to her appointment, she was chairman of the Research Institute of the Cleveland Clinic Foundation, where she directed the research programs of nine departments including efforts in cardiovascular disease, neurobiology, Immunology, cancer, artificial organs, and molecular biology. From her appointment in November 1985, she also served as a staff member of the clinic’s department of cardiology.

In February 1984, Dr. Healy became deputy director of the Office of Science and Technology Policy at the White House. Her appointment, made by President Reagan and confirmed by the Senate in June of 1984, involved her heavily in life science and regulatory issues at the Federal level. She served as chairman of the White House Cabinet Working Group on Biotechnology, was executive secretary of the White House Science Council’s Panel on the Health of Universities, and served as member of several advisory groups, including the councils of the NHLBI, NCI, as well as the White House Working Group on Health Policy and Economics. From June 1976 until February 1984, she was professor of medicine at Johns Hopkins University School of Medicine and Hospital, where she also had clinical responsibilities, directed a program in cardiovascular research, and was director of the coronary care unit. In addition to serving on the medical school faculty, she assumed the role of assistant dean for postdoctoral programs and faculty development.

Among her other professional affiliations, Dr. Healy has served on the board of governors of the American College of Cardiology and has been president of the American Federation of Clinical Research (1983-84) and was chairman of its public policy committee for several years. She was president of the American Heart Association in 1988-1989 and has served as a member of its board of directors since 1983. As AHA president, she initiated a women's minority leadership task force and a women and heart disease program that took hold in affiliates nationwide.

She is a member of the Institute of Medicine of NAS. In 1989 she was elected as a member of the board of overseers of Harvard College and has served on the board of trustees of Vassar College. She has also been chairman of the Ohio Council on Research and Economic Development, and served on several other advisory committees and boards, including the Ohio Board of Regents.

Dr. Healy has been active in several Federal advisory groups. Until her NIH appointment, she was a member of the advisory committee to the NIH director. She has been a member of the White House Science Council and chairman of the advisory panel for new developments in biotechnology of the Office of Technology Assessment of the U.S. Congress and a member of the NASA Life Sciences Strategic Planning Study Committee. In 1990 she was appointed to the President's Council of Advisers on Science and Technology (PCAST) and served as its vice chairman. She also chaired the advisory panel for basic research for the 1990s of the Office of Technology Assessment, and served on the special medical advisory committee of the Department of Veterans Affairs.

She received her bachelor's degree from Vassar College in 1965, and her M.D., cum laude, from Harvard Medical School in June 1970. She completed training in internal medicine and cardiology at Johns Hopkins School of Medicine.

Dr. Healy has written extensively in the areas of cardiovascular research and medicine, and has served on the editorial boards of numerous scientific journals.

She stepped down as director of NIH on June 30, 1993, to return to the Cleveland Clinic in Ohio. Dr. Healy was dean of the Ohio State University Medical School and President and Chief Executive Officer of the American Red Cross.

Harold E. Varmus, M.D.

Dr. Harold E. Varmus became 14th director of NIH on November 23, 1993. Winner of the Nobel Prize in 1989 for his work in cancer research, he came to NIH from the University of California, San Francisco. He is a leader in the study of cancer-causing genes called "oncogenes," and an internationally recognized authority on retroviruses, the viruses that cause AIDS and many cancers in animals.

Prior to his appointment, he was professor of microbiology, biochemistry, and biophysics, and the American Cancer Society professor of molecular virology at UCSF. He has been working at the cutting edge of modern cell and molecular biology, and has had an active relationship with NIH for about 30 years as an intramural scientist, grantee, and public advisor.

Dr. Varmus and his UCSF colleague Dr. J. Michael Bishop shared the 1989 Nobel in Physiology or Medicine for demonstrating that cancer genes (oncogenes) can arise from normal cellular genes, called proto-oncogenes. While investigating a retroviral gene, v-src, responsible for causing tumors in chickens, they discovered a nonviral src gene, very similar to v-src, present in the normal cells of birds and mammals.

In recent years his work has assumed special relevance to AIDS, through a focus on biochemical properties of HIV, and to breast cancer, through investigation of mammary tumors in mice. His research activities included grants from NCI, NIAID, NIGMS, American Cancer Society, and the Melanie Bronfman Award for Breast Cancer.

Dr. Varmus has served as chairman of the board of biology for the National Research Council, an advisor to the Congressional Caucus for Biomedical Research, a member of the joint steering committee for Public Policy of Biomedical Societies, and cochairman of the New Delegation for Biomedical Research, a coalition of leaders in the biomedical community. He directed “Winding Your Way Through DNA,” a popular public symposium on recombinant DNA staged by UCSF.

Author or editor of four books and nearly 300 scientific papers, he has been elected to the Institute of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences. His most recent book, Genes and the Biology of Cancer, intended for a general audience, was coauthored with Robert Weinberg for the Scientific American Library. He has edited several professional journals, and served on a variety of review and advisory boards for government, biotechnology firms, and pharmaceutical companies.

Dr. Varmus was a member of the IOM committee that advised the Department of Defense on the use of $210 million allocated by Congress in 1992 for breast cancer research. In 1986 he chaired the subcommittee of the International Committee on the Taxonomy of Viruses that gave the AIDS virus its name, HIV.
He attended public schools in Freeport, Long Island; his father practiced family medicine and his mother was a psychiatric social worker. He is a graduate of
Amherst College (B.A., 1961), where he majored in English literature and edited the school newspaper; Harvard University (M.A., 1962); and Columbia University
(M.D., 1966). While in medical school, he worked for 3 months at a mission hospital in northern India.

After an internship and residency in internal medicine at Columbia-Presbyterian Hospital in New York, he served as a clinical associate for 2 years (1968-70) at the
National Institute of Arthritis and Metabolic Diseases, where he did his first scientific work in the area of bacterial genetics with Dr. Ira Pastan, who is now chief of
NCI's Laboratory of Molecular Biology. He came to UCSF as a postdoctoral fellow in Bishop's laboratory in 1970, initiating a long-standing collaboration to study
tumor viruses, and was appointed to the faculty later that year.

He became a full professor in 1979 and an ACS research professor in 1984. Dr. Varmus left NIH in December 1999 to become the President and Chief Executive
Officer of the Memorial Sloan-Kettering Cancer Center.

Elias A. Zerhouni, M.D.

Former NIH Director, Elias A. Zerhouni, M.D., lead the nation’s medical research agency and oversaw the NIH’s 27 Institutes and Centers
with more than 18,000 employees and a fiscal year 2008 budget of $29.5 billion.

The NIH investigates the causes, treatments, and preventive strategies for both common and rare diseases, helping to lead the way toward
important medical discoveries that improve people’s health and save lives. More than 83% of the NIH’s funding is awarded through almost
50,000 competitive grants and awards to more than 325,000 scientists and research support staff at more than 3,000 universities, medical
schools, and other research institutions in every state and around the world. About 10% of the NIH’s budget supports projects conducted by
nearly 6,000 scientists in its own laboratories, most of which are on the NIH campus in Bethesda, Maryland.

Dr. Zerhouni, a world renowned leader in the field of radiology and medicine, has spent his career providing clinical, scientific, and
administrative leadership. He is credited with developing imaging methods used for diagnosing cancer and cardiovascular disease. As one of the world’s premier
experts in magnetic resonance imaging (MRI), he has extended the role of MRI from taking snapshots of gross anatomy to visualizing how the body works at the
molecular level. He pioneered magnetic tagging, a non-invasive method of using MRI to track the motions of a heart in three dimensions. He is also renowned for
refining an imaging technique called computed tomographic (CT) densitometry that helps discriminate between non-cancerous and cancerous nodules in the lung.

Milestones

Since being named by President George W. Bush to serve as the 15th Director of the National Institutes of Health in May 2002, Dr. Zerhouni has overseen a number
of milestones:

Reauthorization demonstrated renewed confidence in NIH

Congress passed and President Bush signed into law the National Institutes of Health Reform Act of 2006. The agency's third reauthorization in history and first
since 1993, it signaled renewed confidence in the NIH mission, its employees and its leadership. The new law provides the NIH director expanded authority to
manage the agency, encourages NIH Institutes and Centers (ICs) to collaborate on trans-NIH research and reforms the agency's reporting system. Reauthorization
will strengthen the links within NIH and between the intramural and extramural research communities. Ultimately, it will help NIH more effectively balance what
has traditionally worked in science — freedom of exploration, autonomy, decentralization — with providing opportunities for people to collaborate and cooperate
more freely.

Development of a new office to improve trans-NIH initiatives

In 2005, NIH launched the Office of Portfolio Analysis and Strategic Initiatives (OPASI) in the Office of the NIH Director to transform the way NIH finds and funds
cutting-edge research, improve our ability to identify public health challenges, and increase trans-NIH dialogue, decision-making and priority-setting. OPASI will
build upon the model of the NIH Roadmap for Medical Research and will coordinate with NIH ICs and external stakeholders to identify research priorities that will
ultimately improve NIH's ability to be nimble, dynamic, and responsive to emerging scientific opportunities and public health needs.

Although OPASI will not have grant-making authority, it will provide an “incubator space” to jump-start trans-NIH initiatives and support ICs that will take the lead
on priority projects on a time-limited basis (5 to 10 years). These OPASI initiatives will be supported by the “Common Fund for Shared Needs,” a central funding
source built upon the Roadmap budget model. Building from current Roadmap funds, which amount to about 1.6 percent of NIH's total budget in fiscal year 2007,
the Fund will increase to up to 5 percent of the total NIH budget depending on NIH budget growth, scientific opportunities and public health needs.

Initiated the NIH Roadmap for Medical Research

Launched in September 2003, the NIH Roadmap for Medical Research, a new research vision to accelerate medical discovery to improve health, focuses the
attention of the biomedical research community on new pathways of discovery, research teams for the future and the re-engineering of the clinical research
enterprise. It aims to accelerate the pace of discovery and speed the application of new knowledge to the development of new prevention strategies, new
diagnostics and new treatments, and, ultimately, to transfer these innovations to health care providers, and the public.

Established an NIH-wide research initiative to address the obesity epidemic

The Strategic Plan for NIH Obesity Research is a multi-dimensional research agenda that addresses one of the nation’s most dramatic health challenges. In the U.S.
population, recent figures show that 65 percent of adults—or 130 million people are overweight or obese. The strategic plan enhances both the development of
new research in areas of greatest scientific opportunity and the coordination of obesity research across the NIH. The plan calls for interdisciplinary research teams
to bridge the study of behavioral and environmental causes of obesity with the study of genetic and biologic causes.

Supported the NIH Neuroscience Blueprint

Mental illness, neurological disorders and a range of behavioral disorders are major causes of human suffering and contribute greatly to the burden of disease.
These illnesses exact a cost of $500 billion each year. NIH Directors from 17 Institutes and Centers have developed a model of strategic leadership to address
several of the most common causes of death and disability, as well as rare disorders that affect the brain, spinal cord, or nerve cells throughout the body. The blueprint leverages the abilities of the Institutes and Centers to create new resources, tackle common scientific problems, and train the next generation of neuroscientists through collaboration and leadership.

**Made health disparities a research priority**

“Broadening the collaborative relationships developed through partnerships between NIH and institutions and researchers from all populations,” is the focus of Dr. Zerhouni’s commitment to eliminating health disparities and disparities in the burden of disease. In 2007, NIH announced the awarding of $66.7 million to support the advancement of health disparities research. This was the most recent in a series of commitments of funds to this research. NIH has made 58 awards under the Centers of Excellence program. NIH as a whole expects to spend $2.8 billion on research funding for health disparities.

**Ensured public access to NIH-funded research results**

February 3, 2005, Dr. Zerhouni announced an historic public access policy. For the first time, the public will have access to peer-reviewed research publications that resulted from studies funded by NIH. Dr. Zerhouni has urged maximum participation by investigators, encouraging scientists to submit their publications as soon as possible and within twelve months of publication to the archive.

**Committed to earn the public’s trust**

Dr. Zerhouni continues to seek advice from the public through the Council of Public Representatives (COPR), a recent public trust workshop, and, more locally, through community liaison efforts. He is committed as well to producing the most scientifically-accurate, useful and accessible health information through public health campaigns, fact sheets, over the Web and through a full complement of outreach efforts with special attention to cultural competence designed to keep the public informed.

**Enhanced the leadership of NIH**

Since becoming the NIH Director, Dr. Zerhouni named a new NIH Deputy Director (Raynard S. Kington, M.D., Ph.D.) and directors for nine institutes and three centers: Center for Scientific Review (Antonio Scarpa, M.D., Ph.D.), John E. Fogarty International Center (Roger I. Glass, M.D., Ph.D.), National Cancer Institute (John E. Niederhuber, M.D.), National Center for Research Resources (Barbara Alving, M.D.), National Heart, Lung, and Blood Institute (Elizabeth G. Nabel, M.D.), National Institute of Diabetes and Digestive and Kidney Diseases (Griffin P. Rodgers, M.D.), National Institute of Environmental Health Sciences and the National Toxicology Program (David A. Schwartz, M.D.), National Institute of General Medical Sciences (Jeremy M. Berg, Ph.D.), National Institute of Mental Health (Thomas R. Insel, M.D.), National Institute of Neurological Disorders and Stroke (Story C. Landis, Ph.D.), National Institute on Alcohol Abuse and Alcoholism (Ting-Kai Li, M.D.), National Institute on Drug Abuse (Nora D. Volkow, M.D.), and National Center for Complementary and Alternative Medicine (Josephine Briggs, M.D.).

Prior to joining the NIH, Dr. Zerhouni served as executive vice-dean of Johns Hopkins University School of Medicine, chair of the Russell H. Morgan department of radiology and radiological science, and Martin Donner professor of radiology, and professor of biomedical engineering. Before that, he was vice dean for research at Johns Hopkins.

Dr. Zerhouni’s imaging research has led to advances in Computerized Axial Tomography (CAT scanning) and Magnetic Resonance Imaging (MRI). It has earned him a Gold Medal from the American Roentgen Ray Society for CT research and two Paul Lauterbur Awards for MRI research. Dr. Zerhouni has also received the Special Presidential Award of the European Congress of Radiology.

From 1998-2002, he served on the National Cancer Institute’s Board of Scientific Advisors. He was a consultant to both the World Health Organization (1988), and to the White House under President Ronald Reagan (1985).

In April 2008, France bestowed its highest honor on Dr. Zerhouni. In a ceremony at Elysée Palace in Paris, French President Nicholas Sarkozy made him a Knight of the Légion d'honneur (French National Order of the Legion of Honor).

He has been a member of the Institute of Medicine since 2000.

Dr. Zerhouni is the author of 212 publications and holds 8 patents.
PRESIDENTIAL IMAGES

President Franklin D. Roosevelt dedicated the new NIH campus in Bethesda on October 31, 1940. This event was held to celebrate NIH's historic move from one building in Washington, D.C. to its new campus setting in Maryland on 45 acres of land donated by Luke and Helen Wilson.

On June 22, 1951, President Harry S Truman applied the first trowel of mortar to the NIH Clinical Center cornerstone. To symbolize advances in clinical medicine at the time, the cornerstone included samples of therapeutic aids, drugs, and techniques and devices to represent diagnosis, treatment and prevention of disease.

President Lyndon B. Johnson stepping off helicopter onto the lawn of the NIH Clinical Center, August 9, 1965. He is being greeted by PHS Surgeon General William H. Stewart, NIH Director Dr. James Shannon, and Dr. Jack Masur, Clinical Center Director.

President Johnson with PHS Surgeon General William H. Stewart and NIH Director Dr. James Shannon arrived at the NIH on August 9, 1965, to sign into law an extension of the Research Facilities Construction Program. In his remarks, President Johnson noted that “Here on this quiet battleground our Nation today leads a worldwide war on disease.”

Dr. Theodore Cooper, President Gerald Ford, and Dr. Donald S. Fredrickson listening to HEW Secretary Casper Weinberger speak at the July 1, 1975, swearing in ceremonies of Dr. Cooper as the HEW Assistant Secretary for Health, and Dr. Fredrickson as Director of the NIH.

President Gerald Ford speaking at the July 1, 1975, ceremony swearing in Dr. Donald S. Fredrickson as NIH Director. In his speech, President Ford says of the NIH “Through your accomplishments, NIH has become a symbol of hope, not just for the patients who are here in this or the other buildings, but all people, everywhere.”

President Gerald Ford observes Dr. Donald S. Fredrickson taking his oath of office as Director of the National Institutes of Health on July 1, 1975. HEW Secretary Casper Weinberger administers the oath as Mrs. Fredrickson holds the family Bible.

President Gerald Ford shakes hands with NIH staff, patients, and guests at the Clinical Center. He was on hand to observe the swearing in of Dr. Donald S. Fredrickson as the Director of the NIH, July 1, 1975.

First Lady Rosalyn Carter, and Mrs. James Callaghan, wife of the British Prime Minister, are shown speaking with a patient in the Clinical Center’s Laminar Flow Room facilities. Mrs. Carter and Mrs. Callaghan visited the Clinical Center on March 11, 1977.

On March 11, 1977, First Lady Rosalyn Carter, and Mrs. James Callaghan, wife of the British Prime Minister, visited the NIH campus and met with NIH Director Dr. Donald S. Fredrickson for a tour of the Clinical Center.
On July 23, 1987 President Ronald Reagan visited the NIH Clinical Center to announce his 13-member Commission on the Human Immunodeficiency Virus Epidemic. HHS Secretary Otis R. Bowen and President Ronald Reagan listen as NIH Director James B. Wyngaarden briefed the president on the NIH’s efforts in fighting AIDS.

HHS Secretary Otis R. Bowen and NIH Director James B. Wyngaarden greet President Ronald Reagan during his July 23, 1987 visit to the NIH Clinical Center. President Reagan visited the NIH to announce his 13-member Commission on the Human Immunodeficiency Virus Epidemic.

President Ronald Reagan, HHS Secretary Otis R. Bowen, Dr. James B. Wyngaarden and members of the Commission on the Human Immunodeficiency Virus Epidemic. In his remarks, the president said, “I hope the commission will help us all put aside our suspicions and work together with common sense against this threat.”

President Bill Clinton speaking with HHS Secretary Donna Shalala and NIH Director Dr. Harold Varmus after the cornerstone dedication ceremony for the Dale and Betty Bumpers Vaccine Research Center on June 9, 1999.

Mrs. Betty Bumpers, President Bill Clinton, and Sen. Dale Bumpers during the cornerstone dedication ceremony for the Dale and Betty Bumpers Vaccine Research Center on June 9, 1999. In his speech, President Clinton praised the Bumpers by saying “It is entirely fitting that today we dedicate this state-of-the-art facility to them. They are two great Americans.”

On June 9, 1999, HHS Secretary Donna Shalala, President Bill Clinton, Arkansas Sen. Dale Bumpers, and Mrs. Betty Bumpers unveil the cornerstone to the Dale and Betty Bumpers Vaccine Research Center. President Clinton called the NIH ‘one of America’s great citadels of hope, not only for our people, but also for the world.’

President George W. Bush tours the Vaccine Research Center on February 2, 2003. He is accompanied by (from left) NIAID Director Anthony Fauci, NIH Director Elias A. Zerhouni, HHS Secretary Tommy Thompson, and Secretary of the Department of Homeland Security, Tom Ridge.

President George W. Bush delivers an address on Project BioShield to a full audience at Natcher Auditorium during his visit to NIH on February 3, 2003.

President George W. Bush visits NIH on May 12, 2004 and participates in a panel discussion about reading education and development. Touting his No Child Left Behind legislation and its Reading First initiative, President Bush talks with other panel members, including G. Reid Lyon (l) of NICHD and Alabama kindergarten teacher Cynthia Henderson (r).

President George W. Bush visited NIH on November 1, 2005 to announce the government’s pandemic influenza preparations and response. At a Natcher Bldg. address of just under half an hour, he outlined a $7.1 billion plan to meet the threat of avian flu. Bush credited NIH for more than a century of work “at the forefront of this country’s efforts to prevent, detect and treat disease, and I appreciate the good work you’re doing here. This is an important facility, an important complex, and the people who work here are really important to the security of this nation.”

President George W. Bush visits NIH on January 26, 2005 to hold a 40-minute town hall meeting in Masur auditorium called strengthening health care. Greeting him in the lobby of the Clinical Research Center is: NIH director Dr. Elias Zerhouni joined by NCI director Dr. Andrew von Eschenbach (l) and Maryland Gov. Robert L. Ehrlich, Jr.

On January 17, 2007, President George W. Bush makes his fifth visit to the NIH campus during his presidency. In his tour of a cancer research laboratory and a roundtable discussion, the president learned about the Cancer Genome Atlas project and other NIH-funded research efforts.

On Thursday, April 10, 2008, French President Nicolas Sarkozy awarded NIH Director Dr. Elias A. Zerhouni the Légion d’honneur (French National Order of the Legion of Honor), the highest decoration in France. In the United States, Generals of the Army Dwight D. Eisenhower and Douglas MacArthur, are among the Americans who have received the honor. Others include General Wesley Clark, Actor Kirk Douglas, Film Producer and Actor Clint Eastwood, and former Secretary of State Colin Powell.

Photo Credit: Service Photo Elysée A.R.
President Barack Obama (right) gets an update on NIH activities from NIH director Dr. Francis Collins (third from left). Also on hand are (from left) Bill Corr, deputy HHS secretary; HHS Secretary Kathleen Sebelius and Dr. John Holdren, the President's science advisor.

CAMPUS PHOTOS

Building 1, the “Shannon Building,” serves as NIH headquarters in the heart of the campus in Bethesda, Maryland.

Building 10, the “Warren Grant Magnuson Clinical Center,” has served as the nation’s clinical research hospital since 1953.

The Mark O. Hatfield Clinical Research Center opened in 2005. The facility houses inpatient units, day hospitals, and research labs and connects to the original Warren Grant Magnuson Clinical Center. Together, the Magnuson and Hatfield buildings form the NIH Clinical Center. The Clinical Center provides patient care and the environment clinical researchers need to advance clinical science. It was named in honor of Senator Mark O. Hatfield of Oregon, who supported medical research throughout his congressional career.

The Children’s Inn at NIH provides pediatric patients and their families a place to stay during treatment at the Clinical Center.

The Edmond J. Safra Family Lodge at NIH is the temporary residence for families and loved ones of adult patients receiving care at the Clinical Center.

Building 16, the “Lawton Chiles International House,” is a locus for international activities supported by NIH and the Department of Health and Human Services (HHS).

The C.W. Bill Young Center (Building 33) is a new laboratory complex constructed for the National Institute of Allergy and Infectious Diseases (NIAID) to expand its research programs for developing new and improved diagnostics, vaccines, and treatments for emerging diseases caused by infectious agents that may occur naturally or be deliberately released into civilian populations.

Buildings 38 (and 38A—shown in the background) house the National Library of Medicine, the world’s largest collection of medical literature, and the Lister Hill National Center for Biomedical Communications, the research component of the NLM.

Building 40, the “Dale and Betty Bumpers Vaccine Research Center,” was established to facilitate research in vaccine development.

Building 45, the “William H. Natcher Building,” is the gateway to the NIH campus. It houses a 1,000-seat auditorium, nine conference rooms, a spacious cafeteria, and underground parking for visitors.

Building 50, “The Louis Stokes Laboratories,” provides 250,000 GSF of state-of-the-art laboratory, office and conference facilities for scientists from nine NIH institutes.

This view of the NIH campus looks north past the Natcher Building (right) to the Stokes Labs (center) and beyond to the Clinical Center (upper left). Building 31, the “Claude D. Pepper Building,” (upper right) provides office space for most Institute directors and their immediate staff.
This view of the NIH campus looks south beyond the Stokes Labs and Natcher Building (center) to the reflective façade of the National Library of Medicine (upper right).

HISTORICAL PHOTOS OF SCIENTISTS

The NIH began in 1887 as a one-room Hygienic Laboratory in this Marine Hospital on Staten Island, New York. The Hygienic Laboratory was located here until 1891, when it was moved to Washington, D.C.

This is a photograph of a PHS research laboratory, circa 1899. The staff is shown at workstations with microscopes and laboratory glassware.

In 1910, U.S. Public Health Service workers prepared poisons to be used for the extermination of plague-carrying rats.

In 1910, researchers worked at a U.S. Public Health Service laboratory equipped with a bunsen burner, microscope, and petri dishes.

In 1916, Dr. Ida A. Bengston became the first woman on the professional staff at the U.S. Public Health Service Hygienic Laboratory. Dr. Bengston worked on ways of developing vaccines for spotted fever.

In 1919, field laboratory technicians for the Rocky Mountain Laboratory collected research specimens from the north side of Blodgett canyon, Montana.

A 1937 NIH laboratory technician surrounded by tools of the trade; a rack of cotton-stoppered test tubes, a microscope and various glass jars.

In 1939, laboratory technicians performed tick research at a field laboratory in Boulder, Colorado. The laboratory was equipped with a refrigerator, an autoclave, and a wood-burning stove.

In 1946, researchers work at a field laboratory set up in the basement of the Kew Gardens apartments in New York City.

In 1953, NIH scientists were seeking the cause of the hypersensitivity that develops during a 10-21 day lapse after infection before the onset of rheumatic fever or nephritis.

In 1954, NIH researchers were studying weight and blood changes in rats with folic acid deficiency.

In 1975, NIH's central computer facility housed computers to aid in the collection, analysis and display of data from laboratory instruments, such as this mass spectrometer.

Dr. Martin Rodbell, former scientific director of NIEHS, won the 1994 Nobel Prize in Physiology or Medicine. Photo courtesy of Andrew M. Rodbell.

Former NIEHS Director Kenneth Olden (l) with senior members of the NIEHS component of the team that identified the first breast cancer susceptibility gene, BRCA1. Also pictured (left to right) are Dr. J. Carl Barrett, Dr. Roger W. Wiseman, and Dr. Andrew Futreal. Photo by Steven...
Recent Photos from the National Eye Institute (NEI)

2008 PHOTOS

On a trip to China in 2008, NEI Director Dr. Paul A. Sieving (l) met with Dr. Kanxing Zhao (r), director of the Tianjin Eye Hospital. While other health care professionals observed, Dr. Sieving examined a 60-year-old man whose vision had been deteriorating. Their discussions resulted in a diagnosis of choroidal neovascular age-related macular degeneration, which causes loss of vision from the growth of new blood vessels in the eye. The man underwent imaging tests and was later evaluated for treatment.

lo-res | hi-res

2005 PHOTOS

NIH Director Dr. Elias A. Zerhouni (seated left) and Dr. Maharaj K. Bhan, secretary of the Department of Biotechnology, India (seated right) sign the Statement of Intent for the Indo-U.S. Collaboration on Expansion of Vision Research, August 24, 2005. The signing took place at the Lawton Chiles International House on the NIH campus in Bethesda, Maryland. Looking on are Tina Chung of NIH's John E. Fogarty International Center (left) and Dr. Kamal K. Dwivedi, counsellor for science and technology, Embassy of India (right).

lo-res | hi-res

This page last reviewed on February 24, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the National Heart, Lung, and Blood Institute (NHLBI)

2009 PHOTOS

NHLBI Program Director Dr. Cristina Rabadán-Diehl greets Centers of Excellence representatives from around the globe, UnitedHealth Group members, scientific advisors, and NHLBI staff, including Acting Director Susan B. Shurin, M.D., on December 16, 2009 in Bethesda, Md.

Students from Umana Middle School Academy and their principal, Jose Salgado, Ed.D., playing at a We Can! event held at the Boston Children's Museum's Kid Power exhibit.

2007 PHOTOS

NHLBI Director Dr. Elizabeth G. Nabel speaks at the January 2007 launch of the NHLBI's Learn More Breathe Better campaign to raise awareness of chronic obstructive pulmonary disease. Photo courtesy of NHLBI.

At a November 2007 news conference, Ivonne Borrero, mother of 2, describes how the We Can! parents' program has helped her family learn to eat healthier and be more physically active. We Can! (Ways to Enhance Children's Activity and Nutrition) is a science-based national education program developed by NHLBI to help children ages 8 to 13 stay at a healthy weight by improving food choices, increasing physical activity, and reducing recreational screen time. The news conference announced the expansion of We Can! through a partnership with the Association of Children's Museums. Additional speakers (pictured, left to right) included Dr. Elias Zerhouni, NIH Director; Dr. Steven K. Galson, Acting U.S. Surgeon General; Lou Casagrande, president and CEO of Boston Children's Museum, which hosted the event. Photo by Les Veilleux Photography.
Recent Photos from the National Human Genome Research Institute (NHGRI)

2009 PHOTOS

In November 2009, Eric D. Green, M.D., Ph.D., is appointed as director of the National Human Genome Research Institute.

An image of a cross-section of a cell from NHGRI’s Talking Glossary of Genetic Terms, updated in 2009.

This page last reviewed on February 24, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the National Institute on Alcohol Abuse and Alcoholism (NIAAA)

2010 PHOTOS

In celebration of its 40-year anniversary, in 2010 NIAAA installed commemorative banners across the NIH campus.

Presenters at the NIAAA 40th Anniversary Symposium, as well as NIAAA Acting Director, Dr. Kenneth R. Warren and past Director, Dr. Enoch Gordis. (Credit: Ernie Branson)

2007 PHOTOS

Dr. Boris Tabakoff (right), professor and chairman in the Department of Pharmacology, University of Colorado School of Medicine, accepts the 2007 Mark Keller Honorary Award from NIAAA Director Dr. T.-K. Li. (Photo by Bill Branson, NIH Medical Arts and Photography Branch)
Recent Photos from the National Institute of Allergy and Infectious Diseases (NIAID)

2009 PHOTOS

W. Ian Lipkin, M.D. delivers the 2009 Kinyoun lecture.

Poster for the 2009 Kinyoun Lecture.

2007 PHOTOS

NIAID Director Dr. Anthony S. Fauci receives the 2007 Mary Woodard Lasker Award for Public Service. The award recognized Dr. Fauci's role in developing two major U.S. public health programs, in AIDS and biodefense.

Harvard Medical School’s Dr. Paul Farmer focused on community-based care for chronic infectious disease when he delivered the 2007 James C. Hill Memorial Lecture, presented in April 2007 on the NIH campus. The Hill lecture honors the memory of the former NIAID deputy director, who helped build the Institute's HIV/AIDS research program during the early years of the epidemic.
Recent Photos from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

2010 PHOTOS

The trans-NIH American Indian/Alaska Native (AI/AN) Health Communications and Information Work Group hosted a half-day workshop on December 8, 2010 for NIH communications staff on “Creating Connections: Building Partnerships between the Indian Health Service (IHS) and the National Institutes of Health (NIH).” Speakers and moderators at the 2010 NIH AI/AN Workshop. From left: Wilbur Woodis, OASH; Leo Nolan, IHS; Susan Anderson, IHS; Thomas Sweeney, IHS; Mimi Lising, NIAMS; Ben Smith, IHS; and Marin Allen, OD/OCPL.

In September 2010, NIAMS, NCI, NIAID and the Office of Research on Women’s Health cosponsored “Systemic Lupus Erythematosus: From Mouse Models to Human Disease and Treatment.” Organizers included (from l) Dr. Howard Young, NCI; Dr. Silvia Bolland, NIAID; and Dr. Juan Rivera, NIAMS.

The 2-day meeting at Lister Hill Center brought together basic research scientists working on models of autoimmune disease relevant to systemic lupus erythematosus and clinicians treating lupus patients. The conference generated ideas regarding future steps needed to further lupus research and the use of mouse models.

2009 PHOTOS

NIAMS researchers Raphaela T. Goldbach-Mansky, M.D., M.H.S. (left) and Nicole Plass, R.N., M.P.A., U.S. Public Health Service, with a DIRA patient. NIAMS’ research has led to the identification and successful treatment of DIRA (deficiency of the interleukin-1 receptor antagonist), a genetic autoinflammatory disorder in children.

Osteoarthritis Initiative (OAI) researchers at Ohio State University look through the opening of an MRI machine, used to image the knees of patients. The OAI, a public-private partnership, led by NIAMS and the National Institute on Aging with additional support from five other Institutes and Centers, funds research and information sharing resources to aid in the identification of biological markers for osteoarthritis.

NIAMS Director Stephen I. Katz, M.D., Ph.D., (center left) with former Congressman the Hon. John Porter and the co-chairs of the NIAMS Coalition. Mr. Porter gave the keynote address at the Coalition’s Education and Outreach Day, November 3, 2009. The meeting gave NIAMS Coalition members an opportunity to network and share best practices on the importance of connecting science to the public, while learning more about the inner workings of the NIH and NIAMS.

2007 PHOTOS

In September 2007, NIH Director Dr. Elias Zerhouni and NASA Administrator Dr. Michael D. Griffin signed an agreement making U.S. resources on the International Space Station available for NIH-funded research. Sen. Kay Bailey Hutchison (l), Sen. Barbara Mikulski, and NIAMS Director Dr. Steve Katz witnessed the occasion.
Recent Photos from the National Institute of Biomedical Imaging and Bioengineering (NIBIB)

2009 PHOTOS


2007 PHOTOS

At NIBIB's 5th Anniversary Symposium, held in June 2007, NIBIB Director Dr. Roderic Pettigrew (l) chatted with special guest speaker Dr. Charles Townes, recipient of the 1964 Nobel Prize in Physics for his discovery of the laser.

In June 2007, NIBIB Director Dr. Roderic Pettigrew (l) presented the first NIBIB Landmark Achievement Award to M. Joan Dawson, wife of the late Dr. Paul Lauterbur. As a 2003 Nobel Laureate in Physiology or Medicine, Dr. Lauterbur was recognized for his pioneering contributions to the development of magnetic resonance imaging.

At a meeting in New Delhi, Dr. Maharaj Bhan (l), Secretary of the Republic of India's Department of Biotechnology, Ministry of Science, shakes hands with NIBIB Director Dr. Roderic Pettigrew following the signing of a bilateral agreement in 2007. Witnessing the occasion (left to right) were Steven White, Deputy Chief of Mission, U.S. Embassy, New Delhi; Elias Zerhouni, NIH Director; Kapil Sibal, Science Minister; T.S. Rao, Medical Biotechnology Group Leader; and Roger Glass, Director of NIH's Fogarty International Center.
Recent Photos from the National Institute on Deafness and Other Communication Disorders (NIDCD)

2010 PHOTOS

Dr. Jay Rubinstein (left) and Dr. Jennifer Hsia implant a novel vestibular prosthesis in a patient at the University of Washington Medical Center. This is the first time a prosthesis for balance disorders has ever been implanted in a human. In the United States, more than 150,000 individuals are estimated to suffer from severe to profound bilateral vestibular deficiency, and a prosthesis like this potentially could benefit many of them, as well as patients with episodic disabling vestibular dysfunction such as Ménière's disease. NIDCD funding helped support development of the device and preclinical animal testing for its use in the treatment of balance disorders. (Photo credit: Clare McLean, University of Washington)

Dr. Peter Gillespie, professor of otolaryngology at Oregon Health and Science University, delivered the first Robert J. Wenthold Memorial lecture on The Hair Bundles' Protein Constellation. The seminar, part of the NIH Neuroscience Seminar Series, was in honor of Bob Wenthold who served as NIDCD's scientific director from 1998 through 2008, and was a vital force in helping build the NIDCD intramural program's research foundation in such areas as genetics, molecular and developmental biology, computational modeling and brain imaging. On the clinical side, he championed NIDCD's Otolaryngology Research Fellow Program, a program that provides research training under the mentorship of NIDCD scientists and helps move research findings on potential treatments from the laboratory into clinical practice. (Photo credit: NIH Medical Arts)

2008 PHOTOS

In February 2008, NIDCD researchers reported that they'd used functional MRI to study the brains of musicians playing improvised jazz. The images revealed that a large brain region involved in monitoring one's performance shuts down during creative improvisation, while a small region involved in organizing self-initiated thoughts and behaviors is highly activated. (Image courtesy of Charles J. Limb and Allen R. Braun, NIDCD.)

In October 2008, NIDCD launched a new campaign to protect the hearing of tweens. A new web site offers parents resources to help tweens avoid hearing loss from noise.

NIDCD Director Dr. James Battey, Jr., delivered opening remarks at the Institute's anniversary symposium highlighting 20 years of research accomplishments on October 23, 2008. (Photo by Bill Branson, NIH Medical Arts and Photography Branch)

Dr. Richard Axel, university professor and investigator in the Howard Hughes Medical Institute, Columbia University, spoke on 'Internal Representations of the Olfactory World' at the NIDCD 20th Anniversary Symposium. Dr. Axel is a recipient of the 2004 Nobel Prize in Physiology or Medicine for his groundbreaking research on the sense of smell. (Photo by Bill Branson, NIH Medical Arts and Photography Branch)
Recent Photos from the National Institute of Dental and Craniofacial Research (NIDCR)

2010 PHOTOS

On August 19, 2010, NIH Director Francis S. Collins appointed NIDCR Director Lawrence Tabak as Principal Deputy Director, NIH. Dr. Tabak had served as director of NIDCR since September 2000.

With funding from the American Recovery and Reinvestment Act, NIDCR issued a grant to Dr. Tracie Ferreira’s lab to map the location of a gene in zebrafish that is involved in cartilage development. The gene could be a key component in craniofacial development in vertebrates, including humans. The grant also provides the means for students from underserved communities a chance to work with Dr. Ferreira in her lab at the University of Massachusetts at Dartmouth.

Attack of the S. mutans! was featured in the NIH pavilion at the October 23-24, 2010 USA Science & Engineering Expo on the National Mall in Washington, D.C. The finale of a two-week-long festival, the Expo had more than 500 exhibitors, 1,500 hands-on activities, and 75 stage shows. Attack of the S. mutans! is a 3-D interactive game that aims to advance understanding of the tooth decay process, including the role of a bacterium known as S. mutans, while assessing how the use of games can change behavior. The game was created with funding from NIDCR and NIH's National Center on Minority Health and Health Disparities.

2009 PHOTOS

NIDCR's new Strategic Plan 2009-2013 is built on four key goals: widening the scope of inquiry, strengthening the research pipeline, fostering novel clinical research avenues, and eliminating oral health disparities.

In 2009, NIDCR issued the first research and technology grants for its new FaceBase Consortium. This project will enhance understanding of the genetic and environmental influences that drive craniofacial development and will yield new opportunities for preventing and treating craniofacial defects, like cleft lip and palate. (Courtesy of the Rowden Family)

2008 PHOTOS

On June 24, 1948, President Harry S. Truman signed legislation that created the National Institute of Dental Research as the third institute of the National Institutes of Health.

NIDCR commemorated its 60th anniversary with scientific symposia held at NIH and at major dental research meetings around the country and abroad.
Recent Photos from the National Institute on Drug Abuse (NIDA)

2010 PHOTOS

NIDA's new in 2010 “Drug Facts: Shatter the Myths” Q&A booklet answers teens’ most frequently asked questions about drugs and drug abuse.

In November, 2010, NIDA launched National Drug Facts week, a health observance week for teens that aims to shatter the myths about drugs and drug abuse.

Daevion Caves (age 18) and Jordan Earle Atkins (age 16) of Alton High School in Alton, IL won first place in the Teen Substance Abuse Awareness through Music Contest—a collaboration between NIDA and the MusiCares and GRAMMY Foundations.

2009 PHOTOS


The NIDAMED initiative stresses the importance of the patient-doctor relationship in identifying unhealthy behaviors before they evolve into life threatening conditions. This patient-tested poster—one of the NIDAMED resources—encourages patients to “Tell Your Doctors About All the Drugs You Use.” Doctors are encouraged to put the poster on display in their waiting rooms.

2008 PHOTOS

NIH's Biomedical Research Center, located on the Johns Hopkins University Bayview campus in Baltimore, Maryland, opened on June 2, 2008. The Biomedical Research Center contains major components of the intramural research programs of the National Institute on Drug Abuse, including 500,000 gross square feet of laboratory, vivarium, and administration space.

2007 PHOTOS

The cover of the NIDA’s first plain language booklet explaining the science behind addiction—Drugs, Brains & Behavior - The Science of Addiction.

During NIDA’s first national “Drug Facts Chat Day,” more than 40 scientists and science writers who specialize in addiction issues answered over 36,000 questions submitted online by high school students across the country. The students asked wide-ranging questions on drug abuse-related topics, and experts tried to answer them as soon as possible.

NIDA Director Dr. Nora Volkow was among the experts who assisted during the chat day's 10-hour question-and-answer session. The scientists and writers sometimes fielded as many as 6,000 questions per hour.

NIDA staffers David Anderson, Dr. Ruben Baler, and Dr. Barry Hoffer answered students’ questions about how drugs affect the brain during NIDA’s Drug Facts Chat Day.
Recent Photos from the National Institute of Environmental Health Sciences (NIEHS)

2007 PHOTOS

Panoramic photograph of the main NIEHS building in Research Triangle Park, NC. Photo by Steven R. McCaw.


This page last reviewed on February 24, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the National Institute of General Medical Sciences (NIGMS)

For more scientific images, illustrations, and videos, visit the NIGMS Image Gallery.

2010 PHOTOS

Long-time NIGMS grantee Ei-ichi Negishi shared the 2010 Nobel Prize in chemistry with Richard F. Heck and Akira Suzuki for developing carbon-carbon bond-forming methods. The methods, now widely used in the production of substances ranging from medicines to plastics, let scientists bring two molecules very close together. This allows the molecules to couple, form a compound with a new carbon-carbon bond, release the product and be ready for another cycle. To date, NIGMS has supported the research of 74 Nobel Prize winners. (Structure image courtesy of PubChem)

2009 PHOTOS

NIH grantees Venkatraman Ramakrishnan, Thomas A. Steitz, and Ada E. Yonath shared the 2009 Nobel Prize in chemistry for their “studies of the structure and function of the ribosome.” Ribosomes are the molecular factories that manufacture proteins in humans and other organisms. Knowing the structure and function of the ribosome has helped us understand one of life's most fundamental processes and manipulate it—many of our antibiotics work by disrupting bacterial ribosomes. (Image courtesy of Catherine Lawson, Rutgers University, and the RCSB Protein Data Bank.)

NIH grantees Elizabeth H. Blackburn, Carol W. Greider, and Jack W. Szostak shared the 2009 Nobel Prize in physiology or medicine for their discovery of "how chromosomes are protected by telomeres and the enzyme telomerase." Like the plastic tips of shoelaces, telomeres protect chromosomes and the genetic information they contain. We now know that these chromosomal caps play critical roles in human health and disease. (Image courtesy of Hesed Padilla-Nash and Thomas Ried.)

2008 PHOTOS

NIH grantees Martin Chalfie and Roger Y. Tsien shared the 2008 Nobel Prize in chemistry with former grantee Osamu Shimomura for their groundbreaking work on green fluorescent protein. This naturally glowing protein found in jellyfish has become a powerful tool for studying molecules inside living cells. (Image courtesy of Roger Tsien, University of California, San Diego)

2007 PHOTOS

This model of the enzyme nicotinic acid phosphoribosyltransferase is one of more than 2,000 protein structures solved as part of NIGMS's Protein Structure Initiative. Although the enzyme is from a bacterium, its amino acid sequence suggests that it is structurally similar to a clinically important human protein called B-cell colony enhancing factor. (Image courtesy of Berkeley Structural Genomics Center)

Hailed as a scientific breakthrough, NIGMS grantee James Thomson used human skin cells to create ones that appear to be indistinguishable from embryonic stem cells. In 2007, Thomson and his colleagues reported that they'd reset the skin cells to the embryonic state by supplying them with 4 genes, giving them the potential to become any of the 220 cell types in the body. The new technique is expected to bring stem cells within easier reach of more scientists, providing them with better models for studying many human diseases and possibly speeding the advent of cell-based therapies for conditions such as diabetes and arthritis. This work also was supported by NIH's National Center for Research Resources (NCRR). (Image courtesy of Junying Yu, University of Wisconsin-Madison)
Recent Photos from the National Institute of Mental Health (NIMH)

2009 PHOTOS

Cover of the NIMH Strategic Plan. Implementation of the Strategic Plan's four major objectives began in 2008.

In October 2008, NIMH and the U.S. Army entered into a $50 million memorandum of agreement to study suicide and suicidal behavior among soldiers. Signing the agreement are (L-R seated at table) U.S. Army Chief of Staff General George W. Casey, Jr., Army Secretary Pete Geren, and NIMH Director Dr. Thomas R. Insel.

This page last reviewed on February 24, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the National Institute of Nursing Research (NINR)

2010 PHOTOS

NINR Director Dr. Patricia A. Grady (l) with NIH Director Dr. Francis Collins (c) at the May 2010 meeting of the National Advisory Council for Nursing Research. (Michael Spencer, photographer)

NINR Director Dr. Patricia A. Grady (c) with the graduating class of the 2010 NINR Summer Genetics Institute. (Charles Rose, photographer)

NINR Director Dr. Patricia A. Grady (r), with former NINR Director Dr. Ada Sue Hinshaw (c), and NINR Deputy Director Dr. Mary E. Kerr (l), at the unveiling of Dr. Hinshaw’s portrait during the NINR 25th Anniversary Kickoff Science Symposium. (September 2010). (Michael Spencer, photographer)

2009 PHOTOS

The graduating class of the 2009 NINR Summer Genetics Institute, July 2009

NINR Director Dr. Patricia A. Grady, speaking at the Oklahoma Statewide Nursing Research Day conference, April 2009. (Photo supplied by: Beverly Bowers, PhD, RN, CNS, University of Oklahoma, College of Nursing)

NINR director Dr. Patricia A. Grady addresses the NIH Partners in Research investigator workshop, October 2009. Dr. Howard K. Koh, Assistant Secretary for Health in the U.S. Department of Health and Human Services, also spoke at this workshop.

2008 PHOTOS

NINR Director Dr. Patricia A. Grady receives an honorary doctor of science degree in June 2008 from Dr. John C. LaRosa, president of the State University of New York Downstate Medical Center.

NINR director Dr. Patricia A. Grady (l) with former First Lady Rosalynn Carter at the Friends of NINR NightinGala, held in October 2008 in Washington, D.C. Hosted by the Friends of the National Institute of Nursing Research, this annual event celebrates nursing science and NINR. (Photo by James Tkatch)

NINR Deputy Director Dr. Mary Kerr (2nd from r) during an outreach visit to Alaska in October 2008 with members of the NIH Office of Equal Opportunity and Diversity Management and the NIDDK Office of Minority Health Research Coordination. The NIH representatives met with state government and university officials, health care professionals and students, and members of the Alaska Native/American Indian (AN/AI) community to provide information about NIH research and training opportunities and to learn about the health conditions and needs of the AN/AI population.

Dr. Anne Ersig (r), NINR's first graduate from its Graduate Partnership Program in Biobehavioral Research, receives her certificate in November 2008 from NINR Deputy Director Dr. Mary Kerr. (Photo by Michael Spencer, NIH)
2007 PHOTOS

NINR Director Dr. Patricia A. Grady speaks at a science symposium launching a year-long celebration of the Institute's 20th Anniversary. The celebration officially concluded in October 2006.

lo-res | hi-res

NINR Director Dr. Patricia A. Grady (seated, third from right) with the 2007 National Advisory Council for Nursing Research.

lo-res | hi-res
Recent Photos from the National Library of Medicine (NLM)

2010 PHOTOS

NLM MedlinePlus.gov
NLM's popular consumer Web site, MedlinePlus (www.medlineplus.gov) undertook a complete (and well-received) makeover of its site, in English and en español, in 2010.
lo-res

NLM Mobile MedlinePlus
MedlinePlus also launched a mobile version, http://m.medlineplus.gov/, to provide users with on-the-go access to many resources located on the Web site.
lo-res | hi-res

NLM Data Standards
Key elements in the implementation of electronic health records nationwide are standardization of medical terminology and interoperability of those records. NLM has a long and distinguished history in this area and continues to work closely with policymakers at HHS and the White House, and to conduct its own research.
lo-res | hi-res

NLM Disaster Information Management Resource Center
Resources were added this year to the DIMRC site, to aid those coping with earthquakes in Chile and Haiti, and the Gulf oil spill. This year, NLM also activated the Emergency Access Initiative, to provide free reference materials to Haiti and Pakistan.
lo-res | hi-res

NLM medlineplus4you
In 2010, social media really took off at NLM. NLM has more Twitter feeds and Facebook accounts than any other NIH Institute or Center, and we're employing those to spread the word about NLM's many programs and services to our audiences all over the world.
lo-res | hi-res

2009 PHOTOS

BHEPP Disaster Drill
On October 15, 2009, NLM participated in a disaster drill in Bethesda, MD. Joining forces were the other members of the Bethesda Hospitals Emergency Preparedness Partnership (BHEPP)—the NIH Clinical Center, the National Naval Medical Center, and Suburban Hospital, Johns Hopkins Medical. This unique alliance pulls together public, private, and military facilities, creating a model that could be replicated around the country and also serving as a laboratory for the development of cutting-edge disaster-related technologies. NLM's effort is coordinated by the Disaster Information Management Research Center (DIMRC) office at the Division of Specialized Information Service (SIS).
lo-res | hi-res

NCBI's 20th Anniversary
The National Center for Biotechnology Information (NCBI), a component of NLM, celebrated its 20th anniversary with a program February 5, 2009 in Natcher Conference Center. NCBI is a national and international resource for molecular biology information. It creates public databases, conducts research in computational biology, develops software tools for analyzing genome data, and disseminates biomedical information—all for the better understanding of molecular processes affecting human health and disease.

NLA Director Dr. Donald A.B. Lindberg, who helped lead the charge for the creation of NCBI in the mid-1980s, gave an overview of the planning process. Here, he is showing an image of Congressman Claude Pepper (D-FL), whose House Select Committee on Aging Subcommittee on Health and Long-Term Care held hearings on the need for a national biotechnology information center. On the left is Aging Committee member Cong. Lindy Boggs (D-LA), while Frances Humphrey Howard, an NLM employee who was also a driving force in NCBI's creation, is on the right. She was the sister of U.S. Vice President Hubert H. Humphrey.
lo-res | hi-res

Powwows
Begun as an effort by the Office of the NIH Director and the NIH Office of Equal Opportunity (OEO) office in 2001, the NIH Native American Powwow Initiative has brought together several NIH offices during its history. It is now under the auspices of NLM. Participating in the powwows allows NLM to build and nurture relationship with Native American communities on the east coast and in other areas of the US. Specifically, these gatherings afford excellent opportunities for NLM staff to share health information (online and in print), while informing Native Americans about NIH as a
biomedical resource. These festive gatherings allows staff to engage Native Americans in conversation, learning about their specific health concerns and also learning more about their customs.

*This colorful scene is from the Mashpee-Wampanoag powwow, Cape Cod, Massachusetts, 4th of July weekend, 2009.*

**NIH MedlinePlus Magazine**

In 2009, NLM celebrated its third year of producing the NIH MedlinePlus quarterly magazine, an outreach effort made possible support from NIH and the non-profit Friends of the NLM. The free magazine contains no advertising and is widely distributed to the public via physician offices, libraries, and other locations, with a readership of up to 5 million nationwide. Each magazine focuses on the latest research results, clinical trials, and new or updated guidelines from the various NIH Institutes. A Spanish/English version, NIH MedlinePlus Salud (Spanish for “health”), was launched in January 2009 with support from the National Alliance for Hispanic Health to address the specific health needs of the growing Hispanic population and to showcase the many Hispanic outreach efforts and NIH-funded research results.

This page last reviewed on April 5, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the Center for Scientific Review (CSR)

2010 PHOTOS

CSR division directors discuss small business applications for tax credits and grants under the IRS Qualifying Therapeutic Discovery Project program.
lo-res | hi-res

CSR reviewers meet to review a group of the 20,000 Challenge grant applications submitted for Federal stimulus funds.
lo-res

The new NIH Rocket Boys of NIH Cartoon tells what happened to two real kids who got an NIH “grant” in 1957.
lo-res | hi-res

2009 PHOTOS

CSR Director Toni Scarpa presents the Marcy Speer Outstanding CSR Reviewer Award to Dr. John Raymond from the Medical University of South Carolina and the Ralph H. Johnson VA Medical Center.
lo-res | hi-res

CSR reviewers meet to review a group of the 20,000 Challenge grant applications submitted for Federal stimulus funds.
lo-res | hi-res

2008 PHOTOS

Study section chairs from 2 Integrated Review Groups convene during one of CSR's new biannual rounds of in-depth IRG reviews. The exercise helps CSR gain insights into emerging areas of science and ways to improve study section performance.
lo-res | hi-res

CSR Director Toni Scarpa (left) presents the Marcy Speer Outstanding Reviewer Award—CSR's top honor for excellence in review—to peer-review veteran Dr. David Sahn of Oregon Health and Science University. Photo by Ernie Branson, NIH Medical Arts and Photography Branch.
lo-res | hi-res

This page last reviewed on April 5, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the Fogarty International Center (FIC)

2010 PHOTOS

Dr. Hans Rosling of the Karolinska Institute drew a standing-room only crowd at his talk titled, "The New Health Gap: Science for Emerging Economies vs. the Bottom Billion." (Photo by Ernie Branson)

G8 representatives and leading African researchers met at NIH to discuss African research capacity. (Photo by Bill Branson)

Fulbright logo courtesy of U.S. Department of State

Longtime Fogarty grantee Dr. Jean ‘Bill’ Pape visited NIH to report his center’s HIV/AIDS research has resumed, just months after Haiti’s devastating 2010 quake. (Photo by Bill Branson).

NIH Director Dr. Francis S. Collins learns about one participant’s experience in Fogarty’s Scholars and Fellows program. (Photo courtesy of the Vanderbilt Institute for Global Health.)

Fogarty Director Dr. Roger I. Glass greets Bill Gates, who was a keynote speaker at the 2010 mHealth summit. (Photo Courtesy of Foundation for the National Institutes of Health.)

2009 PHOTOS

Fogarty Director Dr. Roger I. Glass introduces NIH Director Dr. Francis Collins to longtime Fogarty grantee Dr. Patricia Garcia, of Peru’s Cayetano Heredia University at the first meeting of the Consortium of Universities for Global Health. (Photo by Will Kirk, Johns Hopkins University)

Boston University associate provost and former Fogarty director, Dr. Gerald Keusch (center), catches up with Fogarty staffers Dr. Ken Bridbord (left) and Dr. Flora Katz (right) during the Consortium of Universities for Global Health meeting at NIH. (Photo by Jeff Gray, Fogarty International Center)

U.S. Department of Health and Human Services Secretary Kathleen Sebelius was one of the keynote speakers at the 2009 mHealth Summit, sponsored by the Foundation for the National Institutes of Health and Microsoft Research.

Health economist and Fogarty Scholar-in-Residence Dr. Jeffrey Sachs, tells an overflow audience at NIH, “We still have the need, we still have the opportunity” to improve global health. “The question is whether we can get organized.” (Photo by Bill Branson, NIH Medical Arts and Photography Branch)

NIH director Dr. Francis Collins urges members of the new trans-NIH working group on global health research to find better ways to leverage resources and coordinate international activities to improve human health. (Photo by Michael Spencer, NIH Medical Arts and Photography Branch)

2008 PHOTOS

Fogarty International Center marked its 40th anniversary with a gala dinner at the Italian Embassy in Washington on October 15, 2008. The event—sponsored by the Foundation for NIH—brought together leaders from Congress, federal agencies, the scientific community, advocacy groups, the diplomatic corps, and business
Recent Photos from the Fogarty International Center (FIC) - The NIH Almanac - National... Page 2 of 2

leaders to celebrate Fogarty's 4 decades of contributions to global health. (From left): Foundation for NIH Chairman Dr. Charles A. Sanders greeted Fogarty Director Dr. Roger I. Glass and Sen. Richard Lugar (R-Ind.).

As part of Fogarty's 40th anniversary celebrations, the Center co-sponsored a symposium titled "The Role of Science in Advancing Global Health Diplomacy," held at the Georgetown University Law Center on Nov. 12, 2008. Panelists included (from left): Former U.S. Ambassador to Uganda Jimmy Kolker; former NIH Director Dr. Elias Zerhouni, and Harvard School of Public Health Professor Dr. Jim Kim. (Photo by Jeff Gray, Fogarty International Center)

Former NIH Director Dr. Harold Varmus delivered the 2008 David E. Barmes Global Health Lecture titled "The U.S. Commitment to Global Health." Fogarty co-sponsors the annual event with the National Institute of Dental and Craniofacial Research in honor of the late David E. Barmes, who was a special expert for international health at NIDCR. (Photo by Ernie Branson, NIH Medical Arts and Photography Branch)

2007 PHOTOS

On October 22, 2007, NIH's Fogarty International Center and National Library of Medicine co-sponsored the launch of the Council of Science Editor's global theme issue on poverty and human development. The event coincided with the publication of related research by more than 230 journals worldwide. Researchers gathered from around the world to present scientific discoveries published as part of the theme issue.

Fogarty Director Dr. Roger I. Glass (center) accompanied U.S. Health and Human Services Secretary Michael Leavitt (left) on a visit to Africa in August 2007. They met with local officials and observed U.S. government programs that are delivering health care to underserved communities.

This page last reviewed on May 4, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

"NIH...Turning Discovery into Health" is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the National Center for Complementary and Alternative Medicine (NCCAM)

2009 PHOTOS

This figure shows total out-of-pocket U.S. spending in 2007 for conventional health care and CAM, for prescriptions versus natural products, and for visits to CAM practitioners versus visits to physicians. Out of the total $33.9 billion spent on CAM, an estimated $22 billion was for self-care—i.e., CAM products, classes, and materials—mostly in the form of natural products. The remaining $11.9 billion was for CAM practitioner visits. The $14.8 billion spent on natural products was about 1/3 of out-of-pocket spending on prescription drugs, and the $11.9 billion spent on CAM practitioner visits was about 1/4 of out-of-pocket spending on physician visits.

Credit: NCCAM
lo-res | hi-res

2008 PHOTOS

Poster for NCCAM’s 10th Anniversary Symposium, Exploring the Science of Complementary and Alternative Medicine
lo-res | hi-res

NCCAM’s “Time To Talk” campaign, launched in June 2008, encourages patients and their health care providers to openly discuss the use of complementary and alternative medicine, to help ensure safe and coordinated care. Free toolkits (as pictured) are available. (Photo copyright Matt Fletcher)
lo-res | hi-res

Massage therapy appeared to ease pain and improve mood in the short term in a group of advanced cancer patients, according to findings from an NCCAM-funded study in 2008. The study, led by a University of Colorado Denver team at 15 U.S. hospices, found benefit also, to a lesser degree, from simple touch. (Photo copyright Bob Stockfield)
lo-res | hi-res

2007 PHOTOS

Participants discuss issues related to NCCAM and complementary and alternative medicine at an “NCCAM Stakeholder Dialogue” meeting, held at NIH in June 2007.
lo-res

This page last reviewed on February 24, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Recent Photos from the National Center for Research Resources (NCRR)

2010 PHOTOS

With pilot funding from the Northwestern University Clinical and Translational Sciences Institute, supported through the CTSA program, researchers studied sticky proteins produced by the foot of the common mussel (*Mytilus edulis*). Northwestern University researcher Phillip Messersmith developed synthetic materials mimicking these proteins that can stick to different surfaces even in wet environments. Messersmith tested these mussel-based "glues" to repair tears that occur in amniotic sacs, a complication of some pregnancies. (Photo courtesy of Northwestern University.)

Lo-res | Hi-res

The ImageVis3D mobile visualization program — free to download via the Apple iTunes store — allows anyone to view realistic, high-resolution 3-D pictures of medical image data. Scientists and doctors now can observe patients' CAT scans, MRIs, ultra-sounds, electron microscopy and other data in 3-D right from their phones. (Photo courtesy of the Scientific Computing and Imaging Institute, University of Utah.)

Lo-res | Hi-res

A research team led by Qi-Long Ying at the University of Southern California demonstrated that a gene-targeting mutation in rat embryonic stem cells can be transmitted through the germline to produce rats with the same mutation, providing a powerful new approach for creating models to study gene function relevant to human diseases. Photo courtesy of Qi-Long Ying, assistant professor of cell and neurobiology at the Keck School of Medicine of USC.

Lo-res | Hi-res

With both a residency in anesthesiology and a Ph.D., Rebecca Johnson divides her time between clinical work and research at the University of Wisconsin-Madison School of Veterinary Medicine. In the clinic, Johnson serves as the anesthesiologist for all types of animals, from domestic cats to tigers. Photo courtesy of the University of Wisconsin-Madison.

Lo-res | Hi-res

2009 PHOTOS

Architect Nannette Rodriguez (left) and builder Mark Crudup discuss plans for a new facility at the University of Puerto Rico. Behind them is an artist's rendition of the building — the first in Puerto Rico to be designed exclusively to support research. NCRR supported the building's construction with Extramural Research Facilities Improvement grants. Professor Loyda Meléndez (right) and other university colleagues will use the new facility to conduct research in such areas as neuroscience, cancer and molecular studies. (Artist rendition courtesy of the University of Puerto Rico; portraits by Paco Márquez.)

Lo-res | Hi-res

Sandy Yoder, MT, senior research specialist, works in Vanderbilt University Medical Center's Pediatric Infectious Diseases Lab. She uses liquid nitrogen to keep vials at 220 degrees below zero. Yoder is putting away influenza samples obtained in vaccine trials at Vanderbilt. (Photo by Neil Brake, courtesy of Vanderbilt University Medical Center.)

Lo-res | Hi-res

A prototype helmet bears 90 overlapping coils that pick up an MRI signal. The helmet, designed by NCRR-supported researchers at Massachusetts General Hospital, defied scientific dogma to make more powerful brain scans possible. (Lawrence Wald and Graham Wiggins, Massachusetts General Hospital.)

Lo-res | Hi-res

Science Education Partnership Awards provide two to five years of grant support to stimulate scientific curiosity and encourage hands-on science education activities among students in kindergarten through 12th grade. (Photo courtesy of Palladian Partners, Inc.)

Lo-res | Hi-res

2008 PHOTOS

Dr. Nasser Altorki, director of the Division of Thoracic Surgery at New York-Presbyterian Hospital/Weill Cornell Medical Center, confers with a colleague about a CT scan of a patient's chest. Weill Cornell Medical College became a member of the Clinical and Translational Science Awards (CTSA) consortium in October 2009. The CTSA Program—led by NCRR—is designed to speed discoveries from the laboratory to clinical practice. (Photo courtesy of Weill Cornell Medical College.)

Lo-res | Hi-res
Researchers at the NCRR-supported Yerkes National Primate Research Center introduced—for the first time ever—a gene for a human disease into a primate. The result is an animal model that shows disease progression and symptoms characteristic of human Huntington's disease, which may make it possible to test new therapies for human patients. Here, cells isolated from the monkeys glow because they express a jellyfish gene for green fluorescent protein, which signals the successful transfer of the human disease gene. (Photo by Dr. Anthony Chan/Yerkes National Primate Research Center)

2007 PHOTOS

Dr. Nasser Altorki, director of the Division of Thoracic Surgery at New York-Presbyterian Hospital/Weill Cornell Medical Center, confers with a colleague about a CT scan of a patient's chest. Weill Cornell Medical College became a member of the Clinical and Translational Science Awards (CTSA) consortium in October 2007. The CTSA Program—led by NCRR—is designed to speed discoveries from the laboratory to clinical practice. (Photo courtesy of Weill Cornell Medical College)

The sequencing of the rhesus macaque genome—funded by NIH's National Human Genome Research Institute—was performed at the Baylor College of Medicine Human Genome Sequencing Center in Houston, Texas; the Genome Sequencing Center at Washington University in St. Louis, Missouri; and the J. Craig Venter Institute in Rockville, Maryland. This effort was supported by several NCRR-funded National Primate Research Centers. (Photo by Randall C. Kyes / University of Washington)

Nashville's Vanderbilt University Institute of Imaging Science received a $2 million High-End Instrumentation (HEI) grant from NCRR to support the purchase of a 7-tesla human magnetic resonance imaging and spectroscopy system. It provides the highest magnetic imaging available for humans and is one of only several such instruments in the country. (Photo by Dana Johnson, courtesy of Vanderbilt University Medical Center)

Physicians, scientists, and engineers at Rhode Island Hospital and The Warren Albert Medical School of Brown University are establishing a multidisciplinary Center of Biomedical Research Excellence in Skeletal Health and Repair to develop treatment strategies for bone and joint diseases such as osteoarthritis. The Center is funded by NCRR's Institutional Development (I DeA) Program, which builds capacity in underserved states. Pictured is Dr. Qian Chen, director of the Center at Rhode Island Hospital. (Photo courtesy of Lifespan/Robin Dunn Blossom)
Recent Photos from the Clinical Center (CC)

2009 PHOTOS

Precision is the goal of a new collaboration involving the Clinical Center, the National Cancer Institute, and the National Heart, Lung, and Blood Institute. The Center for Interventional Oncology will pull on the strengths of each to investigate how imaging technology can diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. Chief of the new Center for Interventional Oncology, Dr. Bradford Wood, demonstrates image-guided tumor ablation in a CC Radiology and Imaging Sciences suite.

BTRIS, the Biomedical Translational Research System, was implemented in two phases in 2009. The July launch of the NIH-wide intramural research data repository allowed principal investigators to view identified data from their active protocols. In December, intramural researchers were able to access de-identified from clinical and research systems across the intramural program. On hand to help launch BTRIS on July 30 were (from left) Elaine Ayres, deputy chief of the CC Laboratory for Informatics Development (LID); Dr. Jack Jones, NIH chief information officer; Dr. Jim Cimino, BTRIS project director and chief of the CC Laboratory for Informatics Development; and Dr. Michael Gottesman, NIH deputy director of intramural research.

This page last reviewed on February 24, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Legislative Chronology


This legislative chronology is limited to enactments that had a major influence upon the Marine Hospital Service as it evolved into the PHS, to legislation leading to the establishment of the National Institutes of Health, and to specific NIH legislation with the exception of appropriations bills, unless such bills provided significant new authorities for or restrictions on NIH components. To view the actual public law, see the Office of NIH History website http://history.nih.gov/research/sources_legislative_chronology.html.

1700

July 16, 1798—"An Act for the relief of sick and disabled Seamen" established the Marine Hospital Service for merchant seamen. The Marine Hospital Service—foreunner of the present-day PHS—became a component of the Treasury Department. A monthly hospital tax of 20 cents was deducted from the pay of merchant seamen in the first prepaid medical care plan in the United States. (1 Stat. L. 605.)

March 2, 1799—An amending act to the legislation of 1798 extended Marine Hospital Service benefits to officers and men of the U.S. Navy. This arrangement continued until 1818 after which the Navy built its own hospitals. However, the deduction of 20 cents per month from the pay of Navy and Marine Corps personnel continued until June 15, 1943. (1 Stat. L. 729.)

1800

June 29, 1870—A bill to reorganize the Marine Hospital Service and establish a central controlling office in Washington, D.C., was enacted. This act also increased the amount of hospital tax paid by seamen from 20 cents to 40 cents per month, a tax which continued until 1884. (16 Stat. L. 169.) (After the seamen's hospital tax was abolished July 1, 1884, the cost of maintaining Marine hospitals was paid out of a tonnage tax until 1906. Since then medical care for merchant seamen and other beneficiaries of the service has been supported by direct congressional appropriations.)

March 3, 1875—An act was passed authorizing the admission of seamen from the Navy and other government services to Marine hospitals on a reimbursable basis. The Surgeon General of the Marine Hospital Service was to be appointed by the President, by and with the advice and consent of the Senate. (18 Stat. L. 377.)

April 29, 1878—The first Federal Quarantine Act "to prevent the introduction of contagious or infectious diseases into the United States" was passed. (20 Stat. L. 37.)

March 3, 1879—The National Board of Health was created by law and given quarantine powers; first organized, comprehensive Federal medical research effort. (20 Stat. L. 484.)

January 4, 1889—A bill to establish a commissioned officer corps in the Marine Hospital Service was passed. This law established a mobile corps subject to duty anywhere upon assignment, a policy that had been in effect since Dr. Woodworth assumed leadership of the Marine Hospital Service in 1871. (25 Stat. L. 639.)

March 27, 1890—Congress gave the Marine Hospital Service interstate quarantine authority. (26 Stat. L. 31.)

February 15, 1893—A new Quarantine Act was passed following outbreaks of cholera in Europe, strengthening the inadequate Quarantine Act of 1878 by giving the Federal Government the right of quarantine inspection. The act of March 3, 1879, was repealed. (27 Stat. L. 449.)

March 2, 1899—The Marine Hospital Service was directed by Congress to investigate leprosy in the United States. (30 Stat. L. 976.)

1900

March 3, 1901—An appropriation of $35,000 was made for the Hygienic Laboratory building (first legislative mention of Hygienic Laboratory). Thus "investigations of contagious and infectious diseases and matters pertaining to public health" were given definite status in law. (31 Stat. L. 1086.)

July 1, 1902—A bill to increase the efficiency and change the name of the Marine Hospital Service to Public Health and Marine Hospital Service was enacted. The law authorized the establishment of specified administrative divisions and, for the first time, designated a bureau of the Federal Government as an agency in which public health matters could be coordinated. (32 Stat. L. 712.)

Another law, usually referred to as the Biologics Control Act, authorized the Public Health and Marine Hospital Service to regulate the transportation or sale for human use of viruses, serums, vaccines, antitoxins, and analogous products in interstate traffic or from any foreign country into the United States. (P.L. 57-244, 32 Stat. L. 728.)
1910

August 14, 1912—Under an act, the name Public Health and Marine Hospital Service was changed to Public Health Service. The legislation broadened the PHS research program to include "diseases of man" and contributing factors such as pollution of navigable streams, and information dissemination. (37 Stat. L. 309.)

July 9, 1918—The Chamberlain-Kahn Act provided for the study of venereal diseases by the PHS. (40 Stat. L. 886.)

October 27, 1918—A PHS reserve corps was established. The 1918 influenza pandemic emphasized the need for a reserve corps to meet such emergency situations. (40 Stat. L. 1017.)

1920

January 19, 1929—The Narcotics Control Act provided for construction of two hospitals for the care and treatment of drug addicts, and authorized creation of a Narcotics Division in the PHS Office of the Surgeon General. (P.L. 70-672, 45 Stat. L. 1085.)

1930

April 9, 1930—A law changed the name of the Advisory Board for the Hygienic Laboratory to the National Advisory Health Council. (P.L. 71-106, 46 Stat. L. 152.)

May 26, 1930—The Ransdell Act reorganized, expanded, and redesignated the Hygienic Laboratory as the National Institute of Health. The act authorized $750,000 for the construction of two buildings for NIH and authorized a system of fellowships. (P.L. 71-251, 46 Stat. L. 379.)

June 14, 1930—A law authorized creation of a separate Bureau of Narcotics in the Treasury Department to control trading in narcotic drugs and their use for therapeutic purposes. Also, the legislation redesignated the PHS Narcotics Division to the Division of Mental Hygiene, giving the Surgeon General authority to investigate abuse of narcotics and the causes, treatment, and prevention of mental and nervous diseases. (P.L. 71-357, 46 Stat. L. 585.)

August 14, 1935—The Social Security Act was an event of major importance in the progress of public health in the United States. This act authorized health grants to the states on the principle that the most effective way to prevent the interstate spread of disease is to improve state and local public health programs. With this legislation, the PHS became adviser and practical assistant to state and local health services. (P.L. 74-271, 49 Stat. L. 634.)

August 5, 1937—A law established the National Cancer Institute to conduct and support research relating to the cause, diagnosis, and treatment of cancer. The law authorized the Surgeon General to make grants-in-aid for research in the field of cancer, provide fellowships, train personnel, and assist the states in their efforts toward cancer prevention and control. (P.L. 75-244, 50 Stat. L. 559.)


1940

July 1, 1944—The PHS act consolidated and revised laws pertaining to the PHS and divided the service into the Office of the Surgeon General, Bureau of Medical Services, Bureau of State Services, and the National Institute of Health. The act gave the Surgeon General broad powers to conduct and support research into the diseases and disabilities of man, authorized projects and fellowships, and made the National Cancer Institute a division of NIH. The act also empowered the Surgeon General to treat at PHS medical facilities, for purposes of study, persons not otherwise eligible for such treatment. (P.L. 78-410, 58 Stat. L. 682.) Under this provision, the Clinical Center was later established. (Under this act, the Research Grants Office, January 1, 1946; the Experimental Biology and Medicine Institute and the National Microbiological Institute, November 1, 1948; and the Division of Research Services, January 1, 1956, were established.)

July 3, 1946—The National Mental Health Act was designed to improve the mental health of U.S. citizens through research into the causes, diagnosis, and treatment of psychiatric disorders. It authorized the Surgeon General to support research, training, and assistance to state mental health programs. (P.L. 79-487, 60 Stat. L. 421.) (The National Institute of Mental Health was established under the authority of this law on April 15, 1949.)

August 13, 1946—The Hospital Survey and Construction Act (Hill-Burton Act) authorized grants to the states for construction of hospitals and public health centers, for planning construction of additional facilities, and for surveying existing hospitals and other facilities. (P.L. 79-725, 60 Stat. L. 1040.)

July 8, 1947—Under P.L. 80-165, research construction provisions of the Appropriations Act for FY 1948 provided funds "for the acquisition of a site, and the preparation of plans, specifications, and drawings, for additional research buildings and a 600-bed clinical research hospital and necessary accessory buildings related thereto to be used in general medical research...."

June 16, 1948—The National Heart Act authorized the National Heart Institute to conduct, assist, and foster research; provide training; and assist the states in the prevention, diagnosis, and treatment of heart diseases. In addition, the act changed the name of National Institute of Health to National Institutes of Health. (P.L. 80-655, 62 Stat. L. 464.)

June 24, 1948—The National Dental Research Act authorized the National Institute of Dental Research to conduct, assist, and foster dental research; provide training; and cooperate with the states in the prevention and control of dental diseases. (P.L. 80-755, 62 Stat. L. 598.)
1950

August 15, 1950—The Omnibus Medical Research Act authorized the Surgeon General to establish the National Institute of Neurological Diseases and Blindness, as well as additional institutes, to conduct and support research and research training relating to other diseases and groups of diseases. (P.L. 81-692, 64 Stat. L. 443.) (The National Institute of Arthritis and Metabolic Diseases and the National Institute of Neurological Diseases and Blindness were established under the authority of this act on November 22, 1950. Under this same act, the National Institute of Allergy and Infectious Diseases was established on December 29, 1955, replacing the National Microbiological Institute which was originally established November 1, 1948, under authority of section 202 of the PHS act.)

April 1, 1953—Reorganization plan #1 assigned the PHS to the new Department of Health, Education, and Welfare.

July 30, 1956—The Health Research Facilities Act of 1956 (Title VII of the PHS act) authorized a PHS program of Federal matching grants to public and nonprofit institutions for the construction of health research facilities. (P.L. 84-652, 70 Stat. L. 489.)

July 30, 1956—The Health Research Facilities Act of 1956 (Title VII of the PHS act) authorized grants to non-governmental organizations for partial support of a nationwide study and reevaluation of the problems of mental illness. Under this act, the Joint Committee on Mental Illness and Health was awarded grant support for 3 years. (P.L. 84-182, 69 Stat. L. 381.)

July 3, 1956—The National Health Survey Act authorized the Surgeon General to survey sickness and disabilities in the United States on a sampling basis. (P.L. 84-652, 70 Stat. L. 489.)

July 28, 1956—The Alaska Mental Health Enabling Act provided for territorial treatment facilities to eliminate the need to transport the mentally ill outside Alaska. It also authorized PHS grants to Alaska for its mental health program. (P.L. 84-830, 70 Stat. L. 709.)

July 30, 1956—The Health Research Facilities Act of 1956 (Title VII of the PHS act) authorized a PHS program of Federal matching grants to public and nonprofit institutions for the construction of health research facilities. (P.L. 84-835, 70 Stat. L. 717.)

August 2, 1956—The Health Amendments Act of 1956 authorized the Surgeon General to assist in increasing the number of adequately trained nurses and professional public health personnel. It also authorized PHS grants to support the development of improved methods of care and treatment of the mentally ill. (P.L. 84-911, 70 Stat. L. 923.)

August 3, 1956—An amendment to Title III of the PHS act, the National Library of Medicine Act, placed the Armed Forces Medical Library under the PHS, and renamed it the National Library of Medicine. (P.L. 84-941.)

June 30, 1958—The Mutual Security Act of 1958 amended P.L. 83-480, authorizing the President to enter into agreements with friendly nations to use foreign currencies accruing under title I for collection, translation, and dissemination of scientific information and to conduct research and support scientific activities overseas. (P.L. 85-477.)

1960

July 12, 1960—Congress passed the International Health Research Act. The law authorized the Surgeon General to establish and make grants for fellowships in the United States and participating foreign countries; make grants or loans of equipment and other materials to participating foreign countries for use by public or nonprofit institutions and agencies; participate in international health meetings, conferences, and other activities; and facilitate the interchange of research scientists and experts between the United States and participating foreign countries. (P.L. 86-610, 74 Stat. L. 364.)

September 15, 1960—A law amended the PHS act to authorize grants-in-aid to universities, hospitals, laboratories, and other public and nonprofit institutions to strengthen their programs of research and research training in the sciences related to health. The act also authorized the use of funds appropriated for research or research training to be set aside by the Surgeon General in a special account for general research support grants. (P.L. 86-798, 74 Stat. L. 1053.)

October 17, 1962—An act authorized the Surgeon General to establish the National Institute of General Medical Sciences and the National Institute of Child Health and Human Development. The latter was authorized to conduct and support research and training relating to maternal health; child health; human development, in particular the special health problems of mothers and children; and the basic sciences relating to the processes of human growth and development. The former was authorized to conduct and support research in the basic medical sciences and related behavioral sciences that have significance for two or more institutes, or which are outside the general area of responsibility of any other institute. (P.L. 87-838, 76 Stat. L. 1072.) (On January 30, 1963, the NICHD and the NIGMS were established under this act.)

September 24, 1963—A law amended the Health Research Facilities Act of 1956 (Title VII to the PHS act) to allow grants for multipurpose facilities that would provide teaching space as well as essential research space. (P.L. 88-129, 77 Stat. L. 164.)

October 24, 1963—The Maternal and Child Health and Mental Retardation Planning Amendments of 1963 amended the Social Security Act of 1935 by authorizing a five-point grant program of $265 million, over a 5-year period. Major provisions designed to prevent mental retardation included increased Federal grants for maternal and child health services and crippled children's service administered by the Children's Bureau; a new 5-year program of grants to the states for health care of expectant mothers who have, or are likely to have, conditions associated with childbearing which may lead to mental retardation; funds for research to improve maternal and child health and crippled children's services; and grants to the states to assist in developing plans for comprehensive state and community programs to combat mental retardation. (P.L. 88-156, 77 Stat. L. 273.)

October 31, 1963—A companion measure to P.L. 88-156 was the Mental Retardation Facilities and Community Mental Health Centers Construction Act of 1963. This act authorized a total of $129 million over 5 years for grants to assist in the construction of mental retardation research centers and community mental health centers, and to train teachers of mentally retarded and other handicapped children. (P.L. 88-164, 77 Stat. L. 282.)

August 18, 1964—The Hospital and Medical Facilities Amendments of 1964 extended the Hospital Survey and Construction Act of 1946 (Hill-Burton Act) for 5 years with a total authorization of $1.4 billion. (P.L. 88-443, 78 Stat. L. 447.)


August 4, 1965—The Mental Retardation Facilities and Community Mental Health Centers Construction Act Amendments of 1965 provided monies through FY 1972 to help finance initial staffing of community mental health centers which were authorized in the original act; extended and increased appropriations authority for mental retardation education research and demonstration projects; and authorized increased annual funds through FY 1969 for training teachers of the handicapped young. (P.L. 89-105.)

August 9, 1965—The Health Research Facilities Amendments of 1965 extended the program for construction of health research facilities for 3 years with $280 million authorized for that period in lieu of the previous $50 million annual appropriations authorizations. (P.L. 89-115.)

August 31, 1965—A supplemental appropriations act resulting from recommendations of the President's Commission on Heart Disease, Cancer and Stroke provided an additional $20,250,000 (shared by NCI, NHL, NIGMS and NINDB) to intensify and expand support of research in the three major ‘killer’ diseases. (P.L. 89-156.)

October 6, 1965—The Heart Disease, Cancer and Stroke Amendments of 1965 provided for establishment of regional cooperative programs in research, training, continuing education and demonstration activities in patient care among medical schools, clinical research institutions and hospitals so that the latest treatment methods for the three diseases may be more widely available to patients. Under this act, the Division of Regional Medical Programs was created February 1, 1966. (P.L. 89-239.)

October 22, 1965—The Medical Library Assistance Act was passed, authorizing NLM's extramural programs. (P.L. 89-291.)

August 3, 1968—A law authorized the designation of a national center for biomedical communications as the Lister Hill National Center for Biomedical Communications. (P.L. 90-456.)

August 16, 1968—An amendment to the PHS act authorized the secretary to establish a National Eye Institute and to rename NINDB the National Institute of Neurological Diseases. The new institute was formed from NINDB programs to conduct and support research for new treatment and cures, and training relating to blinding eye diseases and visual disorders. (P.L. 90-489.)

The Health Manpower Act of 1968 extended and expanded the following five health laws then in effect: Health Professions Educational Assistance Act of 1963, as amended; Nurse Training Act of 1964, as amended; Allied Health Professions Personnel Training Act of 1966; Health Research Facilities Act of 1956, as amended; and Public Health Service Act of 1944, as amended. The measure provided a 2-year extension, through FY 1971, of the above legislation except for the Allied Health Professions Act, extended only through FY 1970. (P.L. 90-490.)

October 24, 1968—The President signed legislation further amending the name of NIND to National Institute of Neurological Diseases and Stroke. (P.L. 90-639.)

1970

March 12, 1970—An amendment to the PHS act extended and made coterminous through June 30, 1973, the authority to make formula grants to schools of public health, project grants for graduate training in public health, and traineeships for professional public health personnel. (P.L. 91-208, 84 Stat. 2.)


October 30, 1970—The PHS act was amended to provide: 1) extension of research contract authority in areas of public health through June 30, 1974; 2) authorization of mission-related clinical training (as well as research training) by the NIGMS; 3) clarification of terms in the regulation of biological products; 4) clarifying and technical directives relating to appointment, compensation and functions of advisory councils and committees, and 5) extension of statutory authority for regional medical programs, comprehensive medical planning, and health services research and development. (P.L. 91-315.)

November 2, 1970—The Health Training Improvement Act of 1970 extended and amended allied health professions training authority (which expired June 30, 1970) and established eligibility of new health professions educational assistance schools for "start-up" grants. (P.L. 91-519.)


May 22, 1971—Congress passed into law the Supplemental Appropriations Bill, which included $100 million for cancer research. This appropriation was made in response to the President's State of the Union address, in which he called for "an intensive campaign to find a cure for cancer." The appropriation includes authority under grants and contracts, as well as direct construction authority for NCi. (P.L. 92-18.)

July 9, 1971—A law amended the Public Health Service Act to provide for extension of student loan scholarship programs for up to four fiscal years. (P.L. 92-52.)

November 18, 1971—The President signed the Comprehensive Health Manpower Training Act of 1971 to provide increased manpower in the health professions, and the Nurse Training Act of 1971 to provide training for increased numbers of nurses. (P.L. 92-157, P.L. 92-158.)

December 23, 1971—The National Cancer Act of 1971 enlarged the authorities of NCi and NIH in order to advance the national effort against cancer. The authority of the director, NCi, was expanded, a National Cancer Advisory Board was established, and appropriations in excess of $400 million were authorized for 1972, with further increases in subsequent years. (P.L. 92-218.)
May 16, 1972—The National Sickle Cell Anemia Control Act of 1972 became law and established a national program for diagnosis and treatment of, and counseling and research in, sickle cell disease. (P.L. 92-294.)

May 19, 1972—The need for further support of research and training in the field of digestive diseases was emphasized by adding a new section 434 to the PHS act and renaming NIAMD the National Institute of Arthritis, Metabolism, and Digestive Diseases. (P.L. 92-305.)

August 29, 1972—The National Cooley's Anemia Control Act authorized over $9 million for 3 years for research in the diagnosis and treatment of Cooley's anemia, and for counseling and public information programs. (P.L. 92-414.)

September 19, 1972—The National Heart, Blood Vessel, Lung, and Blood Act expanded the authorities of the National Heart and Lung Institute to augment the national effort against heart, lung, and blood diseases. Appropriations of $375 million for 1973 were authorized with further increases in subsequent years. (P.L. 92-423.)

October 25, 1972—The National Advisory Commission on Multiple Sclerosis Act established a commission charged to determine the most productive avenue of researching possible causes and cures of MS, and make specific recommendations for the maximum utilization of national resources directed toward MS. (P.L. 92-563.)

June 18, 1973—The Health Programs Extension Act of 1973 extended the medical library assistance programs of NLM (with the exception of the construction program) for 1 year. Population research and family planning activities were also extended through FY 1974, along with other Federal health programs. (P.L. 93-45.)

November 16, 1973—The Emergency Medical Services System Act of 1973 amended the PHS act to provide assistance and encouragement for the development of comprehensive area emergency medical services systems, including grants and contracts for the support of research in emergency medical techniques, methods, devices, and delivery. (P.L. 93-154.)

April 22, 1974—The Sudden Infant Death Syndrome Act of 1974 amended the PHS act to authorize specific and general research on the sudden infant death syndrome through the NICHD. The collection, analysis, and public dissemination of information and data and the support of counseling programs were also authorized. The act did not authorize specific funds for research, but did authorize appropriations of $9 million over a 3-year period for the other programs. (P.L. 93-270.)

May 31, 1974—The Research on Aging Act of 1974 established a National Institute on Aging. The act authorized the NIA to conduct and support biomedical, social, and behavioral research and training related to the aging process and the diseases and other special problems and needs of the aged. (P.L. 93-296.)

June 22, 1974—The Energy Supply and Coordination Act directed the secretary through NEIHS to study the effects of chronic exposure to sulfur oxides, and authorized $3.5 million for that purpose. (P.L. 93-319.)

July 12, 1974—The National Research Act of 1974 amended the PHS act by repealing existing research training and fellowship authorities and consolidating such authorities in the national research service awards authority. The NRSAs (both individual and institutional grants) are restricted on the basis of subject area shortages and would involve service obligations and payback provisions. The act established a temporary National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research within the department to make a comprehensive investigation of the ethical principles involved in biomedical and behavioral research (including psychosurgery and living fetus research), and to develop ethical guidelines for conducting such research. Also, a permanent National Advisory Council for the Protection of Subjects of Biomedical and Behavioral Research was to be established. (P.L. 93-348.)

July 23, 1974—The National Cancer Act Amendments of 1974 authorized $2.565 billion over a 3-year period to extend and improve the National Cancer Program as well as $210.5 million over 3 years for cancer control programs. The act also: 1) established the President's Biomedical Research Panel to make a comprehensive investigation of Federal biomedical and behavioral research; 2) extended indefinitely the research contract authority of section 301(h) of the PHS act; 3) provided that the director, NIH, shall be appointed by the President by and with the advice of the Senate; and 4) required peer review of NIH and ADAMHA grant applications and contract projects. (P.L. 93-352.)

The Health Services Research, Health Statistics, and Medical Libraries Act of 1974 extended and amended NLM program authorities ($37.5 million over a 2-year period). The act also extended the FIC's authority to engage in international cooperative efforts in health. (P.L. 93-353.)

The National Diabetes Mellitus Research and Education Act provided for regional research and training centers ($40 million authorized over a 3-year period), a long-range plan prepared by a National Commission on Diabetes, expanded research and training programs, a Diabetes Mellitus Coordinating Committee, and an associate director for diabetes in the National Institute of Arthritis, Metabolism, and Digestive Diseases. (P.L. 93-354.)

October 29, 1974—The Federal Fire Prevention and Control Act authorized $5 million and $8 million for fiscal years 1975-76 for establishment of 25 research and treatment centers, 25 burn units, and 90 burn programs by NIH. (P.L. 93-498.)

January 4, 1975—The National Arthritis Act established a National Commission on Arthritis and Related Musculoskeletal Diseases, authorized $2 million to develop a long-range plan involving research, training, services and data systems; established an associate director for arthritis in NIAMDD; and provided 3-year authorizations for arthritis screening, detection, prevention, and referral projects and for arthritis research and demonstration centers. (P.L. 93-640.)

July 29, 1975—A law extended and amended authorities of Title X relating to family planning and population research and made Title X sole authority for all departmental extramural, collaborative, and intramural research in "biomedical, contraceptive development, behavioral, and program implementation activities related to family planning and population;" and created two temporary national commissions for the control of epilepsy and Huntington's disease. (P.L. 94-63.)

April 22, 1976—The Health Research and Health Services Amendments 1) extended authorization through FY 1977 and amended provisions governing the programs of the National Heart and Lung Institute, placed increased emphasis on blood-related research, and changed the institute's name to the National Heart, Lung, and
Blood Institute; 2) mandated studies by the President's Biomedical Research Panel and the National Commission for the Protection of Human Subjects of the implications of public disclosure of information contained in grant applications and contract proposals; 3) authorized broad-based genetic diseases research under section 301 of the PHS act, and provided for programs of counseling, testing, and information dissemination about genetically transmitted diseases; and 4) extended authorization through FY 1977 for national research service awards for NIH and ADAMHA. The act prohibited consideration of political affiliation in making appointments to health advisory committees. (P.L. 94-278.)

October 19, 1976—The 1976 Arthritis, Diabetes, and Digestive Diseases Amendments 1) provided for an arthritis data system; 2) emphasized public information and encouragement of proper treatment for arthritis; 3) established a National Arthritis Advisory Board; 4) provided for a National Diabetes Board; and 5) established a National Commission on Digestive Diseases to develop a long-range plan for research. (P.L. 94-562.)

October 21, 1976—The Emergency Medical Services Amendments of 1976 extended the National Commission on Arthritis; extended the Commission for the Protection of Human Subjects of Biomedical and Behavioral Research; and authorized research and demonstration programs on burn injuries under Title XII of the PHS act. (P.L. 94-573.)

August 1, 1977—Health Planning and Health Services Research and Statistics Extension, Biomedical Research Extension, and Health Services Extension Acts of 1977 continued the following programs through September 30, 1978: the Medical Library Assistance Program; cancer research and control programs; heart, blood vessel, lung and blood disease research, prevention and control programs; national research service awards; population research and voluntary family planning programs; and sudden infant death syndrome information and counseling programs. It also extended various health service programs. (P.L. 95-83.)

August 7, 1977—The Clean Air Act Amendments established a coordinating committee to review and comment on plans, execution, and results of research relating to the stratosphere. NCI and NIEHS are members. It also established a Task Force on Environmental Cancer and Heart and Lung Disease, with NCI, NHLBI, and NIEHS among the members. (P.L. 95-95.)

September 29, 1977—The Food and Agriculture Act of 1977 designated the Department of Agriculture as the lead agency of the Federal Government for agricultural research (except with respect to the biomedical aspects of human nutrition concerned with diagnosis or treatment of disease). The act also required establishment of procedures for coordinating nutrition research in areas of mutual interest between DHEW and Department of Agriculture. (P.L. 95-113.)

November 9, 1977—The Federal Mine Safety and Health Amendments of 1977 gave the HEW secretary authority to appoint an advisory committee on coal or other mine health research. One member of this committee is to be the director of the NIH or delegate. (P.L. 95-164.)


November 9, 1978—The Family Planning, Population Research and SIDS Amendments authorized a 3-year extension for the aforementioned programs through FY 1981. This was the only authority for population research programs in NICHD, the Center for Population Research. (P.L. 95-613.)

Amendments to the Community Mental Health Centers Act authorized a 3-year extension for NLM programs, and NRSA's expiring September 30, 1981, and a 2-year extension for each of the following: Community Mental Health Centers, NHLBI, and NCI. This legislation also authorized the secretary, HEW, to: 1) conduct studies and tests of substances for carcinogenicity, teratogenicity, mutagenicity and other harmful biological effects; 2) establish and conduct a comprehensive research program on the biological effects of low-level radiation; 3) conduct and support research and studies on human nutrition; and 4) publish an annual report which lists all substances known to be carcinogenic and to which a significant number of Americans are exposed. (P.L. 95-622.)

Other important provisions of this act included the authority given to the director of NIH to appoint 200 experts and consultants for the use of NIH components other than NCI and NHLBI and the establishment of the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research.

The Health Services Research, Health Statistics, and Health Care Technology Act of 1978 (P.L. 95-623) established in the Office of the Assistant Secretary for Health, the National Center for Health Care Technology, and reauthorized for 3 years the National Center for Health Statistics and the National Center for Health Services Research.

The legislation also established the National Council on Health Care Technology on which the director, NIH, serves as an ex officio member. The director, NIH, is required annually to submit to the center a listing of all technologies under development which appear likely to be used in the practice of medicine.

NLA is required to disseminate, publish, and make available all standards, norms, and criteria developed by the council concerning the use of particular health care technologies. (P.L. 95-623.)

October 17, 1979—The Department of Education Organization Act established a Department of Education and renamed the DHEW the Department of Health and Human Services. (P.L. 96-88.)

December 12, 1979—The Emergency Medical Services Systems Amendments and Sudden Infant Death Syndrome Amendments of 1979 required the NICHD to assure that "adequate amounts" of its appropriated dollars are used for research into identification of infants at risk of SIDS and for prevention of SIDS. In addition, the NICHD is required to provide information on expenditure of funds for these purposes, the number of SIDS grant applications received and approved, the latest research findings on SIDS, and estimates of needs for funds in succeeding years. (P.L. 96-142.)

December 29, 1979—P.L. 96-167 extended the tax exemption for NRSA's for 1 year.

P.L. 96-171 required that the NIH Director, in consultation with the secretary of transportation, conduct a study to determine the effect of aging on the ability of individuals to perform the duties of pilots. The report on the study was to be submitted to Congress within 1 year after enactment.
1980

September 26, 1980—P.L. 96-359 requires the HHS secretary to conduct a study to determine the long-term effects of hypochloremic metabolic ankylosis resulting from chloride-deficient formulas. The responsibility for the study was assigned to NICHD.

December 12, 1980—P.L. 96-517 revised the patent and trademark laws and in particular awarded title to the patent rights for inventions made with Federal assistance to nonprofit organizations and small businesses.

The Clinical Center was redesignated as the Warren Grant Magnuson Clinical Center of NIH. (P.L. 96-518.)

December 17, 1980—P.L. 96-538 reauthorized for 2 years programs for NHLBI and NCI; changed the name of the NiAMDD to the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases, extensively revised its authorities, and reauthorized its programs for 3 years; and required the NIH to conduct a study and submit a report on spinal cord regeneration and other neurological research.

P.L. 96-541 extended for 1 year the tax exemption on NRSAs.

August 13, 1981—P.L. 97-35, the Omnibus Budget Reconciliation Act of 1981, reauthorized NRSAs for 2 years through FY 1983, reauthorized the Medical Libraries Assistance program for 1 year, and repealed the prohibition in Title X against using other PHS authority to fund population research, thus eliminating the need for reauthorizations for this program located in the NICHD.

July 22, 1982—The Small Business Innovation Development Act of 1982 requires that each Federal agency with an annual research and development budget exceeding $100 million set aside a certain portion of its extramural R&D budget for a Small Business Innovation Research (SBIR) program as follows: 0.2 percent in FY 1983; 0.6 percent in FY 1984; 1.0 percent in FY 1985; and 1.25 percent in FY 1986 and all subsequent years. (P.L. 97-219.)

September 3, 1982—The Tax Equity and Fiscal Responsibility Act of 1982 included among its provisions an extension of the partial exclusion of NRSAs from taxable gross income. This extension will expire at the end of calendar year 1983; during this time, the Treasury Department will complete a study of the taxability of NRSAs and other government educational grants which, like NRSAs, have payback or service requirements. (P.L. 97-248.)

January 4, 1983—The Orphan Drug Act made changes in the law to encourage development and marketing of orphan drugs (drugs for rare diseases or conditions which are not economically feasible for private industry to develop and market). The act included a requirement to prepare radioepidemiological tables relating radiation-related cancer to specific radiation doses, and a report on the risks of thyroid cancer associated with doses of I131. These responsibilities were assigned to NIH and NCI respectively. The act further provided that NHLBI help develop and support not less than 10 comprehensive sickle cell centers. (P.L. 97-414.)

July 30, 1983—The supplemental appropriations for FY 1983 provided funds for PHS AIDS activities, $9.375 million of which was earmarked for NIH. This marked the first time the Congress directly appropriated money for AIDS research for NIH. The supplemental also provided $5.9 million for NLM and development of a Biomedical Information Communication Center in Portland, Ore. (P.L. 97-63.)

October 1 and November 17, 1983—Continuing resolutions supported unauthorized NIH programs including NRSAs and Medical Library Assistance. (P.L. 98-107 and P.L. 98-151.)

May 24, 1984—P.L. 98-297 designated the convent and surrounding land as the Mary Woodard Lasker Center for Health Research and Education.

October 12 and November 8, 1984—Appropriations legislation reauthorized NRSAs, provided construction funds for NIH, and medical library funding. (P.L. 98-473, P.L. 98-619.)

October 19, 1984—The National Organ Transplant Act authorized the secretary to establish a Task Force on Organ Procurement and Transplantation to examine relevant issues and report to the Congress within 12 months. Its membership included the director, NIH, ex officio. OMAR will sponsor the required conference on bone marrow transplantation. (P.L. 98-507.)

October 24, 1984—The Veterans' Dioxin and Radiation Exposure Compensation Standards Act required the director, NIH, to conduct a study of devices and techniques for determining previous radiation exposure and submit a report; to enter into an interagency agreement with the VA administrator to identify agencies capable of furnishing such services; and to provide an independent expert who could prepare radiation dose estimates for use by VA administrator in adjudicating claims. (P.L. 98-542.)

October 30, 1984—The Health Promotion and Disease Prevention Amendments of 1984 amended the PHS act to extend provisions relating to health promotion and disease prevention and to establish centers for research and demonstration in those areas. It required that the director, NIH, be consulted as to procedures for peer review of applications; that NCHSR cooperate with NIH in its responsibilities pertaining to health care technologies; and that the director, NIH, serve on the newly established National Advisory Council on Health Care Technology Assessment. (P.L. 98-551.)

The Human Services Reauthorization Act, Title V, ordered the secretary, through NCI, to establish or support at least one facility for cancer screening and research in St. George, Utah, to be affiliated with a health science center and accessible to most residents of the areas that received greatest fallout from Nevada nuclear tests. (P.L. 98-558.)

August 15, 1985—The Orphan Drug Act was amended, establishing a 20-member National Commission on Orphan Diseases, to be appointed by the secretary (including NIH representative), to assess the activities of NIH and other entities in connection with research and dissemination of knowledge related to rare diseases. NIH was required to allocate to the commission $1 million from its FY 1986 appropriation. (P.L. 99-91.)
November 20, 1985—The Health Research Extension Act of 1985 reauthorized NIH programs for 3 years; established the National Institute of Arthritis and Musculoskeletal and Skin Diseases, renaming the remaining component the National Institute of Diabetes and Digestive and Kidney Diseases; created a new National Center for Nursing Research; established positions of associate director for prevention in OD, NCI, NHBLI, and NICHD; and required the development of guidelines for the care and use of laboratory animals. Additional provisions included establishment of committees to develop a plan for research into methods that reduce animal use or animal pain, to study research on lupus erythematosus, to study the NRSA program, to plan and develop Federal initiatives in spinal cord injury research, to study personnel for health needs of the elderly through the year 2020, to review research activities in learning disabilities, and to review the research programs of NIDDK. The act also established NIH and all of its ICD’s in law and consolidated and made uniform many authorities and responsibilities of institute directors and advisory councils. (P.L. 99-158.)

December 12, 1985—Under the Balanced Budget and Emergency Deficit Control Act of 1985 (Gramm-Rudman-Hollings), aimed at reducing the Federal deficit to zero within 5 years, starting in FY 1986, budget authority was reduced in accordance with the deficit targets. For NIH this reduction amounted to $236 million. The revised total NIH appropriation after “sequestration” became $5.3 billion, 4.3 percent below the original FY 1986 appropriation. The mandated across-the-board reduction was applied again to the total amount appropriated to each NIH institute, to each research mechanism, and to each identified program, project, or activity. (P.L. 99-177.)

In the FY 1986 Labor-HHS-Education Appropriation bill, the number of new and competing renewal research project grants to be supported by NIH (6,100) was specified in law for the first time. The act, which included $5.498 billion for NIH, provided that $4.5 million of this amount be transferred to the departmental management account for construction of the Mary Babb Randolph Cancer Center in West Virginia and that $70 million for AIDS research be added to the account of the Office of the Director. (P.L. 99-178.)

December 23, 1985—The Food Security Act, title XVII, subtitle F, amended the Animal Welfare Act, requiring the secretary of agriculture to promulgate standards including exercise of dogs and consideration of the psychological well-being of primates, minimization of pain and distress, use of anesthetics, and consideration of alternatives; formation of an institutional animal committee at each research facility; and provision of annual training for those involved in animal care and treatment. An information service was established at the National Agricultural Library, in cooperation with NLM. Title XIV, subtitle B, required an assessment of existing scientific literature relating to dietary cholesterol and calcium to be conducted by the secretaries of agriculture and HHS. (P.L. 99-198.)

December 28, 1985—P.L. 99-231 designated 1986 as the “Sesquicentennial Year of the National Library of Medicine.”

July 2, 1986—The Urgent Supplemental Appropriations Act provided an additional $6 million for NCI cancer research and demonstration centers and specified that funds for the Clinical Center should be available for payment of nurses at rates of pay authorized for VA nurses. (P.L. 99-349.)

October 6, 1986—P.L. 99-443 amended the Small Business Act to extend by 5 years the Small Business Innovation Research Program.

October 16, 1986—P.L. 99-489 specified the period from October 1, 1986, through September 30, 1987, as “National Institutes of Health Centennial Year” and requested the President to issue a proclamation calling upon the people of the United States to observe the year with appropriate ceremonies and activities.

October 18, 1986—P.L. 99-500 and P.L. 99-591 (October 31, corrected version), making continuing appropriations for FY 1987, included $6.18 billion for NIH, a requirement to support 6,200 research project grants, funding for 10,700 research trainees and 559 centers; and $247.7 million in AIDS money for components.

October 20, 1986—The Federal Technology Transfer Act amended the Stevenson-Wydler Technology Innovation Act of 1980, authorizing directors of government-operated Federal laboratories to enter into collaborative R&D agreements with other government agencies, universities, and private organizations; established a Federal Laboratory Consortium in the National Bureau of Standards; and mandated that royalties received by a Federal agency be shared with the inventor. (P.L. 99-502.)

November 14, 1986—Title IX, the Alzheimer’s Disease and Related Dementias Services Research Act, of P.L. 99-660 established an interagency council and an advisory panel on Alzheimer’s disease (AD). It authorized the director, NIA, to make awards for distinguished research on AD, to plan for and conduct research, to establish an AD clearinghouse, to make a grant to or enter into a contract with a national organization representing Alzheimer's patients, to establish an information system and national toll-free telephone line, and to provide information to caregivers of Alzheimer's patients and to safety and transportation personnel. Title III—Vaccine Compensation—named the director, NIH, as an ex officio member of the newly established Advisory Commission on Childhood Vaccines.

July 11, 1987—The FY 1987 Supplemental Appropriations bill, P.L. 100-71, allocated funds to NIA for clinical trials, to NCNR and HRSA for studies related to the nurse shortage and nurse retention, and to OD/NIH for costs associated with pay raises and the new Federal Employees Retirement System.


October 8, 1987—P.L. 100-126 designated October 1, 1987, as “National Medical Research Day,” acknowledging 100 years of contributions by NIH and other federally supported research institutions to improving the health and well-being of Americans and all humankind.

November 29, 1987—The Older Americans Act Amendments, Title III—Alzheimer’s Disease Research, authorized the director, NIA, to provide for conduct of clinical trials on therapeutic agents for Alzheimer’s disease recommended for further analysis by NIA and FDA. It also authorized the President to call a White House Conference on Aging in 1991. (P.L. 100-175.)

December 22, 1987—P.L. 100-202, making further continuing appropriations for the fiscal year ending September 30, 1988, provided $6.667 billion to NIH, including $448 million to be allocated among the institutes for AIDS. It also restricted forward or multiyear funding, required expeditious testing of experimental drugs for AIDS, and included $3.8 million for a National Center on Biotechnology Information within NLM.
September 20, 1988—The Labor-HHS-Education Appropriations Act, 1989, provided $7,152,207,000 for NIH (which included a 1.2 percent across-the-board reduction and a $6.8 million reduction for procurement reform). Of the amount appropriated for NINCDS, up to $96,100,000 was to go to the new National Institute on Deafness and Other Communication Disorders, following enactment of authorizing legislation. The pay rate for NIH nurses and allied health specialists having direct patient care responsibilities was equated to that of nurses at the Veterans Administration. Fifteen million dollars was appropriated to develop specifications and design for a consolidated office building at NIH, $14 million for the new Building 49, and $5 million for renovation of AIDS facilities. In addition, a biotechnology training program was established, as well as human genome and biotechnology panels.

Funds were authorized to support no less than 13,252 FTEs, including an additional 200 for AIDS and 150 for non-AIDS. Funding was also authorized for new magnetic resonance imaging equipment at the cardiac energetic laboratory and for a National Bone Marrow Registry at NHLBI; $8.7 million was earmarked for AIDS clinical trials.

Building 31 was renamed the Claude Denson Pepper Building. (P.L. 100-436.)

September 22, 1988—The Treasury, Postal Service and General Government Appropriations Act, 1989, provided that no Federal agency could receive funds appropriated for FY 1989 unless it had in place a written policy ensuring that its workplaces were free from illegal use, possession, or distribution of controlled substances. This restriction also applied to grant recipients, contractors, and parties to other agreements. (Subsequent legislation required implementation of this law in January 1989.) (P.L. 100-440.)

September 29, 1988—The National Defense Authorization Act, FY 1989, provided a special pay retention bonus for medical officers below grade O-7 who met certain criteria. Although officers of the commissioned corps were not specifically mentioned, 42 U.S.C. 210(a) states that they shall receive special pay received by commissioned medical and dental officers of the Armed Forces. (P.L. 100-456.)

October 4, 1988—P.L. 100-471 amended the PHS act to authorize the secretary, HHS, to make grants to the states to provide drugs determined to prolong the life of individuals suffering from AIDS; $15 million was authorized to be appropriated through March 31, 1989. (Funds appropriated for FY 1989 were transferred from NIH and other PHS agencies to pay for this program, according to transfer authority contained in P.L. 100-436.)

October 28, 1988—The National Deafness and Other Communication Disorders Act of 1988 established that institute at NIH and renamed NINCDS the National Institute of Neurological Disorders and Stroke. The legislation included a program, a data system and information clearinghouse, centers, and an advisory board, as well as a Deafness and Other Communication Disorders Interagency Coordinating Committee, to be chaired by the director of NIH or designee. (P.L. 100-553.)

November 4, 1988—Title I of the Health Omnibus Programs Extension of 1988 (HOPE), the National Institute on Deafness and Other Communication Disorders and Health Research Extension Act of 1988, established the NICCD and reauthorized expiring programs of NIH for 2 years. Since the new institute had already been established by P.L. 100-553, the provision in this bill is not valid. (P.L. 100-607)

A National Center for Biotechnology Information was established in the National Library of Medicine; the provision for VA pay for nurses and allied health professionals was reiterated; NCI, NHLBI, and NRSA programs were reauthorized; responsibility for the primary care training program was shifted to HRSA; the Interagency Technical Committee was abolished; the Alzheimer’s disease provisions of P.L. 99-660 were shifted to the NIA section of the PHS act; the moratorium on fetal research was extended through November 4, 1990; funds were appropriated for the Biomedical Ethics Advisory Board and a report specified; the secretary was directed to consult with the director, NIH, on establishment of a National Commission on Sleep Disorders, which would include among the ex officio members the directors of NINCDS, NHLBI, NIMH, NIA, and NICHD, with a report and a plan required. Finally, the bill extended confidentiality provisions to subjects of all biomedical, behavioral, clinical, or other research, including research on mental health.

Title II, “Programs with Respect to Acquired Immune Deficiency Syndrome,” laid the foundation for a Federal policy on AIDS. In addition to provisions for AIDS research, the bill included provisions for information dissemination, education, prevention, anonymous testing, and establishment of a National Commission on AIDS. The review process for AIDS-related grants was expedited, provision was made for priority requests for personnel and administrative support, a clinical research review committee was established within NIAID, the AIDS outpatient capacity at the Clinical Center was doubled, community-based clinical trials were mandated, awards for international clinical research were authorized, research centers were supported, and information services were expanded. An Office of AIDS Research was established within OD. Title VI, the Health Professions Reauthorization Act of 1988, established a loan repayment program for scientists who agree to conduct AIDS research while employed at NIH. (P.L. 100-607.)

November 21, 1989—Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1990, provided for the purchase of an advanced design supercomputer and named four NIH buildings for members of Congress. (P. L. 101-166)

November 29, 1989—An act to provide for the construction of biomedical facilities in order to ensure a continued supply of specialized strains of mice essential to biomedical research in the United States, and for other purposes, provided authority to make construction grants for this purpose. (P.L. 100-190)

1990

August 18, 1990—Ryan White Comprehensive AIDS Resources Emergency Act of 1990, authorized NIH to make demonstration grants to community health centers and other entities providing primary health care and servicing a significant number of pediatric patients and pregnant women with HIV disease. Awardees were to provide clinical data to NIH for evaluation. (P.L. 101-381)

November 5, 1990—Omnibus Budget Reconciliation Act of Response, Compensation, and Liability Act of 1980 (under which NIEHS operates some programs) and called on the secretary, with NCI, to review periodically the appropriate frequency for performing screening mammography.

Treasury, Postal Service and General Government Appropriations Act, 1991, established the PHS senior biomedical research service. (P.L. 101-509)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1991, provided for the first time, a 1 percent NIH director's transfer authority for high-priority activities and capped the NIH contribution for salaries for individuals receiving extramural funding. (P.L. 101-517)

November 15, 1990—Clean Air Act Amendments of 1990, required NIEHS to conduct a study of mercury exposure; to be available, with NCI, for membership on a panel for the Mickey Leland Urban Air Toxics Research Center and an inter-agency task force on air pollution; and authorized an NIEHS program of basic research on human health risks from air pollutants. (P.L. 101-549)

Home Health Care and Alzheimer's Disease Amendments of 1990, broadened the authority for Alzheimer's disease research centers and authorized Claude D. Pepper Older Americans Independence Centers grants. (P.L. 101-557)

November 16, 1990—The NIH Amendments of 1990, had two purposes: it authorized a nonprofit organization the National Foundation for Biomedical Research (membership amended by P.L. 102-170) and created NICHD's National Center for Medical Rehabilitation Research. (P.L. 101-613)

Hazardous Materials Transportation Uniform Safety Act of 1990, authorized NIEHS to provide grants for the training and education of workers who are or may be engaged in activities related to hazardous waste removal, containment or emergency response. (P.L. 101-615)

Transplant Amendments of 1990, reauthorized and amended the PHS act as it concerns the National Bone Marrow Donor Registry in the NHLBI and called for the establishment of national standards and procedures. (P.L. 101-616)

August 14, 1991—Terry Beirn Community Based AIDS Research Initiative Act of 1991, authorized this initiative in the PHS act and NIAID. (P.L. 102-96)

November 26, 1991—Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 1992, established NCI's Matsunaga-Conte Prostate Cancer Research Center, a women's health study, and provided authority to transfer funds to emergency activities. (P.L. 102-170)

December 9, 1991—The High Performance Computing Act of 1991, authorized Federal agencies such as NIH to allow recipients of research grant funds to pay for computer networking expenses. (P.L. 102-194)

February 4, 1992—The American Technology Preeminence Act of 1991 gave authority to the directors of Federal laboratories (NIH) to give research equipment that is excess to the needs of the laboratory to an educational institution or nonprofit organization for the conduct of technical and scientific education and research activities. (P.L. 102-245)

July 10, 1992—The Alcohol, Drug Abuse, and Mental Health (ADAMHA) Reorganization Act, amended by the PHS act to provide for the incorporation of the three ADAMHA research institutes —NIMH, NIAAA, and NIDA—into the NIH as of October 1, 1992. A new PHS act section 409 was added and defined "health services research" as research endeavors that study the impact of organization, financing, and management of health services of the quality, cost, access to and outcomes of care. This is an entirely new programmatic undertaking for NIH and these three new institutes. Of particular interest are provisions that authorize a bypass budget for these three institutes for FY 1994 and 1995. (P.L. 102-321)

October 13, 1992—The DES Education and Research Amendments of 1992, require the director, NIH, to establish a program for the conduct and support of research and training, dissemination of health information, and other programs with respect to the diagnosis and treatment of conditions associated with exposure to DES. (P.L. 102-409)

The Agency for Health Care Policy and Research Reauthorization Act of 1992, requires that the NLM establish an information center on health service research, and on selected technology assessments and clinical practice guidelines produced by AHCPR and other public and private sources. The AHCPR administrator, in consultation with the NLM director, is required to develop and publish criteria for the inclusion of practice guidelines and technology assessments in the information center database. (P.L. 102-410)

October 24, 1992—The Cancer Registries Act requires the establishment of a national program of cancer registries, with the overall goal being the assurance of minimal standards for quality and completeness of (cancer) case information. Provisions also require the DHHS secretary, acting through the NCI director, to conduct a study for the purpose of determining the factors contributing to the fact that breast cancer mortality rates in 9 states and the District of Columbia are elevated compared to rates in the other 43 states. (P.L. 102-515)

The Energy Policy Act of 1992 authorizes electric and magnetic fields research and public information activities by the NIEHS director. (P.L. 102-486)

October 26, 1992—The Preventive Health Amendments of 1992 provide authorities regarding the coordination of Federal programs related to preventable cases of infertility arising as a result of sexually transmitted diseases; also delineates coordination between the director, CDC, and director, NIH. (P.L. 102-531)

October 28, 1992—The Small Business Innovation Research and Development and Enhancement Act of 1992 reauthorizes the SBIR program through September 30, 2000, and increases set aside percentages for each Federal agency with an extramural budget for research and development in excess of $100 million in FY 1992 (1.25 percent) upward to 2.5 percent by 1997 and onward. Legislation also requires enhancement of agency outreach efforts to increase participation of women-owned and socially and economically disadvantaged small business concerns, and tracking of awards to document their participation in the program. (P.L. 102-564)

The Housing and Community Development Act of 1992 requires the secretary, HHS, acting through the director, CDC, and director, NIEHS, to jointly conduct a study of the sources of lead exposure in children who have elevated blood lead levels (or other indicators of elevated lead body burden) as defined by the director, CDC. (P.L. 102-550)

November 4, 1992—The National Aeronautics and Space Administration (NASA) Authorization Act includes provisions offered as an amendment requiring NIH and NASA to jointly establish a working group, with equal representation from NASA and NIH, to coordinate biomedical research activities in areas where microgravity environment may contribute to significant progress in the understanding and treatment of diseases and other medical conditions; establishment of a joint program of biomedical research grants in the above described areas, where such research requires access to a microgravity environment, and annual issuance of joint
June 10, 1993—The NIH Revitalization Act of 1993 reauthorized certain expiring authorities of the NIH; mandated establishment of the Office of Research Integrity in DHHS; lifted the moratorium on human fetal tissue transplantation research; mandated inclusion of women and minorities in clinical research protocols; created in statute the Office of Alternative Medicine, the Office of Research on Women's Health, the Office of Research on Minority Health, the Office of Biobehavioral and Social Sciences Research, and the National Center for Human Genome Research; mandated establishment of an intramural laboratory and clinical research program on obstetrics and gynecology within NICHD and the National Center on Sleep Disorders Research in NHLBI; codified in statute the establishment of the Office of AIDS Research, and strengthened and expanded its authorities, including authorizing OAR receipt of all appropriated AIDS funds for distribution to the ICs; authorized the establishment of an NIH director's discretionary fund; provided the director, NIH, with extramural construction authority; required from extramural construction funds a $5 million set aside for Centers of Excellence; mandated establishment of the IDEA program; required the NCI to conduct the Long Island breast cancer study; authorized establishment of scholarship and loan repayment programs for individuals from disadvantaged backgrounds; changed the designation from center to institute for NIRF and from division to center for the Division of Blood Resources, NHLBI; and provided other new NIH authorities and directives. (P.L. 103-43)


December 14, 1993—The Preventive Health Amendments of 1993 required the director, NIAID, to conduct or support research and research training regarding the cause, early detection, prevention and treatment of tuberculosis, and to authorized to be appropriated $50 million for FY 1994 and such sums as necessary for FYs 1995-98. (P.L. 103-183)

September 30, 1994—The Department of Labor, HHS, and Education Appropriations Act, 1995, provided for the first time a consolidated appropriation for NIH AIDS research to the Office of AIDS Research. (P.L. 103-333)

October 25, 1994—The Dietary Supplement Health and Education Act of 1994 mandated establishment of an Office of Dietary Supplements within NIH to conduct and coordinate NIH research relating to dietary supplements and the extent to which their use reduces the risk of certain diseases. (P.L. 103-14)

May 22, 1995—The Paperwork Reduction Act of 1995 amends the U.S. Code to reduce by 5 percent the Federal paperwork burdens imposed on individuals, small businesses, state and local governments, education and nonprofit institutions and Federal contractors; also had the effect of establishing in statute the NIH Office of Information Resources Management. (P.L. 103-14)

December 21, 1995—The Federal Reports Elimination and Sunset Act of 1995 provides for improvement of the efficiency of agency operations by reducing staff time and resources spent on producing "unneccessary" reports to Congress. (P.L. 104-66)

November 1, 1995—The Biotechnology Process Patents Protection Act of 1995 strengthens patent protection and clarifies the circumstances under which a patent using biotechnological processes can be issued; allows U.S. researchers to enforce their patents claiming a certain starting material against the unfair importation of products made overseas using such material; and stops international theft of intellectual property; and makes U.S. patent law consistent with that of the Europeans and the Japanese. (P.L. 104-41)

January 26, 1996—The Balanced Budget Downpayment Act I, a continuing resolution, contained an amendment prohibiting the use of NIH funds for human embryo research; and cited NIH's FY 1996 funding in P.L. 104-91, such that the prohibition would continue for the duration of the FY 1996 funding year. (P.L. 104-99)

March 7, 1996—The National Technology Transfer and Advancement act of 1995 amended the Stevenson-Wydler Technology Innovation Act of 1980 with respect to reinvention made under Cooperative Research and Development Agreements; addressed the assignment of intellectual property rights and the use and deregulation of royalty income. (P.L. 104-113)

April 24, 1996—The Antiterrorism and Effective Death Penalty Act of 1996 required that the Secretary, HHS, establish safety procedures for use of biological agents, training in handling and proper laboratory containment, safeguards to prevent their use for criminal purposes, and procedures to protect the public safety. The act provided, however, that the Secretary must ensure availability of biological agents for research purposes. (P.L. 104-132)

May 20, 1996—The Ryan White CARE Reauthorization Act revised and extended authorization of the 1990 act, which provided for care and services for persons living with HIV/AIDS. Title IV provisions require the administrator, HRSA, to consult with the director, NIH, in carrying out a grants program to provide health care and opportunities for women, infants, children, and youth to participate as voluntary subjects of clinical research on HIV disease that is of potential benefit to them. (P.L. 104-146)

July 29, 1996—The Traumatic Brain Injury Act amended the PHS Act to provide for the conduct of expanded studies and establishment of innovative programs with respect to traumatic brain injury. The act authorizes the Secretary, acting through the director, NIH, to award grants or contracts for the conduct of basic and applied research regarding traumatic brain injury. (P.L. 104-166)

August 6, 1996—The Safe Drinking Water Act amendments reauthorized the Safe Drinking Water Act, toughened standards and required the Environmental Protection Agency to consult with NIH and the CDC in announcing an interim national primary drinking water regulation for a contaminant in the case of an urgent threat to public health. (P.L. 104-182)

October 2, 1996—The Electronic Freedom of Information Act established the right of the public to obtain access to Agency records, including electronically stored documents, and requires Federal agencies to make available certain Agency information to the public for inspection and copying. (P.L. 104-231)
October 18, 1996—The General Accounting Office Management Reform Act amended the PHS Act to limit the amount NIH may obligate for administrative expenses each fiscal year and repealed a requirement that the U.S. Comptroller General conduct, audit, and report to the Congress regarding the National Foundation for Biomedical Research. (P.L. 104-316)

September 30, 1996—The FY 1997 Labor, HHS, and Education Appropriations Act continued the prohibition on use of NIH funds for human embryo research. The act provided for construction of the new Mark O. Hatfield Clinical Research Center. (P.L. 104-208)


August 5, 1997—The Balanced Budget Act authorized a $150 million increase for research on the prevention and care of type-1 diabetes. (P.L.105-33)

November 21, 1997—The Food and Drug Administration Regulatory Modernization Act of 1997 directed NIH, in coordination with the CDC, to develop and maintain a database and information service that provides centralized information on research, treatment, detection, and prevention activities related to serious or life-threatening diseases. The act also directed NIH, the FDA, and medical and scientific societies to identify published and unpublished studies by clinicians and researchers that may support a supplemental application for a licensed product and to encourage manufacturers to submit a supplemental application or to conduct further research to support a supplemental application. (P.L. 105-115)

December 2, 1997—The Small Business Reauthorization Act, reauthorized the Small Business Technology Transfer (STTR) program for 4 years and required that the STTR program be submitted as a part of Federal agency performance plans and be made available to the Congress. (P.L. 105-135)

December 17, 1997—The Federal Advisory Committee Act Amendment included provisions that permit the public to attend taxpayer-funded advisory committee meetings and receive minutes and other documents prepared for or by such committees. (P.L. 105-153)

June 23, 1998—The Agricultural Research, Extension, and Education Reform Act of 1998 required the Secretary, U.S. Department of Agriculture, to establish a Food Safety Research Information Office whose activities are carried out in cooperation with the NIH, the FDA, CDC, and public and private institutions. (P.L. 105-185)

July 16, 1998—The National Marrow Donor Program was reauthorized. (P.L. 105-196)

August 7, 1998—The Workforce Investment Partnership Act of 1997 is omnibus legislation that created in statute an Interagency Committee on Disability Research whose membership includes the directors of NIH and NINH. (P.L. 105-220)

October 9, 1998—The Mammography Quality Standards Reauthorization Act reauthorized through FY 2002 such sums as may be necessary for the award of grants for breast cancer screening surveillance research. (P.L. 105-248)

October 21, 1998—The Appropriations for the Department of Veterans Affairs and Housing and Urban Development for FY 1999 provided appropriations for the NIEHS Superfund Worker Training Program and for the NIEHS Superfund Research Program. (P.L. 105-276)

October 21, 1998—FY 1999 Treasury and General Government Appropriations prohibited interagency financing of commissions, councils, committees, or similar groups. Section 622 prohibited Federal agencies from purchasing information technology that is not Year 2000 compliant unless the agency's chief information officer determines that noncompliance would be necessary to the function and operation of the agency.

October 21, 1998—The Omnibus Consolidated and Emergency Supplemental Appropriations Act, 1999, created in statute at NIH the National Center for Complementary and Alternative Medicine; renamed the NIDR as the National Institute of Dental and Craniofacial Research; and named two new NIH buildings after retiring members of Congress: 1) the Louis Stokes Laboratories and 2) the Dale and Betty Bumpers Vaccine Research Facility.

The act continued human embryo research prohibition, the NIH director's transfer authorities, and third-party payment authority for the NIH Clinical Center. In addition, permanent authority was provided to NIH for transit subsidies for non-full-time equivalent bearing positions, including visiting fellows, trainees, and volunteers. General provisions were provided for prohibition on the use of funds for programs for sterile needle distribution; and a prohibition on the use of funds for promoting legalization of controlled substances, except where there is evidence of therapeutic advantage or that federally sponsored clinical trials are being conducted to determine advantage.

This act authorized NICHD to be represented on a peer review panel established by the Secretary of Education to review applications from the states for scientifically based reading research activities.

Provisions included amendment of OMB Circular A-110, requiring Federal funding agencies to ensure that all data produced under an award will be made available to the public through the procedures established under the Freedom of Information Act.

The director of the Office of National Drug Control Policy was directed to consult with the directors of appropriate NIH institutes to establish criteria for evaluation of substance abuse treatment and prevention programs.

The conference report included the following:

- Directive language for the NCI on prostate cancer research.
- The NIDDK and other ICs were urged to expand funding for juvenile diabetes.
- The NIEHS and ORMH would enhance support for environmental health effects/minority health centers; NIEHS is to work with NIOSH on the national occupational research agenda (NORA).
- NIA is to launch a full-scale prevention initiative for Alzheimer’s disease and is to work with NIOSH on NORA.
- The NIAMS is to expand research on Osteogenesis Imperfecta.
- The Office of Rare Diseases is to develop an information program on biological samples and human cell and tissue banks available for research purposes.
- The Office of Behavioral and Social Sciences Research is urged to establish two to five mind/body centers.
- NIH is to focus resources on the cause and treatment for Parkinson's disease.
- NIH is to enhance research on Multiple Sclerosis and other autoimmune disorders. (P.L. 105-78)


October 31, 1998—The Women's Health Research and Prevention Amendments of 1998 extended and/or amended various NIH authorities related to women's health research, including: the drug DES (diethylstilbestrol); osteoporosis, Paget's disease and related disorders; breast, ovarian and related cancers; heart attack, stroke, and other cardiovascular diseases; aging processes; and the Office of Research on Women's Health. (P.L. 105-340)


November 13, 1998—The Health Professions Education Partnership Act reauthorized and consolidated health professions, nursing, and minority and disadvantaged health education programs within the Department of Health and Human Services. The act provided additional research training and Title 38 appointment authorities for the NIH director; reauthorized the NIH AIDS loan repayment program (LRP); and increased the maximum annual loan repayment from $20,000 to $35,000 for this and other NIH LRP; authorized tax relief benefits for participants in the NIH Clinical Researchers from Disadvantaged Backgrounds LRP; and made discretionary the National Center for Research Resources director's authority for construction awards to the regional primate research centers and reduced the amount that may be reserved from $5.0 million to $2.5 million. (P.L. 105-392)

November 20, 1999—Federal Financial Assistance Management Improvement Act of 1999 required agencies to develop plans to streamline grant administration activities. OMB was directed to 1) develop a common application, or set of common applications, for applying for Federal assistance; 2) develop a common system, including electronic processes, for grant administration activities; and 3) develop uniform administrative rules for Federal financial assistance programs across different agencies. (P.L. 106-107)

November 29, 1999—Omnibus Appropriations for NIH, Fiscal Year 2000, provided NIH with an increase of $2.3 billion over FY 1999. This legislation also included the Newborn and Infant Screening and Intervention Act which directed the National Institute on Deafness and Other Communication Disorders (NIDCD) to carry out a program of research on the efficacy of new screening techniques and technology, including clinical trials of screening methods, studies on the efficacy of intervention, and related basic and applied research on hearing loss in newborns. (P.L. 106-113)

December 6, 1999—Healthcare Research and Quality Act reauthorized and renamed the Agency for Health Care Policy and Research as the Agency for Healthcare Research and Quality (AHRQ). Provisions required the AHRQ Director, to promote innovation in evidence-based clinical practice and healthcare technologies to consult with the NIH Director and work with the National Library of Medicine to develop an electronic clearinghouse of currently available assessments and those in progress. The NIH Director will serve on the AHRQ Advisory Council as an ex officio member. (P.L. 106-129)

2000

June 30, 2000—The Electronic Signatures in Global and National Commerce Act mandated that electronic contracts with electronic signatures have the same legal force as paper contracts. (P.L. 106-229).

July 10, 2000—The Radiation Exposure Compensation Act (RECA) Amendments of 2000 amended the Public Health Service Act to establish a grant program to States for education, prevention, and early detection of radiogenic cancers and diseases. Entities eligible to receive such grants include National Cancer Institute-designated cancer centers. The competitive grants would be made by the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, in consultation with the Directors of the National Institutes of Health and Indian Health Service. (P.L. 106-245)

July 13, 2000—The Emergency Supplemental Act, Fiscal Year 2000, repealed Section 216 of P.L. 106-113, the Omnibus Consolidated Appropriations Act, which funded the NIH for fiscal year (FY) 2000. Section 216 of that Act specified that $3 billion of the funds appropriated for NIH were not available for obligation until September 29, 2000, and would not be available for obligation until October 15, 2000. This provision was repealed, thus releasing the funds for use prior to September 29, 2000. (P.L. 106-246)

July 28, 2000—The Semipostal Authorization Act amended the Postal Service Reorganization Act to extend the authority to issue semipostal stamps for breast cancer research until July 29, 2002. Seventy percent of the profits of this stamp go to the NIH to fund breast cancer research and thirty percent go to the U.S. Department of Defense for its breast cancer research program. Appropriations to NIH was not affected by any proceeds received from the sale of semipostal stamps. (P.L. 106-253)
October 17, 2000—The Children's Health Act of 2000 authorized Federal programs for research and other activities related to autism, Fragile X, juvenile arthritis, juvenile diabetes, asthma, hearing loss, epilepsy, traumatic brain injuries, childhood skeletal malignancies, muscular dystrophy, autoimmune diseases, birth defects and genetic mental impairment, among other conditions. The bill also required an NIH pediatric research initiative within the Office of the Director, NIH, with provisions addressing loan repayment for pediatric researchers and pediatric research human subject protections. (P.L. 106-310)

October 17, 2000—The American Competitiveness in the 21st Century Act of 2000 increased the cap on the number of H1-B visas from 115,000 to 195,000 each year for the next 3 years. The legislation eliminated the cap on H1-B visas for government, academic, non-profit and affiliated workers. (P.L. 106-313)

October 20, 2000—The Ryan White CARE Act Amendments of 2000 provisions required an NIH review of the distribution and availability of ongoing and appropriate HIV/AIDS research projects to existing Ryan White sites for the purpose of enhancing and expanding voluntary access to HIV-related research, particularly in communities underserved by such projects. In addition, the NIH is required to conduct research on development of rapid diagnostic test kits. (P.L. 106-345)

November 1, 2000—The Technology Transfer Commercialization Act of 1999 is intended to “improve the ability of Federal agencies to license Federally-owned inventions.” (P.L. 106-404)

November 6, 2000—The Needlestick Safety and Prevention Act required changes in the blood-borne pathogens standards in effect under the Occupational Safety and Health Act of 1970 to protect workers whose occupations expose them to pathogens such as HIV. Employers are required to use needles and other medical devices that have built-in safety mechanisms to reduce accidental punctures and to keep a log of needlestick injuries that would protect confidentiality of injured employees. (P.L. 106-430)


November 13, 2000—The Public Health Improvement Act of 2000 is a compilation of bills which amended the Public Health Service Act and provided new authorities to NIH and other Public Health Service agencies, or placed in statute ongoing activities or programs. This law provided the following: 1) established in statute the National Center for Research Resources (NCRR's) general clinical research centers, the NIH Career Awards in Patient-Oriented Research, which include the Mentored Patient-Oriented Research Career Development Award (K23), the Mid-Career Investigator Award in Patient-Oriented Research (K24), and the Clinical Research Curriculum Award (K30); 2) required the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to expand and intensify research and related activities regarding lupus; 3) substantially increased the authorization for NIH extramural facilities construction and authorized $100 million to allow the continued operation of NCRR's Shared Instrumentation Grant Program; 4) established in statute an extramural clinical loan repayment program for qualified health professionals who agree to conduct clinical research; 5) created in statute the Alzheimer's Disease Clinical Research and Training program within the National Institute on Aging (NIA); 6) extended the current authority to conduct basic and clinical research in combating prostate cancer research at the National Cancer Institute; 7) directed NIH to evaluate the effectiveness of screening strategies; and 8) included a technical amendment to the Children's Health Act of 2000 (Public Law 106-310) which corrects an inaccurate citation to a provision in the Code of Federal Regulations. (P.L. 106-505)

November 22, 2000—The Minority Health and Health Disparities Research and Education Act of 2000 created in statute a National Center on Minority Health and Health Disparities at the NIH to coordinate: 1) health disparities research performed or supported by NIH, 2) a grant program through the new Center to further biomedical and behavioral research education and training, 3) an endowment program to facilitate minority and other health disparities research at centers of excellence, and 4) a loan repayment program to train members of minority or other health disparities populations as biomedical research professionals. (P.L. 106-525)

December 19, 2000—The Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Authorization Act of 2000 codifies the existing ICCVAM as a permanent standing committee to be administered by the National Institute on Environmental Health Sciences. The statute requires the ICCVAM to establish, whenever feasible, guidelines, recommendations, and regulations that promote the regulatory acceptance of new or revised scientifically valid toxicological tests that protect human and animal health and the environment while reducing animal tests and ensuring human safety and product effectiveness. (P.L. 106-545)

December 20, 2000—The Chimpanzee Health Improvement, Maintenance, and Protection Act requires NIH to enter into a contract with a nonprofit private entity for the purpose of operating a sanctuary system for the long-term care of chimpanzees that are no longer needed in research conducted or supported by the NIH, the Food and Drug Administration, and other Federal agencies. The law provides for standards for permanent retirement of chimpanzees into the system, including prohibiting using sanctuary chimpanzees for research except in specified circumstances. (P.L. 106-551)

December 21, 2000—The Consolidated Appropriations Act, 2001, provides funding for the U.S. Departments of Labor, Health and Human Services (HHS) and Education; the legislative branch; and the Treasury and Postal Service, and H.R. 5667, the Small Business Reauthorization Act. For the NIH this law provides an appropriation of a $2.523 billion, or 14 percent increase over fiscal year 2000. Specific provisions of the law: 1) provides $47.3 million within Buildings and Facilities for the National Neuroscience Research Center, to be named the John Edward Porter Neurosciences Research Center; 2) permits the Director of NIH to enter into and administer a longterm lease for facilities for the purpose of providing laboratory, office and other space for biomedical and behavioral research at the Bayview Campus in Baltimore, Maryland; 3) expands the intramural loan repayment program for clinical researchers from disadvantaged backgrounds to the extramural community; and 4) raises the salary cap for extramural investigators to Executive Level I from Level II. (P.L. 106-554)

December 28, 2000—The Federal Physicians Comparability Allowance Amendments of 2000 makes physician comparability allowances a permanent authority and requires the allowances to be treated as part of basic pay for retirement purposes. (P.L. 106-571)

December 29, 2000—The National Institute of Biomedical Imaging and Bioengineering Establishment Act amends the Public Health Service Act to create at NIH the National Institute of Biomedical Imaging and Bioengineering. The statute authorizes an amount equal to (plus inflation) the amount currently spent by NIH
Institutes for imaging and engineering programs. In establishing the Institute, the Director of NIH is authorized to transfer personnel, use appropriate facilities to house the new Institute, and obtain administrative support from other agencies of NIH. The Institute is required to have a 12-member advisory council, and prepare a plan to address the consolidation and coordination of NIH biomedical imaging and engineering programs, as well as related activities of other Federal agencies. (P.L. 106-580)

May 24, 2001—The Animal Disease Risk Assessment, Prevention and Control Act of 2001 mandates that the Secretary of Agriculture submit a final report to Congress on plans by Federal agencies (including the National Institutes of Health and the Agriculture Research Service and Cooperative State Research, Education, and Extension Service of the U.S. Department of Agriculture) to carry out in partnership with the private sector 1) research programs into the causes and mechanisms of transmission of foot and mouth disease and bovine spongiform encephalopathy (BSE), variant Creutzfeldt-Jacob disease, and related diseases, and 2) diagnostic tools and preventive and therapeutic agents needed for foot and mouth disease, BSE, variant Creutzfeldt-Jacob disease, and related diseases. In addition, this legislation mandates that the final report to Congress contain plans by Federal agencies (including the Centers for Disease Control and Prevention) 1) to monitor the incidence and prevalence of the transmission of foot and mouth disease, BSE, variant Creutzfeldt-Jacob disease, and related diseases in the United States; and 2) to assess the effectiveness of efforts to prevent and control the spread of foot and mouth disease, BSE, variant Creutzfeldt-Jacob disease, and related diseases in the United States. (P.L. 107-9)

July 24, 2001—The 2001 Supplemental Appropriations Act included 1) provisions to permit the transfer of funds from the National Library of Medicine (NLM) to the National Institutes of Health (NIH) Buildings and Facilities account to complete the design phase of a new NLM facility, 2) report language to permit the new National Institute of Biomedical Imaging and Bioengineering (NIBIB) to use funds appropriated to the NIH Office of the Director (OD) for start up of the new Institute, and 3) language directing that information requested from the Committee on Appropriations was to be transmitted "uncensored and without delay." (P.L. 107-20)

October 26, 2001—The Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism (PATRIOT) Act of 2001 amends a number of titles of the United States Code in an effort to expand the Nation's ability to intercept and thwart terrorist threats. Of particular interest are amendments to Title 18 regarding possession, use, and transport of biological agents. These amendments seek to ensure that only those persons who have a lawful purpose for possessing, using, and/or transporting such agents are permitted to work with these agents, and that penalties are established for certain "restricted" individuals who are in possession of such agents. The Act also enhances the powers of the Attorney General, law enforcement officials, and the courts regarding wire, oral, and electronic communications. (P.L. 107-56)

December 18, 2001—The Muscular Dystrophy Community Assistance Research and Education Amendments of 2001 (MD-CARE Act) amends the Public Health Service Act. Of particular interest to NIH this legislation mandates that the Director of the National Institutes of Health, in coordination with the Directors of the National Institute of Neurological Disorders and Stroke, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Child Health and Human Development, and other national research institutes, as appropriate, expand and intensify programs with respect to research and related activities concerning Duchenne, myotonic, facioscapulohumeral, and other forms of muscular dystrophy (MD). In addition, the legislation 1) requires the establishment of Muscular Dystrophy Centers of Excellence, 2) requires the Secretary of Health and Human Services (HHS) to contract with the Institute of Medicine to study centers at NIH and make recommendations when their establishment is appropriate, 3) creates a Muscular Dystrophy Interagency Coordinating Committee that is required to develop a plan for conducting and supporting research and education on MD through the national research institutes and submits a biennial report to Congress describing research activities; 4) establishes a program in which samples of tissues and genetic materials that are of use in research on MD are donated, collected, preserved, and made available for such research; 5) requires the Secretary of HHS to provide a means of public input on existing and planned MD research activities; 6) requires the Centers for Disease Control and Prevention to carry out activities with respect to Duchenne MD epidemiology. (P.L. 107-84)

January 4, 2002—The Best Pharmaceuticals for Children Act reauthorizes the pediatric studies provision of the Food and Drug Administration Modernization and Accountability Act of 1997 to improve the safety and efficacy of pharmaceuticals for children. It continues to encourage pharmaceutical companies to conduct pediatric studies of on-patent drugs that are used in pediatric populations, but are not labeled for such use, by extending their market exclusivity. In addition, this legislation authorizes studies for "off-patent" drugs by the Federal Government or other entities with the expertise to conduct pediatric clinical trials. (P.L. 107-109)

January 10, 2002—The Department of Defense Appropriations Act, 2002 provides funding for NIH for bioterrorism under the Emergency Supplemental Act, 2002 (which is part of this legislation). The "conferees encourage the National Institute of Allergy and Infectious Diseases (NIAID) to conduct research on safer alternatives to the existing smallpox vaccine, such as an inactivated smallpox virus." In addition, funds are provided for the construction of a level-4 biosafety laboratory and related infrastructure costs at NIAID and for improving laboratory security at CDC and NIH. The bill also includes funds for the National Institute of Environmental Health Sciences (NIEHS) "for carrying out under current authorities, worker training, research, and education activities in response to the September 11 terrorist attacks. (P.L. 107-117)

May 14, 2002—The Hematological Cancer Research Investment and Education Act, amends the Public Health Service Act to require 1) the Director of the National Institutes of Health, through the National Cancer Institute, to expand and coordinate blood cancer research programs, particularly with respect to leukemia, lymphoma, and multiple myeloma (the Joe Mokley Research Excellence Program); and 2) the Secretary of Health and Human Services to establish a related education program for patients and the general public (the Geraldine Ferraro Cancer Education Program). (P.L. 107-172)

June 12, 2002—The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 amends Section 319 of the Public Health Service Act to strengthen protections related to public health. The Act requires the Secretary of Health and Human Services (HHS), in coordination with appropriate Federal department and agency officials, to establish a joint interdepartmental working group on preparedness for acts of bioterrorism. Among its activities, this group is charged with providing consultations on, assistance in, and recommendations regarding provision of appropriate safety and health training; coordination and prioritization of countermeasures to treat, prevent, or identify exposures to biological agents; and research on pathogens likely to be used in a biological threat or attack on the civilian population. (P.L. 107-188)

August 2, 2002—The Supplemental Appropriations for FY 2002 bill names in statute the National Research Service Awards (NRSA) the Ruth L. Kirschstein National Research Service Awards. (P.L. 107-206)
October 26, 2002—The Medical Device User Fee and Modernization Act of 2002 amends Section 215 of the Public Health Service Act to authorize the Director of NIH to conduct or support research to examine the long-term health implications of gel and saline-filled breast implants. This authorization includes studies to 1) develop and examine techniques to measure concentrations of silicone in body fluids and tissues, and 2) track silicone breast implant recipients. Within 6 months of enactment, the Director of NIH is required to submit a report to Congress describing the status of research on breast implants being conducted or supported by the Agency. (P.L. 107-250)

October 26, 2002—The Health Care Safety Net Amendments, repeals the requirement for the Health Resources and Services Administration loan repayment program (LRP) reporting requirements, which also repeals the National Institutes of Health LRP reporting requirements, which were mandated under the National Health Service (NHS) authorities. Specifically, this repeals Section 338B(i) of the Public Health Service Act, which required an annual report to Congress on the NHS Corps Loan Repayment Program. (P.L. 107-251)

November 2, 2002—The 21st Century Department of Justice Appropriations Authorization Act contains a provision that amends Section 464N of the Public Health Service Act addressing drug abuse and addiction research. The law provides that the Director of NIDA may make grants or enter into cooperative agreements to expand the current and ongoing interdisciplinary research and clinical trials with treatment centers of the National Drug Abuse Treatment Clinical Trials Network that relate to drug abuse and addiction, including related biomedical, behavioral, and social issues. The law mandates that the Director of NIDA shall promptly disseminate research results to Federal, State, and local entities involved in combating drug abuse and addiction. The law also requires NIDA to conduct a study of methamphetamine treatment. (P.L. 107-273)

November 6, 2002—The Rare Diseases Act provides statutory authorization for the existing NIH Office of Rare Diseases (ORD). The measure requires the Director of the Office of Rare Diseases to recommend an agenda for research on rare diseases, promote coordination and cooperation among NIH Institutes and Centers, promote sufficient allocation of NIH resources related to rare diseases, promote the establishment of a centralized rare diseases information clearinghouse, prepare a biennial report of rare disease research activities and opportunities, prepare the annual report of the Director of NIH to Congress on rare disease research, and serve as the principal advisor on orphan diseases to the Director of NIH. In addition, the legislation establishes regional Centers of Excellence on Rare Diseases. (P.L. 107-280)

November 25, 2002—The Homeland Security Act of 2002 establishes a new Executive Branch agency known as the U.S. Department of Homeland Security (DHS). Among its research provisions, the Act: 1) establishes within DHS a Directorate of Science and Technology, to conduct basic and applied research, development, demonstration, testing, and evaluation activities that are relevant to any or all elements of DHS with the exception of human health-related research and development activities; 2) requires the Secretary of DHS to set priorities, goals, objectives, and policies and to develop a coordinated strategy for these activities in collaboration with the Secretary of Homeland Security; and 3) authorizes the Secretary of Homeland Security to draw upon the expertise of any Federally-supported laboratory, and to establish a headquarters laboratory and additional laboratory units for the Department at any laboratory or site. The Act also includes provisions regarding Federal agency information security protections; acquisitions and procurement improvements; permanent extension, revision, and expansion of authorities for use of voluntary separation incentive pay and voluntary early retirement; and other authorities relevant to human resources management. (P.L. 107-296)

December 18, 2002—The Public Health Service Amendment on Diabetes amends Section 319 of the Public Health Service Act to renew funding for the special diabetes programs for Type 1 diabetes research, and also the parallel services program for diabetes in Native Americans, at $150 million for each of the FYs 2004 through 2008. This measure provides additional funding separate from the regular appropriations process for the special diabetes programs for Type 1 diabetes research at NIH. (P.L. 107-360)

May 27, 2003—The United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 has the following provisions: 1) requires the President to establish a comprehensive, integrated 5-year strategy to combat global HIV/AIDS, including specific objectives, approaches and strategies; 2) assigns priorities for relevant executive branch agencies; 3) improves coordination among such agencies; and 4) projects general levels of resources needed to achieve the stated goals. This legislation also requires the President to establish a position of HIV/AIDS Response Coordinator at the U.S. Department of State, who would have primary responsibility for oversight and coordination of all U.S. international activities to combat the HIV/AIDS pandemic. (P.L. 108-25)

August 15, 2003—The Mosquito Abatement for Safety and Health Act authorizes grants through the Centers for Disease Control and Prevention for mosquito control programs to prevent mosquito-borne diseases. This legislation requires the Director of the National Institute of Environmental Health Sciences to conduct or support research on methods of controlling the population of insects and vermin that transmit dangerous, diseases to humans. (P.L. 108-75)

December 8, 2003—The Project Bioshield Act of 2004 authorizes NIAID to award grants or contracts to public and nonprofit private entities to expand, remodel, renovate, or alter existing research facilities or construct new research facilities. (P.L. 108-276)

August 2, 2004—The Minor Use and Minor Species Animal Health Act of 2004 requires NIH to convene an ad hoc panel of nationally known experts in the fields of allergy and immunology to review current basic and clinical research activities related to food allergies. The panel is to make recommendations to the Secretary regarding the enhancement and coordination of food allergies research not later than 1 year after the date of enactment of the Act. (P.L. 108-282)

October 25, 2004—The Pancreatic Islet Cell Transplantation Act of 2004 requires the Diabetes Mellitus Interagency Coordinating Committee to include in its annual report an assessment of the Federal activities and programs related to pancreatic islet cell transplantation, which shall address: 1) the adequacy of funding; 2) policies and regulations affecting the supply of pancreata; 3) the effect of xenotransplantation; 4) the effect of the United Network for Organ Sharing
policies; 5) the existing mechanisms to collect and coordinate outcome data from trials; 6) implementation of multi-agency clinical investigations; and 7) recommendations for legislation and administrative actions to increase the supply of pancreata. (P.L. 108-362)

**November 30, 2004**—The Research Review Act of 2004 requires the NIH to submit an NIH Roadmap for Medical Research progress report to Congress no later than February 1, 2005. The bill also incorporated a component of an earlier bill, the Christopher Reeve Paralysis Act, requiring NIH to prepare a report describing NIH Roadmap efforts with respect to spinal cord injury and paralysis research. (P.L. 108-427)

**December 8, 2004**—The Consolidated Appropriations Act, 2005, provided that “The Center for Biodefense and Emerging Infectious Diseases (Building 33) at the National Institutes of Health is hereby named the C.W. Bill Young Center for Biodefense and Emerging Infectious Diseases.” (P.L. 108-447)

**November 11, 2005**—The Breast Cancer Research Stamp Reauthorization Act reauthorized the issuance of semipostal stamps for breast cancer research, from which NIH receives seventy percent of the profits and the Department of Defense receives 30 percent for their respective breast cancer research activities. These funds are in addition to annual appropriations received. (P.L. 109-100)

**December 5, 2005**—The Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2006, provided new language permitting the Office of AIDS Research to use its funding in this Act to make grants for the construction or renovation of facilities in order to expand a breeding colony that will serve as a new national resource to breed nonhuman primates for AIDS research; and a general provision stating that "None of the funds made available in this Act may be used to request that a candidate for appointment to a Federal scientific advisory committee disclose the political affiliation or voting history of the candidate or the position that the candidate holds with respect to political issues not directly related to and necessary for the work of the committee involved.” These provisions carry a time limitation relevant to FY 2006 activities only. (P.L. 109-149)

**December 19, 2006**—The Combating Autism Act of 2006 requires the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate autism spectrum disorders (ASD)-related research. Specifically, the Act sets forth a nonexhautive list of research areas to be included in NIH’s ASD initiatives, including research into possible environmental causes of autism. It expands the scope of autism research under NIH and the Centers of Excellence in such research to address the entire scope of ASD, rather than only autism. The new law also authorizes the Director to consolidate program activities to improve efficiencies and outcomes. (P.L. 109-416)

**December 20, 2006**—The Sober Truth on Preventing Underage Drinking Act requires the Secretary of Health and Human Services to formally establish and enhance the efforts of the interagency coordinating committee that began operating in 2004, focusing on underage drinking. The Director of the National Institute on Alcohol Abuse and Alcoholism, and such other Federal officials as the Secretary of Health and Human Services determines to be appropriate will serve as members of this interagency coordinating committee. (P.L. 109-422)

**January 15, 2007**—The NIH Reform Act revises Title IV of the PHS Act and creates the Division of Program Coordination, Planning, and Strategic Initiatives, to be supported by a Common Fund. There is no growth formula for the Fund and a review is required when the Fund reaches five percent of the total NIH budget. In addition, provisions establish a Council of Councils to advise on research proposals that would be funded by the Common Fund; establish a Scientific Management Review Board (SMRB) to conduct periodic organizational reviews of NIH every seven years, and make recommendations on the use of NIH organizational authorities; and require a public process for reorganizing NIH programs. Provisions authorize (but do not appropriate) for NIH $30,331,309,000 for FY 2007, $32,831,309,000 for FY 2008 and such sums as may be necessary for FY 2009. Provisions also authorize the NIH Director to award grants for demonstration projects for research bridging the biological sciences with the physical, chemical, mathematical, and computational sciences; and authorize the establishment of demonstration programs that award grants, contracts, or engage in other transactions, for high-impact, cutting-edge research demonstration programs. (P.L. 109-482)

**May 25, 2007**—Supplemental Appropriations for FY 2007 (Rescission for NIH) transferred a total of $99 million from the FY 2007 NIH appropriation to the Assistant Secretary for Preparedness and Response for advanced development of medical biodefense countermeasures. This work is to be conducted by the Assistant Secretary, consistent with the authority provided in the “Pandemic and All-Hazards Preparedness Act.” The transfer consists of $49.5 million from the NIH Office of the Director. (P.L. 110-28)

**September 27, 2007**—The Food and Drug Administration Amendments Act of 2007, although primarily affecting authorities of the FDA, requires (1) NIH to identify a point of contact to help innovators and physicians identify sources of funding for the development of such devices; (2) the HHS Secretary, acting through FDA and NIH, to create a research plan to expand research on pediatric medical devices; (3) NIH to develop a list of those areas of medicine that require additional testing involving children; (4) NIH to conduct pediatric studies in cases in which a drug is no longer under patent or the manufacturer of a patented drug has declined to conduct a requested study and other funds are not available; and (5) NIH to expand ClinicalTrials.gov to include information on a broader scope of trials and ultimately to include certain information regarding the results of those trials. (P.L. 110-85)

**December 13, 2007**—The Breast Cancer Research Stamp Reauthorization Act reauthorizes the Breast Cancer Research stamp through December 31, 2011, and requires an annual report to Congress describing how the funds generated by the stamp are used. (P.L. 110-150)

**December 26, 2007**—The Consolidated Appropriations Act of 2008 provides in Division D $29.456 billion for NIH; this includes $150 million for Type 1 diabetes. The Act includes a transfer of $295 million within NIH for the Global AIDS Fund; $111 million for the National Children’s Study; $504,420,000 for the Common Fund; $96,030,090 for research on chemical, radiological and nuclear countermeasure; $10,000,000 for the Director’s Discretionary Fund; and $25,000,000 for the flexible research authority. (P.L. 110-161)

**December 29, 2007**—The Medicare, Medicaid, and SCHIP Extension Act of 2007 includes a provision that amends Section 319 of the PHS Act to extend the funding for the special program for Type 1 diabetes at the current funding level of $150 million through FY 2011. This program, which was set to expire in FY 2008, provides additional funding for the special program for Type 1 diabetes research at NIH that is separate from the regular appropriations process. (P.L. 110-173)

**April 28, 2008**—Traumatic Brain Injury (TBI) Act of 2008 authorizes (1) funding for trauma-related research, treatment, surveillance, and education activities by CDC, HRSA, and NIH trauma research program and provided authorizations for FYs 2009-2012; (2) requires that CDC and NIH report to the relevant congressional
committees on activities and procedures that can be implemented by CDC, the U.S. Department of Defense, and the U.S. Department of Veterans Affairs to improve the collection and dissemination of compatible epidemiological studies on the incidence and prevalence of TBI in the military and veterans populations. (P.L. 110-206)

June 30, 2008—The Supplemental Appropriations Act, 2008, provides $150 million for the NIH, which shall be transferred to its Institutes and Centers and to the Common Fund established under section 402A(c)(1) of the PHS Act in proportion to the appropriations otherwise made to such Institutes, Centers, and Common Fund for FY 2008; provisions also set forth the conditions under which these funds may be utilized. Although specific to the Department of Defense, provisions include $75,000,000 appropriated to the “Defense Health Program” for operation and maintenance for psychological health and TBI, to remain available until September 30, 2009. Note: Report language accompanying the Act explains that within that amount is $70,000,000 to increase investigators and research capabilities in TBI and regenerative medicine across the Armed Forces involving an intramural start-up for the study of blast injury to the brain and post traumatic stress by studying actual combat casualties cared for at Walter Reed Army Medical Center and the National Naval Medical Center and using sophisticated neuroimaging technology at the NIH Clinical Center. (P.L. 110-252)

July 29, 2008—The Carolyn Pryce Walker Conquer Childhood Cancer Act amends Title IV of the PHS Act to require the HHS secretary, in collaboration with the NIH director and other Federal agencies with an interest in the prevention and treatment of pediatric cancer, to continue to enhance, expand, and intensify pediatric cancer research. The Act authorizes the HHS secretary to award grants for public awareness of pediatric cancers and available treatments and research and requires the secretary, acting through the director of the CDC, to award a grant to enhance and expand the infrastructure to track the epidemiology of pediatric cancer into a comprehensive nationwide registry. (P.L. 110-285)

October 8, 2008—The Breast Cancer and the Environment Act requires the HHS secretary to establish an Interagency Breast Cancer and Environmental Research Coordinating Committee on which representatives from 7 Federal agencies will serve, including the NIH, as well as 12 additional non-Federal members. The Interagency Breast Cancer and Environmental Research Coordinating Committee will share and coordinate information on existing research activities and make recommendations to NIH and other Federal agencies regarding improving existing research programs related to breast cancer research; develop a comprehensive strategy; and advise NIH and other Federal agencies in the solicitation of proposals for collaborative, multidisciplinary research. (P.L. 110-354)

October 8, 2008—The Paul D. Wellstone Muscular Dystrophy Community Assistance, Research, and Education Amendments Act, 2008, creates in statute the Muscular Dystrophy Centers of Excellence as the Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers; names NHLBI as a member of the Muscular Dystrophy Coordinating Committee (MDCC); and authorizes MDCC to give special consideration to enhancing the clinical research infrastructure to test emerging therapies for the various forms of muscular dystrophy. (P.L. 110-361)

October 8, 2008—The Prenatally and Postnatally Diagnosed Conditions Awareness Act provides that the HHS secretary may, acting through the director of NIH, the director of CDC, or administrator of HRSA, oversee activities such as the awarding of grants and contracts in order to accomplish the goals of providing information and coordination of available support networks to parents of children diagnosed with Down syndrome or other prenatally or postnatally diagnosed conditions. Grant awardees are required to provide “up to date, evidence based, written information concerning the range of outcomes for individuals living with the diagnosed condition, including physical, developmental, educational, and psychosocial outcomes.” (P.L. 110-374)

October 13, 2008—The Comprehensive Tuberculosis Elimination Act of 2008 amends the PHS Act to authorize the NIH director to expand, intensify, and coordinate tuberculosis research and development and related activities of the national research institutes with the goal of eliminating the disease. These activities may include enhancing basic and clinical research on TB, including drug-resistant TB; expanding research on the relationship between TB and HIV; and developing new tools for the elimination of TB, including public health interventions and methods to enhance the detection of and responses to outbreaks of TB and its drug-resistant forms. (P.L. 110-392)

February 17, 2009—The American Recovery and Reinvestment Act of 2009 included $10 billion for NIH, which is available until September 30, 2010 (plus $400 million from AMHRQ. Funds for NIH were specified as follows:

$1.3 billion for NCRR, of which $1 billion is for competitive awards for the construction and renovation of extramural research facilities and $300 million for the acquisition of shared instrumentation and other capital research equipment.

$8.2 billion for the NIH Office of the Director, of which $7.4 billion is designated for transfer to Institutes and Centers and to the Common Fund, with the remaining $800 million to be retained in the OD to be used for purposes that can be completed within 2 years; priority is to be placed on short-term grants that focus on specific scientific challenges, new research that expands the scope of ongoing projects, and research on public and international health priorities. Bill language is included to permit the NIH director to use $400 million for the flexible research authority authorized in section 215 of Division G of P.L. 110-161. The funds available to NIH can be used to enhance central research support activities. Bill language also indicates that the funds provided in this Act to NIH are not subject to Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) set-aside requirements.

$500 million for NIH Buildings and Facilities, for construction as well as renovation.

For purposes of this stimulus funding, there are some requirements regarding “Buy American” pertaining to American iron, steel and manufactured goods. (P.L. 111-5)

March 11, 2009—The FY 2009 Omnibus Appropriations Act includes $30.3 billion for the 26 accounts that comprise the NIH total appropriation; continues the allocation to NIH of $8,200,000 in program evaluation set-aside funding, consistent with the budget request; transfers $1,000,000 from the Office of the Secretary to be provided to NIMH for the Interagency Autism Coordinating Committee; modifies a general provision requiring NIH-funded authors to deposit final manuscripts in the NL/M's PubMed Central by making the provision permanent; and includes a general provision requiring the HHS secretary to issue an advanced notice of proposed rulemaking regarding conflicts of interest among extramural NIH investigators.

The Interior portion of the law includes $78 million for NIEHS worker training and research programs. The Financial Services and General Government portion contains a moratorium on A-76 studies and competitions for FY 2009. (P.L. 111-8)
March 30, 2009—Omnibus Public Land Management Act of 2009 included provisions of the Christopher and Dana Reeve Paralysis Act, which authorized NIH to develop mechanisms to coordinate the paralysis research and rehabilitation activities of its Institutes and Centers in order to further advance such activities and avoid duplication; establish research consortia, to be designated the Christopher and Dana Reeve Paralysis Research Consortium; and the NIH director to award grants for multicenter networks of clinical sites that will collaborate to design clinical rehabilitation intervention protocols and measures of outcomes on different forms of paralysis. (P.L. 111-11)

September 20, 2009—The Small Business Act and Small Business Investment Act of 1958, Extension, provided a 1-month temporary extension of programs authorized under the 2 Acts, including the SBIR and SBTT programs of NIH. (P.L. 111-66)

October 28, 2009—The National Defense Authorization Act for FY 2010 required the Department of Defense “to provide” for chiropractic clinical trials to be conducted by NIH or an independent academic institution. (P.L. 111-84)

October 30, 2009—The Small Business Act and Small Business Investment Act of 1958, Extension, provided a one-month temporary extension of programs authorized under the two Acts, including the Small Business Innovation Research and Small Business Technology Transfer programs of NIH. (P.L. 111-89)

December 16, 2009—The Consolidated Appropriations Act, 2010, provides $31 billion for NIH. Provisions of note in Section IV (Labor, HHS, and Education include the following:

Provides up to $193.8 million for continuation of the National Children's Study.

Changes the current needle or syringe exchange prohibition such that the use of funds to distribute any needle or syringe to prevent the spread of blood-borne pathogens would be prohibited in areas that local public health or law enforcement agencies determine to be inappropriate—thus allowing the use of funds in areas that are deemed appropriate.

Continues provisions that bar the use of funds for the creation of human embryos for research or research in which embryos are destroyed. (P.L. 111-117)

2010


March 23, 2010—The Patient Protection and Affordable Care Act establishes the Cures Acceleration Network within the Office of the NIH director, names the NIH director (or his designee) as a member of the Patient-Centered Outcomes Research Institute (comparative effectiveness research) Board of Governors, and redesignates the National Center for Minority Health and Health Disparities as an institute. In addition, the Act requires the HHS secretary to contract with the Institute of Medicine to hold a conference on pain and to establish an Interagency Pain Research Coordinating Committee; the Secretary delegated these responsibilities to NIH. (P.L. 111-148)

For more information on legislation affecting NIH, go to http://olpa.od.nih.gov/legislation/.

This page last reviewed on February 22, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH…Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
Deputy Directors

Lawrence Tabak, Principal Deputy Director, NIH
Kathy Hudson, Deputy Director for Science, Outreach, and Policy
Michael Gottesman, Deputy Director for Intramural Research
Sally J. Rockey, Deputy Director for Extramural Research
Colleen Barros, Deputy Director for Management and Chief Financial Officer
James M. Anderson, Deputy Director for Program Coordination, Planning, and Strategic Initiatives

CHRONOLOGY OF DEPUTY DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>C. J. Van Slyke</td>
<td>December 3, 1958</td>
<td>December 1, 1959</td>
</tr>
<tr>
<td>David E. Price</td>
<td>July 1, 1960</td>
<td>June 30, 1962</td>
</tr>
<tr>
<td>Stuart M. Sessions</td>
<td>August 1, 1962</td>
<td>July 31, 1968</td>
</tr>
<tr>
<td>G. Burroughs Mider</td>
<td>July 1, 1960</td>
<td>May 19, 1968</td>
</tr>
<tr>
<td>John F. Sherman</td>
<td>November 1, 1968</td>
<td>March 16, 1974</td>
</tr>
<tr>
<td>Robert W. Berliner</td>
<td>February 23, 1969</td>
<td>September 1, 1973</td>
</tr>
<tr>
<td>Carl M. Leventhal</td>
<td>September 1973</td>
<td>February 1974</td>
</tr>
<tr>
<td>DeWitt Stetten, Jr.</td>
<td>March 17, 1974</td>
<td>September 11, 1979</td>
</tr>
<tr>
<td>Ronald W. Lamont-Havers</td>
<td>August 4, 1974</td>
<td>September 25, 1976</td>
</tr>
<tr>
<td>Thomas E. Malone</td>
<td>March 24, 1977</td>
<td>Aug. 1, 1986</td>
</tr>
<tr>
<td>Joseph E. Rall</td>
<td>July 2, 1981</td>
<td>June 6, 1982</td>
</tr>
<tr>
<td>Phillip S. Chen, Jr.</td>
<td>June 7, 1982</td>
<td>March 18, 1983</td>
</tr>
<tr>
<td>Joseph E. Rall</td>
<td>June 1983</td>
<td>May 13, 1991</td>
</tr>
<tr>
<td>Katherine Bick</td>
<td>May 19, 1987</td>
<td>March 1990</td>
</tr>
<tr>
<td>John Diggs</td>
<td>August 1990</td>
<td>June 14, 1993</td>
</tr>
<tr>
<td>Lance Liotta</td>
<td>July 6, 1992</td>
<td>August 1993</td>
</tr>
<tr>
<td>Jay Moskowitz</td>
<td>March 1993</td>
<td>October 1993</td>
</tr>
<tr>
<td>John D. Mahoney</td>
<td>March 21, 1993</td>
<td>February 19, 1995</td>
</tr>
<tr>
<td>Ruth L. Kirschstein</td>
<td>November 1993</td>
<td>December 1999</td>
</tr>
<tr>
<td>Michael Gottesman</td>
<td>November 1993</td>
<td>Present</td>
</tr>
<tr>
<td>Wendy Baldwin</td>
<td>February 1994</td>
<td>December 2002</td>
</tr>
<tr>
<td>Anthony Itteilag</td>
<td>January 7, 1996</td>
<td>October 2001</td>
</tr>
<tr>
<td>Yvonne Maddox (Acting)</td>
<td>January 1, 2000</td>
<td>May 18, 2002</td>
</tr>
<tr>
<td>Charles E. Leasure, Jr.</td>
<td>October 7, 2001</td>
<td>February 3, 2004</td>
</tr>
<tr>
<td>Raynard S. Kington</td>
<td>February 9, 2003</td>
<td>October 2008</td>
</tr>
<tr>
<td></td>
<td>August 17, 2009</td>
<td>August 20, 2010</td>
</tr>
<tr>
<td>Name</td>
<td>Start Date</td>
<td>End Date</td>
</tr>
<tr>
<td>-----------------------</td>
<td>------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Colleen Barros</td>
<td>May 30, 2004</td>
<td>Present</td>
</tr>
<tr>
<td>Alan Krensky</td>
<td>July 8, 2007</td>
<td>October 31, 2008</td>
</tr>
<tr>
<td>Sally J. Rockey</td>
<td>August 15, 2010</td>
<td>Present</td>
</tr>
<tr>
<td>Lawrence A. Tabak</td>
<td>August 23, 2010</td>
<td>Present</td>
</tr>
<tr>
<td>Kathy Hudson</td>
<td>October 24, 2010</td>
<td>Present</td>
</tr>
<tr>
<td>James M. Anderson</td>
<td>September 27, 2010</td>
<td>Present</td>
</tr>
</tbody>
</table>

1 Held title Director of Laboratories and Clinics.
2 For Science.
3 For Science, Acting.
4 For Extramural Research.
5 For Intramural Research.
6 Named by NIH director as NIH principal deputy director and NIH deputy director for Science Policy and Technology Transfer.
7 For Management.
8 For Management and Chief Financial Officer.
9 For Portfolio Analysis and Strategic Initiatives.

**BIOGRAPHICAL SKETCHES**

**Cassius James Van Slyke, M.D.**

Dr. Van Slyke, first deputy director of NIH, served in that position from December 3, 1958, until his retirement on December 1, 1959. He received his M.D. in 1928 from the University of Minnesota and entered the PHS reserve corps that same year.

In 1932 he was commissioned in the regular corps and from 1936 to 1944 pursued a distinguished research career at the PHS Venereal Disease Research Laboratory in Staten Island, N.Y. In 1944, he was made assistant chief, Venereal Disease Division, Washington, D.C.

Dr. Van Slyke joined NIH in 1946 as chief of the newly established Research Grants Office, later renamed the Division of Research Grants, serving there until he was named director of the National Heart Institute (NHI) on August 1, 1948. He left NHI on November 30, 1952, to serve as associate director of NIH, a post he held until he was named NIH deputy director.

**David E. Price, M.D.**

Dr. Price earned his medical degree at the University of California School of Medicine at Berkeley in 1940, and served his internship at the PHS Hospital in San Francisco. In 1946, he received his doctorate in public health at Johns Hopkins University School of Hygiene and Public Health.

Following a tour of duty in the Venereal Disease Division, PHS, he was assigned first to the DRG as assistant to the chief (1946-47) and then to the NCI as chief of the Research Grants Branch (1947-48). He returned to DRG in 1948 as chief, a post he held until he was named NIH associate director for extramural affairs (1950-52).

After a series of key appointments in the Office of the Surgeon General, the Bureau of Medical Services and the Bureau of State Services, Dr. Price was named deputy director of NIH on July 1, 1960. Two years later, he was appointed deputy surgeon general, PHS.

He retired from the service in 1965. After his retirement, he was associated with the Ford Foundation and the American Public Health Association.

Dr. Price was director of planning of the medical institutions, the Johns Hopkins Medical Institution, Baltimore, MD, until his retirement on July 1, 1980.

**Stuart M. Sessoms, M.D.**

Dr. Sessoms came to NIH in 1953 as a member of the NCI staff. From 1955 to 1957 he was assistant director of the Clinical Center. He was appointed assistant director, NCI, on January 1, 1958, prior to his appointment in November 1958 as chief of NCI's Cancer Chemotherapy National Service Center.

During this period, Dr. Sessoms also served as NCI associate director (1960), and associate director for collaborative research (1961) with responsibility for the institute's Virology Research Resources Branch, in addition to his duties at the Cancer Chemotherapy National Service Center.

He became the third NIH deputy director on August 1, 1962, serving in that capacity until his retirement July 31, 1968. On retirement, he held the rank of assistant surgeon general (rear admiral) in the PHS.

During his career at NIH, Dr. Sessoms was the recipient of two Meritorious Service Awards for his accomplishments as head of the Cancer Chemotherapy National Service Center, and for “outstanding ability and achievements in the development, operation and staffing” of the Regional Medical Programs.

He received his B.S. in pharmacy at the University of North Carolina in 1943 and his M.D. from the Medical College of Virginia in 1946.
On retiring after 25 years of government service, Dr. Sessoms joined Duke University.

On Jan. 1, 1976, he was named president of Blue Cross and Blue Shield of North Carolina.

G. Burroughs Mider, M.D.

Dr. Mider, whose career at NIH reaches back to 1939, is well-known on the campus. Just prior to transferring to the National Library of Medicine, an NIH component, in 1968, Dr. Mider had served for 8 years as NIH director of laboratories and clinics (1960-68), in which he functioned as deputy director as well.

He first came to NIH as a research fellow, NCI, in 1939. On completing the fellowship, he became an instructor in pathology and assistant professor of pathology (1941-44) at Cornell Medical College. Concurrently, he was an assistant pathologist at New York Hospital.

Then came assignments as associate professor of pathology, University of Virginia School of Medicine (1944-45) and research associate in surgery and professor of cancer research, University of Rochester School of Medicine and Dentistry (1945-52).

On returning to NIH in 1952, he became NCI associate director in charge of research. In 1960 he was appointed NIH director of laboratories and clinics. In May 1968, Dr. Mider transferred to the NLM as special assistant to the director for medical program development and evaluation. The following year he was named acting deputy director, and in 1970 became NLM deputy director.

In 1960, he was the recipient of a DHEW Distinguished Service Award. Dr. Mider retired from the Library on June 30, 1972, to become executive officer for the Universities Associated for Research and Education in Pathology, Inc., and the American Society of Experimental Pathology.

John F. Sherman, Ph.D.

Dr. Sherman was appointed deputy director of NIH on November 1, 1968, after a long career in research and research grants administration. He was designated by HEW Secretary Richardson as acting director of NIH on January 21, 1973, and served until a new director was appointed on May 29, 1973. He then returned to the position of deputy director.

He came to NIH in January 1953 as a research pharmacologist in the Laboratory of Tropical Diseases, National Microbiological Institute, which became the NIAID in 1955.

In July 1956, Dr. Sherman joined the staff of the NIAMD as assistant to the chief of extramural programs. He became assistant chief of the institute's extramural programs in August 1957, and deputy chief in October 1958.

On July 1, 1961, he was appointed associate director for extramural programs, NINDB. He rejoined the NIAMD in 1962 as associate director for extramural programs, serving in that capacity until January 1, 1964, when he was named NIH associate director for extramural programs.

Dr. Sherman received his B.S. in 1949 from Union University College of Pharmacy in Albany, N.Y., and his Ph.D. in pharmacology in 1953 from Yale University.

He is the author of numerous scientific papers and articles in his field of research. In 1971, he received a DHEW Distinguished Service Award.

Dr. Sherman left NIH in 1974 to become vice president of the Association of American Medical Colleges and director of the association's department of planning and policy development.

Robert W. Berliner, M.D.

Dr. Berliner, the first NIH deputy director for science, is an internationally renowned renal physiologist whose research in the field has contributed to understanding of the control of the excretion of sodium and potassium salts.

For 12 years (1950-62), he was chief of the Laboratory of Kidney and Electrolyte Metabolism, NHI, and from 1954 to 1968 served as the institute's director of intramural research.

In 1968, he was appointed director of laboratories and clinics, NIH. He was named to the newly created post of deputy director for science in 1969.

Prior to joining NIH in 1950, Dr. Berliner was assistant professor of medicine at Columbia University, and research associate with the New York City department of hospitals.

He received his B.S. from Yale University and his M.D. from Columbia University in 1939. He served his internship and residency at the Presbyterian Hospital and Goldwater Memorial Hospital, respectively, both in New York.

He was elected to the National Academy of Sciences in 1968. Other honors include the PHS Distinguished Service Award (1962), the Homer W. Smith Award (1965), the Modern Medicine Award for Distinguished Achievement (1969), and the American Heart Association's Research Achievement Award (1970).

Dr. Berliner left NIH to accept appointment as dean of the Yale University Medical School in September 1973.

DeWitt Stetten, Jr., M.D., Ph.D.

Dr. Stetten, an eminent medical educator and researcher in metabolic diseases, was named NIH deputy director for science on March 17, 1974.
He received his A.B. degree from Harvard College in 1930, and his M.D. and Ph.D. from Columbia University in 1934 and 1940, respectively. From 1934 to 1937, he took his internship and residency at Bellevue Hospital in New York. Dr. Stetten then joined the staff at Columbia University for 9 years, serving successively as assistant instructor and assistant professor of biochemistry. In 1947, he was appointed assistant professor in biological chemistry at the Harvard Medical School. From 1948 to 1954, he was chief of the division of nutrition and physiology for the Public Health Research Institute of New York City.

Dr. Stetten first came to NIH in 1954 as director of the intramural research program of the National Institute of Arthritis and Metabolic Diseases. In that capacity, he directed institute programs on basic and clinical research in diabetes, vitamin deficiencies, and disorders of the blood, bone, and liver. He left NIH in 1962 to become the first dean of the Rutgers Medical School, a position he held until his return to NIH on October 1, 1970, as director of the National Institute of General Medical Sciences.

The American Diabetes Association awarded Dr. Stetten the Banting Medal in 1957. In 1963, he delivered the 22nd annual NIH Lecture on the “History and Natural History of Gout.”

Among his many honors were the DHEW Superior Service Honor Award (1973) and the DHEW Distinguished Service Award (1977). He also received honorary D.Sc. degrees from Washington University (1974), and from the College of Medicine and Dentistry of New Jersey (1976).

Author of more than 100 original papers in his field of research, and coauthor of the early editions of the textbook, Principles of Biochemistry, Dr. Stetten served on the editorial boards of numerous scientific and medical journals. He was president of the Foundation for Advanced Education in the Sciences (1972-74), and was a member of the National Academy of Sciences and the NAS Council. He was president of the Society for Experimental Biology and Medicine, 1977-79.

Dr. Stetten was named senior scientific advisor to the NIH director in September 1979.

Ronald W. Lamont-Havers, M.D.

Dr. Lamont-Havers, internationally known rheumatologist, was appointed deputy director of NIH on August 4, 1974, after serving in an acting capacity since May 20.

Prior to this appointment, he had been deputy director of the National Institute of Arthritis, Metabolism, and Digestive Diseases (1972-74), and NIH associate director for extramural research and training for 4 years (1968-72).

He received his B.A. in 1942 from the University of British Columbia, Canada, and M.D. in 1946 from the University of Toronto. He took staff and residency training (1946-48) at the Vancouver General Hospital, and residency in internal medicine (1949-51) at the Queen Mary Veterans Hospital in Montreal. From 1951 to 1953, he was a fellow of the Canadian Arthritis and Rheumatism Society at Columbia Presbyterian Hospital, College of Physicians and Surgeons, Columbia University. He also received a diploma in internal medicine in 1953 from McGill University.

He came to NIH in 1964 as associate director for extramural programs, NIAMD. From 1955 to 1964 he was national medical director of the Arthritis Foundation and an instructor in medicine, College of Physicians and Surgeons, Columbia University. Previously, he served as medical director of the Canadian Arthritis and Rheumatism Society, British Columbia division, Vancouver, from 1953 to 1955, and as associate medical director, Student Health Service, University of British Columbia (1948-49).

Dr. Lamont-Havers, author or coauthor of numerous papers on arthritis and rheumatism, was honored in June 1973 with a DHEW Superior Service Award.

He left NIH in September 1976 to become deputy for research policy and administration to the general director, Massachusetts General Hospital, Boston.

Thomas E. Malone, Ph.D.

Dr. Malone, whose career at the NIH began in 1962, was named the sixth deputy director of NIH in March 1977.

He earned his B.S. and M.S. degrees from North Carolina Central University in 1948 and 1949 respectively, and his Ph.D. from Harvard University in 1952. During the period 1950-52 he held a teaching fellowship at Harvard University.

Dr. Malone was professor of zoology at N.C. Central University in Durham from 1952 to 1958. He left that position to accept a postdoctoral fellowship of the NAS National Research Council, serving as a resident research associate at Argonne National Laboratory from 1958 to 1959. He subsequently served on the faculty at Loyola University in Chicago until joining the NIH staff in 1962.

He came to NIH as a member of the Grants Associates Program. After completing a year's training, he joined the staff of the National Institute of Dental Research in 1963, serving in several capacities - from 1963 to 1964 he was assistant chief of the research grants section; 1964 to 1966, deputy chief, extramural programs; and 1966 to 1967, chief, periodontal diseases and soft tissue studies, extramural programs.

In 1967 Dr. Malone accepted a position as professor and chairman of the department of biology at the American University of Beirut, Lebanon. He returned to NIDR in 1969, where he was associate director for extramural programs until 1972 when he was appointed NIH associate director for extramural research and training, a position which he held until his appointment as deputy director of NIH.

He is a member of the Institute of Medicine and of numerous other professional organizations in health research and administration.

In June of 1971 Dr. Malone received the DHEW Superior Service Award and was honored in April 1974 with the DHEW Distinguished Service Award. In October 1975 the American College of Dentists presented him with a Certificate of Merit. He received a Senior Executive Service Presidential Merit Award in 1980 and a Senior Executive Service Presidential Distinguished Executive Rank Award in 1983.
He served as a member of the U.S. Delegation to the 31st through 35th World Health Assemblies and has participated in numerous other international health activities.

Upon the resignation of Dr. Fredrickson, Dr. Malone was named acting NIH director until the appointment of Dr. Wyngaarden.

**Robert Goldberger, M.D.**

A highly regarded scientist in biomedical research, Dr. Goldberger became NIH deputy director for science in September 1979.

After receiving his A.B. degree from Harvard College in 1954, he attended the New York University Medical School, where he obtained an M.D. in 1958. He interned at Mt. Sinai Hospital in New York, and then spent 2 years as a post-doctoral fellow at the University of Wisconsin's Institute for Enzyme Research. He came to the NIH as a research associate in the National Heart Institute in 1961, working with Dr. C. B. Anfinsen on the mechanism by which newly synthesized polypeptide chains attain three-dimensional structures characteristic of native proteins. In 1963 he was a visiting scientist at the Weizmann Institute of Science.

Dr. Goldberger served as a biochemist in the Laboratory of Chemical Biology, NIMD, from 1963 to 1966, when he became chief of that laboratory's Biosynthesis and Control Section. He worked on regulation of gene expression in bacteria.

In 1973 he moved to the NCI's Division of Cancer Biology and Diagnosis, where, as chief of the cellular regulation section, he worked on hormonal regulation of gene expression in avian liver.

Dr. Goldberger has written one book on biochemistry and has edited a multivolume treatise on biological regulation. From 1970 to 1971 he served as president of NIH's Inter-Assembly Council of the Assemblies of Scientists. He received the Superior Service Award, DHEW, in 1973 and the Meritorious Service Medal, USPHS, in 1977.

At the end of June 1981, he left NIH to accept a dual position as provost of Columbia University and vice president for health sciences, and as a professor of chemistry.

**William F. Raub, Ph.D.**

Dr. Raub was appointed deputy director in August 1986. Since June 1983, he had served as deputy director for extramural research and training coordinating the development and implementation of policies affecting extramural programs.

Upon the resignation of Dr. Wyngaarden, July 31, 1989, Dr. Raub was named acting NIH director.

He was NIH associate director for extramural research and training previous to this appointment. He has served as associate director, National Eye Institute (1975-78), and chief, Biotechnology Resources Branch, Division of Research Resources (1969-75). He joined NIH in 1966.

Dr. Raub led the effort to develop the PROPHET system, a national computer resource for pharmacologists and others who study chemical/biological interactions. PROPHET is the most nearly comprehensive set of information-handling tools for this area of science ever to be presented in a unified system, and offered as a service to the biomedical community.

A graduate of Wilkes College in Wilkes-Barre, Pa., in 1961, he received his Ph.D. in 1965 from the University of Pennsylvania.

**Joseph E. Rall, M.D., Ph.D.**

Dr. Rall was appointed deputy director for intramural research in June 1983. He advised the NIH director on general scientific matters and intramural research policies and coordinated the intramural research program.

With NIH since 1955, he was director of the division of intramural research at the National Institute of Arthritis, Diabetes, and Digestive and Kidney Diseases for more than 20 years.

Dr. Rall received his M.D. from Northwestern University School of Medicine (1945) and Ph.D. from the University of Minnesota (1952). He received honorary degrees from North Central College, (1966), the Free University of Brussels (1975), and the University of Naples (1985). He was elected to the NAS in 1980 and to the American Academy of Arts and Sciences in 1985. In 1988 he was invited to become a member of the scientific advisory committee for the International Human Frontier Science Program.

A member of many organizations and the coauthor of more than 160 scientific articles, his research involves thyroid hormones, iodine metabolism, and thyroid diseases.

In addition to the Van Meter Prize (1950) and the Robert Williams Distinguished Leadership Award of the Endocrine Society (1983), Dr. Rall has received the Arthur S. Flemming Award (1959), the DHHS Superior Service Award (1965), and the Distinguished Service Award (1968).

**Katherine L. Bick, Ph.D.**

Dr. Bick was named NIH deputy director for extramural research in April 1987. As a principal advisor to the NIH director, she coordinated the development and implementation of policies affecting NIH extramural programs.
She joined NIH in 1976 as a scientist administrator in the Neurological Disorders Program, NINCDS. In September 1983 she was appointed NINCDS deputy director, after serving in an acting capacity since February 1981. While in this position she received a PHS Special Achievement Award for sustained superior work performance.

Dr. Bick received her undergraduate degree from Acadia University, Nova Scotia, and earned her Ph.D. from Brown University. She has held academic positions at Georgetown University and California State University, Northridge, and research positions at the UCLA School of Medicine and the University of Western Ontario.

Among her many honors are the PHS Superior Service Award (1986), Senior Executive Service Bonus Award for Performance (1984-88), and the NIH Director’s Award (1977). In 1989 she received a Presidential Senior Rank Award.

Dr. Bick left NIH in April 1990.

John W. Diggs, Ph.D.

Dr. Diggs was appointed NIH deputy director for extramural research on July 29, 1990. He had been director of the NIAID Division of Extramural Activities since 1982.

A biology major at Lane College in Jackson, Tenn., he earned his M.S. (1969) and Ph.D. (1972) in physiology from Howard University. His postdoctoral work included serving as a senior research physiologist at Walter Reed Army Institute of Research.

Dr. Diggs joined NINDS in 1974 as a health scientist administrator and received the Institute's Special Achievement Award in 1979. He received the NIH Director's Award in 1985, the Presidential Meritorious Executive Rank Award in 1987, and the PHS Superior Service Award in 1990.

Included in his other honors are the Super Achiever in Science Award of Lane College National Alumni (1989), Merit Award of the District of Columbia General Hospital (1989), Outstanding Service Award of Montgomery County Department of Health (1989), Outstanding Service Award of Maryland Congress of Parents and Teachers, Inc. (1989), the Distinguished Senior Professional Award from the Inter-national Professional Management Association (1986), and Howard's Distinguished Alumni Award (1979).

He served the NIH until 1993.

Lance A. Liotta, Ph.D., M.D.

Dr. Liotta was named NIH deputy director for intramural research and training on July 6, 1992. He joined the Office of the Director after simultaneously serving since 1982 in three NCI Laboratory of Pathology positions: chief, tumor invasion and metastases section; lab chief; and codirector, Anatomic Pathology Residency Program.

He earned his A.B. degree in general science and biology from Hiram College in Ohio, followed by his Ph.D. in biomedical engineering and biomathematics from Case Western Reserve University. In 1976 he earned his M.D. from Case Western and joined NIH as a PHS resident physician in the NCI Laboratory of Pathology.

Dr. Liotta has devoted his career to the study of cancer invasion and metastasis, the major cause of cancer treatment failure. He was one of the first scientists to investigate this process at the molecular level. In 1975 he proposed that tumor cell attachment and degradation of the basement membrane (a collagenous sheath that surrounds epithelial ducts, blood vessels and nerves, and separates tissue compartments) was crucial to invasion and metastasis.

He found that disruption of the basement membrane is the general hallmark of the transition from in situ to invasive cancer for all human epithelial cancers. He discovered metallo-proteinases produced by tumor cells that degrade the metastasis; TIMP-2 (Dr. William Stetler-Stevenson), a new protein that inhibits invasion and angiogenesis; laminin-binding proteins (Dr. Mark Sobel) that mediate tumor cell attachment; and autotaxin (Dr. Mary Stracke), a protein that profoundly stimulates motility.

Dr. Liotta's group also developed the first synthetic compound (CAI) (Dr. Elise Kohn) that blocks cancer metastasis growth by inhibiting selected signal transduction pathways. CAI has now entered clinical phase I trials under support from the Division of Cancer Treatment.

He is a member of the International Metastasis Research Society, American Association for Cancer Research, American Association of Pathologists, American Society of Cell Biology, American Society for Clinical Investigation, and the International Academy of Pathology.

Dr. Liotta has received numerous awards including three PHS Commissioned Corps Medals, the Arthur S. Flemming Award, the Warner Lambert/Parke Davis Award, the Josef Steiner Prize, and the Lil Gruber Research Award. He holds more than 30 patents for his work.

Jay Moskowitz, Ph.D.

Dr. Moskowitz was named by the NIH director as NIH principal deputy director and NIH deputy director for science policy and technology transfer in March 1993. He voluntarily resigned in October 1993.

In October 1993, Dr. Moskowitz became deputy director of the National Institute on Deafness and Other Communication Disorders (NIDCD) and acting director of NIDCD’s Division of Intramural Research. He earlier served as founding and acting director of NIDCD, which was established in 1988.

Dr. Moskowitz joined NIH in 1969 as a postdoctoral pharmacology research associate with the National Institute of General Medical Sciences. In 1971 he became a grants associate with the Division of Research Grants.
From 1972 to 1986, Dr. Moskowitz held several administrative positions with the National Heart, Lung, and Blood Institute (NHLBI). As acting chief of the Special Programs and Resources Branch, NHLBI, he was responsible for planning and developing the Young Investigator Pulmonary Research Grant Program.

From 1986 to 1987, Dr. Moskowitz was NIH associate director for program planning and evaluation and executive director of the NIH Centennial Observance. From 1987 to 1993, Dr. Moskowitz was NIH associate director for science policy and legislation.

A graduate of Queens College, City University of New York, Dr. Moskowitz received his Ph.D. in 1969 from Brown University. He is the recipient of numerous honors and awards, including the NIH Director's Award in 1987, the PHS Superior Service Award in 1980, the Senior Executive Service Meritorious Executive Rank Award in 1989, and the DHHS Distinguished Service Award in 1991.

Dr. Moskowitz left NIH in 1995. He became senior associate dean (science and technology) and professor of public health sciences at the Wake Forest University School of Medicine in Winston-Salem, North Carolina, and in 2002 was appointed associate vice president for health sciences research and professor of health policy and administration and vice dean for research and professor of medicine at Penn State College of Medicine.

John D. Mahoney

Mr. Mahoney was named NIH deputy director for management on March 21, 1993. He became senior advisor to the NIH director on August 7, 1994.

Mr. Mahoney began his career in the U.S. Public Health Service in 1970 as a budget analyst for the National Institute of Mental Health. From 1972 to 1979, he held several positions in financial and budget management with the Alcohol, Drug Abuse and Mental Health Administration. From 1979 to 1984, he was chief of the Budget Branch in the Office of the Assistant Secretary for Health. In this position he was responsible for planning and coordinating budget estimates for programs of the agencies of the U.S. Public Health Service, including NIH.

From 1984 to 1986, Mr. Mahoney was director of the Office of Financial Management and Administrative Systems for the Health Care Financing Administration.

In 1986, Mr. Mahoney was named NIH associate director for administration, responsible for advising the NIH director on administrative matters and for developing and implementing administrative policies in support of NIH's research mission. He held that position until 1993. Mr. Mahoney was also acting deputy assistant secretary for health operations from 1990 to 1991.

Mr. Mahoney earned a B.A. and M.B.A. from the University of Maryland. He has received numerous awards including the Presidential Rank Award for Meritorious Service in 1990 and 1996; the General Services Administration, Excellence in Administration, Certificate of Merit in 1992; the Department's Distinguished Service Award and the PHS Special Achievement Award in 1990; the Secretary's Award for Exceptional Achievement in 1983; and the PHS Superior Service Award in 1982.

Mr. Mahoney became the deputy administrator, Health Resources and Services Administration, on February 19, 1995, and retired from federal service on December 31, 1996. Since that time he has been an independent consultant to various agencies of the Department of Health and Human Services and nonprofit organizations.

Ruth Kirschstein, M.D.

Dr. Ruth L. Kirschstein served as the NIH Deputy Director until February 8, 2003. She also served as NIH Deputy Director between November 1993 and December 1999. On January 1, 2002, Dr. Kirschstein was named Acting Director, NIH, and continued to serve in that role (technically called Principal Deputy Director) until May 20, 2002. She also served as Acting Director, NIH between July 1993 and November 1993.

Dr. Kirschstein received a B.A. degree magna cum laude in 1947 from Long Island University. She went on to earn her M.D. in 1951 from Tulane University School of Medicine in New Orleans, LA. She interned in medicine and surgery at Kings County Hospital, Brooklyn, and did residencies in pathology at Providence Hospital, Detroit; Tulane University School of Medicine; and the Warren G. Magnuson Clinical Center, NIH.

From 1957 to 1972, Dr. Kirschstein performed research in experimental pathology at the Division of Biologics Standards (now the Center for Biologics Evaluation and Research, FDA). During that time, she helped develop and refine tests to assure the safety of viral vaccines for such diseases as polio, measles, and rubella. Her work on polio led to selection of the Sabin vaccine for public use. For her role, she received the DH.E.W Superior Service Award in 1971.

In 1972, Dr. Kirschstein became Assistant Director of the Division of Biologics Standards. That same year, when the division was transferred to the FDA as a bureau, she was appointed Deputy Director. She subsequently served as Deputy Associate Commissioner for Science, FDA.

In 1974, Dr. Kirschstein was named Director of the National Institute of General Medical Sciences, NIH. She held that position for over nineteen years. From September 1990 to September 1991, she also served as Acting Associate Director of the NIH for research on women's health.

Dr. Kirschstein has twice taken part in World Health Organization deliberations in Geneva, Switzerland, in 1965 as a member of the WHO Expert Group on International Requirements for Biological Substances, and in 1967 as a consultant on problems related to the use of live poliovirus oral vaccine.

Dr. Kirschstein has received many honors and awards, including the PHS Superior Service Award, 1978; the Presidential Meritorious Executive Rank Award, 1980; election to the Institute of Medicine, 1982; the Public Health Service Equal Opportunity Achievement Award, 1983; a doctor of science, honoris causa, degree from Mt. Sinai School of Medicine, 1984; the PHS Special Recognition Award, 1985; the Presidential Distinguished Executive Rank Award, 1985; the Distinguished Executive Service Award of the Senior Executive Association, 1985; an honorary doctor of laws degree from Atlanta University, 1985; an honorary doctor of science degree from the Medical College of Ohio, 1986; the Harvey Wiley FDA Commissioner's Special Citation, 1987; selection by the Office of Personnel Management as 1 of 10 outstanding executives and organizations for its first group of "Profiles in Excellence," 1989; the Dr. Nathan Davis Award from the AMA, 1990; an honorary doctor of humane letters from Long Island University in 1991; election as a fellow of the American Academy of Arts and Sciences, 1992; and the Public Service Award from the Federation of American Societies for Experimental Biology in 1993.
In 2000, Dr. Kirschstein received the Albert B. Sabin Heroes of Science Award from the Americans for Medical Progress Education Foundation. The following year, she received honorary degrees from Spelman College in Atlanta, GA, and from Georgetown University Medical School in Washington, DC. She was also recognized by the Anti-Defamation League, which bestowed her with their Women of Achievement Award.

Michael Gottesman, M.D.

A well-known and respected basic cancer researcher who has focused on multidrug resistance in human cancer cells, Dr. Gottesman was appointed NIH deputy director for intramural research (DDIR) in November 1993. He had been acting DDIR for the previous year and was acting director of the National Center for Human Genome Research from 1992 to 1993. He continues as chief of NCI's Laboratory of Cell Biology.

He received his B.A. degree from Harvard College in 1966 and earned his M.D. at Harvard Medical School in 1970. He did a medical internship and residency at the Peter Bent Brigham Hospital at the Harvard Medical School.

In 1971 Dr. Gottesman came to NIH as a research associate in the National Institute of Arthritis, Metabolism, and Digestive Diseases (now NIDDK), where he worked for 3 years. He spent a year as an assistant professor at Harvard Medical School and, together with his wife, joined the permanent staff of NCI in 1976. He became chief of the molecular cell genetics section, Laboratory of Molecular Biology, NCI, in 1980 and chief of the Laboratory of Cell Biology, NCI, in 1990.

At NIH, his research interests have ranged from how DNA is replicated in bacteria to how cancer cells elude chemotherapy. In the past several years—collaborating with Dr. Ira Pastan, chief of NCI's Laboratory of Molecular Biology, and others—Dr. Gottesman has identified the human gene responsible for resistance of cancer cells to many of the most common anticancer drugs and has shown that this gene encodes a protein that acts to pump anticancer drugs out of drug-resistant human cancers.

This evidence supports the proposal, now widely accepted, that P-glycoprotein (P-gp), the product of the MDR1 gene, is an energy-dependent pump, ferrying toxins or drugs out of the cell. For several years, Dr. Gottesman has been examining clinical applications of his P-gp findings using transporter reversing agents to fight multidrug resistance and agents that specifically kill P-gp expression cells. Recently, his lab has extended studies of multidrug resistance in cancer to the 47 other known ABC transporters, and drug uptake transporters, and to mechanisms of resistance to the anti-cancer drug cisplatin.

His research has earned him many awards, including the Milken Family Foundation Award for Cancer Research, 1990; C.E. Aiken Prize, 1991; the Rosenthal Foundation Award, 1992; and the American Society for Pharmacology and Experimental Therapeutics (ASPET) award, 1997. He was elected a fellow in the American Association for the Advancement of Science in 1988, elected to the Institute of Medicine of the National Academies in 2003, elected to the Association of American Physicians in 2006, and elected to the American Academy of Arts and Sciences in 2010. He received the Public Health Service Commendation, Outstanding Service and Distinguished Service awards, the NIH Director's award in 2002, and the HHS Secretary's Award for Distinguished Service in 2005.

Dr. Gottesman is also a member of the American Association for Cancer Research, the American Society for Biochemistry and Molecular Biology, the Genetics Society of America, the American Society for Pharmacology and Experimental Therapeutics, and the American Society for Cell Biology. He has served on several editorial boards including the Journal of Cell Biology, Journal of Biological Chemistry, Molecular Pharmacology, Molecular Biology of the Cell, Cancer Research, and Human Gene Therapy. He has also been involved in initiating several training and mentoring initiatives at NIH for high school, undergraduate, graduate, medical, post-baccalaureate, and postdoctoral students.

As DDIR, Dr. Gottesman has created the NIH Academy (supporting post-baccalaureate students in the study of health disparities); the Graduate Partnerships Program (which permits graduate students to conduct thesis research at NIH); and loan repayment programs for biomedical researchers supported by NIH. He has institutionalized an intramural tenure-track, new career tracks for clinical investigators, new fellows' training programs, the NIH Intramural Database (providing online information about all researchers and research at NIH), and other career development programs to help prepare biomedical research leaders of tomorrow.

Wendy Baldwin, Ph.D.

Dr. Baldwin was appointed NIH deputy director for extramural research in February 1994, after serving in an acting capacity since June 1993. She was responsible for guiding the NIH institutes and centers in the development of policies for their extramural research and research training programs. She also managed—for NIH and PHS—programs aimed at protection of human subjects in research and the proper care and use of laboratory animals in scientific studies.

She has made significant scientific contributions, primarily in adolescent fertility, contraceptive practice, childbirth patterns, AIDS risk behaviors, and infant mortality. She has published widely and has served on many NIH panels and committees, including the panel on NIH research on antisocial, aggressive, and violence-related behaviors, as well as the NIH advisory committee on women's health issues.

Dr. Baldwin joined NIH in 1973 as a health scientist administrator with NICHD. In 1979 she became chief of NICHD's Demographic and Behavioral Sciences Branch in the Center for Population Research. She was named deputy director of NICHD in 1991, a position she held until her appointment as NIH deputy director for extramural research.

She earned her Ph.D. in demography in 1973 and her M.A. in 1970 from the University of Kentucky. She received her B.A. from Stetson University in 1967.

Among her professional activities, she served as a temporary advisor to the WHO task force for social science research on reproductive health, on a National Academy of Sciences panel on adolescent pregnancy, and on a scientific advisory committee for demographic and health sciences. She is a past member of several editorial boards.

Dr. Baldwin has received many professional awards from PHS, NIH, and outside organizations.
Anthony L. Itteilag

Mr. Itteilag was NIH deputy director for management and chief financial officer, NIH, from January 1996 to October 2001.

Mr. Itteilag began his Federal career as a management intern in the Navy Department in 1964. After positions at Navy and at ACTION, in 1975 he became Chief of the Budget Branch in the U.S. Public Health Service (PHS). In 1978 he became the Director of the Division of Budget Policy and Management for the Department of Health and Human Services (DHHS).

From 1980 to 1984, he was Deputy Assistant Secretary for Budget, DHHS, and from 1984 to 1990 he was Director of Budget at the Department of the Interior.

In 1991 Mr. Itteilag became the Deputy Assistant Secretary for Health (Management and Budget), PHS, DHHS. He held that position through 1995.

Mr. Itteilag has a B.A. (summa cum laude) from the University of Rhode Island. He is the recipient of numerous awards including the Clifford R. Gross Award for Federal Public Service, American Society for Public Administration, (Maryland Chapter) in 2001; the Presidential Rank Award (Distinguished Senior Executive) in 1983 and 1992 and (Meritorious Senior Executive) in 1982 and 1988; the Department of the Interior Distinguished Service Award in 1991; the HHS Distinguished Service Award in 1981, 1997 (group) and 2001 (group); and the Public Health Service Exemplary Service Award in 1976. In 1980 he was coreipient of the Secretary's Exceptional Achievement Award, HHS.

He also is a member of the American Society for Public Administration, the American Association for Budget and Program Analysis, the American Political Science Association, the Federal Executive Institute Alumni Association, and the Senior Executives Association.

Mr. Itteilag has been a Senior Advisor to the NIH Director since October 2001.

Yvonne Thompson Maddox, Ph.D.

Dr. Yvonne Thompson Maddox was named Acting Deputy Director, NIH in January 2000 and continued to serve in that role until May 20, 2002. In this position, she guided the organizations and programs within the Office of the Director, NIH and was a chief advisor to the Acting Director, NIH. In addition, Dr. Maddox is the Deputy Director of the National Institute of Child Health and Human Development (NICHD), a position she has held since 1995.

Dr. Maddox received her B.S. in biology from Virginia Union University, Richmond and a Ph.D. in Physiology from Georgetown University. Following completion of the Ph.D., she served as a National Research Service Award (NRSA) Post Doctoral Fellow and as an Assistant Professor of Physiology in the Department of Physiology and Biophysics at Georgetown. She studied as a Visiting Scientist at the French Atomic Energy Commission, Saclay, France, and is a graduate of the Senior Managers in Government Program of the Kennedy School of Government, Harvard University.

Dr. Maddox came to NIH in November 1985 as a health scientist administrator in the National Institute of General Medical Sciences (NIGMS), where she managed the Congressionally mandated clinical and basic research grants program in trauma and burn injury. Following her initial appointment, she served NIGMS in various capacities: Acting Director, Minority Access to Research Careers (MARC) Program; Chief, Pharmacology and Physiological Sciences Section; and Deputy Director, Biophysics and Physiological Sciences Program.

In January 1995, Dr. Maddox joined NICHD as its Deputy Director. At the NICHD, Dr. Maddox manages the institute's diverse extramural program that supports research on population issues, reproductive biology, contraception, pregnancy, child development, nutrition, developmental biology, AIDS, mental retardation, and medical rehabilitation.

During her career at NIH, Dr. Maddox has received numerous honors and awards, including the Presidential Meritorious Executive Rank Award, the Public Health Service Special Recognition Award and the NIH Director's Award. She is a member of the American Physiological Society and serves on several public service and academic boards, including the Center for Development and Population Activities Advisory Board and the Robert Woods Johnson Health Policy Fellowship Advisory Board.

Dr. Maddox is author or coauthor of a number of scientific articles, book chapters and conference proceedings, including the often-cited paper on a method she developed to extract peritoneal macrophages from peritoneal dialysate, "A routine clinical source of peritoneal macrophages and their release of prostaglandins in vitro," which was published in 1984. She has delivered more than 100 lectures.

Charles E. Leasure, Jr.

Mr. Leasure was named NIH deputy director for management on October 7, 2001. He also served as NIH's chief financial officer and was acting executive officer for the Office of the Director, NIH, from 2000 to 2004.

Mr. Leasure began his career at NIH in 1965 as an employee management relations specialist in the Office of the Director. From 1966 to 1974 he held various administrative positions with the National Cancer Institute.

In 1974, Mr. Leasure became the associate director for administration at the National Institute of Allergy and Infectious Diseases. In 1984, he was named associate director for management at the National Institute of Environmental Health Sciences. He left that position in 1998 to become the associate director for management at the National Human Genome Research Institute.

Mr. Leasure has served as chair of the Administrative Training Committee that oversees the Presidential Management Intern Program, and as a member of the NIH-wide Leadership Development Committee. He has mentored NIH employees in several programs, including the Management Cadre Program, the Presidential Management Intern Program, and the Leadership Development Program.
Raynard S. Kington, M.D.

Dr. Kington served as the Principal Deputy Director of NIH from February 9, 2003, to October 2008 and again from August 2009 to August 2010. He served as Acting NIH Director from October 31, 2008, until the appointment of Dr. Francis S. Collins on August 17, 2009. During his tenure as Acting NIH Director, Dr. Kington led the agency through the development of NIH’s plan for the use of the $10.4 billion American Recovery and Reinvestment Act resources designed to accelerate biomedical science and the economy. In July 2009, NIH published the final “NIH Guidelines for Human Stem Cell Research” under his directorship. Dr. Kington resumed his role as Principal Deputy Director on August 17, 2009. Prior to his present appointment, Dr. Kington was Director of the Office of Behavioral and Social Sciences Research (2000-2003). In addition to this role, from January 2002 to November 2006, he served as Acting Director of the National Institute on Alcohol Abuse and Alcoholism.

Before coming to NIH, Dr. Kington was Director of the Division of Health Examination Statistics at the National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC). As Division Director, he also served as Director of the National Health and Nutrition Examination Survey (NHANES), one of the nation's largest studies to assess the health of the American people. Prior to coming to NCHS, he was a Senior Scientist in the Health Program at the RAND Corporation. While at RAND, Dr. Kington was a Co-Director of the Drew/RAND Center on Health and Aging, a National Institute on Aging Exploratory Minority Aging Center.

Dr. Kington attended the University of Michigan, where he received his B.S. with distinction and his M.D. He subsequently completed his residency in Internal Medicine at Michael Reese Medical Center in Chicago. He was then appointed a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania. While at the University of Pennsylvania, he completed his M.B.A. with distinction and his Ph.D. with a concentration in Health Policy and Economics at the Wharton School and was awarded a Fantaine Fellowship. He is board-certified in Internal Medicine and Public Health and Preventive Medicine. In 2006, Dr. Kington was elected to membership in the Institute of Medicine of the National Academy of Sciences.

Dr. Kington's research has focused on the role of social factors, especially socioeconomic status, as determinants of health. His research has included studies of the health and socioeconomic status of black immigrants, demographic correlates of the willingness to participate in genetic research, the relationship between wealth and health status, and determinants of health care services utilization.

Norka Ruiz Bravo, Ph.D.

Dr. Ruiz Bravo began her tenure as NIH deputy director for extramural research on November 16, 2003, after her appointment was announced by the Director of NIH on October 30, 2003. She oversees the NIH external grants and awards program—a portfolio totaling approximately 83% of the NIH budget—providing trans-NIH coordination and directing the development of policies, guidelines, and staff training for extramural research.

A biologist by training, Dr. Ruiz Bravo earned her Ph.D. degree in 1983 from Yale University. Her postdoctoral tour included completion of an NSRA Fellowship that began at the Johns Hopkins University and ended at the University of Texas M.D. Anderson Cancer Research Center in the fields of biochemistry and molecular biology. She then held a research faculty position at the M.D. Anderson Cancer Research Center and a tenure-track faculty position at Baylor College of Medicine. In 1990, Dr. Ruiz Bravo joined the NIH as a scientific review administrator in the National Institute of General Medical Sciences (NIGMS) Office of Review Activities. During the years that followed, she actively pursued and was appointed to numerous special assignments. Some of these included: acting deputy director, NIGMS Division of Minority Opportunities in Research; special assistant, NIGMS Office of Extramural Activities; and, scientific review administrator at the National Center for Human Genome Research. She was concurrently a program director in the Division of Genetics and Developmental Biology, where she managed an active portfolio of grants in the field of transcriptional mechanisms.

In early 1997, Dr. Ruiz Bravo transferred her scientific, managerial, and administrative expertise to the National Cancer Institute (NCI), where she served as deputy director and then acting director for the Division of Cancer Biology.

She returned to the NIGMS in late 1999 as deputy associate director for extramural activities, and in 2000 was appointed associate director for extramural activities. In this role, Dr. Ruiz Bravo oversaw the $1.7 billion (FY2003) NIGMS budget for research, and research training grant programs supporting basic biomedicine. She was a principal advisor to the NIGMS director, providing counsel for strategic planning, development, and management of Institute grant activities.

Involved in leadership activities trans-NIH, Dr. Ruiz Bravo currently chairs the Extramural Program Management Committee, co-chairs the Extramural Activities Working Group, and is a member of the Information Technology Working Group. The Working Groups are subcommittees of the NIH Director’s Steering Committee, the NIH’s governance body. Formerly, she participated in a variety of service committees, chaired the Office of Research Services Advisory Committee, was the chair and co-founder of the Extramural Information Systems Advisory Group at NCI and chaired the Staff Training in Extramural Programs Committee. In addition to her trans-NIH leadership activities, Dr. Ruiz Bravo co-chairs the National Science and Technology Council's (NSTC) Subcommittee on Research Business Models, a trans-agency group tasked with facilitating research by harmonizing policies and regulations across the government. She is a former member of the NSTC’s Working Group on Aligning Mechanisms with Scientific Opportunity. Dr. Ruiz Bravo is a member of the American Association for the Advancement of Science, the American Society for Cell Biology, and the Society for Developmental Biology.

Colleen Barros, M.A.

Ms. Barros received her M.A. in Public Administration from American University and has served in a variety of Federal administrative positions with special expertise in managing technical and scientific information systems and in R&D management. She began her career with NIH in 1979 as a Budget Analyst and served as Senior Administrative Officer in the NIH Office of the Director. In that position she was responsible for directing the efforts in establishing several new offices such as the Office of AIDS Research, the Office of Human Genome Research, the Office of Research on Minority Health, and the Office of Alternative Medicine.
In 1995, Ms. Barros was selected as the Associate Director for Administration in the National Institute on Aging where she received several awards for her outstanding contributions toward improving the administrative operations of both the NIH and the NIA. In addition, she participated in several trans-NIH committees and projects including serving on the NIH Information Technology Central Committee responsible for advising the NIH Director on NIH information technology issues and as the NBRSS Project Leader responsible for the development and implementation of NIH's new business system.

In February of 2004, Ms. Barros joined the Office of the Director again as she took on the role of Acting Deputy Director for Management until May 30th, when she was appointed Deputy Director for Management.

Her honors include the 2008 Presidential Rank of Distinguished Executive Award, the 2003 Presidential Rank of Meritorious Executive Award, and 4 NIH Director’s Awards.

Alan Krensky, M.D.

Dr. Krensky is the first Director of the Office of Portfolio Analysis and Strategic Initiatives (OPASI) and a Deputy Director of the National Institutes of Health. For the past 23 years, he was at Stanford University where he served as the Shleagh Galligan Professor of Pediatrics, Associate Dean for Children's Health, Associate Chair for Research, Chief of the Division of Immunology and Transplantation Biology and Executive Director of the Children's Health Initiative. A medical graduate of the University of Pennsylvania in 1977, he trained in pediatrics and nephrology at Boston Children's Hospital and immunology with Steven Burakoff at the Dana-Farber Cancer Institute. After one year on the faculty at Harvard, he moved to Stanford as Assistant Professor of Pediatrics in 1984. He was appointed Shleagh Galligan Professor in 1995 and has been at NIH since July 8, 2007.

Dr. Krensky is a member of the American Society of Clinical Investigation, Association of American Physicians, Society for Pediatric Research, American Pediatric Society, American Society of Nephrology, American Society of Pediatric Nephrology, American Association of Immunologists and Transplantation Society. He has served as Councilor and President of the Society for Pediatric Research and Councilor and Secretary-Treasurer of the American Society of Nephrology. He has served on several Scientific Advisory Boards and holds nine patents. Dr. Krensky is a past recipient of the Society for Pediatric Research Young Investigator Award, American Society for Histocompatibility and Immunogenetics Young Investigator Award, American Society of Nephrology Young Investigator Award, American Academy of Pediatrics Award for Excellence in Pediatric Research, E. Mead Johnson Award for Research in Pediatrics, and Novartis Established Investigator Award of the American Society of Transplantation. He presented the David C. Orndorf Lecture at Children's Hospital of Philadelphia, the David Hume Lecture at the American Society of Transplant Surgeons, the Roche Visiting Professorship at Harvard Medical School, the Robert Haslam Lecture at the Hospital for Sick Children, and the John Capp Clark lecture at the University of Pennsylvania. He has been supported by the American Heart Association Clinician-Scientist and Established Investigator Awards, the Medical Foundation Fellowship, the Joseph A. Shankman Award of the National Kidney Foundation of Massachusetts, Basil O'Connor Award of the March of Dimes, Mellon Foundation Fellowship, Burroughs Wellcome Scholar in Experimental Therapeutics and a MERIT Award from the National Institutes of Health.

As Executive Director of the Children's Health Initiative and Associate Dean for Children's Health at Stanford, Dr. Krensky planned and implemented a $500 million investment in preeminence and sustainability of the Lucile Packard Children's Hospital at Stanford. He helped develop six centers of excellence, five multidisciplinary cores, and the recruitment of more than forty faculty. In this role, he chaired the CHI Executive Committee, was involved in fund raising and served as a liaison between the Lucile Packard Foundation for Children's Health, Lucile Packard Children's Hospital and Stanford University School of Medicine. During his tenure, the endowment of the Packard Children's Hospital increased 500%.

Dr. Krensky's research program was continuously funded by the National Institutes of Health from 1984 to his assumption of the NIH post. He has made important contributions to understanding the role of human T lymphocytes in human disease and applying this information to the development of new diagnostic and therapeutic approaches to disease. He first identified the human lymphocyte function-associated antigens (1-3), the chemokine RANTES, the host defense molecule Granulysin, and the transcription factor KLF-13 (RFLAT-1). He has published more than 250 scientific articles and reviews and has served on the editorial boards of the Journal of Immunology (Associate Editor), Current Opinion in Pediatrics (Section Editor), Pediatric Nephrology (Assistant Editor), Journal of the American Society of Nephrology (Associate Editor), Pediatric Transplantation, Graft, and Annual Review of Medicine. Dr. Krensky has trained more than 46 graduate students and post-doctoral fellows in his laboratory and has a special interest in training undergraduate and high school students.

Dr. Krensky has enjoyed long service with several organizations, serving as Chairman of the Experimental Immunology Study Section at the National Institutes of Health, American Heart Association National Peer Review Group, American Cancer Society Institutional Review Group, Medical Advisory Board of the National Kidney Foundation of Northern California, the Burroughs Wellcome Fund Translational Research Advisory Committee, and the Steering Committee of the Immune Tolerance Network (NIH-JDRF).

Sally J. Rockey, Ph.D.

Dr. Rockey is the Deputy Director for Extramural Research, leading extramural research activities at NIH. The Office of Extramural Research (OER), which she also serves as Director, is the focal point for policies and guidelines for extramural research administration within NIH and in partnership with the biomedical research community.

Dr. Rockey received her Ph.D. in Entomology from Ohio State University, and has spent the majority of her career in the area of extramural research administration and information technology. She leads or is active on a number of Federal committees related to science, research administration, and electronic government and collaborates closely with academic and scientific communities.

In 1986 she joined the U.S. Department of Agriculture’s Extramural Research arm, where she quickly rose to the post of Deputy Administrator for the Competitive Research Grants and Award Management Unit of the Cooperative State Research, Education, and Extension Service, overseeing the extramural grants process and portfolio. In 2002, she became Chief Information Officer, applying her breadth of government knowledge to IT, aligning state-of-the-art information technologies with the department’s goals and objectives. In 2005, Dr. Rockey was appointed to the position of Deputy Director of OER within the Office of the Director at NIH to bring her extensive experience in research administration and federal assistance to the biomedical research community. She assumed the role of Acting NIH Deputy Director for Extramural Research on October 31, 2008, and became permanent in that position on August 15, 2010.
Dr. Tabak has received several honors for his work, including being elected a fellow of the AAAS and a member of the Institute of Medicine of the National Academies. A native of Brooklyn, New York, he received his undergraduate degree from City College of the City University of New York, his D.D.S. from Columbia University, and a Ph.D. from the University of Buffalo.

Kathy Hudson, Ph.D.

Dr. Kathy Hudson was appointed to the role of Deputy Director for Science, Outreach, and Policy at the National Institutes of Health on October 24, 2010. Prior to this appointment, Dr. Kathy Hudson served as the Chief of Staff to the NIH Director. In her new role, Dr. Hudson will be overseeing and coordinating the work of The Office of Communications & Public Liaison, the Office of Legislative Policy and Analysis, and the Office of Science Policy within the Office of the Director.

Before joining the NIH, Dr. Hudson was the founder and Director of the Genetics and Public Policy Center and an Associate Professor in the Berman Institute of Bioethics, Institute of Genetic Medicine, and the Department of Pediatrics at The Johns Hopkins University. She founded the Center to fill an important niche in the science policy landscape and to focus exclusively on public policy issues that emerged as a result of advances in human genetics. Prior to her appointment with Johns Hopkins University, Dr. Hudson was the Assistant Director of the National Human Genome Research Institute (NHGRI) responsible for communications, legislation, planning, and education activities.

Dr. Hudson has served on the AAAS Committee on Science, Engineering and Public Policy, the Institute of Medicine Roundtable on Translating Genomic Based Research for Health, the CDC Evaluation of Genomic Applications in Practice and Prevention Stakeholders Group, the Genome Canada Science and Industry Advisory Committee, the National Govenors Association Health Information Protection Taskforce, the Social Issues Committee of the American Society of Human Genetics, the Guttmacher Institute Board of Directors, and the Annual Review of Genomics and Human Genetics Editorial Board. She has published articles about legislation, planning, and education activities.

She holds a Ph.D. in Molecular Biology from the University of California at Berkeley, an M.S. in Microbiology from the University of Chicago, and a B.A. in Biology from Carleton College.

James M. Anderson, M.D., Ph.D.

Dr. James Anderson was appointed as the Deputy Director for Program Coordination, Planning, and Strategic Initiatives, and Director of the Division of Program Coordination, Planning, and Strategic Initiatives, on September 27, 2010. Prior to joining NIH, Dr. Anderson was Professor and Chair of the Department of Cell and Molecular Physiology in the School of Medicine at the University of North Carolina at Chapel Hill, a position he held since 2002. Before his appointment at Chapel Hill, he was Professor of Medicine and Cell Biology and Chief, Section of Digestive Diseases, at the Yale School of Medicine. Dr. Anderson has extensive clinical experience in both Internal Medicine and Hepatology, and he is considered among the top authorities in the world in his primary research field of tight junctions and paracellular transport. Dr. Anderson will continue his research of the paracellular barrier in a laboratory located in the intramural research program of the National Heart, Lung, and Blood Institute. He has been a principal investigator on NIH grants for almost twenty years. With experience in clinical medicine, in academic research, and in administration, Dr. Anderson has a broad understanding of the biomedical research spectrum that will inform his work with the NIH community in evaluating, prioritizing, and coordinating a wide range of trans-NIH research opportunities. Dr. Anderson graduated from Yale University in 1974, received his Ph.D. in Biology from Harvard University in 1979, and his M.D. from Harvard Medical School in 1983.
Associate Directors

Diane Frazier, Associate Director for Administration
Jack E. Whitescarver, Ph.D., Associate Director for AIDS Research
Neil K. Shapiro, J.D., M.B.A., Associate Director for Budget
Francis Patrick White, Associate Director for Legislative Policy and Analysis
Deborah Oster, Ph.D., Acting Associate Director for Behavioral and Social Sciences Research
John T. Burklow, Associate Director for Communications and Public Liaison
Barnett S. Kramer, M.D., M.P.H., Associate Director for Disease Prevention
Alfred C. Johnson, Ph.D., Associate Director for Research Services
Janine A. Clayton, M.D., Acting Associate Director for Research on Women’s Health
Amy Patterson, M.D., Associate Director for Science Policy

CHRONOLOGY OF ASSOCIATE DIRECTORS

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norman H. Topping</td>
<td>1948</td>
<td>1952</td>
</tr>
<tr>
<td>David E. Price</td>
<td>December 1, 1950</td>
<td>January 30, 1952</td>
</tr>
<tr>
<td>James A. Shannon</td>
<td>December 1, 1952</td>
<td>July 31, 1955</td>
</tr>
<tr>
<td>C.J. Van Slyke</td>
<td>December 1, 1952</td>
<td>December 2, 1958</td>
</tr>
<tr>
<td>Joseph E. Smadel</td>
<td>May 1, 1956</td>
<td>June 30, 1960</td>
</tr>
<tr>
<td>Kenneth M. Endicott</td>
<td>January 6, 1958</td>
<td>June 30, 1960</td>
</tr>
<tr>
<td>Jack Masur</td>
<td>July 1, 1960</td>
<td>March 8, 1969</td>
</tr>
<tr>
<td>Charles V. Kidd</td>
<td>September 13, 1960</td>
<td>December 9, 1964</td>
</tr>
<tr>
<td>Ernest M. Allen</td>
<td>August 10, 1960</td>
<td>January 8, 1963</td>
</tr>
<tr>
<td>Martin M. Cummings</td>
<td>July 11, 1963</td>
<td>January 1, 1964</td>
</tr>
<tr>
<td>John F. Sherman</td>
<td>January 1, 1964</td>
<td>October 31, 1968</td>
</tr>
<tr>
<td>Robert Q. Marston</td>
<td>February 1, 1966</td>
<td>March 31, 1968</td>
</tr>
<tr>
<td>Thomas J. Kennedy, Jr.</td>
<td>August 8, 1968</td>
<td>August 31, 1974</td>
</tr>
<tr>
<td>Leonard D. Fenninger</td>
<td>November 10, 1969</td>
<td>May 4, 1973</td>
</tr>
<tr>
<td>Thomas C. Chalmers</td>
<td>February 9, 1970</td>
<td>October 20, 1973</td>
</tr>
<tr>
<td>Storm Whaley</td>
<td>July 1, 1970</td>
<td>February 3, 1992</td>
</tr>
<tr>
<td>Leon M. Schwartz</td>
<td>February 6, 1972</td>
<td>June 30, 1979</td>
</tr>
<tr>
<td>Thomas E. Malone</td>
<td>November 26, 1972</td>
<td>March 24, 1977</td>
</tr>
<tr>
<td>Leon Jacobs</td>
<td>July 30, 1972</td>
<td>July 3, 1978</td>
</tr>
<tr>
<td>Robert S. Gordon, Jr.</td>
<td>November 7, 1974</td>
<td>September 1, 1975</td>
</tr>
<tr>
<td>Mortimer Lipsett</td>
<td>August 29, 1976</td>
<td>June 30, 1982</td>
</tr>
<tr>
<td>Seymour Perry</td>
<td>January 3, 1978</td>
<td>March 1980</td>
</tr>
<tr>
<td>William F. Raub</td>
<td>April 4, 1978</td>
<td>April 2, 1983</td>
</tr>
<tr>
<td>Edwin D. Becker</td>
<td>March 1980</td>
<td>April 1988</td>
</tr>
<tr>
<td>Calvin Baldwin</td>
<td>August 1, 1980</td>
<td>January 31, 1986</td>
</tr>
<tr>
<td>Mark S. Beaubien (Acting)</td>
<td>July 1, 1982</td>
<td>January 18, 1984</td>
</tr>
<tr>
<td>Jay R. Shapiro (Acting)</td>
<td>July 1, 1982</td>
<td>July 1983</td>
</tr>
<tr>
<td>Name</td>
<td>Start Date</td>
<td>End Date</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
<td>--------------</td>
</tr>
<tr>
<td>J. Richard Crout</td>
<td>July 12, 1982</td>
<td>April 16, 1984</td>
</tr>
<tr>
<td>Michael I. Goldberg</td>
<td>November 28, 1982</td>
<td>September 17, 1984</td>
</tr>
<tr>
<td>John L. Decker</td>
<td>August 1, 1983</td>
<td>June 1, 1990</td>
</tr>
<tr>
<td>Craig K. Wallace</td>
<td>January 19, 1984</td>
<td>February 8, 1991</td>
</tr>
<tr>
<td>George Galasso</td>
<td>February 5, 1984</td>
<td>January 2, 1996</td>
</tr>
<tr>
<td>Jay Moskowitz</td>
<td>January 1986</td>
<td>April 1993</td>
</tr>
<tr>
<td>John D. Mahoney</td>
<td>June 1986</td>
<td>April 1993</td>
</tr>
<tr>
<td>Itzhak Jacoby (Acting)</td>
<td>July 10, 1987</td>
<td>December 1999</td>
</tr>
<tr>
<td>Anthony S. Fauci</td>
<td>April 5, 1988</td>
<td>1994</td>
</tr>
<tr>
<td>Norman D. Mansfield</td>
<td>October 10, 1988</td>
<td>February 1992</td>
</tr>
<tr>
<td>John Ferguson (Acting)</td>
<td>September 1989</td>
<td>June 19, 1991</td>
</tr>
<tr>
<td>James D. Watson</td>
<td>October 1, 1989</td>
<td>April 10, 1992</td>
</tr>
<tr>
<td>Saul Rosen (Acting)</td>
<td>June 1990</td>
<td>June 1994</td>
</tr>
<tr>
<td>Ruth Kirschstein</td>
<td>September 1990</td>
<td>September 1991</td>
</tr>
<tr>
<td>Vivian Pinn</td>
<td>September 1991</td>
<td>August 31, 2011</td>
</tr>
<tr>
<td>Stephen A. Ficca</td>
<td>February 1992</td>
<td>March 2004</td>
</tr>
<tr>
<td>R. Anne Thomas</td>
<td>April 14, 1996</td>
<td>April 21, 2002</td>
</tr>
<tr>
<td>William E. Paul</td>
<td>March 1994</td>
<td>November 21, 1997</td>
</tr>
<tr>
<td>Leamon Lee</td>
<td>July 10, 1994</td>
<td>January 2004</td>
</tr>
<tr>
<td>John Ruffin</td>
<td>August 26, 1990</td>
<td>January 9, 2001</td>
</tr>
<tr>
<td>Diane Wax</td>
<td>May 1995</td>
<td>October 1998</td>
</tr>
<tr>
<td>Norman Anderson</td>
<td>July 1995</td>
<td>March 2000</td>
</tr>
<tr>
<td>Lana Skriboll</td>
<td>August 1995</td>
<td>April 30, 2010</td>
</tr>
<tr>
<td>Sue Quantius</td>
<td>September 1999</td>
<td>April 2002</td>
</tr>
<tr>
<td>Marc Smolonsky</td>
<td>July 1999</td>
<td>May 2009</td>
</tr>
<tr>
<td>Raynard Kington</td>
<td>October 2000</td>
<td>February 2003</td>
</tr>
<tr>
<td>Jack Whitescarver</td>
<td>October 20, 2000</td>
<td>Present</td>
</tr>
<tr>
<td>Barnett Kramer</td>
<td>May 6, 2001</td>
<td>Present</td>
</tr>
<tr>
<td>Donald Poppke</td>
<td>April 17, 2002</td>
<td>September 26, 2003</td>
</tr>
<tr>
<td>John Burklow</td>
<td>April 22, 2002</td>
<td>Present</td>
</tr>
<tr>
<td>Richard Turman</td>
<td>October 9, 2003</td>
<td>July 22, 2005</td>
</tr>
<tr>
<td>Andy Baldus (Acting)</td>
<td>July 23, 2005</td>
<td>October 2006</td>
</tr>
<tr>
<td>Diane Frasier</td>
<td>January 23, 2006</td>
<td>Present</td>
</tr>
<tr>
<td>John Bartrum</td>
<td>October 15, 2006</td>
<td>December 2009</td>
</tr>
<tr>
<td>Alfred Johnson</td>
<td>October 29, 2006</td>
<td>Present</td>
</tr>
<tr>
<td>Christine Bachrach (Acting)</td>
<td>April 7, 2008</td>
<td>March 2010</td>
</tr>
<tr>
<td>Roz Gray (Acting)</td>
<td>May 2009</td>
<td>February 28, 2010</td>
</tr>
<tr>
<td>Louise Myers (Acting)</td>
<td>December 2009</td>
<td>April 2, 2010</td>
</tr>
<tr>
<td>Francis Patrick White</td>
<td>March 1, 2010</td>
<td>Present</td>
</tr>
<tr>
<td>Deborah Olster (Acting)</td>
<td>March 2010</td>
<td>Present</td>
</tr>
<tr>
<td>Mark Rotarius (Acting)</td>
<td>April 3, 2010</td>
<td>September 2010</td>
</tr>
<tr>
<td>Neil K. Shapiro</td>
<td>September 2010</td>
<td>Present</td>
</tr>
<tr>
<td>Amy Patterson</td>
<td>January 16, 2011</td>
<td>Present</td>
</tr>
<tr>
<td>Janine A. Clayton (Acting)</td>
<td>September 2011</td>
<td>Present</td>
</tr>
</tbody>
</table>

This page last reviewed on September 15, 2011
Department of Health and Human Services*

**Kathleen Sebelius**, Secretary, HHS

### CHRONOLOGY OF HHS SECRETARIES

<table>
<thead>
<tr>
<th>Name</th>
<th>In Office from</th>
<th>To</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oveta Culp Hobby</td>
<td>April 11, 1953</td>
<td>July 31, 1955</td>
</tr>
<tr>
<td>Marion B. Folsom</td>
<td>August 1, 1955</td>
<td>July 31, 1958</td>
</tr>
<tr>
<td>Arthur S. Flemming</td>
<td>August 1, 1958</td>
<td>January 1, 1961</td>
</tr>
<tr>
<td>Anthony J. Celebrezze</td>
<td>July 31, 1962</td>
<td>August 17, 1965</td>
</tr>
<tr>
<td>John W. Gardner</td>
<td>August 18, 1965</td>
<td>February 29, 1968</td>
</tr>
<tr>
<td>Wilbur J. Cohen</td>
<td>May 9, 1968</td>
<td>January 19, 1969</td>
</tr>
<tr>
<td>Robert H. Finch</td>
<td>January 22, 1969</td>
<td>June 24, 1970</td>
</tr>
<tr>
<td>Elliot L. Richardson</td>
<td>June 24, 1970</td>
<td>January 29, 1973</td>
</tr>
<tr>
<td>Caspar W. Weinberger</td>
<td>February 12, 1973</td>
<td>August 10, 1975</td>
</tr>
<tr>
<td>David Mathews</td>
<td>August 8, 1975</td>
<td>January 20, 1977</td>
</tr>
<tr>
<td>Patricia Roberts Harris</td>
<td>July 27, 1979</td>
<td>January 19, 1981</td>
</tr>
<tr>
<td>Richard S. Schweiker</td>
<td>January 22, 1981</td>
<td>February 3, 1983</td>
</tr>
<tr>
<td>Margaret M. Heckler</td>
<td>March 9, 1983</td>
<td>December 12, 1985</td>
</tr>
<tr>
<td>Otis R. Bowen</td>
<td>December 13, 1985</td>
<td>January 20, 1989</td>
</tr>
<tr>
<td>Louis Sullivan</td>
<td>March 1, 1989</td>
<td>January 1993</td>
</tr>
<tr>
<td>Donna Shalala</td>
<td>January 22, 1993</td>
<td>January 19, 2001</td>
</tr>
<tr>
<td>Tommy G. Thompson</td>
<td>February 2, 2001</td>
<td>January 25, 2005</td>
</tr>
<tr>
<td>Mike Leavitt</td>
<td>January 26, 2005</td>
<td>January 20, 2009</td>
</tr>
<tr>
<td>Kathleen Sebelius</td>
<td>April 28, 2009</td>
<td>present</td>
</tr>
</tbody>
</table>

*Name changed from Department of Health, Education, and Welfare on May 14, 1980; separate Department of Education formed.*

---

This page last reviewed on February 22, 2011

National Institutes of Health (NIH), 9000 Rockville Pike, Bethesda, Maryland 20892

“NIH...Turning Discovery into Health” is a trademark of the U.S. Department of Health and Human Services.
# Nobel Laureates

Read about the [NIH Scientists](#) who have won Nobel prizes.

<table>
<thead>
<tr>
<th>Laureate</th>
<th>Field</th>
<th>Year</th>
<th>Supporting NIH Institute(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roger D. Kornberg, U.S.A.</td>
<td>Chemistry</td>
<td>2006</td>
<td>NIGMS, NIAID, NCI</td>
</tr>
<tr>
<td>Andrew Z. Fire, U.S.A., and Craig C. Mello, U.S.A.</td>
<td>Physiology or Medicine</td>
<td>2006</td>
<td>NIGMS, NICHD</td>
</tr>
<tr>
<td>Irwin A. Rose, U.S.A., Avram Hershko, Israel (shared with Aaron Ciechanover, Israel)</td>
<td>Chemistry</td>
<td>2004</td>
<td>NIAMS, NCI, NIAAA, NIGMS, NIDDK</td>
</tr>
<tr>
<td>John B. Fenn, U.S.A. (shared with K. Tanaka, Japan and K. Wüthrich, Switzerland)</td>
<td>Chemistry</td>
<td>2002</td>
<td>NIGMS</td>
</tr>
<tr>
<td>Günter Blobel, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1999</td>
<td>NIGMS, NCI</td>
</tr>
<tr>
<td>Name</td>
<td>Award Category</td>
<td>Year</td>
<td>Institutions</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------</td>
<td>------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>Louis Ignarro, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1998</td>
<td>NHLBI, NIAMS, NICHD</td>
</tr>
<tr>
<td>Ferid Murad, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1998</td>
<td>NIGMS, NHLBI, NIDDK</td>
</tr>
<tr>
<td>Paul D. Boyer, U.S.A.</td>
<td>Chemistry</td>
<td>1997</td>
<td>NIGMS, NIDDK</td>
</tr>
<tr>
<td>Jens C. Skou, Denmark</td>
<td>Chemistry</td>
<td>1997</td>
<td>NINDS</td>
</tr>
<tr>
<td>Stanley B. Prusiner, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1997</td>
<td>NINDS, NIA, NCRR, NIGMS</td>
</tr>
<tr>
<td>Peter C. Doherty, U.S.A.</td>
<td>Physiology or Medicine</td>
<td>1996</td>
<td>NIAID</td>
</tr>
<tr>
<td>Edward B. Lewis, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1995</td>
<td>NICHID, NIGMS</td>
</tr>
<tr>
<td>Eric F. Wieschaus, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1995</td>
<td>NICHID</td>
</tr>
<tr>
<td>Alfred G. Gilman, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1994</td>
<td>NIGMS, NINDS</td>
</tr>
<tr>
<td>Martin Rodbell, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1994</td>
<td>NIEHS, NIDDK</td>
</tr>
<tr>
<td>George A. Olah, U.S.A.</td>
<td>Chemistry</td>
<td>1994</td>
<td>NCI, NIGMS</td>
</tr>
<tr>
<td>Phillip A. Sharp, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1993</td>
<td>NIGMS, NCI, NIAID, NCRR</td>
</tr>
<tr>
<td>Richard Roberts, U.K.</td>
<td>Physiology or medicine</td>
<td>1993</td>
<td>NCRR, NLM, NCHGR, NCI, NIGMS</td>
</tr>
<tr>
<td>Robert W. Fogel, Ph.D.</td>
<td>Economic Sciences</td>
<td>1993</td>
<td>NIA</td>
</tr>
<tr>
<td>Kary B. Mullis, U.S.A.</td>
<td>Chemistry</td>
<td>1993</td>
<td>NHBLI, NIAID, NIGMS</td>
</tr>
<tr>
<td>Michael Smith, Canada</td>
<td>Chemistry</td>
<td>1993</td>
<td>NIGMS</td>
</tr>
<tr>
<td>Edwin G. Krebs, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1992</td>
<td>NIDDK, NIGMS, NIAMS</td>
</tr>
<tr>
<td>Edmond H. Fisher, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1992</td>
<td>NIDDK, NIGMS, NIAMS</td>
</tr>
<tr>
<td>Gary Becker, U.S.A.</td>
<td>Economics</td>
<td>1992</td>
<td>NICHID</td>
</tr>
<tr>
<td>Elias J. Corey, U.S.A.</td>
<td>Chemistry</td>
<td>1990</td>
<td>NIGMS, NCRR, NCI, NIHBI, NIAID</td>
</tr>
<tr>
<td>E. Donnall Thomas, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1990</td>
<td>NCI, NIAID, NIDDK</td>
</tr>
<tr>
<td>Joseph E. Murray, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1990</td>
<td>NHLBI, NIAID</td>
</tr>
<tr>
<td>Sidney Altman, U.S.A.</td>
<td>Chemistry</td>
<td>1989</td>
<td>NIGMS, NICHD</td>
</tr>
<tr>
<td>Thomas Cech, U.S.A.</td>
<td>Chemistry</td>
<td>1989</td>
<td>NIGMS, NCI</td>
</tr>
<tr>
<td>J. Michael Bishop, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1989</td>
<td>NCI</td>
</tr>
<tr>
<td>Harold E. Varmus, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1989</td>
<td>NCI, NIAID</td>
</tr>
<tr>
<td>Susumu Tonegawa, Japan</td>
<td>Physiology or medicine</td>
<td>1987</td>
<td>NIAID</td>
</tr>
<tr>
<td>Donald J. Cram, U.S.A.</td>
<td>Chemistry</td>
<td>1987</td>
<td>NIGMS</td>
</tr>
<tr>
<td>Stanley Cohen, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1986</td>
<td>NICHID, NIGMS</td>
</tr>
<tr>
<td>Rita Levi-Montalcini, U.S.A./Italy</td>
<td>Physiology or medicine</td>
<td>1986</td>
<td>NIMH, NINDS</td>
</tr>
<tr>
<td>Herbert A. Hauptman, U.S.A.</td>
<td>Chemistry</td>
<td>1985</td>
<td>NIGMS, NIADDK, NHLBI, DRR</td>
</tr>
<tr>
<td>Michael S. Brown, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1985</td>
<td>NHLBI, NIGMS, DRR</td>
</tr>
<tr>
<td>Joseph L. Goldstein, U.S.A.</td>
<td>Physiology or medicine</td>
<td>1985</td>
<td>NHLBI, NIGMS, DRR</td>
</tr>
<tr>
<td>R. Bruce Merrifield, U.S.A.</td>
<td>Chemistry</td>
<td>1984</td>
<td>NIDDK</td>
</tr>
<tr>
<td>Name</td>
<td>Field</td>
<td>Year</td>
<td>Institute</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>------------------------</td>
<td>------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>Henry Taube, U.S.A.</td>
<td>Chemistry</td>
<td>1983</td>
<td>NIGMS</td>
</tr>
<tr>
<td>Sune Bergstrom, Sweden (shared with J. R. Vane, U.K. and B. Samuelsson, Sweden)</td>
<td>Physiology or medicine</td>
<td>1982</td>
<td>NHLBI, NLM, NICHID</td>
</tr>
<tr>
<td>John R. Vane, U.K. (shared with S. Bergstrom and B. Samuelsson, Sweden)</td>
<td>Physiology or medicine</td>
<td>1982</td>
<td>DRG, NIGMS, NIMH</td>
</tr>
<tr>
<td>Aaron Klug, U.K.</td>
<td>Chemistry</td>
<td>1982</td>
<td>NIAID</td>
</tr>
<tr>
<td>Roald Hoffmann, U.S.A. (shared with K. Fukui, Japan)</td>
<td>Chemistry</td>
<td>1981</td>
<td>NIGMS</td>
</tr>
<tr>
<td>Jean Dausset, France (shared with B. Benacerraf and G. D. Snell, U.S.A.)</td>
<td>Physiology or medicine</td>
<td>1980</td>
<td>NIAID, NCI</td>
</tr>
<tr>
<td>Herbert C. Brown, U.S.A. (shared with G. Wittig, W. Germany)</td>
<td>Chemistry</td>
<td>1979</td>
<td>NIGMS</td>
</tr>
<tr>
<td>Andrew V. Schally, U.S.A. (shared with R. C. L. Guillemin and R. S. Yalow, U.S.A.)</td>
<td>Physiology or medicine</td>
<td>1977</td>
<td>NIDDK, NICHD, NIGMS</td>
</tr>
<tr>
<td>D. Carleton Gajdusek, U.S.A. (shared with B. S. Blumberg, U.S.A.)</td>
<td>Physiology or medicine</td>
<td>1976</td>
<td>NINDS</td>
</tr>
<tr>
<td>William N. Lipscomb, U.S.A</td>
<td>Chemistry</td>
<td>1976</td>
<td>NIGMS, DRG</td>
</tr>
<tr>
<td>Albert Claude, Belgium (shared with C. de Duve, Belgium, and G. E. Palade, U.S.A.)</td>
<td>Physiology or medicine</td>
<td>1974</td>
<td>NCI</td>
</tr>
<tr>
<td>George E. Palade, U.S.A. (shared with C. de Duve and A. Claude, Belgium)</td>
<td>Physiology or medicine</td>
<td>1974</td>
<td>NHLBI, NIGMS</td>
</tr>
<tr>
<td>Christian de Duve, Belgium (shared with A. Claude, Belgium, and G. E. Palade, U.S.A.)</td>
<td>Physiology or medicine</td>
<td>1974</td>
<td>NICHD, NIGMS, NHLBI, NIA</td>
</tr>
<tr>
<td>Name</td>
<td>Country</td>
<td>Field</td>
<td>Year</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>------------------</td>
<td>------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>William H. Stein</td>
<td>U.S.A.</td>
<td>Chemistry</td>
<td>1972</td>
</tr>
<tr>
<td>Earl W. Sutherland, Jr.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1971</td>
</tr>
<tr>
<td>Julius Axelrod</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1970</td>
</tr>
<tr>
<td>Ulf von Euler, Sweden</td>
<td>Sweden</td>
<td>Chemistry</td>
<td>1970</td>
</tr>
<tr>
<td>Louis Leloir, Argentina</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Max Delbruck, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1969</td>
</tr>
<tr>
<td>Alfred D. Hershey, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1969</td>
</tr>
<tr>
<td>Salvador Luria, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1969</td>
</tr>
<tr>
<td>Robert W. Holley, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1968</td>
</tr>
<tr>
<td>H. Gobind Khorana, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1968</td>
</tr>
<tr>
<td>Marshall W. Nirenberg, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1968</td>
</tr>
<tr>
<td>Lars Onsager, U.S.A.</td>
<td></td>
<td>Chemistry</td>
<td>1968</td>
</tr>
<tr>
<td>Haldan K. Hartline, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1967</td>
</tr>
<tr>
<td>George Wald, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1967</td>
</tr>
<tr>
<td>Charles B. Huggins, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1966</td>
</tr>
<tr>
<td>Jacques L. Monod, France</td>
<td>France</td>
<td>Physiology or medicine</td>
<td>1965</td>
</tr>
<tr>
<td>Robert B. Woodward, U.S.A.</td>
<td></td>
<td>Chemistry</td>
<td>1965</td>
</tr>
<tr>
<td>Konrad Bloch, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1964</td>
</tr>
<tr>
<td>James D. Watson, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1962</td>
</tr>
<tr>
<td>Melvin Calvin, U.S.A.</td>
<td></td>
<td>Chemistry</td>
<td>1961</td>
</tr>
<tr>
<td>Peter B. Medawar, U.K.</td>
<td>U.K.</td>
<td>Physiology or medicine</td>
<td>1960</td>
</tr>
<tr>
<td>Arthur Kornberg, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1959</td>
</tr>
<tr>
<td>Severo Ochoa, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1959</td>
</tr>
<tr>
<td>George W. Beadle, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1958</td>
</tr>
<tr>
<td>Joshua Lederberg, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1958</td>
</tr>
<tr>
<td>Edward L. Tatum, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1958</td>
</tr>
<tr>
<td>Dickinson W. Richards, Jr.,</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1956</td>
</tr>
<tr>
<td>Vincent du Vigneaud, U.S.A.</td>
<td></td>
<td>Chemistry</td>
<td>1955</td>
</tr>
<tr>
<td>Thomas H. Weiler, U.S.A.</td>
<td>U.S.A.</td>
<td>Physiology or medicine</td>
<td>1954</td>
</tr>
<tr>
<td>Linus C. Pauling, U.S.A.</td>
<td></td>
<td>Chemistry</td>
<td>1954</td>
</tr>
</tbody>
</table>

Physiology or medicine 1953 NIGMS, NCI


Physiology or medicine 1950 NIGMS

E. O. Lawrence, U.S.A.

Physics 1939 NCI

NIH Scientists

1968 - Dr. Marshall W. Nirenberg, National Heart, Lung, and Blood Institute, shared the Nobel Prize in Physiology or Medicine for discovering the key to deciphering the genetic code. Dr. Nirenberg and two other researchers, working independently, with whom he shared the prize, made major advances in understanding the chemical mechanisms by which genetic language or information is translated into various proteins that determine the nature and characteristics of all living things. Dr. Nirenberg was the first NIH Nobelist and also the first federal scientist to receive a Nobel Prize.

1970 - Dr. Julius Axelrod, National Institute of Mental Health, shared the Nobel Prize in Physiology or Medicine with two scientists from England and Sweden for independent research into the chemistry of nerve transmission. The three were cited for their “discoveries concerning the humoral transmitters in the nerve terminals and the mechanisms for their storage, release and inactivation.” Specifically, Dr. Axelrod found an enzyme that terminates the action of the nerve transmitter, noradrenaline. He also demonstrated that some antidepressant drugs act by preventing the reuptake of noradrenaline and thus prolong its action in the brain.

1972 - Dr. Christian B. Anfinsen (formerly with the National Institute of Arthritis, Metabolism, and Digestive Diseases) won the Nobel Prize in Chemistry for his work “on ribonuclease, especially concerning the connection between the amino acid sequence and the biologically active conformation.” Dr. Anfinsen provided the first clue to the structure of ribonuclease by demonstrating that it is comprised of a single polypeptide chain. He and his colleagues at Rockefeller University (with whom he shared the prize) demonstrated that the information required to fold the polypeptide chain of ribonuclease into the specific three-dimensional form of the active enzyme resides in the sequence of amino acids. Therefore, it became clear that this protein could be synthesized in the laboratory by joining the proper amino acids in the correct order and then allowing the chain of amino acids to fold spontaneously. This led to the first synthesis of an enzyme from chemicals in the laboratory. Such studies are basic to an understanding of normal life processes as well as of inherited metabolic diseases.

1976 - Dr. D. Carleton Gajdusek, National Institute of Neurological Disorders and Stroke, shared the Nobel Prize in Physiology or Medicine with Dr. Baruch S. Blumberg, of the Institute for Cancer Research in Philadelphia. They won the award for their discoveries concerning new mechanisms for the origin and dissemination of infectious diseases. Dr. Blumberg was at NIH (with the National Institute of Arthritis and Metabolic Diseases) in the 1960s, and did part of his prizewinning research at NIH.

1994 - Dr. Martin Rodbell, National Institute of Environmental Health Sciences, shared the Nobel Prize in Physiology or Medicine with Dr. G. Alfred Gilman of the University of Texas Southwestern Medical Center in Dallas, Texas. Dr. Rodbell discovered in 1970 that signal transmission requires a cellular molecule called GTP. In 1977 Dr. Gillman identified the proteins to which GTP binds and named them “G proteins.” They are a family of proteins bound to the cell surface membranes that serve as intermediaries between incoming signals and cellular proteins that respond to these signals. Dr. Rodbell conducted this research while an intramural scientist with the National Institute of Arthritis and Metabolic Diseases (now NIDDK).
Major NIH Lectures

The constant exchange of ideas is crucial to progress in medical research. Findings in one field often unexpectedly affect thinking in others. To encourage this exchange of ideas in its own laboratories, NIH hosts more than 1,200 scientific lectures each year by its own researchers and by distinguished visiting scientists from other research institutions. Here are a few highlights of the many lectures NIH hosted in 2008 and 2009.

The NIH Director's Lectures
As part of NIH's Wednesday Afternoon Lecture Series, the Director's Lectures feature leading researchers from around the globe. Nominated by scientists and interest groups throughout NIH, the NIH Director specifically approves these annual lectures.

- "Mouse Models of Human Disease: From Cancer to Neuropsychiatric Disorders"—Mario Capecchi, March 11, 2010.
- "Neurobiology of Rett Syndrome and Related Disorders"—Huda Zoghbi, June 17, 2009.
- "From Worms to Mammals: Genes that Control the Rate of Aging"—Cynthia Kenyon, February 20, 2008.

Astute Clinician Lecture
This annual lecture, begun in 1998 and part of the Wednesday Afternoon Lecture Series, honors a U.S. scientist who has observed an unusual occurrence, and by investigating it, has opened an important new avenue of research. The lectureship exemplifies how astute clinical observations can lead to innovative research.


**David E. Barmes Global Health Lecture**

This annual lecture honors the late Dr. David E. Barmes, a World Health Organization expert in oral health, special expert for international health in the National Institute of Dental and Craniofacial Research (NIDCR) Office of International Health, and ardent spokesman for global health. Established in 2001, the lecture series is jointly sponsored by NIDCR and NIH’s Fogarty International Center.


**Cantoni Memorial Lecture Series**

This lecture series honors Giulio Leonardo Cantoni, who joined the National Institutes of Mental Health in 1954 as the Chief of the Laboratory of Cellular Pharmacology, now the Laboratory of General and Comparative Biochemistry. He directed that laboratory until 1994.


**James Cassedy Memorial Lecture**

To honor the distinguished historian of medicine and long-time National Library of Medicine (NLM) staffer Jim Cassedy, the NLM History of Medicine Division sponsored the first annual James Cassedy Memorial Lecture in 2008.


**John W. Diggs Lecture**

Established in 1995 to honor the late Dr. John W. Diggs, former NIH Deputy Director for Extramural Research. The lecture is sponsored by the NIH Office of Intramural Research, the NIH Office of Research on Women's Health, and the NIH Black Scientists Association.


**John Doppman Memorial Lecture for Imaging Sciences**

This annual lecture honors the memory of a devoted physician, researcher, and teacher who spent more than 30 years at NIH and was chief of the Clinical Center’s Diagnostic Radiology Department.


**R.E. Dyer Lecture**

Established in 1950 in honor of former NIH director Dr. Rolla E. Dyer, a noted authority on infectious diseases. The lecture, part of the Wednesday Afternoon Lecture Series, features internationally renowned researchers who have contributed substantially to medical as well as biological knowledge of infectious diseases.


**Robert S. Gordon Lecture in Epidemiology**

Named in honor of Robert S. Gordon, Jr., former Assistant Surgeon General of the U.S. Public Health Service and Special Assistant to former NIH Director James Wyngaarden, it is part of the Wednesday Afternoon Lecture Series. Topics focus on clinical research and epidemiology.


**George Khoury Lecture**

Organized by NIH scientists to honor the memory of Dr. George Khoury, who was highly regarded as a superb scientist and caring mentor of the postdoctoral fellows in his laboratory. This annual lecture is part of the Wednesday Afternoon Lecture Series.


**Joseph J. Kinyoun Lecture**

Established by the National Institute of Allergy and Infectious Diseases in 1979 to honor Dr. Joseph J. Kinyoun, who established in 1887 the Laboratory of Hygiene on Staten Island, the predecessor of the National Institutes of Health.
Lecture Series [http://wals.od.nih.gov/]. Established by NIGMS in 1982 and presented annually in honor of Dr. Stetten, the third NIGMS director, this annual lecture is part of the Wednesday Afternoon Lecture Series [http://wals.od.nih.gov/].

Margaret Pittman Lecture
Part of the Wednesday Afternoon Lecture Series [http://wals.od.nih.gov/], the lecture is given by a researcher dedicated to advancing and improving the careers of women scientists. Since 1994 when this annual lecture began, every speaker has exemplified the intelligence, scientific excellence and drive that made Margaret Pittman a leader as the first female laboratory chief at NIH.

J. Edward Rall Cultural Lecture
The NIH Director's Cultural Lecture, part of the Wednesday Afternoon Lecture Series was renamed in 2008 in honor of Joseph “Ed” Rall, who helped to define NIH's modern intramural research program and, in the 1950s, to establish a stable academic-like community within a rapidly expanding government agency.

Sayer Vision Research Lecture
Dr. Jane Sayer, an NIH research scientist in NIDDK, established the Sayer Vision Research Lecture and Award at the Foundation for the National Institutes of Health, in partnership with NEI, to honor her family and the memory of her parents, Winthrop and Laura Sayer. The lecture and award series will provide an opportunity for honorees to explore areas of interdisciplinary collaboration that may lead to advances in diverse medical specialties relevant to vision research.

DeWitt Stetten Jr., Lecture
Established by NIGMS in 1982 and presented annually in honor of Dr. Stetten, the third NIGMS director, this annual lecture is part of the Wednesday Afternoon Lecture Series [http://wals.od.nih.gov/].

Matilda White Riley Lecture
Named for noted NIH social scientist who died in 2004 at age 93 to honor her extraordinary life and work in behavioral and social research.


Florence Mahoney Lecture on Aging
Sponsored by the National Institute on Aging, the series recognizes Mrs. Mahoney's lifetime commitment to medical research and its benefits to people worldwide. Florence Stephenson Mahoney is widely known for her dedicated efforts in shaping national health science policy, particularly with respect to aging.


G. Burroughs Mider Lecture
Established in 1968 in honor of the first NIH director of laboratories and clinics. The lecture, part of the Wednesday Afternoon Lecture Series [http://wals.od.nih.gov/], is presented by an NIH intramural scientist to recognize and appreciate outstanding contributions to biomedical research.


Margaret Pittman Lecture
Part of the Wednesday Afternoon Lecture Series [http://wals.od.nih.gov/], the lecture is given by a researcher dedicated to advancing and improving the careers of women scientists. Since 1994 when this annual lecture began, every speaker has exemplified the intelligence, scientific excellence and drive that made Margaret Pittman a leader as the first female laboratory chief at NIH.


J. Edward Rall Cultural Lecture
The NIH Director's Cultural Lecture, part of the Wednesday Afternoon Lecture Series was renamed in 2008 in honor of Joseph "Ed" Rall, who helped to define NIH's modern intramural research program and, in the 1950s, to establish a stable academic-like community within a rapidly expanding government agency.

"An Afternoon with Maya Angelou"—Maya Angelou, September 23, 2009.


Sayer Vision Research Lecture
Dr. Jane Sayer, an NIH research scientist in NIDDK, established the Sayer Vision Research Lecture and Award at the Foundation for the National Institutes of Health, in partnership with NEI, to honor her family and the memory of her parents, Winthrop and Laura Sayer. The lecture and award series will provide an opportunity for honorees to explore areas of interdisciplinary collaboration that may lead to advances in diverse medical specialties relevant to vision research.


DeWitt Stetten Jr., Lecture
Established by NIGMS in 1982 and presented annually in honor of Dr. Stetten, the third NIGMS director, this annual lecture is part of the Wednesday Afternoon Lecture Series [http://wals.od.nih.gov/].


Matilda White Riley Lecture
Named for noted NIH social scientist who died in 2004 at age 93 to honor her extraordinary life and work in behavioral and social research.


This page last reviewed on January 5, 2012
## Appropriations (Section 1)

### AMOUNTS IN THOUSANDS OF DOLLARS

<table>
<thead>
<tr>
<th>FY</th>
<th>NCI11</th>
<th>NHLBI</th>
<th>NIDCR</th>
<th>NIDDK1</th>
<th>NINDS2</th>
<th>NIAID12</th>
<th>NIGMS</th>
<th>NICHD3</th>
<th>NEI</th>
<th>NEHS4</th>
<th>NIA</th>
<th>NIAMS</th>
<th>NIDCD</th>
<th>NIMH5</th>
</tr>
</thead>
<tbody>
<tr>
<td>1938</td>
<td>400</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1939</td>
<td>400</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1940</td>
<td>570</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1941</td>
<td>570</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1942</td>
<td>565</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1943</td>
<td>535</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1944</td>
<td>530</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1945</td>
<td>561</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1946</td>
<td>549</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1947</td>
<td>1,821</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1948</td>
<td>14,500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1949</td>
<td>14,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1950</td>
<td>18,900</td>
<td>10,725</td>
<td>1,780</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1951</td>
<td>20,086</td>
<td>14,200</td>
<td>1,955</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1952</td>
<td>19,657</td>
<td>10,083</td>
<td>1,618</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1953</td>
<td>17,887</td>
<td>12,000</td>
<td>1,650</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1954</td>
<td>20,237</td>
<td>15,168</td>
<td>1,740</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1955</td>
<td>21,737</td>
<td>16,668</td>
<td>1,990</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1956</td>
<td>21,737</td>
<td>16,668</td>
<td>1,990</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1957</td>
<td>24,978</td>
<td>18,898</td>
<td>2,176</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1958</td>
<td>27,980</td>
<td>20,901</td>
<td>2,541</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1959</td>
<td>30,981</td>
<td>23,981</td>
<td>3,007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960</td>
<td>33,982</td>
<td>26,982</td>
<td>3,473</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1961</td>
<td>36,983</td>
<td>29,983</td>
<td>3,939</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1962</td>
<td>39,984</td>
<td>32,984</td>
<td>4,405</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1963</td>
<td>42,985</td>
<td>35,985</td>
<td>4,871</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1964</td>
<td>45,986</td>
<td>38,986</td>
<td>5,337</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1965</td>
<td>48,987</td>
<td>41,987</td>
<td>5,803</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1966</td>
<td>52,988</td>
<td>44,988</td>
<td>6,269</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1967</td>
<td>56,989</td>
<td>47,989</td>
<td>6,735</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1968</td>
<td>60,990</td>
<td>50,990</td>
<td>7,201</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1969</td>
<td>64,991</td>
<td>53,991</td>
<td>7,667</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970</td>
<td>69,992</td>
<td>56,992</td>
<td>8,133</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1971</td>
<td>74,993</td>
<td>59,993</td>
<td>8,699</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1972</td>
<td>79,994</td>
<td>62,994</td>
<td>9,265</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1973</td>
<td>84,995</td>
<td>65,995</td>
<td>9,831</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974</td>
<td>89,996</td>
<td>68,996</td>
<td>10,407</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1975</td>
<td>94,997</td>
<td>71,997</td>
<td>10,973</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1976</td>
<td>99,998</td>
<td>74,998</td>
<td>11,539</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1977</td>
<td>104,999</td>
<td>77,999</td>
<td>12,105</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1978</td>
<td>109,999</td>
<td>80,999</td>
<td>12,671</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1979</td>
<td>114,999</td>
<td>83,999</td>
<td>13,237</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>119,999</td>
<td>86,999</td>
<td>13,803</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1981</td>
<td>124,999</td>
<td>89,999</td>
<td>14,369</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>129,999</td>
<td>92,999</td>
<td>14,935</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983</td>
<td>134,999</td>
<td>95,999</td>
<td>15,501</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1984</td>
<td>139,999</td>
<td>98,999</td>
<td>16,067</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td>144,999</td>
<td>102,999</td>
<td>16,633</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1986</td>
<td>149,999</td>
<td>105,999</td>
<td>17,299</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Note: Excludes subsequent transfers of funds (real and comparable).

Only current appropriations are shown. Excludes the Division of Regional Medical Programs, transferred to the Health Services and Mental Health Administration in 1968. Excludes the Division of Biologic Standards, transferred to FDA in 1973. The amounts identified for each IC in FY 2009 exclude their respective shares of the $10.0 billion appropriated to NIH for short-term stimulus purposes under the American Recovery & Reinvestment Act (ARRA) available for obligation across a two-year timeframe until September 30, 2010. The FY 2009 amount for OD also excludes the $0.4 billion transferred from AHRQ to NIH for Comparative Effectiveness Research consistent with ARRA requirements.

1 Beginning with the FY 1998 Appropriation, includes amounts authorized to the NIDDK for Type 1 diabetes research.

2 Starting in 1970, excludes funds for blindness, established as a separate appropriation, the "National Eye Institute."

3 Congress authorized the transfer of $34,000 from other NIH appropriations to establish the "National Institute of Child Health and Human Development." Starting in 1976, excludes funds for aging, established as a separate appropriation, the "National Institute on Aging."

4 In FY 2001, NIH began receiving a separate appropriation for Superfund Research activities at NIERS.

5 NIWH separated from NIH in 1967 and was raised to bureau status in PHS, became a component of PHS's Health Services and Mental Health Administration (HSMAH), later became a component of ADAMHA (successor organization of HSMAH), and rejoined the NIH in 1993.

6 Funding for General Research and Services (GRS) is shown for FY 1938 to FY 1962, at which time the Division of Research Facilities and Resources (DRFR) was established. In 1969, the Bureau of Health Manpower was renamed the Bureau of Health Professions Education and Manpower Training (BEMT). Within the BEMT, the Division of Research Resources (DRR) was established. Functions of DRFR were transferred to this new Division. In 1970, DRR transferred out of this Bureau. Renamed the National Center for Research Resources in 1990.

7 Starting in 1966, excludes funds for the newly established "National Institute of General Medical Sciences." Starting in 1970, excludes the "Office of International Operations," transferred to the "National Institute of Allergy and Infectious Diseases" and the "John E. Fogarty International Center for Advanced Study in the Health Sciences."

8 Prior to 1970, were included under the National Institutes of Health Management Fund. Separate NIH appropriation enacted in 1970.

9 Prior to 1970, Buildings and Facilities funds were included under PHS. Separate NIH appropriation enacted in 1970.

10 "Office of AIDS Research."

11 Includes $7.9 million for NCI Frederick B&F.

* FY 2010 HIV/AIDS research amounts of $3,084,348,000 appropriated to the ICs. Reflects transfer of $300 million to the Global Fund from NIAID. NIDDK includes $150 million for special type 1 diabetes mandatory appropriation.
### Appropriations (Section 2)

**AMOUNTS IN THOUSANDS OF DOLLARS**

<table>
<thead>
<tr>
<th>FY</th>
<th>NIDA</th>
<th>NIAAA</th>
<th>NINR</th>
<th>NHGRI</th>
<th>NIBIB</th>
<th>NCCR</th>
<th>NCCAM</th>
<th>NCRR</th>
<th>FIC</th>
<th>NLM</th>
<th>OD</th>
<th>B&amp;F</th>
<th>OAR</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>1938</td>
<td>64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>464</td>
<td></td>
</tr>
<tr>
<td>1939</td>
<td>64</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>464</td>
<td></td>
</tr>
<tr>
<td>1940</td>
<td>137</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>707</td>
<td></td>
</tr>
<tr>
<td>1941</td>
<td>141</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>711</td>
<td></td>
</tr>
<tr>
<td>1942</td>
<td>135</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>700</td>
<td></td>
</tr>
<tr>
<td>1943</td>
<td>743</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,278</td>
<td></td>
</tr>
<tr>
<td>1944</td>
<td>2,205</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,555</td>
<td></td>
</tr>
<tr>
<td>1945</td>
<td>2,274</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,835</td>
<td></td>
</tr>
<tr>
<td>1946</td>
<td>2,866</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,415</td>
<td></td>
</tr>
<tr>
<td>1947</td>
<td>6,254</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8,075</td>
<td></td>
</tr>
<tr>
<td>1948</td>
<td>10,126</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24,626</td>
<td></td>
</tr>
<tr>
<td>1949</td>
<td>14,540</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>28,540</td>
<td></td>
</tr>
<tr>
<td>1950</td>
<td>12,075</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>52,714</td>
<td></td>
</tr>
<tr>
<td>1951</td>
<td>14,314</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>64,755</td>
<td></td>
</tr>
<tr>
<td>1952</td>
<td>15,757</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>56,928</td>
<td></td>
</tr>
<tr>
<td>1953</td>
<td>16,599</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>58,610</td>
<td></td>
</tr>
<tr>
<td>1954</td>
<td>4,675</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>70,999</td>
<td></td>
</tr>
<tr>
<td>1955</td>
<td>4,675</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>81,151</td>
<td></td>
</tr>
<tr>
<td>1956</td>
<td>5,929</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>98,509</td>
<td></td>
</tr>
<tr>
<td>1957</td>
<td>12,122</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>177,816</td>
<td></td>
</tr>
<tr>
<td>1958</td>
<td>14,026</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>210,423</td>
<td></td>
</tr>
<tr>
<td>1959</td>
<td>28,974</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>291,817</td>
<td></td>
</tr>
<tr>
<td>1960</td>
<td>45,994</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>399,380</td>
<td></td>
</tr>
<tr>
<td>1961</td>
<td>83,900</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>551,023</td>
<td></td>
</tr>
<tr>
<td>1962</td>
<td>127,637</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>737,170</td>
<td></td>
</tr>
<tr>
<td>1963</td>
<td>159,826</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>876,718</td>
<td></td>
</tr>
<tr>
<td>1964</td>
<td>163,869</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>901,369</td>
<td></td>
</tr>
<tr>
<td>1965</td>
<td>164,759</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>959,159</td>
<td></td>
</tr>
<tr>
<td>1966</td>
<td>60,469</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,100,519</td>
<td></td>
</tr>
<tr>
<td>1967</td>
<td>68,534</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,014,254</td>
<td></td>
</tr>
<tr>
<td>1968</td>
<td>81,141</td>
<td>500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,076,461</td>
<td></td>
</tr>
<tr>
<td>1969</td>
<td>84,810</td>
<td>600</td>
<td>18,160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,109,757</td>
<td></td>
</tr>
<tr>
<td>1970</td>
<td>67,925</td>
<td>2,775</td>
<td>19,251</td>
<td>7,541</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,061,007</td>
<td></td>
</tr>
<tr>
<td>1971</td>
<td>66,320</td>
<td>3,666</td>
<td>21,440</td>
<td>8,903</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,061,487</td>
<td></td>
</tr>
<tr>
<td>1972</td>
<td>74,981</td>
<td>4,207</td>
<td>24,127</td>
<td>11,712</td>
<td>3,565</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,508,156</td>
<td></td>
</tr>
<tr>
<td>1973</td>
<td>75,073</td>
<td>4,666</td>
<td>28,568</td>
<td>12,042</td>
<td>8,500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,762,565</td>
<td></td>
</tr>
<tr>
<td>1974</td>
<td>129,426</td>
<td>4,767</td>
<td>25,871</td>
<td>12,000</td>
<td>8,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1,790,425</td>
<td></td>
</tr>
<tr>
<td>1975</td>
<td>127,200</td>
<td>5,589</td>
<td>28,850</td>
<td>17,326</td>
<td>3,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,092,897</td>
<td></td>
</tr>
<tr>
<td>1976</td>
<td>130,265</td>
<td>5,705</td>
<td>29,065</td>
<td>18,370</td>
<td>54,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,362,126</td>
<td></td>
</tr>
<tr>
<td>1976Q</td>
<td>20,282</td>
<td>1,135</td>
<td>6,572</td>
<td>4,642</td>
<td>750</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>439,107</td>
<td></td>
</tr>
<tr>
<td>1977</td>
<td>137,500</td>
<td>7,992</td>
<td>35,234</td>
<td>16,394</td>
<td>67,400</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,544,078</td>
<td></td>
</tr>
<tr>
<td>1978</td>
<td>145,095</td>
<td>8,483</td>
<td>37,619</td>
<td>18,900</td>
<td>65,650</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2,842,936</td>
<td></td>
</tr>
<tr>
<td>1979</td>
<td>154,164</td>
<td>8,989</td>
<td>41,431</td>
<td>19,673</td>
<td>30,950</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,189,976</td>
<td></td>
</tr>
<tr>
<td>1980</td>
<td>169,196</td>
<td>8,987</td>
<td>43,979</td>
<td>21,036</td>
<td>3,250</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,428,935</td>
<td></td>
</tr>
<tr>
<td>1981</td>
<td>175,627</td>
<td>9,124</td>
<td>44,666</td>
<td>22,531</td>
<td>11,750</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,569,406</td>
<td></td>
</tr>
<tr>
<td>1982</td>
<td>184,177</td>
<td>9,205</td>
<td>45,035</td>
<td>23,618</td>
<td>9,898</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3,641,875</td>
<td></td>
</tr>
<tr>
<td>1983</td>
<td>213,917</td>
<td>10,147</td>
<td>51,943</td>
<td>24,683</td>
<td>17,500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,023,969</td>
<td></td>
</tr>
<tr>
<td>1984</td>
<td>243,177</td>
<td>11,336</td>
<td>49,613</td>
<td>26,720</td>
<td>25,040</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4,493,588</td>
<td></td>
</tr>
<tr>
<td>1985</td>
<td>304,025</td>
<td>11,728</td>
<td>55,910</td>
<td>38,304</td>
<td>21,730</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,149,459</td>
<td></td>
</tr>
<tr>
<td>1986</td>
<td>292,523</td>
<td>11,054</td>
<td>55,322</td>
<td>111,961</td>
<td>14,259</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5,262,211</td>
<td></td>
</tr>
</tbody>
</table>
Only current appropriations are shown. Excludes the Division of Regional Medical Programs, transferred to the Health Services and Mental Health Administration in 1968. Excludes the Division of Biologic Standards, transferred to FDA in 1973. The amounts identified for each IC in FY 2009 exclude their respective shares of the $10.0 billion appropriated to NIH for short-term stimulus purposes under the American Recovery & Reinvestment Act (ARRA) available for obligation across a two-year timeframe until September 30, 2010. The FY 2009 amount for OD also excludes the $0.4 billion transferred from AHRQ to NIH for Comparative Effectiveness Research consistent with ARRA requirements.

1 Beginning with the FY 1998 Appropriation, includes amounts authorized to the NIDDK for Type 1 diabetes research.

2 Starting in 1970, excludes funds for blindness, established as a separate appropriation, the "National Eye Institute."

3 Congress authorized the transfer of $34,000 from other NIH appropriations to establish the "National Institute of Child Health and Human Development." Starting in 1976, excludes funds for aging, established as a separate appropriation, the "National Institute on Aging."

4 In FY 2001, NIH began receiving a separate appropriation for Superfund Research activities at NIEHS.

5 NIH separated from NIH in 1967 and was raised to bureau status in PHS, became a component of PHS's Health Services and Mental Health Administration (HSMA), later became a component of ADAMHA (successor organization of HSMA), and rejoined the NIH in 1993.

6 Funding for General Research and Services (GRS) is shown for FY 1938 to FY 1962, at which time the Division of Research Facilities and Resources (DRFR) was established. In 1969, the Bureau of Health Manpower was renamed the Bureau of Health Professions Education and Manpower Training (BEMT). Within the BEMT, the Division of Research Resources (DRR) was established. Functions of DRFR were transferred to this new Division. In 1970, DRR transferred out of this Bureau. Renamed the National Center for Research Resources in 1990.

7 Starting in 1966, excludes funds for the newly established "National Institute of General Medical Sciences." Starting in 1970, excludes the "Office of International Operations;" transferred to the "National Institute of Allergy and Infectious Diseases" and the "John E. Fogarty International Center for Advanced Study in the Health Sciences."

8 Prior to 1970, funds were included under the National Institutes of Health Management Fund. Separate NIH appropriation enacted in 1970.

9 Prior to 1970, Buildings and Facilities funds were included under PHS. Separate NIH appropriation enacted in 1970.

10 "Office of AIDS Research."

11 Includes $7.9 million for NCI Frederick B&F.

* FY 2010 HIV/AIDS research amounts of $3,084,348,000 appropriated to the ICs. Reflects transfer of $300 million to the Global Fund from NIAID. NIDDK includes $150 million for special type 1 diabetes mandatory appropriation.
Past Issues

If you have questions about past issues of the NIH Almanac, or you need more information about the history of NIH's programs and activities, please contact the Office of NIH History [http://history.nih.gov] at history@nih.gov.

The Office of NIH History works with all NIH components to foster documentation, preservation, and interpretation of the history of the National Institutes of Health.